"DRAVP_ID" "Sequence" "Sequence_Length" "Name" "Source" "Uniprot_ID" "Validation" "Taxon_ID" "Gene_Name_ID" "GenBank" "Amino acid position" "Domain_Accession_ID" "Nucleotide_sequence_ID" "Molecular_Type" "Chromosomal position" "PDB_ID" "Target_Organism" "Family" "Assay" "Activity" "Hemolytic_Activity" "Cytotoxicity_Activity" "Predicted_structure_ID" "Structure" "Linear_Cyclic" "N-terminal_Modification" "C-terminal_Modification" "Other_Modification" "Stereochemistry" "Binding_Target" "Mechanism" "Mass" "Formula" "Absent_amino_acids" "Common_amino_acids" "pI" "Basic_residues" "Acidic_residues" "Net_charge" "Polar_residues" "Hydrophobic_residues" "Hydrophobicity" "Boman_Index" "Half_Life_Mammalian_" "Half_Life__Yeast_" "Half_Life__E_coli_" "Aliphatic_Index" "Extinction_Coefficient_cystines" "Absorbance_280nm" "Pubmed_ID" "Reference" "Author" "Title" "Doi" "Other_link" "Connectives" "DRAVPe01811" "IFKAIWSGIKSLF" "13" "Hp1090" "Heterometrus petersii" "P0DJ02,T1DEJ9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "In vitro HCV RNA inhibitory assay" "[Ref.20950663]Hepatitis C virus (HCV): inhibition of viral infection in Huh7.5.1 cells(IC50 = 7.62 μg/ml (5.0 μM))." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20950663]the peptide concentration was less than 20 μg/ml, the viability of the peptide-treated cells was greater than 90%." "No predicted structure available" "DRAVPe01811.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "Has the ability to prevent the initiation step of HCV infection by direct interaction with HCV virus and readily disrupting their phospholipid membrane." "1509.85" "C76H116N16O16" "CDEHMNPQRTVY" "I" "10" "2" "0" "2" "3" "8" "107.69" "1282" "20 hour" "30 min" ">10 hour" "127.69" "5500" "458.33" "20950663" "Peptides. 2011 Jan;32(1):11-9." "Yan R, Zhao Z, He Y, Wu L, Cai D, Hong W, Wu Y, Cao Z, Zheng C, Li W. " "A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV." "10.1016/j.peptides.2010.10.008" "Anti-HCV" "DRAVPe01809" "FIKRIARLLRKIF" "13" "Kn2-7" "Synthetic construct(derived from BmKn2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase Assay " "[Ref.22536342]human Immunodeficiency viruses-1(HIV-1): inhibition of viral particle(EC50= 2.76 μg/ml (1.65 μM))." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22536342]TZM-bl cells: CC50 = 38.46 µg/ml." "No predicted structure available" "DRAVPe01809.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Kn2-7 aggregates and inserts into viral envelope so that the hydrophobic peptide region aligns with the lipid core region and the hydrophilic peptide regions form the interior region of the pore, with the help of positive charge of peptide somehow" "1674.15" "C81H140N24O14" "CDEGHMNPQSTVWY" "IR" "12.31" "5" "0" "5" "0" "8" "55.38" "-2349" "1.1 hour" "3 min" "2 min" "157.69" "0" "0" "22536342" "PLoS One. 2012;7(4):e34947." "Chen Y, Cao L, Zhong M, Zhang Y, Han C, Li Q, Yang J, Zhou D, Shi W, He B, Liu F, Yu J, Sun Y, Cao Y, Li Y, Li W, Guo D, Cao Z, Yan H." "Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. " "10.1371/journal.pone.0034947" "Anti-HIV" "DRAVPe01808" "MITHGCYTRTRHKHKLKKTL" "20" "SA-35" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Antiviral assay" "[Ref.32124885]Respiratory syncytial virus (RSV):SA-35 caused a significant decrease of the RSV infectivity by 33 times at concentrations 1 mg/ml." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32124885]MA-104 cells:CC50= 2.1 ± 0.1 mg/ml." "No predicted structure available" "DRAVPe01808.cif" "Linear" "Free" "Free" "None" "L" "Not found" "It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell." "2452.97" "C107H182N36O26S2" "ADEFNPQSVW" "KT" "10.58" "9" "0" "9" "7" "3" "-111" "-5711" "30 hour" ">20 hour" ">10 hour" "58.5" "1490" "78.42" "32124885" "J Mater Chem B. 2020 Apr 1;8(13):2607-2617" "Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR" "Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus." "10.1039/c9tb02485a" "Anti-RSV" "DRAVPe01807" "KRRGGGKLLKLLLKLLLKLLKC" "22" "NC-783" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Antiviral assay" "[Ref.32124885]Respiratory syncytial virus (RSV):inhibition of viral infection in the MA-104 cell(IC50=0.04mg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32124885]MA-104 cells:CC50= 0.04 ± 0.01 mg/ml." "No predicted structure available" "DRAVPe01807.cif" "Linear" "Free" "Free" "None" "L" "Not found" "It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell." "2505.32" "C117H222N34O23S" "ADEFHIMNPQSTVWY" "L" "11.27" "8" "0" "8" "4" "10" "31.36" "-984" "1.3 hour" "3 min" "2 min" "177.27" "0" "0" "32124885" "J Mater Chem B. 2020 Apr 1;8(13):2607-2617" "Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR" "Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus." "10.1039/c9tb02485a" "Anti-RSV" "DRAVPe01806" "gikefkrivqrikdflrnlv" "20" "GI-20D" "Synthetic construct(derived from LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Plaque assay" "[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.99 µM);inhibition of viral infection in primary macrophages(IC50=2.2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01806.cif" "Linear" "Free" "Amidation" "None" "D" "Not found" "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." "2473.01" "H-38O-19" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "11" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "32252021" "iScience. 2020 Apr 24;23(4):100999." "Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." "Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection." "10.1016/j.isci.2020.100999" "Anti-EBOV" "DRAVPe01805" "GXKRlVQRlKDXlRNLV" "17" "17BIPHE2" "Synthetic construct(derived from LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Plaque assay" "[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.71 µM);inhibition of viral infection in primary macrophages(IC50=5.6 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01805.cif" "Linear" "Free" "Amidation" "The 'X' at position 2 and 12 indicates biphenylalanine." "Mixed(D-Leu5, 9, 13)" "Not found" "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." "2030.86" "C61H103N25O12" "ACEFHIMPSTWY" "R" "11.72" "5" "1" "4" "2" "3" "-117.65" "-6282" "30 hour" ">20 hour" ">10 hour" "57.06" "0" "0" "32252021" "iScience. 2020 Apr 24;23(4):100999." "Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." "Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection." "10.1016/j.isci.2020.100999" "Anti-EBOV" "DRAVPe01803" "RGAHINGRWDSRCHRF" "16" "FBP1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01803.cif" "Linear" "Free" "Free" "None" "L" "HA" "FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway." "1968.19" "C83H126N34O21S" "EKLMPQTVY" "R" "11.52" "6" "1" "5" "5" "4" "-139.38" "-7256" "1 hour" "2 min" "2 min" "30.63" "5500" "366.67" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " "10.1080/22221751.2022.2051753" "Anti-Anti-Influenza A virus" "DRAVPe01804" "RGAHIKGRWDSRCHRF" "16" "FBP2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 50 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01804.cif" "Linear" "Free" "Free" "None" "L" "HA" "FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway." "1982.26" "C85H132N34O20S" "ELMNPQTVY" "R" "11.54" "7" "1" "6" "4" "4" "-141.88" "-7147" "1 hour" "2 min" "2 min" "30.63" "5500" "366.67" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " "10.1080/22221751.2022.2051753" "Anti-Anti-Influenza A virus" "DRAVPe01802" "RGAHIKGRWKSRCHRF" "16" "FBP" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus, Influenza B virus, SARS-CoV-2" "Orthomyxoviridae, Coronaviridae" "Plaque reduction assay" "[Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(IC50=3.9 μg/ml);##influenza A virus(H3N2): inhibition of viral replication in MDCK cells(IC50=1.6 μg/ml);##influenza B virus: inhibition of viral replication in MDCK cells(IC50=7.1 μg/ml);##SARS-CoV-2 HKU001a: inhibition of viral replication in Vero E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 B.1.1.63: inhibition of viral replication in Vero E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2 Delta: inhibition of viral replication in Vero E6 cells(IC50=3.9 μg/ml)." "[Ref.35259078]No significant haemolysis was observed when Turkey red blood cells (RBC) were treated with FBP." "[Ref.35259078]no significant cytotoxicity was detected in MDCK cells treated with 1 mg/ml of FBP." "No predicted structure available" "DRAVPe01802.cif" "Linear" "Free" "Free" "None" "L" "HA" "FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.the notable antiviral activity and fusion inhibition activity of FBP on SARS-CoV-2 could be attributed to the inhibition of FBP on endosomal acidification" "1995.34" "C87H139N35O18S" "DELMNPQTVY" "R" "12.01" "8" "0" "8" "4" "4" "-144.38" "-6830" "1 hour" "2 min" "2 min" "30.63" "5500" "366.67" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " "10.1080/22221751.2022.2051753" "Anti-Anti-Influenza A virus, Anti-Influenza B virus, Anti-SARS-CoV-2" "DRAVPe01801" "IPLRGAFINGRWDSQCHRFS" "20" "U5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=12.9 μg/ml);" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01801.cif" "Linear" "Free" "Free" "None" "L" "HA" "Bind to the HA stem of group 1 influenza A virus." "2360.68" "C105H158N34O27S" "EKMTVY" "R" "10.26" "4" "1" "3" "6" "7" "-47" "-4910" "20 hour" "30 min" ">10 hour" "63.5" "5500" "289.47" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " "10.1080/22221751.2022.2051753" "Anti-Anti-Influenza A virus" "DRAVPe01800" "FINGRWDSQCHRFSNGAIACA" "21" "U4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=6.6 μg/ml);" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01800.cif" "Linear" "Free" "Free" "None" "L" "HA" "Bind to the HA stem of group 1 influenza A virus." "2353.62" "C101H149N33O29S2" "EKLMPTVY" "A" "8.08" "3" "1" "2" "8" "8" "-21.43" "-4084" "1.1 hour" "3 min" "2 min" "51.43" "5625" "281.25" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " "10.1080/22221751.2022.2051753" "Anti-Anti-Influenza A virus" "DRAVPe01799" "WEDWVR" "6" "C6b" "Synthetic construct(derived from gp36 membrane proximal external region of FIV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50>50 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01799.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. " "889.97" "C42H55N11O11" "ACFGHIKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "3" "-151.67" "-2175" "2.8 hour" "3 min" "2 min" "48.33" "11000" "2200" "30240422" "PLoS One. 2018 Sep 21;13(9):e0204042" "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." "Structural basis of antiviral activity of peptides from MPER of FIV gp36" "10.1371/journal.pone.0204042" "Anti-FIV" "DRAVPe01798" "DWVRWI" "6" "C6a" "Synthetic construct(derived from gp36 membrane proximal external region of FIV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.06-0.15 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01798.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. " "874.01" "C43H59N11O9" "ACEFGHKLMNPQSTY" "W" "5.84" "1" "1" "0" "0" "4" "-18.33" "-1002" "1.1 hour" "3 min" ">10 hour" "113.33" "11000" "2200" "30240422" "PLoS One. 2018 Sep 21;13(9):e0204042" "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." "Structural basis of antiviral activity of peptides from MPER of FIV gp36" "10.1371/journal.pone.0204042" "Anti-FIV" "DRAVPe01797" "WEDWVRWI" "8" "C8" "Synthetic construct(derived from gp36 membrane proximal external region of FIV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "[Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.05-0.06 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01797.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. " "1189.34" "C59H76N14O13" "ACFGHKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-68.75" "-1450" "2.8 hour" "3 min" "2 min" "85" "16500" "2357.14" "30240422" "PLoS One. 2018 Sep 21;13(9):e0204042" "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." "Structural basis of antiviral activity of peptides from MPER of FIV gp36" "10.1371/journal.pone.0204042" "Anti-FIV" "DRAVPe01796" "XGSGSGVALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI" "42" "Chol-PEG4-VG" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0001 nM,IC50<0.0007 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50>10000 nM." "No predicted structure available" "DRAVPe01796.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 1 indicates cholesterol-PEG4 conjugated cysteine." "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4510.27" "C190H316N54O64" "CFHMQTY" "S" "5.05" "6" "7" "-1" "13" "14" "-38.33" "-8236" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01795" "XGSGSGVALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI" "42" "Chol-VG" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=1.7 ± 0.42 nM,IC50=0.06 ± 0.035 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50=9000 nM." "No predicted structure available" "DRAVPe01795.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 1 indicates cholesterol-conjugated cysteine." "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4510.27" "C190H316N54O64" "CFHMQTY" "S" "5.05" "6" "7" "-1" "13" "14" "-38.33" "-8236" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01794" "VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX" "42" "VG-PEG24-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0003 nM,IC50=0.007 ± 0.007 nM);##Nipah virus(NiV):inhibition of virus infection in Vero cells(IC90~2 nM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50=1300 nM." "No predicted structure available" "DRAVPe01794.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 42 indicates cholesterol-PEG24 conjugated cysteine." "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4510.27" "C190H316N54O64" "CFHMQTY" "S" "5.05" "6" "7" "-1" "13" "14" "-38.33" "-8236" "100 hour" ">20 hour" ">10 hour" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01792" "VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX" "42" "VG-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.26 nM,IC50=0.015 ± 0.07 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50+10000 nM." "No predicted structure available" "DRAVPe01792.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 42 indicates cholesterol-conjugated cysteine." "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4510.27" "C190H316N54O64" "CFHMQTY" "S" "5.05" "6" "7" "-1" "13" "14" "-38.33" "-8236" "100 hour" ">20 hour" ">10 hour" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01793" "VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX" "42" "VG-PEG4-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.007 nM,IC50=0.03 ± 0.04 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50=4500 nM." "No predicted structure available" "DRAVPe01793.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 42 indicates cholesterol-PEG4 conjugated cysteine." "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4510.27" "C190H316N54O64" "CFHMQTY" "S" "5.05" "6" "7" "-1" "13" "14" "-38.33" "-8236" "100 hour" ">20 hour" ">10 hour" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01791" "VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGC" "42" "VG" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV 3" "Paramyxoviridae" "Plaque reduction assay" "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=280 ± 247 nM,IC50=1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28344321]Vero cells: CC50>10000 nM." "No predicted structure available" "DRAVPe01791.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." "4502.08" "C193H323N55O66S" "FHMQTY" "S" "5.05" "6" "7" "-1" "14" "14" "-32.38" "-8108" "100 hour" ">20 hour" ">10 hour" "102.14" "5500" "134.15" "28344321" "Sci Rep. 2017 Mar 8;7:43610." "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" "Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides" "10.1038/srep43610" "Anti-HPIV 3" "DRAVPe01790" "SKVNGQSGRMEFFWTIAK" "18" "m15 /Leu17" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01790.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2086.4" "C94H144N26O26S" "CDHLPY" "FGKS" "9.99" "3" "1" "2" "6" "6" "-48.89" "-3109" "1.9 hour" ">20 hour" ">10 hour" "43.33" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01789" "SKVNGQSGRMEFFWTALK" "18" "m14 /lle16" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>10% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01789.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2086.4" "C94H144N26O26S" "CDHIPY" "FGKS" "9.99" "3" "1" "2" "6" "6" "-52.78" "-3109" "1.9 hour" ">20 hour" ">10 hour" "43.33" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01787" "SKVNGQSGRMAFFWTILK" "18" "m9 /Glu11" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01787.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2070.44" "C95H148N26O24S" "CDEHPY" "FGKS" "11.17" "3" "0" "3" "6" "7" "-8.33" "-1936" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01788" "SKVNGQSGRMEFAWTILK" "18" "m11 /Phe13" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01788.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2052.38" "C91H146N26O26S" "CDHPY" "GKS" "9.99" "3" "1" "2" "6" "6" "-43.33" "-2915" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01786" "SKVNGQSGRAEFFWTILK" "18" "m8 /Met10" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01786.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2068.36" "C95H146N26O26" "CDHMPY" "FGKS" "9.99" "3" "1" "2" "6" "7" "-38.33" "-2852" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01785" "SKVNGQAGRMEFFWTILK" "18" "m6 /Ser7" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~60% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01785.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2112.48" "C97H150N26O25S" "CDHPY" "FGK" "9.99" "3" "1" "2" "5" "7" "-23.33" "-2277" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01784" "SKVNGASGRMEFFWTILK" "18" "m5 /GIn6" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01784.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2071.42" "C95H147N25O25S" "CDHPQY" "FGKS" "9.99" "3" "1" "2" "6" "7" "-8.33" "-2063" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01783" "SKVAGQSGRMEFFWTILK" "18" "m4 /Asn4" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>70% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01783.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2085.45" "C96H149N25O25S" "CDHNPY" "FGKS" "9.99" "3" "1" "2" "5" "7" "-8.33" "-1953" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01782" "SKANGQSGRMEFFWTILK" "18" "m3 /Val3" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01782.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2100.42" "C95H146N26O26S" "CDHPVY" "FGKS" "9.99" "3" "1" "2" "6" "6" "-51.11" "-3021" "1.9 hour" ">20 hour" ">10 hour" "48.89" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01781" "SAVNGQSGRMEFFWTILK" "18" "m2 /Arg2 " "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~20% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01781.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2071.38" "C94H143N25O26S" "CDHPY" "FGS" "8.46" "2" "1" "1" "6" "7" "-6.11" "-2062" "1.9 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01780" "AKVNGQSGRMEFFWTILK" "18" "m1 /Ser1" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>20% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01780.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2112.48" "C97H150N26O25S" "CDHPY" "FGK" "9.99" "3" "1" "2" "5" "7" "-23.33" "-2277" "4.4 hour" ">20 hour" ">10 hour" "65" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Anti-Influenza A virus" "DRAVPe01779" "PxTXXLPX" "8" "Plitidepsin, Aplidine" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "antiviral assay" "[Ref.33495306]SARS-CoV-2:inhibition of replication In Vero E6 cells(IC50=0.70 nM,IC90=1.76 nM);inhibition of replication In hACE2-HEK293T cells(IC50=0.73 nM,IC90=0.88 nM);inhibition of replication In pneumocyte-like cells(IC50=1.62 nM,IC90=3.14 nM).##[Ref.35231500]SARS-CoV-2 D614G:inhibition of replication in Vero E6 cells(IC50=5.2 nM);##SARS-CoV-2 Delta:inhibition of replication in Vero E6 cells(IC50=3.9 nM);##SARS-CoV-2 Omicron:inhibition of replication in Vero E6 cells(IC50=4.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33495306]Vero E6 cells:CC10=0.36 nM,CC50=1.99 nM;hACE2-293T cells:CC10=2.00 nM,CC50>200 nM;pneumocyte-like cells:CC10=20.88 nM,CC50=65.43 nM." "No predicted structure available" "DRAVPe01779.cif" "Linear" "Pyruvoyl" "Free" "The 'X' at position 2 is N-methylleucine,position 4 is 4-amino-3-hydroxy-5-methyl-Heptanoic acid, position 5 is Hydroxyisovalerylpropionyl, and position 8 is N-methyl-4-methyl-tyrosine.There is a Sidechain-Mainchain Bond between position 3 and 8." "Mixed(D-meth-Leu2)" "Not found" "The antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A)." "871.84" "C20H26N4O2" "ACDEFGHIKMNQRSVWY" "X" "5.96" "0" "0" "0" "1" "1" "-1.25" "235" ">20 hour" ">20 hour" "?" "48.75" "0" "0" "35231500##33495306" "Antiviral Res. 2022 Apr;200:105270.##Science. 2021 Feb 26;371(6532):926-931. " "Sachse M, Tenorio R, Fernández de Castro I, Muñoz-Basagoiti J, Perez-Zsolt D, Raïch-Regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C.##White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, Garc" "Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.##Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. " "10.1016/j.antiviral.2022.105270##10.1126/science.abf4058" "Anti-SARS-CoV-2" "DRAVPe01778" "XxXVXAaXXXX" "11" "Alisporivir, Debio-025" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "plaque assay" "[Ref.32376613]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=0.46±0.04 µM,E90=3.10±1.40 μM).##[Ref.32568027]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=4.9±1.3 µM);##SARS-CoV:Inhibition of infection in Vero E6 cells(EC50=4.3±1.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32376613]Vero E6 cells:CC50>20µM." "No predicted structure available" "DRAVPe01778.cif" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 1 is alpha-aminobutyric acid,position 2 is N-methylalanine,the 'V' at position 3 is N-methylalanine,the 'X' at position 5,8,9 are N-methylleucine,the 'X' at position 10 is N-methylvaline and position 11 is N-methyl-(4R)-4-[(E)-but-2-enyl]-4-methyl-L-threonyl" "Mixed(D-Ala7,D-meth-Ala2)" "Not found" "Comment: No comments found on DRAMP database" "0" "C8H-2N2O-6" "CDEFGHIKLMNPQRSTWY" "X" "0" "0" "0" "0" "0" "2" "54.55" "585" "35.45" "0" "0" "32376613##32568027" "Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. ##J Gen Virol. 2020 Sep;101(9):925-940." "Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A.##Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ." "Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).##SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology." "10.1128/AAC.00876-20##10.1099/jgv.0.001453" "Anti-SARS-CoV-2" "DRAVPe01777" "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "35" "P3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Neutralizing assay" "[Ref.32482145]HCoV-19:inhibition of HCoV-19 S mediated cell–cell fusion(EC50=0.72 μM);neutralizing activities against pseudotype HCoV-19 virus(EC50=0.32 μM);inhibition of authentic HCoV-19 virus infection in Vero E6 cells(EC50=0.58 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01777.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Comment: No comments found on DRAMP database" "3893.41" "C168H287N47O58" "CFHMPTWY" "ILN" "4.36" "3" "6" "-3" "9" "15" "-8.29" "-5930" "20 hour" "30 min" ">10 hour" "142" "0" "0" "32482145" "Emerg Microbes Infect. 2020 Dec;9(1):1238-1241." "Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G, Yan J, Gao GF, Qi J, Wang Q. " "Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry." "10.1080/22221751.2020.1770631" "Anti-SARS-CoV-2" "DRAVPe01776" "RGAHIKGRWKSRCHRF" "16" "FBP" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Plaque reduction assay" "[Ref.35259078]A(H1N1)(IC50 = 3.9 μg/ml);A(H3N2)(IC50 = 1.6 μg/ml);FluB (IC50 = 7.1 μg/ml);##SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 μg/ml)." "[Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC)." "[Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50 > 1 mg/ml)." "No predicted structure available" "DRAVPe01776.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters." "1995.34" "C87H139N35O18S" "DELMNPQTVY" "R" "12.01" "8" "0" "8" "4" "4" "-144.38" "-6830" "1 hour" "2 min" "2 min" "30.63" "5500" "366.67" "35259078" "Emerg Microbes Infect. 2022 Dec;11(1):926-937." "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants." "10.1080/22221751.2022.2051753" "Anti-SARS-CoV-2" "DRAVPe01775" "SALEEQYKTFLDKFMHELEDLLYQLAL" "27" "P10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "plaque assay " "[Ref.33580154]SARS-CoV-2:95% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=42 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells." "No predicted structure available" "DRAVPe01775.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." "3288.76" "C152H231N33O46S" "CGINPRVW" "L" "4.35" "3" "6" "-3" "4" "11" "-20" "-3140" "1.9 hour" ">20 hour" ">10 hour" "108.52" "2980" "114.62" "33580154" "Commun Biol. 2021 Feb 12;4(1):197." "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." "Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection." "10.1038/s42003-021-01736-8" "Anti-SARS-CoV-2" "DRAVPe01774" "SALEEQYKTFLDKFMHELEDLLYQLSL" "27" "P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "plaque assay " "[Ref.33580154]SARS-CoV-2:93% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=53 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells." "No predicted structure available" "DRAVPe01774.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." "3304.76" "C152H231N33O47S" "CGINPRVW" "L" "4.35" "3" "6" "-3" "5" "10" "-29.63" "-3661" "1.9 hour" ">20 hour" ">10 hour" "104.81" "2980" "114.62" "33580154" "Commun Biol. 2021 Feb 12;4(1):197." "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." "Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection." "10.1038/s42003-021-01736-8" "Anti-SARS-CoV-2" "DRAVPe01773" "SALEEQLKTFLDKFMHELEDLLYQLAL" "27" "P8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "plaque assay " "[Ref.33580154]SARS-CoV-2:91% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=46 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells." "No predicted structure available" "DRAVPe01773.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." "3238.74" "C149H233N33O45S" "CGINPRVW" "L" "4.35" "3" "6" "-3" "3" "12" "-1.11" "-2634" "1.9 hour" ">20 hour" ">10 hour" "122.96" "1490" "57.31" "33580154" "Commun Biol. 2021 Feb 12;4(1):197." "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." "Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection." "10.1038/s42003-021-01736-8" "Anti-SARS-CoV-2" "DRAVPe01772" "SALEEQYKTFLDKFLHELEDLLYQLALAL" "29" "P7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "plaque assay " "[Ref.33580154]SARS-CoV-2:54% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50>1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01772.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." "3454.96" "C162H249N35O48" "CGIMNPRVW" "L" "4.35" "3" "6" "-3" "4" "14" "7.24" "-2210" "1.9 hour" ">20 hour" ">10 hour" "131.38" "2980" "106.43" "33580154" "Commun Biol. 2021 Feb 12;4(1):197." "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." "Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection." "10.1038/s42003-021-01736-8" "Anti-SARS-CoV-2" "DRAVPe01771" "RFDGKGLGIYQYMEEIEHAASRFAYFFYQHLA" "32" "Covid_extented_1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "virus neutralization assay" "[Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=5.76 ± 1.65 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=5.57 ± 4.04 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=7.37 ± 1.80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01771.cif" "Linear" "Acylation" "Amidation" "None" "D" "Not found" "The peptide acts as an inhibitor of the RBD–ACE2 interaction" "3859.33" "C181H253N45O48S" "CNPTVW" "AFY" "6.03" "5" "4" "1" "8" "12" "-33.13" "-4489" "1 hour" "2 min" "2 min" "61.25" "5960" "192.26" "34624194" "J Med Chem. 2021 Oct 28;64(20):14955-14967." "Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. " "Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2." "10.1021/acs.jmedchem.1c00655" "Anti-SARS-CoV-2" "DRAVPe01770" "LQTALYALMEEIHIAALEKTWTALRHQYT" "29" "Covid3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "virus neutralization assay" "[Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=6.56 ± 2.14 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=33.40 ± 10.75 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=11.13 ± 3.82 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01770.cif" "Linear" "Acylation" "Amidation" "None" "D" "Not found" "The peptide acts as an inhibitor of the RBD–ACE2 interaction " "3415.95" "C156H244N40O44S" "CDFGNPSV" "AL" "6.02" "4" "3" "1" "6" "13" "1.03" "-2369" "5.5 hour" "3 min" "2 min" "111.38" "8480" "302.86" "34624194" "J Med Chem. 2021 Oct 28;64(20):14955-14967." "Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. " "Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2." "10.1021/acs.jmedchem.1c00655" "Anti-SARS-CoV-2" "DRAVPe01769" "RVKR" "4" "CMK" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Plaque assay" "[Ref.33007239]SARS-CoV-2:inhibition of virus production in Vero E6 cells(IC50=0.057 µM).##[Ref.31683742]Virus:Zika virus (ZIKV):inhibition of virus release in Vero cells(IC50=18.59 µM);Japanese encephalitis virus (JEV):inhibition of virus release in BHK-21 cells(IC50=19.91 µM).##[Ref.23617302]Hepatitis B virus (HBV):Inhibition of HBeAg secretion in HepG2.2.15 cells(26±11% inhibition at 20 µM,21±13% Inhibition at 100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31683742]Vero cells:CC50=712.9 µM.##[Ref.33007239]Vero E6 cells:IC50=318.2 µM." "No predicted structure available" "DRAVPe01769.cif" "Linear" "Decanoyl(C10)" "chloromethylketone(CMK)" "None" "L" "Not found" "CMK blocks virus entry, but it further suppresses cleavage of spikes and the syncytium." "557.7" "C23H47N11O5" "ACDEFGHILMNPQSTWY" "R" "12.01" "3" "0" "3" "0" "1" "-217.5" "-3135" "1 hour" "2 min" "2 min" "72.5" "0" "0" "23617302##31683742##33007239" "Liver Int. 2013 Sep;33(8):1230-8. ##Viruses. 2019 Oct 31;11(11):1011.##Cell Rep. 2020 Oct 13;33(2):108254." "Pang YJ, Tan XJ, Li DM, Zheng ZH, Lei RX, Peng XM.##Imran M, Saleemi MK, Chen Z, Wang X, Zhou D, Li Y, Zhao Z, Zheng B, Li Q, Cao S, Ye J.##Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH." "Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.##Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage.##Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. " "10.1111/liv.12185##10.3390/v11111011##10.1016/j.celrep.2020.108254" "Anti-SARS-CoV-2" "DRAVPe01768" "PHSCN" "5" "ATN-161" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "ELISA" "[Ref.33102950]SARS-CoV-2:inhibition of virus replication In VeroE6 cells(IC50=3.16 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01768.cif" "Linear" "Acylation" "Amidation" "None" "L" "Not found" "The peptide inhibits the spike protein interaction with α5β1 integrin and the interaction between α5β1 integrin and ACE2." "556.59" "C21H32N8O8S" "ADEFGIKLMQRTVWY" "CHNPS" "7.12" "1" "0" "1" "3" "0" "-132" "-1342" ">20 hour" ">20 hour" "?" "0" "0" "0" "33102950" "JACC Basic Transl Sci. 2021 Jan;6(1):1-8." "Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ." "The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection." "10.1016/j.jacbts.2020.10.003" "Anti-SARS-CoV-2" "DRAVPe01767" "ANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ" "42" "SARS-CoV-2 HR1P" "Synthetic construct" "P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "Cell-cell fusion assay" "[Ref.32047258]SARS-CoV-2(No inhibition of cell-cell fusion up to 40 µM in Huh-7 cells,No inhibition of infection up to 40 µM in 293T/ACE2 cells)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01767.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection." "4386.89" "C187H314N56O65" "CEHMPRWY" "AQ" "8.54" "3" "2" "1" "14" "17" "-21.9" "-6039" "4.4 hour" ">20 hour" ">10 hour" "100" "0" "0" "32047258" "Cell Mol Immunol. 2020 Jul;17(7):765-767." "Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L." "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." "10.1038/s41423-020-0374-2" "Anti-SARS-CoV-2" "DRAVPe01766" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC" "42" "EK1-GSGSGC" "Synthetic construct" "Q8BB25" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=293±60 nM,IC90>900 nM),inhibition of infection in Vero E6 cells(IC50~ 41 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=261±136 nM,IC90=892±100 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=286±104 nM,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=194±107 nM,IC90=893±77 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50>1000 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 2 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=36±5 nM,IC90>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33082259]Human embryonic kidney HEK293T cells:<5% Cytotoxicity at 10 µM;Vero E6 cells:18% Cytotoxicity at 10 µM." "No predicted structure available" "DRAVPe01766.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. " "4780.43" "C211H341N49O72S2" "HPRW" "EL" "4.36" "5" "10" "-5" "12" "13" "-37.86" "-6573" "1.9 hour" ">20 hour" ">10 hour" "102.14" "2980" "72.68" "33082259" "mBio. 2020 Oct 20;11(5):e01935-20." "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M." "Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain." "10.1128/mBio.01935-20" "Anti-SARS-CoV-2" "DRAVPe01765" "SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC" "42" "MERS-CoV-HR2P-GSGSGC" "Synthetic construct" "R9UQ53,K9N5Q8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50>650 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 36 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=1000 nM,IC90>1000 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50>1000,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50>700 nM,IC90>1000 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=417±180 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 4 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=40±34 nM,IC90>700 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33082259]Human embryonic kidney HEK293T cells:<10% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 10 µM." "No predicted structure available" "DRAVPe01765.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. " "4590.23" "C200H331N49O69S2" "FHPRW" "L" "4.18" "2" "5" "-3" "17" "14" "10.48" "-3597" "1.9 hour" ">20 hour" ">10 hour" "118.33" "2980" "72.68" "33082259" "mBio. 2020 Oct 20;11(5):e01935-20." "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M." "Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain." "10.1128/mBio.01935-20" "Anti-SARS-CoV-2" "DRAVPe01764" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC" "42" "SARS-CoV-2-S(1168–1203)-GSGSGC" "Synthetic construct" "P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=10±8 nM,IC90=98±57 nM),inhibition of infection in Vero E6 cells(IC50~ 6 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=8±4 nM,IC90=96±50 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=6±4 nM,IC90=75±42 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=9±7 nM,IC90=78±59 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=35±10 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 3 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=7±5 nM,IC90=43±6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33082259]Human embryonic kidney HEK293T cells:18% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 1 µM,30% Cytotoxicity at 10 µM;Human airway epithelial cells:25% Cytotoxicity at 1 µM." "No predicted structure available" "DRAVPe01764.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. " "4456.95" "C187H316N54O69S" "FHMPTWY" "ILNS" "4.2" "3" "7" "-4" "15" "15" "-15.95" "-7072" "1.1 hour" "3 min" ">10 hour" "118.33" "0" "0" "33082259##33597220" "mBio. 2020 Oct 20;11(5):e01935-20.##Science. 2021 Mar 26;371(6536):1379-1382." "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.##de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, Haagmans BL, Herfst S, Stearns KN, Drew-Bear J, Biswas S, Rockx B, McGill G, Dorrello NV, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M." "Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.##Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets." "10.1128/mBio.01935-20##10.1126/science.abf4896" "Anti-SARS-CoV-2" "DRAVPe01763" "NGAICWGPCPTAFRQIGNCGRFRVRCCRIR" "30" "8P9R(branched P9R)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Plaque reduction assay" "[Ref.33750821]SARS-CoV-2:inhibition of replication in high salt condition(IC50 = 0.3 μg/ml)" "[Ref.33750821]No obvious hemolysis was observed when turkey red blood cells were treated at 200 μg/ml." "[Ref.33750821]Vero-E6 cells:the cytotoxicity indicated that TC50 of 8P9R was higher than 200 μg/ml." "No predicted structure available" "DRAVPe01763.cif" "Branched" "Free" "Free" "None" "L" "Not found" "Have dual-antiviral mechanisms of cross-linking viruses to stop viral entry (mediated by TMPRSS2 for SARS-CoV-2) and of reducing endosomal acidification to inhibit viral entry through endocytic pathway." "3412.05" "C144H232N52O35S5" "DEHKLMSY" "R" "10.46" "6" "0" "6" "12" "9" "-15" "-7004" "1.4 hour" "3 min" ">10 hour" "55.33" "5750" "198.28" "33750821" "Nat Commun. 2021 Mar 9;12(1):1517. " "Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY." "Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2." "10.1038/s41467-021-21825-w" "Anti-SARS-CoV-2" "DRAVPe01762" "NGAICWGPCPTAFRQIGNCGRFRVRCCRIR" "30" "MBD-4 (11-40) (P9 [H21R,K23R,K28R], P9R)" "Synthetic construct" "P82019" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "6M56" "SARS-CoV-2" "Coronaviridae" "Plaque reduction assay" "[Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=0.9 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=4.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=22 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=5.7 µg/ml);##Human parainfluenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=0.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=0.9 µg/ml)." "[Ref.32843628]P9R did not cause the hemolysis of Chicken red blood cells." "[Ref.32843628]The CC50 of P9R was >300 μg/ml for MDCK, VeroE6 and A549 cells." "No predicted structure available" "DRAVPe01762.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Mechanistic studies show that positively charged P9R broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. " "3412.05" "C144H232N52O35S5" "DEHKLMSY" "R" "10.46" "6" "0" "6" "12" "9" "-15" "-7004" "1.4 hour" "3 min" ">10 hour" "55.33" "5750" "198.28" "32843628" "Nat Commun. 2020 Aug 25;11(1):4252." "Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY." "A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2." "10.1038/s41467-020-17986-9" "Anti-SARS-CoV-2" "DRAVPe01761" "NGAICWGPCPTAFRQIGNCGHFKVRCCKIR" "30" "MBD-4 (11-40)(P9)" "Synthetic construct" "P82019" "Experimentally Validated" "10090" "Defb4" "AF155882.2" "Not available" "pfam00711" "AF155882" "mRNA" "Chromosome 8, Location: NC_000074.7 (19213172..19245342)" "6M56" "SARS-CoV-2" "Coronaviridae" "Plaque reduction assay" "[Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=2.4 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=6.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=8.8 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=34 µg/ml);##Human parainfluenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=1.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=3.3 µg/ml).##[Ref.26911565]Human Influenza A Virus H1N1(IC50=1.2 µg/ml);Human Influenza A Virus H3N2(IC50=1.2 µg/ml);Human Influenza A Virus H5N1(IC50=2.4 µg/ml);Human Influenza A Virus H7N7(IC50=0.8 µg/ml);Human Influenza A Virus H7N9(IC50=4.6 µg/ml);MERS-CoV(IC50=4.8 µg/ml);SARS-CoV(IC50=4.8 µg/ml)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26911565]Cytotoxicity against Madin-Darby canine kidney cells(TC50=380 μg/ml)." "No predicted structure available" "DRAVPe01761.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Mechanistic studies show that positively charged P9 broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. " "3336.98" "C144H227N47O35S5" "DELMSY" "C" "9.41" "6" "0" "6" "12" "9" "-6.67" "-4104" "1.4 hour" "3 min" ">10 hour" "55.33" "5750" "198.28" "26911565##32843628" "Sci Rep. 2016 Feb 25;6:22008. ##Nat Commun. 2020 Aug 25;11(1):4252." "Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin DY, Yuen KY, Zheng BJ.##Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY." "A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. ##A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2." "10.1038/srep22008##10.1038/s41467-020-17986-9" "Anti-SARS-CoV-2" "DRAVPe01760" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "36" "2019-nCoV-HR2P(SARS-CoV-2-S(1168-1203),SARS-HR2P)" "Synthetic construct" "Q5DIC5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "Cell-cell fusion assay" "[Ref.32047258]SARS-CoV-2:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.18 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.98 µM).##[Ref.30989115]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.52±0.11 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2.81 µM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##CoV-WIV1:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=2.73 µM);##CoV-Rs3367:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.05 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01760.cif" "Linear" "Free" "Free" "None" "L" "membrane" "2019-nCoV HR1 and HR2 regions are able to interact with each other to form 6-HB and suggest that 2019-nCoV-HR2P may inhibit 2019-nCoV fusion with and entry into the target cell." "4008.5" "C172H292N48O61" "CFHMPTWY" "ILN" "4.2" "3" "7" "-4" "9" "15" "-17.78" "-6802" "1.1 hour" "3 min" ">10 hour" "138.06" "0" "0" "30989115##32047258" "Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767." "Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L.##Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L." "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.##Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." "10.1126/sciadv.aav4580##10.1038/s41423-020-0374-2" "Anti-SARS-CoV-2" "DRAVPe01758" "AWDFGSLGGVFTSIGKALHQVFGAIYGAA" "29" "DENV2 Ep (419-447)" "Synthetic construct" "Q9WDA6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV-2" "Flaviviridae" "Plaque assay" "[Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~250µM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01758.cif" "Linear" "Free" "Free" "None" "L" "low-pH endosome" "an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem" "2941.34" "C139H202N34O37" "CEMNPR" "G" "6.79" "2" "1" "1" "10" "15" "73.79" "1974" "4.4 hour" ">20 hour" ">10 hour" "91.03" "6990" "249.64" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-Anti-DENV-2" "DRAVPe01759" "GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG" "38" "SARS-CoV-S (1149–1186)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Fusion inhibition assay" "[Ref.15158473]SARS-CoV: inhibition of SARS-CoV cytopathic effect in Vero E6 cells ( synthetic HR2-38 IC50=0.5-5nM, GST-HR2-38 IC50=66.2nM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01759.cif" "Linear" "Free" "Free" "None" "L" "GST" "as GST-fusion polypeptide" "4122.6" "C176H298N50O63" "CFHMPTWY" "ILN" "4.2" "3" "7" "-4" "11" "15" "-18.95" "-6614" "30 hour" ">20 hour" ">10 hour" "130.79" "0" "0" "15158473" "Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8." "Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF." "Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors." "10.1016/j.bbrc.2004.04.141" "Anti-SARS-CoV" "DRAVPe01757" "AWDFGSLGGVFTSIGKALHQVFGGAFGAA" "29" "DENV2 Ep (419-447)[A24G,I25A,Y26F]" "Synthetic construct" "Q9WDA6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV-2" "Flaviviridae" "Plaque assay" "[Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~2µM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01757.cif" "Linear" "Free" "Free" "None" "L" "low-pH endosome" "an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem" "2869.23" "C135H194N34O36" "CEMNPRY" "G" "6.79" "2" "1" "1" "10" "15" "71.03" "1888" "4.4 hour" ">20 hour" ">10 hour" "77.59" "5500" "196.43" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-Anti-DENV-2" "DRAVPe01756" "ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL" "33" "SARS-CoV Sgp (471-503)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16153058]SARS-CoV(Severe acute respiratory syndrome): inhibition of SARS-CoV infction in Vero cells (EC50=41.6µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01756.cif" "Linear" "Free" "Free" "None" "L" "not found" "block the binding between the RBD and angiotensin-convertingenzyme 2, resulting in the inhibition of SARS-CoV entrance into host cells in vitro" "3864.39" "C184H260N40O50S" "HKM" "Y" "4.37" "1" "2" "-1" "15" "12" "16.67" "-1016" "4.4 hour" ">20 hour" ">10 hour" "88.48" "12950" "404.69" "16153058" "J Comb Chem. 2005 Sep-Oct;7(5):648-56." "Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A, Cui L, Fan B, Guo F, Rao S, Jiang C, Li Q, Sun M, He W, Liu G." "Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library." "10.1021/cc0500607" "Anti-SARS-CoV" "DRAVPe01755" "SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL" "36" "MERS-CoV-HR2P [T1263E,L1267R]" "Synthetic construct" "K9N5Q8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Cell–cell fusion" "[Ref.24473083]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of cell–cell fusion infection in Huh-7 and 293T/MERS/EGFP cells (IC50=0.93±0.15µM); inhibition of MERS-CoV infection in Vero cells (IC50=0.6µM); inhibition of MERS-CoV infection in Calu-3 cells (IC50=0.6µM); inhibition of MERS-CoV infection in HFL cells (IC50=13.9µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24473083]HR2P has low or no in vitro toxic effect." "No predicted structure available" "DRAVPe01755.cif" "Linear" "Free" "Free" "None" "L" "HR1 domain" "interact with the viral HR1 domain to form heterologous 6-HB and block viral fusion coreformation, resulting in inhibition of MERS-CoV S protein-mediated membrane fusion." "4212.82" "C186H308N46O62S" "CFGHPW" "L" "4.36" "3" "6" "-3" "10" "13" "-17.78" "-5735" "1.9 hour" ">20 hour" ">10 hour" "127.22" "2980" "85.14" "24473083" "Nat Commun. 2014;5:3067." "Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S." "Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor." "10.1038/ncomms4067" "Anti-MERS-CoV" "DRAVPe01754" "LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL" "35" "MERS-S (1252-1286)" "Synthetic construct" "K9N5Q8##R9UQ53" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV PsV" "Coronaviridae" "pseudovirus entry inhibition assay" "[Ref.24067982]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of MERS-CoV PsV infection in 293T/Huh7 cells (EC50~3.013µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01754.cif" "Linear" "Free" "Free" "None" "L" "membrane" "inhibit MERS-CoV fusion and entry by using a pseudotyped-virus system" "4054.71" "C182H302N42O59S" "CFGHPRW" "L" "4.18" "2" "5" "-3" "10" "14" "15.71" "-2987" "5.5 hour" "3 min" "2 min" "142" "2980" "87.65" "24067982" "J Virol. 2013 Dec;87(24):13134-40." "Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF." "Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus." "10.1128/JVI.02433-13" "Anti-MERS-CoV" "DRAVPe01753" "RIQQIEQKIHHIEQRIQQIEQRISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL" "59" "T21N36" "Synthetic construct" "A1YNW7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV-1" "Retroviridae" "Cell-cell fusion assay" "[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=81.8±5.69nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01753.cif" "Linear" "Acetylation" "Free" "None" "L" "gp41" "function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds" "7070.23" "C312H526N100O87" "CDFMPY" "Q" "10.78" "10" "4" "6" "6" "24" "-45.25" "-12299" "1 hour" "2 min" "2 min" "133.9" "5500" "94.83" "31932193" "Bioorg Med Chem. 2020 Feb 15;28(4):115214." "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." "Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection." "10.1016/j.bmc.2019.115214" "Anti-HIV-1" "DRAVPe01752" "RIQQIEQKIHHIEQRIQQIEQRAIEAQQHLLQLTVWGIKQLQARIL" "46" "T21N23" "Synthetic construct" "None" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV-1" "Retroviridae" "Cell-cell fusion assay" "[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=38.9±35.8nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01752.cif" "Linear" "Acetylation" "Free" "None" "L" "gp41" "function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds" "5605.54" "C249H417N79O68" "CDFMNPSY" "Q" "9.97" "9" "4" "5" "2" "19" "-52.83" "-9943" "1 hour" "2 min" "2 min" "131.52" "5500" "122.22" "31932193" "Bioorg Med Chem. 2020 Feb 15;28(4):115214." "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." "Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection." "10.1016/j.bmc.2019.115214" "Anti-HIV-1" "DRAVPe01751" "RIQQIEQKIHHIEQRIQQIEQLLQLTVWGIKQLQARIL" "38" "T21N17" "Synthetic construct" "None" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Cell-cell fusion assay" "[Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=251±41.1nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01751.cif" "Linear" "Acetylation" "Free" "None" "L" "gp41" "function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds" "4671.52" "C210H354N64O56" "CDFMNPSY" "Q" "9.98" "7" "3" "4" "2" "16" "-37.37" "-7050" "1 hour" "2 min" "2 min" "143.68" "5500" "148.65" "31932193" "Bioorg Med Chem. 2020 Feb 15;28(4):115214." "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." "Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection." "10.1016/j.bmc.2019.115214" "Anti-HIV-1" "DRAVPe01750" "LHQNIVDVQYMYGLS" "15" "HCV gp (696–710), E2-79" "Synthetic construct" "Q99IB8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "HCV infection assay" "[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM" "No predicted structure available" "DRAVPe01750.cif" "Linear" "Free" "Free" "None" "L" "Envelope protein" "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." "1780.03" "C80H122N20O24S" "ACEFKPRTW" "LQVY" "5.08" "1" "1" "0" "5" "5" "9.33" "-865" "5.5 hour" "3 min" "2 min" "116.67" "2980" "212.86" "28638089" "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "10.1038/s41598-017-04274-8" "Anti-HCV" "DRAVPe01749" "GLLHLHQNIVDVQYM" "15" "HCV gp (692–706), E2-78" "Synthetic construct" "Q99IB8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "HCV infection assay" "[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM" "No predicted structure available" "DRAVPe01749.cif" "Linear" "Free" "Free" "None" "L" "Envelope protein" "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." "1780.07" "C80H126N22O22S" "ACEFKPRSTW" "L" "5.97" "2" "1" "1" "3" "6" "27.33" "-485" "30 hour" ">20 hour" ">10 hour" "142.67" "1490" "106.43" "28638089" "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "10.1038/s41598-017-04274-8" "Anti-HCV" "DRAVPe01748" "FGCTWMNSTGFTKTC" "15" "HCV gp (552–566), E2-43" "Synthetic construct" "Q99IB8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "HCV infection assay" "[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM" "No predicted structure available" "DRAVPe01748.cif" "Linear" "Free" "Free" "None" "L" "Envelope protein" "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." "1683.93" "C73H106N18O22S3" "ADEHILPQRVY" "T" "8.06" "1" "0" "1" "10" "3" "-1.33" "-1079" "1.1 hour" "3 min" "2 min" "0" "5625" "401.79" "28638089" "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "10.1038/s41598-017-04274-8" "Anti-HCV" "DRAVPe01747" "QGSWFGCTWMNSTGF" "18" "HCV gp (548–562), E2-42" "Synthetic construct" "Q99IB8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "HCV infection assay" "[Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM" "No predicted structure available" "DRAVPe01747.cif" "Linear" "Free" "Free" "None" "L" "Envelope protein" "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." "1708.88" "C77H101N19O22S2" "ADEHIKLPRVY" "G" "5.52" "0" "0" "0" "9" "4" "-20" "-705" "0.8 hour" "10 min" ">10 hour" "0" "11000" "785.71" "28638089" "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." "A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2." "10.1038/s41598-017-04274-8" "Anti-HCV" "DRAVPe01746" "VEPGQLKLNWFKK" "13" "P7(DENV-2 gp (662-674))" "Synthetic construct" "P14340" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV-1, DENV-2" "Flaviviridae" "Plaque assay" "[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 6% inhibition at 40 μM,55± 12% inhibition at 20 μM,41± 13% inhibition at 10 μM,IC50=12.86±5.96µM);##DENV-1(dengue virus serotype 1): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 12% inhibition at 40 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM" "No predicted structure available" "DRAVPe01746.cif" "Linear" "Free" "Free" "None" "L" "β3 integrin" "might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin)." "1586.9" "C76H119N19O18" "ACDHIMRSTY" "K" "9.7" "3" "1" "2" "2" "5" "-80.77" "-1551" "100 hour" ">20 hour" ">10 hour" "82.31" "5500" "458.33" "29709564" "Antiviral Res. 2018 Jul;155:20-27." "Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J." "Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin." "10.1016/j.antiviral.2018.04.018" "Anti-Anti-DENV-1, Anti-Anti-DENV-2" "DRAVPe01745" "CKIPFEIMDLEKRHV" "15" "P4(DENV-2 gp (613-627))" "Synthetic construct" "P14340" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV-2" "Flaviviridae" "Plaque assay" "[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(70 ± 9% inhibition at 40 μM,44 ± 10% inhibition at 20 μM,40± 6% inhibition at 10 μM,IC50=19.08±2.52µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM" "No predicted structure available" "DRAVPe01745.cif" "Linear" "Free" "Free" "None" "L" "β3 integrin" "might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin)." "1858.25" "C83H136N22O22S2" "AGNQSTWY" "EIK" "6.75" "4" "3" "1" "1" "5" "-22.67" "-2761" "1.2 hour" ">20 hour" ">10 hour" "97.33" "0" "0" "29709564" "Antiviral Res. 2018 Jul;155:20-27." "Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J." "Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin." "10.1016/j.antiviral.2018.04.018" "Anti-Anti-DENV-2" "DRAVPe01744" "DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE" "39" "MHV-S (1216-1254)" "Synthetic construct" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM);##MHV(mouse hepatitis virus): inhibition of MHV infection in Vero 118 cells (EC50=0.9±0.1µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01744.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "4644.31" "C207H337N51O67S" "CGHPW" "L" "4.51" "5" "8" "-3" "10" "14" "-42.56" "-7826" "1.1 hour" "3 min" ">10 hour" "120" "2980" "78.42" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01742" "ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "60" "SARS-CoV-S (1134-1185)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=34±4.0µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01742.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "6817.53" "C298H478N78O104" "CMW" "LDE" "4.27" "7" "14" "-7" "15" "21" "-56.17" "-13509" "1 hour" "30 min" ">10 hour" "107.17" "1490" "25.25" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01743" "NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT" "46" "SARS-CoV-S (935-980)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01743.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "5040.71" "C218H369N63O73" "CHMPWY" "L" "4.86" "4" "5" "-1" "13" "20" "-0.43" "-7678" "1.4 hour" "3 min" ">10 hour" "127.17" "0" "0" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01741" "ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "68" "SARS-CoV-S (1134-1193)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=17±3.0µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01741.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "7827.69" "C346H549N89O117" "CMW" "ELDK" "4.46" "9" "15" "-6" "18" "22" "-69.12" "-15296" "1 hour" "30 min" ">10 hour" "100.29" "4470" "66.72" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01740" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "40" "SARS-CoV-S (1150-1189)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01740.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "4486.01" "C194H323N53O68" "CFHMPTW" "EILN" "4.33" "4" "8" "-4" "11" "15" "-38.75" "-7958" "1.1 hour" "3 min" ">10 hour" "124.25" "1490" "38.21" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01739" "LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "56" "SARS-CoV-S (1134-1189)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50>50µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01739.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "6317.03" "C277H446N74O94" "CMW" "LDN" "4.5" "7" "11" "-4" "16" "19" "-54.82" "-11645" "5.5 hour" "3 min" "2 min" "107.86" "2980" "54.18" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01738" "ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "64" "SARS-CoV (1126-1189)[F5P]" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=43±6.4µM);##MHV(mouse hepatitis virus): inhibition of MHV infection in Vero 118 cells (EC50>50µM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01738.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "7244.99" "C316H507N83O111" "CMW" "ELD" "4.34" "8" "15" "-7" "17" "20" "-73.75" "-14963" "1 hour" "30 min" ">10 hour" "100.47" "2980" "47.3" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01737" "PKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "60" "SARS-CoV (1130-1189)[F1P]" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV, MHV" "Coronaviridae" "Infection inhibition assay" "[Ref.15150417]SARS-CoV: inhibition of SARS-CoV infection in Vero 118 cells (EC50=24±2.8µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01737.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits virus infection by interfering with six-helix bundle formation(fusion inhibitor)." "6800.55" "C298H479N79O102" "CMW" "ELDKN" "4.49" "8" "13" "-5" "16" "19" "-72" "-13562" ">20 hour" ">20 hour" "?" "100.67" "2980" "50.51" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV, Anti-MHV" "DRAVPe01736" "DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI" "48" "SARS-Cov-S (1145-1192)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV PsV" "Coronaviridae" "HIV‐luc/SARS Pseudotyped Virus Entry Inhibition Assay" "[Ref.18442051]SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells (EC50=2.15μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01736.cif" "Linear" "Free" "Free" "None" "L" "not found" "No machanism information found in the reference(s) presented in this entry" "5390" "C235H384N62O82" "CFHMPTW" "IL" "4.11" "4" "10" "-6" "13" "18" "-31.67" "-8788" "1.1 hour" "3 min" ">10 hour" "125.83" "2980" "63.4" "18442051" "J Cell Biochem. 2008 Aug 15;104(6):2335-47." "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM." "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors." "10.1002/jcb.21790" "Anti-SARS-CoV" "DRAVPe01735" "YENQKQIANQFNKAISQIQESLTTTSTA" "28" "SARS-Cov-S (899-926)" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV PsV" "Coronaviridae" "HIV‐luc/SARS Pseudotyped Virus Entry Inhibition Assay" "[Ref.18442051]SARS-CoV PsV: inhibition of HIV-luc/SARS PsV infection in Vero-E6 cells (EC50=1.16μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01735.cif" "Linear" "Free" "Free" "None" "L" "not found" "No machanism information found in the reference(s) presented in this entry" "3157.44" "C135H218N38O49" "CDGHMPRVW" "Q" "6.14" "2" "2" "0" "11" "8" "-85" "-6487" "2.8 hour" "10 min" "2 min" "66.43" "1490" "55.19" "18442051" "J Cell Biochem. 2008 Aug 15;104(6):2335-47." "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM." "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors." "10.1002/jcb.21790" "Anti-SARS-CoV" "DRAVPe01733" "GNHILSLVQNAPYGLYFIHFSW" "22" "MHV (1096–1117)[Y1117W]" "Synthetic construct" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MHV" "Plaque reduction assay" "[Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(22% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on L2 cells" "No predicted structure available" "DRAVPe01733.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2576.94" "C125H174N30O30" "CDEKMRT" "L" "6.92" "2" "0" "2" "8" "10" "34.55" "540" "30 hour" ">20 hour" ">10 hour" "106.36" "8480" "403.81" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-MHV" "DRAVPe01734" "GYFVQDDGEWKFTGSSYYY" "19" "MHV (1144–1162)" "Synthetic construct" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MHV" "Plaque reduction assay" "[Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(98% inhibition at 30 Μm, IC50=4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on L2cells" "No predicted structure available" "DRAVPe01734.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2312.43" "C110H138N22O34" "ACHILMNPR" "Y" "4.03" "1" "3" "-2" "10" "4" "-93.16" "-3012" "30 hour" ">20 hour" ">10 hour" "15.26" "11460" "636.67" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-MHV" "DRAVPe01732" "AACEVAKNLNESLIDLQELGKYEQYIKW" "28" "AAC-SARS-CoV (1170–1194)" "Synthetic construct" "Q19QX0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(42% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells" "No predicted structure available" "DRAVPe01732.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "3269.72" "C147H230N36O46S" "FHMPRT" "EL" "4.59" "3" "5" "-2" "7" "11" "-41.43" "-3711" "4.4 hour" ">20 hour" ">10 hour" "104.64" "8480" "314.07" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01731" "GVFVFNGTSWFITQRNFFS" "19" "SARS-CoV (1075–1093)" "Synthetic construct" "Q19QX0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(83% inhibition at 30 μM,IC50~2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells" "No predicted structure available" "DRAVPe01731.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2254.53" "C109H148N26O27" "ACDEHKLMPY" "F" "9.75" "1" "0" "1" "8" "9" "37.89" "-1357" "30 hour" ">20 hour" ">10 hour" "51.05" "5500" "305.56" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01730" "GYHLMSFPQAAPHGVVFLHVTW" "22" "SARS-CoV (1028–1049)[Y1049W]" "Synthetic construct" "Q19QX0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(90% inhibition at 30 μM,IC50~2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells" "No predicted structure available" "DRAVPe01730.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2607.98" "C120H166N30O26S" "CDEIKNR" "HV" "7.02" "3" "0" "3" "5" "10" "45.65" "1247" "30 hour" ">20 hour" ">10 hour" "80.43" "6990" "317.73" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01729" "ATAGWTFGAGAALQIPFAMQMAY" "23" "SARS-CoV (864-886)" "Synthetic construct" "Q19QX0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(39% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells" "No predicted structure available" "DRAVPe01729.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2374.76" "C110H160N26O29S2" "CDEHKNRSV" "A" "5.57" "0" "0" "0" "6" "12" "73.48" "2196" "4.4 hour" ">20 hour" ">10 hour" "64.35" "6990" "317.73" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01727" "TLKPIFKLPLGINITNFR" "18" "SARS-CoV-S (215-232), peptide 9626" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV PsV" "Coronaviridae" "western blot" "[Ref.19853613]SARS-COV: inhibition of SARS-CoV/HIV PsV virus infection in 293T/ACE2 cells (IC50=11µM); inhibition of SARS-CoV/HIV PsV virus entry in 293T/ACE2 cells(80% at 50µM) " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01727.cif" "Linear" "Free" "Free" "None" "L" "not found" "Presumably inhibit virus entry by binding to Spike protein, hACE2, or an unknown co-receptor." "2085.56" "C100H165N25O23" "ACDEHMQSVWY" "IL" "11.17" "3" "0" "3" "5" "8" "34.44" "-802" "7.2 hour" ">20 hour" ">10 hour" "130" "0" "0" "19853613" "J Mol Biol. 2009 Dec 11;394(4):600-5." "Guo Y, Tisoncik J, McReynolds S, Farzan M, Prabhakar BS, Gallagher T, Rong L, Caffrey M." "Identification of a new region of SARS-CoV S protein critical for viral entry." "10.1016/j.jmb.2009.10.032" "Anti-SARS-CoV PsV" "DRAVPe01728" "MWKTPTLKYFGGFNFSQIL" "19" "SARS-CoV (770-788)[Y771W]" "Synthetic construct" "Q19QX0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque reduction assay" "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(58% inhibition at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells" "No predicted structure available" "DRAVPe01728.cif" "Linear" "Free" "Free" "None" "L" "cell membrane" "inhibits viral entry through coiled coil interactions." "2278.7" "C111H160N24O26S" "ACDEHRV" "F" "9.7" "2" "0" "2" "7" "7" "4.21" "-170" "30 hour" ">20 hour" ">10 hour" "61.58" "6990" "388.33" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein." "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01726" "QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE" "46" "N46eg(SARS-CoV (902-947)[K2N,I4S,N9Q,A11E,Q16N,S18V,S23N,A25S,V32D,A37N,A39S,V44Q,Q46E])" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "cell fusion inhibition assay" "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=5.07 ± 0.17 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM." "No predicted structure available" "DRAVPe01726.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Binding to the HR2 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." "5205.59" "C216H356N66O83" "CHMPRWY" "Q" "4.51" "3" "5" "-2" "18" "11" "-119.13" "-13570" "0.8 hour" "10 min" ">10 hour" "74.13" "0" "0" "18983873" "Antiviral Res. 2009 Jan;81(1):82-7." "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors." "10.1016/j.antiviral.2008.10.001" "Anti-SARS-CoV" "DRAVPe01725" "QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ" "46" "N46(SARS-CoV (902-947))" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "cell fusion inhibition assay" "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=3.97 ± 1.40 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM." "No predicted structure available" "DRAVPe01725.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Binding to the HR2 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." "5027.67" "C216H366N64O73" "CHMPRWY" "Q" "9.53" "4" "2" "2" "14" "17" "-45.65" "-7939" "0.8 hour" "10 min" ">10 hour" "97.61" "0" "0" "18983873" "Antiviral Res. 2009 Jan;81(1):82-7." "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors." "10.1016/j.antiviral.2008.10.001" "Anti-SARS-CoV" "DRAVPe01723" "GINASVVNIQKEIDRLNEVAKNLNESLIDL" "30" "P4(SARS-CoV (1153–1182))" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "cell fusion inhibition assay" "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.80 ± 0.21 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.17 ± 0.24 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM." "No predicted structure available" "DRAVPe01723.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." "3322.76" "C143H245N41O49" "CFHMPTWY" "N" "4.51" "3" "5" "-2" "8" "13" "-11.33" "-5339" "30 hour" ">20 hour" ">10 hour" "139.67" "0" "0" "18983873" "Antiviral Res. 2009 Jan;81(1):82-7." "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors." "10.1016/j.antiviral.2008.10.001" "Anti-SARS-CoV" "DRAVPe01724" "GINASVVNIQKEIDRLNEVAKNL" "23" "P6(SARS-CoV (1153–1175))" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "cell fusion inhibition assay" "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=1.04 ± 0.22 μM); inhibition of SARS-CoV infection in Vero-E6 cells (IC50=2.28 ± 0.81 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM." "No predicted structure available" "DRAVPe01724.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." "2537.9" "C109H189N33O36" "CFHMPTWY" "N" "6.18" "3" "3" "0" "6" "10" "-18.26" "-4258" "30 hour" ">20 hour" ">10 hour" "131.3" "0" "0" "18983873" "Antiviral Res. 2009 Jan;81(1):82-7." "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors." "10.1016/j.antiviral.2008.10.001" "Anti-SARS-CoV" "DRAVPe01722" "GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "37" "P1(SARS-CoV (1153-1189))" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "cell fusion inhibition assay" "[Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.62 ± 0.20 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.04 ± 0.06 μM).##[Ref.15043961]SARS-CoV:inhibition of the cytopathic effect in Vero E6 cells(IC50~19 μM/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM." "No predicted structure available" "DRAVPe01722.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." "4170.69" "C181H302N50O62" "CFHMPTW" "ELN" "4.49" "4" "7" "-3" "10" "14" "-42.43" "-7238" "30 hour" ">20 hour" ">10 hour" "123.78" "1490" "41.39" "18983873##15043961" "Antiviral Res. 2009 Jan;81(1):82-7.##Lancet. 2004 Mar 20;363(9413):938-47." "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.##Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S." "Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.##Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors." "10.1093/infdis/jiv325.##10.1016/j.antiviral.2008.10.001.##10.1016/S0140-6736(04)15788-7." "Anti-SARS-CoV" "DRAVPe01721" "AWDFGSVGGVFNSLGKGIHQIFGAAFKSL" "29" "ZIKV Ep (424-452)" "Synthetic construct" "Q32ZE1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay" "[Ref.28232248]Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=1.32μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01721.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Peptide derived from protein E stem may inhibit virus infection by blocking virus entry." "3011.43" "C142H208N36O37" "CEMPRTY" "G" "8.64" "3" "1" "2" "10" "14" "49.66" "622" "4.4 hour" ">20 hour" ">10 hour" "84.14" "5500" "196.43" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-ZIKV" "DRAVPe01719" "AWDFGSIGGVFNSIGRAVHQVFGGAFRTL" "29" "JEV Ep (424–452)" "Synthetic construct" "P0DOH7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay" "[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=7.66 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01719.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Peptide derived from protein E stem may inhibit virus infection by blocking virus entry." "3067.46" "C142H208N40O37" "CEKMPY" "G" "9.65" "3" "1" "2" "10" "14" "47.24" "-1257" "4.4 hour" ">20 hour" ">10 hour" "80.69" "5500" "196.43" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-JEV" "DRAVPe01720" "AWDFGSIGGVFNSIGRAVHQVF" "22" "JEV Ep (424–445)" "Synthetic construct" "P0DOH7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV, ZIKV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay" "[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3.93 nM);##Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=3.27μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01720.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevented JEV infection in mice by reducing viral load and the inflammatory response in the brain, thereby improving the survival rate." "2364.65" "C110H158N30O29" "CEKLMPTY" "G" "6.79" "2" "1" "1" "7" "11" "51.36" "-667" "4.4 hour" ">20 hour" ">10 hour" "84.09" "5500" "261.9" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-JEV, Anti-ZIKV" "DRAVPe01718" "AALGDTAWDFGSIGGVFNSIGRAVHQVFGGAFRTL" "35" "JEV Ep (418–452)" "Synthetic construct" "P0DOH7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay" "[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=58.07 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01718.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Peptide derived from protein E stem may inhibit virus infection by blocking virus entry." "3596.02" "C164H244N46O46" "CEKMPY" "G" "6.79" "3" "2" "1" "12" "17" "47.14" "-1438" "4.4 hour" ">20 hour" ">10 hour" "83.71" "5500" "161.76" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-JEV" "DRAVPe01717" "SIGGVFNSIGRAVHQVFGGAFRTL" "24" "JEV Ep (428–452)" "Synthetic construct" "P0DOH7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "JEV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay" "[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=94.10 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01717.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Peptide derived from protein E stem may inhibit virus infection by blocking virus entry." "2490.85" "C113H176N34O30" "CDEKMPWY" "G" "12" "3" "0" "3" "9" "11" "57.92" "-1191" "1.9 hour" ">20 hour" ">10 hour" "93.33" "0" "0" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-JEV" "DRAVPe01716" "STLGKAFSTTLKGAQRLAALGDTAWDFG" "28" "JEV Ep (401–428)" "Synthetic construct" "P0DOH7" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "JEV" "Flaviviridae" "qRT-PCR, western blotting, the plaque assay, immunofluorescence analysis" "[Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3790.71 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01716.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Peptide derived from protein E stem may inhibit virus infection by blocking virus entry." "2884.24" "C129H203N35O40" "CEHIMNPVY" "A" "8.31" "3" "2" "1" "10" "12" "0.36" "-2530" "1.9 hour" ">20 hour" ">10 hour" "73.57" "5500" "203.7" "28232248" "Antiviral Res. 2017 May;141:140-149." "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." "Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses." "10.1016/j.antiviral.2017.02.009" "Anti-JEV" "DRAVPe01714" "LDLSDEMAMLLQEVVKQLNDSYIDLKELGNYTYYNKW" "37" "HKU4-HR2P3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.55 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.48 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.52 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM." "No predicted structure available" "DRAVPe01714.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection." "4457.05" "C201H308N46O64S2" "CFHPR" "L" "4.14" "3" "7" "-4" "11" "12" "-47.03" "-5567" "5.5 hour" "3 min" "2 min" "102.7" "11460" "318.33" "30646495" "Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056" "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4." "10.3390/v11010056" "Anti-MERS-CoV" "DRAVPe01715" "GGGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL" "39" "MERS-HR2P" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.07 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.14 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.71 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM." "No predicted structure available" "DRAVPe01715.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection." "4312.94" "C191H316N46O64S" "CFHPRW" "L" "4.18" "2" "5" "-3" "14" "14" "8.97" "-3045" "30 hour" ">20 hour" ">10 hour" "127.44" "2980" "78.42" "30646495" "Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056" "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4." "10.3390/v11010056" "Anti-MERS-CoV" "DRAVPe01713" "EISKINTTLLDLSDEMAMLLQEVVKQLNDSYIDLKEL" "37" "HKU4-HR2P2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.38 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.34 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.44 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM." "No predicted structure available" "DRAVPe01713.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection." "4266.93" "C187H314N44O64S2" "CFGHPRW" "L" "4.07" "3" "8" "-5" "8" "14" "-2.43" "-4990" "1 hour" "30 min" ">10 hour" "134.32" "1490" "41.39" "30646495" "Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056" "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4." "10.3390/v11010056" "Anti-MERS-CoV" "DRAVPe01712" "GPNFAEISKINTTLLDLSDEMAMLLQEVVKQLNDSYI" "37" "HKU4-HR2P1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.09 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.15 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.72 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM." "No predicted structure available" "DRAVPe01712.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection." "4154.76" "C183H298N44O61S2" "CHRW" "L" "4.02" "2" "6" "-4" "10" "14" "4.05" "-3957" "30 hour" ">20 hour" ">10 hour" "115.95" "1490" "41.39" "30646495" "Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056" "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4." "10.3390/v11010056" "Anti-MERS-CoV" "DRAVPe01711" "ISLTPLLVCVAALLLLEQ" "18" "E1P52-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01711.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1909.4" "C89H157N19O24S" "DFGHKMNRWY" "L" "4" "0" "1" "-1" "3" "12" "197.22" "3402" "20 hour" "30 min" ">10 hour" "216.67" "0" "0" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01709" "GVISLTPLLVCVAALLLL" "18" "E1P52" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=55.7± 5.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01709.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1808.34" "C86H154N18O21S" "DEFHKMNQRWY" "L" "5.52" "0" "0" "0" "4" "13" "257.22" "5135" "30 hour" ">20 hour" ">10 hour" "232.78" "0" "0" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01710" "VISLTPLLVCVAALLLLE" "18" "E1P52-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01710.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1880.4" "C89H158N18O23S" "DFGHKMNQRWY" "L" "4" "0" "1" "-1" "3" "13" "240" "4360" "100 hour" ">20 hour" ">10 hour" "232.78" "0" "0" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01708" "RGVISLTPLLVCVAALLL" "18" "E1P51-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01708.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1851.36" "C86H155N21O21S" "DEFHKMNQWY" "L" "8.25" "1" "0" "1" "4" "12" "211.11" "3151" "1 hour" "2 min" "2 min" "211.11" "0" "0" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01707" "WRGVISLTPLLVCVAALL" "18" "E1P51-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01707.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1924.42" "C91H154N22O21S" "DEFHKMNQY" "L" "8.25" "1" "0" "1" "4" "12" "185" "2892" "2.8 hour" "3 min" "2 min" "189.44" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01705" "DFWRGVISLTPLLVCVAA" "18" "E1P50-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01705.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1960.36" "C92H146N22O23S" "EHKMNQY" "LV" "5.83" "1" "1" "0" "4" "11" "138.89" "1334" "1.1 hour" "3 min" ">10 hour" "146.11" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01706" "FWRGVISLTPLLVCVAAL" "18" "E1P51" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01706.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1958.44" "C94H152N22O21S" "DEHKMNQY" "L" "8.25" "1" "0" "1" "4" "12" "179.44" "2698" "1.1 hour" "3 min" "2 min" "167.78" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01704" "FDFWRGVISLTPLLVCVA" "18" "E1P50-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01704.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2036.46" "C98H150N22O23S" "EHKMNQY" "LV" "5.83" "1" "1" "0" "4" "11" "144.44" "1451" "1.1 hour" "3 min" "2 min" "140.56" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01703" "PFDFWRGVISLTPLLVCV" "18" "E1P50" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01703.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2062.5" "C100H152N22O23S" "AEHKMNQY" "LV" "6.22" "1" "1" "0" "4" "10" "125.56" "1270" ">20 hour" ">20 hour" "?" "135" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01702" "VPFDFWRGVISLTPLLVC" "18" "E1P49-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01702.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2062.5" "C100H152N22O23S" "AEHKMNQY" "LV" "5.8" "1" "1" "0" "4" "10" "125.56" "1270" "100 hour" ">20 hour" ">10 hour" "135" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01701" "KVPFDFWRGVISLTPLLV" "18" "E1P49-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=63.3 ± 5.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01701.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2087.54" "C103H159N23O23" "ACEHMNQY" "LV" "8.75" "2" "1" "1" "3" "10" "90" "587" "1.3 hour" "3 min" "2 min" "135" "5500" "323.53" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01699" "LWKVPFDFWRGVISLTPL" "18" "E1P48-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=14.7 ± 0.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01699.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2174.62" "C109H160N24O23" "ACEHMNQY" "L" "8.75" "2" "1" "1" "3" "10" "61.67" "416" "5.5 hour" "3 min" "2 min" "118.89" "11000" "647.06" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01700" "WKVPFDFWRGVISLTPLL" "18" "E1P49" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=17.3 ± 3.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01700.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2174.62" "C109H160N24O23" "ACEHMNQY" "L" "8.75" "2" "1" "1" "3" "10" "61.67" "416" "2.8 hour" "3 min" "2 min" "118.89" "11000" "647.06" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01697" "EYLWKVPFDFWRGVISLT" "18" "E1P48" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.7 ± 3.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01697.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2256.63" "C112H158N24O26" "ACHMNQ" "FLVW" "6.17" "2" "2" "0" "4" "9" "22.78" "-771" "1 hour" "30 min" ">10 hour" "97.22" "12490" "734.71" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01698" "YLWKVPFDFWRGVISLTP" "18" "E1P48-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=70.7 ±9.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01698.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2224.63" "C112H158N24O24" "ACEHMNQ" "FLPVW" "8.59" "2" "1" "1" "4" "9" "33.33" "-90" "2.8 hour" "10 min" "2 min" "97.22" "12490" "734.71" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01695" "ILEYLWKVPFDFWRGVIS" "18" "E1P47-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=5.4 ± 0.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01695.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2268.69" "C114H162N24O25" "ACHMNQT" "FILVW" "6.07" "2" "2" "0" "3" "10" "51.67" "-22" "20 hour" "30 min" ">10 hour" "118.89" "12490" "734.71" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01696" "LEYLWKVPFDFWRGVISL" "18" "E1P47-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.6± 0.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01696.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2268.69" "C114H162N24O25" "ACHMNQT" "L" "6.07" "2" "2" "0" "3" "10" "47.78" "-22" "5.5 hour" "3 min" "2 min" "118.89" "12490" "734.71" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01694" "WILEYLWKVPFDFWRGVI" "18" "E1P47" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=2.7 ± 0.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01694.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2367.82" "C122H167N25O24" "ACHMNQST" "W" "6.07" "2" "2" "0" "2" "11" "51.11" "551" "2.8 hour" "3 min" "2 min" "118.89" "17990" "1058.24" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01692" "NYWILEYLWKVPFDFWRG" "18" "E1P46-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.3 ± 0.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01692.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2432.81" "C124H162N26O26" "ACHMQST" "W" "6.07" "2" "2" "0" "4" "9" "-23.89" "-1023" "1.4 hour" "3 min" ">10 hour" "81.11" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01693" "YWILEYLWKVPFDFWRGV" "18" "E1P46-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=32.3 ± 11.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01693.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2417.84" "C125H165N25O25" "ACHMNQST" "W" "6.07" "2" "2" "0" "3" "10" "18.89" "45" "2.8 hour" "10 min" "2 min" "97.22" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01691" "SNYWILEYLWKVPFDFWR" "18" "E1P46" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 8.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01691.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2462.84" "C125H164N26O27" "ACGHMQT" "W" "5.79" "2" "2" "0" "4" "9" "-26.11" "-1457" "1.9 hour" ">20 hour" ">10 hour" "81.11" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01690" "ASNYWILEYLWKVPFDFW" "18" "E1P45-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 3.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01690.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2377.73" "C122H157N23O27" "CGHMQRT" "W" "4.37" "1" "2" "-1" "4" "10" "8.89" "216" "4.4 hour" ">20 hour" ">10 hour" "86.67" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01689" "LASNYWILEYLWKVPFDF" "18" "E1P45-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.7 ±1.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01689.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2304.67" "C117H158N22O27" "CGHMQRT" "L" "4.37" "1" "2" "-1" "4" "10" "35" "475" "5.5 hour" "3 min" "2 min" "108.33" "13980" "822.35" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01688" "QLASNYWILEYLWKVPFD" "18" "E1P45" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=27.7 ±5.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01688.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2285.63" "C113H157N23O28" "CGHMRT" "L" "4.37" "1" "2" "-1" "4" "9" "0" "-377" "0.8 hour" "10 min" ">10 hour" "108.33" "13980" "822.35" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01686" "TEQLASNYWILEYLWKVP" "18" "E1P44-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01686.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2253.58" "C109H157N23O29" "CDFGHMR" "L" "4.53" "1" "2" "-1" "5" "8" "-19.44" "-741" "7.2 hour" ">20 hour" ">10 hour" "108.33" "13980" "822.35" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01687" "EQLASNYWILEYLWKVPF" "18" "E1P44-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=90.3 ± 15.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01687.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2299.65" "C114H159N23O28" "CDGHMRT" "L" "4.53" "1" "2" "-1" "4" "9" "0" "-186" "1 hour" "30 min" ">10 hour" "108.33" "13980" "822.35" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01685" "WTEQLASNYWILEYLWKV" "18" "E1P44" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01685.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2342.68" "C115H160N24O29" "CDFGHMPR" "LW" "4.53" "1" "2" "-1" "5" "9" "-15.56" "-508" "2.8 hour" "3 min" "2 min" "108.33" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01684" "RWTEQLASNYWILEYLWK" "18" "E1P43-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 9.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01684.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2399.73" "C116H163N27O29" "CDFGHMPV" "LW" "6.14" "2" "2" "0" "5" "8" "-63.89" "-2404" "1 hour" "2 min" "2 min" "92.22" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01683" "WRWTEQLASNYWILEYLW" "18" "E1P43-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.8 ± 0.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01683.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2457.77" "C121H161N27O29" "CDFGHKMPV" "W" "4.53" "1" "2" "-1" "5" "9" "-47.22" "-1616" "2.8 hour" "3 min" "2 min" "92.22" "24980" "1469.41" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01682" "FWRWTEQLASNYWILEYL" "18" "E1P43" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=43.0 ± 10.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01682.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2418.74" "C119H160N26O29" "CDGHKMPV" "LW" "4.53" "1" "2" "-1" "5" "9" "-26.67" "-1551" "1.1 hour" "3 min" "2 min" "92.22" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01680" "SEFWRWTEQLASNYWILE" "18" "E1P42-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=31.0 ± 3.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01680.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2358.59" "C112H152N26O31" "CDGHKMPV" "EW" "4.25" "1" "3" "-2" "5" "8" "-64.44" "-3050" "1.9 hour" ">20 hour" ">10 hour" "70.56" "17990" "1058.24" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01681" "EFWRWTEQLASNYWILEY" "18" "E1P42-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01681.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2434.69" "C118H156N26O31" "CDGHKMPV" "EW" "4.25" "1" "3" "-2" "5" "8" "-67.22" "-2724" "1 hour" "30 min" ">10 hour" "70.56" "19480" "1145.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01679" "ESEFWRWTEQLASNYWIL" "18" "E1P42" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=50.0 ± 8.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01679.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2358.59" "C112H152N26O31" "CDGHKMPV" "EW" "4.25" "1" "3" "-2" "5" "8" "-64.44" "-3050" "1 hour" "30 min" ">10 hour" "70.56" "17990" "1058.24" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01677" "KWESEFWRWTEQLASNYW" "18" "E1P41-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=66.7 ± 20.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01677.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2446.66" "C117H152N28O31" "CDGHIMPV" "W" "4.79" "2" "3" "-1" "5" "7" "-137.22" "-4356" "1.3 hour" "3 min" "2 min" "27.22" "23490" "1381.76" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01678" "WESEFWRWTEQLASNYWI" "18" "E1P41-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=22.0 ± 0.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01678.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2431.65" "C117H151N27O31" "CDGHKMPV" "W" "4.25" "1" "3" "-2" "5" "8" "-90.56" "-3309" "2.8 hour" "3 min" "2 min" "48.89" "23490" "1381.76" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01676" "LKWESEFWRWTEQLASNY" "18" "E1P41" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01676.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2373.61" "C112H153N27O31" "CDGHIMPV" "EW" "4.79" "2" "3" "-1" "5" "7" "-111.11" "-4097" "5.5 hour" "3 min" "2 min" "48.89" "17990" "1058.24" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01675" "ELKWESEFWRWTEQLASN" "18" "E1P40-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01675.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2339.55" "C108H151N27O32" "CDGHIMPVY" "E" "4.49" "2" "4" "-2" "4" "7" "-123.33" "-4764" "1 hour" "30 min" ">10 hour" "48.89" "16500" "970.59" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01674" "CELKWESEFWRWTEQLAS" "18" "E1P40-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=34.0 ± 15.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01674.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2328.58" "C107H150N26O31S" "DGHIMNPVY" "E" "4.49" "2" "4" "-2" "4" "7" "-90" "-3972" "1.2 hour" ">20 hour" ">10 hour" "48.89" "16500" "970.59" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01673" "ACELKWESEFWRWTEQLA" "18" "E1P40" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01673.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2312.58" "C107H150N26O30S" "DGHIMNPVY" "E" "4.49" "2" "4" "-2" "3" "8" "-75.56" "-3451" "4.4 hour" ">20 hour" ">10 hour" "54.44" "16500" "970.59" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01671" "AVACELKWESEFWRWTEQ" "18" "E1P39-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.0 ± 13.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01671.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2298.56" "C106H148N26O30S" "DGHIMNPY" "E" "4.49" "2" "4" "-2" "3" "8" "-73.33" "-3539" "4.4 hour" ">20 hour" ">10 hour" "48.89" "16500" "970.59" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01672" "VACELKWESEFWRWTEQL" "18" "E1P39-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=37.7 ± 7.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01672.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2340.64" "C109H154N26O30S" "DGHIMNPY" "E" "4.49" "2" "4" "-2" "3" "8" "-62.22" "-3228" "100 hour" ">20 hour" ">10 hour" "65" "16500" "970.59" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01670" "CAVACELKWESEFWRWTE" "18" "E1P39" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 1.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01670.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2273.57" "C104H145N25O29S2" "DGHIMNPQY" "E" "4.49" "2" "4" "-2" "4" "8" "-40" "-2857" "1.2 hour" ">20 hour" ">10 hour" "48.89" "16625" "977.94" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01668" "LTCAVACELKWESEFWRW" "18" "E1P38-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01668.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2257.61" "C105H149N25O27S2" "DGHIMNPQY" "EW" "4.79" "2" "3" "-1" "4" "9" "0.56" "-1684" "5.5 hour" "3 min" "2 min" "70.56" "16625" "977.94" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01669" "TCAVACELKWESEFWRWT" "18" "E1P38-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01669.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2245.56" "C103H145N25O28S2" "DGHIMNPQY" "EW" "4.78" "2" "3" "-1" "5" "8" "-24.44" "-2433" "7.2 hour" ">20 hour" ">10 hour" "48.89" "16625" "977.94" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor." "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01667" "NLTCAVACELKWESEFWR" "18" "E1P38" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01667.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2185.5" "C98H145N25O28S2" "DGHIMPQY" "E" "4.79" "2" "3" "-1" "5" "8" "-13.89" "-2581" "1.4 hour" "3 min" ">10 hour" "70.56" "11125" "654.41" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. " "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01665" "VPNLTCAVACELKWESEF" "18" "E1P37-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=80.0 ± 62.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01665.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2039.35" "C91H139N21O28S2" "DGHIMQRY" "E" "4.25" "1" "3" "-2" "5" "8" "30.56" "-918" "100 hour" ">20 hour" ">10 hour" "86.67" "5625" "330.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. " "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01666" "PNLTCAVACELKWESEFR" "18" "E1P37-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=99.0 ± 22.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01666.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "2096.4" "C92H142N24O28S2" "DGHIMQY" "E" "4.79" "2" "3" "-1" "5" "7" "-17.78" "-2814" ">20 hour" ">20 hour" "?" "70.56" "5625" "330.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. " "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01664" "PVPNLTCAVACELKWESE" "18" "E1P37" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Fluorescence resonance energy transfer (FRET) assay" "[Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=41.0 ± 8.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01664.cif" "Linear" "Free" "Free" "None" "L" "gp41" "The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection." "1989.29" "C87H137N21O28S2" "DFGHIMQRY" "E" "4.25" "1" "3" "-2" "5" "7" "6.11" "-1216" ">20 hour" ">20 hour" "?" "86.67" "5625" "330.88" "26905802" "Biochim Biophys Acta. 2016 Jun;1860(6):1139-48." "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." "Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. " "10.1016/j.bbagen.2016.02.008" "Anti-HIV" "DRAVPe01663" "yAIIXYNKYXNC" "12" "compound 6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.2 ± 0.4 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01663.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 5 indicates N-methyl-4-O-methyl-tyrosine, position 10 indicates N-methyl-leucine." "Mixed(D-Tyr1)" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1487.12" "C50H70N12O11S" "DEFGHLMPQRSTVW" "INYX" "8.15" "1" "0" "1" "5" "3" "-1.67" "-618" "73.33" "2980" "270.91" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01662" "YTLPFHNXTFFC" "12" "compound 5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥50 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01662.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 8 indicates N-methyl-glycine." "L" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1500.92" "C68H86N14O15S" "ADEGIKMQRSVW" "F" "6.73" "1" "0" "1" "5" "4" "30.83" "-144" "2.8 hour" "10 min" "2 min" "32.5" "1490" "135.45" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01661" "YXIAKYNXXIPC" "12" "compound 4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=4.6 ± 0.3 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01661.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 2 indicates N-methyl-glycine, position 8 and 9 indicates N-methyl-4-O-methyl-tyrosine." "L" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1418.29" "C51H71N11O10S" "DEFGHLMQRSTVW" "X" "8.18" "1" "0" "1" "4" "3" "14.17" "46" "2.8 hour" "10 min" "2 min" "73.33" "2980" "270.91" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01660" "YTNFYLYPYXFC" "12" "compound 3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=2.2 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01660.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine)." "L" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1605.03" "C76H90N12O17S" "ADEGHIKMQRSVW" "Y" "5.52" "0" "0" "0" "7" "3" "7.5" "239" "2.8 hour" "10 min" "2 min" "32.5" "5960" "541.82" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01659" "YXKXKXXKXXKC" "12" "compound 2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=0.25 ± 0.01 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.7 ± 0.1 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.9 ± 0.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01659.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 2,7,9 and 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine), position 4 indicates MeF(N-methyl-phenylalanine), position 6 indicates MeS(N-methyl-serine)." "L" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1465.01" "C36H52N10O2S" "ADEFGHILMNPQRSTVW" "X" "9.87" "4" "0" "4" "2" "0" "-120" "-2106" "2.8 hour" "10 min" "2 min" "0" "1490" "135.45" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01658" "YWKIXNTLVNIC" "12" "compound 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV,DENV,WNV" "Flaviviridae" "protease enzymatic inhibition assay" "[Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.5 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus: inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01658.cif" "Linear" "Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue)" "Amidation" "The 'X' at position 4 indicates MeYMe(N-methyl-4-O-methyl-tyrosine)." "L" "NS2B-NS3 protease" "No machanism information found in the reference(s) presented in this entry" "1477.97" "C64H97N15O15S" "ADEFGHMPQRS" "IN" "8.2" "1" "0" "1" "5" "5" "47.5" "87" "2.8 hour" "10 min" "2 min" "121.67" "6990" "635.45" "30783498" "ACS Med Chem Lett. 2019 Jan 4;10(2):168-174." "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " "De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. " "10.1021/acsmedchemlett.8b00535" "Anti-ZIKV,Anti-DENV,Anti-WNV" "DRAVPe01657" "GVLV" "4" "Peptide 6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" "Cytopathic effect assay" "[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>4 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34502335]Vero cell:CC50=77.4 ±0.7 µM." "No predicted structure available" "DRAVPe01657.cif" "Linear" "Acylation" "Methyl amidation" "None" "L" "Main protease" "No machanism information found in the reference(s) presented in this entry" "386.49" "C18H34N4O5" "ACDEFHIKMNPQRSTWY" "V" "5.52" "0" "0" "0" "1" "3" "295" "1394" "30 hour" ">20 hour" ">10 hour" "242.5" "0" "0" "34502335" "Int J Mol Sci. 2021 Aug 30;22(17):9427." "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." "10.3390/ijms22179427" "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" "DRAVPe01656" "GVLVQ" "5" "Peptide 5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" "Cytopathic effect assay" "[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=59.80 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34502335]Vero cell:CC50=75.0 ±2.2 µM." "No predicted structure available" "DRAVPe01656.cif" "Linear" "Acylation" "Methyl amidation" "None" "L" "Main protease" "No machanism information found in the reference(s) presented in this entry" "514.62" "C23H42N6O7" "ACDEFHIKMNPRSTWY" "V" "5.52" "0" "0" "0" "1" "3" "166" "840" "30 hour" ">20 hour" ">10 hour" "194" "0" "0" "34502335" "Int J Mol Sci. 2021 Aug 30;22(17):9427." "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." "10.3390/ijms22179427" "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" "DRAVPe01655" "GGVLVQPG" "8" "Peptide 4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" "Cytopathic effect assay" "[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=78.20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34502335]Vero cell:CC50=74.9 ± 4.9 µM." "No predicted structure available" "DRAVPe01655.cif" "Linear" "Pivaloylation" "Methyl amidation" "None" "L" "Main protease" "No machanism information found in the reference(s) presented in this entry" "725.84" "C32H55N9O10" "ACDEFHIKMNRSTWY" "G" "5.52" "0" "0" "0" "3" "3" "73.75" "1028" "30 hour" ">20 hour" ">10 hour" "121.25" "0" "0" "34502335" "Int J Mol Sci. 2021 Aug 30;22(17):9427." "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." "10.3390/ijms22179427" "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" "DRAVPe01653" "GGVLVQPG" "8" "Peptide 2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" "Cytopathic effect assay" "[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥17.6 ± 2.4 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=50.05 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=48.42 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34502335]Vero cell:CC50=83.0 ± 17.0 µM." "No predicted structure available" "DRAVPe01653.cif" "Linear" "Acylation" "Amidation" "None" "L" "Main protease" "No machanism information found in the reference(s) presented in this entry" "725.84" "C32H55N9O10" "ACDEFHIKMNRSTWY" "G" "5.52" "0" "0" "0" "3" "3" "73.75" "1028" "30 hour" ">20 hour" ">10 hour" "121.25" "0" "0" "34502335" "Int J Mol Sci. 2021 Aug 30;22(17):9427." "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." "10.3390/ijms22179427" "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" "DRAVPe01654" "GGVLVQPG" "8" "Peptide 3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" "Cytopathic effect assay" "[Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50>20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=58.09 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=81.09 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34502335]Vero cell:CC50=81.8 ± 2.1 µM." "No predicted structure available" "DRAVPe01654.cif" "Linear" "Acylation" "Methyl amidation" "None" "L" "Main protease" "No machanism information found in the reference(s) presented in this entry" "725.84" "C32H55N9O10" "ACDEFHIKMNRSTWY" "G" "5.52" "0" "0" "0" "3" "3" "73.75" "1028" "30 hour" ">20 hour" ">10 hour" "121.25" "0" "0" "34502335" "Int J Mol Sci. 2021 Aug 30;22(17):9427." "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." "10.3390/ijms22179427" "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" "DRAVPe01652" "SAHS" "4" "Ac-SAHS-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.34681184]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=5.77 ± 0.01 × 10−7 μM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.3 × 10−10 μM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=9.36 ± 0.1 × 10−7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01652.cif" "Linear" "Acylation" "Amidation" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "400.39" "C15H24N6O7" "CDEFGIKLMNPQRTVWY" "S" "6.46" "1" "0" "1" "2" "1" "-75" "-965" "1.9 hour" ">20 hour" ">10 hour" "25" "0" "0" "34681184" "Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. " "Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." "10.3390/ph14100959" "Anti-Influenza virus" "DRAVPe01651" "SKHS" "4" "Peptide 17(lactoferrin 418–421)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=3 ± 0.61 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.048 ± 0.0012 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.02 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01651.cif" "Linear" "Acylation" "Amidation" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "457.49" "C18H31N7O7" "ACDEFGILMNPQRTVWY" "S" "8.49" "2" "0" "2" "2" "0" "-217.5" "-1701" "1.9 hour" ">20 hour" ">10 hour" "0" "0" "0" "28878220##34681184" "Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. " "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." "10.1038/s41598-017-10492-x##10.3390/ph14100959" "Anti-Influenza virus" "DRAVPe01650" "SLDC" "4" "Peptide 15(lactoferrin 422-425)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.001 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.6 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.03 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01650.cif" "Linear" "Acylation" "Amidation" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "436.48" "C16H28N4O8S" "AEFGHIKMNPQRTVWY" "CDLS" "3.8" "0" "1" "-1" "2" "1" "50" "-592" "1.9 hour" ">20 hour" ">10 hour" "97.5" "0" "0" "28878220##34681184" "Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. " "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." "10.1038/s41598-017-10492-x##10.3390/ph14100959" "Anti-Influenza virus" "DRAVPe01649" "SKHSSLDC" "8" "Peptide 16(lactoferrin 418-425)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=80 ± 0.19 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.1 ± 0.001 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.45 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01649.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "875.95" "C34H57N11O14S" "AEFGIMNPQRTVWY" "S" "6.46" "2" "1" "1" "4" "1" "-83.75" "-2293" "1.9 hour" ">20 hour" ">10 hour" "48.75" "0" "0" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01648" "VLRP" "4" "Peptide 14(lactoferrin 426–429)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.45 ± 0.1 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=1 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=250 ± 0.42 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01648.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "483.61" "C22H41N7O5" "ACDEFGHIKMNQSTWY" "LPRV" "9.72" "1" "0" "1" "0" "2" "47.5" "-596" "100 hour" ">20 hour" ">10 hour" "170" "0" "0" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01647" "SLDCVLRP" "8" "Peptide 13(lactoferrin 422–429)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.3 ± 0.5 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=2.5± 0.37 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=300± 0.2 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01647.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "902.08" "C38H67N11O12S" "AEFGHIKMNQTWY" "L" "5.55" "1" "1" "0" "2" "3" "48.75" "-1188" "1.9 hour" ">20 hour" ">10 hour" "133.75" "0" "0" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01646" "KSETKN" "6" "Peptide 8(lactoferrin 633-638)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.01 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=500 ± 0.46 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=400.000 ± 210 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01646.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "705.77" "C28H51N9O12" "ACDFGHILMPQRVWY" "K" "8.59" "2" "1" "1" "3" "0" "-271.67" "-3052" "1.3 hour" "3 min" "2 min" "0" "0" "0" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01645" "TNGESTADWAKN" "12" "Peptide 6(lactoferrin 552-563)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=400 ±0.02 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 230 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=10.000± 120 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01645.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "1293.31" "C53H80N16O22" "CFHILMPQRVY" "ANT" "4.37" "1" "2" "-1" "6" "3" "-148.33" "-3601" "7.2 hour" ">20 hour" ">10 hour" "16.67" "5500" "500" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01644" "KANEGLTWNSLKDK" "14" "Peptide 4(lactoferrin 441–454)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=1± 0.15 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 250 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=1.000 ± 360 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01644.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "1603.8" "C70H114N20O23" "CFHIMPQRVY" "K" "8.5" "3" "2" "1" "5" "4" "-136.43" "-3651" "1.3 hour" "3 min" "2 min" "62.86" "5500" "423.08" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01643" "SKHSSLDCVLRP" "12" "Peptide 1(lactoferrin 418–429)" "Synthetic construct" "P24627" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "3IB0" "Influenza virus" "Orthomyxoviridae" "Neutralization assay" "[Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=4 ± 0.37 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=3.1 ± 0.12 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.8 ± 0.7 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01643.cif" "Linear" "Free" "Free" "None" "L" "hemagglutinin (HA)" "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." "1341.55" "C56H96N18O18S" "AEFGIMNQTWY" "S" "7.97" "3" "1" "2" "4" "3" "-40" "-2889" "1.9 hour" ">20 hour" ">10 hour" "89.17" "0" "0" "28878220" "Sci Rep. 2017 Sep 6;7(1):10593." "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors." "10.1038/s41598-017-10492-x" "Anti-Influenza virus" "DRAVPe01642" "AGVSGHGQHGVHG" "13" "Alloferon-1 [H1A]" "Synthetic construct" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HHV,CBV2" "Herpesviridae, Picornaviridae" "Antiviral assay(cytopathic effect)" "[Ref.21766388]Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=358.00 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 187.50 µg/ml." "No predicted structure available" "DRAVPe01642.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may inhibit the replication of DNA and RNA viruses." "1199.25" "C49H74N20O16" "CDEFIKLMNPRTWY" "G" "7.06" "3" "0" "3" "6" "3" "-43.85" "-833" "4.4 hour" ">20 hour" ">10 hour" "52.31" "0" "0" "21766388" "J Pept Sci. 2011 Nov;17(11):715-9." "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." "Further studies on the antiviral activity of alloferon and its analogues." "10.1002/psc.1388" "Anti-HHV,Anti-CBV2" "DRAVPe01641" "RGVSGHGQHGVHG" "13" "Alloferon-1 [H1R]" "Synthetic construct" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HHV,CBV2" "Herpesviridae, Picornaviridae" "Antiviral assay(cytopathic effect)" "[Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=321.10 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=277.50 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=602.18 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=577.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=167.71 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=355.18 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 143.75 µg/ml." "No predicted structure available" "DRAVPe01641.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may inhibit the replication of DNA and RNA viruses." "1284.36" "C52H81N23O16" "ACDEFIKLMNPTWY" "G" "9.77" "4" "0" "4" "6" "2" "-92.31" "-2506" "1 hour" "2 min" "2 min" "44.62" "0" "0" "21766388" "J Pept Sci. 2011 Nov;17(11):715-9." "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." "Further studies on the antiviral activity of alloferon and its analogues." "10.1002/psc.1388" "Anti-HHV,Anti-CBV2" "DRAVPe01640" "KGVSGHGQHGVHG" "13" "Alloferon-1 [H1K]" "Synthetic construct" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HHV,CBV2" "Herpesviridae, Picornaviridae" "Antiviral assay(cytopathic effect)" "[Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=147.09 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=241.90 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=9.19 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=12.98 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=157.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=107.04 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=190.67 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=74.00 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 218.75 µg/ml." "No predicted structure available" "DRAVPe01640.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may inhibit the replication of DNA and RNA viruses." "1256.35" "C52H81N21O16" "ACDEFILMNPRTWY" "G" "8.77" "4" "0" "4" "6" "2" "-87.69" "-1569" "1.3 hour" "3 min" "2 min" "44.62" "0" "0" "21766388" "J Pept Sci. 2011 Nov;17(11):715-9." "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." "Further studies on the antiviral activity of alloferon and its analogues." "10.1002/psc.1388" "Anti-HHV,Anti-CBV2" "DRAVPe01639" "GQGKAHNGRLITANP" "15" "DENV Envelope glycoprotein (340 – 354)" "Synthetic construct(derived from DENV Envelope glycoprotein)" "Q5UB51##P17763" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Focus-forming assay (FFA)" "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(83%±3.72% inhibition at 50 μM,IC50=33 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM." "No predicted structure available" "DRAVPe01639.cif" "Linear" "Free" "Free" "None" "L" "E protein" "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." "1533.71" "C64H108N24O20" "CDEFMSVWY" "G" "11" "3" "0" "3" "6" "4" "-91.33" "-3024" "30 hour" ">20 hour" ">10 hour" "65.33" "0" "0" "30508603" "Virus Res. 2019 Jan 15;260:142-150." "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." "In vitro analysis of synthetic peptides in blocking the entry of dengue virus." "10.1016/j.virusres.2018.11.016" "Anti-DENV" "DRAVPe01638" "DRGWGNGCGLFG" "12" "DENV Envelope glycoprotein (98-109)" "Synthetic construct(derived from DENV Envelope glycoprotein)" "Q5UB51##P17763" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus-forming assay (FFA)" "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(88%±3.89% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM." "No predicted structure available" "DRAVPe01638.cif" "Linear" "Free" "Free" "None" "L" "E protein" "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." "1238.34" "C53H75N17O16S" "AEHIKMPQSTVY" "G" "5.83" "1" "1" "0" "7" "3" "-44.17" "-1407" "1.1 hour" "3 min" ">10 hour" "32.5" "5500" "500" "30508603" "Virus Res. 2019 Jan 15;260:142-150." "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." "In vitro analysis of synthetic peptides in blocking the entry of dengue virus." "10.1016/j.virusres.2018.11.016" "Anti-DENV" "DRAVPe01637" "LEHGSCVTTMAKDKPTL" "17" "DENV Envelope glycoprotein (25-41)" "Synthetic construct(derived from DENV Envelope glycoprotein)" "Q5UB51##P17763" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus-forming assay (FFA)" "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(58%±2.55% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM." "No predicted structure available" "DRAVPe01637.cif" "Linear" "Free" "Free" "None" "L" "E protein" "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." "1831.13" "C77H131N21O26S2" "FINQRWY" "T" "6.74" "3" "2" "1" "6" "4" "-28.82" "-2214" "5.5 hour" "3 min" "2 min" "68.82" "0" "0" "30508603" "Virus Res. 2019 Jan 15;260:142-150." "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." "In vitro analysis of synthetic peptides in blocking the entry of dengue virus." "10.1016/j.virusres.2018.11.016" "Anti-DENV" "DRAVPe01636" "RRRRRRRXPLSPPLRNTHPQAMQWNSTTF" "29" "7R-Ahx-HBV Large envelope protein (96-116)" "Synthetic construct" "P03138" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "FQ-PCR" "[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=6.5 ± 1.5 μM;EC90=41.4 ±8.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21144865]HepG2.2.15:LC50=515.9± 43.8 μM." "No predicted structure available" "DRAVPe01636.cif" "Linear" "Free" "Free" "The 'X' at position 8 is 6-aminocaproic acid." "L" "DNA" "The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles." "3628.37" "C150H245N59O37S" "CDEGIKVY" "R" "12.85" "9" "0" "9" "7" "5" "-172.76" "-14358" "1 hour" "2 min" "2 min" "30.34" "5500" "196.43" "21144865" "Antiviral Res. 2011 Jan;89(1):109-14." "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." "Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production." "10.1016/j.antiviral.2010.12.001" "Anti-HBV" "DRAVPe01635" "RRRRRRRXLDPAFR" "14" "7R-Ahx-HBV Large envelope protein (19-24)" "Synthetic construct" "P03138" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "FQ-PCR" "[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=3.0 ± 1.0 μM;EC90=10.9 ± 3.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21144865]No cytotoxicity was observed at 1mM of peptide concentration against HepG2.2.15." "No predicted structure available" "DRAVPe01635.cif" "Linear" "Free" "Free" "The 'X' at position 8 is 6-aminocaproic acid." "L" "DNA" "The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles." "1922.47" "C75H133N37O15" "CEGHIKMNQSTVWY" "R" "12.48" "8" "1" "7" "0" "3" "-233.57" "-11837" "1 hour" "2 min" "2 min" "35" "0" "0" "21144865" "Antiviral Res. 2011 Jan;89(1):109-14." "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." "Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production." "10.1016/j.antiviral.2010.12.001" "Anti-HBV" "DRAVPe01633" "RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF" "33" "7R-Ahx-HBV Large envelope protein (219-243)" "Synthetic construct" "P03138" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "FQ-PCR" "[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=12.8 ± 2.0 μM;EC90=85.6 ± 9.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21144865]HepG2.2.15:LC50=457.9 ± 41.0 μM." "No predicted structure available" "DRAVPe01633.cif" "Linear" "Free" "Free" "The 'X' at position 8 is 6-aminocaproic acid." "L" "DNA" "The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles." "4099.99" "C167H270N66O40S4" "ADEIKQV" "R" "12" "11" "0" "11" "12" "3" "-153.94" "-16119" "1 hour" "2 min" "2 min" "11.82" "7115" "222.34" "21144865" "Antiviral Res. 2011 Jan;89(1):109-14." "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." "Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production." "10.1016/j.antiviral.2010.12.001" "Anti-HBV" "DRAVPe01634" "RRRRRRRXGSLLGRMKGA" "18" "7R-Ahx-P3" "Synthetic construct" "None" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HBV" "Hepadnaviridae" "FQ-PCR" "[Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=2.5 ±1.0 μM;EC90=8.6± 3.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21144865]HepG2.2.15:LC50=828.7 ± 50.3 μM." "No predicted structure available" "DRAVPe01634.cif" "Linear" "Free" "Free" "The 'X' at position 8 is 6-aminocaproic acid." "L" "DNA" "The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles." "2193.84" "C83H158N42O18S" "CDEFHINPQTVWY" "R" "12.85" "9" "0" "9" "4" "3" "-170" "-11149" "1 hour" "2 min" "2 min" "48.89" "0" "0" "21144865" "Antiviral Res. 2011 Jan;89(1):109-14." "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." "Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production." "10.1016/j.antiviral.2010.12.001" "Anti-HBV" "DRAVPe01632" "EEQAKTFLDKFNHEAEDLFYQSSGLGKGDFR" "31" "P6(ACE2 (4-26)-G-ACE2 (333-339))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=0.1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01632.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "3607.89" "C161H236N42O53" "CIMPVW" "EF" "4.7" "5" "7" "-2" "8" "9" "-106.45" "-8374" "1 hour" "30 min" ">10 hour" "44.19" "1490" "49.67" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01631" "EEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEE" "36" "P5(ACE2 (4-39))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=6 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01631.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "4313.57" "C192H275N47O67" "CGMPRV" "E" "4.16" "3" "8" "-5" "12" "11" "-106.39" "-9351" "1 hour" "30 min" ">10 hour" "51.67" "8480" "242.29" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01630" "EEQAKTFLDKFNHEAEDLFYQSS" "23" "P4(ACE2 (4-26))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01630.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "2776.95" "C124H178N30O43" "CGIMPRVW" "E" "4.35" "3" "6" "-3" "5" "7" "-115.22" "-6527" "1 hour" "30 min" ">10 hour" "42.61" "1490" "67.73" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01629" "NHEAEDLFY" "9" "P3(ACE2 (15-23))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(30% inhibition at 100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01629.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "1137.17" "C51H68N12O18" "CGIKMPQRSTVW" "E" "4.13" "1" "3" "-2" "2" "3" "-112.22" "-2407" "1.4 hour" "3 min" ">10 hour" "54.44" "1490" "186.25" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01628" "DKFNHEAED" "9" "P2(ACE2 (12-20))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(40% inhibition at 100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01628.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "1104.1" "C46H65N13O19" "CGILMPQRSTVWY" "DE" "4.31" "2" "4" "-2" "1" "2" "-222.22" "-4312" "1.1 hour" "3 min" ">10 hour" "11.11" "0" "0" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01627" "EEQAKTFLDK" "10" "P1(ACE2 (4-13))" "Synthetic construct(derived from angiotensin-converting enzyme 2)" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Pseudovirus infection assay" "[Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(25% inhibition at 100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01627.cif" "Linear" "Free" "Free" "None" "L" "spike glycoprotein" "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." "1208.33" "C53H85N13O19" "CGHIMNPRSVWY" "EK" "4.68" "2" "3" "-1" "1" "3" "-141" "-3184" "1 hour" "30 min" ">10 hour" "49" "0" "0" "16510163" "Virology. 2006 Jun 20;350(1):15-25." "Han DP, Penn-Nicholson A, Cho MW." "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor." "10.1016/j.virol.2006.01.029" "Anti-SARS-CoV" "DRAVPe01625" "HAKFWW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01625.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "874.01" "C46H55N11O7" "CDEGILMNPQRSTVY" "W" "8.76" "2" "0" "2" "0" "4" "-71.67" "-76" "3.5 hour" "10 min" ">10 hour" "16.67" "11000" "2200" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01626" "HCAFWW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=49 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01626.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "848.98" "C43H48N10O7S" "DEGIKLMNPQRSTVY" "W" "6.73" "1" "0" "1" "1" "4" "35" "607" "3.5 hour" "10 min" ">10 hour" "16.67" "11000" "2200" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe00001" "EEHEKYHSNW" "10" "NL1" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00001" "DRAVPe00001.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1358.39" "C60H79N17O20" "ACDFGILMPQRTV" "E" "5.33" "3" "3" "0" "3" "1" "-273" "-4315" "1 hour" "30 min" ">10 hour" "0" "6990" "776.67" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00002" "ASCDKCQLKG" "10" "NL2" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00002" "DRAVPe00002.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1052.23" "C41H73N13O15S2" "EFHIMNPRTVWY" "CK" "8.09" "2" "1" "1" "4" "2" "-54" "-1853" "4.4 hour" ">20 hour" ">10 hour" "49" "125" "13.89" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00003" "HGQVDCSPGIWQLDCTH" "17" "NL3 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=1000 µM);inhibition of strand transfer catalyzed by integrase(IC50=1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00003" "DRAVPe00003.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1896.08" "C80H118N24O26S2" "AEFKMNRY" "CDGHQ" "5.05" "2" "2" "0" "6" "4" "-45.29" "-2316" "3.5 hour" "10 min" ">10 hour" "62.94" "5625" "351.56" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00004" "VHVASGY" "7" "NL4" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00004" "DRAVPe00004.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "731.81" "C33H49N9O10" "CDEFIKLMNPQRTW" "V" "6.71" "1" "0" "1" "3" "3" "64.29" "263" "100 hour" ">20 hour" ">10 hour" "97.14" "1490" "248.33" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00005" "PAETGQET" "8" "NL5" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00005" "DRAVPe00005.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "831.83" "C33H53N9O16" "CDFHIKLMNRSVWY" "ET" "3.8" "0" "2" "-2" "3" "1" "-151.25" "-2155" ">20 hour" ">20 hour" "?" "12.5" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00006" "TAYFLLKLAGRW" "12" "NL-6 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=21±7 µM);inhibition of strand transfer catalyzed by integrase(IC50=2.7±1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00006" "DRAVPe00006.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1438.74" "C71H107N17O15" "CDEHIMNPQSV" "L" "9.99" "2" "0" "2" "3" "7" "50.83" "145" "7.2 hour" ">20 hour" ">10 hour" "114.17" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00007" "GRWPVKT" "7" "NL7" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00007" "DRAVPe00007.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "843" "C39H62N12O9" "ACDEFHILMNQSY" "GKPRTVW" "11" "2" "0" "2" "2" "2" "-111.43" "-1573" "30 hour" ">20 hour" ">10 hour" "41.43" "5500" "916.67" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00008" "HTDNGSNF" "8" "NL8" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00008" "DRAVPe00008.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "890.86" "C36H50N12O15" "ACEIKLMPQRVWY" "N" "5.08" "1" "1" "0" "5" "1" "-160" "-2871" "3.5 hour" "10 min" ">10 hour" "0" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00009" "ACWWAGIKQEF" "11" "NL-9 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=95±9 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00009" "DRAVPe00009.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1338.55" "C64H87N15O15S" "DHLMNPRSTVY" "AW" "6.04" "1" "1" "0" "2" "6" "2.73" "50" "4.4 hour" ">20 hour" ">10 hour" "53.64" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00010" "FGIPYNPQSQ" "10" "NL10" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00010" "DRAVPe00010.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1150.26" "C53H75N13O16" "ACDEHKLMRTVW" "PQ" "5.52" "0" "0" "0" "4" "2" "-89" "-1242" "1.1 hour" "3 min" "2 min" "39" "1490" "165.56" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00011" "ESMNKELKKI" "10" "NL11" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00011" "DRAVPe00011.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1219.46" "C52H94N14O17S" "ACDFGHPQRTVWY" "K" "8.59" "3" "2" "1" "2" "2" "-128" "-2812" "1 hour" "30 min" ">10 hour" "78" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00012" "VRDQAEHLKT" "10" "NL12" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00012" "DRAVPe00012.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1196.33" "C50H85N17O17" "CFGIMNPSWY" "ADEHKLQRTV" "6.72" "3" "2" "1" "1" "3" "-130" "-3800" "100 hour" ">20 hour" ">10 hour" "78" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00013" "FIHNFKRK" "8" "NL13" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00013" "DRAVPe00013.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1089.31" "C52H80N16O10" "ACDEGLMPQSTVWY" "FK" "11.17" "4" "0" "4" "1" "3" "-111.25" "-2644" "1.1 hour" "3 min" "2 min" "48.75" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00014" "GYSAGERIVD" "10" "NL14" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00014" "DRAVPe00014.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1066.14" "C45H71N13O17" "CFHKLMNPQTW" "G" "4.37" "1" "2" "-1" "4" "3" "-39" "-2134" "30 hour" ">20 hour" ">10 hour" "78" "1490" "165.56" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00015" "WKGPAKLLWK" "10" "NL15" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00015" "DRAVPe00015.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1226.53" "C62H95N15O11" "CDEFHIMNQRSTVY" "K" "10.3" "3" "0" "3" "1" "5" "-61" "60" "2.8 hour" "3 min" "2 min" "88" "11000" "1222.22" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00016" "VPRRKAKI" "8" "NL16" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00016" "DRAVPe00016.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "967.23" "C43H82N16O9" "CDEFGHLMNQSTWY" "KR" "12.02" "4" "0" "4" "0" "3" "-98.75" "-3017" "100 hour" ">20 hour" ">10 hour" "97.5" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00017" "AAYFLLKLAGRW" "12" "NL6-T1A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=100±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=47±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00017" "DRAVPe00017.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1408.71" "C70H105N17O14" "CDEHIMNPQSTV" "AL" "9.99" "2" "0" "2" "2" "8" "71.67" "583" "4.4 hour" ">20 hour" ">10 hour" "122.5" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00018" "TAAFLLKLAGRW" "12" "NL6-Y3A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=193±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=119±11 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00018" "DRAVPe00018.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1346.64" "C65H103N17O14" "CDEHIMNPQSVY" "AL" "11" "2" "0" "2" "2" "8" "76.67" "340" "7.2 hour" ">20 hour" ">10 hour" "122.5" "5500" "500" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00019" "TAYALLKLAGRW" "12" "NL6-F4A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00019" "DRAVPe00019.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1362.64" "C65H103N17O15" "CDEFHIMNPQSV" "AL" "9.99" "2" "0" "2" "3" "7" "42.5" "28" "7.2 hour" ">20 hour" ">10 hour" "122.5" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00020" "TAYFALKLAGRW" "12" "NL6-L5A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=115±21 µM);inhibition of strand transfer catalyzed by integrase(IC50=51±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00020" "DRAVPe00020.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1396.65" "C68H101N17O15" "CDEHIMNPQSV" "A" "9.99" "2" "0" "2" "3" "7" "34.17" "-166" "7.2 hour" ">20 hour" ">10 hour" "90" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00021" "TAYFLAKLAGRW" "12" "NL6-L6A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00021" "DRAVPe00021.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1396.65" "C68H101N17O15" "CDEHIMNPQSV" "A" "9.99" "2" "0" "2" "3" "7" "34.17" "-166" "7.2 hour" ">20 hour" ">10 hour" "90" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00022" "TAYFLLALAGRW" "12" "NL6-K7A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=113±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00022" "DRAVPe00022.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1381.64" "C68H100N16O15" "CDEHIKMNPQSV" "AL" "8.41" "1" "0" "1" "3" "8" "98.33" "881" "7.2 hour" ">20 hour" ">10 hour" "122.5" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00023" "TAYFLLKAAGRW" "12" "NL6-L8A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50=106±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00023" "DRAVPe00023.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1396.65" "C68H101N17O15" "CDEHIMNPQSV" "A" "9.99" "2" "0" "2" "3" "7" "34.17" "-166" "7.2 hour" ">20 hour" ">10 hour" "90" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00024" "TAYFLLKLAARW" "12" "NL6-G10A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=118±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=19±6 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00024" "DRAVPe00024.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1452.76" "C72H109N17O15" "CDEGHIMNPQSV" "AL" "9.99" "2" "0" "2" "2" "8" "69.17" "232" "7.2 hour" ">20 hour" ">10 hour" "122.5" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00025" "TAYFLLKLAGAW" "12" "NL6-R11A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=83±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=80±8 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00025" "DRAVPe00025.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1353.63" "C68H100N14O15" "CDEHIMNPQRSV" "AL" "8.26" "1" "0" "1" "3" "8" "103.33" "1818" "7.2 hour" ">20 hour" ">10 hour" "122.5" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00026" "TAYFLLKLAGRA" "12" "NL6-W12A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00026" "DRAVPe00026.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1323.6" "C63H102N16O15" "CDEHIMNPQSVW" "AL" "9.99" "2" "0" "2" "3" "7" "73.33" "93" "7.2 hour" ">20 hour" ">10 hour" "122.5" "1490" "135.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00027" "AAWWAGIKQEF" "11" "NL9-C2A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=277±47 µM);inhibition of strand transfer catalyzed by integrase(IC50=311±19 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00027" "DRAVPe00027.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1306.49" "C64H87N15O15" "CDHLMNPRSTVY" "A" "6.05" "1" "1" "0" "1" "7" "-3.64" "103" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00028" "ACAWAGIKQEF" "11" "NL9-W3A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=33±6 µM);inhibition of strand transfer catalyzed by integrase(IC50=34±8 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00028" "DRAVPe00028.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1223.41" "C56H82N14O15S" "DHLMNPRSTVY" "A" "6.04" "1" "1" "0" "2" "6" "27.27" "-2" "4.4 hour" ">20 hour" ">10 hour" "62.73" "5500" "550" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00029" "ACWAAGIKQEF" "11" "NL9-W4A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00029" "DRAVPe00029.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1223.41" "C56H82N14O15S" "DHLMNPRSTVY" "A" "6.04" "1" "1" "0" "2" "6" "27.27" "-2" "4.4 hour" ">20 hour" ">10 hour" "62.73" "5500" "550" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00030" "ACWWAAIKQEF" "11" "NL9-G6A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=90±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=43±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00030" "DRAVPe00030.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1352.57" "C65H89N15O15S" "DGHLMNPRSTVY" "A" "6.04" "1" "1" "0" "1" "7" "22.73" "137" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00031" "ACWWAGAKQEF" "11" "NL9-I7A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00031" "DRAVPe00031.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1296.47" "C61H81N15O15S" "DHILMNPRSTVY" "A" "6.04" "1" "1" "0" "2" "6" "-21.82" "-261" "4.4 hour" ">20 hour" ">10 hour" "27.27" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00032" "ACWWAGIAQEF" "11" "NL9-K8A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=62±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=55±7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00032" "DRAVPe00032.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1281.45" "C61H80N14O15S" "DHKLMNPRSTVY" "A" "4" "0" "1" "-1" "2" "7" "54.55" "786" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00033" "ACWWAGIKAEF" "11" "NL9-Q9A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00033" "DRAVPe00033.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1281.49" "C62H84N14O14S" "DHLMNPQRSTVY" "A" "6.04" "1" "1" "0" "2" "7" "50.91" "785" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00034" "ACWWAGIKQAF" "11" "NL9-E10A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00034" "DRAVPe00034.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1280.51" "C62H85N15O13S" "DEHLMNPRSTVY" "A" "8.27" "1" "0" "1" "2" "7" "50.91" "912" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00035" "ACWWAGIKQEA" "11" "NL9-F11A " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=245±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=206±12 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00035" "DRAVPe00035.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1262.45" "C58H83N15O15S" "DFHLMNPRSTVY" "A" "6.04" "1" "1" "0" "2" "6" "-6.36" "-67" "4.4 hour" ">20 hour" ">10 hour" "62.73" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00036" "TASFLLKLAGRW" "12" "NL6-1 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=186±23 µM);inhibition of strand transfer catalyzed by integrase(IC50=11±2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00036" "DRAVPe00036.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1362.64" "C65H103N17O15" "CDEHIMNPQVY" "L" "11" "2" "0" "2" "3" "7" "55" "-181" "7.2 hour" ">20 hour" ">10 hour" "114.17" "5500" "500" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00037" "TAYFLLILAGRW" "12" "NL6-2 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.1±0.7 µM);inhibition of strand transfer catalyzed by integrase(IC50=3.0±1.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00037" "DRAVPe00037.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1423.72" "C71H106N16O15" "CDEHKMNPQSV" "L" "8.41" "1" "0" "1" "3" "8" "120.83" "1192" "7.2 hour" ">20 hour" ">10 hour" "146.67" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00038" "TAYFLLKLAGRL" "12" "NL6-3 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=315±30 µM);inhibition of strand transfer catalyzed by integrase(IC50=38±2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00038" "DRAVPe00038.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1365.68" "C66H108N16O15" "CDEHIMNPQSVW" "L" "9.99" "2" "0" "2" "3" "7" "90" "404" "7.2 hour" ">20 hour" ">10 hour" "146.67" "1490" "135.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00039" "ASWWAGIKQEF" "11" "NL9-1 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=294±41 µM);inhibition of strand transfer catalyzed by integrase(IC50=163±15 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00039" "DRAVPe00039.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1322.49" "C64H87N15O16" "CDHLMNPRTVY" "AW" "6.05" "1" "1" "0" "2" "6" "-27.27" "-418" "4.4 hour" ">20 hour" ">10 hour" "53.64" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00040" "ACGWAGIKQEF" "11" "NL9-2 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=46±5 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00040" "DRAVPe00040.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1209.38" "C55H80N14O15S" "DHLMNPRSTVY" "AG" "6.04" "1" "1" "0" "3" "5" "7.27" "-89" "4.4 hour" ">20 hour" ">10 hour" "53.64" "5500" "550" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00041" "ACWGAGIKQEF" "11" "NL9-3 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00041" "DRAVPe00041.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1209.38" "C55H80N14O15S" "DHLMNPRSTVY" "AG" "6.04" "1" "1" "0" "3" "5" "7.27" "-89" "4.4 hour" ">20 hour" ">10 hour" "53.64" "5500" "550" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00042" "ACWWAGIRQEF" "11" "NL9-4 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00042" "DRAVPe00042.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1366.56" "C64H87N17O15S" "DHKLMNPSTVY" "AW" "6.04" "1" "1" "0" "2" "6" "-2.73" "-887" "4.4 hour" ">20 hour" ">10 hour" "53.64" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00043" "TAYFLL" "6" "NL6-4" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=500 µM);inhibition of strand transfer catalyzed by integrase(IC50=500 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00043" "DRAVPe00043.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "726.87" "C37H54N6O9" "CDEGHIKMNPQRSVW" "L" "5.18" "0" "0" "0" "2" "4" "170" "1192" "7.2 hour" ">20 hour" ">10 hour" "146.67" "1490" "298" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00044" "YFLLKL" "6" "NL6-5 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=20 µM);inhibition of strand transfer catalyzed by integrase(IC50=20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00044" "DRAVPe00044.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "796.02" "C42H65N7O8" "ACDEGHIMNPQRSTVW" "L" "8.59" "1" "0" "1" "1" "4" "150" "1205" "2.8 hour" "10 min" "2 min" "195" "1490" "298" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00045" "KLAGRW" "6" "NL6-6" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00045" "DRAVPe00045.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "729.88" "C34H55N11O7" "CDEFHIMNPQSTVY" "AGKLRW" "11" "2" "0" "2" "1" "3" "-68.33" "-1047" "1.3 hour" "3 min" "2 min" "81.67" "5500" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00046" "ACWWAG" "6" "NL9-5 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00046" "DRAVPe00046.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "692.79" "C33H40N8O7S" "DEFHIKLMNPQRSTVY" "AW" "5.56" "0" "0" "0" "2" "4" "65" "1050" "4.4 hour" ">20 hour" ">10 hour" "33.33" "11000" "2200" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00047" "WAGIKQ" "6" "NL9-6 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00047" "DRAVPe00047.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "701.82" "C33H51N9O8" "CDEFHLMNPRSTVY" "AGIKQW" "8.75" "1" "0" "1" "1" "3" "-40" "-109" "2.8 hour" "3 min" "2 min" "81.67" "5500" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00048" "IKQEF" "5" "NL9-7 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00048" "DRAVPe00048.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "663.77" "C31H49N7O9" "ACDGHLMNPRSTVWY" "EFIKQ" "6" "1" "1" "0" "0" "2" "-72" "-1000" "20 hour" "30 min" ">10 hour" "78" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00049" "tayfllklagrw" "12" "DNL-6" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=65±8 µM);inhibition of strand transfer catalyzed by integrase(IC50=13±1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00049.cif" "Linear" "Free" "Free" "None" "D" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1438.74" "H-22O-11" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "9.99" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00050" "WRGALKLLFYAT" "12" "RNL-6" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=96±2 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±4 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00050" "DRAVPe00050.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1438.74" "C71H107N17O15" "CDEHIMNPQSV" "L" "9.99" "2" "0" "2" "3" "7" "50.83" "145" "2.8 hour" "3 min" "2 min" "114.17" "6990" "635.45" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00051" "wrgalkllfyat" "12" "RDNL-6" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.5±1 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.0±1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00051.cif" "Linear" "Free" "Free" "None" "D" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1438.74" "H-22O-11" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "9.99" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00052" "acwwagikqef" "11" "DNL-9 " "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00052.cif" "Linear" "Free" "Free" "None" "D" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1338.55" "H-20O-10" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "6.04" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00053" "FEQKIGAWWCA" "11" "RNL-9" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00053" "DRAVPe00053.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1338.55" "C64H87N15O15S" "DHLMNPRSTVY" "AW" "5.99" "1" "1" "0" "2" "6" "2.73" "50" "1.1 hour" "3 min" "2 min" "53.64" "11000" "1100" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00054" "feqkigawwca" "11" "RDNL-9" "Synthetic construct(derived from HIV-1 integrase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase Assay" "[Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00054.cif" "Linear" "Free" "Free" "None" "D" "Integrase" "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." "1338.55" "H-20O-10" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "5.99" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "16854053" "J Med Chem. 2006 Jul 27;49(15):4477-86." "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." "Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme." "10.1021/jm060307u" "Anti-HIV" "DRAVPe00055" "DFRELNKRTQDFWEVQLGIP" "20" "4277(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00055" "DRAVPe00055.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2491.79" "C113H171N31O33" "ACHMSY" "DEFLQR" "4.78" "3" "4" "-1" "3" "7" "-95.5" "-5871" "1.1 hour" "3 min" ">10 hour" "73" "5500" "289.47" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00056" "SPAIFQSSMTKILEPFRKQN" "20" "4285(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=35 µM);inhibition of strand transfer catalyzed by integrase(IC50=270 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00056" "DRAVPe00056.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2322.71" "C104H168N28O30S" "CDGHVWY" "S" "9.99" "3" "1" "2" "5" "6" "-52.5" "-3844" "1.9 hour" ">20 hour" ">10 hour" "63.5" "0" "0" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00057" "FRKQNPDIVIYQYMD" "15" "4286’-1(derived from the DNA-polymerase domain of HIV-1 RT (14-mer) )" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=119 µM);inhibition of strand transfer catalyzed by integrase(IC50=97 µM);inhibition of disintegration catalyzed by integrase(IC50>270 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00057" "DRAVPe00057.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "1930.21" "C88H132N22O25S" "ACEGHLSTW" "DIQY" "5.96" "2" "2" "0" "3" "4" "-81.33" "-3670" "1.1 hour" "3 min" "2 min" "71.33" "2980" "212.86" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00058" "KILEPFRKQNPDIVIYQYMD" "20" "4286(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.5 µM);inhibition of disintegration catalyzed by integrase(IC50=9.4 µM);##HIV-1:the level of peptide binding to HIV integrase is high." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00058" "DRAVPe00058.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2510.93" "C116H180N28O32S" "ACGHSTW" "I" "6.12" "3" "3" "0" "3" "6" "-64.5" "-3922" "1.3 hour" "3 min" "2 min" "92.5" "2980" "156.84" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00059" "PDIVIYQYMDDLYVGSDLEI" "20" "4287(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),34(derived from the HIV-1 HXB2 Pol region of the viral genome)" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=22 µM);inhibition of strand transfer catalyzed by integrase(IC50=54 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=10±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=28±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=23±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=41±2 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=20 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00059" "DRAVPe00059.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2361.65" "C108H161N21O36S" "ACFHKNRTW" "D" "3.28" "0" "5" "-5" "5" "7" "18.5" "-1508" ">20 hour" ">20 hour" "?" "126.5" "4470" "235.26" "15790559##16879966" "J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. " "10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022" "Anti-HIV" "DRAVPe00060" "DIQKLVGKLNWASQIYPGIK" "20" "4295(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00060" "DRAVPe00060.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2271.69" "C106H171N27O28" "CEFHMRT" "IK" "9.53" "3" "1" "2" "5" "8" "-20" "-1197" "1.1 hour" "3 min" ">10 hour" "117" "6990" "367.89" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00061" "IAEIQKQGQGQWTYQIYQEP" "20" "4302(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00061" "DRAVPe00061.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2408.65" "C109H162N28O34" "CDFHLMNRSV" "Q" "4.53" "1" "2" "-1" "5" "5" "-116" "-3448" "20 hour" "30 min" ">10 hour" "63.5" "8480" "446.32" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00062" "KQLTEAVQKITTESIVIWGK" "20" "4306(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),53(derived from the HIV-1 HXB2 Pol region of the viral genome)" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=7±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=51±7 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=31±7 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=29±1 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=15 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=10 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00062" "DRAVPe00062.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2272.67" "C103H174N26O31" "CDFHMNPRY" "IKT" "8.5" "3" "2" "1" "5" "8" "-12" "-1962" "1.3 hour" "3 min" "2 min" "112" "5500" "289.47" "15790559##16879966" "J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. " "10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022" "Anti-HIV" "DRAVPe00063" "TPKFKLPIQKETWETWWTEY" "20" "4308(derived from DNA-polymerase domain of HIV-1 RT (20-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00063" "DRAVPe00063.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2611.98" "C127H179N27O33" "ACDGHMNRSV" "T" "5.9" "3" "3" "0" "5" "6" "-123" "-3323" "7.2 hour" ">20 hour" ">10 hour" "39" "17990" "946.84" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00064" "ETWETWWTEYWQATWIPEWE" "20" "4309(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),56(derived from the HIV-1 HXB2 Pol region of the viral genome)" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=13±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=9±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=126±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=27±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=25 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00064" "DRAVPe00064.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." "2757.95" "C135H165N27O37" "CDFGHKLMNRSV" "W" "3.51" "0" "5" "-5" "5" "8" "-129" "-2930" "1 hour" "30 min" ">10 hour" "24.5" "34490" "1815.26" "15790559##16879966" "J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. " "10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022" "Anti-HIV" "DRAVPe00065" "GYVTNRGRQKVVTLTDTTNQ" "20" "4315(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00065" "DRAVPe00065.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2251.48" "C94H159N31O33" "ACEFHIMPSW" "T" "9.99" "3" "1" "2" "10" "4" "-98" "-6254" "30 hour" ">20 hour" ">10 hour" "63" "1490" "78.42" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00066" "VVTLTDTTNQKTELQAIYLA" "20" "4316(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00066" "DRAVPe00066.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2222.52" "C98H164N24O34" "CFGHMPRSW" "T" "4.37" "1" "2" "-1" "7" "8" "8.5" "-2041" "100 hour" ">20 hour" ">10 hour" "117" "1490" "78.42" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00067" "KTELQAIYLALQDSGLEVNI" "20" "4317(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00067" "DRAVPe00067.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2218.53" "C99H164N24O33" "CFHMPRW" "L" "4.14" "1" "3" "-2" "5" "9" "19.5" "-1360" "1.3 hour" "3 min" "2 min" "141.5" "1490" "78.42" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00068" "LQDSGLEVNIVTDSQYALGI" "20" "4318(derived from the RNase H domain of HIV-1 RT (20-mes)),65(derived from the HIV-1 HXB2 Pol region of the viral genome)" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=11±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50>167 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=36±14 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=18±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50>167 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=20 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00068" "DRAVPe00068.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2135.36" "C93H151N23O34" "CFHKMPRW" "L" "3.49" "0" "3" "-3" "7" "8" "26" "-1511" "5.5 hour" "3 min" "2 min" "131.5" "1490" "78.42" "15790559##16879966" "J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. " "10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022" "Anti-HIV" "DRAVPe00069" "VTDSQYALGIIQAQPDQSES" "20" "4319(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00069" "DRAVPe00069.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2150.28" "C91H144N24O36" "CFHKMNRW" "Q" "3.49" "0" "3" "-3" "6" "6" "-51.5" "-3596" "100 hour" ">20 hour" ">10 hour" "83" "1490" "78.42" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00070" "IQAQPDQSESELVNQIIEQL" "20" "4320(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00070" "DRAVPe00070.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2282.49" "C97H160N26O37" "CFGHKMRTWY" "Q" "3.5" "0" "4" "-4" "3" "7" "-55.5" "-3984" "20 hour" "30 min" ">10 hour" "117" "0" "0" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00071" "ELVNQIIEQLIKKEKVYLAW" "20" "4321(derived from the RNase H domain of HIV-1 RT (20-mes)),64(derived from the HIV-1 HXB2 Pol region of the viral genome)" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=6.9 µM);inhibition of strand transfer catalyzed by integrase(IC50=5 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=15±2 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=14±4 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=113±11 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=83±5 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=136±5 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=7±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=45 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=15 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00071" "DRAVPe00071.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2457.94" "C116H189N27O31" "CDFGHMPRST" "EIKL" "6.32" "3" "3" "0" "2" "10" "1" "-1320" "1 hour" "30 min" ">10 hour" "151" "6990" "367.89" "15790559##16879966" "J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. " "10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022" "Anti-HIV" "DRAVPe00072" "NQIIEQLIKKEKVY" "14" "4321’-1( derived from the RNase H domain of HIV-1 RT (15-mer))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>240 µM);inhibition of strand transfer catalyzed by integrase(IC50>240 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00072" "DRAVPe00072.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "1746.08" "C80H136N20O23" "ACDFGHMPRSTW" "IK" "8.43" "3" "2" "1" "2" "5" "-64.29" "-2441" "1.4 hour" "3 min" ">10 hour" "132.14" "1490" "114.62" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00073" "IKKEKVYLAWVPAHKGIGN" "19" "4322(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00073" "DRAVPe00073.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2151.58" "C102H163N27O24" "CDFMQRST" "K" "9.83" "5" "1" "4" "4" "8" "-29.47" "-978" "20 hour" "30 min" ">10 hour" "102.63" "6990" "388.33" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00074" "EQVDKLVSAGIRKVLFLDGI" "20" "4324(derived from the RNase H domain of HIV-1 RT (20-mes))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00074" "DRAVPe00074.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "2200.61" "C100H170N26O29" "CHMNPTWY" "LV" "6.22" "3" "3" "0" "3" "10" "48.5" "-1582" "1 hour" "30 min" ">10 hour" "146" "0" "0" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00075" "ESELVSQIIEQLIKK" "15" "5628(derived from RNase H domain of HIV-1 RT (15-mers))" "Synthetic construct(derived from HIV-1 Reverse Transcriptase)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot assay" "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50=60 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00075" "DRAVPe00075.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication." "1757.06" "C78H137N19O26" "ACDFGHMNPRTWY" "EI" "4.79" "2" "3" "-1" "2" "6" "-10.67" "-2077" "1 hour" "30 min" ">10 hour" "149.33" "0" "0" "15790559" "J Biol Chem. 2005 Jun 10;280(23):21987-96." "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." "Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase." "10.1074/jbc.M414679200" "Anti-HIV" "DRAVPe00076" "LQQLLFIHFRIGCQH" "15" "Vpr 15" "Synthetic construct(HIV-1 gene product)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=5.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00076" "DRAVPe00076.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "1853.22" "C86H133N25O19S" "ADEKMNPSTVWY" "LQ" "8.27" "3" "0" "3" "2" "7" "44.67" "-808" "5.5 hour" "3 min" "2 min" "130" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00077" "TNWLWYIKIFIMIV" "14" "Env4-4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=1.9 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00077" "DRAVPe00077.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "1840.3" "C94H138N18O18S" "ACDEGHPQRS" "I" "8.26" "1" "0" "1" "3" "9" "139.29" "2373" "7.2 hour" ">20 hour" ">10 hour" "160" "12490" "960.77" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00078" "LQQLLF" "6" "Vpr-1" "Synthetic construct(derived from HIV-1 gene products(Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>11 µM);inhibition of strand transfer catalyzed by integrase(IC50=68±1.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00078" "DRAVPe00078.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "760.93" "C37H60N8O9" "ACDEGHIKMNPRSTVWY" "L" "5.52" "0" "0" "0" "0" "4" "120" "666" "5.5 hour" "3 min" "2 min" "195" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00079" "LQQLLFRRRRRRRR" "14" "Vpr-1 R8" "Synthetic construct(derived from HIV-1 gene products(Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=6.1±1.1 µM);inhibition of strand transfer catalyzed by integrase(IC50>11 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00079" "DRAVPe00079.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "2010.43" "C85H156N40O17" "ACDEGHIKMNPSTVWY" "R" "12.85" "8" "0" "8" "0" "4" "-205.71" "-11270" "5.5 hour" "3 min" "2 min" "83.57" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00080" "IHFRIGRRRRRRRR" "14" "Vpr-2 R8" "Synthetic construct(derived from HIV-1 gene products(Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.70±0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.83±0.07 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00080" "DRAVPe00080.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "1991.39" "C83H151N43O15" "ACDEKLMNPQSTVWY" "R" "12.9" "10" "0" "10" "1" "3" "-230.71" "-12518" "20 hour" "30 min" ">10 hour" "55.71" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00081" "LQQLLFIHFRIGRRRRRRRR" "20" "Vpr-3 R8" "Synthetic construct(derived from HIV-1 gene products(Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.004±0.0001 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.008±0.001 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00081" "DRAVPe00081.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "2734.31" "C120H209N51O23" "ACDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-125.5" "-11852" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00082" "EAIIRILQQLLFIHFRIGRRRRRRRR" "26" "Vpr-4 R8" "Synthetic construct(derived from HIV-1 gene products(Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.005±0.002 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.006±0.006 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00082" "DRAVPe00082.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." "3430.17" "C152H266N60O31" "CDKMNPSTVWY" "R" "12.6" "11" "1" "10" "1" "11" "-68.46" "-12368" "1 hour" "30 min" ">10 hour" "123.85" "0" "0" "20586421" "J Med Chem. 2010 Jul 22;53(14):5356-60." "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " "Peptide HIV-1 integrase inhibitors from HIV-1 gene products." "10.1021/jm1003528" "Anti-HIV" "DRAVPe00083" "TYGDTWAGVEAIIRI" "15" "Vpr 49-63 " "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of Rnase H(IC50>>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00083" "DRAVPe00083.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1664.88" "C76H117N19O23" "CFHKLMNPQS" "I" "4.37" "1" "2" "-1" "5" "7" "36" "-910" "7.2 hour" ">20 hour" ">10 hour" "110.67" "6990" "499.29" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00084" "TWAGVEAIIRILQQL" "15" "Vpr 53-67" "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of Rnase H(IC50=6.9 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);inhibition of strand transfer catalyzed by integrase(IC50=144 µM);inhibition of disintegration catalyzed by integrase(IC50=27 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00084" "DRAVPe00084.cif" "Linear" "Free" "Free" "None" "L" "Integrase,Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1711.04" "C79H131N21O21" "CDFHKMNPSY" "I" "5.66" "1" "1" "0" "2" "9" "79.33" "15" "7.2 hour" ">20 hour" ">10 hour" "162.67" "5500" "392.86" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00085" "VEAIIRILQQLLFIH" "15" "Vpr 57-71" "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of Rnase H(IC50=2 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=7.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=16 µM);inhibition of disintegration catalyzed by integrase(IC50=3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00085" "DRAVPe00085.cif" "Linear" "Free" "Free" "None" "L" "Integrase,Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1806.22" "C86H144N22O20" "CDGKMNPSTWY" "I" "6.72" "2" "1" "1" "0" "10" "133.33" "580" "100 hour" ">20 hour" ">10 hour" "208" "0" "0" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00086" "IRILQQLLFIHFRIG" "15" "Vpr 61-75" "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.7 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=1.3 µM);inhibit the activity of Rnase H(IC50=5.25 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=1.3 µM);inhibition of strand transfer catalyzed by integrase(IC50=1 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00086" "DRAVPe00086.cif" "Linear" "Free" "Free" "None" "L" "Integrase,Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1867.31" "C90H147N25O18" "ACDEKMNPSTVWY" "I" "12" "3" "0" "3" "1" "9" "102.67" "-424" "20 hour" "30 min" ">10 hour" "182" "0" "0" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00087" "QQLLFIHFRIGCQHS" "15" "Vpr 65-79 " "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=33 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=43 µM);inhibit the activity of Rnase H(IC50=16.5 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=76 µM);inhibition of strand transfer catalyzed by integrase(IC50=14 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00087" "DRAVPe00087.cif" "Linear" "Free" "Free" "None" "L" "Integrase,Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1827.14" "C83H127N25O20S" "ADEKMNPTVWY" "Q" "8.27" "3" "0" "3" "3" "6" "14" "-1640" "0.8 hour" "10 min" ">10 hour" "104" "0" "0" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00088" "FIHFRIGCQHSRIGI" "15" "Vpr 69-83" "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of Rnase H(IC50>>200 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>>200 µM);inhibition of strand transfer catalyzed by integrase(IC50>>200 µM);inhibition of disintegration catalyzed by integrase(IC50>>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00088" "DRAVPe00088.cif" "Linear" "Free" "Free" "None" "L" "Integrase,Reverse Transcriptase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1." "1784.11" "C81H126N26O18S" "ADEKLMNPTVWY" "I" "10.35" "4" "0" "4" "4" "6" "37.33" "-1930" "1.1 hour" "3 min" "2 min" "104" "0" "0" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00089" "HFPRIWLHSLGQHIY" "15" "Vpr 33-47 " "Synthetic construct(derived from HIV-1 viral protein R (Vpr))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Dot-blot binding assay" "[Ref.17490682]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=187 µM);inhibition of strand transfer catalyzed by integrase(IC50=41 µM);inhibition of disintegration catalyzed by integrase(IC50=73 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00089" "DRAVPe00089.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and thus inhibit the replication of HIV-1." "1904.21" "C92H130N26O19" "ACDEKMNTV" "H" "8.77" "4" "0" "4" "3" "6" "-21.33" "-1205" "3.5 hour" "10 min" ">10 hour" "104" "6990" "499.29" "17490682" "J Mol Biol. 2007 Jun 22;369(5):1230-43." "Gleenberg IO, Herschhorn A, Hizi A." "Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr)." "10.1016/j.jmb.2007.03.073" "Anti-HIV" "DRAVPe00090" "QLLIRMIYKNILFYLVPGPGHGAEPERRNIKYL" "33" "I33" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=9 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00090" "DRAVPe00090.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide bound tightly to the integrase(IN) and inhibited both in vitro IN activities, containing 3′ end processing and strand transfer." "3913.69" "C183H291N49O44S" "CDSTW" "L" "9.82" "6" "2" "4" "8" "12" "-12.73" "-3510" "0.8 hour" "10 min" ">10 hour" "118.18" "4470" "139.69" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00091" "RMIYKNILFYLVPGPGHGAEPERRNIKYL" "29" "I29" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=85 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00091" "DRAVPe00091.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "3446.08" "C160H250N44O39S" "CDQSTW" "GILPRY" "9.82" "6" "2" "4" "8" "9" "-44.14" "-4432" "1 hour" "2 min" "2 min" "94.14" "4470" "159.64" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00092" "QLLIRMI" "7" "LCD278B" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00092" "DRAVPe00092.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "886.16" "C40H75N11O9S" "ACDEFGHKNPSTVWY" "IL" "9.75" "1" "0" "1" "0" "4" "150" "157" "0.8 hour" "10 min" ">10 hour" "222.86" "0" "0" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00093" "AEPERRNIKYL" "11" "EBR24" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00093" "DRAVPe00093.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1388.59" "C61H101N19O18" "CDFGHMQSTVW" "ER" "8.63" "3" "2" "1" "2" "3" "-147.27" "-4414" "4.4 hour" ">20 hour" ">10 hour" "80" "1490" "149" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00094" "LFYLVPGPGH" "10" "EBR26" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00094" "DRAVPe00094.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1099.3" "C55H78N12O12" "ACDEIKMNQRSTW" "GLP" "6.74" "1" "0" "1" "3" "4" "61" "1394" "5.5 hour" "3 min" "2 min" "107" "1490" "165.56" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00095" "YQLLIRMIYKNI" "12" "EBR28" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=40 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00095" "DRAVPe00095.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1567.95" "C74H122N18O17S" "ACDEFGHPSTVW" "I" "9.7" "2" "0" "2" "3" "5" "41.67" "-598" "2.8 hour" "10 min" "2 min" "162.5" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00096" "YALLIRMIYKNI" "12" "EBR28[Q2A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=8 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00096" "DRAVPe00096.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1510.9" "C72H119N17O16S" "CDEFGHPQSTVW" "I" "9.7" "2" "0" "2" "3" "6" "85.83" "137" "2.8 hour" "10 min" "2 min" "170.83" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00097" "YQALIRMIYKNI" "12" "EBR28[L3A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=165 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00097" "DRAVPe00097.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1525.87" "C71H116N18O17S" "CDEFGHPSTVW" "I" "9.7" "2" "0" "2" "3" "5" "25" "-909" "2.8 hour" "10 min" "2 min" "138.33" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00098" "YQLAIRMIYKNI" "12" "EBR28[L4A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=14 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00098" "DRAVPe00098.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1525.87" "C71H116N18O17S" "CDEFGHPSTVW" "I" "9.7" "2" "0" "2" "3" "5" "25" "-909" "2.8 hour" "10 min" "2 min" "138.33" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00099" "YQLLARMIYKNI" "12" "EBR28[I5A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=45 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00099" "DRAVPe00099.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1525.87" "C71H116N18O17S" "CDEFGHPSTVW" "ILY" "9.7" "2" "0" "2" "3" "5" "19.17" "-909" "2.8 hour" "10 min" "2 min" "138.33" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00100" "YQLLIAMIYKNI" "12" "EBR28[R6A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=34 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00100" "DRAVPe00100.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1482.84" "C71H115N15O17S" "CDEFGHPRSTVW" "I" "8.5" "1" "0" "1" "3" "6" "94.17" "1075" "2.8 hour" "10 min" "2 min" "170.83" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00101" "YQLLIRAIYKNI" "12" "EBR28[M7A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=70 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00101" "DRAVPe00101.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1507.84" "C72H118N18O17" "CDEFGHMPSTVW" "I" "9.7" "2" "0" "2" "3" "6" "40.83" "-652" "2.8 hour" "10 min" "2 min" "170.83" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00102" "YQLLIRMAYKNI" "12" "EBR28[I8A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=35 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00102" "DRAVPe00102.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1525.87" "C71H116N18O17S" "CDEFGHPSTVW" "ILY" "9.7" "2" "0" "2" "3" "5" "19.17" "-909" "2.8 hour" "10 min" "2 min" "138.33" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00103" "YQLLIRMIAKNI" "12" "EBR28[Y9A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=40 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00103" "DRAVPe00103.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1475.86" "C68H118N18O16S" "CDEFGHPSTVW" "I" "9.99" "2" "0" "2" "2" "6" "67.5" "-403" "2.8 hour" "10 min" "2 min" "170.83" "1490" "135.45" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00104" "YQLLIRMIYANI" "12" "EBR28[K10A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00104" "DRAVPe00104.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1510.86" "C71H115N17O17S" "CDEFGHKPSTVW" "I" "8.59" "1" "0" "1" "3" "6" "89.17" "138" "2.8 hour" "10 min" "2 min" "170.83" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00105" "YQLLIRMIYKAI" "12" "EBR28[N11A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=7 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00105" "DRAVPe00105.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1524.93" "C73H121N17O16S" "CDEFGHNPSTVW" "I" "9.7" "2" "0" "2" "2" "6" "85.83" "247" "2.8 hour" "10 min" "2 min" "170.83" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00106" "YQLLIRMIYKNA" "12" "EBR28[I12A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00106" "DRAVPe00106.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1525.87" "C71H116N18O17S" "CDEFGHPSTVW" "ILY" "9.7" "2" "0" "2" "3" "5" "19.17" "-909" "2.8 hour" "10 min" "2 min" "138.33" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00107" "YQLLIRMIY" "9" "LCE41" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=55 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00107" "DRAVPe00107.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1212.52" "C58H93N13O13S" "ACDEFGHKNPSTVW" "ILY" "8.59" "1" "0" "1" "2" "4" "87.78" "129" "2.8 hour" "10 min" "2 min" "173.33" "2980" "372.5" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00108" "YQLLIRMI" "8" "LCE40" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=120 µM);no inhibition of HIV-1 infection up to 100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00108" "DRAVPe00108.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1049.34" "C49H84N12O11S" "ACDEFGHKNPSTVW" "IL" "8.75" "1" "0" "1" "1" "4" "115" "143" "2.8 hour" "10 min" "2 min" "195" "1490" "212.86" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00109" "QLLIRMIYKNI" "11" "LCD278C" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=21 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00109" "DRAVPe00109.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1404.78" "C65H113N17O15S" "ACDEFGHPSTVW" "I" "9.99" "2" "0" "2" "2" "5" "57.27" "-584" "0.8 hour" "10 min" ">10 hour" "177.27" "1490" "149" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00110" "YQLLIRPIYKNI" "12" "ProEBR28" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00110" "DRAVPe00110.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "1533.88" "C74H120N18O17" "ACDEFGHMSTVW" "I" "9.7" "2" "0" "2" "3" "5" "12.5" "-833" "2.8 hour" "10 min" "2 min" "162.5" "2980" "270.91" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00111" "LSELDDRADALQAGASQFETSAAKLKRKYWWKN" "33" "C35" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Disintegration assay" "[Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM." "DRAVPe00111" "DRAVPe00111.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus." "3798.23" "C169H262N48O52" "CHIMPV" "A" "8.38" "6" "5" "1" "7" "13" "-92.12" "-8333" "5.5 hour" "3 min" "2 min" "65.45" "12490" "390.31" "12054767" "J Mol Biol. 2002 Apr 19;318(1):45-58." "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " "A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase." "10.1016/S0022-2836(02)00033-5" "Anti-HIV" "DRAVPe00112" "TGEKVWDRGNVTLLCDCP" "18" "P11(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=439.7 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=162.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=484.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=208.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00112" "DRAVPe00112.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2006.28" "C85H136N24O28S2" "AFHIMQSY" "CDGLTV" "4.56" "2" "3" "-1" "7" "5" "-33.89" "-3181" "7.2 hour" ">20 hour" ">10 hour" "75.56" "5625" "330.88" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00113" "LPAFCQAIGWGDPITHWS" "18" "P19(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=369.5 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=46.0 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=194.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=71.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00113" "DRAVPe00113.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "1999.27" "C94H131N23O24S" "EKMNRVY" "AGIPW" "5.08" "1" "1" "0" "5" "8" "23.33" "429" "5.5 hour" "3 min" "2 min" "76.11" "11000" "647.06" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00114" "FCQAIGWGDPITHWSHGQ" "18" "P20(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=347.6 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=70.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=125.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=111.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00114" "DRAVPe00114.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2040.24" "C93H126N26O25S" "EKLMNRVY" "G" "5.97" "2" "1" "1" "6" "6" "-38.33" "-1170" "1.1 hour" "3 min" "2 min" "48.89" "11000" "647.06" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00115" "AIGWGDPITHWSHGQNRW" "18" "P21(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=832.9 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=44.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=529.1 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=371.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00115" "DRAVPe00115.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2118.3" "C97H132N30O25" "CEFKLMVY" "GW" "6.96" "3" "1" "2" "6" "6" "-97.78" "-2965" "4.4 hour" ">20 hour" ">10 hour" "48.89" "16500" "970.59" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00116" "PITHWSHGQNRWPLSCPQ" "18" "P23(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=508.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00116" "DRAVPe00116.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2144.4" "C96H138N30O25S" "ADEFKMVY" "P" "8.68" "3" "0" "3" "6" "4" "-110.56" "-3461" ">20 hour" ">20 hour" "?" "43.33" "11000" "647.06" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00117" "HGQNRWPLSCPQYVYGSV" "18" "P25(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=304.4 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00117" "DRAVPe00117.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2091.33" "C94H135N27O26S" "ADEFIKMT" "GPQSVY" "8.21" "2" "0" "2" "8" "4" "-70" "-2589" "3.5 hour" "10 min" ">10 hour" "53.89" "8480" "498.82" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00118" "SWFASTGGRDSKIDVWSL" "18" "P34(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=237.4 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=411.2 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=118.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00118" "DRAVPe00118.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2012.21" "C91H134N24O28" "CEHMNPQY" "S" "5.68" "2" "2" "0" "7" "7" "-26.67" "-2887" "1.9 hour" ">20 hour" ">10 hour" "65" "11000" "647.06" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00119" "SDRDTVVELSEWGVPCAT" "18" "P45(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=141.2 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=48.8 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=505.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=43.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00119" "DRAVPe00119.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "1964.13" "C83H130N22O31S" "FHIKMNQY" "V" "3.92" "1" "4" "-3" "6" "6" "-20.56" "-3452" "1.9 hour" ">20 hour" ">10 hour" "75.56" "5500" "323.53" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00120" "DTVVELSEWGVPCATCIL" "18" "P46(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=428.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=39.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=462.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=24.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00120" "DRAVPe00120.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "1935.24" "C85H135N19O28S2" "FHKMNQRY" "V" "3.57" "0" "3" "-3" "6" "8" "88.33" "364" "1.1 hour" "3 min" ">10 hour" "118.89" "5625" "330.88" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00121" "VELSEWGVPCATCILDRR" "18" "P47(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=330.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=58.6 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=140.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=20.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00121" "DRAVPe00121.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2047.37" "C88H143N25O27S2" "FHKMNQY" "CELRV" "4.68" "2" "3" "-1" "5" "7" "18.89" "-2767" "100 hour" ">20 hour" ">10 hour" "102.78" "5625" "330.88" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00122" "RFPFHRCGAGPKLTKDLE" "18" "P59(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=529.6 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00122" "DRAVPe00122.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2072.42" "C93H146N28O24S" "IMNQSVWY" "FGKLPR" "9.31" "5" "2" "3" "4" "5" "-78.89" "-4293" "1 hour" "2 min" "2 min" "48.89" "0" "0" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00123" "LVRRRSELMGRRNPVCPG" "18" "P97(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=537.6 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00123" "DRAVPe00123.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2096.5" "C86H154N34O23S2" "ADFHIKQTWY" "R" "11.82" "5" "1" "4" "5" "4" "-77.22" "-6802" "5.5 hour" "3 min" "2 min" "75.56" "0" "0" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00124" "LQEVDAGNFIPPPRWLLL" "18" "P109(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=687.1 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=37.5 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=294.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=60.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00124" "DRAVPe00124.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "2078.44" "C99H152N24O25" "CHKMSTY" "L" "4.37" "1" "2" "-1" "2" "9" "21.67" "-593" "5.5 hour" "3 min" "2 min" "130" "5500" "323.53" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00125" "WVNQLAVLGLPAVDAAVA" "18" "P124(derived from E2 envelope protein of GB virus C)" "Synthetic construct(derived from E2 envelope protein of GB virus C)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Gp41-Mediated Cell-Cell Fusion Assay" "[Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=332.7 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=94.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00125" "DRAVPe00125.cif" "Linear" "Free" "Free" "None" "L" "membrane" "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." "1807.12" "C84H135N21O23" "CEFHIKMRSTY" "A" "3.8" "0" "1" "-1" "2" "13" "132.22" "2234" "2.8 hour" "3 min" "2 min" "157.22" "5500" "323.53" "20718496" "J Med Chem. 2010 Aug 26;53(16):6054-63. " "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " "Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection." "10.1021/jm100452c" "Anti-HIV" "DRAVPe00126" "SVSVGMKPSPRP" "12" "VMI5" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Affinity binding assay" "[Ref.12480936]HIV-1:binding with vif proteins." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00126" "DRAVPe00126.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1241.47" "C53H92N16O16S" "ACDEFHILNQTWY" "PS" "11" "2" "0" "2" "4" "2" "-47.5" "-1930" "1.9 hour" ">20 hour" ">10 hour" "48.33" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00127" "SNQGGSPLPRSV" "12" "VMI7" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Affinity binding assay" "[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=7.43 μM);##The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM." "DRAVPe00127" "DRAVPe00127.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1198.3" "C49H83N17O18" "ACDEFHIKMTWY" "S" "9.47" "1" "0" "1" "6" "2" "-82.5" "-2646" "1.9 hour" ">20 hour" ">10 hour" "56.67" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00128" "LPLPAPSFHRTT" "12" "VMI9" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Affinity binding assay" "[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=4.84 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM." "DRAVPe00128" "DRAVPe00128.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1336.56" "C62H97N17O16" "CDEGIKMNQVWY" "P" "9.76" "2" "0" "2" "3" "4" "-20.83" "-1349" "5.5 hour" "3 min" "2 min" "73.33" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00129" "SPYPSWSTPAGR" "12" "VMI16" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Affinity binding assay" "[Ref.12480936]HIV-1:binding with vif proteins." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00129" "DRAVPe00129.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1305.41" "C59H84N16O18" "CDEFHIKLMNQV" "PS" "8.46" "1" "0" "1" "6" "2" "-110" "-2275" "1.9 hour" ">20 hour" ">10 hour" "8.33" "6990" "635.45" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00130" "KPKQIKPPLPSV" "12" "vif 155-166" "Synthetic construct(derived from the proline-enriched C terminus of Vif)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=17.39 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM." "DRAVPe00130" "DRAVPe00130.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1331.66" "C63H110N16O15" "ACDEFGHMNRTWY" "P" "10.3" "3" "0" "3" "1" "3" "-82.5" "-1171" "1.3 hour" "3 min" "2 min" "89.17" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00131" "WQVMIVWQVDRMRIR" "15" "vif 5-19" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00131" "DRAVPe00131.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "2016.46" "C91H146N28O20S2" "ACEFGHKLNPSTY" "RV" "11.7" "3" "1" "2" "0" "7" "-2.67" "-3324" "2.8 hour" "3 min" "2 min" "110" "11000" "785.71" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00132" "RHHYESTHPRISSEV" "15" "vif 41-55" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00132" "DRAVPe00132.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1834.97" "C78H119N27O25" "ACDFGKLMNQW" "HS" "7.03" "5" "2" "3" "5" "2" "-152.67" "-6139" "1 hour" "2 min" "2 min" "45.33" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00133" "ESTHPRISSEVHIPL" "15" "vif 45-59" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00133" "DRAVPe00133.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1701.9" "C74H120N22O24" "ACDFGKMNQWY" "S" "6.01" "3" "2" "1" "4" "4" "-48" "-3183" "1 hour" "30 min" ">10 hour" "97.33" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00134" "HTGERDWHLGQGVSI" "15" "vif 73-87" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00134" "DRAVPe00134.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1691.82" "C73H110N24O23" "ACFKMNPY" "G" "5.99" "3" "2" "1" "5" "4" "-83.33" "-3225" "3.5 hour" "10 min" ">10 hour" "71.33" "5500" "392.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00135" "RDWHLGQGVSIEWRK" "15" "vif 77-91" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00135" "DRAVPe00135.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1867.1" "C84H127N27O22" "ACFMNPTY" "GRW" "8.75" "4" "2" "2" "3" "5" "-116.67" "-4410" "1 hour" "2 min" "2 min" "71.33" "11000" "785.71" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00136" "LGQGVSIEWRKKRYS" "15" "vif 81-95" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00136" "DRAVPe00136.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1807.09" "C81H131N25O22" "ACDFHMNPT" "GKRS" "10.28" "4" "1" "3" "5" "4" "-106" "-4214" "5.5 hour" "3 min" "2 min" "71.33" "6990" "499.29" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00137" "RYSTQVDPDLADQLI" "15" "vif 93-107" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00137" "DRAVPe00137.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1733.9" "C75H120N20O27" "CEFGHKMNW" "D" "3.93" "1" "3" "-2" "3" "5" "-55.33" "-3766" "1 hour" "2 min" "2 min" "104" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00138" "QVDPDLADQLIHLYY" "15" "vif 97-111" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00138" "DRAVPe00138.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1803" "C83H123N19O26" "CEFGKMNRSTW" "DL" "3.93" "1" "3" "-2" "2" "6" "-20" "-1665" "0.8 hour" "10 min" ">10 hour" "130" "2980" "212.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00139" "DLADQLIHLYYFDCF" "15" "vif 101-115" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00139" "DRAVPe00139.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1876.11" "C89H122N18O25S" "EGKMNPRSTVW" "DL" "3.93" "1" "3" "-2" "3" "7" "40" "-791" "1.1 hour" "3 min" ">10 hour" "110.67" "2980" "212.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00140" "QLIHLYYFDCFSESA" "15" "vif 105-119" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00140" "DRAVPe00140.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1836.05" "C86H118N18O25S" "GKMNPRTVW" "FLSY" "4.35" "1" "2" "-1" "5" "6" "27.33" "-900" "0.8 hour" "10 min" ">10 hour" "84.67" "2980" "212.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00141" "LYYFDCFSESAIRKA" "15" "vif 109-123" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00141" "DRAVPe00141.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1813.06" "C84H121N19O24S" "GHMNPQTVW" "AFSY" "6.06" "2" "2" "0" "5" "6" "2.67" "-2238" "5.5 hour" "3 min" "2 min" "65.33" "2980" "212.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00142" "ESAIRKAILGHIVSP" "15" "vif 117-131" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00142" "DRAVPe00142.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1590.89" "C71H123N21O20" "CDFMNQTWY" "I" "8.85" "3" "1" "2" "3" "7" "42.67" "-1046" "1 hour" "30 min" ">10 hour" "136.67" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00143" "RKAILGHIVSPRCEY" "15" "vif 121-135" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00143" "DRAVPe00143.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1742.07" "C77H128N24O20S" "DFMNQTW" "IR" "9.31" "4" "1" "3" "4" "5" "-16" "-2757" "1 hour" "2 min" "2 min" "104" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00144" "VSPRCEYQAGHNKVG" "15" "vif 129-143" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00144" "DRAVPe00144.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1644.83" "C69H109N23O22S" "DFILMTW" "GV" "8.18" "3" "1" "2" "6" "3" "-92.67" "-3461" "100 hour" ">20 hour" ">10 hour" "45.33" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00145" "CEYQAGHNKVGSLQY" "15" "vif 133-147" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00145" "DRAVPe00145.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1696.85" "C73H109N21O24S" "DFIMPRTW" "GQY" "6.74" "2" "1" "1" "7" "3" "-86.67" "-2449" "1.2 hour" ">20 hour" ">10 hour" "52" "2980" "212.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00146" "AGHNKVGSLQYLALA" "15" "vif 137-151" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00146" "DRAVPe00146.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1541.77" "C69H112N20O20" "CDEFIMPRTW" "AL" "8.64" "2" "0" "2" "5" "7" "26.67" "18" "4.4 hour" ">20 hour" ">10 hour" "117.33" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00147" "KVGSLQYLALAALIT" "15" "vif 141-155" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00147" "DRAVPe00147.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1560.9" "C73H125N17O20" "CDEFHMNPRW" "L" "8.59" "1" "0" "1" "4" "9" "124.67" "1781" "1.3 hour" "3 min" "2 min" "169.33" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00148" "LQYLALAALITPKKI" "15" "vif 145-159" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00148" "DRAVPe00148.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1656.08" "C80H138N18O19" "CDEFGHMNRSVW" "L" "9.7" "2" "0" "2" "2" "9" "98" "1560" "5.5 hour" "3 min" "2 min" "176" "1490" "106.43" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00149" "ALAALITPKKIKPPL" "15" "vif 149-163" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00149" "DRAVPe00149.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1574.03" "C76H136N18O17" "CDEFGHMNQRSVWY" "AKLP" "10.3" "3" "0" "3" "1" "8" "57.33" "1081" "4.4 hour" ">20 hour" ">10 hour" "150" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00150" "LITPKKIKPPLPSVT" "15" "vif 153-167" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00150" "DRAVPe00150.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1632.06" "C78H138N18O19" "ACDEFGHMNQRWY" "P" "10.3" "3" "0" "3" "3" "5" "3.33" "-147" "5.5 hour" "3 min" "2 min" "123.33" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00151" "KKIKPPLPSVTKLTE" "15" "vif 157-171" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00151" "DRAVPe00151.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1679.08" "C78H139N19O21" "ACDFGHMNQRWY" "K" "10" "4" "1" "3" "3" "4" "-65.33" "-1875" "1.3 hour" "3 min" "2 min" "97.33" "0" "0" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00152" "PPLPSVTKLTEDRWN" "15" "vif 161-175" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00152" "DRAVPe00152.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1752.99" "C79H125N21O24" "ACFGHIMQY" "P" "6.49" "2" "2" "0" "4" "4" "-100" "-3497" ">20 hour" ">20 hour" "?" "71.33" "5500" "392.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00153" "SVTKLTEDRWNKPQK" "15" "vif 165-179" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00153" "DRAVPe00153.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1830.07" "C80H132N24O25" "ACFGHIMY" "K" "9.7" "4" "2" "2" "4" "3" "-179.33" "-5653" "1.9 hour" ">20 hour" ">10 hour" "45.33" "5500" "392.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00154" "LTEDRWNKPQKTKGH" "15" "vif 169-183" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00154" "DRAVPe00154.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1838.06" "C80H128N26O24" "ACFIMSVY" "K" "9.7" "5" "2" "3" "4" "2" "-226" "-6089" "5.5 hour" "3 min" "2 min" "26" "5500" "392.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00155" "RWNKPQKTKGHRGSH" "15" "vif 173-187" "Synthetic construct(derived from HIV-1 Vif protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.12480936]HIV-1:inhibit vif-vif binding." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00155" "DRAVPe00155.cif" "Linear" "Free" "Free" "None" "L" "Vif proteins" "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." "1817.05" "C78H125N31O20" "ACDEFILMVY" "K" "12.02" "7" "0" "7" "5" "1" "-259.33" "-6975" "1 hour" "2 min" "2 min" "0" "5500" "392.86" "12480936" "J Biol Chem. 2003 Feb 21;278(8):6596-602." "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." "Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins." "10.1074/jbc.M210164200" "Anti-HIV" "DRAVPe00156" "PTGERVWDRGNVTLLCDCPN" "20" "P4" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=15.07 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=18.28 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00156" "DRAVPe00156.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2245.51" "C94H149N29O31S2" "AFHIKMQSY" "CDGLNPRTV" "4.56" "2" "3" "-1" "8" "5" "-59" "-4782" ">20 hour" ">20 hour" "?" "68" "5625" "296.05" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00157" "WDRGNVTLLCDCPNGPWVWV" "20" "P4-7" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.59 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.66 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00157" "DRAVPe00157.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2330.66" "C106H152N28O28S2" "AEFHIKMQSY" "VW" "4.21" "1" "2" "-1" "7" "8" "-3.5" "-1482" "2.8 hour" "3 min" "2 min" "82.5" "16625" "875" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00158" "WDRGNVTLLCDCPNGPWVWV" "20" "P4-7" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=3.0 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=5.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00158.cif" "Linear" "Acetylation" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2330.66" "C106H152N28O28S2" "AEFHIKMQSY" "VW" "4.21" "1" "2" "-1" "7" "8" "-3.5" "-1482" "2.8 hour" "3 min" "2 min" "82.5" "16625" "875" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00159" "GPWVWVPAFCQAVGWGDPIT" "20" "P6" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=16.80 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=3.57 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00159" "DRAVPe00159.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2186.52" "C106H144N24O25S" "EHKLMNRSY" "GPVW" "3.8" "0" "1" "-1" "5" "10" "48" "1790" "30 hour" ">20 hour" ">10 hour" "73" "16500" "868.42" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00160" "TLLCDCPNGPWVWVPAFCQA" "20" "P6-1" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.36 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.29 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00160" "DRAVPe00160.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2220.61" "C102H146N24O26S3" "EHIKMRSY" "CP" "3.8" "0" "1" "-1" "6" "9" "58.5" "1049" "7.2 hour" ">20 hour" ">10 hour" "78" "11125" "585.53" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00161" "LCDCPNGPWVWVPAFCQAVG" "20" "P6-2" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=3.33 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.32 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00161" "DRAVPe00161.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2162.53" "C99H140N24O25S3" "EHIKMRSTY" "CPV" "3.8" "0" "1" "-1" "6" "9" "62" "1312" "5.5 hour" "3 min" "2 min" "73" "11125" "585.53" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00162" "LCDCPNGPWVWVPAFCQAVG" "20" "P6-2" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=2.3 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=2.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00162.cif" "Linear" "Acetylation" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2162.53" "C99H140N24O25S3" "EHIKMRSTY" "CPV" "3.8" "0" "1" "-1" "6" "9" "62" "1312" "5.5 hour" "3 min" "2 min" "73" "11125" "585.53" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00163" "DCPNGPWVWVPAFCQAVGWG" "20" "P6-3" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=4.00 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.00 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00163" "DRAVPe00163.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2189.49" "C103H137N25O25S2" "EHIKLMRSTY" "GPVW" "3.8" "0" "1" "-1" "6" "9" "24" "1019" "1.1 hour" "3 min" ">10 hour" "53.5" "16625" "875" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00164" "PNGPWVWVPAFCQAVGWGDP" "20" "P6-4" "Synthetic construct(derived from region of GB virus C glycoprotein E2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Luciferase assay" "[Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=11.88 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=8.04 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00164" "DRAVPe00164.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells." "2183.47" "C105H139N25O25S" "EHIKLMRSTY" "P" "3.8" "0" "1" "-1" "5" "9" "3.5" "891" ">20 hour" ">20 hour" "?" "53.5" "16500" "868.42" "21543477" "J Virol. 2011 Jul;85(14):7037-47." "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition." "10.1128/JVI.02366-10" "Anti-HIV" "DRAVPe00165" "RGTKALTEVIPLTEEAEC" "18" "PepA" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 5 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00165" "DRAVPe00165.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1960.23" "C83H142N22O30S" "DFHMNQSWY" "E" "4.49" "2" "4" "-2" "5" "6" "-22.78" "-3078" "1 hour" "2 min" "2 min" "92.22" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00166" "GTKALTEVIPLTEEAEC" "17" "P1" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =7.5±2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=78.2 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00166" "DRAVPe00166.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1804.04" "C77H130N18O29S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "5" "6" "2.35" "-1586" "30 hour" ">20 hour" ">10 hour" "97.65" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00167" "ATKALTEVIPLTEEAEC" "17" "P2" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =28 ±11 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00167" "DRAVPe00167.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1818.07" "C78H132N18O29S" "DFGHMNQRSWY" "E" "4.09" "1" "4" "-3" "4" "7" "15.29" "-1499" "4.4 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00168" "GAKALTEVIPLTEEAEC" "17" "P3" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =10.3 ± 2.1 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00168" "DRAVPe00168.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1774.02" "C76H128N18O28S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "4" "7" "17.06" "-1148" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00169" "GTAALTEVIPLTEEAEC" "17" "P4" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ± 2.9 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00169" "DRAVPe00169.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1746.95" "C74H123N17O29S" "DFHKMNQRSWY" "E" "3.58" "0" "4" "-4" "5" "7" "35.88" "-850" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00170" "GTKGLTEVIPLTEEAEC" "17" "P5" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =20 ± 3.7 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00170" "DRAVPe00170.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1790.02" "C76H128N18O29S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "6" "5" "-10.59" "-1673" "30 hour" ">20 hour" ">10 hour" "91.76" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00171" "GTKAATEVIPLTEEAEC" "17" "P6" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =5.7 ± 2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=170 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00171" "DRAVPe00171.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1761.96" "C74H124N18O29S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "5" "6" "-9.41" "-1897" "30 hour" ">20 hour" ">10 hour" "80.59" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00172" "GTKALAEVIPLTEEAEC" "17" "P7" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =13.5 ± 2.1 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00172" "DRAVPe00172.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1774.02" "C76H128N18O28S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "4" "7" "17.06" "-1148" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00173" "GTKALTAVIPLTEEAEC" "17" "P8" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =57 ± 19 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=290 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00173" "DRAVPe00173.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1746.01" "C75H128N18O27S" "DFHMNQRSWY" "AET" "4.25" "1" "3" "-2" "5" "7" "33.53" "-724" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00174" "GTKALTEAIPLTEEAEC" "17" "P9" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ±7.3 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00174" "DRAVPe00174.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1775.99" "C75H126N18O29S" "DFHMNQRSVWY" "E" "4.09" "1" "4" "-3" "5" "6" "-11.76" "-1809" "30 hour" ">20 hour" ">10 hour" "86.47" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00175" "GTKALTEVAPLTEEAEC" "17" "P10" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7.3 ± 2.9 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=140 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00175" "DRAVPe00175.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1761.96" "C74H124N18O29S" "DFHIMNQRSWY" "E" "4.09" "1" "4" "-3" "5" "6" "-13.53" "-1897" "30 hour" ">20 hour" ">10 hour" "80.59" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00176" "GTKALTEVIALTEEAEC" "17" "P11" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7 ± 1.4 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00176" "DRAVPe00176.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1778" "C75H128N18O29S" "DFHMNPQRSWY" "E" "4.09" "1" "4" "-3" "5" "7" "22.35" "-1405" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00177" "GTKALTEVIPATEEAEC" "17" "P12" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =22 ± 3 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00177" "DRAVPe00177.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1761.96" "C74H124N18O29S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "5" "6" "-9.41" "-1897" "30 hour" ">20 hour" ">10 hour" "80.59" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00178" "GTKALTEVIPLAEEAEC" "17" "P13" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =10.2 ± 2.5 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00178" "DRAVPe00178.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1774.02" "C76H128N18O28S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "4" "7" "17.06" "-1148" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00179" "GTKALTEVIPLTAEAEC" "17" "P14" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 3 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00179" "DRAVPe00179.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1746.01" "C75H128N18O27S" "DFHMNQRSWY" "AET" "4.25" "1" "3" "-2" "5" "7" "33.53" "-724" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00180" "GTKALTEVIPLTEAAEC" "17" "P15" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 2.2 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00180" "DRAVPe00180.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1746.01" "C75H128N18O27S" "DFHMNQRSWY" "AET" "4.25" "1" "3" "-2" "5" "7" "33.53" "-724" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00181" "GTKWLTEVWPLC" "12" "P16" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 4 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00181" "DRAVPe00181.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1432.7" "C68H101N15O17S" "ADFHIMNQRSY" "LTW" "5.99" "1" "1" "0" "4" "5" "14.17" "326" "30 hour" ">20 hour" ">10 hour" "89.17" "11000" "1000" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00182" "GTKAWTEVWPLC" "12" "P17" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 11 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00182" "DRAVPe00182.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1390.62" "C65H95N15O17S" "DFHIMNQRSY" "TW" "5.99" "1" "1" "0" "4" "5" "-2.5" "15" "30 hour" ">20 hour" ">10 hour" "65" "11000" "1000" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00183" "GTKALTEVIPLTC" "13" "P18" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1);inhibition of polymerase activity of HIV-1 RT(Ki =53± 12 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00183" "DRAVPe00183.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1345.62" "C59H104N14O19S" "DFHMNQRSWY" "T" "5.99" "1" "1" "0" "5" "5" "70" "276" "30 hour" ">20 hour" ">10 hour" "120" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00184" "GTKAATEVIPLTC" "13" "P19" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =49 ± 9 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00184" "DRAVPe00184.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1303.54" "C56H98N14O19S" "DFHMNQRSWY" "T" "5.99" "1" "1" "0" "5" "5" "54.62" "-35" "30 hour" ">20 hour" ">10 hour" "97.69" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00185" "GTKWLTEWIPLC" "12" "P24" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=2.3 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.05 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00185" "DRAVPe00185.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1446.73" "C69H103N15O17S" "ADFHMNQRSVY" "LTW" "5.99" "1" "1" "0" "4" "5" "16.67" "414" "30 hour" ">20 hour" ">10 hour" "97.5" "11000" "1000" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00186" "KWLTEWIPLTAEAEC" "15" "P26" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =1.8± 0.7 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00186" "DRAVPe00186.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1790.06" "C83H124N18O24S" "DFGHMNQRSVY" "E" "4.25" "1" "3" "-2" "3" "7" "-6.67" "-680" "1.3 hour" "3 min" "2 min" "91.33" "11000" "785.71" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00187" "GTKWLTEWIPLTAEC" "15" "P27" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50<0.32 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.05 ± 0.01 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00187" "DRAVPe00187.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1748.03" "C81H122N18O23S" "DFHMNQRSVY" "T" "4.53" "1" "2" "-1" "5" "6" "-2.67" "-343" "30 hour" ">20 hour" ">10 hour" "84.67" "11000" "785.71" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00188" "GTKWATEWAPLTAEAEC" "17" "P28" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =2 ± 0.6 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00188" "DRAVPe00188.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1864.06" "C83H122N20O27S" "DFHIMNQRSVY" "A" "4.25" "1" "3" "-2" "5" "7" "-40" "-1465" "30 hour" ">20 hour" ">10 hour" "46.47" "11000" "687.5" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00189" "KWLTEWIPLTAEC" "13" "P29" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =1 ± 0.4 μM).##NOTE:Ki: inhibition constants " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00189" "DRAVPe00189.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1589.87" "C75H112N16O20S" "DFGHMNQRSVY" "ELTW" "4.53" "1" "2" "-1" "3" "6" "5.38" "-180" "1.3 hour" "3 min" "2 min" "97.69" "11000" "916.67" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00190" "GTKWLTEWIPLTAEAEC" "17" "PAW" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.2 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=1.8 nM,associated with Pep-1)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00190" "DRAVPe00190.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1948.22" "C89H134N20O27S" "DFHMNQRSVY" "ET" "4.25" "1" "3" "-2" "5" "7" "-12.35" "-843" "30 hour" ">20 hour" ">10 hour" "80.59" "11000" "687.5" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00191" "GAKTETLVIPETELEAC" "17" "Pscr" "Synthetic construct(derived from Pep-A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "RT-Polymerase Assay" "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =61 ± 12 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00191" "DRAVPe00191.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." "1804.04" "C77H130N18O29S" "DFHMNQRSWY" "E" "4.09" "1" "4" "-3" "5" "6" "2.35" "-1586" "30 hour" ">20 hour" ">10 hour" "97.65" "0" "0" "18952602" "J Biol Chem. 2009 Jan 2;284(1):254-264." "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." "A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility." "10.1074/jbc.M802199200" "Anti-HIV" "DRAVPe00192" "LEAIPMSIPPEVKFNKPFVF" "20" "VIRIP" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=14.79±2.56 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "DRAVPe00192" "DRAVPe00192.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2303.79" "C112H171N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "39" "118" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00193" "AEAIPMSIPPEVKFNKPFVF" "20" "VIRIP[A1]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00193" "DRAVPe00193.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2261.71" "C109H165N23O27S" "CDGHLQRTWY" "P" "6.19" "2" "2" "0" "2" "9" "29" "-193" "4.4 hour" ">20 hour" ">10 hour" "78" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00194" "LAAIPMSIPPEVKFNKPFVF" "20" "VIRIP[A2]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00194" "DRAVPe00194.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2245.75" "C110H169N23O25S" "CDGHQRTWY" "P" "8.59" "2" "1" "1" "2" "10" "65.5" "980" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00195" "LEAAPMSIPPEVKFNKPFVF" "20" "VIRIP[A4]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00195" "DRAVPe00195.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2261.71" "C109H165N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "25.5" "-193" "5.5 hour" "3 min" "2 min" "78" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00196" "LEAIAMSIPPEVKFNKPFVF" "20" "VIRIP[A5]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.50±5.19 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00196" "DRAVPe00196.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2277.75" "C110H169N23O27S" "CDGHQRTWY" "FP" "6.14" "2" "2" "0" "2" "10" "56" "299" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00197" "LEAIPASIPPEVKFNKPFVF" "20" "VIRIP[A6]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=13.00±1.04 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00197" "DRAVPe00197.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2243.67" "C110H167N23O27" "CDGHMQRTWY" "P" "6.14" "2" "2" "0" "2" "10" "38.5" "64" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00198" "LEAIPMSAPPEVKFNKPFVF" "20" "VIRIP[A8]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.46±0.28 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00198" "DRAVPe00198.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2261.71" "C109H165N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "25.5" "-193" "5.5 hour" "3 min" "2 min" "78" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00199" "LEAIPMSIAPEVKFNKPFVF" "20" "VIRIP[A9]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=16.33±4.34 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00199" "DRAVPe00199.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2277.75" "C110H169N23O27S" "CDGHQRTWY" "FP" "6.14" "2" "2" "0" "2" "10" "56" "299" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00200" "LEAIPMSIPAEVKFNKPFVF" "20" "VIRIP[A10]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=9.72±1.66 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00200" "DRAVPe00200.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2277.75" "C110H169N23O27S" "CDGHQRTWY" "FP" "6.14" "2" "2" "0" "2" "10" "56" "299" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00201" "LEAIPMSIPPAVKFNKPFVF" "20" "VIRIP[A11]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=11.00±4.75 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00201" "DRAVPe00201.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2245.75" "C110H169N23O25S" "CDGHQRTWY" "P" "8.59" "2" "1" "1" "2" "10" "65.5" "980" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00202" "LEAIPMSIPPEAKFNKPFVF" "20" "VIRIP[A12]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.64±2.23 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00202" "DRAVPe00202.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2275.73" "C110H167N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "27" "-105" "5.5 hour" "3 min" "2 min" "83" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00203" "LEAIPMSIPPEVAFNKPFVF" "20" "VIRIP[A13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.73±0.61 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00203" "DRAVPe00203.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2246.69" "C109H164N22O27S" "CDGHQRTWY" "P" "4.53" "1" "2" "-1" "2" "10" "67.5" "854" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00204" "LEAIPMSIPPEVKANKPFVF" "20" "VIRIP[A14]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.62±1.32 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00204" "DRAVPe00204.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2227.69" "C106H167N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "34" "1" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00205" "LEAIPMSIPPEVKFAKPFVF" "20" "VIRIP[A15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=17.41±3.66 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00205" "DRAVPe00205.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2260.76" "C111H170N22O26S" "CDGHNQRTWY" "P" "6.14" "2" "2" "0" "1" "10" "65.5" "963" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00206" "LEAIPMSIPPEVKFNAPFVF" "20" "VIRIP[A16]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.81±0.68 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00206" "DRAVPe00206.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2246.69" "C109H164N22O27S" "CDGHQRTWY" "P" "4.53" "1" "2" "-1" "2" "10" "67.5" "854" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00207" "LEAIPMSIPPEVKFNKAFVF" "20" "VIRIP[A17]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=12.72±10.17 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00207" "DRAVPe00207.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2277.75" "C110H169N23O27S" "CDGHQRTWY" "FP" "6.14" "2" "2" "0" "2" "10" "56" "299" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00208" "LEAIPMSIPPEVKFNKPAVF" "20" "VIRIP[A18]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00208" "DRAVPe00208.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2227.69" "C106H167N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "34" "1" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00209" "LEAIPMSIPPEVKFNKPFAF" "20" "VIRIP[A19]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00209" "DRAVPe00209.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2275.73" "C110H167N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "27" "-105" "5.5 hour" "3 min" "2 min" "83" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00210" "LEAIPMSIPPEVKFNKPFVA" "20" "VIRIP[A20]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00210" "DRAVPe00210.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2227.69" "C106H167N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "34" "1" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00211" "LEAIPMSIPPEVKFNKPFVF" "20" "N-Ac-VIRIP" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00211.cif" "Linear" "Acetylation" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2303.79" "C112H171N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "39" "118" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00212" "LEAIPMSIPPEVKFNKPFVF" "20" "VIRIP-amide" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00212.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2303.79" "C112H171N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "39" "118" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00213" "LEAIPMSIPPEVKFNKPFVF" "20" "N-Ac-VIRIP-amide" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00213.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2303.79" "C112H171N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "39" "118" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00214" "LEAIPMSIPPEVAFAKPFVF" "20" "VIRIP[A13,A15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=3.45±0.44 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00214" "DRAVPe00214.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2203.67" "C108H163N21O26S" "CDGHNQRTWY" "P" "4.53" "1" "2" "-1" "1" "11" "94" "1699" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00215" "LEAIPMSIPPEVFFNKPFVF" "20" "VIRIP[F13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.66±0.06 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00215" "DRAVPe00215.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2322.79" "C115H168N22O27S" "CDGHQRTWY" "FP" "4.53" "1" "2" "-1" "2" "10" "72.5" "971" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00216" "LEAIPMCIPPECAFNKPFVF" "20" "VIRIP[A13,C7,C12]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.00±0.21 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00216" "DRAVPe00216.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys7 and Cys12" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2266.76" "C107H160N22O26S3" "DGHQRSTWY" "P" "4.53" "1" "2" "-1" "3" "9" "75.5" "1046" "5.5 hour" "3 min" "2 min" "83" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00217" "LEAIPCSIPPCVAFNKPFVF" "20" "VIRIP[A13,C6,C11]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.18±0.08 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00217" "DRAVPe00217.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2192.66" "C105H158N22O25S2" "DGHMQRTWY" "P" "5.99" "1" "1" "0" "4" "10" "100.5" "1556" "5.5 hour" "3 min" "2 min" "97.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00218" "LEAIPCSIPpCVAFNKPFVF" "20" "VIRIP[A13,C6,C11,p10]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.94±0.54 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00218.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "Mixed(D-Pro10)" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2192.66" "C100H149N21O23S2" "DGHMQRTWY" "FP" "5.99" "1" "1" "0" "4" "10" "108.5" "1556" "5.5 hour" "3 min" "2 min" "97.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00219" "LEAIPCSIPPCVGFGKPFVF" "20" "VIRIP[C6,C11,G13,G15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.73±0.13 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00219" "DRAVPe00219.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2121.58" "C102H153N21O24S2" "DHMNQRTWY" "P" "5.99" "1" "1" "0" "5" "9" "105" "2227" "5.5 hour" "3 min" "2 min" "92.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00220" "LEAIPCSIPPCVLFNKPFVF" "20" "VIRIP[C6,C11,L13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.84±0.08 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00220" "DRAVPe00220.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2234.74" "C108H164N22O25S2" "DGHMQRTWY" "P" "5.99" "1" "1" "0" "4" "10" "110.5" "1867" "5.5 hour" "3 min" "2 min" "112" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00221" "LEAIPCSIPPCVFFNKPFVF" "20" "VIRIP[C6,C11,F13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.93±0.05 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "DRAVPe00221" "DRAVPe00221.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2268.76" "C111H162N22O25S2" "DGHMQRTWY" "FP" "5.99" "1" "1" "0" "4" "10" "105.5" "1673" "5.5 hour" "3 min" "2 min" "92.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00222" "LEAIPCSIPPCFAFNKPFVF" "20" "VIRIP[A13,C6,C11,F12]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.27±0.04 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "DRAVPe00222" "DRAVPe00222.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2240.71" "C109H158N22O25S2" "DGHMQRTWY" "FP" "5.99" "1" "1" "0" "4" "10" "93.5" "1450" "5.5 hour" "3 min" "2 min" "83" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00223" "LEAIPMSIPPEFLFGKPFVF" "20" "VIRIP[F12,L13,G15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.34±0.42 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "DRAVPe00223" "DRAVPe00223.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2279.77" "C114H167N21O26S" "CDHNQRTWY" "FP" "4.53" "1" "2" "-1" "2" "10" "86" "1817" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00224" "LEAIPCSIPPCVFFGKPFVF" "20" "VIRIP[C6,C11,F13,G15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.02 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00224" "DRAVPe00224.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2211.71" "C109H159N21O24S2" "DHMNQRTWY" "FP" "5.99" "1" "1" "0" "4" "10" "121" "2431" "5.5 hour" "3 min" "2 min" "92.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00225" "LEAIPCSIPPCFLFGKPFVF" "20" "VIRIP[C6,C11,F12,L13,G15]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.39±0.13 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00225" "DRAVPe00225.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2225.73" "C110H161N21O24S2" "DHMNQRTWY" "FP" "5.99" "1" "1" "0" "4" "10" "119" "2519" "5.5 hour" "3 min" "2 min" "97.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00226" "LEAIPCSIPpCVFFNKPFVF" "20" "VIRIP[C6,C11,p10,F13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.33±0.07 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00226.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "Mixed(D-Pro10)" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2268.76" "C106H153N21O23S2" "DGHMQRTWY" "F" "5.99" "1" "1" "0" "4" "10" "113.5" "1673" "5.5 hour" "3 min" "2 min" "92.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00227" "LEAIPCSIPpCFLFNKPFVF" "20" "VIRIP[C6,C11,p10,F12,L13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.20±0.04 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "No predicted structure available" "DRAVPe00227.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys6 and Cys11" "Mixed(D-Pro10)" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2282.79" "C107H155N21O23S2" "DGHMQRTWY" "F" "5.99" "1" "1" "0" "4" "10" "111.5" "1761" "5.5 hour" "3 min" "2 min" "97.5" "125" "6.58" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00228" "LEAIPMGIPpEVXFNKPFVF" "20" "VIRIP[G7,p10,L-Tic13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.08 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "No predicted structure available" "DRAVPe00228.cif" "Linear" "Free" "Free" "The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic)." "Mixed(D-Pro10)" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2256.92" "C100H146N20O22S" "CDHQRSTWY" "FP" "4.53" "1" "2" "-1" "2" "9" "68.5" "1107" "5.5 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00229" "LEKIPMSIPpEVXFNKPFVF" "20" "VIRIP[K3,p10,L-Tic13]" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.41±0.13 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00229.cif" "Linear" "Free" "Free" "The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic)." "Mixed(D-Pro10)" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2344.04" "C104H155N21O23S" "ACDGHQRTWY" "FP" "6.14" "2" "2" "0" "2" "8" "38" "-63" "5.5 hour" "3 min" "2 min" "87.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00230" "KVINPEPIVEPFMSKPFALF" "20" "scrambled VIRIP" "Synthetic construct(derived from α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM." "DRAVPe00230" "DRAVPe00230.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane." "2303.79" "C112H171N23O27S" "CDGHQRTWY" "P" "6.14" "2" "2" "0" "2" "9" "39" "118" "1.3 hour" "3 min" "2 min" "92.5" "0" "0" "17448989" "Cell. 2007 Apr 20;129(2):263-75." "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." "Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide." "10.1016/j.cell.2007.02.042" "Anti-HIV" "DRAVPe00231" "YTSLIHSLIEEGQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138G]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=1.3± 0.5 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=65± 8.8 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=141±26 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=185±68 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00231" "DRAVPe00231.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4420.86" "C201H296N50O63" "CMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-86.39" "-6825" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00232" "YTSLIHSLIEEAQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138A]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.6 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=3.6± 1.7 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=3.5 ±0.9 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=3.2 ± 1.0 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00232" "DRAVPe00232.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4434.89" "C202H298N50O63" "CGMPRV" "EL" "4.3" "3" "7" "-4" "8" "14" "-80.28" "-6738" "2.8 hour" "10 min" "2 min" "92.22" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00233" "YTSLIHSLIEEVQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138V]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.4 ± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=31 ± 14 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=22 ± 3.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=23 ± 5.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00233" "DRAVPe00233.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4462.94" "C204H302N50O63" "CGMPR" "EL" "4.3" "3" "7" "-4" "8" "14" "-73.61" "-6515" "2.8 hour" "10 min" "2 min" "97.5" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00234" "YTSLIHSLIEELQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138L]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=13± 6 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.7 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.2± 0.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00234" "DRAVPe00234.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4476.97" "C205H304N50O63" "CGMPRV" "L" "4.3" "3" "7" "-4" "8" "14" "-74.72" "-6427" "2.8 hour" "10 min" "2 min" "100.28" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00235" "YTSLIHSLIEEIQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138I]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.5 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.9± 2 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.8 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.4 ± 0.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00235" "DRAVPe00235.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4476.97" "C205H304N50O63" "CGMPRV" "EL" "4.3" "3" "7" "-4" "8" "14" "-72.78" "-6427" "2.8 hour" "10 min" "2 min" "100.28" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00236" "YTSLIHSLIEEMQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138M]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.4± 0.1 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=1.7±0.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=1.2± 0.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00236" "DRAVPe00236.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4495" "C204H302N50O63S" "CGPRV" "EL" "4.3" "3" "7" "-4" "8" "13" "-80" "-6684" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00237" "YTSLIHSLIEEPQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138P]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=446± 167 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00237" "DRAVPe00237.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4460.92" "C204H300N50O63" "CGMRV" "EL" "4.3" "3" "7" "-4" "8" "13" "-89.72" "-6919" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00238" "YTSLIHSLIEETQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138T]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.9± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=39± 8.5 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=161±35 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=124±43nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00238" "DRAVPe00238.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4464.91" "C203H300N50O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-87.22" "-7176" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00239" "YTSLIHSLIEEFQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138F]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=9.4± 2.6 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=203± 89 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=393 ± 119 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=478 ± 116 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00239" "DRAVPe00239.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4510.98" "C208H302N50O63" "CGMPRV" "EL" "4.3" "3" "7" "-4" "8" "14" "-77.5" "-6621" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00240" "YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138Y]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=25 ±9nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=516 ±223 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00240" "DRAVPe00240.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4526.98" "C208H302N50O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-88.89" "-6933" "2.8 hour" "10 min" "2 min" "89.44" "19480" "556.57" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00241" "YTSLIHSLIEEWQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138W]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=29± 14 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00241" "DRAVPe00241.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4550.02" "C210H303N51O63" "CGMPRV" "EL" "4.3" "3" "7" "-4" "8" "14" "-87.78" "-6686" "2.8 hour" "10 min" "2 min" "89.44" "23490" "671.14" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00242" "YTSLIHSLIEENQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138N]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=19± 4 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00242" "DRAVPe00242.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4477.91" "C203H299N51O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-95" "-7583" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00243" "YTSLIHSLIEEQQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138Q]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=34± 11 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00243" "DRAVPe00243.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4491.94" "C204H301N51O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "8" "13" "-95" "-7473" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00244" "YTSLIHSLIEEDQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138D]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 94 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00244" "DRAVPe00244.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4478.89" "C203H298N50O65" "CGMPRV" "EL" "4.16" "3" "8" "-5" "8" "13" "-95" "-7791" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00245" "YTSLIHSLIEEEQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138E]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=283± 80 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00245" "DRAVPe00245.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4492.92" "C204H300N50O65" "CGMPRV" "E" "4.21" "3" "8" "-5" "8" "13" "-95" "-7600" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00246" "YTSLIHSLIEEHQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138H]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 85 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00246" "DRAVPe00246.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4500.95" "C205H300N52O63" "CGMPRV" "EL" "4.53" "4" "7" "-3" "8" "13" "-94.17" "-7385" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00247" "YTSLIHSLIEEKQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138K]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=708±145 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00247" "DRAVPe00247.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4491.98" "C205H305N51O63" "CGMPRV" "EL" "4.54" "4" "7" "-3" "8" "13" "-96.11" "-7474" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00248" "YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF" "36" "T-20S[138R]" "Synthetic construct(derived from Enfuvirtide)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=362± 114 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00248" "DRAVPe00248.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4519.99" "C205H305N53O63" "CGMPV" "EL" "4.54" "4" "7" "-3" "8" "13" "-97.78" "-8411" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00249" "WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL" "34" "C34S[138A]" "Synthetic construct(derived from C34)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.0± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.7± 0.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=2.0 ±0.6 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=1.3 ±0.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00249" "DRAVPe00249.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4232.6" "C184H280N50O63S" "CFGPV" "E" "4.21" "3" "8" "-5" "8" "10" "-119.41" "-9649" "2.8 hour" "3 min" "2 min" "83.24" "12490" "378.48" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00250" "WMEWDREINNYTSLIHSLIEELQNQQEKNEQELL" "34" "C34S[138L]" "Synthetic construct(derived from C34)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=1.5± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.2± 0.6 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=0.5 ±0.2 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=0.4±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00250" "DRAVPe00250.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4274.68" "C187H286N50O63S" "ACFGPV" "E" "4.21" "3" "8" "-5" "8" "10" "-113.53" "-9338" "2.8 hour" "3 min" "2 min" "91.76" "12490" "378.48" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00251" "WMEWDREINNYTSLIHSLIEETQNQQEKNEQELL" "34" "C34S[138T]" "Synthetic construct(derived from C34)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.6± 0.2 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=4.8± 1.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=32 ± 5.5 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=24 ±6.6nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00251" "DRAVPe00251.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4262.63" "C185H282N50O64S" "ACFGPV" "E" "4.21" "3" "8" "-5" "9" "9" "-126.76" "-10087" "2.8 hour" "3 min" "2 min" "80.29" "12490" "378.48" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00252" "WMEWDREINNYTSLIHSLIEEWQNQQEKNEQELL" "34" "C34S[138W]" "Synthetic construct(derived from C34)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50>1000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00252" "DRAVPe00252.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4347.74" "C192H285N51O63S" "ACFGPV" "E" "4.21" "3" "8" "-5" "8" "10" "-127.35" "-9597" "2.8 hour" "3 min" "2 min" "80.29" "17990" "545.15" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00253" "WMEWDREINNYTSLIHSLIEEPQNQQEKNEQELL" "34" "C34S[138P]" "Synthetic construct(derived from C34)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=46±11 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=436± 125 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=250 ± 80 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=176±50 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00253" "DRAVPe00253.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4258.64" "C186H282N50O63S" "ACFGV" "E" "4.21" "3" "8" "-5" "8" "9" "-129.41" "-9830" "2.8 hour" "3 min" "2 min" "80.29" "12490" "378.48" "19073606" "J Biol Chem. 2009 Feb 20;284(8):4914-20." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20." "10.1074/jbc.M807169200" "Anti-HIV" "DRAVPe00254" "WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF" "39" "1249" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.003 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013 μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.363 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=8.140 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00254.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4995.58" "C233H338N56O67" "CGHMPRV" "EQ" "4.43" "4" "8" "-4" "4" "16" "-109.49" "-7562" "2.8 hour" "3 min" "2 min" "77.69" "28990" "762.89" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "DRAVPa0873" "Anti-HIV" "DRAVPe00255" "MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL" "36" "651" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.033μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.060 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.151 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=7.599 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00255" "DRAVPe00255.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4480.9" "C193H296N52O67S2" "ACFGPV" "E" "4.21" "3" "8" "-5" "10" "9" "-116.67" "-10192" "30 hour" ">20 hour" ">10 hour" "75.83" "12490" "356.86" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "DRAVPa0971" "Anti-HIV" "DRAVPe00256" "MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL" "38" "2410" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.032μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.137 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=4.975 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00256" "DRAVPe00256.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4723.18" "C204H314N54O71S2" "ACFGPV" "E" "4.14" "3" "9" "-6" "10" "10" "-109.74" "-10381" "30 hour" ">20 hour" ">10 hour" "82.11" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00257" "TTWEEWDREINEYTSRIESLIRESQEQQEKNEQELREL" "38" "2429" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.056 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.037 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.167 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00257" "DRAVPe00257.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4826.14" "C205H319N59O76" "ACFGHMPV" "E" "4.29" "5" "12" "-7" "9" "8" "-177.89" "-16817" "7.2 hour" ">20 hour" ">10 hour" "61.58" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00258" "MTWMAWDRAIANYAALIHALIEAAQNQQEKNEAALLEL" "38" "2638" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.061 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.079μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.120 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.250 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00258" "DRAVPe00258.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4312.93" "C192H300N52O57S2" "CFGPSV" "A" "4.57" "3" "5" "-2" "5" "20" "1.05" "-3352" "30 hour" ">20 hour" ">10 hour" "108.42" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00259" "TTWEAWDRAIAEYAARIEALIRASQEQQEKNEAELREL" "38" "290676" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.006 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.072 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=1.314 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00259" "DRAVPe00259.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4489.93" "C195H307N57O65" "CFGHMPV" "AE" "4.52" "5" "9" "-4" "5" "16" "-87.89" "-11171" "7.2 hour" ">20 hour" ">10 hour" "82.63" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00260" "MTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL" "38" "2544" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.026μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.033 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.014 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.021 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00260" "DRAVPe00260.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4445.98" "C194H307N57O61S" "CFGHPSV" "A" "4.64" "5" "8" "-3" "3" "18" "-60.26" "-9296" "30 hour" ">20 hour" ">10 hour" "87.89" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00261" "TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAILREL" "38" "267209" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.034 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.024 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00261" "DRAVPe00261.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4457.97" "C196H311N57O62" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "18" "-60" "-9477" "7.2 hour" ">20 hour" ">10 hour" "95.53" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00262" "TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL" "38" "267221" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.011 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.035μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.050 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00262" "DRAVPe00262.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4457.97" "C196H311N57O62" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "18" "-61.84" "-9477" "7.2 hour" ">20 hour" ">10 hour" "95.53" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "DRAVPa1316" "Anti-HIV" "DRAVPe00263" "TTWEAWDRAIAEYAARIEALIRAAQELQEKNEAALREL" "38" "267226" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.020 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00263" "DRAVPe00263.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4400.92" "C194H308N56O61" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "19" "-47.89" "-8742" "7.2 hour" ">20 hour" ">10 hour" "98.16" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00264" "TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAILREL" "38" "267225" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.019 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.043μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.038 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.196 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00264" "DRAVPe00264.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4500.05" "C199H317N57O62" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "18" "-54.74" "-9166" "7.2 hour" ">20 hour" ">10 hour" "103.16" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00265" "TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL" "38" "267227" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.045μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.025 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.044 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00265" "DRAVPe00265.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4414.94" "C195H310N56O61" "CFGHMNPSV" "A" "4.64" "5" "8" "-3" "3" "19" "-47.89" "-8632" "7.2 hour" ">20 hour" ">10 hour" "98.16" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "DRAVPa1317" "Anti-HIV" "DRAVPe00266" "TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAVLREL" "38" "291022" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.049μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.093 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.046 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00266" "DRAVPe00266.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4443" "C197H314N56O61" "CFGHMNPS" "A" "4.64" "5" "8" "-3" "3" "19" "-41.58" "-8409" "7.2 hour" ">20 hour" ">10 hour" "103.16" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00267" "TTWEAWDRAIAEYAARIEALIRALQELQEKNEAALREL" "38" "290822" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.054μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.084 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.147 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00267" "DRAVPe00267.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4443" "C197H314N56O61" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "19" "-42.63" "-8431" "7.2 hour" ">20 hour" ">10 hour" "105.79" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00268" "TTWEAWDRAIAEYAARIEALIRALQELQEKNEAILREL" "38" "290821" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.065 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.118μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.154 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.192 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00268" "DRAVPe00268.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4485.08" "C200H320N56O61" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "19" "-35.53" "-8120" "7.2 hour" ">20 hour" ">10 hour" "113.42" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00269" "TTWEAWDRAIAEYAARIEALIRAAQELQEKLEAALREL" "38" "267228" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.172 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.600μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.416 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.555 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.987 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00269" "DRAVPe00269.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4399.97" "C196H313N55O60" "CFGHMNPSV" "A" "4.64" "5" "8" "-3" "3" "20" "-28.68" "-7586" "7.2 hour" ">20 hour" ">10 hour" "108.42" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00270" "TTWEAWDRAIAEYAARIEALIRALQELQEKLEAILREL" "38" "267229" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=3.162 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50>20μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50>20 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00270" "DRAVPe00270.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4484.13" "C202H325N55O60" "CFGHMNPSV" "A" "4.64" "5" "8" "-3" "3" "20" "-16.32" "-6964" "7.2 hour" ">20 hour" ">10 hour" "123.68" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "Anti-HIV" "DRAVPe00271" "AEAMSQVTN" "9" "p2(gag) peptide[Δ10-14]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=5 μM)." "DRAVPe00271" "DRAVPe00271.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "950.03" "C37H63N11O16S" "CDFGHIKLPRWY" "A" "4" "0" "1" "-1" "3" "3" "-25.56" "-1495" "4.4 hour" ">20 hour" ">10 hour" "54.44" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00272" "AAAMSQVTN" "9" "p2(gag) peptide[Δ10-14,E2A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=100 μM)." "DRAVPe00272" "DRAVPe00272.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "891.99" "C35H61N11O14S" "CDEFGHIKLPRWY" "A" "5.57" "0" "0" "0" "3" "4" "33.33" "-633" "4.4 hour" ">20 hour" ">10 hour" "65.56" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00273" "AEAMAQVTN" "9" "p2(gag) peptide[Δ10-14,S5A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=124 μM)." "DRAVPe00273" "DRAVPe00273.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "934.03" "C37H63N11O15S" "CDFGHIKLPRSWY" "A" "4" "0" "1" "-1" "2" "4" "3.33" "-974" "4.4 hour" ">20 hour" ">10 hour" "65.56" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00274" "AEAMSQVTNTATIM" "14" "p2(gag) peptide" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=10 μM)." "DRAVPe00274" "DRAVPe00274.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "1467.67" "C59H102N16O23S2" "CDFGHKLPRWY" "AT" "4" "0" "1" "-1" "5" "5" "32.14" "-1101" "4.4 hour" ">20 hour" ">10 hour" "70" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00275" "AEAASQVTNTATIM" "14" "p2(gag) peptide[M4A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=142 μM)." "DRAVPe00275" "DRAVPe00275.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "1407.56" "C57H98N16O23S" "CDFGHKLPRWY" "A" "4" "0" "1" "-1" "5" "6" "31.43" "-1155" "4.4 hour" ">20 hour" ">10 hour" "77.14" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00276" "AEASQVTNTATIM" "13" "p2(gag) peptide[ΔM4]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=126 μM)." "DRAVPe00276" "DRAVPe00276.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "1336.48" "C54H93N15O22S" "CDFGHKLPRWY" "AT" "4" "0" "1" "-1" "5" "5" "20" "-1336" "4.4 hour" ">20 hour" ">10 hour" "75.38" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00277" "AEAMSQVANTATIM" "14" "p2(gag) peptide[T8A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Protease inhibition assay" "[Ref.15113844]HIV:inhibition of protease activity in CEM/LAV-1 cells(IC50=110 μM)." "DRAVPe00277" "DRAVPe00277.cif" "Linear" "Free" "Free" "None" "L" "autolysis" "The peptide blocks the autolysis of HIV-1 virions for the conservation of viral species." "1437.65" "C58H100N16O22S2" "CDFGHKLPRWY" "A" "4" "0" "1" "-1" "4" "6" "50" "-663" "4.4 hour" ">20 hour" ">10 hour" "77.14" "0" "0" "15113844" "J Biochem. 2004 Mar;135(3):447-53. " "Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S." "Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. " "10.1093/jb/mvh052" "Anti-HIV" "DRAVPe00278" "GIPCGESCVWIPCISAALGCSCKNKVCYRN" "30" "Circulin-A (CIRA; Plant defensin)" "Chassalia parviflora " "P56871" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1BH4" "HIV" "Retroviridae" "[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40-260 nM)." "[Ref.10430870] EC50 = 1020 μM against blood type A human erythrocytes." "[Ref.18008336]CEM-SS cells:IC50=500 nM." "DRAVPe00278" "DRAVPe00278.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (C termini to N termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22, Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3175.78" "C134H216N38O39S6" "DFHMQT" "C" "8.33" "3" "1" "2" "15" "9" "41.67" "-1224" "30 hour" ">20 hour" ">10 hour" "78" "7365" "253.97" "18008336##10430870" "Biopolymers. 2008;90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8. " "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tam JP, Lu YA, Yang JL, Chiu KW." "Cyclotides as natural anti-HIV agents.##An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides." "10.1002/bip.20886##10.1073/pnas.96.16.8913" "Anti-HIV" "DRAVPe00279" "GVIPCGESCVFIPCISTLLGCSCKNKVCYRN" "31" "Circulin-B (CIRB; Plant defensin)" "Chassalia parviflora " "P56879" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2ERI" "HIV" "Retroviridae" "[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40-260 nM)." "[Ref.10430870] EC50 = 550 μM against blood type A human erythrocytes." "[Ref.10430870] It caused 50% cell growth inhibition of mouse fibroblasts at 820 μM.##[Ref.18008336]CEM-SS cells:IC50=500 nM." "DRAVPe00279" "DRAVPe00279.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (C termini to N termini)" "Disulfide bonds between Cys5 and Cys19, Cys9 and Cys21, Cys14 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3307.98" "C141H232N38O41S6" "ADHMQW" "C" "8.33" "3" "1" "2" "16" "9" "64.19" "-882" "30 hour" ">20 hour" ">10 hour" "90.97" "1865" "62.17" "18008336##10430870" "Biopolymers. 2008;90(1):51-60.##Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8913-8. " "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tam JP, Lu YA, Yang JL, Chiu KW." "Cyclotides as natural anti-HIV agents.##An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides." "10.1002/bip.20886##10.1073/pnas.96.16.8913" "Anti-HIV" "DRAVPe00280" "GIPCGESCVFIPCITSVAGCSCKSKVCYRN" "30" "Circulin-C (CIRC; Plant defensin)" "Chassalia parviflora " "P84641" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV-1:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM).##[Ref.10691702]HIV-1(HIV-1 IIIB):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=73 nM);##HIV-1(HIV-1 RF):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=165 nM);##HIV-1(HIV-1 214):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=213 nM);##HIV-1(HIV-1 205):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=155 nM);##HIV-1(HIV-1 G):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=111 nM);##HIV-1(HIV-1 SK1):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=51 nM);##HIV-1(HIV-1 N119):inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=241 nM);##HIV-1(HIV-1 A17):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=247 nM);##HIV-1(HIV-1G9106):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=67 nM);##HIV-1(HIV-1 H1122):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=48 nM);##HIV-1(HIV-1 IIIB):inhibition the cytopathic effects of HIV-1 infection in MT-2 cells(EC50=200 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00280" "DRAVPe00280.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3125.72" "C131H214N36O40S6" "DHLMQW" "C" "8.33" "3" "1" "2" "16" "8" "56" "-1361" "30 hour" ">20 hour" ">10 hour" "71.33" "1865" "64.31" "18008336##10691702" "Biopolymers. 2008;90(1):51-60.##J Nat Prod. 2000 Feb;63(2):176-8." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Gustafson KR, Walton LK, Sowder RC Jr, Johnson DG, Pannell LK, Cardellina JH Jr, Boyd MR." "Cyclotides as natural anti-HIV agents.##New circulin macrocyclic polypeptides from Chassalia parvifolia." "10.1002/bip.20886##10.1021/np990432r" "Anti-HIV" "DRAVPe00281" "KIPCGESCVWIPCVTSIFNCKCENKVCYHD" "30" "Circulin-D (CIRD; Plant defensin)" "Chassalia parviflora " "P84642" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "XTT [2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide]" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00281" "DRAVPe00281.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3420.03" "C148H228N38O43S6" "ALMQR" "C" "6.71" "4" "3" "1" "13" "8" "11.33" "-2563" "1.3 hour" "3 min" "2 min" "68" "7365" "253.97" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00282" "KIPCGESCVWIPCLTSVFNCKCENKVCYHD" "30" "Circulin-E (CIRE; Plant defensin)" "Chassalia parviflora " "P84643" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00282" "DRAVPe00282.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3420.03" "C148H228N38O43S6" "AMQR" "C" "6.71" "4" "3" "1" "13" "8" "9" "-2563" "1.3 hour" "3 min" "2 min" "68" "7365" "253.97" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00283" "AIPCGESCVWIPCISAAIGCSCKNKVCYR" "29" "Circulin-F (CIRF; Plant defensin)" "Chassalia parviflora" "P84644" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=50-275 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00283" "DRAVPe00283.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3075.7" "C131H212N36O37S6" "DFHLMQT" "C" "8.34" "3" "1" "2" "13" "10" "65.17" "-473" "4.4 hour" ">20 hour" ">10 hour" "84.14" "7365" "263.04" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00284" "GVIPCGESCVFIPCISAAIGCSCKNKVCYRN" "31" "Cycloviolin-A (Plant defensin)" "Leonia cymosa (Sacha uba)" "P84637" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18008336]CEM-SS cells:IC50=560 nM." "DRAVPe00284" "DRAVPe00284.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys5 and Cys21, Cys9 and Cys23,Cys14 and Cys28." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3235.88" "C137H224N38O40S6" "DHLMQTW" "C" "8.33" "3" "1" "2" "15" "10" "68.06" "-755" "30 hour" ">20 hour" ">10 hour" "84.84" "1865" "62.17" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00285" "GTACGESCYVLPCFTVGCTCTSSQCFKN" "28" "Cycloviolin-B (Plant defensin)" "Leonia cymosa (Sacha uba)" "P84638" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18008336]CEM-SS cells:IC50=560 nM." "DRAVPe00285" "DRAVPe00285.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys18, Cys8 and Cys20,Cys13 and Cys25." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2910.33" "C120H185N31O41S6" "DHIMRW" "C" "5.96" "1" "1" "0" "18" "6" "38.93" "-1389" "30 hour" ">20 hour" ">10 hour" "38.21" "1865" "69.07" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00286" "GIPCGESCVFIPCLTTVAGCSCKNKVCYRN" "30" "Cycloviolin-C (Plant defensin)" "Leonia cymosa (Sacha uba)" "P84639" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18008336]CEM-SS cells:IC50=560 nM." "DRAVPe00286" "DRAVPe00286.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3166.77" "C133H217N37O40S6" "DHMQW" "C" "8.33" "3" "1" "2" "16" "8" "45" "-1602" "30 hour" ">20 hour" ">10 hour" "71.33" "1865" "64.31" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00287" "GFPCGESCVFIPCISAAIGCSCKNKVCYRN" "30" "Cycloviolin-D (Plant defensin)" "Leonia cymosa (Sacha uba)" "P84640" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=130 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18008336]CEM-SS cells:IC50=560 nM." "DRAVPe00287" "DRAVPe00287.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20, Cys8 and Cys22,Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3170.76" "C135H213N37O39S6" "DHLMQTW" "C" "8.33" "3" "1" "2" "15" "9" "50.67" "-1353" "30 hour" ">20 hour" ">10 hour" "65" "1865" "64.31" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00288" "GIPCGESCVWIPCISAAIGCSCKSKVCYRN" "30" "Cycloviolacin-O13 (Cyclotide c3; Plant defensin)" "Viola odorata (Sweet violet)" "Q5USN8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=320 nM)." "[Ref.16872274] It has 50% hemolytic activity at 1.0 μM and 75% hemolytic activity at 1.5 μM against human type A red blood cells" "[Ref.18008336]CEM-SS cells:IC50=6400 nM." "DRAVPe00288" "DRAVPe00288.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20; Cys8 and Cys22; Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3148.75" "C133H215N37O39S6" "DFHLMQT" "C" "8.33" "3" "1" "2" "15" "9" "53" "-900" "30 hour" ">20 hour" ">10 hour" "78" "7365" "253.97" "18008336##16872274" "Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ." "Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability." "10.1002/bip.20886##10.1042/BJ20060627" "Anti-HIV" "DRAVPe00289" "GSIPACGESCFKGKCYTPGCSCSKYPLCAKN" "31" "Cycloviolacin-O14 (Plant defensin)" "Viola odorata (Sweet violet)" "P85177" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2GJ0" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=440 nM)." "[Ref:16872274] It has 3% hemolytic activity at 1.0 μM and 13% hemolytic activity at 1.5 μM against human type A red blood cells" "[Ref.18008336]CEM-SS cells:IC50=4800 nM." "DRAVPe00289" "DRAVPe00289.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys6 and Cys20; Cys10 and Cys22; Cys15 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3203.74" "C135H212N36O42S6" "DHMQRVW" "C" "8.64" "4" "1" "3" "18" "5" "-18.71" "-2422" "30 hour" ">20 hour" ">10 hour" "31.61" "3355" "111.83" "18008336##16872274" "Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ." "Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability." "10.1002/bip.20886##10.1042/BJ20060627" "Anti-HIV" "DRAVPe00290" "GLPTCGETCFGGTCNTPGCTCDPWPVCTHN" "30" "Cycloviolacin-O24 (Plant defensin)" "Viola odorata (Sweet violet)" "P84637" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=308 nM)." "[Ref:16872274] It has 75% hemolytic activity at 25.0 μM against human type A red blood cells." "[Ref.18008336]CEM-SS cells:IC50=6170 nM." "DRAVPe00290" "DRAVPe00290.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys5 and Cys19; Cys9 and Cys21; Cys14 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3072.44" "C126H187N35O43S6" "AIKMQRSY" "CT" "4.35" "1" "2" "-1" "19" "4" "-16.33" "-2224" "30 hour" ">20 hour" ">10 hour" "22.67" "5875" "202.59" "18008336##16872274" "Biopolymers. 2008;90(1):51-60.##Biochem J. 2006 Nov 15;400(1):1-12." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Ireland DC, Colgrave ML, Craik DJ." "Cyclotides as natural anti-HIV agents.##A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability." "10.1002/bip.20886##10.1042/BJ20060627" "Anti-HIV" "DRAVPe00291" "GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN" "33" "Cycloviolacin-Y1 (Plants)" "Viola yedoensis (Chinese herb)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18081258] Anti-HIV activity:EC50=1.2μM, IC50>4.5μM. ##NOTE:EC50 refers to the values for HIV-infected cell cultures, IC50 refers to the values for uninfected cell cultures.##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=1210 nM)." "[Ref.18081258] It has hemolytic activity." "[Ref.18008336]CEM-SS cells:IC50>4470 nM." "DRAVPe00291" "DRAVPe00291.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys7 and Cys21; Cys11 and Cys23; Cys16 and Cys29." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3412.77" "C145H203N35O49S6" "AHKMQRVW" "G" "3.67" "0" "2" "-2" "25" "5" "14.24" "-1150" "30 hour" ">20 hour" ">10 hour" "23.64" "4845" "151.41" "18008336##18081258" "Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ." "Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis." "10.1002/bip.20886##10.1021/np070393g" "Anti-HIV" "DRAVPe00292" "GDPTFCGETCRVIPVCTYSAALGCTCDDRSDGLCKRN" "37" "Palicourein (Cyclotides; Plants)" "Palicourea condensata (Cappel)" "P84645" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1R1F" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=100 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.11430013] Cytotoxicity: human T-lymphoblastoid cell line (CEM-SS)(EC50=0.10 Μm, IC50=1.5 μM) . ##[Ref.18008336]CEM-SS cells:IC50=1500 nM." "DRAVPe00292" "DRAVPe00292.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys1 and Cys19; Cys5 and Cys21; Cys11 and Cys28;hydrogen bonds between the oxygen atoms of the Glu3 carboxyl group and the backbone amides of residues Thr12, Thr13, and Ser14, and the side chain of Ser14. " "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3928.43" "C159H256N48O56S6" "HMQW" "C" "4.78" "4" "5" "-1" "18" "8" "-18.92" "-7498" "30 hour" ">20 hour" ">10 hour" "52.7" "1865" "51.81" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00293" "GVPCGESCVFIPCITGVIGCSCSSNVCYLN" "30" "Cycloviolacin-Y4 (Plants)" "Viola yedoensis (Chinese herb)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18618891]Effects: H. contortus( IC50=2.01μM, IC99=6.73μM) and T. colubriformis(IC50=2.27μM, IC99=5.26μM).##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=120 nM)." "[Ref:18081258] HD50=9.3 μM against human type A red blood cells." "[Ref.18008336]CEM-SS cells:IC50=1720 nM." "DRAVPe00293" "DRAVPe00293.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20; Cys8 and Cys22; Cys13 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3025.55" "C127H202N32O41S6" "ADHKMQRW" "C" "4" "0" "1" "-1" "18" "9" "104.67" "1386" "30 hour" ">20 hour" ">10 hour" "90.67" "1865" "64.31" "18008336##18081258" "Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ." "Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis." "10.1002/bip.20886##10.1021/np070393g" "Anti-HIV" "DRAVPe00294" "GIPCAESCVWIPCTVTALVGCSCSDKVCYN" "30" "Cycloviolacin-Y5 (Plants)" "Viola yedoensis (Chinese herb)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18618891]Effects: H. contortus( IC50=2.28μM, IC99=22.24μM) and T. colubriformis(IC50=2.40μM, IC99=10.97μM).##[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=40 nM)." "[Ref:18081258] HD50=8.7 μM against human type A red blood cells." "[Ref.18008336]CEM-SS cells:IC50=1760 nM." "DRAVPe00294" "DRAVPe00294.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys21; Cys8 and Cys23; Cys13 and Cys28." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3122.67" "C132H209N33O42S6" "FHMQR" "C" "4.37" "1" "2" "-1" "15" "10" "79.33" "323" "30 hour" ">20 hour" ">10 hour" "84.33" "7365" "253.97" "18008336##18081258" "Biopolymers. 2008;90(1):51-60.## J Nat Prod. 2008 Jan;71(1):47-52." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Wang CK, Colgrave ML, Gustafson KR, Ireland DC, Goransson U, Craik DJ." "Cyclotides as natural anti-HIV agents.##Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis." "10.1002/bip.20886##10.1021/np070393g" "Anti-HIV" "DRAVPe00295" "SISCGESCAMISFCFTEVIGCSCKNKVCYLN" "31" "Leaf cyclotide 1 (Vhl-1; Plant defensin)" "Viola hederacea (Australian violet)" "P84522" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZA8" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=870 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00295" "DRAVPe00295.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys21; Cys8 and Cys23; Cys13 and Cys28." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3340.94" "C140H223N35O45S7" "DHPQRW" "C" "5.85" "2" "2" "0" "17" "9" "69.03" "-1027" "1.9 hour" ">20 hour" ">10 hour" "72.26" "1865" "62.17" "18008336" "Biopolymers. 2008;90(1):51-60." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ." "Cyclotides as natural anti-HIV agents." "10.1002/bip.20886" "Anti-HIV" "DRAVPe00296" "GLPVCGETCVGGTCNTPGCTCSWPVCTRN" "29" "Kalata-B1 (Plant defensin)" "Oldenlandia affinis " "P56254" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2KHB##1NB1" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=140 nM)." "[Ref.12779323] HD50 = 300 μM against Human type A red blood cells." "[Ref.18008336]CEM-SS cells:IC50=3500 nM." "DRAVPe00296" "DRAVPe00296.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (C termini to N termini)" "Disulfide bonds between Cys5 and Cys19, Cys9 and Cys21, Cys14 and Cys26." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2916.34" "C117H187N35O40S6" "ADFHIKMQY" "C" "5.96" "1" "1" "0" "19" "5" "15.17" "-1951" "30 hour" ">20 hour" ">10 hour" "43.45" "5875" "209.82" "18008336##12779323" "Biopolymers. 2008;90(1):51-60.##Biochemistry. 2003 Jun 10;42(22):6688-95." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Barry DG, Daly NL, Clark RJ, Sando L, Craik DJ." "Cyclotides as natural anti-HIV agents.##Linearization of a naturally occurring circular protein maintains structure but eliminates hemolytic activity. " "10.1002/bip.20886##10.1021/bi027323n" "Anti-HIV" "DRAVPe00297" "GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD" "31" "Kalata-B8 (Plant defensin)" "Oldenlandia affinis" "P85175" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2B38" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=2500 nM)." "[Ref.20564013] It produced 7% hemolysis at the 62μM." "[Ref.18008336]CEM-SS cells:IC50>11000 nM." "DRAVPe00297" "DRAVPe00297.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (C termini to N termini)" "Disulfide bonds between Cys6 and Cys20; Cys10 and Cys22; Cys15 and Cys28." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3307.81" "C134H220N38O47S6" "AFHIMPQW" "CT" "7.76" "3" "2" "1" "21" "5" "-2.26" "-3965" "30 hour" ">20 hour" ">10 hour" "56.45" "3355" "111.83" "18008336##20564013" "Biopolymers. 2008;90(1):51-60.##Biopolymers. 2010;94(5):647-58." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Plan MR, Rosengren KJ, Sando L, Daly NL, Craik DJ." "Cyclotides as natural anti-HIV agents.##Structural and biochemical characteristics of the cyclotide kalata B5 from Oldenlandia affinis." "10.1002/bip.20886##10.1002/bip.21409" "Anti-HIV" "DRAVPe00298" "GLPICGETCVGGTCNTPGCSCSWPVCTRN" "29" "Varv peptide E (Varv E; Plant defensin)" "Viola arvensis (European field pansy) (Field violet)" "P83835" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18008336]HIV:inhibition the cytopathic effects of HIV-1 infection in cultured human T-lymphoblast (CEM-SS) cells(EC50=350 nM)." "[Ref.20580652] HD50=6.96 µM against human type O red blood cells." "[Ref.20580652] Cytotoxicity: U251(IC50=38.84μg/mL), MDA-MB-231(IC50>10μg/mL), A549(IC50>10μg/mL), DU145(IC50>10μg/mL), BEL-7402(IC50>10μg/mL).##[Ref.14987049] Cytotoxicity: U-937 GTB (lymphoma)(IC50 =" "DRAVPe00298" "DRAVPe00298.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (C termini to N termini)" "Disulfide bonds between Cys5 and Cys19; Cys9 and Cys21; Cys14 and Cys26." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2916.34" "C117H187N35O40S6" "ADFHKMQY" "C" "5.96" "1" "1" "0" "19" "5" "15.86" "-1946" "30 hour" ">20 hour" ">10 hour" "46.9" "5875" "209.82" "18008336##20580652" "Biopolymers. 2008;90(1):51-60.##Peptides. 2010 Aug;31(8):1434-40." "Ireland DC, Wang CK, Wilson JA, Gustafson KR, Craik DJ.##Tang J, Wang CK, Pan X, Yan H, Zeng G, Xu W, He W, Daly NL, Craik DJ, Tan N." "Cyclotides as natural anti-HIV agents.##Isolation and characterization of cytotoxic cyclotides from Viola tricolor." "10.1002/bip.20886##10.1016/j.peptides.2010.05.004" "Anti-HIV" "DRAVPe00299" "ACYCRIPACIAGERRYGTCIYQGRLWAFCC" "30" "Neutrophil defensin 1 (Defensin, alpha 1; HNP-1, HP-1; Human, mammals, animals)" "Homo sapiens (Human)" "P59665##P11479##Q14125##Q6EZF6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2KHT" "SARS-CoV-2" "Coronaviridae" "[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM));##SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(67% inbibition at 50 μg/mL);##SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(58% inbibition at 50 μg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL." "DRAVPe00299" "DRAVPe00299.cif" "Cyclic" "Free" "Cyclization(Cys2 and Cys30)." "Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3448.09" "C150H228N44O38S6" "DHKMNSV" "C" "8.68" "4" "1" "3" "13" "10" "30" "-3229" "4.4 hour" ">20 hour" ">10 hour" "65.33" "10345" "356.72" "34206990" "Viruses. 2021 Jun 26;13(7):1246." "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL." "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry." "10.3390/v13071246" "DRAVPa1304" "Anti-SARS-CoV-2" "DRAVPe00300" "CYCRIPACIAGERRYGTCIYQGRLWAFCC" "29" "Neutrophil defensin 2 (HNP-2, HP-2, HP2; Human, mammals, animals)" "Homo sapiens (Human)" "P59665##P11479##Q14125##Q6EZF6##P59666##P11479##Q14125" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZMH##1ZMI##1ZMK" "SARS-CoV-2" "Coronaviridae" "[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM))." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00300" "DRAVPe00300.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys1 and Cys29,Cys3 and Cys18,Cys8 and Cys28." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3377.01" "C147H223N43O37S6" "DHKMNSV" "C" "8.67" "4" "1" "3" "13" "9" "24.83" "-3410" "1.2 hour" ">20 hour" ">10 hour" "64.14" "10345" "369.46" "34206990" "Viruses. 2021 Jun 26;13(7):1246." "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL." "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry." "10.3390/v13071246" "Anti-SARS-CoV-2" "DRAVPe00301" "DCYCRIPACIAGERRYGTCIYQGRLWAFCC" "30" "Neutrophil defensin 3 (Defensin, alpha 3; HNP-3, HP-3, HP3; Human, mammals, animals)" "Homo sapiens (Human)" "P59666##P11479##Q14125" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1DFN##2PM4##2PM5" "SARS-CoV-2" "Coronaviridae" "[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM))." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00301" "DRAVPe00301.cif" "Cyclic" "Free" "Cyclization of a C-terminal Cys residue (forming a disulfide bond)" "Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3492.1" "C151H228N44O40S6" "HKMNSV" "C" "8.33" "4" "2" "2" "13" "9" "12.33" "-4282" "1.1 hour" "3 min" ">10 hour" "62" "10345" "356.72" "34206990" "Viruses. 2021 Jun 26;13(7):1246." "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL." "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry." "10.3390/v13071246" "Anti-SARS-CoV-2" "DRAVPe00302" "VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV" "33" "Neutrophil defensin 4 (Defensin, alpha 4; HNP-4, HP-4; Human, mammals, animals)" "Homo sapiens (Human)" "P12838" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZMM" "SARS-CoV-2" "Coronaviridae" "[Ref.34206990]SARS-CoV-2: showed inhibition against SARS-CoV-2." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00302" "DRAVPe00302.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys2 and Cys30,Cys4 and Cys19,Cys9 and Cys29." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3715.46" "C157H261N49O43S6" "ADHKMPQW" "C" "8.98" "5" "1" "4" "16" "11" "66.06" "-4636" "100 hour" ">20 hour" ">10 hour" "91.21" "1865" "58.28" "34206990" "Viruses. 2021 Jun 26;13(7):1246." "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL." "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry." "10.3390/v13071246" "Anti-SARS-CoV-2" "DRAVPe00303" "AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL" "32" "Human defensin-6 (HD-6; Defensin, alpha 6; Human, mammals, animals)" "Homo sapiens (Human)" "Q01524" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZMQ##3QTE" "SARS-CoV-2" "Coronaviridae" "[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(HD6 only blocked SARS-CoV-2 infection at the highest concentration tested (50 μg/mL, 13 μM))." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL." "DRAVPe00303" "DRAVPe00303.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys4 and Cys31,Cys6 and Cys20,Cys10 and Cys30." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3714.27" "C156H234N46O46S7" "DKPQW" "C" "8.35" "5" "1" "4" "19" "6" "0" "-5487" "4.4 hour" ">20 hour" ">10 hour" "36.56" "4845" "156.29" "34206990" "Viruses. 2021 Jun 26;13(7):1246." "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL." "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry." "10.3390/v13071246" "Anti-SARS-CoV-2" "DRAVPe00304" "GWFDVVKHIAKRF" "13" "D70(Derived from Uperin 7.1)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.99 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 10.6 µM." "DRAVPe00304" "DRAVPe00304.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1602.9" "C78H115N21O16" "CELMNPQSTY" "FKV" "9.99" "4" "1" "3" "1" "7" "0" "-1536" "30 hour" ">20 hour" ">10 hour" "82.31" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00305" "VDKPDYRPRPRPPNM" "15" "Metalnikowin-1 (Metalnikowin I; Insects, animals)" "Palomena prasina (Green shield bug) (Cimex prasinus)" "P80408" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>54.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >54.4 µM." "DRAVPe00305" "DRAVPe00305.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1838.12" "C80H128N26O22S" "ACEFGHILQSTW" "P" "9.98" "4" "2" "2" "2" "1" "-207.33" "-6814" "100 hour" ">20 hour" ">10 hour" "19.33" "1490" "106.43" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00306" "FLFPLITSFLSKVL" "14" "Ranatuerin-9 (Frogs, amphibians, animals)" "Lithobates catesbeiana (American bullfrog) (Rana catesbeiana)" "P82824" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=16.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 34.6 µM." "DRAVPe00306" "DRAVPe00306.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1625.03" "C83H129N15O18" "ACDEGHMNQRWY" "L" "8.75" "1" "0" "1" "3" "9" "175" "2266" "1.1 hour" "3 min" "2 min" "160" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00307" "INLKAIAALAKKLL" "14" "Mastoparan M" "Hornet Vespa mandarinia" "P04205" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>67.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >67.6 µM." "DRAVPe00307" "DRAVPe00307.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1479.91" "C70H130N18O16" "CDEFGHMPQRSTVWY" "AL" "10.3" "3" "0" "3" "1" "10" "115.71" "1347" "20 hour" "30 min" ">10 hour" "195.71" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00308" "IKWKKLLRAAKRIL" "14" "DASamP2(D74,derived from polybia-MPI)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>57.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 1.3 µM." "DRAVPe00308" "DRAVPe00308.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1737.25" "C83H149N25O15" "CDEFGHMNPQSTVY" "K" "12.03" "6" "0" "6" "0" "8" "-10.71" "-2149" "20 hour" "30 min" ">10 hour" "153.57" "5500" "423.08" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00309" "FRPALIVRTKGTRL" "14" "Hyposin-5 (frog)" "Phyllomedusa hypochondrialis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>61.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >61.4 µM." "DRAVPe00309" "DRAVPe00309.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1628" "C74H130N24O17" "CDEHMNQSWY" "R" "12.3" "4" "0" "4" "3" "6" "0.71" "-3092" "1.1 hour" "3 min" "2 min" "111.43" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00310" "FFGKVLKLIRKIF" "13" "DASamP1(D76,derived from temporin-PTa)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.63 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 6.78 µM." "DRAVPe00310" "DRAVPe00310.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1609.08" "C82H133N19O14" "ACDEHMNPQSTWY" "FK" "11.26" "4" "0" "4" "1" "8" "96.92" "203" "1.1 hour" "3 min" "2 min" "142.31" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00311" "GNNRPVYIPQPRPPHPRI" "18" "Apidaecin IA (insect)" "Apis mellifera L" "P35581" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>47.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >47.4 µM." "DRAVPe00311" "DRAVPe00311.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2108.44" "C95H150N32O23" "ACDEFKLMSTW" "P" "11.71" "4" "0" "4" "4" "3" "-140.56" "-5356" "30 hour" ">20 hour" ">10 hour" "59.44" "1490" "87.65" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00312" "GKPRPYSPRPTSHPRPIRV" "19" "Drosocin (insect)" "Drosophila melanogaster" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "4EZR" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>45.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >45.5 µM." "DRAVPe00312" "DRAVPe00312.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2198.56" "C98H160N34O24" "ACDEFLMNQW" "P" "12.01" "6" "0" "6" "5" "2" "-157.89" "-6950" "30 hour" ">20 hour" ">10 hour" "35.79" "1490" "82.78" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00313" "VFQFLGRIIHHVGNFVHGFSHVF" "23" "Clavanin-B (His-rich; chordates, animals)" "Styela clava (Sea squirt)" "P80711" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=7.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 37.1 µM." "DRAVPe00313" "DRAVPe00313.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2695.13" "C131H184N36O27" "ACDEKMPTWY" "F" "9.75" "5" "0" "5" "5" "12" "75.22" "-50" "100 hour" ">20 hour" ">10 hour" "101.3" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00314" "TRSSRAGLQFPVGRVHRLLRK" "21" "Buforin II (toad)" "Synthetic construct(derived from buforin I after treatment with endoproteinase)" "P55897" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>41.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >41.1 µM." "DRAVPe00314" "DRAVPe00314.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2434.88" "C106H184N40O26" "CDEIMNWY" "R" "12.6" "7" "0" "7" "5" "7" "-63.81" "-7021" "7.2 hour" ">20 hour" ">10 hour" "88.1" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00315" "GFGKAFHSVSNFAKKHKTA" "19" "Styelin A (tunicate)" "Styela clava" "P81469" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>48.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >48.5 µM." "DRAVPe00315" "DRAVPe00315.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2062.36" "C95H144N28O24" "CDEILMPQRWY" "K" "10.48" "6" "0" "6" "6" "7" "-55.79" "-2724" "30 hour" ">20 hour" ">10 hour" "31.05" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00316" "LLKELWTKIKGAGKAVLGKIKGLL" "24" "Ponericin-L2 (ants, insects, animals)" "Pachycondyla goeldii (Ponerine ant)" "P82422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 24.7 µM." "DRAVPe00316" "DRAVPe00316.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2578.27" "C123H217N31O28" "CDFHMNPQRSY" "KL" "10.3" "6" "1" "5" "5" "12" "39.58" "1043" "5.5 hour" "3 min" "2 min" "150.42" "5500" "239.13" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00317" "HVDKKVADKVLLLKQLRIMRLLTRL" "25" "Spinigerin (Insects, animals)" "Pseudacanthotermes spiniger (Termite)" "P82357" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZRW##1ZRV" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=3.05 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >33.3 µM." "DRAVPe00317" "DRAVPe00317.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3000.77" "C136H247N41O32S" "CEFGNPSWY" "L" "11.07" "8" "2" "6" "1" "12" "15.6" "-4153" "3.5 hour" "10 min" ">10 hour" "163.6" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00318" "GLNTLKKVFQGLHEAIKLINNHVQ" "24" "Pseudin 1 (frog)" "Pseudis paradoxa" "P83188" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=35.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >36.8 µM." "DRAVPe00318" "DRAVPe00318.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2715.19" "C123H204N36O33" "CDMPRSWY" "L" "9.7" "5" "1" "4" "6" "10" "-14.17" "-2208" "30 hour" ">20 hour" ">10 hour" "125.83" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00319" "RQRVEELSKFSKKGAAARRRK" "21" "Misgurin (fish)" "Misgurnus anguillicaudatus" "P81474" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>40.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >40.0 µM." "DRAVPe00319" "DRAVPe00319.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2501.92" "C106H189N41O29" "CDHIMNPTWY" "R" "11.84" "9" "2" "7" "3" "6" "-163.81" "-10445" "1 hour" "2 min" "2 min" "46.67" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00320" "NLVSGLIEARKYLEQLHRKLKNRKV" "25" "D88 (frog)" "Synthetic construct(derived from chain A of distinctin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>33.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >33.3 µM." "DRAVPe00320" "DRAVPe00320.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3006.59" "C134H233N43O35" "CDFMPTW" "L" "10.55" "8" "2" "6" "5" "9" "-74.4" "-6725" "1.4 hour" "3 min" ">10 hour" "120.8" "1490" "62.08" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00321" "IWLTALKFLGKHAAKHLAKQQLSKL" "25" "Lycotoxin I (spider)" "Lycosa carolinensis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "7MMM" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>35.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 2.4 µM." "DRAVPe00321" "DRAVPe00321.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2844.49" "C135H223N37O30" "CDEMNPRVY" "L" "10.6" "7" "0" "7" "3" "13" "6.4" "-619" "20 hour" "30 min" ">10 hour" "125.2" "5500" "229.17" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00322" "GLFDIIKKIAESW" "13" "B1(derived from Aurein 1.2)" "Synthetic construct(derived from Aurein 1.2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=11.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 37.0 µM." "DRAVPe00322" "DRAVPe00322.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00323" "GLWEKIDKFASII" "13" "B2(derived from Caerin 3.2)" "Synthetic construct(derived from Caerin 3.2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>65.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00323" "DRAVPe00323.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00324" "GIIDIAKKLFESW" "13" "B3(derived from Uperin 2.7)" "Synthetic construct(derived from Uperin 2.7)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=20.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00324" "DRAVPe00324.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00325" "GWFDIIKKIASEL" "13" "B4(derived from Uperin 7.1)" "Synthetic construct(derived from Uperin 7.1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=10.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 38.9 µM." "DRAVPe00325" "DRAVPe00325.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00326" "GIFDKLAKEISIW" "13" "B5(derived from Brevinin-2DYd)" "Synthetic construct(derived from Brevinin-2DYd)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>65.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00326" "DRAVPe00326.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00327" "GIWSDLAEIIKKF" "13" "B6(derived from Ponericin W3)" "Synthetic construct(derived from Ponericin W3)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=11.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00327" "DRAVPe00327.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00328" "GFLDIIEKIAKSW" "13" "B7(derived from Ranatuerin 3)" "Synthetic construct(derived from Ranatuerin 3)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=10.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00328" "DRAVPe00328.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00329" "GWLKKIESIIDAF" "13" "B8(derived from Cecropin)" "Synthetic construct(derived from Cecropin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=29.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >65.8 µM." "DRAVPe00329" "DRAVPe00329.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1519.8" "C73H114N16O19" "CHMNPQRTVY" "I" "6.07" "2" "2" "0" "2" "7" "38.46" "-229" "30 hour" ">20 hour" ">10 hour" "127.69" "5500" "458.33" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00330" "ILGPVLGLVSDTLDDVLGIL" "20" "Maximin H5" "Bombina maxima" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>49.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >49.7 µM." "DRAVPe00330" "DRAVPe00330.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2022.41" "C93H160N20O29" "ACEFHKMNQRWY" "L" "3.42" "0" "3" "-3" "5" "11" "148" "2217" "20 hour" "30 min" ">10 hour" "199.5" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00331" "ILGPVLGLVSRTLRRVLGIL" "20" "Maximin H5r3" "Synthetic construct(derived from Maximin H5)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 8.7 µM." "DRAVPe00331" "DRAVPe00331.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2145.71" "C99H181N29O23" "ACDEFHKMNQWY" "L" "12.3" "3" "0" "3" "5" "11" "133" "357" "20 hour" "30 min" ">10 hour" "199.5" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00332" "GFKRIVQRIKDFLRNLV" "17" "GF-17" "Synthetic construct(derived from LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV, EBOV" "Retroviridae, Filoviridae" "Plaque assay" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.76 μM);##[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.98 μM).(EC50:50% effective concentration for inhibition of virus replication);##[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=10.1 µM);inhibition of viral infection in primary macrophages(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 10.8 µM.##[Ref.18591279]CEM-SS cells:TC50=8.9 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe00332" "DRAVPe00332.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." "2102.56" "C97H164N30O22" "ACEHMPSTWY" "R" "11.72" "5" "1" "4" "2" "8" "-9.41" "-4210" "30 hour" ">20 hour" ">10 hour" "125.88" "0" "0" "20086159##18591279##32252021" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. ##iScience. 2020 Apr 24;23(4):100999." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Wang G, Watson KM, Buckheit RW Jr. ##Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.##Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection." "10.1128/AAC.01448-09##10.1128/AAC.00452-08##10.1016/j.isci.2020.100999" "Anti-HIV, Anti-EBOV" "DRAVPe00333" "GFNEIVQDIEDFLQNLV" "17" "GF-17−" "Synthetic construct(derived from LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>25.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >25.1 µM." "DRAVPe00333" "DRAVPe00333.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1993.2" "C90H137N21O30" "ACHKMPRSTWY" "DEFILNQV" "3.43" "0" "4" "-4" "3" "8" "12.94" "-2076" "30 hour" ">20 hour" ">10 hour" "125.88" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00334" "GLRSKIWLWVLLMIWQESNKFKKM" "24" "DRS S9" "Synthetic construct(derived from Dermaseptin S9)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=31.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >32.9 µM." "DRAVPe00334" "DRAVPe00334.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3035.75" "C145H228N36O31S2" "ACDHPTY" "KL" "10.46" "5" "1" "4" "4" "11" "-1.25" "-1374" "30 hour" ">20 hour" ">10 hour" "109.58" "16500" "717.39" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00335" "GLRSRIWLWVLLMIWQESNRFKRM" "24" "DRS S9r3" "Synthetic construct(derived from Dermaseptin S9)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >32.1 µM." "DRAVPe00335" "DRAVPe00335.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3119.79" "C145H228N42O31S2" "ACDHPTY" "LR" "12" "5" "1" "4" "4" "11" "-8.75" "-4185" "30 hour" ">20 hour" ">10 hour" "109.58" "16500" "717.39" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00336" "GLKKLLGKLLKKLGKLLLK" "19" "GLK-19" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>47.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 25.1 µM." "DRAVPe00336" "DRAVPe00336.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2104.82" "C102H194N26O20" "ACDEFHIMNPQRSTVWY" "L" "10.78" "7" "0" "7" "3" "9" "30" "825" "30 hour" ">20 hour" ">10 hour" "184.74" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00337" "GLRRLLGRLLRRLGRLLLR" "19" "GLR-19" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 25.7 µM." "DRAVPe00337" "DRAVPe00337.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2300.92" "C102H194N40O20" "ACDEFHIKMNPQSTVWY" "L" "12.78" "7" "0" "7" "3" "9" "7.89" "-5734" "30 hour" ">20 hour" ">10 hour" "184.74" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00338" "KGRGKQGGKVRAKAKTRSS" "19" "Parasin I (fish)" "Parasilurus asotus" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>50.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >50.0 µM." "DRAVPe00338" "DRAVPe00338.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2000.34" "C82H154N34O24" "CDEFHILMNPWY" "K" "12.32" "8" "0" "8" "7" "3" "-171.58" "-7600" "1.3 hour" "3 min" "2 min" "25.79" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00339" "GIWDTIKSMGKVFAGKILQNL" "21" "Brevinin-2-related peptide (Frogs, amphibians, animals)" "Rana septentrionalis (mink frog)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.65 μM)." "[Ref.15556063]HC50=70 µM against human erythrocytes" "[Ref.20086159]CEM-SS cells:50% Cell death at 7.42 µM." "DRAVPe00339" "DRAVPe00339.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2319.79" "C107H175N27O28S" "CEHPRY" "GIK" "9.7" "3" "1" "2" "6" "9" "28.57" "-259" "30 hour" ">20 hour" ">10 hour" "111.43" "5500" "275" "20086159##15556063" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):31-38." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Bevier CR, Sonnevend A, Kolodziejek J, Nowotny N, Nielsen PF, Conlon JM." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Purification and characterization of antimicrobial peptides from the skin secretions of the mink frog (Rana septentrionalis)." "10.1128/AAC.01448-09##10.1016/j.cca.2004.08.019" "Anti-HIV" "DRAVPe00340" "GLLGLLGSVVSHVVPAIVGHF" "21" "Maculatin-1.3 (frog, amphibia, animals)" "Litoria eucnemis (Australian anurans)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 8.02 µM." "DRAVPe00340" "DRAVPe00340.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2071.49" "C98H159N25O24" "CDEKMNQRTWY" "V" "6.92" "2" "0" "2" "6" "12" "162.38" "3723" "30 hour" ">20 hour" ">10 hour" "166.67" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00341" "SWKSMAKKLKEYMEKLKQRA" "20" "M-zodatoxin-Lt3a (M-ZDTX-Lt3a; Latarcin-3a, Ltc-3a; spiders, Arthropods, animals)" "Lachesana tarabaevi (Spider)" "Q1ELU3" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=32.7 μM)." "[Ref.16735513]20% hemolytic activity at >120 μM against rabbit erythrocytes " "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >40.3 µM." "DRAVPe00341" "DRAVPe00341.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2484.02" "C111H187N31O29S2" "CDFGHINPTV" "K" "10.12" "7" "2" "5" "3" "5" "-136" "-5383" "1.9 hour" ">20 hour" ">10 hour" "49" "6990" "367.89" "20086159##16735513" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##J Biol Chem. 2006 Jul 28;281(30):20983-209892." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Kozlov SA, Vassilevski AA, Feofanov AV, Surovoy AY, Karpunin DV, Grishin EV." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity." "10.1128/AAC.01448-09##10.1074/jbc.M602168200" "Anti-HIV" "DRAVPe00342" "GAWKNFWSSLRKGFYDGEAGRAIRR" "25" "D94 (bacteria)" "Synthetic construct(derived from chain A of plantaricin JK)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>34.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >34.1 µM." "DRAVPe00342" "DRAVPe00342.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2929.3" "C133H198N42O34" "CHMPQTV" "GR" "10.93" "6" "2" "4" "8" "9" "-93.2" "-7024" "30 hour" ">20 hour" ">10 hour" "43.2" "12490" "520.42" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00343" "GFKDLLKGAAKALVKTVLF" "19" "Ascaphin-8 (Frogs, amphibians, animals)" "Ascaphus truei (Coastal tailed frog)" "P0CJ32" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=1.2 μM)." "[Ref.15207717]HC50=50 μM against human erythrocytes" "[Ref.20086159]CEM-SS cells:50% Cell death at 2.9 µM." "DRAVPe00343" "DRAVPe00343.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2019.5" "C97H163N23O23" "CEHIMNPQRSWY" "KL" "10" "4" "1" "3" "3" "11" "73.68" "754" "30 hour" ">20 hour" ">10 hour" "128.42" "0" "0" "20086159##15207717" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Biochem Biophys Res Commun. 2004 Jul 16;320(1):170-175." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Conlon JM, Sonnevend A, Davidson C, Smith DD, Nielsen PF." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei." "10.1128/AAC.01448-09##10.1016/j.bbrc.2004.05.141" "Anti-HIV" "DRAVPe00344" "GLADFLNKAVGKVVDFVKS" "19" "Desertcolin 1 (frog)" "Crinia deserticola" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>49.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >49.9 µM." "DRAVPe00344" "DRAVPe00344.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2007.36" "C93H151N23O26" "CEHIMPQRTWY" "V" "8.5" "3" "2" "1" "4" "10" "51.58" "-667" "30 hour" ">20 hour" ">10 hour" "112.63" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00345" "GFLSILKKVLPKVMAHMK" "18" "Melectin (MEP; Insects, animals)" "Melecta albifrons (Cuckoo bee) (Melecta punctata)" "P86170" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=4.34 μM)." "[Ref.18942691]LC50>100 μM against rat red blood cells" "[Ref.20086159]CEM-SS cells:50% Cell death at 7.75 µM." "DRAVPe00345" "DRAVPe00345.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2040.64" "C96H166N24O20S2" "CDENQRTWY" "K" "10.48" "5" "0" "5" "2" "8" "61.67" "793" "30 hour" ">20 hour" ">10 hour" "124.44" "0" "0" "20086159##18942691" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Chembiochem. 2008 Nov 24;9(17):2815-2821." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Cerovský V, Hovorka O, Cvacka J, Voburka Z, Bednárová L, Borovicková L, Slaninová J, Fucík V." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Melectin: a novel antimicrobial peptide from the venom of the cleptoparasitic bee Melecta albifrons." "10.1128/AAC.01448-09##10.1002/cbic.200800476" "Anti-HIV" "DRAVPe00346" "SLSRFLRFLKIVYRRAF" "17" "D98 (frog,derived from temporin-LTc)" "Synthetic construct(derived from temporin-LTc)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.83 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 8.6 µM." "DRAVPe00346" "DRAVPe00346.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2172.65" "C104H166N30O21" "CDEGHMNPQTW" "R" "12.01" "5" "0" "5" "3" "9" "32.35" "-3770" "1.9 hour" ">20 hour" ">10 hour" "114.71" "1490" "93.13" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00347" "RPKHPIKHQGLPQEVLNENLLRF" "23" "Isracidin (cow)" "bovine colostrum" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>36.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >36.2 µM." "DRAVPe00347" "DRAVPe00347.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2764.23" "C125H203N39O32" "ACDMSTWY" "L" "9.99" "6" "2" "4" "3" "7" "-98.7" "-5568" "1 hour" "2 min" "2 min" "97.39" "0" "0" "20086159" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database." "10.1128/AAC.01448-09" "Anti-HIV" "DRAVPe00348" "GIGTKILGGVKTALKGALKELASTYAN" "27" "Maximin-1 (Toads, amphibians, animals)" "Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)" "P83080##Q58T87" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=15.5 µg/ml, EC50=21.4 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%." "[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00348" "DRAVPe00348.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2675.16" "C120H208N32O36" "CDFHMPQRW" "G" "9.83" "4" "1" "3" "11" "11" "25.19" "-140" "30 hour" ">20 hour" ">10 hour" "112.22" "1490" "57.31" "11835991" "Peptides. 2002 Mar;23(3):427-435." "Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y." "Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima." "Anti-HIV" "DRAVPe00349" "GIGGKILSGLKTALKGAAKELASTYLH" "27" "Maximin-3 (Toads, amphibians, animals)" "Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)" "P83082##Q58T40##Q58T43##Q58T46##Q58T48##Q58T64##Q58T65##Q58T68##Q58T69" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=11.4 µg/ml, EC50=1.5 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%." "[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00349" "DRAVPe00349.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2698.2" "C122H209N33O35" "CDFMNPQRVW" "GL" "9.83" "5" "1" "4" "10" "11" "24.44" "63" "30 hour" ">20 hour" ">10 hour" "115.93" "1490" "57.31" "11835991" "Peptides. 2002 Mar;23(3):427-435." "Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y." "Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima." "Anti-HIV" "DRAVPe00350" "GIGGVLLSAGKAALKGLAKVLAEKYAN" "27" "Maximin-4 (Toads, amphibians, animals)" "Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)" "P83083##Q58T42##Q58T44##Q58T52##Q58T62##Q58T77##Q58T79" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2MHW" "HIV" "Retroviridae" "[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=24.2 µg/ml, EC50=21.9 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%." "[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00350" "DRAVPe00350.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2613.14" "C119H206N32O33" "CDFHMPQRTW" "A" "9.83" "4" "1" "3" "8" "14" "59.26" "1397" "30 hour" ">20 hour" ">10 hour" "130.37" "1490" "57.31" "11835991" "Peptides. 2002 Mar;23(3):427-435." "Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y." "Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima." "Anti-HIV" "DRAVPe00351" "SIGAKILGGVKTFFKGALKELASTYLQ" "27" "Maximin-5 (Toads, amphibians, animals)" "Bombina maxima (Giant fire-bellied toad) (Chinese red belly toad)" "P83084##Q58T60##Q58T61" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.11835991]HIV-1:inhibition the cytopathic effects of HIV-1 (IC50=34.4 µg/ml, EC50=39.8 µg/ml).##NOTE: IC50 means the concentration that can inhibit 50% growth of cells. EC50 was defined as the concentration of antiviral agent reducing HIV-1 replication by 50%." "[Ref:11835991]Little hemolytic activity at 50 μg/ml against red blood cells" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00351" "DRAVPe00351.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2841.39" "C133H218N32O36" "CDHMNPRW" "GKL" "9.82" "4" "1" "3" "9" "12" "40.37" "208" "1.9 hour" ">20 hour" ">10 hour" "108.52" "1490" "57.31" "11835991" "Peptides. 2002 Mar;23(3):427-435." "Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, Lee WH, Tang SZ, Zhang Y." "Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima." "Anti-HIV" "DRAVPe00352" "GLFGVLAKVAAHVVPAIAEHF" "21" "Maculatin-1.1" "Litoria genimaculata (Green-eyed tree frog)" "P82066" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.16140737]HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=11.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00352" "DRAVPe00352.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could prevent HIV infection by disrupting the integrity of the virion membrane, and inhibit the transfer of HIV from DCs to T cells." "2146.56" "C103H160N26O24" "CDMNQRSTWY" "A" "6.92" "3" "1" "2" "2" "14" "130" "2613" "30 hour" ">20 hour" ">10 hour" "134.76" "0" "0" "16140737" "J Virol. 2005 Sep;79(18):11598-606." "VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D." "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells." "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe00353" "GLLSVLGSVAKHVLPHVVPVIAEHL" "25" "Caerin-1.1" "Litoria splendida (Magnificent tree frog) (Litoria gilleni) (Litoria caerulea)" "P62568##P62569##Q800R2##P56226" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.16140737]HIV:inhibit 50% of PBS-treated HIV infection of T cells(IC50=7.8 μM);inhibition of HIV transfer by dendritic cells to T cells(IC50=12.6 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00353" "DRAVPe00353.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could prevent HIV infection by disrupting the integrity of the virion membrane, and inhibit the transfer of HIV from DCs to T cells." "2585.13" "C121H202N32O30" "CDFMNQRTWY" "V" "7.02" "4" "1" "3" "4" "14" "118.8" "2612" "30 hour" ">20 hour" ">10 hour" "171.2" "0" "0" "16140737" "J Virol. 2005 Sep;79(18):11598-606." "VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D." "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells." "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe00354" "GLFGVLGSIAKHVLPHVVPVIAEKL" "25" "Caerin 1.9" "Litoria chloris" "P81252" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=4 µM).##[Ref.16140737]Human immunodeficiency virus (HIV):inhibit 50% of PBS-treated HIV infection of T cells(IC50=1.2 μM);inhibition of HIV transfer by dendritic cells to T cells(IC50=1.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 20 µM." "DRAVPe00354" "DRAVPe00354.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "Prevent HIV infection by disrupting the integrity of the virion membrane at concentrations that are not toxic to target cells, the peptide also inhibit the transfer of HIV from DCs to T cells." "2594.18" "C124H205N31O29" "CDMNQRTWY" "V" "8.61" "4" "1" "3" "4" "14" "114.8" "2851" "30 hour" ">20 hour" ">10 hour" "159.6" "0" "0" "26026377##16140737##33008028" "Peptides. 2015 Sep;71:296-303.##J Virol. 2005 Sep;79(18):11598-606.##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.1128/JVI.79.18.11598-11606.2005##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00355" "GLFSVLGAVAKHVLPHVVPVIAEKL" "25" "Caerin-1.6" "Litoria xanthomera (Orange-thighed frog) (Litoria chloris)" "P62546##P56231##P81249##P62547" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 10 µM." "DRAVPe00355" "DRAVPe00355.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection." "2594.18" "C124H205N31O29" "CDMNQRTWY" "V" "8.61" "4" "1" "3" "3" "15" "122.4" "2850" "30 hour" ">20 hour" ">10 hour" "159.6" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00356" "GLFKVLGSVAKHLLPHVAPVIAEKL" "25" "Caerin-1.7" "Litoria xanthomera (Orange-thighed frog) (Litoria chloris)" "P62548##P62549##P56232##P81250" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 12.5 µM." "DRAVPe00356" "DRAVPe00356.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection." "2637.25" "C126H210N32O29" "CDMNQRTWY" "L" "9.7" "5" "1" "4" "3" "14" "88.4" "1979" "30 hour" ">20 hour" ">10 hour" "152" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00357" "GLFKVLGSVAKHLLPHVAPIIAEKL" "25" "Caerin-1.19" "Litoria gracilenta (Dainty green tree frog)" "P0C2A8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00357" "DRAVPe00357.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection." "2651.28" "C127H212N32O29" "CDMNQRTWY" "L" "9.7" "5" "1" "4" "3" "14" "89.6" "2067" "30 hour" ">20 hour" ">10 hour" "156" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00358" "GLLSVLGSVAKHVLPHVVPVIAEKL" "25" "Caerin 1.10" "Litoria splendida" "P86502##P82104" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 22 µM." "DRAVPe00358" "DRAVPe00358.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2576.16" "C121H207N31O30" "CDFMNQRTWY" "V" "8.61" "4" "1" "3" "4" "14" "116" "2523" "30 hour" ">20 hour" ">10 hour" "171.2" "0" "0" "26026377##33008028" "Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00359" "GLLGVLGSVAKHVLPHVVPVIAEHL" "25" "Caerin 1.2" "Litoria caerulea " "P56227" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 22 µM." "DRAVPe00359" "DRAVPe00359.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2555.11" "C120H200N32O29" "CDFMNQRTWY" "V" "7.02" "4" "1" "3" "4" "14" "120.4" "3046" "30 hour" ">20 hour" ">10 hour" "171.2" "0" "0" "26026377##33008028" "Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00360" "GLLSVLGSVVKHVIPHVVPVIAEHL" "25" "Caerin-1.5" "Litoria caerulea (Green tree frog)" "P56230" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]HIV: inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]Human endocervical cells End1/E6E7:50% cell death at 12.5 µM." "DRAVPe00360" "DRAVPe00360.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "The peptide could disrupt the viral envelope and release p24 protein.And the more effective they were at disruption of the viral envelope, the better they were at inhibiting infection." "2613.19" "C123H206N32O30" "CDFMNQRTWY" "V" "7.02" "4" "1" "3" "4" "14" "131.2" "2835" "30 hour" ">20 hour" ">10 hour" "178.8" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00361" "GLLSVLGSVAKHVLPHVVPVIAAAL" "25" "Caerin 1.1 mod 7(Caerin 1.1 [E23A,H24A])" "Sythetic construct(derived from Caerin 1.1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00361" "DRAVPe00361.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2461.03" "C116H198N30O28" "CDEFMNQRTWY" "V" "8.76" "3" "0" "3" "4" "16" "160" "4121" "30 hour" ">20 hour" ">10 hour" "179.2" "0" "0" "26026377##33008028" "Peptides. 2015 Sep;71:296-303. ##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00362" "GLLSVLGSVAKHVLPHVVPVIAKLH" "25" "Caerin 1.1 mod 9(Caerin 1.1 [E23K,H24L,L25H])" "Sythetic construct(derived from Caerin 1.1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=2.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 17 µM." "DRAVPe00362" "DRAVPe00362.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2584.19" "C122H207N33O28" "CDEFMNQRTWY" "V" "10" "5" "0" "5" "4" "14" "117.2" "2738" "30 hour" ">20 hour" ">10 hour" "171.2" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303. " "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00363" "GLLKVLGSVAKKVLPKVVPVIAEKL" "25" "Caerin 1.1 mod 10(Caerin 1.1 [S4K;H12K,H16K,H24K])" "Sythetic construct(derived from Caerin 1.1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=4 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00363" "DRAVPe00363.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2599.33" "C124H224N30O29" "CDFHMNQRTWY" "V" "10.18" "5" "1" "4" "3" "14" "98" "2130" "30 hour" ">20 hour" ">10 hour" "171.2" "0" "0" "26026377" "Peptides. 2015 Sep;71:296-303. " "Inhibition of HIV infection by caerin 1 antimicrobial peptides." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA." "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe00364" "GLFGVLGSIAKHLLPHVVPVIAEKL" "25" "Caerin 1.9 sm(Caerin 1.9 [V13L])" "Sythetic construct(derived from Caerin 1.9)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 17.5 µM." "DRAVPe00364" "DRAVPe00364.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2608.21" "C125H207N31O29" "CDMNQRTWY" "L" "8.61" "4" "1" "3" "4" "14" "113.2" "2939" "30 hour" ">20 hour" ">10 hour" "163.6" "0" "0" "26026377##33008028" "Peptides. 2015 Sep;71:296-303. ##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00365" "GLFGILGSVAKHVLPHVIPVVAEHL" "25" "Caerin 1.20" "Litoria caerulea/Litoria splendida" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.26026377]Human immunodeficiency virus (HIV): inhibition of HIV Pseudovirus (PsV) infection in CD4+ T cells(IC50=7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26026377]CD4+ T Lymphocytes:50% cell death at 25 µM;Human endocervical cells End1/E6E7:50% cell death at 22 µM." "DRAVPe00365" "DRAVPe00365.cif" "Linear" "Free" "Amidation" "None" "L" "virion envelope" "[Ref.26026377]Inhibit the infection of HIV by disrupting the HIV envelope and release viral core protein (p24)." "2603.15" "C124H200N32O29" "CDMNQRTWY" "V" "7.02" "4" "1" "3" "4" "14" "117.6" "2940" "30 hour" ">20 hour" ">10 hour" "159.6" "0" "0" "26026377##33008028" "Peptides. 2015 Sep;71:296-303.##Antibiotics (Basel). 2020 Sep 30;9(10):661." "Inhibition of HIV infection by caerin 1 antimicrobial peptides.##Caerin 1 Antimicrobial Peptides That Inhibit HIV and Neisseria May Spare Protective Lactobacilli." "VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA.##Rollins-Smith LA, Smith PB, Ledeczi AM, Rowe JM, Reinert LK." "10.1016/j.peptides.2015.05.004##10.3390/antibiotics9100661" "Anti-HIV" "DRAVPe00366" "FLGFLKNLF" "9" "Ctry2459-WT (Ctry2459, scorpions,animals)" "Chaerilus tryznai (Scorpion)" "P0DMF3" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=1.84 μg/ml)." "[Ref.23415044] HC50 = 137.9 μg/ml against human red blood cells." "[Ref.23415044] CC50=79.8 μg/ml against Huh7.5.1 cells." "DRAVPe00366" "DRAVPe00366.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide potently destabilizes the viral structural integrity, thus reducing the initiation of HCV infection" "1098.35" "C57H83N11O11" "ACDEHIMPQRSTVWY" "FL" "8.75" "1" "0" "1" "2" "6" "133.33" "1245" "1.1 hour" "3 min" "2 min" "130" "0" "0" "23415044" "Biomaterials. 2013 Apr;34(13):3511-22." "Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z." "Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus." "10.1016/j.biomaterials.2013.01.075" "Anti-HCV" "DRAVPe00367" "FLGFLHHLF" "9" "Ctry2459-H2 (Ctry2459 peptide derivative, His-rich)" "Synthetic construct( from a scorpion venom peptide library)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=1.08 μg/ml)." "[Ref.23415044] HC50 = 203.3 μg/ml against human red blood cells." "[Ref.23415044] CC50>500 μg/ml against Huh7.5.1 cells " "DRAVPe00367" "DRAVPe00367.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide effectively enter the cells, break through the endosomes, interact with the mature viral particles, and exhibit significant antiviral activities." "1130.36" "C59H79N13O10" "ACDEIKMNPQRSTVWY" "FL" "6.92" "2" "0" "2" "1" "6" "144.44" "1532" "1.1 hour" "3 min" "2 min" "130" "0" "0" "23415044" "Biomaterials. 2013 Apr;34(13):3511-22." "Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z." "Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus." "10.1016/j.biomaterials.2013.01.075" "Anti-HCV" "DRAVPe00368" "FLHFLHHLF" "9" "Ctry2459-H3 (Ctry2459 peptide derivative, His-rich)" "Synthetic construct(from a scorpion venom peptide library)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.23415044]Hepatitis C virus:inhibition of infection with HCV in Huh 7.5.1 cells (EC50=0.85 μg/ml)." "[Ref.23415044] HC50 = 416.4 μg/ml against human red blood cells." "[Ref.23415044] CC50>500 μg/ml against Huh7.5.1 cells " "DRAVPe00368" "DRAVPe00368.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide effectively enter the cells, break through the endosomes, interact with the mature viral particles, and exhibit significant antiviral activities." "1210.45" "C63H83N15O10" "ACDEGIKMNPQRSTVWY" "FHL" "7.02" "3" "0" "3" "0" "6" "113.33" "972" "1.1 hour" "3 min" "2 min" "130" "0" "0" "23415044" "Biomaterials. 2013 Apr;34(13):3511-22." "Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z." "Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus." "10.1016/j.biomaterials.2013.01.075" "Anti-HCV" "DRAVPe00369" "FLPLIGRVLSGIL" "13" "Temporin A" "Rana temporaria (European common frog)" "P56917" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2MAA" "CCV,FV3" "Herpesviridae, Iridoviridae" "[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 15 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 58 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "DRAVPe00369" "DRAVPe00369.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1397.77" "C68H116N16O15" "ACDEHKMNQTWY" "L" "9.75" "1" "0" "1" "3" "8" "180.77" "2010" "1.1 hour" "3 min" "2 min" "202.31" "0" "0" "15193922" "Virology. 2004 Jun 1;323(2):268-75." "Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1016/j.virol.2004.02.029" "Anti-CCV,Anti-FV3" "DRAVPe00370" "GMASKAGAIAGKIAKVALKAL" "21" "PGLa (frog)" "Xenopus laevis" "Q99134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV,CCV" "Retroviridae, Herpesviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50>50.8 μM).##[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >50.8 µM." "DRAVPe00370" "DRAVPe00370.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1969.46" "C88H161N25O23S" "CDEFHNPQRTWY" "A" "10.48" "4" "0" "4" "4" "12" "84.29" "1596" "30 hour" ">20 hour" ">10 hour" "121.43" "0" "0" "20086159##15193922" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Virology. 2004 Jun 1;323(2):268-75." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1128/AAC.01448-09##10.1016/j.virol.2004.02.029" "Anti-HIV,Anti-CCV" "DRAVPe00371" "FFHHIFRGIVHVGKTIHRLVTG" "22" "Piscidin-1" "Morone saxatilis (Striped bass)" "Q8UUG0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2JOS##2OJM" "CCV,FV3" "Herpesviridae, Iridoviridae" "[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 4 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 13 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.11601906]No cytotoxicity against catfish ovary(CCO) cells at 0.25-25μg/ ml." "DRAVPe00371" "DRAVPe00371.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2572.06" "C122H187N37O25" "ACDEMNPQSWY" "H" "12.01" "7" "0" "7" "5" "10" "45.45" "-1561" "1.1 hour" "3 min" "2 min" "110.45" "0" "0" "15193922" "Virology. 2004 Jun 1;323(2):268-75." "Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1016/j.virol.2004.02.029" "Anti-CCV,Anti-FV3" "DRAVPe00372" "FFHHIFRGIVHVGKTIHKLVTG" "22" "Piscidin-2" "Morone chrysops (White bass)" "Q8UUG2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CCV,FV3" "Herpesviridae, Iridoviridae" "[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 4 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 13 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00372" "DRAVPe00372.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2544.05" "C122H187N35O25" "ACDEMNPQSWY" "H" "11.17" "7" "0" "7" "5" "10" "48.18" "-624" "1.1 hour" "3 min" "2 min" "110.45" "0" "0" "15193922" "Virology. 2004 Jun 1;323(2):268-75." "Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1016/j.virol.2004.02.029" "Anti-CCV,Anti-FV3" "DRAVPe00373" "FIHHIFRGIVHAGRSIGRFLTG" "22" "Piscidin 3 (fish)" "Morone saxatilis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2jos" "HIV,CCV,FV3" "Retroviridae, Herpesviridae, Iridoviridae" "[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=2.1 μM).##[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 11 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 16 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20086159]CEM-SS cells:50% Cell death at 6.9 µM." "DRAVPe00373" "DRAVPe00373.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2491.93" "C116H179N37O25" "CDEKMNPQWY" "GI" "12.3" "6" "0" "6" "6" "10" "45.45" "-2156" "1.1 hour" "3 min" "2 min" "106.36" "0" "0" "20086159##15193922" "Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.##Virology. 2004 Jun 1;323(2):268-75." "Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.##Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.##Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1128/AAC.01448-09##10.1016/j.virol.2004.02.029" "Anti-HIV,Anti-CCV,Anti-FV3" "DRAVPe00374" "GLMDTVKNVAKNLAGHMLDKLKCKITGC" "28" "Ranatuerin-2P (Ranatuerin 2P; Frogs, amphibians, animals)" "Rana pipiens (Northern leopard frog)" "Q8QFQ4##P82847" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2K10" "FV3,CCV" "Iridoviridae, Herpesviridae" "[Ref.11601906]Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 µM);##Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(99% inhibition at 50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00374" "DRAVPe00374.cif" "Cyclic" "Free" "Cyclization of a C-terminal Cys residue (forming a disulfide bond)" "There is a disulfide bond between Cys22 and Cys27." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3002.66" "C128H225N37O37S4" "EFPQRSWY" "K" "9.24" "6" "2" "4" "9" "9" "4.29" "-2189" "30 hour" ">20 hour" ">10 hour" "97.5" "125" "4.63" "11601906" "Virology. 2001 Sep 30;288(2):351-7." "Chinchar VG, Wang J, Murti G, Carey C, Rollins-Smith L." "Inactivation of frog virus 3 and channel catfish virus by esculentin-2P and ranatuerin-2P, two antimicrobial peptides isolated from frog skin." "10.1006/viro.2001.1080" "Anti-FV3,Anti-CCV" "DRAVPe00375" "GFLSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC" "37" "Esculentin-2P (Frogs, amphibians, animals)" "Rana pipiens (northern leopard frog)" "P82846" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FV3,CCV" "Iridoviridae, Herpesviridae" "[Ref.11601906]##Frog Virus 3: inhibition of FV3 infection in fathead minnow(FHM) cells(90% inhibition at 500 µM);##Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells( 90% inhibition at 50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00375" "DRAVPe00375.cif" "Cyclic" "Free" "Cyclization of a C-terminal Cys residue (forming a disulfide bond)" "There is a disulfide bond between Cys31 and Cys37." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3896.71" "C176H296N50O45S2" "EHMPTWY" "GKL" "10.21" "7" "1" "6" "11" "17" "48.11" "-1869" "30 hour" ">20 hour" ">10 hour" "108.11" "125" "3.47" "11601906" "Virology. 2001 Sep 30;288(2):351-7.##Eur J Biochem. 2000 Feb;267(3):894-900." "Chinchar VG, Wang J, Murti G, Carey C, Rollins-Smith L." "Inactivation of frog virus 3 and channel catfish virus by esculentin-2P and ranatuerin-2P, two antimicrobial peptides isolated from frog skin." "10.1006/viro.2001.1080" "Anti-FV3,Anti-CCV" "DRAVPe00376" "FVQWFSKFLGRIL" "13" "Temporin L(TL)" "Rana temporaria (European common frog)" "P57104" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "6GS5" "HSV" "Herpesviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=8.55 μM,IC90=15.66 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=8.28 μM μM,IC90=16.04 μM)." "[Ref.35216177]showing residual hemolytic activity against human erythrocytes only at concentrations equal or above 50 μM." "[Ref.35216177]Vero cells:CC50= 19.61 μM" "DRAVPe00376" "DRAVPe00376.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1640.99" "C83H121N19O16" "ACDEHMNPTY" "F" "11" "2" "0" "2" "2" "8" "82.31" "160" "1.1 hour" "3 min" "2 min" "112.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-HSV" "DRAVPe00377" "FVPWFSKFlGRIL" "13" "Temporin L[Pro3,DLeu9](TL1)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=9.99 μM,IC90=18.69 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=8.86 μM μM,IC90=16.71 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=4.62 μM μM,IC90=12.14 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=7.76 μM,IC90=30.07 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=7.33 μM,IC90=14.98 μM)." "[Ref.35216177]showing residual hemolytic activity against human erythrocytes only at concentrations equal or above 50 μM." "[Ref.35216177]Vero cells:CC50= 42.18 μM" "No predicted structure available" "DRAVPe00377.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1609.98" "C77H107N17O13" "ACDEHMNQTY" "F" "11" "2" "0" "2" "2" "7" "67.69" "222" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00378" "FVPWFSKFlPRIL" "13" "Temporin L[Pro3,DLeu9,Pro10](TL2)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=7.70 μM,IC90=18.76 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=9.83 μM μM,IC90=19.20 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=4.82 μM μM,IC90=13.98 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=10.56 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=11.31 μM,IC90=24.13 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50= 56.52 μM" "No predicted structure available" "DRAVPe00378.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1650.04" "C80H111N17O13" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "58.46" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00379" "FVPWFSKFlpRIL" "13" "Temporin L[Pro3,DLeu9,DPro10](TL3)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50>100 μM" "No predicted structure available" "DRAVPe00379.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9,D-Pro10)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1650.04" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00380" "FVPWFSKFlXRIL" "13" "Temporin L[Pro3,DLeu9,Hyp10](TL4)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=7.73 μM,IC90=15.89 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=9.61 μM μM,IC90=19.02 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=6.72 μM μM,IC90=25.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=11.74 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=11.33 μM,IC90=27.65 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50=60.90 μM" "No predicted structure available" "DRAVPe00380.cif" "Linear" "Free" "Amidation" "The 'X' at position 10 is hydroxyproline (Hyp)." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00381" "FVPWFSKFlxRIL" "13" "Temporin L[Pro3,DLeu9,DHyp10](TL5)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50>50.00 μM μM,IC90>50.00 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00381.cif" "Linear" "Free" "Amidation" "The 'x' at position 10 is D-hydroxyproline (Hyp)." "Mixed(D-Leu9,D-Hyp10)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00382" "FVPWFSKFlxRIL" "13" "Temporin L[Pro3,DLeu9,DNle10](TL7)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.65 μM,IC90=12.83 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=3.13 μM μM,IC90=11.92 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=1.00 μM μM,IC90=17.41 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=6.21 μM,IC90>50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=8.55 μM,IC90=24.74 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50= 32.16 μM" "No predicted structure available" "DRAVPe00382.cif" "Linear" "Free" "Amidation" "The 'x' at position 10 is D-norleucine." "Mixed(D-Leu9,D-Nle10)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00383" "FVPWFSKFlKRIL" "13" "Temporin L[Pro3,DLeu9,Lys10](TL8)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.49 μM,IC90=10.48 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=1.00 μM μM,IC90=7.99 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.88 μM μM,IC90=12.93 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=40.69 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=4.39 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=2.90 μM,IC90=16.30 μM)." "[Ref.35216177]About 20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50=22.32 μM" "No predicted structure available" "DRAVPe00383.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1681.1" "C81H116N18O13" "ACDEGHMNQTY" "F" "11.17" "3" "0" "3" "1" "7" "40.77" "-427" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00384" "FVPWFSKFlkRIL" "13" "Temporin L[Pro3,DLeu9,DLys10](TL9)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.53 μM,IC90=12.71 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=2.80 μM μM,IC90=12.50 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=4.63 μM μM,IC90=25.33 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=40.64 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=5.39 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=8.29 μM,IC90=29.17 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50= 45.92 μM" "No predicted structure available" "DRAVPe00384.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9,D-Lys10)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1681.1" "C75H102N16O11" "ACDEGHMNQTY" "F" "11.17" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00385" "FVPWFSKFlWRIL" "13" "Temporin L[Pro3,DLeu9,Trp10](TL10)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.01 μM,IC90=8.25 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.77 μM μM,IC90=12.50 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.88 μM μM,IC90=27.71 μM);##HPIV-3:inhibition of replication in Vero cells(IC50>50.00 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.91 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.96 μM,IC90=24.17 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50= 35.47 μM" "No predicted structure available" "DRAVPe00385.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1739.14" "C86H114N18O13" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "8" "63.85" "361" "1.1 hour" "3 min" "2 min" "82.31" "11000" "916.67" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00386" "FVPWFSKFlwRIL" "13" "Temporin L[Pro3,DLeu9,DTrp10](TL11)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=1.86 μM,IC90=7.89 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.58 μM μM,IC90=9.76 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=4.07 μM μM,IC90=14.85 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=41.18 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.92 μM,IC90=50.00 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=5.10 μM,IC90=17.41 μM)." "[Ref.35216177]<40% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50=24.12 μM" "No predicted structure available" "DRAVPe00386.cif" "Linear" "Free" "Amidation" "None" "Mixed(D-Leu9,D-Trp10)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1739.14" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00387" "FVPWFSKFlXRIL" "13" "Temporin L[Pro3,DLeu9,Aic10](TL12)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E" "Coronaviridae, Herpesviridae, Paramyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=0.68 μM,IC90=1.58 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.54 μM μM,IC90=11.86 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.65 μM μM,IC90=13.85 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=33.83 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=0.74 μM,IC90=20.90 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.62 μM,IC90=13.18 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 12.5 μM." "[Ref.35216177]Vero cells:CC50=8.28 μM" "No predicted structure available" "DRAVPe00387.cif" "Linear" "Free" "Amidation" "The 'X' at position 10 is 2-aminoindane-2-carboxylic acid." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E" "DRAVPe00388" "FVPWFSKFlXRIL" "13" "Temporin L[Pro3,DLeu9,Nle10](TL6)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV,HCoV-OC43,HPIV-3,HCoV-229E,MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.66 μM,IC90=9.12 μM);##HSV-2:inhibition of HSV-2 replication in Vero cells(IC50=0.92 μM μM,IC90=6.28 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.53 μM μM,IC90=12.15 μM);##HPIV-3:inhibition of replication in Vero cells(IC50=32.35 μM,IC90>50.00 μM);##HCoV-229E:inhibition of replication in Vero cells(IC50=2.08 μM,IC90=13.06 μM);##HCoV-OC43:inhibition of replication in Vero cells(IC50=0.97 μM,IC90=10.04 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=34.58 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=2.66 μM,IC90=9.12 μM)." "[Ref.35216177]<20% hemolysis against human erythrocytes at concentrations equal or above 25 μM." "[Ref.35216177]Vero cells:CC50=64.52 μM" "No predicted structure available" "DRAVPe00388.cif" "Linear" "Free" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV,HCoV-OC43,Anti-HPIV-3,HCoV-229E,Anti-MeV,Anti-H1N1" "DRAVPe00389" "FVPWFSKFlXRILC" "14" "Temporin L[Pro3,DLeu9,Nle10]-C-CHOL(TL6.1)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=6.4 μM,IC90=11.13 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=3.18 μM μM,IC90=12.03 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=39.1 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=5.55 μM,IC90=10.02 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00389.cif" "Linear" "Free" "PEG4-Cholesterol-NH2" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1767.39" "C78H107N17O12S" "ADEGHMNQTY" "F" "9.51" "2" "0" "2" "2" "7" "83.57" "256" "1.1 hour" "3 min" "2 min" "76.43" "5500" "423.08" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00390" "FVPWFSKFlXRILGGC" "16" "Temporin L[Pro3,DLeu9,Nle10]-GGC-CHOL(TL6.2)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=9.54 μM,IC90=47.95 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=12.12 μM μM,IC90=49.95 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=40.89 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=21.12 μM,IC90=49.90 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00390.cif" "Linear" "Free" "PEG4-Cholesterol-NH2" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1881.5" "C82H113N19O14S" "ADEHMNQTY" "F" "9.51" "2" "0" "2" "4" "7" "68.13" "444" "1.1 hour" "3 min" "2 min" "66.88" "5500" "366.67" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00391" "CFVPWFSKFlXRIL" "14" "CHOL-C-Temporin L[Pro3,DLeu9,Nle10](TL6.3)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=0.89 μM,IC90=2.19 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.76 μM μM,IC90=1.89 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=22.3 μM μM,IC90=31.10 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=2.55 μM,IC90=5.89 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00391.cif" "Linear" "Cholesterol-PEG4" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1767.39" "C78H107N17O12S" "ADEGHMNQTY" "F" "9.51" "2" "0" "2" "2" "7" "83.57" "256" "1.2 hour" ">20 hour" ">10 hour" "76.43" "5500" "423.08" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00392" "CGGFVPWFSKFlXRIL" "16" "CHOL-CGG-Temporin L[Pro3,DLeu9,Nle10](TL6.4)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.32 μM,IC90=8.21 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=1.02 μM μM,IC90=10.21 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=28.88 μM μM,IC90=49.90 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=6.02 μM,IC90=9.90 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00392.cif" "Linear" "Cholesterol-PEG4" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1881.5" "C82H113N19O14S" "ADEHMNQTY" "F" "9.51" "2" "0" "2" "4" "7" "68.13" "444" "1.2 hour" ">20 hour" ">10 hour" "66.88" "5500" "366.67" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00393" "FVPWFSKFlXRIL" "13" "Undecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.5)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50<0.10 μM,IC90<0.10 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50<0.10 μM μM,IC90<0.10 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=10.01 μM μM,IC90=29.18 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50<0.10 μM,IC90<0.10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00393.cif" "Linear" "Undecanoic acid" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00394" "FVPWFSKFlXRIL" "13" "Tridecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.6)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=1.39 μM,IC90=2.86 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.39 μM μM,IC90=5.86 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=33.36 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=3.39 μM,IC90=6.66 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00394.cif" "Linear" "Tridecanoic acid" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00395" "FVPWFSKFlXRIL" "13" "Pentadecanoic-Temporin L[Pro3,DLeu9,Nle10](TL6.7)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=2.48 μM,IC90=4.86 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.48 μM μM,IC90=7.86 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=37.77 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=3.48 μM,IC90=7.10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00395.cif" "Linear" "Pentadecanoic acid" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00396" "FVPWFSKFlXRIL" "13" "Hexadecenoic-Temporin L[Pro3,DLeu9,Nle10](TL6.8)" "Synthetic construct(derived from Temporin-L)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,HSV, MeV,H1N1" "Coronaviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae" "[Ref.35216177]HSV-1:inhibition of HSV-1 replication in Vero cells(IC50=3.13 μM,IC90=4.96 μM);##SARS-CoV-2:inhibition of replication in Vero cells(IC50=0.77 μM μM,IC90=6.96 μM);##Measles virus(MeV):inhibition of MeV replication in VERO/hSLAM cells(IC50=39.4 μM μM,IC90>50.00 μM);##influenza virus(H1N1,VR-1894):inhibition of replication in MDKC cells(IC50=4.77 μM,IC90=7.11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35216177]Vero cells:CC50>100.00 μM" "No predicted structure available" "DRAVPe00396.cif" "Linear" "Palmitic acid" "Amidation" "The 'X' at position 10 is norleucine." "Mixed(D-Leu9)" "membrane" "TL peptides may be able to selectively induce pore formation in highly curved membrane structures (below ~250 nm in diameter), resulting in membrane lysis once a critical number of pores is formed, with the consequence of viral infectivity reduction." "1664.26" "C75H102N16O11" "ACDEGHMNQTY" "F" "11" "2" "0" "2" "1" "7" "70.77" "128" "1.1 hour" "3 min" "2 min" "82.31" "5500" "458.33" "35216177" "Int J Mol Sci. 2022 Feb 13;23(4):2060." "Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, Grieco P, Folliero V, De Filippis A, Mangoni M, Nencioni L, Franci G, Galdiero M. " "Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs." "10.3390/ijms23042060" "Anti-SARS-CoV-2,Anti-HSV, Anti-MeV,Anti-H1N1" "DRAVPe00397" "TLLKKVLKAAAKAALNAVLVGANA" "24" "Dermaseptin S4 (5-28)" "Synthetic construct(derived from Dermaseptin S4)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=27.07 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=25.27 μM). " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23161023]Vero cells:CC50=34 μM." "DRAVPe00397" "DRAVPe00397.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2348.9" "C107H194N30O28" "CDEFHIMPQRSWY" "A" "10.48" "4" "0" "4" "4" "16" "92.92" "1409" "7.2 hour" ">20 hour" ">10 hour" "150.83" "0" "0" "23161023" "J Med Virol. 2013 Feb;85(2):272-81." "Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. " " In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2." "10.1002/jmv.23450" "Anti-HSV" "DRAVPe00398" "ALWKTLLKKVLKAAAKAALNAVLVGANA" "28" "Dermaseptin K4S4 " "Synthetic construct(derived from Dermaseptin S4)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.7 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=5.1 μM). " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23161023]Vero cells:CC50=12 μM." "DRAVPe00398" "DRAVPe00398.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2847.53" "C133H232N36O32" "CDEFHIMPQRSY" "A" "10.6" "5" "0" "5" "4" "19" "82.5" "1760" "4.4 hour" ">20 hour" ">10 hour" "146.79" "5500" "203.7" "23161023" "J Med Virol. 2013 Feb;85(2):272-81." "Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. " " In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2." "10.1002/jmv.23450" "Anti-HSV" "DRAVPe00399" "ALWKTLLKKVLKAAAKAALKAVLVGANA" "28" "Dermaseptin K4K20S4 " "Synthetic construct(derived from Dermaseptin S4)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.1 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=5.4 μM). " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23161023]Vero cells:CC50=25 μM." "DRAVPe00399" "DRAVPe00399.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2861.6" "C135H238N36O31" "CDEFHIMPQRSY" "A" "10.7" "6" "0" "6" "3" "19" "81.07" "1869" "4.4 hour" ">20 hour" ">10 hour" "146.79" "5500" "203.7" "23161023" "J Med Virol. 2013 Feb;85(2):272-81." "Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. " " In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2." "10.1002/jmv.23450" "Anti-HSV" "DRAVPe00400" "ALWDTLLKKVLKAAAKAALDAVLVGANA" "28" "Dermaseptin D4D20S4 " "Synthetic construct(derived from Dermaseptin S4)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=5.41 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=9.63 μM). " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23161023]Vero cells:CC50=17.75 μM." "DRAVPe00400" "DRAVPe00400.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2835.43" "C131H224N34O35" "CEFHIMPQRSY" "A" "9.53" "4" "2" "2" "3" "19" "83.93" "1235" "4.4 hour" ">20 hour" ">10 hour" "146.79" "5500" "203.7" "23161023" "J Med Virol. 2013 Feb;85(2):272-81." "Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. " " In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2." "10.1002/jmv.23450" "Anti-HSV" "DRAVPe00401" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL" "36" "EK1" "Synthetic construct(derived from OC43-HR2P)" "Q8BB25" "Experimentally Validated" "2697049 " "S2 (918758)" "MN908947.3,AY585229.1" "EK1 peptide was individually fused to the 3′ end of the HR1 domain from SARS-CoV, MERS-CoV, and HCoV-229E (residues 892 to 970, 984 to 1062, and 785 to 873, respectively) " "cd22380##pfam01601" "MN908947, AY585229" "Genomic RNA" "Long arm (q) of chromosome 3 at position 13.33." "None" "SARS-CoV-2,MERS-CoV,HCoV-229E,HCoV-NL63,CoV-WIV1" "Coronaviridae" "Cell fusion assay" "[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=119.68 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=74.99 nM);inhibition of infection(Pseudovirus)(IC50=309.4 nM);inhibition of infection(Authentic)(IC50=1138 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=131.8 nM);inhibition of infection(Pseudovirus)(IC50=427.55 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=314.6 nM);inhibition of infection(Pseudovirus)(IC50=414.85 nM).##[Ref.32231345]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=409.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=3237 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=239.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=631.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=802.1 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=787.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1398 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=1554 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=207.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=3963 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=4375 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=751.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=7666 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=3693 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=265.7 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=5425 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=237.0 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=6014 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=279.6 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=286.7-315.0 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2375.0 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00401" "DRAVPe00401.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "1.9 hour" ">20 hour" ">10 hour" "119.17" "2980" "85.14" "35087243##32231345" "Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355." "Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-022-00617-x##10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2,Anti-MERS-CoV,Anti-HCoV-229E,Anti-Anti-HCoV-NL63,Anti-CoV-WIV1" "DRAVPe00402" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL" "36" "EK1P" "Synthetic construct(derived from EK1)" "Q8BB25" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=69.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00402.cif" "Linear" "Free" "PEG4-C(Palm)" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "1.9 hour" ">20 hour" ">10 hour" "119.17" "2980" "85.14" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00403" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL" "36" "EK1C" "Synthetic construct(derived from EK1)" "Q8BB25" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=37.3-48.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=139.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00403.cif" "Linear" "Free" "PEG4-C(Chol)" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "1.9 hour" ">20 hour" ">10 hour" "119.17" "2980" "85.14" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00404" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL" "36" "EK1C1" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=56.8 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=480.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00404.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "1.9 hour" ">20 hour" ">10 hour" "119.17" "2980" "85.14" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00405" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG" "39" "EK1C2" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=48.2 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=418.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00405" "DRAVPe00405.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4533.16" "C203H328N46O68S" "CHPRW" "EL" "4.36" "5" "10" "-5" "9" "13" "-44.1" "-6455" "1.9 hour" ">20 hour" ">10 hour" "110" "2980" "78.42" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00406" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG" "39" "EK1C3" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=10.6 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=86.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00406.cif" "Linear" "Free" "PEG4-Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4533.16" "C203H328N46O68S" "CHPRW" "EL" "4.36" "5" "10" "-5" "9" "13" "-44.1" "-6455" "1.9 hour" ">20 hour" ">10 hour" "110" "2980" "78.42" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00407" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1C4" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "31631 " "31631 " "31631 " "Not available" "cd22380##pfam01601" "AY585229" "Genomic RNA" "Long arm (q) of chromosome 3 at position 13.33." "6NZK" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=3.32 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=0.88 nM);inhibition of infection(Pseudovirus)(IC50=8.63 nM);inhibition of infection(Authentic)(IC50=85.38 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=4.04 nM);inhibition of infection(Pseudovirus)(IC50=9.83 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=2.57 nM);inhibition of infection(Pseudovirus)(IC50=5.58 nM).##[Ref.32231345]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=11.7 nM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=2.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=11.1 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=4.2 nM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50=7.7 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=37.7 nM),inhibit the replication of HCoV-OC43 in RD cells(IC50=24.8 nM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50=5.2 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=12.4 nM),inhibit the replication of HCoV-229E in Huh-7 cells(IC50=101.5 nM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50=21.4 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=76.6 nM),inhibit the replication of HCoV-NL63 in LLC-MK2 cells(IC50=187.6 nM);##CoV-WIV1:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.5 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=30.8 nM);##CoV-Rs3367:ihibition of cell-cell fusion in Huh-7 cells(IC50=8.1 nM),inhibition of Pseudovirus (PsV) infection in Huh-7 cells(IC50=66.9 nM);##CoV-SHC014:ihibition of cell-cell fusion in Huh-7 cells(IC50=4.3 nM);##SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=1.3 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=15.8 nM),inhibit the replication of MERS-CoV in VERO-E6 cells(IC50=2468 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32231345]<10% cytotoxicity against VERO-E6 cells, RD cells, LLC-MK2 cells, Huh-7 cells up to 10000 nM." "DRAVPe00407" "DRAVPe00407.cif" "Linear" "Free" "PEG4-Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "35087243##32231345" "Cell Res. 2022 Apr;32(4):404-406.##Cell Res. 2020 Apr;30(4):343-355." "Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-022-00617-x##10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-MERS-CoV,Anti-HCoV-OC43,Anti-HCoV-229E" "DRAVPe00408" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1C5" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.1 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=31.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00408.cif" "Linear" "Free" "PEG8-Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00409" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1C6" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=77.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00409.cif" "Linear" "Free" "PEG12-Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00410" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1C7" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.32231345]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.9 nM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=84.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00410.cif" "Linear" "Free" "PEG24-Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00411" "LKVLLYEEFKLLESLIMEILEYQKDSDIKENAEDTK" "36" "EK1-scrambled" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.32231345]SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43,HCoV-229E,HCoV-NL63,CoV-WIV1,CoV-Rs3367,CoV-SHC014(No inhibition on the concentration up to 10 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00411" "DRAVPe00411.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "5.5 hour" "3 min" "2 min" "119.17" "2980" "85.14" "32231345" "Cell Res. 2020 Apr;30(4):343-355." "Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L." "Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion." "10.1038/s41422-020-0305-x" "Anti-SARS-CoV-2" "DRAVPe00412" "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "35" "IBP02V1" "Synthetic construct(derived from HR2 region of SARS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.1±0.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=17.8 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=14.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.6±0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=50 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=21.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=33.6±3.5 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.9±7.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=62.5±17.2 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=203.9±8.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM." "DRAVPe00412" "DRAVPe00412.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "3893.41" "C168H287N47O58" "CFHMPTWY" "ILN" "4.36" "3" "6" "-3" "9" "15" "-8.29" "-5930" "20 hour" "30 min" ">10 hour" "142" "0" "0" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-Anti-HCoV-NL63" "DRAVPe00413" "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "35" "HR2(1151-1185)" "Synthetic construct(derived from SARS-CoV spike protein)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=0.34 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00413.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3893.41" "C168H287N47O58" "CFHMPTWY" "ILN" "4.36" "3" "6" "-3" "9" "15" "-8.29" "-5930" "20 hour" "30 min" ">10 hour" "142" "0" "0" "18442051" "J Cell Biochem. 2008 Aug 15;104(6):2335-47." "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM." "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. " "10.1002/jcb.21790" "Anti-HIV" "DRAVPe00414" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "36" "IBP02V2" "Synthetic construct(derived from HR2 region of SARS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.6±0.03 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=20.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=18.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.4±0.04 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=19.3 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=20.8 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=56.5±9.4nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=55.3±2.8 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=67.5±8 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=535.7±44.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM." "DRAVPe00414" "DRAVPe00414.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4008.5" "C172H292N48O61" "CFHMPTWY" "ILN" "4.2" "3" "7" "-4" "9" "15" "-17.78" "-6802" "1.1 hour" "3 min" ">10 hour" "138.06" "0" "0" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00415" "EISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "36" "IBP02V3" "Synthetic construct(derived from HR2 region of SARS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.4±0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=14.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=17.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.2±0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=40.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=14.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=48±5.8 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=38.5±6.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=75.8±9.9 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=545.7±0.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM." "DRAVPe00415" "DRAVPe00415.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4022.52" "C173H294N48O61" "CFHMPTWY" "EILN" "4.25" "3" "7" "-4" "9" "15" "-17.78" "-6611" "1 hour" "30 min" ">10 hour" "138.06" "0" "0" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00416" "ELSGINASVVNLQKEIDRLNEVAKNLNESLIDLQEL" "36" "IBP02V4" "Synthetic construct(derived from HR2 region of SARS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.3±0.02 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=18.6 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=15.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.1±0.02 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=29.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=26.3 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=63±1.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=22.4±2.2 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=66.3±3.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=502±24.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM." "DRAVPe00416" "DRAVPe00416.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4022.52" "C173H294N48O61" "CFHMPTWY" "L" "4.25" "3" "7" "-4" "9" "15" "-21.67" "-6611" "1 hour" "30 min" ">10 hour" "138.06" "0" "0" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00417" "SLTQINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "36" "IBP02V5" "Synthetic construct(derived from HR2 region of SARS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "Cell fusion assay" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=2.1±0.5 nM);inhibition of SARS-CoV-2 pseudovirus infection in 293T/ACE2 cells(IC50=21 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=23.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=1.3±0.1 nM);inhibition of pseudovirus infection in 293T/ACE2 cells(IC50=98.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=27.5 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=65.9±13.2 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=68.4±9.7 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=70.8±8.7 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1128.4±148.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34344868]No significant cytotoxicity in both 293T/ACE2 and Huh-7 cells at a concentration of 10 μM." "DRAVPe00417" "DRAVPe00417.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4065.59" "C175H299N49O61" "CFGHMPWY" "L" "4.36" "3" "6" "-3" "9" "15" "-20.56" "-6835" "1.9 hour" ">20 hour" ">10 hour" "138.06" "0" "0" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00418" "SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL" "36" "MERS-LP" "Synthetic construct(derived from HR2 region of MERS-CoV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=102.9±7.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=5046±905.2 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=79.1±9.8 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=82.9±8.6 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50>25000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00418" "DRAVPe00418.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4141.78" "C185H307N43O61S" "CFGHPRW" "L" "4.18" "2" "5" "-3" "11" "14" "13.06" "-3327" "1.9 hour" ">20 hour" ">10 hour" "138.06" "2980" "85.14" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00419" "SLDYINVTFLDLQDEMNRLQEAIKVLNQSYINLKDI" "36" "OC43-LP" "Synthetic construct(derived from HR2 region of OC43-LP)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=4.1±1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=82.8±22.1 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=2.4±0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=97.5±5.9 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=250.4±39.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=5.2±0.5 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=416.5±227.5 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=2008.8±697.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00419" "DRAVPe00419.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4270.86" "C190H306N48O61S" "CGHPW" "L" "4.23" "3" "6" "-3" "9" "14" "-19.44" "-6293" "1.9 hour" ">20 hour" ">10 hour" "127.22" "2980" "85.14" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00420" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELK" "37" "EK1V1" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=273.5±4.1 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=2672.1±384.5 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=214.5±20.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=1790.8±363.2 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=4370.3±719.7 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=499.8±163.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=487.2±41.3 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=1255.6±453.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00420" "DRAVPe00420.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4460.16" "C202H329N45O65S" "CGHPRW" "EL" "4.53" "6" "10" "-4" "6" "13" "-52.7" "-6858" "1.9 hour" ">20 hour" ">10 hour" "115.95" "2980" "82.78" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00421" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL" "36" "EK1V2" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34344868]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.9±0.2 nM);inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells(IC50=87.2±8.3 nM);##SARS-CoV-2 D614G:inhibition of S protein-mediated cell-cell fusion(IC50=0.5±0.2 nM);inhibition of pseudovirus infection in Huh-7 cells(IC50=106.5±5.4 nM);##SARS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=252±5.6 nM);##MERS-CoV:inhibition of pseudovirus infection in Huh-7 cells(IC50=1.1±0.3 nM);##HCoV-NL63:inhibition of pseudovirus infection in Huh-7 cells(IC50=59.4±13.1 nM);##HCoV-229E:inhibition of pseudovirus infection in Huh-7 cells(IC50=503.3±20.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00421.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity." "4331.98" "C196H317N43O64S" "CGHPRW" "EL" "4.36" "5" "10" "-5" "6" "13" "-43.33" "-6303" "1.9 hour" ">20 hour" ">10 hour" "119.17" "2980" "85.14" "34344868" "Signal Transduct Target Ther. 2021 Aug 3;6(1):294. " "Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y." "SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses." "10.1038/s41392-021-00698-x" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00422" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP20" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=1.36 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=50.52 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=33.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=103.17 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=128.87 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=111.41 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=79.09 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=88.49 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=92.16 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=73.86 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=228.4 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=817.21 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=471.54 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00422" "DRAVPe00422.cif" "Linear" "Free" "Chol(cholesterol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00423" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP21" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=7.5 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=191.4 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=126.65 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00423.cif" "Linear" "Free" "C16(palmitic acid)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2" "DRAVPe00424" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP22" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=6.23 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=179.95 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=86.33 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00424.cif" "Linear" "Free" "C18(stearic acid)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2" "DRAVPe00425" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP23" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=39.07 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=1236.38 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=507.32 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00425.cif" "Linear" "Free" "Toc(tocophenol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2" "DRAVPe00426" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP24" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.33 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=2.89 nM);inhibition of live SARS-CoV-2 infection in Vero cells(IC50=8.97 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.29 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.5 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.42 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.97 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.22 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.06 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=21.64 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=69.9 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=375.56 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=421.48 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34057039]Huh-7 cells:CC50=6.6 μM;Vero-E6 cells:CC50=13.67 μM." "No predicted structure available" "DRAVPe00426.cif" "Linear" "Free" "PEG4-K(Chol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00427" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP25" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.29 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.13 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.43 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=25.71 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.8 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.52 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.71 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=5.87 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.76 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=17.69 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=48.5 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=353.22 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=336.14 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34057039]Huh-7 cells:CC50=3.54 μM;Vero-E6 cells:CC50=6.95 μM." "No predicted structure available" "DRAVPe00427.cif" "Linear" "Free" "PEG5-K(Chol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00428" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP26" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.26 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=3.05 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.82 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00428.cif" "Linear" "Free" "PEG6-K(Chol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2" "DRAVPe00429" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "37" "IBP27" "Synthetic construct(derived from HR2 region of SARS-CoV-2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=0.32 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=2.77 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=1.54 nM),inhibition of live SARS-CoV-2 infection in Vero cells(IC50=29.85 nM);##SARS-CoV-2 D614G:inhibition of pseudovirus infections in Huh-7 cells(IC50=6.75 nM);##SARS-CoV-2 N501Y:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.87 nM);##SARS-CoV-2 ΔH69-V70:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.56 nM);##SARS-CoV-2 E484K:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.55 nM);##SARS-CoV-2 B.1.1.7:inhibition of pseudovirus infections in Huh-7 cells(IC50=7.18 nM);##SARS-CoV-2 B.1.351:inhibition of pseudovirus infections in Huh-7 cells(IC50=8.25 nM);##SARS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=24.95 nM);##MERS-CoV:inhibition of pseudovirus infections in Huh-7 cells(IC50=60.08 nM);##HCoV-NL63:inhibition of pseudovirus infections in Huh-7 cells(IC50=179.53 nM);##HCoV-229E:inhibition of pseudovirus infections in Huh-7 cells(IC50=231.18 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34057039]Huh-7 cells:CC50=4.04 μM;Vero-E6 cells:CC50=5.05 μM." "No predicted structure available" "DRAVPe00429.cif" "Linear" "Free" "PEG8-K(Chol)" "None" "L" "membrane" "Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived." "4347.93" "C192H317N51O63" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "9" "13" "-60.27" "-7972" "1.9 hour" ">20 hour" ">10 hour" "121.08" "2980" "82.78" "34057039" "Emerg Microbes Infect. 2021 Dec;10(1):1227-1240." "Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y." "Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants." "10.1080/22221751.2021.1937329" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00430" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW" "45" "EKL0" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.583±0.073 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.442±0.037 μmol/L),inhibition of cell-cell fusion(IC50=0.277±0.029 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00430" "DRAVPe00430.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "5522.3" "C256H392N54O79S" "CHPR" "E" "4.44" "6" "11" "-5" "11" "15" "-54.89" "-7107" "1.9 hour" ">20 hour" ">10 hour" "101.78" "12950" "294.32" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00431" "NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEY" "36" "EKL1" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.622±0.089 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.746±0.152 μmol/L),inhibition of cell-cell fusion(IC50=0.220±0.034 μmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=1.407±0.189 μmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=6.716±5.937 μmol/L), MERS-CoV(IC50=4.086±0.345 μmol/L), HCoV-OC43(IC50=10.530±3.778 μmol/L), HCoV-NL63(IC50=3.700±0.222 μmol/L), SARSr-CoV-WIV1(IC50=30.270±4.713 μmol/L), and HCoV-Rs3367 (IC50=88.300±24.600 μmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=20.290±1.092 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00431" "DRAVPe00431.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4388.99" "C201H312N42O65S" "CHPQRW" "E" "4.39" "5" "10" "-5" "9" "11" "-64.72" "-6393" "1.4 hour" "3 min" ">10 hour" "97.5" "5960" "170.29" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63" "DRAVPe00432" "TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYV" "36" "EKL2" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.526±0.049 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=4.714±1.173 μmol/L),inhibition of cell-cell fusion(IC50=1.240±0.246 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00432" "DRAVPe00432.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4438.06" "C206H315N41O65S" "CHNPQRW" "E" "4.39" "5" "10" "-5" "9" "11" "-58.61" "-5743" "7.2 hour" ">20 hour" ">10 hour" "97.5" "7450" "212.86" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00433" "LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKW" "36" "EKL3" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50>10 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50>5 μmol/L),inhibition of cell-cell fusion(IC50=2.167±0.270 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00433" "DRAVPe00433.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4504.17" "C210H321N43O64S" "CFHNPQR" "E" "4.57" "6" "10" "-4" "8" "11" "-77.78" "-6106" "5.5 hour" "3 min" "2 min" "97.5" "12950" "370" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00434" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC" "49" "EKL0C" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.122±0.012 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.147±0.055 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.162±0.022 μmol/L),inhibition of cell-cell fusion(IC50=0.021±0.003 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00434" "DRAVPe00434.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "5826.62" "C266H408N58O84S2" "HPR" "E" "4.44" "6" "11" "-5" "15" "15" "-48.57" "-7131" "1.9 hour" ">20 hour" ">10 hour" "93.47" "12950" "269.79" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00435" "TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGC" "40" "EKL2C" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.115±0.019 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.054±0.014 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.200±0.020 μmol/L),inhibition of cell-cell fusion(IC50=0.022±0.001 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00435" "DRAVPe00435.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4742.38" "C216H331N45O70S2" "HNPQRW" "E" "4.39" "5" "10" "-5" "13" "11" "-50.5" "-5767" "7.2 hour" ">20 hour" ">10 hour" "87.75" "7450" "191.03" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00436" "LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC" "40" "EKL3C" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.127±0.293 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=1.176±1.230 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.892±0.069 μmol/L),inhibition of cell-cell fusion(IC50=0.045±0.004 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00436" "DRAVPe00436.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4808.49" "C220H337N47O69S2" "FHNPQR" "E" "4.57" "6" "10" "-4" "12" "11" "-67.75" "-6130" "5.5 hour" "3 min" "2 min" "87.75" "12950" "332.05" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00437" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK" "49" "EKL0P" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.093±0.012 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.619±0.341 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.176±0.019 μmol/L),inhibition of cell-cell fusion(IC50=0.083±0.009 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00437" "DRAVPe00437.cif" "Linear" "Free" "Palm" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "5851.66" "C269H415N59O84S" "CHPR" "E" "4.61" "7" "11" "-4" "14" "15" "-61.63" "-7814" "1.9 hour" ">20 hour" ">10 hour" "93.47" "12950" "269.79" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00438" "NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGK" "40" "EKL1P" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.182±0.034 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.812±0.182 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.231±0.022 μmol/L),inhibition of cell-cell fusion(IC50=0.064±0.004 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00438" "DRAVPe00438.cif" "Linear" "Free" "Palm" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4718.35" "C214H335N47O70S" "CHPQRW" "E" "4.57" "6" "10" "-4" "12" "11" "-72" "-7100" "1.4 hour" "3 min" ">10 hour" "87.75" "5960" "152.82" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00439" "TFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVGSGK" "40" "EKL2P" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=1.129±0.166 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.973±0.254 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.304±0.051 μmol/L),inhibition of cell-cell fusion(IC50=0.183±0.028 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00439" "DRAVPe00439.cif" "Linear" "Free" "Palm" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4767.42" "C219H338N46O70S" "CHNPQRW" "E" "4.57" "6" "10" "-4" "12" "11" "-66.5" "-6450" "7.2 hour" ">20 hour" ">10 hour" "87.75" "7450" "191.03" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00440" "LDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGK" "40" "EKL3P" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=3.987±0.682 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50>5 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=2.214±0.371 μmol/L),inhibition of cell-cell fusion(IC50=0.193±0.021 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00440" "DRAVPe00440.cif" "Linear" "Free" "Palm" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4833.52" "C223H344N48O69S" "CFHNPQR" "E" "4.76" "7" "10" "-3" "11" "11" "-83.75" "-6813" "5.5 hour" "3 min" "2 min" "87.75" "12950" "332.05" "34367893" "Acta Pharm Sin B. 2021 Aug 2." "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2" "DRAVPe00441" "NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC" "40" "EKL1C" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63,HCoV-OC43" "Coronaviridae" "Cell fusion assay" "[Ref.35087243]SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=12.18 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=5.52 nM);inhibition of infection(Pseudovirus)(IC50=26.14 nM);inhibition of infection(Authentic)(IC50=182.2 nM);##SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=14.42 nM);inhibition of infection(Pseudovirus)(IC50=31.99 nM);##SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=11.77 nM);inhibition of infection(Pseudovirus)(IC50=23.6 nM).##[Ref.34367893]SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.045±0.006 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.037±0.009 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.040±0.005 μmol/L),inhibition of cell-cell fusion(IC50=0.008±0.001 μmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=0.003±0.001 μmol/L);##SARS-CoV-2 variants(inhibition of Pseudovirus(PsV) infection):V341L(IC50=0.047±0.013 μmol/L);F342L(IC50=0.026±0.007 μmol/L);V367F(IC50=0.066±0.012 μmol/L);R408I(IC50=0.148±0.012 μmol/L);N435D(IC50=0.135±0.013 μmol/L);G476S(IC50=0.065±0.008 μmol/L);V483A(IC50=0.078±0.011 μmol/L);N501Y(IC50=0.069±0.006 μmol/L);D614G(IC50=0.104±0.010 μmol/L);12 mutations(P.1)(IC50=0.046±0.006 μmol/L);K417N-E484K-N501Y(IC50=0.113±0.013 μmol/L);8 mutations(B.1.1.7)(IC50=0.120±0.009 μmol/L);wide type(IC50=0.049±0.007 μmol/L);##inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=0.076±0.014 μmol/L), MERS-CoV(IC50=0.048±0.006 μmol/L), HCoV-OC43(IC50=0.668±0.081 μmol/L), HCoV-NL63(IC50=0.035±0.003 μmol/L), SARSr-CoV-WIV1(IC50=0.218±0.013 μmol/L), and HCoV-Rs3367 (IC50=0.046±0.003 μmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=0.281±0.018 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34367893]Huh-7 cells:CC50=10 μmol/L;Caco-2 cells:CC50=13.81 μmol/L;293T/ACE2 cells:CC50=8.49 μmol/L." "DRAVPe00441" "DRAVPe00441.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4693.31" "C211H328N46O70S2" "HPQRW" "E" "4.39" "5" "10" "-5" "13" "11" "-56" "-6417" "1.4 hour" "3 min" ">10 hour" "87.75" "5960" "152.82" "35087243##34367893" "Cell Res. 2022 Apr;32(4):404-406.##Acta Pharm Sin B. 2021 Aug 2." "Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.##Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q." "Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.##A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases." "10.1038/s41422-022-00617-x##10.1016/j.apsb.2021.07.026" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-NL63,HCoV-OC43" "DRAVPe00442" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1-C16" "Synthetic construct(derived from EK1)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-OC43" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.35336956]SARS-CoV-2 WT:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.48 μM);##SARS-CoV-2 Alpha:inhibition of pseudovirus (PsV) infection(IC50=0.19 μM);##SARS-CoV-2 Beta:inhibition of pseudovirus (PsV) infection(IC50=0.43 μM);##SARS-CoV-2 Gamma:inhibition of pseudovirus (PsV) infection(IC50=0.26 μM);##SARS-CoV-2 Delta:inhibition of pseudovirus (PsV) infection(IC50=0.11 μM);##SARS-CoV-2 Omicron:inhibition of pseudovirus (PsV) infection(IC50=0.23 μM);inhibition of authentic infection in Vero-E6-TMPRSS-2 cells(IC50=0.75 μM);##SARS-CoV:inhibition of pseudovirus (PsV) infection(IC50=0.17 μM);##SARSr-CoV WIV1:inhibition of pseudovirus (PsV) infection(IC50=0.15 μM);##SARSr-CoV Rs3367:inhibition of pseudovirus (PsV) infection(IC50=0.3 μM);##MERS-CoV:inhibition of pseudovirus (PsV) infection in Caco2 cells(IC50=0.10 μM);inhibition of cell-cell fusion(IC50=0.012 μM);##HCoV-OC43:inhibition of authentic infection in RD cells(IC50=0.07 μM);inhibition of cell-cell fusion(IC50=0.01 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35336956]showed no significant cytotoxicity against RD cells at the concentration of 5 μM." "No predicted structure available" "DRAVPe00442.cif" "Linear" "Free" "PEG4-C16(palmitic acid)" "None" "L" "membrane" "The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs plays a key role during the viral membrane fusion process,peptides derived from the HR2 regions can competitively inhibit viral 6-HB formation, thereby preventing viral fusion and entry into host cells." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "35336956" "Viruses. 2022 Mar 6;14(3):549." "Lan Q, Chan JF, Xu W, Wang L, Jiao F, Zhang G, Pu J, Zhou J, Xia S, Lu L, Yuen KY, Jiang S, Wang Q. " "A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern." "10.3390/v14030549" "Anti-SARS-CoV-2,SARS-CoV,Anti-MERS-CoV,Anti-HCoV-OC43" "DRAVPe00443" "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "35" "IPB01(SARS-CoV-S (1151-1185),SR9, SARS-CoV-2-S (1169-1203))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.022±0.005 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=33.74±11.827 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).##[Ref.17942557]SARS-CoV:Inhibition of virus entry in VERO-E6 cells(EC50=0.005 µM).##[Ref.18442051]SARS-CoV: inhibition of PsV entry in Vero-E6 cells(EC50=0.34 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00443.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3893.41" "C168H287N47O58" "CFHMPTWY" "ILN" "4.36" "3" "6" "-3" "9" "15" "-8.29" "-5930" "20 hour" "30 min" ">10 hour" "142" "0" "0" "17942557##18442051##32376627" "J Virol. 2008 Jan;82(1):588-92.##J Cell Biochem. 2008 Aug 15;104(6):2335-47.##J Virol. 2020 Jul 1;94(14):e00635-20." "Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. ##Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. ##Zhu Y, Yu D, Yan H, Chong H, He Y." "Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.##Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.##Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.01697-07##10.1002/jcb.21790##10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00444" "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK" "36" "IPB02(SARS-CoV-2-S (1169-1203)-K)" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.025 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.08±0.017 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=0.251 ± 0.118 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00444" "DRAVPe00444.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "4021.58" "C174H299N49O59" "CFHMPTWY" "ILN" "4.66" "4" "6" "-2" "9" "15" "-18.89" "-6485" "20 hour" "30 min" ">10 hour" "138.06" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00445" "INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK" "34" "IPB03(SARS-CoV-2-S (1172-1205))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.015 ± 0.002 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.947 ± 0.179 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.315 ± 0.463 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00445" "DRAVPe00445.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3821.34" "C165H283N47O56" "CFHMPTWY" "LN" "4.66" "4" "6" "-2" "8" "14" "-30.88" "-6637" "20 hour" "30 min" ">10 hour" "134.71" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00446" "SVVNIQKEIDRLNEVAKNLNESLIDLQELGK" "31" "IPB04(SARS-CoV-2-S (1175-1205))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.033 ± 0.013 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.218 ± 0.063 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.053 ± 0.444 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00446" "DRAVPe00446.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3523" "C152H261N43O52" "CFHMPTWY" "L" "4.66" "4" "6" "-2" "7" "12" "-42.9" "-6646" "1.9 hour" ">20 hour" ">10 hour" "131.94" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00447" "IQKEIDRLNEVAKNLNESLIDLQELGK" "27" "IPB05(SARS-CoV-2-S (1179-1205))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay." "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00447" "DRAVPe00447.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3123.55" "C135H232N38O46" "CFHMPTWY" "L" "4.66" "4" "6" "-2" "5" "10" "-64.44" "-6450" "20 hour" "30 min" ">10 hour" "130" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00448" "IDRLNEVAKNLNESLIDLQELGK" "23" "IPB06(SARS-CoV-2-S (1183-1205))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00448" "DRAVPe00448.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "2624.97" "C113H194N32O39" "CFHMPTWY" "L" "4.51" "3" "5" "-2" "5" "9" "-47.83" "-5152" "20 hour" "30 min" ">10 hour" "135.65" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00449" "IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "33" "IPB07(SARS-CoV-2-S (1179-1211))" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.017 ± 0.001 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.993 ± 0.08 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.037 ± 0.836 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00449" "DRAVPe00449.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3948.49" "C175H288N46O57" "CFHMPTW" "EL" "4.77" "5" "7" "-2" "7" "11" "-80" "-7776" "20 hour" "30 min" ">10 hour" "118.18" "2980" "93.13" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00450" "ISGINASVVNIQKEIDRLNEVAKNLNESLIK" "31" "IPB08(SARS-CoV-2-S (1169-1198)-K)" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=4.66 ± 1.565 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=1.738 ± 0.898 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC=1.13 ± 0.472 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00450" "DRAVPe00450.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "3422.93" "C148H257N43O49" "CFHMPTWY" "IN" "6.26" "4" "4" "0" "9" "13" "-12.58" "-5362" "20 hour" "30 min" ">10 hour" "135.16" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00451" "SVVNIQKEIDRLNEVAKNLNESLIK" "25" "IPB09(SARS-CoV-2-S (1175-1198)-K)" "Synthetic construct(derived from SARS-CoV-2 S protein)" "P59594##P0DTC2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "cell fusion assay, single-cycle infection assay" "[Ref.32376627]SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50>5 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>25 µM);##SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC>25 µM);##Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00451" "DRAVPe00451.cif" "Linear" "Free" "Chol" "None" "L" "membrane" "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can also inhibit the SARS-CoV pseudovirus efficiently." "2867.3" "C124H216N36O41" "CFGHMPTWY" "N" "5.98" "4" "4" "0" "6" "10" "-40" "-5617" "1.9 hour" ">20 hour" ">10 hour" "132.4" "0" "0" "32376627" "J Virol. 2020 Jul 1;94(14):e00635-20." "Zhu Y, Yu D, Yan H, Chong H, He Y." "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity." "10.1128/JVI.00635-20" "Anti-Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-VSV" "DRAVPe00452" "RLFFKCIYRFFEHGLKRG" "18" "M2 AH" "Synthetic construct(derived from influenza virus M2 protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "H1N1" "Orthomyxoviridae" "[Ref.31375212]H1N1(A/Puerto Rico/8/34):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=870 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31375212]Madin-Darby canine kidney epithelial(MDCK) cells:CC50=70.3 μM" "DRAVPe00452" "DRAVPe00452.cif" "Linear" "Free" "Free" "None" "L" "membrane" "M2 AH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 AH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission." "2317.79" "C111H165N31O22S" "ADMNPQSTVW" "F" "10.3" "6" "1" "5" "4" "7" "-23.89" "-3763" "1 hour" "2 min" "2 min" "65" "1490" "87.65" "31375212" "Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512." "Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. " "Envelope-deforming antiviral peptide derived from influenza virus M2 protein." "10.1016/j.bbrc.2019.07.088" "Anti-H1N1" "DRAVPe00453" "RKFFKKIYRFFRKLLKRL" "18" "M2 MH" "Synthetic construct(derived from influenza virus M2 protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "[Ref.31375212]H1N1(A/Puerto Rico/8/34):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=53 nM);##H3N2(A/Sydney/5/97):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.058 μM);##H3N2(A/X31):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.016 μM);##H5N2(A/aquatic bird/Korea/w81/2005 ):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.066 μM);##H1N1(A/Swine/Iowa/15/30):inhibition of infection in Madin-Darby canine kidney epithelial(MDCK) cells(IC50=0.053 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31375212]Madin-Darby canine kidney epithelial(MDCK) cells:CC50=19.2 μM" "DRAVPe00453" "DRAVPe00453.cif" "Linear" "Free" "Free" "None" "L" "membrane" "M2 MH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 MH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission." "2488.16" "C123H199N35O20" "ACDEGHMNPQSTVW" "K" "12.02" "9" "0" "9" "1" "8" "-65" "-5597" "1 hour" "2 min" "2 min" "86.67" "1490" "87.65" "31375212" "Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512." "Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. " "Envelope-deforming antiviral peptide derived from influenza virus M2 protein." "10.1016/j.bbrc.2019.07.088" "Anti-Influenza virus" "DRAVPe00454" "RLAAKCAARFAEHGLKRG" "18" "M2 NH" "Synthetic construct(derived from influenza virus M2 protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H1N1" "Orthomyxoviridae" "[Ref.31375212]H1N1:did not exhibit any inhibitory effect." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31375212]did not show apparent cytotoxicity against Madin-Darby canine kidney epithelial(MDCK) cells up to a concentration of 100 μM." "DRAVPe00454" "DRAVPe00454.cif" "Linear" "Free" "Free" "None" "L" "membrane" "M2 NH is an α-helical amphipathic peptide with basic amino acids positioned at the polar-nonpolar interface. The peptide inserts deeply into the hydrophobic core of the membrane bilayer, resulting in alteration of membrane order and curvature . This ability to alter membrane curvature enables M2 NH to induce membrane budding in vitro and in vivo. It localizes to the neck of the budding virion and plays an important role in membrane scission." "1955.31" "C84H143N31O21S" "DIMNPQSTVWY" "A" "10.92" "6" "1" "5" "3" "8" "-38.33" "-4230" "1 hour" "2 min" "2 min" "71.11" "0" "0" "31375212" "Biochem Biophys Res Commun. 2019 Sep 24;517(3):507-512." "Jung Y, Kong B, Moon S, Yu SH, Chung J, Ban C, Chung WJ, Kim SG, Kweon DH. " "Envelope-deforming antiviral peptide derived from influenza virus M2 protein." "10.1016/j.bbrc.2019.07.088" "Anti-H1N1" "DRAVPe00455" "GFSSLFKAGAKYLLKQVGKAGAQQLACKAANNC" "33" "Brevinin-2GHk(BR2GK)" "Fejervarya limnocharis" "A0A6G6CZ26" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV" "Flaviviridae" "[Ref.34960651]Zika Virus: inhibition of infection of Zika virus in Vero cells(IC50=3.408 ± 0.738 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34960651]exhibited no significant toxicity to Vero, Hela, and Huh7 cells in the concentration range 0-20 µM." "DRAVPe00455" "DRAVPe00455.cif" "Linear" "Free" "Free" "None" "L" "membrane" "BR2GK directly inactivated ZIKV by disrupting the integrity of the envelope and may also penetrate the host cell membrane to inhibit the middle stage of ZIKV infection. " "3386.98" "C150H245N43O42S2" "DEHIMPRTW" "A" "9.79" "5" "0" "5" "11" "14" "3.33" "-1592" "30 hour" ">20 hour" ">10 hour" "77.27" "1615" "50.47" "34960651" "Viruses. 2021 Nov 28;13(12):2382. " "Xiong W, Li J, Feng Y, Chai J, Wu J, Hu Y, Tian M, Lu W, Xu X, Zou M." "Brevinin-2GHk, a Peptide Derived from the Skin of Fejervarya limnocharis, Inhibits Zika Virus Infection by Disrupting Viral Integrity." "10.3390/v13122382" "Anti-ZIKV" "DRAVPe00456" "FLPLILPSIVTALSSFLKQG" "20" "Hs-1" "Hypsiboas semilineatus" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "[Ref.29153860]DENV2:reduced the number of lysis plaques by 100% at 125 µg/mL; by 60% at 7.81 μg/mL;##DENV3:reduced the number of lysis plaques by 100% at 125 µg/mL; by 50% at 7.81 μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29153860]No significant cytotoxicity agaisnt Vero cells up to 125μg/ mL." "DRAVPe00456" "DRAVPe00456.cif" "Linear" "Free" "Free" "None" "L" "envelope" "It was possible to observe that the viral particle lost its ability to infect because of the breakdown on the envelope as the peptide acted directly on the virus. " "2144.63" "C104H170N22O26" "CDEHMNRWY" "L" "8.75" "1" "0" "1" "5" "11" "127.5" "2333" "1.1 hour" "3 min" "2 min" "156" "0" "0" "29153860" "Virology. 2018 Jan 15;514:79-87." "Monteiro JMC, Oliveira MD, Dias RS, Nacif-Marçal L, Feio RN, Ferreira SO, Oliveira LL, Silva CC, Paula SO." "The antimicrobial peptide HS-1 inhibits dengue virus infection." "10.1016/j.virol.2017.11.009" "Anti-DENV" "DRAVPe00457" "GGARDAGKAEWW" "12" "gg-ww" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "[Ref.26248692]dengue virus serotype 2(DENV-2):inhibition the cytopathic effect(CPE) and plaque formation in Vero cells(IC50=77-91 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.26248692]It was not toxic to Vero cells up to 400 μmol/L." "DRAVPe00457" "DRAVPe00457.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide gg-ww could exert its inhibition during the viral entry step of DENV-2 infection by interfering with viral attachment or internalization." "1303.4" "C58H82N18O17" "CFHILMNPQSTVY" "AG" "6.07" "2" "2" "0" "3" "5" "-108.33" "-2309" "30 hour" ">20 hour" ">10 hour" "25" "11000" "1000" "26248692" "J Appl Microbiol. 2015 Oct;119(4):1170-80. " "Chew MF, Tham HW, Rajik M, Sharifah SH. " "Anti-dengue virus serotype 2 activity and mode of action of a novel peptide." "10.1111/jam.12921" "Anti-DENV" "DRAVPe00458" "CNDFRSKTC" "9" "P1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza viruse" "Orthomyxoviridae" "[Ref.19680476]Avian influenza viruses (AIV) H9N2: inhibition of viral attachment on MDCK cells(>50% inhibition at the concentration of 50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00458" "DRAVPe00458.cif" "Linear" "Free" "Free" "None" "L" "membrane" "Avian influenza viruses possess two important surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) against which neutralizing antibodies are produced. This peptide inhibits the replication of the virus in ovo and in vitro by its binding to the HA glycoprotein. " "1073.21" "C42H68N14O15S2" "AEGHILMPQVWY" "C" "8.06" "2" "1" "1" "5" "1" "-101.11" "-3626" "1.2 hour" ">20 hour" ">10 hour" "0" "125" "15.63" "19680476" "Int J Biol Sci. 2009 Aug 8;5(6):543-8." "Rajik M, Omar AR, Ideris A, Hassan SS, Yusoff K." "A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells. " "10.7150/ijbs.5.543" "Anti-Influenza viruse" "DRAVPe00459" "QEGISRFKICPYHWYKQHMSLLFRRYYHKLDSII" "34" "CPXV012" "Synthetic construct(derived from the cowpox virus protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV,HBV,HIV,RVFV" "Herpesviridae, Hepadnaviridae, Retroviridae, Phenuiviridae" "[Ref.32872420]Herpes simplex virus-1(HSV-1):inhibition of HSV-1 infection in MelJuSo(MJS) cells(75.9 ± 5.7% inhibition at 150 µg/mL);##Hepatitis B virus(HBV): decrease of HBeAg and viral DNA infected with HBV-1 in HepRG cells(84.0 ± 3.0% of HBeAg and 73.6 ± 2.3% of viral DNA at 100 µg/mL);##HIV-1:inhibition of virus infection in LC5-RIC reporter cells(82.7 ± 4.9% inhibition at 100 µg/mL);inhibition of virus replication in LC5-RIC reporter cells(62.2 ± 2.4% inhibition at 100 µg/mL);##Rift Valley fever virus(RVFV): inhibition of virus infection in MJS cells(65.5 ± 2.3% inhibition at 160 µg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32872420]Did not observe any decrease in live cells against Vero and Huh7.5 cells up to 200 µg/mL." "DRAVPe00459" "DRAVPe00459.cif" "Linear" "Free" "Free" "None" "L" "envelope(phosphatidylserine)" "Within virus-infected cells, this protein helps to evade the immune system by inhibiting the transporter associated with antigen processing (TAP), thereby interfering with MHC I-dependent antigen presentation. And the peptide is the segment of the CPXV012 protein responsible for blocking TAP." "4358.11" "C204H303N55O48S2" "ANTV" "IY" "9.65" "9" "2" "7" "9" "10" "-58.53" "-6546" "0.8 hour" "10 min" ">10 hour" "80.29" "11460" "347.27" "32872420" "Cells. 2020 Aug 29;9(9):1989." "Luteijn RD, Praest P, Thiele F, Sadasivam SM, Singethan K, Drijfhout JW, Bach C, de Boer SM, Lebbink RJ, Tao S, Helfer M, Bach NC, Protzer U, Costa AI, Killian JA, Drexler I, Wiertz EJHJ." "A Broad-Spectrum Antiviral Peptide Blocks Infection of Viruses by Binding to Phosphatidylserine in the Viral Envelope. " "10.3390/cells9091989" "Anti-HSV,Anti-HBV,Anti-HIV,RVFV" "DRAVPe00460" "TEPSTRGSWKFW" "12" "P1" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV" "Flaviviridae" "[Ref.24468276]Japanese encephalitis virus (JEV): inhibition of JEV infection in BHK-21 cells(IC50~100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00460" "DRAVPe00460.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "E glycoprotein has been identified as the major antigenic determinant on flavivirus particles and mediates binding and fusion during viral entry,DIII has been proposed to act as the binding region for the cellular receptor. And the peptide could bingding with DIII domain and inhibit the initial step of JEV infection." "1481.63" "C69H96N18O19" "ACDHILMNQVY" "STW" "8.41" "2" "1" "1" "5" "3" "-132.5" "-3064" "7.2 hour" ">20 hour" ">10 hour" "0" "11000" "1000" "24468276" "Antiviral Res. 2014 Apr;104:7-14." "Zu X, Liu Y, Wang S, Jin R, Zhou Z, Liu H, Gong R, Xiao G, Wang W." "Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III." "10.1016/j.antiviral.2014.01.011" "Anti-JEV" "DRAVPe00461" "SENRKVPFYSHS" "12" "P3" "Synthetic construct(phage display)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV" "Flaviviridae" "[Ref.24468276]Japanese encephalitis virus (JEV): inhibition of JEV infection in BHK-21 cells(IC50=1.42 ± 0.41 μM determined by plaque assay,IC50=1.12 ± 0.38 μM determined by qRT-PCR,IC90~100 μM determined by plaque assay and qRT-PCR)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00461" "DRAVPe00461.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "E glycoprotein has been identified as the major antigenic determinant on flavivirus particles and mediates binding and fusion during viral entry,DIII has been proposed to act as the binding region for the cellular receptor. And the peptide could bingding with DIII domain and inhibit the initial step of JEV infection." "1450.57" "C64H95N19O20" "ACDGILMQTW" "S" "8.33" "3" "1" "2" "5" "2" "-140.83" "-4190" "1.9 hour" ">20 hour" ">10 hour" "24.17" "1490" "135.45" "24468276" "Antiviral Res. 2014 Apr;104:7-14." "Zu X, Liu Y, Wang S, Jin R, Zhou Z, Liu H, Gong R, Xiao G, Wang W." "Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III." "10.1016/j.antiviral.2014.01.011" "Anti-JEV" "DRAVPe00462" "MVDRGWGNHAGLFGKGSIV" "19" "DN80" "Synthetic construct(derived from the E polyprotein of DENV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(17±10% inhibition at 49.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00462" "DRAVPe00462.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "2001.29" "C89H137N27O24S" "CEPQTY" "G" "8.52" "3" "1" "2" "7" "7" "4.74" "-1180" "30 hour" ">20 hour" ">10 hour" "76.84" "5500" "305.56" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-DENV" "DRAVPe00463" "AWLVHTQWFLDLPLPWLPGADTQGSNWI" "28" "DN57" "Synthetic construct(derived from the E polyprotein of DENV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(7±4% inhibition at 30.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00463" "DRAVPe00463.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "3262.72" "C158H221N37O39" "CEKMRY" "L" "4.2" "1" "2" "-1" "6" "14" "7.14" "300" "4.4 hour" ">20 hour" ">10 hour" "101.07" "22000" "814.81" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-DENV" "DRAVPe00464" "AWLVHRQWFLDLPLPWLPG" "19" "DN81" "Synthetic construct(derived from the E polyprotein of DENV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(25±8% inhibition at 42.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00464" "DRAVPe00464.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "2344.79" "C118H166N28O23" "CEIKMNSTY" "L" "6.79" "2" "1" "1" "1" "11" "27.37" "752" "4.4 hour" ">20 hour" ">10 hour" "123.16" "16500" "916.67" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-DENV" "DRAVPe00465" "MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY" "33" "DN59" "Synthetic construct(derived from the E polyprotein of DENV)" "No entry found" "Experimentally Validated" "11065 " "envelope (E) glycoprotein" "M29095.1" "residues 412 to 444" "residues 412 to 444" "M29095" "M29095" "Not available" "None" "DENV,WNV" "Flaviviridae" "[Ref.31351847]Dengue virus(DENV): inhibition of DENV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM,100.0±0.5% inhibition at 20 μM);##West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(>99% inhibition at <25μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml." "DRAVPe00465" "DRAVPe00465.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "3443.96" "C161H240N38O44S" "CENPR" "G" "5.19" "2" "2" "0" "11" "16" "77.58" "1883" "30 hour" ">20 hour" ">10 hour" "100.61" "6990" "218.44" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-DENV,MNV" "DRAVPe00466" "VVDRGWGNGAGLFGKGSID" "19" "WN82" "Synthetic construct(derived from the E polyprotein of WNV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV" "Flaviviridae" "[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(4±13% inhibition at 52.5μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00466" "DRAVPe00466.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "1905.1" "C84H129N25O26" "CEHMPQTY" "G" "5.93" "2" "2" "0" "8" "7" "-8.95" "-1727" "100 hour" ">20 hour" ">10 hour" "76.84" "5500" "305.56" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-WNV" "DRAVPe00467" "TFLVHREWFMDLNLPWSSAGSTVWR" "25" "WN53" "Synthetic construct(derived from the E polyprotein of WNV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV" "Flaviviridae" "[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM,56.0±3.0% inhibition at 99μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml." "DRAVPe00467" "DRAVPe00467.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "3036.46" "C142H203N37O36S" "CIKQY" "LSW" "6.42" "3" "2" "1" "7" "11" "-8.4" "-3112" "7.2 hour" ">20 hour" ">10 hour" "74" "16500" "687.5" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-WNV" "DRAVPe00468" "TFLVHREWFMDLNLPWSSA" "19" "WN83" "Synthetic construct(derived from the E polyprotein of WNV)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV" "Flaviviridae" "[Ref.31351847]West Nile virus(WNV): inhibition of WNV infection in LLCKM-2 monkey kidney epithelial cells(IC50~10μM, 70.0±3.0% inhibition at 128 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31351847]No cytotoxicity against LLCMK-2 monkey kidney epithelial cells at 100 mg/ml." "DRAVPe00468" "DRAVPe00468.cif" "Linear" "Free" "Free" "None" "L" "envelope" "The peptide may play roles in protein-protein rearrangements or bilayer membrane interactions during the entry and fusion process and thus inhibit infection of DENV or WNV." "2349.69" "C111H157N27O28S" "CGIKQY" "L" "5.29" "2" "2" "0" "4" "9" "5.26" "-1754" "7.2 hour" ">20 hour" ">10 hour" "82.11" "11000" "611.11" "31351847" "Bioorg Med Chem. 2019 Sep 15;27(18):3963-3978. " "da Silva-Júnior EF, de Araújo-Júnior JX. " "Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses." "10.1016/j.bmc.2019.07.038" "Anti-WNV" "DRAVPe00469" "AIGSILGALAKGLPTLISWIKNR" "23" "AR-23" "Rana tagoi (Tago frog)" "A7BJK6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "6dst" "HSV,MeV,HPIV,HCoV-229E" "Herpesviridae, Paramyxoviridae, Coronaviridae" "[Ref.35055066]HSV-1: Co-treatment:simultaneous addition of AR-23 and virus to the cells(IC50=0.78 μM);Virus pre-treatment: virus incubated with the peptide(IC50=0.39 μM);Cell pre-treatment: AR-23 incubated with the cells before the viral infection and Post-treatment: AR-23 added to the infected cells(AR-23 had a slight inhibitory effect);inhibition the entry of virus(IC50=3.125μM);inhibition of viral attachment on the host cell membrane(IC50=6.25 μM);##Measles virus (MeV):Co-treatment: simultaneous addition of AR-23 and virus to the cells(IC50=6.25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##Human parainfluenza virus type-2 (HPIV2):Co-treatment: simultaneous addition of AR-23 and virus to the cells(IC50=6.25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##HCoV-229E:Virus pre-treatment: virus incubated with the peptide(IC50=3.125 μM);##SARS-CoV-2:Co-treatment:simultaneous addition of AR-23 and virus to the cells(60% of inhibition at 25 μM);Virus pre-treatment: virus incubated with the peptide(IC50=12.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35055066]Vero cells:CC50=25 μM; >80% cytotoxic against Vero cells at 100 and 50 µM." "DRAVPe00469" "DRAVPe00469.cif" "Linear" "Free" "Amidation" "None" "L" "envelope glycoprotein" "No machanism information found in the reference(s) presented in this entry" "2392.91" "C111H190N30O28" "CDEFHMQVY" "IL" "11.17" "3" "0" "3" "7" "12" "73.04" "791" "4.4 hour" ">20 hour" ">10 hour" "148.7" "5500" "250" "35055066" " Int J Mol Sci. 2022 Jan 14;23(2):883. " "Chianese A, Zannella C, Monti A, De Filippis A, Doti N, Franci G, Galdiero M." "The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23. " "10.3390/ijms23020883" "Anti-HSV,Anti-MeV,Anti-HPIV,Anti-HCoV-229E" "DRAVPe00470" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1P4HC" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,HCoV-229E,HCoV-OC43,MERS-CoV" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.8 μM);##SARS-CoV-2 B.1.1.7 (Alpha):inhibition of Pseudoviruse infection in Caco2 cells(IC50=2.28 μM);##SARS-CoV-2 B.1.351 (Beta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.62 μM);##SARS-CoV-2 P.1 (Gamma):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.48 μM);##SARS-CoV-2 B.1.617.2 (Delta):inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.11 μM);##HCoV-229E(Authentic):inhibition of infection in Caco2 cells(IC50=0.48 μM);##HCoV-OC43(Authentic):inhibition of infection in Caco2 cells(IC50=0.41 μM);##SARS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.35 μM);##MERS-CoV:inhibition of Pseudoviruse infection in Caco2 cells(IC50=0.10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM." "No predicted structure available" "DRAVPe00470.cif" "Linear" "Free" "PEG4-25-HC" "None" "L" "mambrane" "The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "34769299" "Int J Mol Sci. 2021 Nov 1;22(21):11869. " "Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. " "25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses." "10.3390/ijms222111869" "Anti-SARS-CoV-2,SARS-CoV,Anti-HCoV-229E,Anti-HCoV-OC43,Anti-MERS-CoV" "DRAVPe00471" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1P8HC" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=3.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM." "No predicted structure available" "DRAVPe00471.cif" "Linear" "Free" "PEG8-25-HC" "None" "L" "membrane" "The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "34769299" "Int J Mol Sci. 2021 Nov 1;22(21):11869. " "Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. " "25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses." "10.3390/ijms222111869" "Anti-SARS-CoV-2" "DRAVPe00472" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1P12HC" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=5.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM." "No predicted structure available" "DRAVPe00472.cif" "Linear" "Free" "PEG12-25-HC" "None" "L" "membrane`" "The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "34769299" "Int J Mol Sci. 2021 Nov 1;22(21):11869. " "Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. " "25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses." "10.3390/ijms222111869" "Anti-SARS-CoV-2" "DRAVPe00473" "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG" "41" "EK1P24HC" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.34769299]SARS-CoV-2:inhibition of Pseudoviruse infection in Caco2 cells(IC50=10.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34769299]no apparent cytotoxicity against Caco-2 cells at concentrations of up to 20 μM." "No predicted structure available" "DRAVPe00473.cif" "Linear" "Free" "PEG24-25-HC" "None" "L" "membrane" "The peptide targets two different sites when mediating virus–cell fusion,which are blocking viral 6-HB formation and reducing the membrane cholesterol level." "4677.29" "C208H336N48O71S" "CHPRW" "EL" "4.36" "5" "10" "-5" "11" "13" "-44.88" "-6701" "1.9 hour" ">20 hour" ">10 hour" "104.63" "2980" "74.5" "34769299" "Int J Mol Sci. 2021 Nov 1;22(21):11869. " "Lan Q, Wang C, Zhou J, Wang L, Jiao F, Zhang Y, Cai Y, Lu L, Xia S, Jiang S. " "25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses." "10.3390/ijms222111869" "Anti-SARS-CoV-2" "DRAVPe00474" "TFLDKFNHEAEDLFYQ" "16" "ACE2 (27-42)(SAP1)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,HCoV-OC43,VSV" "Coronaviridae, Rhabdoviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=2.39±0.20 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(80% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00474" "DRAVPe00474.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "2017.18" "C94H129N21O29" "CGIMPRSVW" "F" "4.31" "2" "4" "-2" "3" "6" "-76.88" "-3557" "7.2 hour" ">20 hour" ">10 hour" "55" "1490" "99.33" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2,Anti-SARS-CoV,Anti-HCoV-OC43,Anti-VSV" "DRAVPe00475" "EDLFYQSSL" "9" "ACE2 (37-45)(SAP2)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=3.72±0.37 mM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00475" "DRAVPe00475.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "1101.18" "C50H72N10O18" "ACGHIKMNPRTVW" "LS" "3.67" "0" "2" "-2" "3" "3" "-33.33" "-1519" "1 hour" "30 min" ">10 hour" "86.67" "1490" "186.25" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2" "DRAVPe00476" "LAQMYPL" "7" "ACE2 (79-85)(SAP3)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00476" "DRAVPe00476.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "835.03" "C39H62N8O10S" "CDEFGHIKNRSTVW" "L" "5.52" "0" "0" "0" "1" "3" "70" "832" "5.5 hour" "3 min" "2 min" "125.71" "1490" "248.33" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2" "DRAVPe00477" "GKGDFRIL" "8" "ACE2 (352-359)(SAP4)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00477" "DRAVPe00477.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "905.06" "C41H68N12O11" "ACEHMNPQSTVWY" "G" "8.75" "2" "1" "1" "2" "3" "-20" "-1449" "30 hour" ">20 hour" ">10 hour" "97.5" "0" "0" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2" "DRAVPe00478" "QAKTFLDKFNHEA" "13" "ACE2 (24-36)(SAP5)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50>7.5 mM);No nhibition of infection in 293T/ACE2/GFP cells up to 3 mM;##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(30% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00478" "DRAVPe00478.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "1548.72" "C70H105N19O21" "CGIMPRSVWY" "AFK" "6.75" "3" "2" "1" "2" "5" "-97.69" "-3154" "0.8 hour" "10 min" ">10 hour" "45.38" "0" "0" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2,SARS-CoV,Anti-VSV" "DRAVPe00479" "EDLFYQ" "6" "ACE2 (37-42)(SAP6)" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2,SARS-CoV,VSV" "Coronaviridae, Rhabdoviridae" "pseudovirus inhibition assay" "[Ref.33356169]SARS-CoV-2:Inhibition of infection in 293T/ACE2 cells(IC50=1.9±0.14 mM);Inhibition of infection in 293T/ACE2/GFP cells(IC50=3 mM);##SARS-CoV:Inhibition of infection in 293T/ACE2 cells(85% inhibition at 3 mM);##Vesicular Stomatitis Virus (VSV):No nhibition of infection in 293T/ACE2 cells up to 3 mM;##HCoV-NL63:Inhibition of cytopathic effect in LLC-MK2 cells(30% Inhibition at 3 mM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00479" "DRAVPe00479.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Inhibiting SARS-CoV-2 infection by disrupting the Spike-ACE2 interaction interface with peptide-based inhibitors." "813.86" "C38H51N7O13" "ACGHIKMNPRSTVW" "DEFLQY" "3.67" "0" "2" "-2" "1" "2" "-86.67" "-1331" "1 hour" "30 min" ">10 hour" "65" "1490" "298" "33356169" "Bioconjug Chem. 2021 Jan 20;32(1):215-223." "Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A." "Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2." "10.1021/acs.bioconjchem.0c00664" "Anti-SARS-CoV-2,SARS-CoV,Anti-VSV" "DRAVPe00480" "DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR" "85" "AHB1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV-2" "Coronaviridae" "neutralization assay" "[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=35 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00480" "DRAVPe00480.cif" "Linear" "Free" "Free" "None" "L" "spike protein" "The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. " "10096.13" "C426H695N133O147S2" "CIPW" "E" "4.9" "19" "24" "-5" "8" "25" "-141.88" "-34516" "1.1 hour" "3 min" ">10 hour" "63.29" "2980" "35.48" "32907861" "Science. 2020 Oct 23;370(6515):426-431." "Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. " "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors." "10.1126/science.abd9909" "Anti-SARS-CoV-2" "DRAVPe00481" "ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK" "75" "AHB2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "neutralization assay" "[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=15.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00481" "DRAVPe00481.cif" "Linear" "Free" "Free" "None" "L" "spike protein" "The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. " "9101.25" "C399H633N109O128S3" "CP" "E" "4.56" "13" "22" "-9" "7" "28" "-66.67" "-19283" "1 hour" "30 min" ">10 hour" "102.8" "12490" "168.78" "32907861" "Science. 2020 Oct 23;370(6515):426-431." "Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. " "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors." "10.1126/science.abd9909" "Anti-SARS-CoV-2" "DRAVPe00482" "DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER" "56" "LCB1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "neutralization assay" "[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=23.54 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00482" "DRAVPe00482.cif" "Linear" "Free" "Free" "None" "L" "spike protein" "The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. " "6810.81" "C301H485N79O94S3" "CNPT" "E" "4.59" "10" "16" "-6" "6" "20" "-57.5" "-13897" "1.1 hour" "3 min" ">10 hour" "106.25" "8480" "154.18" "32907861" "Science. 2020 Oct 23;370(6515):426-431." "Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. " "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors." "10.1126/science.abd9909" "Anti-SARS-CoV-2" "DRAVPe00483" "NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS" "64" "LCB3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "neutralization assay" "[Ref.32907861]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=48.1 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00483" "DRAVPe00483.cif" "Linear" "Free" "Free" "None" "L" "spike protein" "The peptide is a high-affinity protein minibinder to the SARS-CoV-2 spike receptor binding domain (RBD) that compete with ACE2 binding. " "7736.88" "C346H556N90O106S2" "CGPW" "L" "4.94" "13" "16" "-3" "7" "24" "-66.25" "-15515" "1.4 hour" "3 min" ">10 hour" "103.59" "2980" "47.3" "32907861" "Science. 2020 Oct 23;370(6515):426-431." "Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D. " "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors." "10.1126/science.abd9909" "Anti-SARS-CoV-2" "DRAVPe00484" "GYIEAEVI" "8" "HIV-1 integrase(82-89)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1 mM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00484" "DRAVPe00484.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "893" "C41H64N8O14" "CDFHKLMNPQRSTW" "EI" "3.79" "0" "2" "-2" "2" "4" "78.75" "287" "30 hour" ">20 hour" ">10 hour" "146.25" "1490" "212.86" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00485" "QETAYFLLKLAGRWP" "15" "HIV-1 integrase(95-109)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00485" "DRAVPe00485.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "1793.1" "C86H129N21O21" "CDHIMNSV" "L" "8.59" "2" "1" "1" "3" "7" "-16.67" "-1090" "0.8 hour" "10 min" ">10 hour" "91.33" "6990" "499.29" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00486" "STTVKAASWWA" "11" "HIV-1 integrase(123-133)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1 mM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00486" "DRAVPe00486.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "1207.35" "C56H82N14O16" "CDEFGHILMNPQRY" "A" "8.47" "1" "0" "1" "4" "6" "8.18" "-336" "1.9 hour" ">20 hour" ">10 hour" "53.64" "11000" "1100" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00487" "HLKTAVQMAVFIHNFKR" "17" "HIV-1 integrase(171-187)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00487" "DRAVPe00487.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "2040.46" "C94H150N28O21S" "CDEGPSWY" "AFHKV" "11.17" "5" "0" "5" "2" "8" "8.24" "-2024" "3.5 hour" "10 min" ">10 hour" "91.76" "0" "0" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00488" "AGERIVDIIATDIQ" "14" "HIV-1 integrase(196-210)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=2.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00488" "DRAVPe00488.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "1513.71" "C65H112N18O23" "CFHKLMNPSWY" "I" "4.03" "1" "3" "-2" "2" "7" "44.29" "-1900" "4.4 hour" ">20 hour" ">10 hour" "146.43" "0" "0" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00489" "QETAYFLLKLAGR" "13" "HIV-1 integrase(95-107)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=150 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00489" "DRAVPe00489.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "1509.77" "C70H112N18O19" "CDHIMNPSVW" "L" "8.59" "2" "1" "1" "3" "6" "0" "-1323" "0.8 hour" "10 min" ">10 hour" "105.38" "1490" "124.17" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00490" "AGERIVDIIA" "10" "HIV-1 integrase(196-206)" "Synthetic construct(derived from HIV-1 integrase)" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "HIV-1 Integrase 30 -DNA Processing Assay" "[Ref.12643937]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=30 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00490" "DRAVPe00490.cif" "Linear" "Free" "Amidation" "None" "L" "Integrase" "The peptide can inhibit the activity of integrase and thus inhibit virus repliaction." "1056.23" "C46H81N13O15" "CFHKLMNPQSTWY" "I" "4.37" "1" "2" "-1" "1" "6" "94" "-709" "4.4 hour" ">20 hour" ">10 hour" "166" "0" "0" "12643937" "Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7." "Zhao L, O'Reilly MK, Shultz MD, Chmielewski J." "Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. " "10.1016/s0960-894x(03)00040-4" "Anti-HIV" "DRAVPe00491" "WNSLKIDNLDV" "11" "LEDGF 361–370" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(81% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00491" "DRAVPe00491.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1316.48" "C59H93N15O19" "ACEFGHMPQRTY" "DLN" "4.21" "1" "2" "-1" "3" "5" "-30" "-1854" "2.8 hour" "3 min" "2 min" "132.73" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00492" "WASLKIDNLDV" "11" "LEDGF 361–370[N361A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(76% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00492" "DRAVPe00492.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1273.45" "C58H92N14O18" "CEFGHMPQRTY" "DL" "4.21" "1" "2" "-1" "2" "6" "18.18" "-1009" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00493" "WNALKIDNLDV" "11" "LEDGF 361–370[S362A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(79% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00493" "DRAVPe00493.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1300.48" "C59H93N15O18" "CEFGHMPQRSTY" "DLN" "4.21" "1" "2" "-1" "2" "6" "-6.36" "-1333" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00494" "WNSAKIDNLDV" "11" "LEDGF 361–370[L363A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(71% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00494" "DRAVPe00494.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1274.4" "C56H87N15O19" "CEFGHMPQRTY" "DN" "4.21" "1" "2" "-1" "3" "5" "-48.18" "-2165" "2.8 hour" "3 min" "2 min" "106.36" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00495" "WNSLAIDNLDV" "11" "LEDGF 361–370[K364A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(68% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00495" "DRAVPe00495.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1259.38" "C56H86N14O19" "CEFGHKMPQRTY" "DLN" "3.56" "0" "2" "-2" "3" "6" "21.82" "-1118" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00496" "WNSLKADNLDV" "11" "LEDGF 361–370[I365A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(65% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00496" "DRAVPe00496.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1274.4" "C56H87N15O19" "CEFGHIMPQRTY" "DLN" "4.21" "1" "2" "-1" "3" "5" "-54.55" "-2165" "2.8 hour" "3 min" "2 min" "106.36" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00497" "WNSLKIANLDV" "11" "LEDGF 361–370[D366A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(58% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00497" "DRAVPe00497.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1272.47" "C58H93N15O17" "CEFGHMPQRTY" "LN" "5.84" "1" "1" "0" "3" "6" "18.18" "-801" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00498" "WNSLKIDALDV" "11" "LEDGF 361–370[N367A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(75% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00498" "DRAVPe00498.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1273.45" "C58H92N14O18" "CEFGHMPQRTY" "DL" "4.21" "1" "2" "-1" "2" "6" "18.18" "-1009" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00499" "WNSLKIDNADV" "11" "LEDGF 361–370[L368A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(75% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00499" "DRAVPe00499.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1274.4" "C56H87N15O19" "CEFGHMPQRTY" "DN" "4.21" "1" "2" "-1" "3" "5" "-48.18" "-2165" "2.8 hour" "3 min" "2 min" "106.36" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00500" "WNSLKIDNLAV" "11" "LEDGF 361–370[D369A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(73% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00500" "DRAVPe00500.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1272.47" "C58H93N15O17" "CEFGHMPQRTY" "LN" "5.84" "1" "1" "0" "3" "6" "18.18" "-801" "2.8 hour" "3 min" "2 min" "141.82" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00501" "WNSLKIDNLDA" "11" "LEDGF 361–370[V370A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(68% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00501" "DRAVPe00501.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1288.42" "C57H89N15O19" "CEFGHMPQRTVY" "DLN" "4.21" "1" "2" "-1" "3" "5" "-51.82" "-2077" "2.8 hour" "3 min" "2 min" "115.45" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00502" "WNSLKIANLAV" "11" "LEDGF 361–370[D366A,D369A]" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(43% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00502" "DRAVPe00502.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1228.46" "C57H93N15O15" "CDEFGHMPQRTY" "ALN" "8.75" "1" "0" "1" "3" "7" "66.36" "252" "2.8 hour" "3 min" "2 min" "150.91" "5500" "550" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00503" "WIDNLD" "6" "LEDGF 365–369" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(30% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00503" "DRAVPe00503.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "774.83" "C35H50N8O12" "ACEFGHKMPQRSTVY" "D" "3.56" "0" "2" "-2" "1" "3" "-51.67" "-1191" "2.8 hour" "3 min" "2 min" "130" "5500" "1100" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00504" "WKFALKVDSPDV" "12" "HRP2 483–493" "Synthetic construct" "Q7Z4V5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "quantitative assay(IN enzymatic activity)" "[Ref.20171172]HIV-1:inhibition of integrase catalytic activity(25% inhibition at 100nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00504" "DRAVPe00504.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide inhibits the catalytic activity of integrase and thus inhibits integration of viral cDNA." "1404.63" "C67H101N15O18" "CEGHIMNQRTY" "DKV" "5.96" "2" "2" "0" "1" "6" "-10.83" "-1182" "2.8 hour" "3 min" "2 min" "89.17" "5500" "500" "20171172" "Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. " "Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A." "Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370." "10.1016/j.bbrc.2010.02.100" "Anti-HIV" "DRAVPe00505" "WEEWDKKIEEYTKKIEELIKKSQNQQ" "26" "WQ(628-653)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=123.4 ±6.5 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=159.5 ± 9.5 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=126.2 ± 9.2 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=81.2-383.3 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=13.5-686.2 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=34.8-433.1 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=195.1-1128.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00505" "DRAVPe00505.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3351.76" "C151H236N38O48" "ACFGHMPRV" "EK" "5.19" "6" "7" "-1" "4" "6" "-189.23" "-8791" "2.8 hour" "3 min" "2 min" "60" "12490" "499.6" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00506" "MTWEEWDKKIEEYTKKIEELIKKSQNQQ" "28" "MT-WQ(626-653)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=8.8 ±0.4 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=14.8 ± 2.8 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=6.7 ± 0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00506" "DRAVPe00506.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3584.06" "C160H252N40O51S" "ACFGHPRV" "EK" "5.19" "6" "7" "-1" "5" "6" "-171.43" "-8813" "30 hour" ">20 hour" ">10 hour" "55.71" "12490" "462.59" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00507" "WEEWDKKIEEYTKKIEELIKKSQNQQSM" "28" "WQ-SM(628-655)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=60.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00507" "DRAVPe00507.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3570.03" "C159H250N40O51S" "ACFGHPRV" "EK" "5.19" "6" "7" "-1" "5" "6" "-171.79" "-8896" "2.8 hour" "3 min" "2 min" "55.71" "12490" "462.59" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00508" "WEEWDKKIEEYTKKIEELIKKSQNQQSW" "28" "WQ-SW(628-655)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=47.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00508" "DRAVPe00508.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3625.05" "C165H251N41O51" "ACFGHMPRV" "EK" "5.19" "6" "7" "-1" "5" "7" "-181.79" "-8898" "2.8 hour" "3 min" "2 min" "55.71" "17990" "666.3" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00509" "WEEWDKKIEEYTKKIEELIKKSQNQQSY" "28" "WQ-SY(628-655)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=54.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00509" "DRAVPe00509.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3602.01" "C163H250N40O52" "ACFGHMPRV" "EK" "5.19" "6" "7" "-1" "6" "6" "-183.21" "-9145" "2.8 hour" "3 min" "2 min" "55.71" "13980" "517.78" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00510" "WEEWDKKIEEYTKKIEELIKKSQNQQSDLD" "30" "WQ-SDLD(628-657)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=44.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00510" "DRAVPe00510.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3782.18" "C168H262N42O57" "ACFGHMPRV" "EK" "4.65" "6" "9" "-3" "5" "7" "-177.33" "-10383" "2.8 hour" "3 min" "2 min" "65" "12490" "430.69" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00511" "WEEWDKKIEEYTKKIEELIKKSQNQQLDL" "29" "WQ-LDL(628-656)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.7 ±1.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=6.4 ±2.7 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.6± 0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00511" "DRAVPe00511.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3693.17" "C167H263N41O53" "ACFGHMPRV" "EK" "4.86" "6" "8" "-2" "4" "8" "-155.52" "-8679" "2.8 hour" "3 min" "2 min" "80.69" "12490" "446.07" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00512" "WEEWDKKIEEYTKKIEELIKKSQNQQIDI" "29" "WQ-IDI(628-656)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.7 ±0.3 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=6.4 ± 1.8 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.2 ± 0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00512" "DRAVPe00512.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3693.17" "C167H263N41O53" "ACFGHMPRV" "EK" "4.86" "6" "8" "-2" "4" "8" "-150.69" "-8679" "2.8 hour" "3 min" "2 min" "80.69" "12490" "446.07" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00513" "WEEWDKKIEEYTKKIEELIKKSQNQQLDI" "29" "WQ-LDI(628-656)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=3.6±0.2nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=7.2 ± 1.0 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=3.1 ± 0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00513" "DRAVPe00513.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3693.17" "C167H263N41O53" "ACFGHMPRV" "EK" "4.86" "6" "8" "-2" "4" "8" "-153.1" "-8679" "2.8 hour" "3 min" "2 min" "80.69" "12490" "446.07" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00514" "WEEWDKKIEEYTKKIEELIKKSQNQQIDL" "29" "WQ-IDL(628-656)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=1.6 ±0.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=5.6± 1.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=2.5 ± 0.1 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=2.0-90.7 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=0.8-37.4 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=1.6-22.0 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=8.5-61.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00514" "DRAVPe00514.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3693.17" "C167H263N41O53" "ACFGHMPRV" "EK" "4.86" "6" "8" "-2" "4" "8" "-153.1" "-8679" "2.8 hour" "3 min" "2 min" "80.69" "12490" "446.07" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00515" "MTWEEWDKKIEEYTKKIEELIKKSQNQQIDL" "31" "MT-WQ-IDL(626-656)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=0.6±0.1 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=1.2± 0.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=0.6 ±0.1 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=0.5-15.1 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=0.1-9.0 nM);##HIV-1 T20-resistant strains(5 strains):inhibition of virus infection in MT-2 cells(IC50=0.1-4.4 nM);##HIV-1 T2635-resistant strain(6 strains):inhibition of virus infection in MT-2 cells(IC50=1.1-11.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00515" "DRAVPe00515.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3925.47" "C176H279N43O56S" "ACFGHPRV" "EK" "4.86" "6" "8" "-2" "5" "8" "-139.35" "-8701" "30 hour" ">20 hour" ">10 hour" "75.48" "12490" "416.33" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00516" "EEQKTQLKNKIEIDWTKMELEQDWSKIYKEI" "31" "MT-WQ-IDL-scrambled" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.27795416]HIV-1 IIIB:inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50>500 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50>500 nM);##" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00516" "DRAVPe00516.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3925.47" "C176H279N43O56S" "ACFGHPRV" "EK" "4.86" "6" "8" "-2" "5" "8" "-139.35" "-8701" "1 hour" "30 min" ">10 hour" "75.48" "12490" "416.33" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-HIV" "DRAVPe00517" "TTLLDLTYEMLSLQQVVKALNESYIDLKEL" "30" "M0" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "ELISA" "[Ref.27795416]MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells(IC50=4.5 μM);inhibition of pseudovirus infection in MT-2 cells(IC50=17.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00517" "DRAVPe00517.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3485.05" "C157H259N35O51S" "CFGHPRW" "L" "4.18" "2" "5" "-3" "8" "12" "16.33" "-2496" "7.2 hour" ">20 hour" ">10 hour" "139.67" "2980" "102.76" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-MERS-CoV" "DRAVPe00518" "EANTTLLDLTYEMLSLQQVVKALNESYIDLKEL" "33" "M1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MERS-CoV" "Coronaviridae" "ELISA" "[Ref.27795416]MERS-CoV:inhibition of MERS-CoV S-medicated cell-cell fusion in MT-2 cells(IC50=0.9 μM);inhibition of pseudovirus infection in MT-2 cells(IC50=2.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00518" "DRAVPe00518.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3799.35" "C169H277N39O57S" "CFGHPRW" "L" "4.08" "2" "6" "-4" "9" "13" "-0.91" "-3660" "1 hour" "30 min" ">10 hour" "130" "2980" "93.13" "27795416" "J Virol. 2016 Dec 16;91(1):e01445-16." "Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1128/JVI.01445-16" "Anti-MERS-CoV" "DRAVPe00519" "WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL" "34" "C34" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=7.3± 2.5 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=15± 2.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=23 ± 5.0 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=19 ±4.7 nM).##[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=7.2±0.2 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=18.8± 1.6 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=7.6±0.2 nM);##" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00519" "DRAVPe00519.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." "4248.6" "C184H280N50O64S" "ACFGPV" "E" "4.21" "3" "8" "-5" "9" "9" "-127.06" "-10170" "2.8 hour" "3 min" "2 min" "80.29" "12490" "378.48" "19073606##27795416" "J Biol Chem. 2009 Feb 20;284(8):4914-20.##J Virol. 2016 Dec 16;91(1):e01445-16." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.##Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.##Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1074/jbc.M807169200##10.1128/JVI.01445-16" "DRAVPa0875" "Anti-HIV" "DRAVPe00520" "YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF" "36" "T-20(Enfuvirtide)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay,neutralization assay" "[Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=2.4 ± 0.6 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=23± 8.2 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=49 ± 10 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=84 ± 16 nM).##[Ref.27795416]HIV-1 IIIB:inhibition of virus infection in MT-2 cells(IC50=71.8±2.2 nM); inhibition of peptide against cell-cell fusion between H9/HIV-1 IIIB cells and MT-2 cells(IC50=91.0± 1.2 nM);##HIV-1 Bal:inhibition of virus infection in MT-2 cells(IC50=70.5 ±0.9 nM);##HIV-1 clinical isolates(8 clinical isolates):inhibition of virus infection in MT-2 cells(IC50=20.4-157.3 nM);##HIV-1 pseudoviruses(7 pseudoviruses):inhibition of pseudoviruses infection in MT-2 cells(IC50=7.1-91.0 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00520" "DRAVPe00520.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4450.88" "C202H298N50O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-87.5" "-7259" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "19073606##27795416" "J Biol Chem. 2009 Feb 20;284(8):4914-20.##J Virol. 2016 Dec 16;91(1):e01445-16." "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.##Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L. " "Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.##Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors." "10.1074/jbc.M807169200##10.1128/JVI.01445-16" "DRAVPa0326" "Anti-HIV" "DRAVPe00521" "LQQLLFIHFRIGRRRRRRRR" "20" "peptide 4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00521.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2734.31" "C120H209N51O23" "ACDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-125.5" "-11852" "5.5 hour" "3 min" "2 min" "97.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00522" "EAIIRILQQLLFIHFRIGRRRRRRRR" "26" "peptide 5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.09 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.04 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00522.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3430.17" "C152H266N60O31" "CDKMNPSTVWY" "R" "12.6" "11" "1" "10" "1" "11" "-68.46" "-12368" "1 hour" "30 min" ">10 hour" "123.85" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00523" "ILQQLLFIHFRIGRRRRRRRR" "21" "peptide 6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.10 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00523" "DRAVPe00523.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2847.47" "C126H220N52O24" "ACDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "8" "-98.1" "-11360" "20 hour" "30 min" ">10 hour" "111.43" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00524" "RILQQLLFIHFRIGRRRRRRRR" "22" "peptide 7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.11 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00524" "DRAVPe00524.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3003.65" "C132H232N56O25" "ACDEKMNPSTVWY" "R" "12.95" "11" "0" "11" "1" "8" "-114.09" "-12852" "1 hour" "2 min" "2 min" "106.36" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00525" "IRILQQLLFIHFRIGRRRRRRRR" "23" "peptide 8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.26 ±0.04 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.11 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00525" "DRAVPe00525.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3116.81" "C138H243N57O26" "ACDEKMNPSTVWY" "R" "12.95" "11" "0" "11" "1" "9" "-89.57" "-12360" "20 hour" "30 min" ">10 hour" "118.7" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00526" "IIRILQQLLFIHFRIGRRRRRRRR" "24" "peptide 9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.11 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00526" "DRAVPe00526.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3229.97" "C144H254N58O27" "ACDEKMNPSTVWY" "R" "12.95" "11" "0" "11" "1" "10" "-67.08" "-11868" "20 hour" "30 min" ">10 hour" "130" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00527" "AIIRILQQLLFIHFRIGRRRRRRRR" "25" "peptide 10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.08 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.05 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00527" "DRAVPe00527.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3301.05" "C147H259N59O28" "CDEKMNPSTVWY" "R" "12.95" "11" "0" "11" "1" "11" "-57.2" "-11687" "4.4 hour" ">20 hour" ">10 hour" "128.8" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00528" "EAIIRILQQLLFIEFRIKRRRRRRRR" "26" "peptide 11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.05± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.01 ± 0.001 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00528" "DRAVPe00528.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3493.26" "C155H275N59O33" "CDGHMNPSTVWY" "R" "12.37" "11" "2" "9" "0" "11" "-83.08" "-13232" "1 hour" "30 min" ">10 hour" "123.85" "0" "0" "3422.14" "C151H266N58O33" "CDHKMNPSTVWY" "R" "12.369999999999999" "Anti-HIV" "DRAVPe00529" "EEIIRKLQQLLFIHFRIGRRRRRRRR" "26" "peptide 12" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.047 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00529" "DRAVPe00529.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3503.22" "C154H269N61O33" "ACDMNPSTVWY" "R" "12.37" "12" "2" "10" "1" "9" "-121.15" "-14277" "1 hour" "30 min" ">10 hour" "105" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00530" "EAIIRILQELLFKHFRIGRRRRRRRR" "26" "peptide 13" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.14 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.065 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00530" "DRAVPe00530.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3446.17" "C152H266N60O32" "CDMNPSTVWY" "R" "12.37" "12" "2" "10" "1" "10" "-100.77" "-13542" "1 hour" "30 min" ">10 hour" "108.85" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00531" "EAIERILKQLLFIHFRIGRRRRRRRR" "26" "peptide 14" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.23± 0.03 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.15 ± 0.002 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00531" "DRAVPe00531.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3446.17" "C152H266N60O32" "CDMNPSTVWY" "R" "12.37" "12" "2" "10" "1" "10" "-100.77" "-13542" "1 hour" "30 min" ">10 hour" "108.85" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00532" "EAEIRIKQQLLFIHFRIGRRRRRRRR" "26" "peptide 15" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.04 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.031± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00532" "DRAVPe00532.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3461.14" "C151H263N61O33" "CDMNPSTVWY" "R" "12.37" "12" "2" "10" "1" "9" "-128.85" "-14588" "1 hour" "30 min" ">10 hour" "93.85" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00533" "EAIIRILQQLEFIHKRIGRRRRRRRR" "26" "peptide 16" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.71 ± 0.21 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.004µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00533" "DRAVPe00533.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3427.12" "C148H265N61O33" "CDMNPSTVWY" "R" "12.37" "12" "2" "10" "1" "9" "-122.31" "-14394" "1 hour" "30 min" ">10 hour" "108.85" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00534" "EEIIRKLQQLLFIEFRIKRRRRRRRR" "26" "peptide 17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.18 ± 0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.08 ± 0.02 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00534" "DRAVPe00534.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "3566.32" "C157H278N60O35" "ACDGHMNPSTVWY" "R" "12.18" "12" "3" "9" "0" "9" "-135.77" "-15141" "1 hour" "30 min" ">10 hour" "105" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00535" "AQQLLFIHFRIGRRRRRRRR" "20" "peptide 18" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.004 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.08 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00535" "DRAVPe00535.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2692.23" "C117H203N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-135.5" "-12163" "4.4 hour" ">20 hour" ">10 hour" "83" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00536" "LAQLLFIHFRIGRRRRRRRR" "20" "peptide 19" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00536" "DRAVPe00536.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2677.26" "C118H206N50O22" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "8" "-99" "-11117" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00537" "LQALLFIHFRIGRRRRRRRR" "20" "peptide 20" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.10 ± 0.004 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00537" "DRAVPe00537.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2677.26" "C118H206N50O22" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "8" "-99" "-11117" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00538" "LQQALFIHFRIGRRRRRRRR" "20" "peptide 21" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.12 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.07 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00538" "DRAVPe00538.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2692.23" "C117H203N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-135.5" "-12163" "5.5 hour" "3 min" "2 min" "83" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00539" "LQQLAFIHFRIGRRRRRRRR" "20" "peptide 22" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.003 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00539" "DRAVPe00539.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2692.23" "C117H203N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-135.5" "-12163" "5.5 hour" "3 min" "2 min" "83" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00540" "LQQLLAIHFRIGRRRRRRRR" "20" "peptide 23" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.34 ± 0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.18 ± 0.03 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00540" "DRAVPe00540.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2658.21" "C114H205N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-130.5" "-11969" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00541" "LQQLLFAHFRIGRRRRRRRR" "20" "peptide 24" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.33 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.22± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00541" "DRAVPe00541.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2692.23" "C117H203N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-139" "-12163" "5.5 hour" "3 min" "2 min" "83" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00542" "LQQLLFIAFRIGRRRRRRRR" "20" "peptide 25" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.13 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.06 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00542" "DRAVPe00542.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2668.25" "C117H207N49O23" "CDEHKMNPSTVWY" "R" "12.9" "9" "0" "9" "1" "8" "-100.5" "-11205" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00543" "LQQLLFIHARIGRRRRRRRR" "20" "peptide 26" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.25 ± 0.02 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.12± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00543" "DRAVPe00543.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2658.21" "C114H205N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-130.5" "-11969" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00544" "LQQLLFIHFAIGRRRRRRRR" "20" "peptide 27" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.11 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.05 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00544" "DRAVPe00544.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2649.2" "C117H202N48O23" "CDEKMNPSTVWY" "R" "12.85" "9" "0" "9" "1" "8" "-94" "-10179" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00545" "LQQLLFIHFRAGRRRRRRRR" "20" "peptide 28" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.20 ± 0.03 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.16 ± 0.02µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00545" "DRAVPe00545.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2692.23" "C117H203N51O23" "CDEKMNPSTVWY" "R" "12.9" "10" "0" "10" "1" "7" "-139" "-12163" "5.5 hour" "3 min" "2 min" "83" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00546" "LQQLLFIHFRIARRRRRRRR" "20" "peptide 29" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Integrase assay" "[Ref.20708407]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=0.09 ± 0.01 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.09 ± 0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00546" "DRAVPe00546.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Integrase" "The peptide acts antiviral activity by inhibiting the activity of integrase." "2748.33" "C121H211N51O23" "CDEGKMNPSTVWY" "R" "12.9" "10" "0" "10" "0" "8" "-114.5" "-11765" "5.5 hour" "3 min" "2 min" "102.5" "0" "0" "20708407" "Bioorg Med Chem. 2010 Sep 15;18(18):6771-5." "Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H." "Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies." "10.1016/j.bmc.2010.07.050" "Anti-HIV" "DRAVPe00547" "RQLLSGIVQQQNNLLRAIEAQQHLLQK" "27" "C8- N27" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=1075±90 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=293±27 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00547" "DRAVPe00547.cif" "Linear" "C8(octanoic acid)" "Free" "None" "L" "membrane" "N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry." "3140.64" "C136H235N45O40" "CDFMPTWY" "Q" "10.84" "4" "1" "3" "4" "11" "-47.04" "-5436" "1 hour" "2 min" "2 min" "133.7" "0" "0" "20605950" "FASEB J. 2010 Nov;24(11):4196-202. " "Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y." "Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. " "10.1096/fj.09-151704" "Anti-HIV" "DRAVPe00548" "RQLLSGIVQQQNNLLRAIEAQQHLLQK" "27" "C12- N27" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=473±74 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=182±15 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00548.cif" "Linear" "C12(dodecanoic acid)" "Free" "None" "L" "membrane" "N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry." "3140.64" "C136H235N45O40" "CDFMPTWY" "Q" "10.84" "4" "1" "3" "4" "11" "-47.04" "-5436" "1 hour" "2 min" "2 min" "133.7" "0" "0" "20605950" "FASEB J. 2010 Nov;24(11):4196-202. " "Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y." "Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. " "10.1096/fj.09-151704" "Anti-HIV" "DRAVPe00549" "RQLLSGIVQQQNNLLRAIEAQQHLLQK" "27" "C16-N27" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=148±4 nM);inhibition of peptide against virus-cell fusion on CD4-expressing cells(IC50=10±1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00549.cif" "Linear" "C16(hexadecanoic acid)" "Free" "None" "L" "membrane" "N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry." "3140.64" "C136H235N45O40" "CDFMPTWY" "Q" "10.84" "4" "1" "3" "4" "11" "-47.04" "-5436" "1 hour" "2 min" "2 min" "133.7" "0" "0" "20605950" "FASEB J. 2010 Nov;24(11):4196-202. " "Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y." "Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. " "10.1096/fj.09-151704" "Anti-HIV" "DRAVPe00550" "RQLLSGIVQQQNNLLRAIEAQQHLL" "25" "C16- N25" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=484±60 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00550" "DRAVPe00550.cif" "Linear" "C16(hexadecanoic acid)" "Free" "None" "L" "membrane" "N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry." "2884.33" "C125H215N41O37" "CDFKMPTWY" "LQ" "9.61" "3" "1" "2" "4" "11" "-21.2" "-4327" "1 hour" "2 min" "2 min" "144.4" "0" "0" "20605950" "FASEB J. 2010 Nov;24(11):4196-202. " "Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y." "Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. " "10.1096/fj.09-151704" "Anti-HIV" "DRAVPe00551" "RQLLSGIVQQQNNLLRAIEAQQH" "23" "C16- N23" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.20605950]HIV-1:inhibition of peptide against cell-cell fusion between Jurkat E6-1 and HXBc2 cells(IC50=1931±187 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00551" "DRAVPe00551.cif" "Linear" "C16(hexadecanoic acid)" "Free" "None" "L" "membrane" "N peptide may target an exposed C-helix region of gp41 and can interact with their coiled coil formation within a gp41 dimer,which can inhibit HIV-1 entry." "2658.02" "C113H193N39O35" "CDFKMPTWY" "Q" "9.61" "3" "1" "2" "4" "9" "-56.09" "-5311" "1 hour" "2 min" "2 min" "123.04" "0" "0" "20605950" "FASEB J. 2010 Nov;24(11):4196-202. " "Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y." "Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. " "10.1096/fj.09-151704" "Anti-HIV" "DRAVPe00552" "XDLTXEMLSLQQVVKALNESY" "21" "P21S1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00552.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 1 and 5) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (1) and X (5) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2404.15" "C95H153N23O31S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "5" "7" "-5.71" "-2320" "106.67" "1490" "74.5" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00553" "LXLTYXMLSLQQVVKALNESY" "21" "P21S2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.90 ± 1.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00553.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 2 and 6) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (2) and X (6) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2436.28" "C101H161N23O28S" "CDFGHIPRW" "L" "6" "1" "1" "0" "6" "8" "39.52" "-289" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00554" "LDLXYEMXSLQQVVKALNESY" "21" "P21S3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00554.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 4 and 8) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (4) and X (8) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2466.22" "C100H155N23O31S" "CFGHIPRTW" "L" "4.14" "1" "3" "-2" "5" "7" "-8.57" "-2077" "5.5 hour" "3 min" "2 min" "106.67" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00555" "LDLTXEMLXLQQVVKALNESY" "21" "P21S4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=7.14 ± 0.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00555.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 5 and 9) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (5) and X (9) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2430.23" "C98H159N23O30S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "4" "8" "16.19" "-1488" "5.5 hour" "3 min" "2 min" "125.24" "1490" "74.5" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00556" "LDLTYEMXSLQXVVKALNESY" "21" "P21S5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.7±2.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00556.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 8 and 12) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (8) and X (12) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2439.19" "C99H154N22O31S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "7" "4.76" "-1780" "5.5 hour" "3 min" "2 min" "106.67" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00557" "LDLTYEMLXLQQXVKALNESY" "21" "P21S6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00557.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 9 and 13) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (9) and X (13) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2494.27" "C102H159N23O31S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "5" "7" "-10" "-1906" "5.5 hour" "3 min" "2 min" "111.43" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00558" "LDLTYEMLSLXQVVXALNESY" "21" "P21S7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00558.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 11 and 15) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (11) and X (15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2424.18" "C99H153N21O31S" "CFGHIKPRW" "L" "3.57" "0" "3" "-3" "6" "8" "41.43" "-733" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00559" "LDLTYEMLSLQXVVKXLNESY" "21" "P21S8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.26±0.05 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=3.03 ± 0.29 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=4.06± 0.34 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.98± 0.28 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29442512]Calu-3 cell:CC50>100 μM" "No predicted structure available" "DRAVPe00559.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2481.27" "C102H160N22O31S" "ACFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "7" "14.29" "-1469" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00560" "LDLTYEMLSLQQVVXALNXSY" "21" "P21S9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=14.1 ± 2.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00560.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 15 and 19) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (15) and X (19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2423.19" "C99H154N22O30S" "CFGHIKPRW" "L" "3.67" "0" "2" "-2" "6" "8" "41.43" "-606" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00561" "LDLTYEMLSLQQVVKXLNEXY" "21" "P21S10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.33 ± 0.04 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.97± 0.08 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.82± 0.28 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.89± 0.07 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29442512]Calu-3 cell:CC50>100 μM" "No predicted structure available" "DRAVPe00561.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 16 and 20) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (16) and X (20) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2522.33" "C104H163N23O31S" "ACFGHIPRW" "L" "4.14" "1" "3" "-2" "5" "7" "1.43" "-1683" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00562" "LXLTYXMLSLQQVVKALNESY" "21" "P21L2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.9 ±1.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00562.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 2 and 6 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2436.28" "C101H161N23O28S" "CDFGHIPRW" "L" "6" "1" "1" "0" "6" "8" "39.52" "-289" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00563" "LDLTXEMLXLQQVVKALNESY" "21" "P21L4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=8.21 ±0.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00563.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 5 and 9 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2430.23" "C98H159N23O30S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "4" "8" "16.19" "-1488" "5.5 hour" "3 min" "2 min" "125.24" "1490" "74.5" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00564" "LDLTYEMXSLQXVVKALNESY" "21" "P21L5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=4.49 ± 0.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00564.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 8 and 12 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2439.19" "C99H154N22O31S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "7" "4.76" "-1780" "5.5 hour" "3 min" "2 min" "106.67" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00565" "LDLTYEMLSLQXVVKXLNESY" "21" "P21L8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=20.6± 3.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00565.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 12 and 16 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2481.27" "C102H160N22O31S" "ACFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "7" "14.29" "-1469" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00566" "LDLTYEMLSLQQVVXALNXSY" "21" "P21L9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=10.9 ± 1.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00566.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 15 and 19 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2423.19" "C99H154N22O30S" "CFGHIKPRW" "L" "3.67" "0" "2" "-2" "6" "8" "41.43" "-606" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00567" "LDLTYEMLSLQQVVKXLNEXY" "21" "P21L10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.55 ± 0.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00567.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 16 and 20 are S5((S)-pentenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2522.33" "C104H163N23O31S" "ACFGHIPRW" "L" "4.14" "1" "3" "-2" "5" "7" "1.43" "-1683" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00568" "LDLTYEMLSLQXVVKXLNESY" "21" "P21R8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=16.3 ± 1.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00568.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' at position 12 and 16 are R5 amino acids. ②X (12) and X (16) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2481.27" "C102H160N22O31S" "ACFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "7" "14.29" "-1469" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00569" "LDLTYEZLSLQXVVKXLNESY" "21" "P21S8Z" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.63 ± 0.05 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=2.80 ± 0.74 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=4.15± 0.25 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=2.49±0.18 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29442512]Calu-3 cell:CC50>100 μM" "No predicted structure available" "DRAVPe00569.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling. The 'Z' at position 7 indicates R8 ((R)-octenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2478.83" "C97H149N21O29" "ACFGHIMPRW" "L" "4.14" "1" "3" "-2" "6" "7" "5.24" "-1704" "5.5 hour" "3 min" "2 min" "120.48" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00570" "LDLTYEMLSLQXVVKXLNESF" "21" "P21S8F" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=2.16± 1.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00570.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2465.27" "C102H160N22O30S" "ACGHIPRW" "L" "4.14" "1" "3" "-2" "5" "8" "33.81" "-1157" "5.5 hour" "3 min" "2 min" "120.48" "1490" "74.5" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00571" "LDLTYEZLSLQXVVKXLNESF" "21" "P21S8ZF" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=3.89 ± 0.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00571.cif" "Cyclic" "Acetylation" "Amidation" "①The 'X' (position: 12 and 16) in sequence indicates S5 stapling amino acid. Note: S5 is (S)-pentenyl alanine. ②X (12) and X (16) are cross-linked by hydrocarbon stapling.,The 'Z' at position 7 indicates R8 ((R)-octenyl alanine)" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2462.83" "C97H149N21O28" "ACGHIMPRW" "L" "4.14" "1" "3" "-2" "5" "8" "24.76" "-1392" "5.5 hour" "3 min" "2 min" "120.48" "1490" "74.5" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00572" "LDLTYEMLSLQQVVKALNESY" "21" "P21" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00572" "DRAVPe00572.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "2457.82" "C110H177N25O36S" "CFGHIPRW" "L" "4.14" "1" "3" "-2" "6" "8" "6.19" "-1842" "5.5 hour" "3 min" "2 min" "125.24" "2980" "149" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00573" "SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL" "36" "HR2P-M2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "Inhibition of MERS-CoV S-Protein-Mediated Cell–Cell Fusion Assay" "[Ref.29442512]MERS-CoV:inhibition of cell-cell fusion in Huh-7 cells(EC50=0.75 ± 0.09 μM);##WT MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.07±0.21 μM);##Q1020H-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=1.25± 0.18 μM);##Q1020R-MERS-CoV pseudovirus:inhibition of pseudovirus infection in calu-3 cells(EC50=0.64± 0.16 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29442512]Calu-3 cell:CC50>100 μM" "DRAVPe00573" "DRAVPe00573.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits MERS-CoV infection and its spike (S) protein-mediated cell–cell fusion." "4299.98" "C193H321N43O64S" "ACFGHPRW" "L" "4.48" "5" "9" "-4" "8" "12" "-40.56" "-6020" "1.9 hour" ">20 hour" ">10 hour" "124.44" "2980" "85.14" "29442512" "J Med Chem. 2018 Mar 8;61(5):2018-2026." "Wang C, Xia S, Zhang P, Zhang T, Wang W, Tian Y, Meng G, Jiang S, Liu K." "Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. " "10.1021/acs.jmedchem.7b01732" "Anti-MERS-CoV" "DRAVPe00574" "FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNI" "36" "FP3(FCoV Sgp (1338-1373))" "Synthetic construct(derived from S protein of FCoV)" "P10033" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FCoV" "Coronaviridae" "plaque reduction assay" "[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=14.21 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24312629]Fcwf-4 cell:CC50>200 μM." "DRAVPe00574" "DRAVPe00574.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication." "4136.62" "C185H292N46O61" "CMPQW" "L" "4.19" "3" "7" "-4" "11" "15" "-3.33" "-5515" "1.1 hour" "3 min" "2 min" "121.94" "1490" "42.57" "24312629" " PLoS One. 2013 Dec 3;8(12):e82081." "Liu IJ, Tsai WT, Hsieh LE, Chueh LL." "Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection." "10.1371/journal.pone.0082081" "Anti-FCoV" "DRAVPe00575" "FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNL" "43" "FP4(FCoV Sgp (1338-1380))" "Synthetic construct(derived from S protein of FCoV)" "P10033" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FCoV" "Coronaviridae" "plaque reduction assay" "[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=1.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24312629]Fcwf-4 cell:CC50>200 μM." "DRAVPe00575" "DRAVPe00575.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication." "4905.49" "C218H348N56O72" "CMPQW" "L" "4.19" "3" "7" "-4" "15" "18" "-1.4" "-6376" "1.1 hour" "3 min" "2 min" "126.98" "1490" "35.48" "24312629" " PLoS One. 2013 Dec 3;8(12):e82081." "Liu IJ, Tsai WT, Hsieh LE, Chueh LL." "Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection." "10.1371/journal.pone.0082081" "Anti-FCoV" "DRAVPe00576" "FNATYLNLTGEIDDLEFRSEKLHNTTVELAILIDNINNTLVNLEWLNRIE" "50" "FP5(FCoV Sgp (1338-1387))" "Synthetic construct(derived from S protein of FCoV)" "P10033" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FCoV" "Coronaviridae" "plaque reduction assay" "[Ref.24312629]feline coronavirus(FCoV):inhibition of virus replication in Fcwf-4 cells(IC50=1.33 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24312629]Fcwf-4 cell:CC50>200 μM." "DRAVPe00576" "DRAVPe00576.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide can interfere the fusion of the viral envelope with host membrane and thus inhibits viral replication." "5846.55" "C261H412N68O84" "CMPQ" "LN" "4.25" "4" "9" "-5" "16" "21" "-16.4" "-8677" "1.1 hour" "3 min" "2 min" "124.8" "6990" "142.65" "24312629" " PLoS One. 2013 Dec 3;8(12):e82081." "Liu IJ, Tsai WT, Hsieh LE, Chueh LL." "Peptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infection." "10.1371/journal.pone.0082081" "Anti-FCoV" "DRAVPe00577" "WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK" "34" "SC34EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.9±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00577" "DRAVPe00577.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4365.95" "C196H315N49O63" "ACFGHMPRV" "EK" "5.43" "10" "11" "-1" "4" "7" "-210.29" "-12689" "2.8 hour" "3 min" "2 min" "57.35" "12490" "378.48" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00578" "WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL" "33" "SC33EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00578" "DRAVPe00578.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4237.77" "C190H303N47O62" "ACFGHMPRV" "E" "5.08" "9" "11" "-2" "4" "7" "-204.85" "-12134" "2.8 hour" "3 min" "2 min" "59.09" "12490" "390.31" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00579" "WEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE" "32" "SC32EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00579" "DRAVPe00579.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4124.61" "C184H292N46O61" "ACFGHMPRV" "E" "5.08" "9" "11" "-2" "4" "6" "-223.13" "-12626" "2.8 hour" "3 min" "2 min" "48.75" "12490" "402.9" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00580" "WEEWDKKIEEYTKKIEELIKKSEEQQKKNEK" "31" "SC31EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00580" "DRAVPe00580.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3995.5" "C179H285N45O58" "ACFGHMPRV" "EK" "5.38" "9" "10" "-1" "4" "6" "-219.03" "-11945" "2.8 hour" "3 min" "2 min" "50.32" "12490" "416.33" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00581" "WEEWDKKIEEYTKKIEELIKKSEEQQKKNE" "30" "SC30EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1±0 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00581" "DRAVPe00581.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3867.32" "C173H273N43O57" "ACFGHMPRV" "E" "5.03" "8" "10" "-2" "4" "6" "-213.33" "-11390" "2.8 hour" "3 min" "2 min" "52" "12490" "430.69" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00582" "WEEWDKKIEEYTKKIEELIKKSEEQQKKN" "29" "SC29EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.2±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00582" "DRAVPe00582.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3738.21" "C168H266N42O54" "ACFGHMPRV" "EK" "5.33" "8" "9" "-1" "4" "6" "-208.62" "-10709" "2.8 hour" "3 min" "2 min" "53.79" "12490" "446.07" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00583" "WEEWDKKIEEYTKKIEELIKKSEEQQKK" "28" "SC28EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=18±3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=13±1.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00583" "DRAVPe00583.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3624.11" "C164H260N40O52" "ACFGHMNPRV" "EK" "5.33" "8" "9" "-1" "3" "6" "-203.57" "-10045" "2.8 hour" "3 min" "2 min" "55.71" "12490" "462.59" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00584" "WEEWDKKIEEYTKKIEELIKKSEEQQK" "27" "SC27EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=29±2.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21.4±2.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00584" "DRAVPe00584.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3495.93" "C158H248N38O51" "ACFGHMNPRV" "E" "4.97" "7" "9" "-2" "3" "6" "-196.67" "-9490" "2.8 hour" "3 min" "2 min" "57.78" "12490" "480.38" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00585" "WEEWDKKIEEYTKKIEELIKKSEEQQ" "26" "SC26EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=44.9±5.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=36.2±4.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00585" "DRAVPe00585.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3367.76" "C152H236N36O50" "ACFGHMNPRV" "E" "4.73" "6" "9" "-3" "3" "6" "-189.23" "-8935" "2.8 hour" "3 min" "2 min" "60" "12490" "499.6" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00586" "WEEWDKKIEEYTKKIEELIKKSEEQ" "25" "SC25EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=79.8±9.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=41.5±3.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00586" "DRAVPe00586.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3239.63" "C147H228N34O48" "ACFGHMNPRV" "E" "4.73" "6" "9" "-3" "3" "6" "-182.8" "-8381" "2.8 hour" "3 min" "2 min" "62.4" "12490" "520.42" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00587" "WEEWDKKIEEYTKKIEELIKKSEE" "24" "SC24EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=107.6±8 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=75.7±11.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00587" "DRAVPe00587.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3111.5" "C142H220N32O46" "ACFGHMNPQRV" "E" "4.73" "6" "9" "-3" "3" "6" "-175.83" "-7827" "2.8 hour" "3 min" "2 min" "65" "12490" "543.04" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00588" "WEEWDKKIEEYTKKIEELIKKSE" "23" "SC23EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=105.1±15.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=94.2±12.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00588" "DRAVPe00588.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2982.38" "C137H213N31O43" "ACFGHMNPQRV" "E" "4.9" "6" "8" "-2" "3" "6" "-168.26" "-7146" "2.8 hour" "3 min" "2 min" "67.83" "12490" "567.73" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00589" "WEEWDKKIEEYTKKIEELIKKS" "22" "SC22EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=66.9±15.9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=98.6±7.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00589" "DRAVPe00589.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2853.26" "C132H206N30O40" "ACFGHMNPQRV" "EK" "5.19" "6" "7" "-1" "3" "6" "-160" "-6465" "2.8 hour" "3 min" "2 min" "70.91" "12490" "594.76" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00590" "WEEWDKKIEEYTKKIEELIKK" "21" "SC21EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=113.2±8 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=105.4±12.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00590" "DRAVPe00590.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2766.19" "C129H201N29O38" "ACFGHMNPQRSV" "EK" "5.19" "6" "7" "-1" "2" "6" "-163.81" "-6125" "2.8 hour" "3 min" "2 min" "74.29" "12490" "624.5" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00591" "WEEWDKKIEEYTKKIEELIK" "20" "SC20EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=126.6±10.7 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=202.4±5.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00591" "DRAVPe00591.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2638.01" "C123H189N27O37" "ACFGHMNPQRSV" "E" "4.82" "5" "7" "-2" "2" "6" "-152.5" "-5570" "2.8 hour" "3 min" "2 min" "78" "12490" "657.37" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00592" "WEEWDKKIEEYTKKIEELI" "19" "SC19EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=70.7±9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=217.2±16.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00592" "DRAVPe00592.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2509.84" "C117H177N25O36" "ACFGHMNPQRSV" "E" "4.55" "4" "7" "-3" "2" "6" "-140" "-5015" "2.8 hour" "3 min" "2 min" "82.11" "12490" "693.89" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00593" "WEEWDKKIEEYTKKIEEL" "18" "SC18EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50>2000 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00593" "DRAVPe00593.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2396.68" "C111H166N24O35" "ACFGHMNPQRSV" "E" "4.55" "4" "7" "-3" "2" "5" "-172.78" "-5507" "2.8 hour" "3 min" "2 min" "65" "12490" "734.71" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00594" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKELK" "36" "MT-SC34EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.7±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00594" "DRAVPe00594.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4598.25" "C205H331N51O66S" "ACFGHPRV" "EK" "5.42" "10" "11" "-1" "5" "7" "-195.28" "-12711" "30 hour" ">20 hour" ">10 hour" "54.17" "12490" "356.86" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00595" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKEL" "35" "MT-SC33EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.2±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00595" "DRAVPe00595.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4470.07" "C199H319N49O65S" "ACFGHPRV" "E" "5.08" "9" "11" "-2" "5" "7" "-189.71" "-12156" "30 hour" ">20 hour" ">10 hour" "55.71" "12490" "367.35" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00596" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEKE" "34" "MT-SC32EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00596" "DRAVPe00596.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4356.91" "C193H308N48O64S" "ACFGHPRV" "E" "5.08" "9" "11" "-2" "5" "6" "-206.47" "-12648" "30 hour" ">20 hour" ">10 hour" "45.88" "12490" "378.48" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00597" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNEK" "33" "MT-SC31EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00597" "DRAVPe00597.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4227.8" "C188H301N47O61S" "ACFGHPRV" "EK" "5.37" "9" "10" "-1" "5" "6" "-202.12" "-11967" "30 hour" ">20 hour" ">10 hour" "47.27" "12490" "390.31" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00598" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKNE" "32" "MT-SC30EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.8±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00598" "DRAVPe00598.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "4099.62" "C182H289N45O60S" "ACFGHPRV" "E" "5.03" "8" "10" "-2" "5" "6" "-196.25" "-11412" "30 hour" ">20 hour" ">10 hour" "48.75" "12490" "402.9" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00599" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN" "31" "MT-SC29EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=0.9±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00599" "DRAVPe00599.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3970.51" "C177H282N44O57S" "ACFGHPRV" "EK" "5.32" "8" "9" "-1" "5" "6" "-191.29" "-10731" "30 hour" ">20 hour" ">10 hour" "50.32" "12490" "416.33" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00600" "MTWEEWDKKIEEYTKKIEELIKKSEEQQKK" "30" "MT-SC28EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.3±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.2±0.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00600" "DRAVPe00600.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3856.4" "C173H276N42O55S" "ACFGHNPRV" "EK" "5.32" "8" "9" "-1" "4" "6" "-186" "-10067" "30 hour" ">20 hour" ">10 hour" "52" "12490" "430.69" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00601" "MTWEEWDKKIEEYTKKIEELIKKSEEQQK" "29" "MT-SC27EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.4±0.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00601" "DRAVPe00601.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3728.23" "C167H264N40O54S" "ACFGHNPRV" "E" "4.97" "7" "9" "-2" "4" "6" "-178.97" "-9512" "30 hour" ">20 hour" ">10 hour" "53.79" "12490" "446.07" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00602" "MTWEEWDKKIEEYTKKIEELIKKSEEQQ" "28" "MT-SC26EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.6±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.1±0.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00602" "DRAVPe00602.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3600.05" "C161H252N38O53S" "ACFGHNPRV" "E" "4.73" "6" "9" "-3" "4" "6" "-171.43" "-8957" "30 hour" ">20 hour" ">10 hour" "55.71" "12490" "462.59" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00603" "MTWEEWDKKIEEYTKKIEELIKKSEEQ" "27" "MT-SC25EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.9±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2±0.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00603" "DRAVPe00603.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3471.92" "C156H244N36O51S" "ACFGHNPRV" "E" "4.73" "6" "9" "-3" "4" "6" "-164.81" "-8403" "30 hour" ">20 hour" ">10 hour" "57.78" "12490" "480.38" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00604" "MTWEEWDKKIEEYTKKIEELIKKSEE" "26" "MT-SC24EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.8±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.3±0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00604" "DRAVPe00604.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3343.79" "C151H236N34O49S" "ACFGHNPQRV" "E" "4.73" "6" "9" "-3" "4" "6" "-157.69" "-7849" "30 hour" ">20 hour" ">10 hour" "60" "12490" "499.6" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00605" "MTWEEWDKKIEEYTKKIEELIKKSE" "25" "MT-SC23EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.1±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1.9±0.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00605" "DRAVPe00605.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3214.68" "C146H229N33O46S" "ACFGHNPQRV" "E" "4.9" "6" "8" "-2" "4" "6" "-150" "-7168" "30 hour" ">20 hour" ">10 hour" "62.4" "12490" "520.42" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00606" "MTWEEWDKKIEEYTKKIEELIKKS" "24" "MT-SC22EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=2.4±0.3 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.2±0.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00606" "DRAVPe00606.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3085.56" "C141H222N32O43S" "ACFGHNPQRV" "EK" "5.19" "6" "7" "-1" "4" "6" "-141.67" "-6487" "30 hour" ">20 hour" ">10 hour" "65" "12490" "543.04" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00607" "MTWEEWDKKIEEYTKKIEELIKK" "23" "MT-SC21EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=3.8±0.4 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3.1±1.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00607" "DRAVPe00607.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2998.48" "C138H217N31O41S" "ACFGHNPQRSV" "EK" "5.19" "6" "7" "-1" "3" "6" "-144.35" "-6147" "30 hour" ">20 hour" ">10 hour" "67.83" "12490" "567.73" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00608" "MTWEEWDKKIEEYTKKIEELIK" "22" "MT-SC20EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=3.7±0.5 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3.3±1.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00608" "DRAVPe00608.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2870.31" "C132H205N29O40S" "ACFGHNPQRSV" "E" "4.82" "5" "7" "-2" "3" "6" "-133.18" "-5592" "30 hour" ">20 hour" ">10 hour" "70.91" "12490" "594.76" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00609" "MTWEEWDKKIEEYTKKIEELI" "21" "MT-SC19EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=5±0.9 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=4.9±1.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00609" "DRAVPe00609.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2742.14" "C126H193N27O39S" "ACFGHNPQRSV" "E" "4.55" "4" "7" "-3" "3" "6" "-120.95" "-5037" "30 hour" ">20 hour" ">10 hour" "74.29" "12490" "624.5" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00610" "MTWEEWDKKIEEYTKKIEEL" "20" "MT-SC18EK" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50>2000 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00610" "DRAVPe00610.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "2628.98" "C120H182N26O38S" "ACFGHNPQRSV" "E" "4.55" "4" "7" "-3" "3" "5" "-149.5" "-5529" "30 hour" ">20 hour" ">10 hour" "58.5" "12490" "657.37" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00611" "MTWEEWDKKIEEYTKKIEELIKKSQNQQEKN" "31" "MT-WQ-EKN" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.1±0.1 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00611" "DRAVPe00611.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3955.45" "C175H277N45O57S" "ACFGHPRV" "EK" "5.26" "7" "8" "-1" "6" "6" "-190" "-10713" "30 hour" ">20 hour" ">10 hour" "50.32" "12490" "416.33" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00612" "WEEWDKKIEEYTKKIEELIKKSQNQQEKN" "29" "WQ-EKN" "Synthetic construct" "Q5DP94" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "dual split-protein (DSP)-based cell-cell fusion assay,luciferase assay" "[Ref.31277353]HIV-1 NL4-3:inhibition of pseudovirus entry in TZM-bl cells(IC50=1.4±0.2 nM);##HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.8±0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00612" "DRAVPe00612.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV fusion by binding to the hydrophobic grooves on the N-terminal heptad repeat (NHR) trimer and blocking six-helix-bundle (6-HB) formation." "3723.15" "C166H261N43O54" "ACFGHMPRV" "EK" "5.26" "7" "8" "-1" "5" "6" "-207.24" "-10691" "2.8 hour" "3 min" "2 min" "53.79" "12490" "446.07" "31277353" "Viruses. 2019 Jul 3;11(7):609. " "Geng X, Liu Z, Yu D, Qin B, Zhu Y, Cui S, Chong H, He Y." "Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors." "10.3390/v11070609" "Anti-HIV" "DRAVPe00613" "YTSLIREILVESRIQQEKNERELRDIDKWASLWNWF" "36" "T20v1(T20 [H6R; S7E; L8,26I; I9L; E10V; Q13,21R; N14I; L24R; E25D])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.10 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.12 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=0.29 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00613" "DRAVPe00613.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4566.16" "C207H319N57O60" "CGHMP" "E" "5.15" "6" "7" "-1" "7" "14" "-81.67" "-10436" "2.8 hour" "10 min" "2 min" "97.5" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00614" "YTSLIHSIIEESRNRQEKNEQALLELDKWASLWNWF" "36" "T20v2(T20 [L8I; Q13,15R; E22A])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.06 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.09 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.05 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00614" "DRAVPe00614.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4448.96" "C202H304N54O60" "CGMPV" "EL" "5.06" "5" "6" "-1" "9" "14" "-76.39" "-8273" "2.8 hour" "10 min" "2 min" "92.22" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00615" "YTSLLRSIIEEGRNQQEKNEQALLELDKWASLWNWF" "36" "T20v3(T20 [I5L, H6R, L8I; S12G; Q13R; E22A])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.13 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.08 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.19 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.08 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.34 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00615" "DRAVPe00615.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4409.92" "C200H303N53O60" "CHMPV" "L" "4.72" "4" "6" "-2" "9" "14" "-78.06" "-7927" "2.8 hour" "10 min" "2 min" "92.22" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00616" "YTSLIRSIIEESRNQQEKNEQKLLEVDKWASLWNWF" "36" "T20v4(T20 [H6R, L8I, Q13R, E22K, L26V])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.15 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.12 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.04 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.22 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=1.80 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00616" "DRAVPe00616.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4483.02" "C203H310N54O61" "CGHMP" "E" "5.11" "5" "6" "-1" "9" "13" "-91.94" "-9185" "2.8 hour" "10 min" "2 min" "86.67" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00617" "YTSLLRSLIEESRNLQEKNEQALLEVDKWASLWNWF" "36" "T20v5(T20 [I5L, H6R, Q13R, Q15L, E22A, L26V])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.17 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.15 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.14 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.29 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.13 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.69 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00617" "DRAVPe00617.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4410.95" "C201H306N52O60" "CGHMP" "L" "4.72" "4" "6" "-2" "9" "15" "-59.72" "-7403" "2.8 hour" "10 min" "2 min" "100.28" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00618" "YTSLLWSIIEEGRNLQEKNEQKLLELDKWASLWNWF" "36" "T20v6(T20 [I5L, H6W, L8I, S12G, Q13R, Q15L, E22K])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.16 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.14 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.21 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.62 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.59 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.10 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.68 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00618" "DRAVPe00618.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4482.07" "C209H311N51O59" "CHMPV" "L" "4.72" "4" "6" "-2" "9" "15" "-63.61" "-5892" "2.8 hour" "10 min" "2 min" "100.28" "23490" "671.14" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00619" "YTSLIWKVLNDAREQQENNQETLVEIDKWASLWNWF" "36" "T20v7(T20 [H6W; S7K; L8,24V; I9L; E10N; E11D; S12A; Q13R; N14E; K18N; E20Q; Q21E; L26I])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.37 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.16 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.45 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=1.12 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.23 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.07 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=5.10 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00619" "DRAVPe00619.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4468.95" "C205H300N52O61" "CGHMP" "ELNW" "4.36" "3" "6" "-3" "9" "15" "-74.17" "-7244" "2.8 hour" "10 min" "2 min" "86.67" "23490" "671.14" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00620" "YTSLIREIMNKSWGQQRRNEGTLAEIDKWASLWNWF" "36" "T20v8(T20 [H6R; S7E; L8,26I; I9M; E10N; E11K; Q13W; N14G; E17R; K18R; Q21G; E22T; L24A])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.40 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.24 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.31 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.53 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=1.11 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.24 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=10.2 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00620" "DRAVPe00620.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4428.99" "C201H300N56O56S" "CHPV" "W" "8.5" "5" "4" "1" "11" "13" "-80.83" "-8182" "2.8 hour" "10 min" "2 min" "70.56" "23490" "671.14" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00621" "YTSLIRELISNARTQQTDNEESLRNVDKWASLWNWF" "36" "T20v9(T20 [H6R; S7E; E10,22S; E11,25N; S12A; Q13R; N14T; E17T; K18D; Q21E; L24R; L26V])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=1.20 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.34 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.41 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.82 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=1.09 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.35 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=16.8 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00621" "DRAVPe00621.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4385.82" "C195H295N55O61" "CGHMP" "LNS" "4.94" "4" "5" "-1" "12" "13" "-84.44" "-10012" "2.8 hour" "10 min" "2 min" "78.61" "17990" "514" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00622" "YTSLIWSIIIDGREQQRDNEGVLADLDKWASLWNWF" "36" "T20v10(T20 [H6W; L8I; E10I;E11D;S12G;Q13R;N14E;E17R;K18D;Q21G;E22V;L24D;E25D])" "Synthetic construct(derived from T20)" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "neutralization assay" "[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=23.3 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.50 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=3.35 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=12.0 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.45 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.11 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=24.4 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00622" "DRAVPe00622.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4339.83" "C200H293N51O58" "CHMP" "DILW" "4.23" "3" "6" "-3" "9" "16" "-35.83" "-5996" "2.8 hour" "10 min" "2 min" "100.28" "23490" "671.14" "31228294" "Protein Sci. 2019 Aug;28(8):1501-1512." "Chen G, Cook JD, Ye W, Lee JE, Sidhu SS." "Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display." "10.1002/pro.3669" "Anti-HIV" "DRAVPe00623" "EKINQSLAFIRKSDELLHNV" "20" "peptide 4(RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "P03420" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50>50 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00623" "DRAVPe00623.cif" "Linear" "Acetylation" "Free" "None" "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2354.69" "C104H172N30O32" "CGMPTWY" "L" "6.86" "4" "3" "1" "4" "8" "-44.5" "-4521" "1 hour" "30 min" ">10 hour" "117" "0" "0" "Anti-RSV" "DRAVPe00624" "EKINQSLXFIRXSDXLLHXV" "20" "peptide 4a(derived from RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.82±0.42 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00624.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2357.54" "C86H134N24O21" "ACGMPTWY" "X" "6.85" "3" "2" "1" "3" "7" "1" "-2802" "1 hour" "30 min" ">10 hour" "112" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00625" "EKIXQSLXFIXKSDXLLHNV" "20" "peptide 4bb(derived from RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.74±0.27 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00625.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2329.53" "C86H134N22O21" "ACGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "4" "-1865" "1 hour" "30 min" ">10 hour" "112" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00626" "EXINXSLXFIRXSDELLHNV" "20" "peptide 4ca(derived from RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.59±0.13 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00626.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 2 indicates R-pentenylalanine; The 'X' at position 5,8,12 indicates S-pentenylalanine, X(2) and X(5), X(8) and X(12) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2344.46" "C84H127N23O23" "ACGKMPQTWY" "X" "4.65" "2" "3" "-1" "4" "7" "3" "-3038" "1 hour" "30 min" ">10 hour" "112" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00627" "XKINQSLXFIRXSDELLHXV" "20" "peptide 4ef(derived from RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=3.07±1.45 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00627.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 1,8 indicates R-octenyl-alanine; The 'X' at position 12,19 indicates S-pentenylalanine, X(1) and X(8), X(12) and X(19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2357.54" "C86H134N24O21" "ACGMPTWY" "X" "6.75" "3" "2" "1" "3" "7" "1" "-2802" "112" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00628" "EKIXQSLXFIRXSDELLHXV" "20" "peptide 4bf(derived from RSV fusion protein(497-515))" "Synthetic construct(derived from RSV fusion protein)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=2.49±0.09 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00628.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 12 indicates R-octenyl-alanine; The 'X' at position 4,8,19 indicates S-pentenylalanine, X(4) and X(8), X(12) and X(19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2372.55" "C87H135N23O22" "ACGMNPTWY" "X" "5.45" "3" "3" "0" "2" "7" "1" "-2819" "1 hour" "30 min" ">10 hour" "112" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00629" "EKIAQSLXFIRXSDXLLHXV" "20" "peptide 4a[N500A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=20.41±2.4 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00629.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2314.52" "C85H133N23O20" "CGMNPTWY" "X" "6.85" "3" "2" "1" "2" "8" "27.5" "-1957" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00630" "EKINQSLXFIAXSDXLLHXV" "20" "peptide 4a[R507A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=175±0.00 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00630.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 8,12,15,19 indicates S-pentenylalanine, X(8) and X(12), X(15) and X(19) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2272.43" "C83H127N21O21" "CGMPRTWY" "X" "5.32" "2" "2" "0" "3" "8" "32.5" "-1129" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00631" "AKIXQSLXFIXKSDXLLHNV" "20" "peptide 4bb[E497A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.16±0.08 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00631.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2271.49" "C84H132N22O19" "CEGMPRTWY" "X" "8.64" "3" "1" "2" "3" "8" "30.5" "-1003" "4.4 hour" ">20 hour" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00632" "EAIXQSLXFIXKSDXLLHNV" "20" "peptide 4bb[K498A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.60±0.02 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00632.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2272.43" "C83H127N21O21" "CGMPRTWY" "X" "5.32" "2" "2" "0" "3" "8" "32.5" "-1129" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00633" "EKAXQSLXFIXKSDXLLHNV" "20" "peptide 4bb[I499A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.30±0.89 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00633.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2287.45" "C83H128N22O21" "CGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "-9.5" "-2176" "1 hour" "30 min" ">10 hour" "97.5" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00634" "EKIXASLXFIXKSDXLLHNV" "20" "peptide 4bb[Q501A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.28±0.43 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00634.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2272.48" "C84H131N21O20" "CGMPQRTWY" "X" "6.85" "3" "2" "1" "3" "8" "30.5" "-1130" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00635" "EKIXQALXFIXKSDXLLHNV" "20" "peptide 4bb[S502A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.66±0.26 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00635.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2313.53" "C86H134N22O20" "CGMPRTWY" "X" "6.85" "3" "2" "1" "2" "8" "17" "-1344" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00636" "EKIXQSAXFIXKSDXLLHNV" "20" "peptide 4bb[L503A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.95±0.53 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00636.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2287.45" "C83H128N22O21" "CGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "-6" "-2176" "1 hour" "30 min" ">10 hour" "97.5" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00637" "EKIXQSLXAIXKSDXLLHNV" "20" "peptide 4bb[F505A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.39±0.10 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00637.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2253.43" "C80H130N22O21" "CFGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "-1" "-1982" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00638" "EKIXQSLXFAXKSDXLLHNV" "20" "peptide 4bb[I506A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=10.44±2.97 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00638.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2287.45" "C83H128N22O21" "CGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "-9.5" "-2176" "1 hour" "30 min" ">10 hour" "97.5" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00639" "EKIXQSLXFIXASDXLLHNV" "20" "peptide 4bb[K508A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=10.93±13.90 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00639.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2272.43" "C83H127N21O21" "CGMPRTWY" "X" "5.32" "2" "2" "0" "3" "8" "32.5" "-1129" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00640" "EKIXQSLXFIXKADXLLHNV" "20" "peptide 4bb[S509A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=82.04±1.56 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00640.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2313.53" "C86H134N22O20" "CGMPRTWY" "X" "6.85" "3" "2" "1" "2" "8" "17" "-1344" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00641" "EKIXQSLXFIXKSAXLLHNV" "20" "peptide 4bb[D510A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.10±0.08 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00641.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2285.52" "C85H134N22O19" "CDGMPRTWY" "X" "8.69" "3" "1" "2" "3" "8" "30.5" "-812" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00642" "EKIXQSLXFIXKSDXALHNV" "20" "peptide 4bb[L512A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.88±0.06 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00642.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2287.45" "C83H128N22O21" "CGMPRTWY" "X" "6.85" "3" "2" "1" "3" "7" "-6" "-2176" "1 hour" "30 min" ">10 hour" "97.5" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00643" "EKIXQSLXFIXKSDXLLANV" "20" "peptide 4bb[H514A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.52±0.07 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00643.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2263.47" "C83H132N20O21" "CGHMPRTWY" "X" "6.17" "2" "2" "0" "3" "8" "29" "-1218" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00644" "EKIXQSLXFIXKSDXLLHAV" "20" "peptide 4bb[N515A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=2.71±2.93 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00644.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2286.5" "C85H133N21O20" "CGMNPRTWY" "X" "6.85" "3" "2" "1" "2" "8" "30.5" "-1020" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00645" "EKIXQSLXFIXKSDXLLHNA" "20" "peptide 4bb[V516A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=0.60±0.03 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00645.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 4,8,11,15 indicates S-pentenylalanine, X(4) and X(8), X(11) and X(15) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2301.47" "C84H130N22O21" "CGMPRTVWY" "X" "6.85" "3" "2" "1" "3" "7" "-8" "-2088" "1 hour" "30 min" ">10 hour" "102.5" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00646" "EXINXSLXFIRXSDALLHNV" "20" "peptide 4ca[E511A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "rHRSV-mCherry inhibition assay" "[Ref.28137809]Respiratory syncytial virus (RSV):inhibition of virus infection in Hep-2 cells(EC50=1.00±0.03 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00646.cif" "Cyclic" "Acetylation" "Free" "The 'X' at position 2 indicates R-pentenylalanine; The 'X' at position 5,8,12 indicates S-pentenylalanine, X(2) and X(5), X(8) and X(12) are cross-linked by hydrocarbon stapling." "L" "membrane" "The peptide disrupts the formation of the postfusion six-helix bundle required for viral cell entry." "2286.42" "C82H125N23O21" "CGKMPQTWY" "X" "5.32" "2" "2" "0" "4" "8" "29.5" "-2176" "1 hour" "30 min" ">10 hour" "117" "0" "0" "28137809" "Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02241-16." "Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O." "A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading." "10.1128/AAC.02241-16" "Anti-RSV" "DRAVPe00647" "YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF" "36" "ENF (T-20)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "MAGI/cMAGI infectivity assay,neutralization assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.006 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.050 μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.526 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=54.958 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=47.822 μg/ml).##[Ref.31228294]HIV-1 N43:inhibition of virus infection in U87 cells(IC50=0.37 µg/ml);##HIV-1 JRCSF:inhibition of virus infection in U87 cells(IC50=0.09 µg/ml);##HIV-1 94UG103:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92BR020:inhibition of pseudovirus infection in U87 cells(IC50=0.30 µg/ml);##HIV-1 IAVI C22:inhibition of pseudovirus infection in U87 cells(IC50=0.03 µg/ml);##HIV-1 92HT021:inhibition of pseudovirus infection in U87 cells(IC50=0.02 µg/ml);##HIV-1 JRCSF-GIA:inhibition of pseudovirus infection in U87 cells(IC50=3.58 µg/ml).##[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=24633±2467 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=10825±1354 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=4503±384 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=34858 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=9.12 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=90.18-2250 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=263.68-829.01 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=490.8-648.49 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=157.87 ± 8.79 μM;##MT-4 cell:CC50=171.73± 23.13 μM;##HEK293T cell:CC50=216.23± 33.08 μM;##PBMC:CC50=81.23± 4.59 μM." "No predicted structure available" "DRAVPe00647.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4450.88" "C202H298N50O64" "CGMPRV" "EL" "4.3" "3" "7" "-4" "9" "13" "-87.5" "-7259" "2.8 hour" "10 min" "2 min" "89.44" "17990" "514" "17640899##31228294##30089693" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. ##Protein Sci. 2019 Aug;28(8):1501-1512.##J Virol. 2018 Sep 26;92(20):e01088-18." "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.##Chen G, Cook JD, Ye W, Lee JE, Sidhu SS.##Chong H, Zhu Y, Yu D, He Y." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.##Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.##Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1073/pnas.0701478104##10.1002/pro.3669##10.1128/JVI.01088-18" "" "Anti-HIV,Anti-SIV" "DRAVPe00648" "YTSLIHSLIEESQNQQEKNEQELLEX" "26" "LP-53" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2949±400 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9968±2224 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=21352±1876 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00648.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 26 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3114.56" "C128H202N34O48" "ACDFGMPRVW" "E" "4.2" "2" "6" "-4" "7" "6" "-112.69" "-6990" "2.8 hour" "10 min" "2 min" "90" "1490" "59.6" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00649" "YTSLIEELIKKSEEQQKKNEEELKX" "25" "LP-54" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=149±48 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=301±26 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1796±340 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00649.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 25 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3048.62" "C128H212N32O45" "ACDFGHMPRVW" "E" "4.86" "5" "7" "-2" "5" "5" "-150.8" "-7805" "2.8 hour" "10 min" "2 min" "78" "1490" "62.08" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00650" "WEQKIEELLKKAEEQQKKNEEELKKX" "26" "LP-55" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=8±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=12±1 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.11-189.34 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=10.67-137.77 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.19-10.61 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=34 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00650.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 25 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3267.91" "C139H229N37O45" "CDFGHMPRSTVY" "E" "5.3" "7" "8" "-1" "1" "6" "-201.92" "-9277" "2.8 hour" "3 min" "2 min" "63.85" "5500" "220" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00651" "WEQKIEELLKKAEEQQKKNEEELKXX" "26" "LP-56" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=12±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=11±2 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00651.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 26 is Lys-C16(palmitic acid),The 'X' at position 25 is Lys-AEEA(8-amino-3,6-dioxaoctanoic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3251.07" "C133H215N35O43" "CDFGHMPRSTVY" "E" "4.94" "6" "8" "-2" "1" "6" "-186.92" "-8722" "2.8 hour" "3 min" "2 min" "63.85" "5500" "220" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00652" "WEQKIEELLKKAEEQQKKNEEEX" "23" "LP-57" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=213±21 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=178±38 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1917±440 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00652.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 23 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2898.41" "C121H194N32O42" "CDFGHMPRSTVY" "E" "4.69" "5" "8" "-3" "1" "5" "-210.87" "-8659" "2.8 hour" "3 min" "2 min" "55.22" "5500" "250" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00653" "WEQKIEELLKKAEEQQKKNEX" "21" "LP-58" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=143000±19911 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=110900±3715 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=107033±9473 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00653.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 21 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2640.18" "C111H180N30O36" "CDFGHMPRSTVY" "E" "5.16" "5" "6" "-1" "1" "5" "-197.62" "-7297" "2.8 hour" "3 min" "2 min" "60.48" "5500" "275" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00654" "WEQKIEELLKKAEEQQKX" "18" "LP-59" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>900000 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=240800±23649 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=210477±25537 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00654.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 18 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2268.78" "C96H155N25O30" "CDFGHMNPRSTVY" "E" "5.07" "4" "5" "-1" "0" "5" "-170" "-5397" "2.8 hour" "3 min" "2 min" "70.56" "5500" "323.53" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00655" "SLIEELIKKSEEQQKKNEEELKKLEX" "26" "LP-60" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=55±6 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=48±6 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=62±27 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00655.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 26 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3154.79" "C132H226N34O46" "ACDFGHMPRTVWY" "E" "4.94" "6" "8" "-2" "3" "6" "-151.15" "-8278" "1.9 hour" ">20 hour" ">10 hour" "90" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00656" "IEELIKKSEEQQKKNEEELKKLEX" "24" "LP-61" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=85±9 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=43±9 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=126±63 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=144 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=193.63±13.92 μM;##MT-4 cell:CC50=164.47±37.69 μM;##HEK293T cell:CC50=140.43± 10.7μM;##PBMC:CC50=46.43± 2.6 μM." "No predicted structure available" "DRAVPe00656.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 24 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2954.55" "C123H210N32O43" "ACDFGHMPRTVWY" "E" "4.94" "6" "8" "-2" "2" "5" "-176.25" "-8430" "20 hour" "30 min" ">10 hour" "81.25" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00657" "EQKIEELLKKAEEQQKKNEEELKKLEX" "27" "LP-62" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=15±1 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=5±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=12±1 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00657.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 27 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3323.98" "C139H237N37O48" "CDFGHMPRSTVWY" "E" "5" "7" "9" "-2" "1" "6" "-190" "-9699" "1 hour" "30 min" ">10 hour" "75.93" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00658" "QKIEELLKKAEEQQKKNEEELKKLEX" "26" "LP-63" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=17±5 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=6±2 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=13±2 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00658.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 26 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3194.86" "C134H230N36O45" "CDFGHMPRSTVWY" "E" "5.3" "7" "8" "-1" "1" "6" "-183.85" "-9018" "0.8 hour" "10 min" ">10 hour" "78.85" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00659" "KIEELLKKAEEQQKKNEEELKKLEX" "25" "LP-64" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=128±27 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=36±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=25±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.04 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.08-140.75 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.23-0.75 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.10-0.11 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=58 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00659.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 25 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3066.73" "C129H222N34O43" "CDFGHMPRSTVWY" "E" "5.3" "7" "8" "-1" "1" "6" "-177.2" "-8464" "1.3 hour" "3 min" "2 min" "82" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00660" "IEELLKKAEEQQKKNEEELKKLEX" "24" "LP-65" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=8±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=7±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.15-88.63 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.23-0.75 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.07-0.04 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=35 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=256.23 ±14.58 μM;##MT-4 cell:CC50=213.4±59.59 μM;##HEK293T cell:CC50=208.43± 22.9μM;##PBMC:CC50=49.95± 2.97 μM." "No predicted structure available" "DRAVPe00660.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 24 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2938.56" "C123H210N32O42" "CDFGHMPRSTVWY" "E" "4.94" "6" "8" "-2" "1" "6" "-168.33" "-7909" "20 hour" "30 min" ">10 hour" "85.42" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00661" "EELLKKAEEQQKKNEEELKKLEX" "23" "LP-66" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=1008±248 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=434±71 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1109±193 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00661.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 23 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2825.4" "C117H199N31O41" "CDFGHIMPRSTVWY" "E" "4.94" "6" "8" "-2" "1" "5" "-195.22" "-8401" "1 hour" "30 min" ">10 hour" "72.17" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00662" "LLEQAEEQQKKNEEELKKLEX" "21" "LP-67" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=3417±419 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=627±154 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1527±565 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00662.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 21 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2568.06" "C105H176N28O38" "CDFGHIMPRSTVWY" "E" "4.6" "4" "7" "-3" "1" "5" "-176.67" "-7164" "5.5 hour" "3 min" "2 min" "79.05" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00663" "AEEQQKKNEEELKKLEX" "17" "LP-68" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>250000 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>250000 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>250000 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00663.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 17 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2084.5" "C83H139N23O31" "CDFGHIMPRSTVWY" "E" "4.77" "4" "6" "-2" "1" "3" "-221.76" "-6913" "4.4 hour" ">20 hour" ">10 hour" "51.76" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00664" "IEELLKKAEEQQKKNEEELKX" "21" "LP-69" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=239±16 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=125±27 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=157±29 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.31 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=2.01-1815.67 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=9.83-152.28 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.56-11.91 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=1391 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00664.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 21 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2568.11" "C106H180N28O37" "CDFGHMPRSTVWY" "E" "4.86" "5" "7" "-2" "1" "5" "-175.24" "-7165" "20 hour" "30 min" ">10 hour" "79.05" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00665" "INNYTSLIEELIKKSEEQQKKNEEELKKLEX" "31" "LP-70" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=25±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=21±4 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=30±10 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00665.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 31 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3760.44" "C159H265N41O55" "ACDFGHMPRVW" "E" "4.94" "6" "8" "-2" "7" "7" "-141.29" "-9385" "20 hour" "30 min" ">10 hour" "88.06" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00666" "IEEYTKKIEEILKKSEEQQKKNEEELKKLEX" "31" "LP-71" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=27±2 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=25±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=55±5 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00666.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 31 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3846.57" "C164H275N41O56" "ACDFGHMPRVW" "E" "5.06" "8" "10" "-2" "4" "6" "-176.13" "-10681" "20 hour" "30 min" ">10 hour" "75.48" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00667" "VRYLEANIEELLKKAEEQQKKNEEELKKLEX" "31" "LP-72" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=23±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=28±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=24±9 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00667.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 31 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3784.51" "C161H269N43O53" "CDFGHMPSTW" "E" "5" "7" "9" "-2" "3" "9" "-140" "-9683" "100 hour" ">20 hour" ">10 hour" "91.29" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00668" "VEELEKKIEELLKKAEEQQKKNEEELKKLEX" "31" "LP-73" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=33±6 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=19±3 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=42±2 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00668.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 31 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3794.54" "C161H275N41O55" "CDFGHMPRSTWY" "E" "4.88" "8" "11" "-3" "1" "8" "-163.55" "-10166" "100 hour" ">20 hour" ">10 hour" "88.06" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00669" "WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX" "38" "LP-74" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=110±10 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=59±11 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=59±32 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00669.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 38 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4862.7" "C213H340N52O69" "ACDFGHMPRV" "E" "4.98" "10" "13" "-3" "4" "8" "-196.58" "-13368" "2.8 hour" "3 min" "2 min" "61.58" "12490" "337.57" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00670" "EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEX" "41" "LP-75" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=100±22 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=65±8 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=86±26 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00670.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 41 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "5224.11" "C227H363N55O75S" "ACDFGHPRV" "E" "4.85" "10" "14" "-4" "5" "8" "-187.8" "-14071" "1 hour" "30 min" ">10 hour" "57.07" "12490" "312.25" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00671" "WQEWEQKITALLEQAQIQQEKNEYELQKLDKX" "32" "LP-46" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=88±4 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=50±8 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=44±7 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00671.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 31 is Lys-C16(palmitic acid)." "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4000.66" "C174H269N45O55" "CFGHMPRSV" "Q" "4.55" "4" "7" "-3" "3" "10" "-137.81" "-8211" "2.8 hour" "3 min" "2 min" "79.38" "12490" "402.9" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00672" "WEQKITALLEQAQIQQEKNEYELQKLDKX" "29" "LP-48" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=83±9 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=47±6 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=37±4 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00672.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C16(palmitic acid)." "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3557.2" "C153H244N40O49" "CFGHMPRSV" "Q" "4.72" "4" "6" "-2" "3" "9" "-124.83" "-7209" "2.8 hour" "3 min" "2 min" "87.59" "6990" "249.64" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00673" "WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLX" "35" "C34-C16" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=247±28 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=65±25 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=109±13 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00673.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 35 is Lys-C16(palmitic acid)." "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4359.93" "C184H278N50O63S" "ACFGPV" "E" "4.21" "3" "8" "-5" "9" "9" "-123.43" "-10170" "2.8 hour" "3 min" "2 min" "78" "12490" "367.35" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00674" "WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLGSGX" "38" "C34-Chol" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=316±62 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24±2 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=37±5 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00674.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 38 is Cys-Chol(cholesterol)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4561.12" "C191H289N53O67S" "ACFPV" "E" "4.21" "3" "8" "-5" "12" "9" "-117.89" "-10322" "2.8 hour" "3 min" "2 min" "71.84" "12490" "337.57" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00675" "YTSLIHSLIEESQNQQEKNEQELLELDK" "28" "P-40" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>2000 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>2000 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>2000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00675" "DRAVPe00675.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3359.65" "C144H232N38O54" "ACFGMPRVW" "E" "4.3" "3" "7" "-4" "7" "7" "-117.5" "-7925" "2.8 hour" "10 min" "2 min" "97.5" "1490" "55.19" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "DRAVPa0419" "Anti-HIV" "DRAVPe00676" "YTSLIEELIKKSEEQQKKNEEELKKLEK" "28" "P-50" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=35.6±1.3 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=191.1±57.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=21.8±3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00676" "DRAVPe00676.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3435.92" "C151H256N38O52" "ACDFGHMPRVW" "E" "5.3" "7" "8" "-1" "5" "6" "-161.43" "-9104" "2.8 hour" "10 min" "2 min" "83.57" "1490" "55.19" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00677" "LEANIEELLKKAEEQQKKNEEELKKLEK" "28" "P-51" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=10.2±0.7 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24.9±2.9 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=45.4±10.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00677" "DRAVPe00677.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3382.86" "C147H253N39O51" "CDFGHMPRSTVWY" "E" "5" "7" "9" "-2" "2" "8" "-163.21" "-9136" "5.5 hour" "3 min" "2 min" "90.71" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00678" "WEQKIEELLKKAEEQQKKNEEELKKLEK" "28" "P-52" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.9±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=1.9±0.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1.9±0.4 nM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=20541 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=916.6 ±42.46 μM;##MT-4 cell:CC50=770.63±131.46 μM;##HEK293T cell:CC50=649.07± 37.03μM;##PBMC:CC50=91.19± 20.46 μM." "DRAVPe00678" "DRAVPe00678.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3527.03" "C156H261N41O51" "CDFGHMPRSTVY" "E" "5.36" "8" "9" "-1" "1" "7" "-200.36" "-10021" "2.8 hour" "3 min" "2 min" "73.21" "5500" "203.7" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00679" "YTSLIEELIKKSEEQQKKNEEELKK" "25" "P-54" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00679" "DRAVPe00679.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3065.47" "C134H226N34O47" "ACDFGHMPRVW" "E" "5.24" "6" "7" "-1" "5" "5" "-166.4" "-8360" "2.8 hour" "10 min" "2 min" "78" "1490" "62.08" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00680" "WEQKIEELLKKAEEQQKKNEEELKK" "25" "P-55" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=14.2±1.8 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=16.9±2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=32.3±9.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00680" "DRAVPe00680.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3156.58" "C139H231N37O46" "CDFGHMPRSTVY" "E" "5.3" "7" "8" "-1" "1" "6" "-210" "-9277" "2.8 hour" "3 min" "2 min" "66.4" "5500" "229.17" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00681" "WEQKIEELLKKAEEQQKKNEEEK" "23" "P-57" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00681" "DRAVPe00681.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2915.25" "C127H208N34O44" "CDFGHMPRSTVY" "E" "4.94" "6" "8" "-2" "1" "5" "-227.83" "-9214" "2.8 hour" "3 min" "2 min" "55.22" "5500" "250" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00682" "WEQKIEELLKKAEEQQKKNEK" "21" "P-58" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00682" "DRAVPe00682.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2657.02" "C117H194N32O38" "CDFGHMPRSTVY" "EK" "6.38" "6" "6" "0" "1" "5" "-216.19" "-7852" "2.8 hour" "3 min" "2 min" "60.48" "5500" "275" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00683" "WEQKIEELLKKAEEQQKK" "18" "P-59" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00683" "DRAVPe00683.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2285.63" "C102H169N27O32" "CDFGHMNPRSTVY" "EK" "6.34" "5" "5" "0" "0" "5" "-191.67" "-5952" "2.8 hour" "3 min" "2 min" "70.56" "5500" "323.53" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00684" "SLIEELIKKSEEQQKKNEEELKKLEK" "26" "P-60" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=591.4±65.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00684" "DRAVPe00684.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3171.64" "C138H240N36O48" "ACDFGHMPRTVWY" "E" "5.29" "7" "8" "-1" "3" "6" "-166.15" "-8833" "1.9 hour" ">20 hour" ">10 hour" "90" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00685" "EQKIEELLKKAEEQQKKNEEELKKLEK" "27" "P-62" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=25.3±2.6 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=44.2±2.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=22.1±3.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00685" "DRAVPe00685.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3340.82" "C145H251N39O50" "CDFGHMPRSTVWY" "E" "5.36" "8" "9" "-1" "1" "6" "-204.44" "-10254" "1 hour" "30 min" ">10 hour" "75.93" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00686" "QKIEELLKKAEEQQKKNEEELKKLEK" "26" "P-63" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=16.1±2.5 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=24±2.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=24.4±2.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00686" "DRAVPe00686.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3211.7" "C140H244N38O47" "CDFGHMPRSTVWY" "EK" "6.44" "8" "8" "0" "1" "6" "-198.85" "-9573" "0.8 hour" "10 min" ">10 hour" "78.85" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00687" "KIEELLKKAEEQQKKNEEELKKLEK" "25" "P-64" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=7.6±1.3 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.3±0.6 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=10.4±2.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00687" "DRAVPe00687.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3083.57" "C135H236N36O45" "CDFGHMPRSTVWY" "EK" "6.44" "8" "8" "0" "1" "6" "-192.8" "-9019" "1.3 hour" "3 min" "2 min" "82" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00688" "IEELLKKAEEQQKKNEEELKKLEK" "24" "P-65" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=17.9±2.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=25.7±1.3 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=25.8±1.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00688" "DRAVPe00688.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2955.4" "C129H224N34O44" "CDFGHMPRSTVWY" "E" "5.3" "7" "8" "-1" "1" "6" "-184.58" "-8464" "20 hour" "30 min" ">10 hour" "85.42" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00689" "IEELLKKAEEQQKKNEEELKK" "21" "P-69" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>7508 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50>750 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00689" "DRAVPe00689.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "2584.95" "C112H194N30O39" "CDFGHMPRSTVWY" "E" "5.24" "6" "7" "-1" "1" "5" "-193.81" "-7720" "20 hour" "30 min" ">10 hour" "79.05" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00690" "INNYTSLIEELIKKSEEQQKKNEEELKKLEK" "31" "P-70" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=8.5±0.5 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=36.5±6.4 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=49.7±5.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00690" "DRAVPe00690.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3777.28" "C165H279N43O57" "ACDFGHMPRVW" "E" "5.3" "7" "8" "-1" "7" "7" "-153.87" "-9940" "20 hour" "30 min" ">10 hour" "88.06" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00691" "IEEYTKKIEEILKKSEEQQKKNEEELKKLEK" "31" "P-71" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2.1±0.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.1±3.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=38.7±7.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00691" "DRAVPe00691.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3863.42" "C170H289N43O58" "ACDFGHMPRVW" "E" "5.41" "9" "10" "-1" "4" "6" "-188.71" "-11236" "20 hour" "30 min" ">10 hour" "75.48" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00692" "VRYLEANIEELLKKAEEQQKKNEEELKKLEK" "31" "P-72" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=4.1±0.9 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=16.2±3.4 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=15.9±1.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00692" "DRAVPe00692.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3801.35" "C167H283N45O55" "CDFGHMPSTW" "E" "5.36" "8" "9" "-1" "3" "9" "-152.58" "-10238" "100 hour" ">20 hour" ">10 hour" "91.29" "1490" "49.67" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00693" "VEELEKKIEELLKKAEEQQKKNEEELKKLEK" "31" "P-73" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=2±0.2 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=5.6±0.7 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=8.2±1.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00693" "DRAVPe00693.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3811.39" "C167H289N43O57" "CDFGHMPRSTWY" "E" "5.11" "9" "11" "-2" "1" "8" "-176.13" "-10721" "100 hour" ">20 hour" ">10 hour" "88.06" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00694" "WEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK" "38" "P-74" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.4±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=0.8±0.1 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=1.4±0.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00694" "DRAVPe00694.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "4879.54" "C219H354N54O71" "ACDFGHMPRV" "E" "5.19" "11" "13" "-2" "4" "8" "-206.84" "-13923" "2.8 hour" "3 min" "2 min" "61.58" "12490" "337.57" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00695" "EMTWEEWEKKIEEYTKKIEEILKKSEEQQKKNEEELKKLEK" "41" "P-75" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=0.4±0.1 nM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=0.9±0.2 nM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=0.6±0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00695" "DRAVPe00695.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "5240.95" "C233H377N57O77S" "ACDFGHPRV" "E" "5.02" "11" "14" "-3" "5" "8" "-197.32" "-14626" "1 hour" "30 min" ">10 hour" "57.07" "12490" "312.25" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00696" "ILPWKWPWWPWRR" "13" "Indolicidin (Cathelicidin-4)" "Bos taurus (Bovine)" "P33046##A3KN14" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "1G8C##1G89" "HSV,HIV" "Herpesviridae, Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=28.68 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=5.00 μM).##[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=60 µM);inhibition of strand transfer catalyzed by integrase(IC50=57 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15081088]Vero cells:CC50>100 μM." "DRAVPe00696" "DRAVPe00696.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1907.3" "C100H131N25O14" "ACDEFGHMNQSTVY" "W" "12.01" "3" "0" "3" "0" "7" "-106.92" "-1390" "20 hour" "30 min" ">10 hour" "60" "27500" "2291.67" "15081088##15482931" " Int J Antimicrob Agents. 2004 Apr;23(4):382-9.##Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Albiol Matanic VC, Castilla V.##Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus.##Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.ijantimicag.2003.07.022##10.1016/j.bmcl.2004.08.061" "Anti-HSV,Anti-HIV" "DRAVPe00697" "ILPWKWPWWPWPP" "13" "Indolicidin [R12P][R13P]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=16 µM);inhibition of strand transfer catalyzed by integrase(IC50=13 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00697" "DRAVPe00697.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1789.16" "C98H121N19O14" "ACDEFGHMNQRSTVY" "PW" "8.75" "1" "0" "1" "0" "7" "-62.31" "1594" "20 hour" "30 min" ">10 hour" "60" "27500" "2291.67" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00698" "LPWKWPWWPWPP" "12" "Indolicidin (2-13)[R12P][R13P]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=185 µM);inhibition of strand transfer catalyzed by integrase(IC50=215 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00698" "DRAVPe00698.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1676" "C92H110N18O13" "ACDEFGHIMNQRSTVY" "PW" "8.75" "1" "0" "1" "0" "6" "-105" "1102" "5.5 hour" "3 min" "2 min" "32.5" "27500" "2500" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00699" "ILPWKWPWWPWP" "12" "Indolicidin (1-12)[R12P]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=180 µM);inhibition of strand transfer catalyzed by integrase(IC50=80 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00699" "DRAVPe00699.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1692.04" "C93H114N18O13" "ACDEFGHMNQRSTVY" "W" "8.75" "1" "0" "1" "0" "7" "-54.17" "1594" "20 hour" "30 min" ">10 hour" "65" "27500" "2500" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00700" "ILPWGWPWWPWPP" "13" "Indolicidin [K5G;R12P;R13P]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00700" "DRAVPe00700.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1718.04" "C94H112N18O14" "ACDEFHKMNQRSTVY" "PW" "5.52" "0" "0" "0" "1" "7" "-35.38" "2243" "20 hour" "30 min" ">10 hour" "60" "27500" "2291.67" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00701" "ILPWGWPWWPWRR" "13" "Indolicidin [K5G]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=49 µM);inhibition of strand transfer catalyzed by integrase(IC50=19 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00701" "DRAVPe00701.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1836.18" "C96H122N24O14" "ACDEFHKMNQSTVY" "W" "12" "2" "0" "2" "1" "7" "-80" "-741" "20 hour" "30 min" ">10 hour" "60" "27500" "2291.67" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00702" "ILAWKWAWWAWPP" "13" "Indolicidin [P3,7,10A,R12,13P]" "Synthetic construct(derived from Indolicidin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 integrase inhibition assay" "[Ref.15482931]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=54 µM);inhibition of strand transfer catalyzed by integrase(IC50=41 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00702" "DRAVPe00702.cif" "Linear" "Free" "Amidtion" "None" "L" "HIV Integrase" "The HIV-1 integrase plays a crucial role in the HIV-1 virus replication cycle. The peptide can inhibit the activity of integrase and thus inhibit virus replication." "1711.04" "C92H115N19O14" "CDEFGHMNQRSTVY" "W" "8.75" "1" "0" "1" "0" "10" "16.15" "2137" "20 hour" "30 min" ">10 hour" "83.08" "27500" "2291.67" "15482931" "Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8." "Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP. " "Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin." "10.1016/j.bmcl.2004.08.061" "Anti-HIV" "DRAVPe00703" "LLEYSI" "6" "peptide 1 from hydrolysate of oyster" "Crassostrea gigas(hydrolysate of oyster)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=20 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00703" "DRAVPe00703.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "736.86" "C35H56N6O11" "ACDFGHKMNPQRTVW" "L" "4" "0" "1" "-1" "2" "3" "108.33" "441" "5.5 hour" "3 min" "2 min" "195" "1490" "298" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00704" "LLEYSL" "6" "peptide 2 from hydrolysate of oyster" "Crassostrea gigas(hydrolysate of oyster)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=15 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00704" "DRAVPe00704.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "736.86" "C35H56N6O11" "ACDFGHIKMNPQRTVW" "L" "4" "0" "1" "-1" "2" "3" "96.67" "441" "5.5 hour" "3 min" "2 min" "195" "1490" "298" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00705" "LLEYS" "5" "peptide derived from hydrolysate of oyster" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=120 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00705" "DRAVPe00705.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "623.7" "C29H45N5O10" "ACDFGHIKMNPQRTVW" "L" "4" "0" "1" "-1" "2" "2" "40" "-51" "5.5 hour" "3 min" "2 min" "156" "1490" "372.5" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00706" "LEYSI" "5" "peptide derived from hydrolysate of oyster" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=550 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00706" "DRAVPe00706.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "623.7" "C29H45N5O10" "ACDFGHKMNPQRTVW" "EILSY" "4" "0" "1" "-1" "2" "2" "54" "-51" "5.5 hour" "3 min" "2 min" "156" "1490" "372.5" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00707" "LLEY" "4" "peptide derived from hydrolysate of oyster" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=5100 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00707" "DRAVPe00707.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "536.63" "C26H40N4O8" "ACDFGHIKMNPQRSTVW" "L" "4" "0" "1" "-1" "1" "2" "70" "289" "5.5 hour" "3 min" "2 min" "195" "1490" "496.67" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00708" "LEYS" "4" "peptide derived from hydrolysate of oyster" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1 protease inhibition assay" "[Ref.9918775]HIV-1:inhibition of HIV-1 protease(IC50=4800 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00708" "DRAVPe00708.cif" "Linear" "Free" "Free" "None" "L" "HIV-1 protease" "The HIV-1 protease is a virally encoded protease that serves to cleave the gag and gag-pol polyprotein precursor into mature, functional proteins. This specific proteolysis occurs late in the viral life cycle and is essential for the maturation of the infectious virus. The peptide inhibits HIV-1 protease and thus acts antiviral activity." "510.54" "C23H34N4O9" "ACDFGHIKMNPQRTVW" "ELSY" "4" "0" "1" "-1" "2" "1" "-45" "-543" "5.5 hour" "3 min" "2 min" "97.5" "1490" "496.67" "9918775" "Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8." "Lee TG, Maruyama S. " "Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins." "10.1006/bbrc.1998.9824" "Anti-HIV" "DRAVPe00709" "FVFLM" "5" "FM5" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00709" "DRAVPe00709.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "655.85" "C34H49N5O6S" "ACDEGHIKNPQRSTWY" "F" "5.52" "0" "0" "0" "0" "4" "310" "1727" "1.1 hour" "3 min" "2 min" "136" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00710" "PFVFLM" "6" "PM6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00710" "DRAVPe00710.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "752.97" "C39H56N6O7S" "ACDEGHIKNQRSTWY" "F" "5.96" "0" "0" "0" "0" "4" "231.67" "1727" ">20 hour" ">20 hour" "?" "113.33" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00711" "KPFVFLM" "7" "KM7" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00711" "DRAVPe00711.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "881.14" "C45H68N8O8S" "ACDEGHINQRSTWY" "F" "8.75" "1" "0" "1" "0" "4" "142.86" "1172" "1.3 hour" "3 min" "2 min" "97.14" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00712" "NKPFVFLM" "8" "NM8" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00712" "DRAVPe00712.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "995.25" "C49H74N10O10S" "ACDEGHIQRSTWY" "F" "8.75" "1" "0" "1" "1" "4" "81.25" "508" "1.4 hour" "3 min" ">10 hour" "85" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00713" "PFVYLI" "6" "PI6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00713" "DRAVPe00713.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "750.94" "C40H58N6O8" "ACDEGHKMNQRSTW" "FILPVY" "5.95" "0" "0" "0" "1" "4" "206.67" "1672" ">20 hour" ">20 hour" "?" "178.33" "1490" "298" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00714" "PFVFLE" "6" "PE6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00714" "DRAVPe00714.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "750.89" "C39H54N6O9" "ACDGHIKMNQRSTWY" "F" "4" "0" "1" "-1" "0" "4" "141.67" "811" ">20 hour" ">20 hour" "?" "113.33" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00715" "EFVFLM" "6" "EM6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00715" "DRAVPe00715.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "784.97" "C39H56N6O9S" "ACDGHIKNPQRSTWY" "F" "4" "0" "1" "-1" "0" "4" "200" "1046" "1 hour" "30 min" ">10 hour" "113.33" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00716" "PEVFLM" "6" "PEM6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00716" "DRAVPe00716.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "734.91" "C35H54N6O9S" "ACDGHIKNQRSTWY" "EFLMPV" "4" "0" "1" "-1" "0" "3" "126.67" "748" ">20 hour" ">20 hour" "?" "113.33" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00717" "PFVFLR" "6" "PR6" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00717" "DRAVPe00717.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "777.96" "C40H59N9O7" "ACDEGHIKMNQSTWY" "F" "10.18" "1" "0" "1" "0" "4" "125" "0" ">20 hour" ">20 hour" "?" "113.33" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00718" "CPFVFLM" "7" "CPM" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=8.96 ± 2.23 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells between H9/HIV-1IIIB cells and MT-2 cells(IC50=67.20 ± 4.05 μM);##HIV-1:inhibition of pseudovirus infection(IC50=5.95 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22406118]MT-2 cells:CC50>200 μM." "DRAVPe00718" "DRAVPe00718.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "None" "L" "Not found" "The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells." "856.11" "C42H61N7O8S2" "ADEGHIKNQRSTWY" "F" "5.52" "0" "0" "0" "1" "4" "234.29" "1855" "1.2 hour" ">20 hour" ">10 hour" "97.14" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00719" "CPFVFLE" "7" "CPE" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=55.84 ± 3.31μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50=115.58 ± 6.28 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22406118]MT-2 cells:CC50>200 μM." "DRAVPe00719" "DRAVPe00719.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "None" "L" "Not found" "The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells." "854.03" "C42H59N7O10S" "ADGHIKMNQRSTWY" "F" "4" "0" "1" "-1" "1" "4" "157.14" "939" "1.2 hour" ">20 hour" ">10 hour" "97.14" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00720" "CPFVFLR" "7" "CPR" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50=74.07± 22.84 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50=73.98 ± 7.44 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22406118]MT-2 cells:CC50>200 μM." "DRAVPe00720" "DRAVPe00720.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "None" "L" "Not found" "The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells." "881.1" "C43H64N10O8S" "ADEGHIKMNQSTWY" "F" "8.25" "1" "0" "1" "1" "4" "142.86" "128" "1.2 hour" ">20 hour" ">10 hour" "97.14" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00721" "CPEVFLM" "7" "CPEM" "Synthetic construct(derived from the C-terminal sequence of α1-antitrypsin)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.22406118]HIV-1 IIIB:inhibition of virus replication(IC50>100 μM);inhibition of cell-cell fusion between H9/HIV-1IIIB cells and MT-2 cells(IC50>200 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22406118]MT-2 cells:CC50>200 μM." "DRAVPe00721" "DRAVPe00721.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "None" "L" "Not found" "The cyclic peptide inhibited HIV-1 infection by blocking virus fusion with and entry into the target cells." "838.05" "C38H59N7O10S2" "ADGHIKNQRSTWY" "CEFLMPV" "4" "0" "1" "-1" "1" "3" "144.29" "876" "1.2 hour" ">20 hour" ">10 hour" "97.14" "0" "0" "22406118" "Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. " "Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K." "Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity." "10.1016/j.bmcl.2012.02.037" "Anti-HIV" "DRAVPe00722" "IWNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNV" "35" "T1562(FIV envelope protein (724-758))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.318 μM,EC90=1.236 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00722" "DRAVPe00722.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4296.78" "C194H288N50O59S" "ACPRS" "IN" "4.5" "3" "5" "-2" "11" "11" "-78.86" "-6406" "20 hour" "30 min" ">10 hour" "86.29" "13980" "411.18" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00723" "WNHGNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQ" "35" "T1568(FIV envelope protein (725-759))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.259 μM,EC90=0.971 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00723" "DRAVPe00723.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4311.75" "C193H285N51O60S" "ACPRS" "NQ" "4.5" "3" "5" "-2" "11" "10" "-101.71" "-7452" "2.8 hour" "3 min" "2 min" "75.14" "13980" "411.18" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00724" "GNITLGEWYNQTKDLQQKFYEIIMDIEQNNVQG" "33" "T1967(FIV envelope protein (728-760))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=2.454 μM,EC90>2.518 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50=2.053 μM,EC90>2.518 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00724" "DRAVPe00724.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3931.35" "C174H265N45O57S" "ACHPRS" "Q" "4.18" "2" "5" "-3" "11" "9" "-86.06" "-6461" "30 hour" ">20 hour" ">10 hour" "79.7" "8480" "265" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00725" "NITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGK" "33" "T1968(FIV envelope protein (729-761))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.586 μM,EC90=2.067 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.473 μM,EC90>2.473 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00725" "DRAVPe00725.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4002.47" "C178H274N46O57S" "ACHPRS" "Q" "4.51" "3" "5" "-2" "10" "9" "-96.67" "-7110" "1.4 hour" "3 min" ">10 hour" "79.7" "8480" "265" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00726" "ITLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGI" "35" "T1569(FIV envelope protein (730-764))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.026 μM,EC90=0.117 μM);inhibition of virus infection in FCD4-E cells(EC50=0.055 μM,EC90=0.106 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.356 μM,EC90>2.356 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00726" "DRAVPe00726.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4186.75" "C188H294N48O58S" "ACHPRS" "IQ" "4.94" "4" "5" "-1" "10" "10" "-80.57" "-6415" "20 hour" "30 min" ">10 hour" "86.29" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00727" "TLGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKG" "33" "T1969(FIV envelope protein (731-763))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.435 μM,EC90=1.413 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00727" "DRAVPe00727.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3960.43" "C176H272N46O56S" "ACHPRS" "Q" "4.93" "4" "5" "-1" "10" "8" "-112.73" "-7399" "7.2 hour" ">20 hour" ">10 hour" "67.88" "8480" "265" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00728" "LGEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQ" "35" "T1577(FIV envelope protein (732-766))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.050 μM,EC90=0.162 μM);inhibition of virus infection in FCD4-E cells(EC50=0.098 μM,EC90=0.177 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50=1.933 μM,EC90>2.342 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00728" "DRAVPe00728.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4228.75" "C188H292N50O59S" "ACHPRS" "Q" "4.94" "4" "5" "-1" "9" "9" "-111.43" "-7758" "5.5 hour" "3 min" "2 min" "75.14" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00729" "GEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQL" "35" "T1971(FIV envelope protein (733-767))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.012 μM,EC90=0.033 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.342 μM,EC90>2.342 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12186891]No cytotoxic effects against HeLa cells at the concentration of 23 μM." "DRAVPe00729" "DRAVPe00729.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4228.75" "C188H292N50O59S" "ACHPRS" "Q" "4.94" "4" "5" "-1" "9" "9" "-111.43" "-7758" "30 hour" ">20 hour" ">10 hour" "75.14" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00730" "EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ" "35" "T1972(FIV envelope protein (734-768))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.012 μM,EC90=0.054 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.304 μM,EC90>2.304 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12186891]No cytotoxic effects against HeLa cells at the concentration of 23 μM." "DRAVPe00730" "DRAVPe00730.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4299.82" "C191H297N51O60S" "ACHPRS" "Q" "4.94" "4" "5" "-1" "8" "9" "-120.29" "-8406" "1 hour" "30 min" ">10 hour" "75.14" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00731" "WYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQK" "35" "T1578(FIV envelope protein (735-769))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.020 μM,EC90=0.090 μM);inhibition of virus infection in FCD4-E cells(EC50=0.053 μM,EC90=0.157 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00731" "DRAVPe00731.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4298.88" "C192H302N52O58S" "ACHPRS" "Q" "8.3" "5" "4" "1" "8" "9" "-121.43" "-8280" "2.8 hour" "3 min" "2 min" "75.14" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00732" "YNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKW" "35" "T1588(FIV envelope protein (736-770))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=0.030 μM,EC90=0.125 μM);inhibition of virus infection in FCD4-E cells(EC50=0.168 μM,EC90=0.4236 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00732" "DRAVPe00732.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4298.88" "C192H302N52O58S" "ACHPRS" "Q" "8.3" "5" "4" "1" "8" "9" "-121.43" "-8280" "2.8 hour" "10 min" "2 min" "75.14" "8480" "249.41" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00733" "NQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWE" "35" "T1988(FIV envelope protein (737-771))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=1.990 μM,EC90>2.322 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.322 μM,EC90>2.322 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00733" "DRAVPe00733.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4264.82" "C188H300N52O59S" "ACHPRS" "Q" "6.28" "5" "5" "0" "7" "9" "-127.71" "-8947" "1.4 hour" "3 min" ">10 hour" "75.14" "6990" "205.59" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00734" "QTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWED" "35" "T1989(FIV envelope protein (738-772))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50>2.321 μM,EC90>2.321 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00734" "DRAVPe00734.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4265.81" "C188H299N51O60S" "ACHPRS" "Q" "5" "5" "6" "-1" "6" "9" "-127.71" "-9155" "0.8 hour" "10 min" ">10 hour" "75.14" "6990" "205.59" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00735" "TKDLQQKFYEIIMDIEQNNVQGKKGIQQLQKWEDW" "35" "T1589(FIV envelope protein (739-773))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV,HIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50=1.145 μM,EC90>2.290 μM);##HIV-1:inhibition of cell-cell fusion between CEM4/IIIb cells and MOLT4 cells(EC50>2.321 μM,EC90>2.321 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00735" "DRAVPe00735.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4323.89" "C194H301N51O59S" "ACHPRS" "Q" "4.99" "5" "6" "-1" "6" "10" "-120.29" "-8368" "7.2 hour" ">20 hour" ">10 hour" "75.14" "12490" "367.35" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV,Anti-HIV" "DRAVPe00736" "FYEIIMDIEQNNVQGKKGIQQLQKWEDWVGWIGNI" "35" "T1566(FIV envelope protein (746-780))" "Synthetic construct(derived from FIV envelope protein)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "plaque-forming assay,RT infectivity assay" "[Ref.12186891]Feline immunodeficiency virus (FIV):inhibition of cell-cell fusion between FIV/CrFK cells and HeLa cells(EC50>2.346 μM,EC90>2.346 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00736" "DRAVPe00736.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4221.8" "C194H291N49O55S" "ACHPRST" "I" "4.51" "3" "5" "-2" "8" "13" "-54" "-4368" "1.1 hour" "3 min" "2 min" "94.57" "17990" "529.12" "12186891" "J Virol. 2002 Sep;76(18):9079-86." "Medinas RJ, Lambert DM, Tompkins WA." "C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. " "10.1128/jvi.76.18.9079-9086.2002" "Anti-FIV" "DRAVPe00737" "XTWXEWDREINNYTSLIHSLIEESQNQQEKNEQELLE" "37" "T649v" "Synthetic construct" "P04582" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "luciferase assay" "[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.9±0.4 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50>3000 nM);##HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=15.8±1.9 nM);##HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=44.4±6.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00737.cif" "Cyclic" "Free" "Free" "The 'X' at position 1 indicates Norleucine." "L" "Not found" "The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein." "4570.29" "C188H281N51O66" "ACFGMPV" "E" "4.14" "3" "9" "-6" "10" "9" "-133.24" "-11343" "73.78" "12490" "346.94" "20660316" "Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8." "Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. " "Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic." "10.1073/pnas.1002713107" "Anti-HIV" "DRAVPe00738" "XTWXEWDXEINNYTSLIHSLIEESQNQQEKNEQELLE" "37" "SAH-gp41(626-662)A" "Synthetic construct" "P04582" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "luciferase assay" "[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.1±0.3 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=339±162 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00738.cif" "Cyclic" "Free" "Free" "The 'X' at position 1 indicates Norleucine,the 'X' at position 4,8 indicates S-2-(4'-pentenyl) alanine. X(4) and X (5) are cross-linked by hydrocarbon stapling." "L" "Not found" "The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein." "4525.44" "C182H267N47O64" "ACFGMPRV" "E" "3.93" "2" "9" "-7" "10" "9" "-121.08" "-9851" "73.78" "12490" "346.94" "20660316" "Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8." "Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. " "Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic." "10.1073/pnas.1002713107" "Anti-HIV" "DRAVPe00739" "XTWMEWDREINNYTSLIHSLIEESQNQXEKNXQELLE" "37" "SAH-gp41(626-662) B" "Synthetic construct" "P04582" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "luciferase assay" "[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=4.5±1.4 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=1958±259 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00739.cif" "Cyclic" "Free" "Free" "The 'X' at position 1 indicates Norleucine,the 'X' at position 28,32 indicates S-2-(4'-pentenyl) alanine. X(28) and X (32) are cross-linked by hydrocarbon stapling." "L" "Not found" "The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein." "4555.57" "C183H273N49O61S" "ACFGPV" "E" "4.21" "3" "8" "-5" "10" "9" "-109.19" "-9873" "73.78" "12490" "346.94" "20660316" "Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8." "Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. " "Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic." "10.1073/pnas.1002713107" "Anti-HIV" "DRAVPe00740" "XTWXEWDXEINNYTSLIHSLIEESQNQXEKNXQELLE" "37" "SAH-gp41(626-662) A,B" "Synthetic construct" "P04582" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "luciferase assay" "[Ref.20660316]HIV-1 HxB2:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=2.5±0.2 nM);##HIV-1 YU2:inhibition of virus infection in Cf2Th-CD4-CCR5 cells(IC50=87±30 nM);##HIV-1 V38A/N42T:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=10.7±2.2 nM);##HIV-1 V38E/N42S:inhibition of virus infection in Cf2Th-CD4-CXCR4 cells(IC50=16.1±3.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00740.cif" "Cyclic" "Free" "Free" "The 'X' at position 1 indicates Norleucine,the 'X' at position 4,8.28,32 indicates S-2-(4'-pentenyl) alanine. X(4) and X (5), X(28) and X (32) are cross-linked by hydrocarbon stapling." "L" "Not found" "The peptide disrupts assembly of the six-helix bundle viral fusion apparatus by mimicking the heptad repeat 2 (HR2) oligomerization domain of the gp41 envelope glycoprotein." "4490.85" "C172H248N44O57" "ACFGMPRV" "E" "3.99" "2" "8" "-6" "10" "9" "-102.16" "-8616" "73.78" "12490" "346.94" "20660316" "Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14093-8." "Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. " "Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic." "10.1073/pnas.1002713107" "Anti-HIV" "DRAVPe00741" "AEEASKKAEEASKKAEEASKKAEEASKKAEEASKKXX" "37" "AAS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=4.47±1.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=2.38±0.9 μM." "No predicted structure available" "DRAVPe00741.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "3959.75" "C155H263N45O59" "CDFGHILMNPQRTVWY" "AEK" "6.53" "10" "10" "0" "5" "10" "-162.16" "-12250" "4.4 hour" ">20 hour" ">10 hour" "27.03" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00742" "VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXX" "37" "VVS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=74.5±6.8 μM." "No predicted structure available" "DRAVPe00742.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4240.29" "C175H303N45O59" "ACDFGHILMNPQRTWY" "EKV" "6.46" "10" "10" "0" "5" "10" "-97.3" "-10020" "100 hour" ">20 hour" ">10 hour" "78.38" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00743" "FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKKXX" "37" "FFS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=3.11±0.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM." "No predicted structure available" "DRAVPe00743.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4720.73" "C215H303N45O59" "ACDGHILMNPQRTVWY" "EFK" "6.49" "10" "10" "0" "5" "10" "-135.14" "-11080" "1.1 hour" "3 min" "2 min" "0" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00744" "YEEYSKKYEEYSKKYEEYSKKYEEYSKKYEEYSKKXX" "37" "YYS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=6.26±2.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=19.8±1.6 μM." "No predicted structure available" "DRAVPe00744.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4880.72" "C215H303N45O69" "ACDFGHILMNPQRTVW" "EKY" "6.48" "10" "10" "0" "15" "0" "-245.95" "-14200" "2.8 hour" "10 min" "2 min" "0" "14900" "413.89" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00745" "LEELSKKLEELSKKLEELSKKLEELSKKLEELSKKXX" "37" "LLS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.24±0.08 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=4.04±0.4 μM." "No predicted structure available" "DRAVPe00745.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4380.56" "C185H323N45O59" "ACDFGHIMNPQRTVWY" "EKL" "6.49" "10" "10" "0" "5" "10" "-108.11" "-9140" "5.5 hour" "3 min" "2 min" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00746" "IEEISKKIEEISKKIEEISKKIEEISKKIEEISKKXX" "37" "IIS" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV,H3N2,H1N1" "Coronaviridae, Orthomyxoviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.10±0.02 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=1.96±0.28 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=6.38±1.06 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=88.8±28 μM;##MDCK cell:CC50>100 μM." "No predicted structure available" "DRAVPe00746.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4380.56" "C185H323N45O59" "ACDFGHLMNPQRTVWY" "EIK" "6.49" "10" "10" "0" "5" "10" "-89.19" "-9140" "20 hour" "30 min" ">10 hour" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV,Anti-H3N2,Anti-H1N1" "DRAVPe00747" "IEEIYKKIEEIYKKIEEIYKKIEEIYKKIEEIYKKXX" "37" "IIY" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV,H3N2,H1N1" "Coronaviridae, Orthomyxoviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.52±0.4 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=3.15±1.79 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=12.9±5.55 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM;##MDCK cell:CC50>100 μM." "No predicted structure available" "DRAVPe00747.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4761.05" "C215H343N45O59" "ACDFGHLMNPQRSTVW" "EIK" "6.48" "10" "10" "0" "5" "10" "-95.95" "-7510" "20 hour" "30 min" ">10 hour" "105.41" "7450" "206.94" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV,Anti-H3N2,Anti-H1N1" "DRAVPe00748" "IEEIWKKIEEIWKKIEEIWKKIEEIWKKIEEIWKKXX" "37" "IIW" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=10.6±2.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM." "No predicted structure available" "DRAVPe00748.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4876.23" "C225H348N50O54" "ACDFGHLMNPQRSTVY" "EIK" "6.49" "10" "10" "0" "0" "15" "-90.54" "-6275" "20 hour" "30 min" ">10 hour" "105.41" "27500" "763.89" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00749" "IEEIHKKIEEIHKKIEEIHKKIEEIHKKIEEIHKKXX" "37" "IIH" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=1.68±0.47 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM." "No predicted structure available" "DRAVPe00749.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4630.87" "C200H333N55O54" "ACDFGLMNPQRSTVWY" "EIK" "7.16" "15" "10" "5" "0" "10" "-121.62" "-9770" "20 hour" "30 min" ">10 hour" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00750" "IEEIQKKIEEIQKKIEEIQKKIEEIQKKIEEIQKKXX" "37" "IIQ" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV,H3N2,H1N1,HIV,EboV" "Coronaviridae, Orthomyxoviridae, Filoviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.11±0.02 μM);inhibition of pseudovirus infection in Huh-7 cells(IC50=0.13±0.1 μM);##A/Puerto Rico/8/34 (H1N1):inhibition of virus infection in MDCK cells(EC50=1.73±0.81 μM);##A/Hong Kong/8/68 (H3N2):inhibition of virus infection in MDCK cells(EC50=0.70±0.09 μM);##HIV-1 inhibition of cell-cell fusion in TZM-bl cells(EC50=3.63 ±0.54 μM);##Ebola virus (EboV):inhibition of pseudovirus infection in TZM-bl cells(EC50=1.02 ± 0.54 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM;##MDCK cell:CC50>100 μM;##TZM-bl cell:CC50>100 μM." "No predicted structure available" "DRAVPe00750.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4585.82" "C195H338N50O59" "ACDFGHLMNPRSTVWY" "EIK" "6.49" "10" "10" "0" "0" "10" "-125.68" "-10210" "20 hour" "30 min" ">10 hour" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV,Anti-H3N2,Anti-H1N1,Anti-HIV,Anti-EBOV" "DRAVPe00751" "IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKKXX" "37" "IIK" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=0.45±0.13 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50=4.54±0.6 μM." "No predicted structure available" "DRAVPe00751.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4586.04" "C200H358N50O54" "ACDFGHLMNPQRSTVWY" "K" "9.56" "15" "10" "5" "0" "10" "-131.08" "-10215" "20 hour" "30 min" ">10 hour" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00752" "IEEIEKKIEEIEKKIEEIEKKIEEIEKKIEEIEKKXX" "37" "IIE" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MERS-CoV" "Coronaviridae" "MERS-CoV S Protein-Mediated Cell–Cell Fusion Assay" "[Ref.30192544]MERS-CoV:inhibition of cell-cell fusion between 293T / MERS / EGPF cells and Huh-7 cells(EC50=2.93±0.95 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30192544]Huh-7 cell:CC50>100 μM." "No predicted structure available" "DRAVPe00752.cif" "Linear" "Acetylation" "Amidation" "The 'X' at 36 indicates β-alanine,the 'X' at 37 indicates Lys-C16(palmitic acid)." "L" "membrane" "The peptide can interact with both MERS-CoV and IAV NHR trimeric coiled coils to prevent virus–cell membrane fusion." "4590.74" "C195H333N45O64" "ACDFGHLMNPQRSTVWY" "E" "4.76" "10" "15" "-5" "0" "10" "-125.68" "-10845" "20 hour" "30 min" ">10 hour" "105.41" "0" "0" "30192544" " J Med Chem. 2018 Oct 11;61(19):8734-8745." "Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K. " "De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. " "10.1021/acs.jmedchem.8b00890" "Anti-MERS-CoV" "DRAVPe00753" "LWGEIWNTVKGLI" "13" "Eval418" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Antiviral assays" "[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=2.48 μg/ml);inhibition of viral attachment in Vero cells(IC50=3.70 μg/ml);inhibition of viral entry in Vero cells(IC50=31.71 μg/ml)." "[Ref.29290802]the cell viability of erythrocytes was also more than 95% at concentrations of Eval418 of 10 μg/mL or less." "[Ref.29290802]Vero cell:CC50=68.50μg/mL; the cell viability of the peptide-treated Vero cells was greater than 95% after treatment with Eval418 at 10 μg/mL." "DRAVPe00753" "DRAVPe00753.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1528.81" "C74H113N17O18" "ACDFHMPQRSY" "GILW" "6" "1" "1" "0" "4" "7" "50.77" "869" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV" "DRAVPe00754" "LWGHIWNFVHGLI" "13" "Eval418-FH2" "Synthetic construct(derived from Eval418)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Antiviral assays" "[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=1.50 μg/ml);inhibition of viral attachment in Vero cells(IC50=1.43 μg/ml);inhibition of viral entry in Vero cells(IC50=8.63 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cell:CC50=27.60 μg/mL." "DRAVPe00754" "DRAVPe00754.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1591.88" "C80H110N20O15" "ACDEKMPQRSTY" "GHILW" "6.92" "2" "0" "2" "3" "8" "85.38" "1728" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV" "DRAVPe00755" "LWHHIWNFVHGLI" "13" "Eval418-FH3" "Synthetic construct(derived from Eval418)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Antiviral assays" "[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=1.01 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.86 μg/ml);inhibition of viral entry in Vero cells(IC50=4.23 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cell:CC50=26.83 μg/mL." "DRAVPe00755" "DRAVPe00755.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1671.97" "C84H114N22O15" "ACDEKMPQRSTY" "H" "7.02" "3" "0" "3" "2" "8" "63.85" "1168" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV" "DRAVPe00756" "LWHHIWNTVHHLI" "13" "Eval418-FH4" "Synthetic construct(derived from Eval418)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Antiviral assays" "[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=0.87 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.63 μg/ml);inhibition of viral entry in Vero cells(IC50=4.37 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cell:CC50=27.58 μg/mL." "DRAVPe00756" "DRAVPe00756.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1705.99" "C83H116N24O16" "ACDEFGKMPQRSY" "H" "7.1" "4" "0" "4" "2" "7" "15.38" "53" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV" "DRAVPe00757" "LWHHIWHTVHHLI" "13" "Eval418-FH5" "Synthetic construct(derived from Eval418)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Antiviral assays" "[Ref.29290802]HSV-1:inhibition of viral inactivation in Vero cells(IC50=0.86 μg/ml);inhibition of viral attachment in Vero cells(IC50=0.67 μg/ml);inhibition of viral entry in Vero cells(IC50=2.88 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cell:CC50=106.68 μg/mL." "DRAVPe00757" "DRAVPe00757.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1729.02" "C85H117N25O15" "ACDEFGKMNPQRSY" "H" "7.16" "5" "0" "5" "1" "7" "17.69" "251" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV" "DRAVPe00758" "WQCLTLTHRGFVLLTITVLR" "20" "IN-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.18201721]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=38 µM);inhibition of strand transfer catalyzed by integrase(IC50=12 µM).##[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(77% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(70% inhibition at 62.5μM);inhibition of intergration(63% inhibition at 62.5μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18201721]No cytotixic against HeLa cells and H9 T-lymphocyte cultured cells up to ~62.5 μM." "DRAVPe00758" "DRAVPe00758.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide can inhibit integrase and thus inhibit virus replication." "2370.88" "C110H180N30O26S" "ADEKMNPSY" "L" "10.35" "3" "0" "3" "6" "10" "87" "-519" "2.8 hour" "3 min" "2 min" "146" "5500" "289.47" "18201721##19850483" "J Mol Biol. 2008 Feb 29;376(4):971-82. ##Bioorg Med Chem. 2009 Nov 15;17(22):7635-42." "Armon-Omer A, Levin A, Hayouka Z, Butz K, Hoppe-Seyler F, Loya S, Hizi A, Friedler A, Loyter A. ##Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. " "Correlation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library.##Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds." "10.1016/j.jmb.2007.11.095##10.1016/j.bmc.2009.09.053" "Anti-HIV" "DRAVPe00759" "WQCLTLTHRG" "10" "IN(1-10)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(73% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(68% inhibition at 62.5μM);inhibition of intergration(64% inhibition at 62.5μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00759" "DRAVPe00759.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide can inhibit integrase and thus inhibit virus replication." "1214.41" "C53H83N17O14S" "ADEFIKMNPSVY" "LT" "8.26" "2" "0" "2" "4" "3" "-38" "-1587" "2.8 hour" "3 min" "2 min" "78" "5500" "611.11" "19850483" "Bioorg Med Chem. 2009 Nov 15;17(22):7635-42." "Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. " "Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds." "10.1016/j.bmc.2009.09.053" "Anti-HIV" "DRAVPe00760" "WFVLLTITVLR" "11" "IN(11-20)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(24% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(29% inhibition at 62.5μM);inhibition of intergration(23% inhibition at 62.5μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00760" "DRAVPe00760.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide can inhibit integrase and thus inhibit virus replication." "1360.71" "C68H109N15O14" "ACDEGHKMNPQSY" "L" "9.75" "1" "0" "1" "2" "8" "184.55" "1301" "2.8 hour" "3 min" "2 min" "194.55" "5500" "550" "19850483" "Bioorg Med Chem. 2009 Nov 15;17(22):7635-42." "Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. " "Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds." "10.1016/j.bmc.2009.09.053" "Anti-HIV" "DRAVPe00761" "WQSLTLTHRG" "10" "IN(1-10)[C3S]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.19850483]HIV-1:inhibition of integrase catalytic activity(62% inhibition at 62.5μM);inhibition of virus replication in TZM-bl cells(60% inhibition at 62.5μM);inhibition of intergration(51% inhibition at 62.5μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00761" "DRAVPe00761.cif" "Linear" "Free" "Free" "None" "L" "Integrase" "The peptide can inhibit integrase and thus inhibit virus replication." "1198.35" "C53H83N17O15" "ACDEFIKMNPVY" "LT" "9.76" "2" "0" "2" "4" "3" "-71" "-2055" "2.8 hour" "3 min" "2 min" "78" "5500" "611.11" "19850483" "Bioorg Med Chem. 2009 Nov 15;17(22):7635-42." "Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A. " "Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds." "10.1016/j.bmc.2009.09.053" "Anti-HIV" "DRAVPe00762" "VSGHGQHGVHG" "11" "Alloferon (3-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=500 µM);##HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells(IC50=117 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=38 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=250 µM);inhibition of virus replication in LLC-MK2 cells(IC50=93 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 165 µM." "DRAVPe00762" "DRAVPe00762.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1071.12" "C44H66N18O14" "ACDEFIKLMNPRTWY" "G" "7" "3" "0" "3" "5" "2" "-64.55" "-1108" "100 hour" ">20 hour" ">10 hour" "52.73" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9. " "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00763" "SGHGQHGVHG" "10" "Alloferon (4-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=186 µM);inhibition of virus replication in Hep-2 cells(IC50=310 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=173 µM);inhibition of virus replication in Hep-2 cells(IC50=450 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=210 µM);inhibition of virus replication in LLC-MK2 cells(IC50=180 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 420 µM." "DRAVPe00763" "DRAVPe00763.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "971.99" "C39H57N17O13" "ACDEFIKLMNPRTWY" "G" "6.78" "3" "0" "3" "5" "1" "-113" "-1512" "1.9 hour" ">20 hour" ">10 hour" "29" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9. " "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00764" "GHGQHGVHG" "9" "Alloferon (5-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Hep-2 cells(IC50=360 µM);##HHV-1 clinical strain:inhibition of virus replication in Hep-2 cells(IC50=290 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in LLC-MK2 cells(IC50=230 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 448 µM." "DRAVPe00764" "DRAVPe00764.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "884.91" "C36H52N16O11" "ACDEFIKLMNPRSTWY" "G" "7.02" "3" "0" "3" "4" "1" "-116.67" "-1172" "30 hour" ">20 hour" ">10 hour" "32.22" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00765" "HGQHGVHG" "8" "Alloferon (6-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=179 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=117 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=78 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=190 µM);inhibition of virus replication in LLC-MK2 cells(IC50=410 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 468 µM." "DRAVPe00765" "DRAVPe00765.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "827.86" "C34H49N15O10" "ACDEFIKLMNPRSTWY" "GH" "7.02" "3" "0" "3" "3" "1" "-126.25" "-1266" "3.5 hour" "10 min" ">10 hour" "36.25" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00766" "GQHGVHG" "7" "Alloferon (7-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=215 µM);inhibition of virus replication in HEp-2 cells(IC50=840 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=168 µM);inhibition of virus replication in Vero cells(IC50=280 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);inhibition of virus replication in LLC-MK2 cells(IC50=190 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=870 µM);inhibition of virus replication in LLC-MK2 cells(IC50=170 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 775 µM." "DRAVPe00766" "DRAVPe00766.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "690.72" "C28H42N12O9" "ACDEFIKLMNPRSTWY" "G" "6.92" "2" "0" "2" "3" "1" "-98.57" "-800" "30 hour" ">20 hour" ">10 hour" "41.43" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00767" "QHGVHG" "6" "Alloferon (8-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=1300 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=950 µM);inhibition of virus replication in Hep-2 cells(IC50=280 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=170 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=500 µM);inhibition of virus replication in LLC-MK2 cells(IC50=210 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 380 µM." "DRAVPe00767" "DRAVPe00767.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "633.66" "C26H39N11O8" "ACDEFIKLMNPRSTWY" "GH" "6.92" "2" "0" "2" "2" "1" "-108.33" "-894" "0.8 hour" "10 min" ">10 hour" "48.33" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00768" "HGVHG" "5" "Alloferon (9-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=300 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=400 µM);##Coxsackie virus B2(clinical strain):inhibition of virus replication in Hep-2 cells(IC50=350 µM);inhibition of virus replication in LLC-MK2 cells(IC50=290 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=350 µM);inhibition of virus replication in LLC-MK2 cells(IC50=180 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 826 µM." "DRAVPe00768" "DRAVPe00768.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "505.53" "C21H31N9O6" "ACDEFIKLMNPQRSTWY" "GH" "6.92" "2" "0" "2" "2" "1" "-60" "-340" "3.5 hour" "10 min" ">10 hour" "58" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00769" "GVHG" "4" "Alloferon (10-13)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus,Coxsackie virus" "Herpesviridae, Picornaviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=500 µM);##HHV-1 clinical strain:inhibition of virus replication in Vero cells(IC50=1500 µM);##Coxsackie virus 971 PT B2:inhibition of virus replication in HEp-2 cells(IC50=1040 µM);inhibition of virus replication in LLC-MK2 cells(IC50=540 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero, Hep-2 and LLC-MK2 cells up to 1174 µM." "DRAVPe00769" "DRAVPe00769.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "368.39" "C15H24N6O5" "ACDEFIKLMNPQRSTWY" "G" "6.74" "1" "0" "1" "2" "1" "5" "126" "30 hour" ">20 hour" ">10 hour" "72.5" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus,Anti-Coxsackie virus" "DRAVPe00770" "HGVSGHGQHGV" "11" "Alloferon (1-11)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=178 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 260 µM." "DRAVPe00770" "DRAVPe00770.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1071.12" "C44H66N18O14" "ACDEFIKLMNPRTWY" "G" "7.02" "3" "0" "3" "5" "2" "-64.55" "-1108" "3.5 hour" "10 min" ">10 hour" "52.73" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00771" "HGVSGHGQHG" "10" "Alloferon (1-10)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=520 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 350 µM." "DRAVPe00771" "DRAVPe00771.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "971.99" "C39H57N17O13" "ACDEFIKLMNPRTWY" "G" "7.02" "3" "0" "3" "5" "1" "-113" "-1512" "3.5 hour" "10 min" ">10 hour" "29" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00772" "HGVSGHGQ" "8" "Alloferon (1-8)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=310 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 447 µM." "DRAVPe00772" "DRAVPe00772.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "777.79" "C31H47N13O11" "ACDEFIKLMNPRTWY" "G" "6.92" "2" "0" "2" "4" "1" "-96.25" "-1140" "3.5 hour" "10 min" ">10 hour" "36.25" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00773" "HGVSGHG" "7" "Alloferon (1-7)" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=550 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 504 µM." "DRAVPe00773" "DRAVPe00773.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "649.66" "C26H39N11O9" "ACDEFIKLMNPQRTWY" "G" "6.92" "2" "0" "2" "4" "1" "-60" "-586" "3.5 hour" "10 min" ">10 hour" "41.43" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00774" "FGVSGHGQHGVHG" "13" "Alloferon [H1F]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=160 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 290 µM." "DRAVPe00774" "DRAVPe00774.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1275.35" "C55H78N20O16" "ACDEIKLMNPRTWY" "G" "7.02" "3" "0" "3" "6" "3" "-36.15" "-716" "1.1 hour" "3 min" "2 min" "44.62" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00775" "YGVSGHGQHGVHG" "13" "Alloferon [H1Y]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 315 µM." "DRAVPe00775" "DRAVPe00775.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1291.35" "C55H78N20O17" "ACDEFIKLMNPRTW" "G" "7.02" "3" "0" "3" "7" "2" "-67.69" "-1028" "2.8 hour" "10 min" "2 min" "44.62" "1490" "124.17" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00776" "WGVSGHGQHGVHG" "13" "Alloferon [H1W]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 282 µM." "DRAVPe00776" "DRAVPe00776.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1314.39" "C57H79N21O16" "ACDEFIKLMNPRTY" "G" "7.02" "3" "0" "3" "6" "3" "-64.62" "-781" "2.8 hour" "3 min" "2 min" "44.62" "5500" "458.33" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00777" "XGVSGHGQHGVHG" "13" "Alloferon [H1Phg]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=190 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 350 µM." "No predicted structure available" "DRAVPe00777.cif" "Linear" "Free" "Free" "The 'X' at position 1 indicates Phenylglycine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1239.5" "C46H67N19O14" "ACDEFIKLMNPRTWY" "G" "7.02" "3" "0" "3" "6" "2" "-57.69" "-1014" "44.62" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00778" "XGVSGHGQHGVHG" "13" "Alloferon [H1Phe(p-Cl)]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=110 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 255 µM." "No predicted structure available" "DRAVPe00778.cif" "Linear" "Free" "Free" "The 'X' at position 1 indicates 4-Chloro-phenylalanine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1239.5" "C46H67N19O14" "ACDEFIKLMNPRTWY" "G" "7.02" "3" "0" "3" "6" "2" "-57.69" "-1014" "44.62" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00779" "XGVSGHGQHGVHG" "13" "Alloferon [H1Phe(p-OME)]" "Synthetic construct(derived from Alloferon-1)" "P83412" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Herpesvirus" "Herpesviridae" "antiviral assay" "[Ref.22883213]Herpesvirus 1 McIntire (HHV-1MC):inhibition of virus replication in Vero cells(IC50=220 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22883213]No cytotoxic against Vero cells up to 312 µM." "No predicted structure available" "DRAVPe00779.cif" "Linear" "Free" "Free" "The 'X' at position 1 indicates 4-Methoxy-phenylalanine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1239.5" "C46H67N19O14" "ACDEFIKLMNPRTWY" "G" "7.02" "3" "0" "3" "6" "2" "-57.69" "-1014" "44.62" "0" "0" "22883213" "Chem Biol Drug Des. 2013 Feb;81(2):302-9." "Kuczer M, Majewska A, Zahorska R. " "New alloferon analogues: synthesis and antiviral properties." "10.1111/cbdd.12020" "Anti-Herpesvirus" "DRAVPe00780" "EMTWEEWEKKIEEYTKKIEEILXX" "24" "LP-11" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=931±68 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=201±41 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=253±40 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00780.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 24 is Lys-C16(palmitic acid),The 'X' at position 23 is Lys-PEG8." "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3107.94" "C132H198N28O40S" "ACDFGHNPQRSV" "E" "4.47" "4" "8" "-4" "3" "6" "-120.42" "-5527" "1 hour" "30 min" ">10 hour" "65" "12490" "543.04" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00781" "EMTWEEWEKKVEELEKKIEELLXX" "24" "LP-19" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=296±45 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=95±18 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=92±11 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00781.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 24 is Lys-C16(palmitic acid),The 'X' at position 23 is Lys-PEG8." "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3071.91" "C129H198N28O40S" "ACDFGHNPQRSY" "E" "4.38" "4" "9" "-5" "1" "7" "-115" "-5533" "1 hour" "30 min" ">10 hour" "77.08" "11000" "478.26" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00782" "YTSLIHSLIEESQNQQEKNEQELLELDX" "28" "LP-40" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=361±60 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=392±73 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=384±33 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=800.8 ± 62.29 μM;##MT-4 cell:CC50=366.3± 119.08 μM;##HEK293T cell:CC50=408± 40.1μM;##PBMC:CC50=212.6± 25.71 μM." "No predicted structure available" "DRAVPe00782.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3342.8" "C138H218N36O52" "ACFGMPRVW" "E" "4.06" "2" "7" "-5" "7" "7" "-103.57" "-7370" "2.8 hour" "10 min" "2 min" "97.5" "1490" "55.19" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV" "DRAVPe00783" "YTSLIEELIKKSEEQQKKNEEELKKLEX" "28" "LP-50" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21±3 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=7±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=23±2 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.06-136.12 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.09-5.81 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.06 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=106.4 ± 2.72 μM;##MT-4 cell:CC50=138.37± 6.55 μM;##HEK293T cell:CC50=166.77± 35.33μM;##PBMC:CC50=40.01± 4.63 μM." "No predicted structure available" "DRAVPe00783.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3419.07" "C145H242N36O50" "ACDFGHMPRVW" "E" "4.94" "6" "8" "-2" "5" "6" "-147.5" "-8549" "2.8 hour" "10 min" "2 min" "83.57" "1490" "55.19" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV,Anti-SIV" "DRAVPe00784" "LEANIEELLKKAEEQQKKNEEELKKLEX" "28" "LP-51" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=21±10 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=6±1 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=27±5 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.02-12.07 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.09-0.84 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.03-0.06 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=434.03±90.38 μM;##MT-4 cell:CC50=135.07±32.3 μM;##HEK293T cell:CC50=130.07± 15.27μM;##PBMC:CC50=46.83±4.65 μM." "No predicted structure available" "DRAVPe00784.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3366.01" "C141H239N37O49" "CDFGHMPRSTVWY" "E" "4.76" "6" "9" "-3" "2" "8" "-149.29" "-8581" "5.5 hour" "3 min" "2 min" "90.71" "0" "0" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV,Anti-SIV" "DRAVPe00785" "WEQKIEELLKKAEEQQKKNEEELKKLEX" "28" "LP-52" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=13±1 pM);##HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=4±0 pM);##HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=5±1 pM);##HIV-1(3 A, 13 B, 7 C, 1 G, 1 A/C, 5 A/E, 6 B/C pseudovirus subtypes):inhibition of pseudovirus infection in TZM-bl cells(IC50=17 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50<0.01 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.01-1.86 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.06-0.34 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.01-0.04 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30089693]TZM-bl cell:CC50=112.9 ± 2.21 μM;##MT-4 cell:CC50=94.06± 4.97 μM;##HEK293T cell:CC50=88.86± 6.68μM;##PBMC:CC50=114.8± 12.68 μM." "No predicted structure available" "DRAVPe00785.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C16(palmitic acid)" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)" "3510.19" "C150H247N39O49" "CDFGHMPRSTVY" "E" "5" "7" "9" "-2" "1" "7" "-186.43" "-9466" "2.8 hour" "3 min" "2 min" "73.21" "5500" "203.7" "30089693" "J Virol. 2018 Sep 26;92(20):e01088-18." "Chong H, Zhu Y, Yu D, He Y." "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus." "10.1128/JVI.01088-18" "Anti-HIV,Anti-SIV" "DRAVPe00786" "WEQKIEELLKKAEEQQKKNEEELKKLEX" "28" "LP-80" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=2.66±0.76 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=7.12±0.28 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=13.00±4.55 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=5 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.003±0.001 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.007-4.006 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.288-0.299 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.034-0.155 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=13.4 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00786.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 28 is Lys-C18(stearic acid)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "3510.19" "C150H247N39O49" "CDFGHMPRSTVY" "E" "5" "7" "9" "-2" "1" "7" "-186.43" "-9466" "2.8 hour" "3 min" "2 min" "73.21" "5500" "203.7" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. " "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00787" "WEQKIEELLKKAEEQQKKNEEELKKLEKX" "29" "LP-83" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=0.49±0.03 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=4.54±1.42 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=4.75±0.83 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=2.91 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.002±0 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.002-0.041 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.02-0.032 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.004-0.006 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=8.55 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30867304]Human PBMC:CC50=40.27 µM;##Human embryonic kidney HEK293T cells:CC50=25.31 µM;##TZM-bl cells:CC50=12.34 μM;##MT-4 cells:CC50=19.65 μM;##C8166 cells:CC50=19.19 μM;##U937 cells:CC50=9.97 μ" "No predicted structure available" "DRAVPe00787.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 29 is Cys-Chol(cholesterol)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "3638.36" "C156H259N41O50" "CDFGHMPRSTVY" "E" "5.36" "8" "9" "-1" "1" "7" "-193.45" "-10021" "2.8 hour" "3 min" "2 min" "70.69" "5500" "196.43" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. " "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00788" "LEANIEELLKKAEEQQKKNEEELKKLEKX" "29" "LP-86" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=0.43±0.03 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=4.78±0.69 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.24±1.36 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=4.91 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.003±0 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.003-0.17 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.014-0.026 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.005-0.006 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=12.27 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00788.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 29 is Cys-Chol(cholesterol)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "3494.19" "C147H251N39O50" "CDFGHMPRSTVWY" "E" "5" "7" "9" "-2" "2" "8" "-157.59" "-9136" "5.5 hour" "3 min" "2 min" "87.59" "0" "0" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. " "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00789" "WEQKIEELLKKAEEQQKKNEEELKX" "25" "LP-93" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=6.27±1.26 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=6.55±1.97 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.57±0.62pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.89 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.006±0.001 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.012-2.17 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=1.244-3.514 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.013-0.773 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=14.51pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00789.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 25 is Lys-Chol(cholesterol)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "3139.74" "C133H217N35O44" "CDFGHMPRSTVY" "E" "4.94" "6" "8" "-2" "1" "6" "-194.4" "-8722" "2.8 hour" "3 min" "2 min" "66.4" "5500" "229.17" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity." "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00790" "IEELLKKAEEQQKKNEEELKKLEX" "24" "LP-94" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Chromosome:21,492 - 25,259" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=1.75±0.23 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=5.90±1.80 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=15.69±1.97 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=6.54 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.004±0.002 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.004-2.295 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.019-0.027 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.011-0.018 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=27.36 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00790.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 24 is Lys-Chol(cholesterol)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "2938.56" "C123H210N32O42" "CDFGHMPRSTVWY" "E" "4.94" "6" "8" "-2" "1" "6" "-168.33" "-7909" "20 hour" "30 min" ">10 hour" "85.42" "0" "0" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity." "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00791" "IEELLKKAEEQQKKNEEELKX" "21" "LP-95" "Synthetic construct" "P03377" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,SIV" "Retroviridae" "cell-fusion assay,single-cycle infection assay" "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=199.92±32.69 pM);##HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=24.36±0.15 pM);##HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=4781.17±699.33 pM);##HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=148.88 pM);##T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.067±0.026 nM);##T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.39-408.556 nM);##HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=2.857-13.512 nM);##SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.556-0.862 nM);##HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=29.84 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00791.cif" "Linear" "Acetylation" "Amidation" "The 'X' at position 21 is Lys-Chol(cholesterol)" "L" "membrane" "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities." "2568.11" "C106H180N28O37" "CDFGHMPRSTVWY" "E" "4.86" "5" "7" "-2" "1" "5" "-175.24" "-7165" "20 hour" "30 min" ">10 hour" "79.05" "0" "0" "30867304" "J Virol. 2019 May 15;93(11):e02312-18." "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y." "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity." "10.1128/JVI.02312-18" "Anti-HIV,Anti-SIV" "DRAVPe00792" "TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL" "38" "T2635" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI/cMAGI infectivity assay" "[Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.018μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.025 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.015 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.021 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00792" "DRAVPe00792.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." "4415.89" "C193H305N57O62" "CFGHMPSV" "A" "4.64" "5" "8" "-3" "4" "18" "-67.11" "-9788" "7.2 hour" ">20 hour" ">10 hour" "87.89" "12490" "337.57" "17640899" "Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. " "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." "10.1073/pnas.0701478104" "DRAVPa1315" "Anti-HIV" "DRAVPe00793" "EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW" "41" "C41" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=1.5 ± 0.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00793" "DRAVPe00793.cif" "Linear" "Free" "Free" "None" "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5060.48" "C223H337N59O76" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-117.8" "-11455" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60. " "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00794" "XEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW" "42" "X- C41(C41 N teminus-PEG conjugation)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=7.2 ± 0.7 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00794.cif" "Linear" "Free" "Free" "The 'X' at position 1 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5171.81" "C223H335N59O75" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-115" "-11455" "85.95" "17990" "438.78" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60. " "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00795" "XEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW" "42" "X- C41(C41 N teminus-PEG conjugation)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=11.2± 1.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00795.cif" "Linear" "Free" "Free" "The 'X' at position 1 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5171.81" "C223H335N59O75" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-115" "-11455" "85.95" "17990" "438.78" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60. " "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00796" "EWDXEINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [R4X](R4C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.1± 1.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00796.cif" "Linear" "Free" "Free" "The 'X' at position 4 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5015.62" "C217H323N55O74" "CFGMPRV" "E" "4.04" "3" "10" "-7" "10" "13" "-106.83" "-9963" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00797" "EWDXEINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [R4X](R4C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=8.7± 1.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00797.cif" "Linear" "Free" "Free" "The 'X' at position 4 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5015.62" "C217H323N55O74" "CFGMPRV" "E" "4.04" "3" "10" "-7" "10" "13" "-106.83" "-9963" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00798" "EWDREINNYTXLIHSLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [S11X](S11C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.4± 0.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00798.cif" "Linear" "Free" "Free" "The 'X' at position 11 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00799" "EWDREINNYTXLIHSLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [S11X](S11C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.9± 0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00799.cif" "Linear" "Free" "Free" "The 'X' at position 11 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00800" "EWDREINNYTSLIHXLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [S15X](S15C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.1± 1.0 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00800.cif" "Linear" "Free" "Free" "The 'X' at position 15 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00801" "EWDREINNYTSLIHXLIEESQNQQEKNEQELLELDKWASLW" "41" "C41 [S15X](S15C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.0± 0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00801.cif" "Linear" "Free" "Free" "The 'X' at position 15 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00802" "EWDREINNYTSLIHSLIXESQNQQEKNEQELLELDKWASLW" "41" "C41 [E18X](E18C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.5± 1.0 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00802.cif" "Linear" "Free" "Free" "The 'X' at position 18 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5042.69" "C218H328N58O72" "CFGMPV" "E" "4.29" "4" "9" "-5" "10" "13" "-109.27" "-10774" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00803" "EWDREINNYTSLIHSLIXESQNQQEKNEQELLELDKWASLW" "41" "C41 [E18X](E18C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.9± 0.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00803.cif" "Linear" "Free" "Free" "The 'X' at position 18 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5042.69" "C218H328N58O72" "CFGMPV" "E" "4.29" "4" "9" "-5" "10" "13" "-109.27" "-10774" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00804" "EWDREINNYTSLIHSLIEESQXQQEKNEQELLELDKWASLW" "41" "C41 [N22X](N22C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=4.2± 0.9 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00804.cif" "Linear" "Free" "Free" "The 'X' at position 22 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5057.7" "C219H329N57O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-109.27" "-10791" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00805" "EWDREINNYTSLIHSLIEESQXQQEKNEQELLELDKWASLW" "41" "C41 [N22X](N22C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.1± 0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00805.cif" "Linear" "Free" "Free" "The 'X' at position 22 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5057.7" "C219H329N57O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-109.27" "-10791" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00806" "EWDREINNYTSLIHSLIEESQNQQEKNEXELLELDKWASLW" "41" "C41 [Q29X](Q29C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.2± 0.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00806.cif" "Linear" "Free" "Free" "The 'X' at position 29 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5043.68" "C218H327N57O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-109.27" "-10901" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00807" "EWDREINNYTSLIHSLIEESQNQQEKNEXELLELDKWASLW" "41" "C41 [Q29X](Q29C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=5.5± 0.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00807.cif" "Linear" "Free" "Free" "The 'X' at position 29 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5043.68" "C218H327N57O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-109.27" "-10901" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00808" "EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWX" "42" "C41 -X(C41 C teminus-PEG conjugation)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=10.9± 2.2 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00808.cif" "Linear" "Free" "Free" "The 'X' at position 42 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5171.81" "C223H335N59O75" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-115" "-11455" "1 hour" "30 min" ">10 hour" "85.95" "17990" "438.78" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00809" "EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWX" "42" "C41 -X(C41 C teminus-PEG conjugation)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50=43.3± 14.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00809.cif" "Linear" "Free" "Free" "The 'X' at position 42 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5171.81" "C223H335N59O75" "CFGMPV" "E" "4.22" "4" "10" "-6" "10" "13" "-115" "-11455" "1 hour" "30 min" ">10 hour" "85.95" "17990" "438.78" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00810" "EWDREINNYTSLIHSLIEEXQNQQEKNEQELLELDKWASLW" "41" "C41 [S20X](S20C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50>400 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00810.cif" "Linear" "Free" "Free" "The 'X' at position 20 indicates PEG750-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00811" "EWDREINNYTSLIHSLIEEXQNQQEKNEQELLELDKWASLW" "41" "C41 [S20X](S20C)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "cell-cell fusion inhibition assay" "[Ref.22770564]HIV-1:inhibition of cell-cell fusion between CHO-WT cells and K652 cells(IC50>400 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe00811.cif" "Linear" "Free" "Free" "The 'X' at position 20 indicates PEG2000-Cys." "L" "envelope glycoprotein(gp41)" "The peptide have been shown to be effective inhibitors to prevent virus–host cell membrane fusion." "5084.73" "C220H330N58O73" "CFGMPV" "E" "4.22" "4" "10" "-6" "9" "13" "-115.85" "-11115" "1 hour" "30 min" ">10 hour" "88.05" "17990" "449.75" "22770564" "Bioconjug Chem. 2012 Aug 15;23(8):1648-60." "Danial M, van Dulmen TH, Aleksandrowicz J, Pötgens AJ, Klok HA." "Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation." "10.1021/bc3002248" "Anti-HIV" "DRAVPe00812" "RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL" "45" "IQN17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.19±0.03 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00812" "DRAVPe00812.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "5431.51" "C243H423N69O68S" "CFHPY" "IK" "9.78" "11" "7" "4" "4" "17" "-62.89" "-10181" "1 hour" "2 min" "2 min" "123.56" "5500" "125" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0204" "Anti-HIV" "DRAVPe00813" "RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWDIKQLQARIL" "45" "IQN17[G572D]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=15±5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00813" "DRAVPe00813.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "5489.55" "C245H425N69O70S" "CFGHPY" "IK" "9.52" "11" "8" "3" "3" "17" "-69.78" "-11147" "1 hour" "2 min" "2 min" "123.56" "5500" "125" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00814" "RMKQIEDKIEEIESKQKKIENEIARIKKLIEAQQHLLQLTVWGIKQLQARIL" "52" "IQN23" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.015±0.007 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00814" "DRAVPe00814.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "6251.43" "C279H480N80O79S" "CFPY" "IK" "9.52" "12" "8" "4" "4" "20" "-61.35" "-11271" "1 hour" "2 min" "2 min" "123.85" "5500" "107.84" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0205" "Anti-HIV" "DRAVPe00815" "RMKQIEDKIEEIESKQKKIENEIARIKKLISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL" "66" "IQN36" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.088±0.035 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00815" "DRAVPe00815.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "7787.19" "C345H594N102O99S" "CFPY" "IQ" "9.77" "13" "8" "5" "8" "26" "-49.24" "-13446" "1 hour" "2 min" "2 min" "127.12" "5500" "84.62" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0206" "Anti-HIV" "DRAVPe00816" "IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL" "41" "IZN17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.022±0.011 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00816" "DRAVPe00816.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "4813.88" "C222H388N58O59" "CDFHMNPSY" "K" "9.7" "10" "6" "4" "2" "19" "-24.88" "-5195" "20 hour" "30 min" ">10 hour" "140.49" "5500" "137.5" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0190" "Anti-HIV" "DRAVPe00817" "IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL" "48" "IZN23" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.030±0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00817" "DRAVPe00817.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "5649.75" "C257H441N69O72" "CDFMNPSY" "IK" "9.11" "11" "8" "3" "2" "21" "-43.96" "-7458" "20 hour" "30 min" ">10 hour" "130.21" "5500" "117.02" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0191" "Anti-HIV" "DRAVPe00818" "IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL" "62" "IZN36" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.026±0.007 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00818" "DRAVPe00818.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "7185.51" "C323H555N91O92" "CDFMPY" "I" "9.46" "12" "8" "4" "6" "27" "-35" "-9633" "20 hour" "30 min" ">10 hour" "132.26" "5500" "90.16" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "DRAVPa0197" "Anti-HIV" "DRAVPe00819" "RMKQIEDKIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL" "45" "IIN17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.14±0.05 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00819" "DRAVPe00819.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "5416.54" "C244H426N68O67S" "CFHPY" "I" "9.78" "11" "7" "4" "4" "18" "-45.11" "-9135" "1 hour" "2 min" "2 min" "132.22" "5500" "125" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00820" "KIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL" "38" "IQ22N17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=1.4±0.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00820" "DRAVPe00820.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "4530.46" "C206H359N57O56" "CDFHMPY" "IK" "9.87" "9" "5" "4" "4" "16" "-41.58" "-6754" "1.3 hour" "3 min" "2 min" "136.05" "5500" "148.65" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00821" "KIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL" "38" "II22N17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=0.16±0.01 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00821" "DRAVPe00821.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "4515.49" "C207H362N56O55" "CDFHMPY" "I" "9.87" "9" "5" "4" "4" "17" "-20.53" "-5708" "1.3 hour" "3 min" "2 min" "146.32" "5500" "148.65" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00822" "KQKKIENEIARIKKLLQLTVWGIKQLQARIL" "31" "IQ15N17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=5.5±1..5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00822" "DRAVPe00822.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "3701.55" "C170H299N49O42" "CDFHMPSY" "K" "10.66" "8" "2" "6" "3" "14" "-30.97" "-4800" "1.3 hour" "3 min" "2 min" "141.61" "5500" "183.33" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00823" "KIKKIENEIARIKKLLQLTVWGIKQLQARIL" "31" "II15N17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "HIV luciferase assay" "[Ref.11572974]HIV-1:inhibition of cell-cell fusion between 293T cells and HOS-CD4/fusion cells(IC50=2.1±0.8 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe00823" "DRAVPe00823.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide inhibits HIV-1 entry by inhibiting the fusion between virus and cell membrane." "3686.58" "C171H302N48O41" "CDFHMPSY" "IK" "10.66" "8" "2" "6" "3" "15" "-5.16" "-3754" "1.3 hour" "3 min" "2 min" "154.19" "5500" "183.33" "11572974" "Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92." "Eckert DM, Kim PS. " "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region." "10.1073/pnas.201392898" "Anti-HIV" "DRAVPe00824" "ALWKTMLKKLGTMALHAGKAALGAAADTI" "29" "Dermaseptin-S1 (1-29)" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=1.7 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50=20 µM;293TT(embryonic human culture cells):CC50=40 µM." "DRAVPe00824" "DRAVPe00824.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2953.6" "C133H226N36O35S2" "CEFNPQRSVY" "A" "10" "5" "1" "4" "6" "15" "52.41" "1056" "4.4 hour" ">20 hour" ">10 hour" "108.28" "5500" "196.43" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens. " "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00825" "ALWTTMLKKLGKMALHAGKAALGAAADTI" "29" "Dermaseptin-S1 (1-29)[K4T,T12K]" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=1.3 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50=20 µM;293TT(embryonic human culture cells):CC50=40 µM." "DRAVPe00825" "DRAVPe00825.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2953.6" "C133H226N36O35S2" "CEFNPQRSVY" "A" "10" "5" "1" "4" "6" "15" "52.41" "1056" "4.4 hour" ">20 hour" ">10 hour" "108.28" "5500" "196.43" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens. " "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00826" "ALWKTMLKKLGTMALHAGK" "19" "Dermaseptin-S1 (1-19)" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=9 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50=80 µM;293TT(embryonic human culture cells):CC50=80 µM." "DRAVPe00826" "DRAVPe00826.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2098.64" "C96H164N26O22S2" "CDEFINPQRSVY" "KL" "10.48" "5" "0" "5" "4" "8" "13.16" "202" "4.4 hour" ">20 hour" ">10 hour" "97.89" "5500" "305.56" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens. " "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00827" "ALXKTMLKKLGTMAL" "15" "Dermaseptin-S1 (1-15)[W31NAL]" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=2.7 µM)." "[Ref.20718719]human red cells:HC50=75 µM." "[Ref.20718719]Vero cells:CC50=50 µM;293TT(embryonic human culture cells):CC50>100 µM." "DRAVPe00827" "DRAVPe00827.cif" "Linear" "Free" "Amidation" "The 'X' at position 3 indicates Nal (3-[1-naphthyl]alanine)." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1630.31" "C68H125N17O16S2" "CDEFHINPQRSVWY" "L" "10.3" "3" "0" "3" "3" "6" "60.67" "715" "4.4 hour" ">20 hour" ">10 hour" "117.33" "0" "0" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00828" "ALHKTMLKKLGTMAL" "15" "Dermaseptin-S1 (1-15)[W3H]" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=5 µM)." "[Ref.20718719]human red cells:HC50=100 µM." "[Ref.20718719]Vero cells:CC50>100 µM;293TT(embryonic human culture cells):CC50>100 µM." "DRAVPe00828" "DRAVPe00828.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1656.12" "C74H134N20O18S2" "CDEFINPQRSVWY" "L" "10.3" "4" "0" "4" "3" "6" "39.33" "249" "4.4 hour" ">20 hour" ">10 hour" "117.33" "0" "0" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00829" "KALXKTMLKKLGTMAL" "16" "K-Dermaseptin-S1 (1-15)[W31NAL]" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=5 µM)." "[Ref.20718719]human red cells:HC50=80 µM." "[Ref.20718719]Vero cells:CC50=50 µM;293TT(embryonic human culture cells):CC50>100 µM." "No predicted structure available" "DRAVPe00829.cif" "Linear" "Free" "Amidation" "The 'X' at position 4 indicates Nal (3-[1-naphthyl]alanine)." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1758.48" "C74H137N19O17S2" "CDEFHINPQRSVWY" "KL" "10.48" "4" "0" "4" "3" "6" "32.5" "160" "1.3 hour" "3 min" "2 min" "110" "0" "0" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00830" "ALWKTMLKKLGTMA" "14" "Dermaseptin-S1 (1-14)" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=10.5 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50=85 µM;293TT(embryonic human culture cells):CC50>100 µM." "DRAVPe00830" "DRAVPe00830.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1592.03" "C73H126N18O17S2" "CDEFHINPQRSVY" "KL" "10.3" "3" "0" "3" "3" "6" "31.43" "456" "4.4 hour" ">20 hour" ">10 hour" "97.86" "5500" "423.08" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00831" "ALWKTMLKKLGTM" "13" "Dermaseptin-S1 (1-13)" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=10 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50=100 µM;293TT(embryonic human culture cells):CC50>100 µM." "DRAVPe00831" "DRAVPe00831.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1520.96" "C70H121N17O16S2" "CDEFHINPQRSVY" "KL" "10.3" "3" "0" "3" "3" "5" "20" "275" "4.4 hour" ">20 hour" ">10 hour" "97.69" "5500" "458.33" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00832" "ALWKTMLKKLGT" "12" "Dermaseptin-S1 (1-12)" "Synthetic construct(derived from Dermaseptin-S1)" "P24302" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "antiviral assay" "[Ref.20718719]HSV-1:inhibition of virus infection in Vero cells(IC50=100 µM)." "[Ref.20718719]human red cells:HC50>100 µM." "[Ref.20718719]Vero cells:CC50>100 µM;293TT(embryonic human culture cells):CC50>100 µM." "DRAVPe00832" "DRAVPe00832.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1389.76" "C65H112N16O15S" "CDEFHINPQRSVY" "KL" "10.3" "3" "0" "3" "3" "5" "5.83" "40" "4.4 hour" ">20 hour" ">10 hour" "105.83" "5500" "500" "20718719" "APMIS. 2010 Sep 1;118(9):674-80." "Savoia D, Donalisio M, Civra A, Salvadori S, Guerrini R." "In vitro activity of dermaseptin S1 derivatives against genital pathogens." "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe00833" "EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL" "32" "HP23-E6-IDL" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "HIV-1-Mediated Cell-Cell Fusion Assay" "[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=338 pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=1.14 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=813 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=748-1543 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=349-1423 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=699-4937 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM." "DRAVPe00833" "DRAVPe00833.cif" "Linear" "Free" "Free" "None" "L" "membrane" "It was a fusion inhibitor and inhibits cell-cell fusion" "4068.61" "C182H288N44O59S" "ACFGHPRV" "E" "4.73" "6" "9" "-3" "5" "8" "-145.94" "-9191" "1 hour" "30 min" ">10 hour" "73.13" "12490" "402.9" "30901967" "Molecules. 2019 Mar 21;24(6):1134." "Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. " "A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life." "10.3390/molecules24061134" "Anti-HIV" "DRAVPe00834" "EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDL" "32" "YIK(625-656)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1-Mediated Cell-Cell Fusion Assay" "[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=275pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=1.12 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=640 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=627-1423 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=460-1490 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=856-5286 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM." "DRAVPe00834" "DRAVPe00834.cif" "Linear" "Free" "Free" "None" "L" "membrane" "It was a fusion inhibitor and inhibits cell-cell fusion" "4080.66" "C184H292N44O58S" "ACFGHPRV" "E" "4.73" "6" "9" "-3" "4" "9" "-129.69" "-8442" "1 hour" "30 min" ">10 hour" "85.31" "12490" "402.9" "30901967" "Molecules. 2019 Mar 21;24(6):1134." "Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. " "A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life." "10.3390/molecules24061134" "Anti-HIV" "DRAVPe00835" "EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDLGSGX" "36" "YIK-C16(625-656)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV-1-Mediated Cell-Cell Fusion Assay" "[Ref.30901967]HIV-1IIIB(X4 virus):inhibition of virus infection in MT-2 cells(IC50=76 pM);inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells(IC50=0.55 nM);##HIV-1Bal(R5 virus):inhibition of virus infection in MT-2 cells(IC50=61 pM);##HIV-1 NL4-3 D36G(6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K):inhibition of virus infection in MT-2 cells(IC50=40-179 pM);##HIV-1 LAI (7 T2635-Resistant Strains,WT,A6V,Q66R,K90E,K154Q,Q79E/N126K,K90E/N126K):inhibition of virus infection in MT-2 cells(IC50=65-106 pM);##HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G):inhibition of virus infection in MT-2 cells(IC50=65-188 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30901967]No cytotoxicity against MT-2 or M7 cells at the concentrations as high as 8 μM." "No predicted structure available" "DRAVPe00835.cif" "Linear" "Free" "Free" "The 'X' at position 36 indicates PEG4-Lys-C16(Palmitic Acid)." "L" "membrane" "It was a fusion inhibitor and inhibits cell-cell fusion" "4393.18" "C191H301N47O61S" "ACFHPRV" "E" "4.73" "6" "9" "-3" "7" "9" "-119.72" "-8594" "1 hour" "30 min" ">10 hour" "75.83" "12490" "356.86" "30901967" "Molecules. 2019 Mar 21;24(6):1134." "Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. " "A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life." "10.3390/molecules24061134" "Anti-HIV" "DRAVPe00836" "GGLKKLGKKLEGAGKRVFNAAEKALPVVAGAKAL" "34" "Cecropin A" "Aedes aegypti (Yellowfever mosquito)" "P01508" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2MMM" "Tacaribe virus,JV,PICV" "Arenaviridae" "[Ref.15081088]Junin virus(JV):inhibtion of JV infection in Vero cells(EC50=3.4 μM,EC90=28.57 μM);##Tacaribe virus:inhibition of tacaribe virus infection in Vero cells(IC50=1.96 μM,EC90=33.39 μM);##Pichinde virus:inhibition of Pichinde virus infection in Vero cells(IC50=6.56 μM,EC90=39 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15081088]Vero cells:CC50>100 μM." "DRAVPe00836" "DRAVPe00836.cif" "Linear" "Free" "Amidtion" "None" "L" "glycoprotein G1" "Cecropin A caused an altered intracellular distribution and membrane expression of the viral glycoprotein G1, as it was shown by membrane and cytoplasmic IF assays,which indicate that the inhibition of G1 transport and/or insertion into the cell membrane might prevent the formation of infectious particles leading to the reduction of cell-associated infectivity." "3391.11" "C154H269N45O40" "CDHIMQSTWY" "AK" "10.39" "8" "2" "6" "7" "16" "2.06" "-1602" "30 hour" ">20 hour" ">10 hour" "103.53" "0" "0" "15081088" " Int J Antimicrob Agents. 2004 Apr;23(4):382-9." "Albiol Matanic VC, Castilla V. " "Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. " "10.1016/j.ijantimicag.2003.07.022" "Anti-Tacaribe virus,Anti-JV,Anti-Pichinde virus" "DRAVPe00837" "GIGAVLKVLTTGLPALISWIKRKRQQ" "26" "Melittin" "Apis mellifera (Honeybee)" "P01501" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2MLT" "JV,HSV, Influenza A virus, EV-71, RSV,VSV, HIV" "Arenaviridae, Herpesviridae, Orthomyxoviridae, Picornaviridae, Pneumoviridae, Rhabdoviridae, Retroviridae" "[Ref.15081088]Junin virus(JV):inhibtion of JV infection in Vero cells(EC50=0.86 μM);##Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=1.35 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=2.05 μM).##[Ref.31422545] GFP-fused influenza A (PR8):exerts antiviral activity in MDCK cells(EC50=1.15 ± 0.09 μg/mL);##Enterovirus A71 (EV-A71):exerts antiviral activity in HeLa cells(EC50=0.76 ± 0.03 μg/mL);##GFP-fused coxsakievirus (H3):exerts antiviral activity in HeLa cells(EC50=0.99 ± 0.09 μg/mL);## GFP-fused RSV:exerts antiviral activity in HEp2 cells(EC50=0.99 ± 0.09 μg/mL);## GFP-fused VSV:exerts antiviral activity in Vero cells(EC50=1.18 ± 0.09 μg/mL);## HIV-1 (NLHX):exerts antiviral activity in Vaginal epithelial cells (VK2)(EC50=2.4 μM);## HIV-2 (NLYU2):exerts antiviral activity in Vaginal epithelial cells (VK2)(EC50=3.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15081088]Vero cells:CC50=8.51 μM." "DRAVPe00837" "DRAVPe00837.cif" "Linear" "Free" "Amidtion" "None" "L" "Not found" "Melittin suppresses cell fusion mediated by HSV-1 syncytial mutants probably by interfering with the activity of the Na, K ATPase, cellular enzyme involved in the membrane fusion process." "2847.49" "C131H228N38O32" "CDEFHMNY" "L" "12.02" "5" "0" "5" "6" "12" "27.31" "-1482" "30 hour" ">20 hour" ">10 hour" "135" "5500" "220" "15081088##31422545" " Int J Antimicrob Agents. 2004 Apr;23(4):382-9.##Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):5-17." "Albiol Matanic VC, Castilla V. ##Memariani H, Memariani M, Moravvej H, Shahidi-Dadras M. " "Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. ##Melittin: a venom-derived peptide with promising anti-viral properties." "10.1016/j.ijantimicag.2003.07.022##10.1007/s10096-019-03674-0" "Anti-JV,Anti-HSV, Anti-Anti-Influenza A virus, EV-71, Anti-RSV,Anti-VSV, Anti-HIV" "DRAVPe00838" "GIGKFLHSAGKFGKAFVGEIMKS" "23" "Magainin-1" "Xenopus laevis (African clawed frog)" "P11006" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=36.59 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=33.20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15081088]Vero cells:CC50>100 μM." "DRAVPe00838" "DRAVPe00838.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2409.87" "C112H177N29O28S" "CDNPQRTWY" "G" "10" "5" "1" "4" "7" "9" "21.74" "-206" "30 hour" ">20 hour" ">10 hour" "72.17" "0" "0" "15081088" " Int J Antimicrob Agents. 2004 Apr;23(4):382-9." "Albiol Matanic VC, Castilla V. " "Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. " "10.1016/j.ijantimicag.2003.07.022" "Anti-HSV" "DRAVPe00839" "GIGKFLHSAKKFGKAFVGEIMNS" "23" "Magainin II" "Xenopus ruwenzoriensis (Uganda clawed frog)" "C0HKN6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2MAG##2LSA" "CCV,HSV" "Herpesviridae" "[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 48 μM).##[Ref.15081088]Herpes simplex virus type 1 (HSV-1):inhibition of HSV-1 infection in Vero cells(EC50=22.16 μM);##Herpes simplex virus type 2 (HSV-2):inhibition of HSV-2 infection in Vero cells(EC50=19.80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15081088]Vero cells:CC50>100 μM." "DRAVPe00839" "DRAVPe00839.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2466.93" "C114H180N30O29S" "CDPQRTWY" "GK" "10" "5" "1" "4" "7" "9" "8.26" "-964" "30 hour" ">20 hour" ">10 hour" "72.17" "0" "0" "15193922##15081088" "Virology. 2004 Jun 1;323(2):268-75.## Int J Antimicrob Agents. 2004 Apr;23(4):382-9." "Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L.##Albiol Matanic VC, Castilla V. " "Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides.##Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. " "10.1016/j.virol.2004.02.029##10.1016/j.ijantimicag.2003.07.022" "Anti-CCV,Anti-HSV" "DRAVPe00840" "PACQDFLGAMIHLKAKTNISIR" "22" "3(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(28% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00840" "DRAVPe00840.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2427.91" "C107H179N31O29S2" "EVWY" "AI" "9.37" "4" "1" "3" "5" "9" "19.09" "-1997" ">20 hour" ">20 hour" "?" "102.27" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00841" "LKAKTNISIREGPTLGNWAR" "20" "4(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00841" "DRAVPe00841.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2225.58" "C98H165N31O28" "CDFHMQVY" "AGIKLNRT" "11" "4" "1" "3" "7" "7" "-63" "-4206" "5.5 hour" "3 min" "2 min" "88" "5500" "289.47" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00842" "EGPTLGNWAREIWATLFKKA" "20" "5(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00842" "DRAVPe00842.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2288.63" "C107H162N28O28" "CDHMQSVY" "A" "8.69" "3" "2" "1" "5" "9" "-40.5" "-2171" "1 hour" "30 min" ">10 hour" "73.5" "11000" "578.95" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00843" "EIWATLFKKATRQCRRGRIW" "20" "6(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(100% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00843" "DRAVPe00843.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2520" "C114H183N37O26S" "DHMNPSVY" "R" "11.56" "6" "1" "5" "4" "8" "-73.5" "-6003" "1 hour" "30 min" ">10 hour" "68.5" "11000" "578.95" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00844" "TRQCRRGRIWKRWNETITGP" "20" "7(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(94% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00844" "DRAVPe00844.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2514.9" "C108H176N40O28S" "ADFHLMSVY" "R" "11.83" "6" "1" "5" "7" "4" "-158.5" "-8919" "7.2 hour" ">20 hour" ">10 hour" "39" "11000" "578.95" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00845" "SGCANNTCYNVSVIVPDYQC" "20" "9(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(24% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00845" "DRAVPe00845.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2150.38" "C89H136N24O32S3" "EFHKLMRW" "CNV" "3.8" "0" "1" "-1" "12" "5" "10" "-2020" "1.9 hour" ">20 hour" ">10 hour" "68" "3105" "163.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00846" "YLDRVDTWLQGKINISLCLT" "20" "11(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00846" "DRAVPe00846.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2351.75" "C106H171N27O31S" "AEFHMP" "L" "5.95" "2" "2" "0" "7" "8" "18.5" "-2066" "2.8 hour" "10 min" "2 min" "131.5" "6990" "367.89" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00847" "GKINISLCLTGGKMLYNKVT" "20" "12(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00847" "DRAVPe00847.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2153.63" "C95H165N25O27S2" "ADEFHPQRW" "GKL" "9.63" "3" "0" "3" "10" "6" "28" "-352" "30 hour" ">20 hour" ">10 hour" "112" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00848" "GGKMLYNKVTKQLSYCTDPL" "20" "13(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00848" "DRAVPe00848.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2259.66" "C100H163N25O30S2" "AEFHIRW" "KL" "9.05" "3" "1" "2" "9" "4" "-47" "-2206" "30 hour" ">20 hour" ">10 hour" "73" "2980" "156.84" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00849" "KQLSYCTDPLQIPLINYTFG" "20" "14(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00849" "DRAVPe00849.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2314.68" "C107H164N24O31S" "AEHMRVW" "L" "5.83" "1" "1" "0" "8" "6" "-3" "-1101" "1.3 hour" "3 min" "2 min" "97.5" "2980" "156.84" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00850" "PNQTCMWNTSQIQDPEIPKC" "20" "16(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00850" "DRAVPe00850.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2333.63" "C98H153N27O33S3" "AFGHLRVY" "PQ" "4.37" "1" "2" "-1" "7" "3" "-102" "-4244" ">20 hour" ">20 hour" "?" "39" "5625" "296.05" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00851" "QIQDPEIPKCGWWNQMAYYN" "20" "17(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00851" "DRAVPe00851.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2484.79" "C113H158N28O32S2" "FHLRSTV" "Q" "4.37" "1" "2" "-1" "6" "5" "-106" "-3038" "0.8 hour" "10 min" ">10 hour" "44" "13980" "735.79" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00852" "FHCQRTQSQPGSWFRAISSWKQ" "22" "20(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00852" "DRAVPe00852.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2665.97" "C119H173N37O32S" "DELMNVY" "QS" "10.86" "4" "0" "4" "7" "6" "-106.36" "-5881" "1.1 hour" "3 min" "2 min" "22.27" "11000" "523.81" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00853" "GSWFRAISSWKQRNRWEWRPDF" "22" "21(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00853" "DRAVPe00853.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2896.23" "C135H187N41O32" "CHLMTVY" "RW" "11.54" "5" "2" "3" "5" "8" "-145.45" "-8019" "30 hour" ">20 hour" ">10 hour" "22.27" "22000" "1047.62" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00854" "KQRNRWEWRPDFKSKKVKISLPC" "23" "22(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00854" "DRAVPe00854.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2930.47" "C133H213N41O32S" "AGHMTY" "K" "10.56" "8" "2" "6" "4" "6" "-155.65" "-8422" "1.3 hour" "3 min" "2 min" "46.52" "11000" "500" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00855" "KSKKVKISLPCNSTKNLTFA" "20" "23(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(10% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00855" "DRAVPe00855.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2207.66" "C98H171N27O28S" "DEGHMQRWY" "K" "10.2" "5" "0" "5" "8" "6" "-42.5" "-3150" "1.3 hour" "3 min" "2 min" "78" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00856" "CNSTKNLTFAMRSSGDYGEV" "20" "24(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00856" "DRAVPe00856.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2180.39" "C90H142N26O33S2" "HIPQW" "S" "6.06" "2" "2" "0" "11" "4" "-56.5" "-4550" "1.2 hour" ">20 hour" ">10 hour" "39" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00857" "MRSSGDYGEVTGAWIEFGCH" "20" "25(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(27% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00857" "DRAVPe00857.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2202.4" "C95H136N26O31S2" "KLNPQ" "G" "4.65" "2" "3" "-1" "9" "5" "-33" "-2796" "30 hour" ">20 hour" ">10 hour" "39" "6990" "367.89" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00858" "TGAWIEFGCHRNKSNLHTEA" "20" "26(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00858" "DRAVPe00858.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2271.49" "C98H147N31O30S" "DMPQVY" "AEGHNT" "6.62" "4" "2" "2" "8" "6" "-77.5" "-4330" "7.2 hour" ">20 hour" ">10 hour" "49" "5500" "289.47" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00859" "RNKSNLHTEARFRIRCRWNV" "20" "27(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(2% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00859" "DRAVPe00859.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2556.94" "C109H178N42O28S" "DGMPQY" "R" "11.83" "7" "1" "6" "6" "6" "-132" "-9523" "1 hour" "2 min" "2 min" "58.5" "5500" "289.47" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00860" "RFRIRCRWNVGSDTSLIDTC" "20" "28(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(40% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00860" "DRAVPe00860.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2398.74" "C101H164N34O30S2" "AEHKMPQY" "R" "9.02" "4" "2" "2" "8" "6" "-40" "-6809" "1 hour" "2 min" "2 min" "73" "5625" "296.05" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00861" "GSDTSLIDTCGNTPNVSGAN" "20" "29(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(12% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00861" "DRAVPe00861.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "1923" "C75H123N23O34S" "EFHKMQRWY" "GNST" "3.56" "0" "2" "-2" "13" "4" "-40" "-3548" "30 hour" ">20 hour" ">10 hour" "58.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00862" "PVDCTMYSNKMYNCSLQNGF" "20" "31(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00862" "DRAVPe00862.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2315.63" "C98H147N25O32S4" "AEHIRW" "N" "6.17" "1" "1" "0" "11" "3" "-43.5" "-2924" ">20 hour" ">20 hour" "?" "34" "3105" "163.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00863" "MYNCSLQNGFTMKVDDLIVH" "20" "32(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(33% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00863" "DRAVPe00863.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2328.7" "C101H158N26O31S3" "AEPRW" "DLMNV" "5.19" "2" "2" "0" "7" "6" "9" "-1984" "30 hour" ">20 hour" ">10 hour" "87.5" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00864" "TMKVDDLIVHFNMTKAVEMV" "20" "33(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(25% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00864" "DRAVPe00864.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2321.79" "C102H169N25O30S3" "CGPQRSWY" "V" "5.35" "3" "3" "0" "3" "8" "45" "-1395" "7.2 hour" ">20 hour" ">10 hour" "102" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00865" "FNMTKAVEMVNIAGNWSCTS" "20" "34(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(15% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00865" "DRAVPe00865.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2203.53" "C94H147N25O30S3" "DHLPQRY" "N" "5.99" "1" "1" "0" "9" "7" "17" "-1537" "1.1 hour" "3 min" "2 min" "58.5" "5500" "289.47" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00866" "NIAGNWSCTSDLPSSWGYMN" "20" "35(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(22% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00866" "DRAVPe00866.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2203.39" "C95H135N25O32S2" "EFHKQRV" "S" "3.8" "0" "1" "-1" "12" "5" "-44.5" "-2313" "1.4 hour" "3 min" ">10 hour" "44" "12490" "657.37" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00867" "CTSDLPSSWGYMNCNCTNSSSS" "22" "36(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(5% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00867" "DRAVPe00867.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2344.5" "C92H138N26O38S4" "AEFHIKQRV" "S" "3.8" "0" "1" "-1" "17" "2" "-54.55" "-4334" "1.2 hour" ">20 hour" ">10 hour" "17.73" "7115" "338.81" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00868" "CNCTNSSSSYSGTKMACPSNRG" "22" "37(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00868" "DRAVPe00868.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2255.45" "C85H139N29O35S4" "DEFHILQVW" "S" "8.68" "2" "0" "2" "17" "1" "-80" "-5619" "1.2 hour" ">20 hour" ">10 hour" "4.55" "1615" "76.9" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00869" "SGTKMACPSNRGILRNWYNP" "20" "38(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00869" "DRAVPe00869.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2265.59" "C97H153N31O28S2" "DEFHQV" "N" "10.05" "3" "0" "3" "10" "4" "-87" "-4533" "1.9 hour" ">20 hour" ">10 hour" "44" "6990" "367.89" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00870" "RGILRNWYNPFAGLRQSLEQ" "20" "39(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00870" "DRAVPe00870.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2418.74" "C109H168N34O29" "CDHKMTV" "LR" "10.74" "3" "1" "2" "6" "7" "-79.5" "-5079" "1 hour" "2 min" "2 min" "83" "6990" "367.89" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00871" "VAGLRQSLEQYQVVKQPDYL" "20" "40(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(48% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00871" "DRAVPe00871.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2334.66" "C105H168N28O32" "CFHIMNTW" "Q" "6.04" "2" "2" "0" "4" "7" "-45" "-3221" "100 hour" ">20 hour" ">10 hour" "107" "2980" "156.84" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00872" "YQVVKQPDYLLVPEEVMEYK" "20" "41(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(38% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00872" "DRAVPe00872.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2470.86" "C115H176N24O34S" "ACFGHINRSTW" "V" "4.41" "2" "4" "-2" "3" "6" "-48" "-2340" "2.8 hour" "10 min" "2 min" "97" "4470" "235.26" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00873" "PDYLLVPEEVMEYKPRRKRAAI" "22" "42(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(54% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00873" "DRAVPe00873.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2674.16" "C121H197N33O33S" "CFGHNQSTW" "EPR" "8.83" "5" "4" "1" "2" "7" "-75.91" "-5648" ">20 hour" ">20 hour" "?" "88.64" "2980" "141.9" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00874" "YKPRRKRAAIHVMLALATVLSI" "22" "43(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(52% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00874" "DRAVPe00874.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2508.11" "C114H199N35O26S" "CDEFGNQW" "A" "11.73" "6" "0" "6" "3" "11" "40.91" "-2436" "2.8 hour" "10 min" "2 min" "133.18" "1490" "70.95" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00875" "HVMLALATVLSIAGAGTGATAI" "22" "44(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(58% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00875" "DRAVPe00875.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2038.43" "C90H156N24O27S" "CDEFKNPQRWY" "A" "6.74" "1" "0" "1" "7" "13" "155.45" "3294" "3.5 hour" "10 min" ">10 hour" "142.27" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00876" "AGAGTGATAIGMVTQYHQVL" "20" "45(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00876" "DRAVPe00876.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "1946.21" "C84H136N24O27S" "CDEFKNPRSW" "AG" "6.78" "1" "0" "1" "8" "8" "53" "768" "4.4 hour" ">20 hour" ">10 hour" "88" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00877" "GMVTQYHQVLATHQEAIEKV" "20" "46(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(43% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00877" "DRAVPe00877.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2282.6" "C100H160N28O31S" "CDFNPRSW" "QV" "6" "3" "2" "1" "4" "7" "-22.5" "-2152" "30 hour" ">20 hour" ">10 hour" "92.5" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00878" "ATHQEAIEKVTGALKINNLR" "20" "47(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(44% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00878" "DRAVPe00878.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2206.53" "C95H164N30O30" "CDFMPSWY" "A" "8.64" "4" "2" "2" "5" "8" "-43" "-3817" "4.4 hour" ">20 hour" ">10 hour" "107.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00879" "TGALKINNLRLVTLEHQVLV" "20" "48(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(73% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00879" "DRAVPe00879.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2231.67" "C100H175N29O28" "CDFMPSWY" "L" "8.44" "3" "1" "2" "5" "10" "52.5" "-1151" "7.2 hour" ">20 hour" ">10 hour" "165.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00880" "LVTLEHQVLVIGLKVEAMEK" "20" "49(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(45% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00880" "DRAVPe00880.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2249.74" "C102H177N25O29S" "CDFNPRSWY" "LV" "5.5" "3" "3" "0" "2" "10" "70.5" "156" "5.5 hour" "3 min" "2 min" "160.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00881" "IGLKVEAMEKFLYTAFAMQE" "20" "50(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(74% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00881" "DRAVPe00881.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2319.76" "C107H167N23O30S2" "CDHNPRSW" "AE" "4.79" "2" "3" "-1" "3" "9" "34.5" "-395" "20 hour" "30 min" ">10 hour" "88" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00882" "FLYTAFAMQELGCNQNQFFC" "20" "51(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(18% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00882" "DRAVPe00882.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2375.72" "C108H151N25O30S3" "DHIKPRSVW" "F" "4" "0" "1" "-1" "7" "8" "29.5" "-819" "1.1 hour" "3 min" "2 min" "49" "1615" "85" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00883" "LGCNQNQFFCKIPLELWTRY" "20" "52(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(21% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00883" "DRAVPe00883.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2473.89" "C114H169N29O29S2" "ADHMSV" "L" "8.05" "2" "1" "1" "7" "7" "-21.5" "-2288" "5.5 hour" "3 min" "2 min" "78" "7115" "374.47" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00884" "NMTINQTIWNHGNITLGEWY" "20" "54(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(4% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00884" "DRAVPe00884.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2405.67" "C108H157N29O32S" "ACDFKPRSV" "N" "5.24" "1" "1" "0" "10" "6" "-55" "-2285" "1.4 hour" "3 min" ">10 hour" "78" "12490" "657.37" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00885" "HGNITLGEWYNQTKDLQQKF" "20" "55(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(35% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00885" "DRAVPe00885.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2420.67" "C109H162N30O33" "ACMPRSV" "Q" "6.75" "3" "2" "1" "7" "5" "-125" "-4452" "3.5 hour" "10 min" ">10 hour" "58.5" "6990" "367.89" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00886" "NQTKDLQQKFYEIIMDIEQN" "20" "56(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(68% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00886" "DRAVPe00886.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2498.79" "C109H172N28O37S" "ACGHPRSVW" "Q" "4.32" "2" "4" "-2" "4" "5" "-114" "-5530" "1.4 hour" "3 min" ">10 hour" "78" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00887" "YEIIMDIEQNNVQGKTGIQQ" "20" "57(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(37% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00887" "DRAVPe00887.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2321.59" "C99H161N27O35S" "ACFHLPRSW" "IQ" "4.14" "1" "3" "-2" "6" "5" "-70.5" "-3809" "2.8 hour" "10 min" "2 min" "92.5" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00888" "NVQGKTGIQQLQKWEDWVRW" "20" "58(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(96% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00888" "DRAVPe00888.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2499.81" "C114H171N33O31" "ACFHMPSY" "Q" "8.59" "3" "2" "1" "4" "7" "-121.5" "-4613" "1.4 hour" "3 min" ">10 hour" "68" "16500" "868.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00889" "LQKWEDWVRWIGNIPQYLKG" "20" "59(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(98% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00889" "DRAVPe00889.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2529.93" "C121H177N31O29" "ACFHMST" "W" "8.5" "3" "2" "1" "4" "8" "-77" "-2682" "5.5 hour" "3 min" "2 min" "92.5" "17990" "946.84" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00890" "IGNIPQYLKGLLGGILGIGL" "20" "60(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(60% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00890" "DRAVPe00890.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2009.46" "C95H161N23O24" "ACDEFHMRSTVW" "G" "8.59" "1" "0" "1" "8" "9" "104" "3205" "20 hour" "30 min" ">10 hour" "175.5" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00891" "LLGGILGIGLGVLLLILCLP" "20" "61(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(88% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00891" "DRAVPe00891.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "1960.58" "C95H170N20O21S" "ADEFHKMNQRSTWY" "L" "5.52" "0" "0" "0" "6" "13" "254" "6906" "5.5 hour" "3 min" "2 min" "248.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00892" "GVLLLILCLPTLVDCIRNCI" "20" "62(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(32% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00892" "DRAVPe00892.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2184.79" "C98H174N24O25S3" "AEFHKMQSWY" "L" "5.82" "1" "1" "0" "6" "11" "190" "2429" "30 hour" ">20 hour" ">10 hour" "204.5" "125" "6.58" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00893" "TLVDCIRNCIHKILGYTVIA" "20" "63(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(9% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00893" "DRAVPe00893.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2245.73" "C100H169N27O27S2" "EFMPQSW" "I" "7.76" "3" "1" "2" "7" "9" "95.5" "-286" "7.2 hour" ">20 hour" ">10 hour" "151" "1615" "85" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00894" "HKILGYTVIAMPEVEGEEIQ" "20" "64(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(8% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00894" "DRAVPe00894.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2256.6" "C101H162N24O32S" "CDFNRSW" "E" "4.48" "2" "4" "-2" "4" "7" "2" "-1190" "3.5 hour" "10 min" ">10 hour" "112" "1490" "78.42" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00895" "MPEVEGEEIQPQMELRRNGR" "20" "65(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(7% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00895" "DRAVPe00895.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2398.69" "C98H164N32O34S2" "ACDFHKSTWY" "E" "4.65" "3" "5" "-2" "3" "3" "-146" "-7607" "30 hour" ">20 hour" ">10 hour" "53.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00896" "PQMELRRNGRQCGMSEKEEE" "20" "66(derived from FIV envelope glycoprotein )" "Synthetic construct(derived from FIV envelope glycoprotein (gE))" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "Syncitia assay" "[Ref.8661378]Feline immunodeficiency virus (FIV):inhibition of virus replication in Crandell feline kidney (CrFK) fibroblastoid cells(6% inhibition at 16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00896" "DRAVPe00896.cif" "Linear" "Free" "Free" "None" "L" "Syncytium formation" "The machanism might be peptide bound the surface of FIV permissive cells and were highly active in blocking FIV infection when administered before the virus." "2407.68" "C94H159N33O35S3" "ADFHITVWY" "E" "5.07" "4" "5" "-1" "5" "1" "-192.5" "-9270" ">20 hour" ">20 hour" "?" "19.5" "0" "0" "8661378" "Virology. 1996 Jun 15;220(2):274-84. " "Lombardi S, Massi C, Indino E, La Rosa C, Mazzetti P, Falcone ML, Rovero P, Fissi A, Pieroni O, Bandecchi P, Esposito F, Tozzini F, Bendinelli M, Garzelli C." "Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides." "10.1006/viro.1996.0315" "Anti-FIV" "DRAVPe00897" "IINFYDPLVFPSDEFDASISQVNEKINQSLAFIRK" "35" "T-104" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2cell from viral cytopathic effect(CPE)(EC50=91 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00897" "DRAVPe00897.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4059.59" "C187H285N45O56" "CGHMTW" "I" "4.44" "3" "5" "-2" "8" "15" "-4.86" "-5248" "20 hour" "30 min" ">10 hour" "100.29" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1211" "Anti-RSV" "DRAVPe00898" "INFYDPLVFPSDEFDASISQVNEKINQSLAFIRKS" "35" "T-105" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=93 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00898" "DRAVPe00898.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4033.51" "C184H279N45O57" "CGHMTW" "S" "4.44" "3" "5" "-2" "9" "14" "-20" "-6080" "20 hour" "30 min" ">10 hour" "89.14" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1212" "Anti-RSV" "DRAVPe00899" "NFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSD" "35" "T-106" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00899" "DRAVPe00899.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4035.44" "C182H273N45O59" "CGHMTW" "S" "4.23" "3" "6" "-3" "9" "13" "-42.86" "-7444" "1.4 hour" "3 min" ">10 hour" "78" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-RSV" "DRAVPe00900" "FYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDE" "35" "T-107" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=20 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00900" "DRAVPe00900.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4050.45" "C183H274N44O60" "CGHMTW" "S" "4.14" "3" "7" "-4" "8" "13" "-42.86" "-7461" "1.1 hour" "3 min" "2 min" "78" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0681" "Anti-RSV" "DRAVPe00901" "YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL" "35" "T-108" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00901" "DRAVPe00901.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4016.43" "C180H276N44O60" "CGHMTW" "S" "4.14" "3" "7" "-4" "8" "13" "-40" "-7267" "2.8 hour" "10 min" "2 min" "89.14" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1214" "Anti-RSV" "DRAVPe00902" "DPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL" "35" "T-109" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00902" "DRAVPe00902.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3966.41" "C177H278N44O59" "CGHMTWY" "S" "4.14" "3" "7" "-4" "7" "14" "-25.43" "-6761" "1.1 hour" "3 min" ">10 hour" "100.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0712" "Anti-RSV" "DRAVPe00903" "PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH" "35" "T-110" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=30 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00903" "DRAVPe00903.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3988.47" "C179H280N46O57" "CGMTWY" "S" "4.58" "4" "6" "-2" "7" "14" "-24.57" "-6355" ">20 hour" ">20 hour" "?" "100.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1216" "Anti-RSV" "DRAVPe00904" "LVFPSDEFDASISQVNEKINQSLAFIRKSDELLHN" "35" "T-111" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=9 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00904" "DRAVPe00904.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4005.45" "C178H279N47O58" "CGMTWY" "S" "4.58" "4" "6" "-2" "8" "14" "-30" "-7019" "5.5 hour" "3 min" "2 min" "100.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1217" "Anti-RSV" "DRAVPe00905" "VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV" "35" "T-112" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=19 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00905" "DRAVPe00905.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3991.43" "C177H277N47O58" "CGMTWY" "S" "4.58" "4" "6" "-2" "8" "14" "-28.86" "-7107" "100 hour" ">20 hour" ">10 hour" "97.43" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1218" "Anti-RSV" "DRAVPe00906" "FPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN" "35" "T-113" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00906" "DRAVPe00906.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4006.4" "C176H274N48O59" "CGMTWY" "S" "4.58" "4" "6" "-2" "9" "13" "-50.86" "-8175" "1.1 hour" "3 min" "2 min" "89.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1219" "Anti-RSV" "DRAVPe00907" "PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA" "35" "T-114" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00907" "DRAVPe00907.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3930.3" "C170H270N48O59" "CGMTWY" "S" "4.58" "4" "6" "-2" "9" "13" "-53.71" "-8292" ">20 hour" ">20 hour" "?" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1220" "Anti-RSV" "DRAVPe00908" "SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG" "35" "T-115" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00908" "DRAVPe00908.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3890.24" "C167H266N48O59" "CMPTWY" "S" "4.58" "4" "6" "-2" "10" "13" "-50.29" "-8198" "1.9 hour" ">20 hour" ">10 hour" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1221" "Anti-RSV" "DRAVPe00909" "DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK" "35" "T-116" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=12 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00909" "DRAVPe00909.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3931.33" "C170H273N49O58" "CMPTWY" "NS" "4.95" "5" "6" "-1" "9" "13" "-59.14" "-8413" "1.1 hour" "3 min" ">10 hour" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1222" "Anti-RSV" "DRAVPe00910" "EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS" "35" "T-117" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=13 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00910" "DRAVPe00910.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3903.32" "C169H273N49O57" "CMPTWY" "S" "5.56" "5" "5" "0" "10" "13" "-51.43" "-7881" "1 hour" "30 min" ">10 hour" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1223" "Anti-RSV" "DRAVPe00911" "FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST" "35" "T-118" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV,HPIV,MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay,antifusion assay,plaque reduction assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.051 μg/ml);##measles virus(MV):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##Human parainfluenza virus type 3(HPIV3):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00911" "DRAVPe00911.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3875.31" "C168H273N49O56" "CMPWY" "S" "6.76" "5" "4" "1" "11" "13" "-43.43" "-7457" "1.1 hour" "3 min" "2 min" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1144" "Anti-RSV,Anti-HPIV,Anti-MeV" "DRAVPe00912" "DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT" "35" "T-119" "Synthetic construct(derived from Respiratory syncytial virus(RSV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Respiratory syncytial virus(RSV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=8 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00912" "DRAVPe00912.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3829.24" "C163H271N49O57" "CMPWY" "S" "6.76" "5" "4" "1" "12" "12" "-53.43" "-8012" "1.1 hour" "3 min" ">10 hour" "92" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa1225" "Anti-RSV" "DRAVPe00913" "YTPNDITLNNSVALDPIDISIELNKAKSDLEESKE" "35" "T-189" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00913" "DRAVPe00913.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3890.27" "C168H274N42O63" "CFGHMQRW" "DEILNS" "4.07" "3" "8" "-5" "11" "11" "-62.29" "-7719" "2.8 hour" "10 min" "2 min" "103.14" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-HPIV-3" "DRAVPe00914" "TPNDITLNNSVALDPIDISIELNKAKSDLEESKEW" "35" "T-190" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00914" "DRAVPe00914.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3913.3" "C170H275N43O62" "CFGHMQRY" "DEILNS" "4.07" "3" "8" "-5" "10" "12" "-61.14" "-7472" "7.2 hour" ">20 hour" ">10 hour" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-HPIV-3" "DRAVPe00915" "PNDITLNNSVALDPIDISIELNKAKSDLEESKEWI" "35" "T-191" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00915" "DRAVPe00915.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3925.36" "C172H279N43O61" "CFGHMQRY" "I" "4.07" "3" "8" "-5" "9" "13" "-46.29" "-6723" ">20 hour" ">20 hour" "?" "114.29" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-HPIV-3" "DRAVPe00916" "NDITLNNSVALDPIDISIELNKAKSDLEESKEWIR" "35" "T-192" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00916" "DRAVPe00916.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3984.43" "C173H284N46O61" "CFGHMQY" "I" "4.29" "4" "8" "-4" "9" "13" "-54.57" "-8215" "1.4 hour" "3 min" ">10 hour" "114.29" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-HPIV-3" "DRAVPe00917" "DITLNNSVALDPIDISIELNKAKSDLEESKEWIRR" "35" "T-193" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00917" "DRAVPe00917.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4026.51" "C175H290N48O60" "CFGHMQY" "I" "4.51" "5" "8" "-3" "8" "13" "-57.43" "-9043" "1.1 hour" "3 min" ">10 hour" "114.29" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-HPIV-3" "DRAVPe00918" "ITLNNSVALDPIDISIELNKAKSDLEESKEWIRRS" "35" "T-194" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=62 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00918" "DRAVPe00918.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3998.5" "C174H290N48O59" "CFGHMQY" "IS" "4.72" "5" "7" "-2" "9" "13" "-49.71" "-8511" "20 hour" "30 min" ">10 hour" "114.29" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0742" "Anti-HPIV-3" "DRAVPe00919" "TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN" "35" "T-195" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=72 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00919" "DRAVPe00919.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3999.45" "C172H285N49O60" "CFGHMQY" "S" "4.71" "5" "7" "-2" "10" "12" "-72.57" "-9667" "7.2 hour" ">20 hour" ">10 hour" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0358" "Anti-HPIV-3" "DRAVPe00920" "LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ" "35" "T-196" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00920" "DRAVPe00920.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4026.47" "C173H286N50O60" "CFGHMTY" "S" "4.72" "5" "7" "-2" "9" "12" "-80.57" "-9964" "5.5 hour" "3 min" "2 min" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0359" "Anti-HPIV-3" "DRAVPe00921" "NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK" "35" "T-197" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00921" "DRAVPe00921.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4041.49" "C173H287N51O60" "CFGHMTY" "S" "5.1" "6" "7" "-1" "9" "11" "-102.57" "-11011" "1.4 hour" "3 min" ">10 hour" "92" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0360" "Anti-HPIV-3" "DRAVPe00922" "NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL" "35" "T-198" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00922" "DRAVPe00922.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4040.54" "C175H292N50O59" "CFGHMTY" "S" "5.1" "6" "7" "-1" "8" "12" "-81.71" "-9855" "1.4 hour" "3 min" ">10 hour" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0361" "Anti-HPIV-3" "DRAVPe00923" "SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD" "35" "T-199" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00923" "DRAVPe00923.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4041.53" "C175H291N49O60" "CFGHMTY" "S" "4.77" "6" "8" "-2" "7" "12" "-81.71" "-10063" "1.9 hour" ">20 hour" ">10 hour" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0362" "Anti-HPIV-3" "DRAVPe00924" "VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS" "35" "T-200" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00924" "DRAVPe00924.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4041.53" "C175H291N49O60" "CFGHMTY" "S" "4.77" "6" "8" "-2" "7" "12" "-81.71" "-10063" "100 hour" ">20 hour" ">10 hour" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0363" "Anti-HPIV-3" "DRAVPe00925" "ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI" "35" "T-201" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00925" "DRAVPe00925.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4055.55" "C176H293N49O60" "CFGHMTVY" "IS" "4.77" "6" "8" "-2" "7" "12" "-80.86" "-9975" "4.4 hour" ">20 hour" ">10 hour" "106" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0364" "Anti-HPIV-3" "DRAVPe00926" "LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG" "35" "T-202" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.03 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00926" "DRAVPe00926.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4041.53" "C175H291N49O60" "CFHMTVY" "IS" "4.77" "6" "8" "-2" "8" "11" "-87.14" "-10062" "5.5 hour" "3 min" "2 min" "103.14" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0365" "Anti-HPIV-3" "DRAVPe00927" "DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN" "35" "T-203" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00927" "DRAVPe00927.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4042.47" "C173H286N50O61" "CFHMTVY" "IS" "4.77" "6" "8" "-2" "9" "10" "-108" "-11218" "1.1 hour" "3 min" ">10 hour" "92" "5500" "161.76" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0366" "Anti-HPIV-3" "DRAVPe00928" "PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW" "35" "T-204" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.07 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00928" "DRAVPe00928.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4113.6" "C180H291N51O59" "CFHMTVY" "IS" "5.1" "6" "7" "-1" "9" "11" "-100.57" "-10113" ">20 hour" ">20 hour" "?" "92" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0367" "Anti-HPIV-3" "DRAVPe00929" "IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH" "35" "T-205" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPIV-3,MeV,RSV,HIV" "Paramyxoviridae, Retroviridae" "Luminescence fusion assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=0.11 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.038 μg/ml);##measles virus(MV):inhibition of cell-cell fusion in HEp2 cell(EC50=1.19 μg/ml);##Respiratory syncytial virus(RSV):inhibition of cell-cell fusion in HEp2 cell(EC50=1.76 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00929" "DRAVPe00929.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4153.62" "C181H291N53O59" "CFMPTVY" "IS" "5.64" "7" "7" "0" "9" "11" "-105.14" "-10579" "20 hour" "30 min" ">10 hour" "92" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0368" "Anti-HPIV-3,Anti-MeV,Anti-RSV,Anti-HIV" "DRAVPe00930" "IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH" "35" "HPIV3 F HRC derived peptide(454-488)" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HeV,HPIV-3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Hendra virus(HeV):inhibition of virus infection in HeLa cells(IC50=50 nM);inhibition of fusion in HeLa cells(IC50=5000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=1500 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe00930.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 10HB structure that is required for fusion." "4153.62" "C181H291N53O59" "CFMPTVY" "IS" "5.64" "7" "7" "0" "9" "11" "-105.14" "-10579" "20 hour" "30 min" ">10 hour" "92" "11000" "323.53" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV-3" "DRAVPe00931" "DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ" "35" "T-206" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00931" "DRAVPe00931.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4168.59" "C180H288N54O60" "CFMPTVY" "S" "5.64" "7" "7" "0" "9" "10" "-128" "-11625" "1.1 hour" "3 min" ">10 hour" "80.86" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0369" "Anti-HPIV-3" "DRAVPe00932" "ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS" "35" "T-207" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00932" "DRAVPe00932.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4140.58" "C179H288N54O59" "CFMPTVY" "S" "6.78" "7" "6" "1" "10" "10" "-120.29" "-11093" "20 hour" "30 min" ">10 hour" "80.86" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0370" "Anti-HPIV-3" "DRAVPe00933" "SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS" "35" "T-208" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00933" "DRAVPe00933.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4114.5" "C176H282N54O60" "CFMPTVY" "S" "6.5" "7" "6" "1" "11" "9" "-135.43" "-11925" "1.9 hour" ">20 hour" ">10 hour" "69.71" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0371" "Anti-HPIV-3" "DRAVPe00934" "IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST" "35" "T-209" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00934" "DRAVPe00934.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4128.53" "C177H284N54O60" "CFMPVY" "S" "6.78" "7" "6" "1" "11" "9" "-135.14" "-11842" "20 hour" "30 min" ">10 hour" "69.71" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0372" "Anti-HPIV-3" "DRAVPe00935" "ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT" "35" "T-210" "Synthetic construct(derived from Human parainfluenza virus type 3(HPIV-3) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPIV-3" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]Human parainfluenza virus type 3(HPIV-3):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2.4 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00935" "DRAVPe00935.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4116.47" "C175H280N54O61" "CFMPVY" "S" "6.87" "7" "6" "1" "12" "8" "-150" "-12591" "1 hour" "30 min" ">10 hour" "58.57" "11000" "323.53" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0373" "Anti-HPIV-3" "DRAVPe00936" "PDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLED" "35" "T-252" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00936" "DRAVPe00936.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3786.3" "C168H274N46O53" "CFMQW" "L" "4.52" "4" "6" "-2" "8" "14" "-8" "-4733" ">20 hour" ">20 hour" "?" "125.43" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "DRAVPa0399" "Anti-MeV" "DRAVPe00937" "DAVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDA" "35" "T-253" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00937" "DRAVPe00937.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3831.34" "C169H277N47O54" "CFMW" "L" "4.52" "4" "6" "-2" "7" "15" "-7.14" "-5200" "1.1 hour" "3 min" ">10 hour" "128.29" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00938" "AVYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAK" "35" "T-254" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50>100 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00938" "DRAVPe00938.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3844.43" "C171H284N48O52" "CFMW" "L" "5.52" "5" "5" "0" "7" "15" "-8.29" "-4883" "4.4 hour" ">20 hour" ">10 hour" "128.29" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00939" "VYLHRIDLGPPISLERLDVGTNLQNAIAKLEDAKE" "35" "T-255" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=85.3 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00939" "DRAVPe00939.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3902.46" "C173H286N48O54" "CFMW" "L" "4.95" "5" "6" "-1" "7" "14" "-23.43" "-5745" "100 hour" ">20 hour" ">10 hour" "125.43" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00940" "YLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKEL" "35" "T-256" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=90.7 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00940" "DRAVPe00940.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3845.41" "C171H283N47O53" "CFMQW" "L" "4.95" "5" "6" "-1" "8" "14" "-15.71" "-5009" "2.8 hour" "10 min" "2 min" "128.29" "1490" "43.82" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00941" "LHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELL" "35" "T-257" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV,RSV,HPIV-3,HIV" "Paramyxoviridae, Retroviridae" "Cytopathic effect(CPE) assay,antifusion assay,plaque reduction assay" "[Ref.8700906]measles virus(MeV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.5 μg/ml);inhibition of cell-cell fusion in HEp2 cell(EC50=0.068 μg/ml);##Human parainfluenza virus type 3(HPIV-3):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##Respiratory syncytial virus(RSV):inhibition of cell-cell fusion in HEp2 cell(EC50>25 μg/ml);##HIV-1 LAI:inhibition of cell-cell fusion in HEp2 cell(EC50>50 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00941" "DRAVPe00941.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3795.39" "C168H285N47O52" "CFMQWY" "L" "4.95" "5" "6" "-1" "7" "15" "-1.14" "-4503" "5.5 hour" "3 min" "2 min" "139.43" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV,Anti-RSV,Anti-HPIV-3,Anti-HIV" "DRAVPe00942" "HRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLE" "35" "T-258" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=2.2 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00942" "DRAVPe00942.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3811.35" "C167H281N47O54" "CFMQWY" "L" "4.7" "5" "7" "-2" "7" "14" "-22" "-5676" "3.5 hour" "10 min" ">10 hour" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00943" "RIDLGPPISLERLDVGTNLGNAIAKLEDAKELLES" "35" "T-259" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.7 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00943" "DRAVPe00943.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3761.29" "C164H279N45O55" "CFHMQWY" "L" "4.44" "4" "7" "-3" "8" "14" "-15.14" "-5550" "1 hour" "2 min" "2 min" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00944" "IDLGPPISLERLDVGTNLGNAIAKLEDAKELLESS" "35" "T-260" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=4.9 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00944" "DRAVPe00944.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3692.18" "C161H272N42O56" "CFHMQWY" "L" "4.2" "3" "7" "-4" "9" "14" "-4.57" "-4398" "20 hour" "30 min" ">10 hour" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00945" "DLGPPISLERLDVGTNLGNAIAKLEDAKELLESSD" "35" "T-261" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=5.7 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00945" "DRAVPe00945.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3694.11" "C159H266N42O58" "CFHMQWY" "L" "4.07" "3" "8" "-5" "9" "13" "-27.43" "-5762" "1.1 hour" "3 min" ">10 hour" "117.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00946" "LGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQ" "35" "T-262" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=6.5 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00946" "DRAVPe00946.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3707.15" "C160H269N43O57" "CFHMWY" "L" "4.2" "3" "7" "-4" "9" "13" "-27.43" "-5444" "5.5 hour" "3 min" "2 min" "117.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00947" "GPPISLERLDVGTNLGNAIAKLEDAKELLESSDQI" "35" "T-263" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=10.1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00947" "DRAVPe00947.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3707.15" "C160H269N43O57" "CFHMWY" "L" "4.2" "3" "7" "-4" "9" "13" "-25.43" "-5444" "30 hour" ">20 hour" ">10 hour" "117.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00948" "PPISLERLDVGTNLGNAIAKLEDAKELLESSDQIL" "35" "T-264" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=1.1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00948" "DRAVPe00948.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3763.26" "C164H277N43O57" "CFHMWY" "L" "4.2" "3" "7" "-4" "8" "14" "-13.43" "-5046" ">20 hour" ">20 hour" "?" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00949" "PISLERLDVGTNLGNAIAKLEDAKELLESSDQILR" "35" "T-265" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=3.1 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00949" "DRAVPe00949.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3822.33" "C165H282N46O57" "CFHMWY" "L" "4.44" "4" "7" "-3" "8" "14" "-21.71" "-6538" ">20 hour" ">20 hour" "?" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00950" "ISLERLDVGTNLGNAIAKLEDAKELLESSDQILRS" "35" "T-266" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=13.0 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00950" "DRAVPe00950.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3812.29" "C163H280N46O58" "CFHMPWY" "L" "4.44" "4" "7" "-3" "9" "14" "-19.43" "-6878" "20 hour" "30 min" ">10 hour" "128.29" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00951" "SLERLDVGTNLGNAIAKLEDAKELLESSDQILRSM" "35" "T-267" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=12.3 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00951" "DRAVPe00951.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3830.32" "C162H278N46O58S" "CFHPWY" "L" "4.44" "4" "7" "-3" "9" "13" "-26.86" "-7135" "1.9 hour" ">20 hour" ">10 hour" "117.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00952" "LERLDVGTNLGNAIAKLEDAKELLESSDQILRSMK" "35" "T-268" "Synthetic construct(derived from measles virus(MV) fusion (F) protein)" "P69353" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MeV" "Paramyxoviridae" "Cytopathic effect(CPE) assay" "[Ref.8700906]measles virus(MV):protection of HEp2 cell from viral cytopathic effect(CPE)(EC50=7.3 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.8700906]No significant cytotoxic against HEp2 cells(CC50>100 μM)." "DRAVPe00952" "DRAVPe00952.cif" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3871.42" "C165H285N47O57S" "CFHPWY" "L" "4.72" "5" "7" "-2" "8" "13" "-35.71" "-7350" "5.5 hour" "3 min" "2 min" "117.14" "0" "0" "8700906" "Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91." "Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr." "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. " "10.1073/pnas.93.5.2186" "Anti-MeV" "DRAVPe00953" "DDSVVCAAMSYSYA" "14" "P1(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00953" "DRAVPe00953.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1481.61" "C62H92N14O24S2" "EFGHIKLNPQRTW" "AS" "3.56" "0" "2" "-2" "6" "5" "44.29" "-1078" "1.1 hour" "3 min" ">10 hour" "62.86" "2980" "229.23" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00954" "DDSVVCAAMSYSFA" "14" "P2(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(29% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00954" "DRAVPe00954.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1465.61" "C62H92N14O23S2" "EGHIKLNPQRTW" "AS" "3.56" "0" "2" "-2" "5" "6" "73.57" "-766" "1.1 hour" "3 min" ">10 hour" "62.86" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00955" "DDSVVCAAMSYSHA" "14" "P3(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00955" "DRAVPe00955.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1455.58" "C59H90N16O23S2" "EFGIKLNPQRTW" "AS" "4.2" "1" "2" "-1" "5" "5" "30.71" "-1530" "1.1 hour" "3 min" ">10 hour" "62.86" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00956" "DDSVVSAAMSYSYA" "14" "P4(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±9% inhibition at 1 µM; 47±1% inhibition at 3 µM; 89±6% inhibition at 10 µM; IC50=3.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00956" "DRAVPe00956.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1465.55" "C62H92N14O25S" "CEFGHIKLNPQRTW" "S" "3.56" "0" "2" "-2" "6" "5" "20.71" "-1546" "1.1 hour" "3 min" ">10 hour" "62.86" "2980" "229.23" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00957" "DDSVVSAAMSYSFA" "14" "P5(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00957" "DRAVPe00957.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1449.55" "C62H92N14O24S" "CEGHIKLNPQRTW" "S" "3.56" "0" "2" "-2" "5" "6" "50" "-1234" "1.1 hour" "3 min" ">10 hour" "62.86" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00958" "DDSVVAAMSYSYA" "13" "P7(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00958" "DRAVPe00958.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1378.47" "C59H87N13O23S" "CEFGHIKLNPQRTW" "AS" "3.56" "0" "2" "-2" "5" "5" "28.46" "-1206" "1.1 hour" "3 min" ">10 hour" "67.69" "2980" "248.33" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00959" "DDSVVAAMSYSFA" "13" "P8(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00959" "DRAVPe00959.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1362.47" "C59H87N13O22S" "CEGHIKLNPQRTW" "AS" "3.56" "0" "2" "-2" "4" "6" "60" "-894" "1.1 hour" "3 min" ">10 hour" "67.69" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00960" "DDSVVAAMSYSHA" "13" "P9(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00960" "DRAVPe00960.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1352.44" "C56H85N15O22S" "CEFGIKLNPQRTW" "AS" "4.2" "1" "2" "-1" "4" "5" "13.85" "-1658" "1.1 hour" "3 min" ">10 hour" "67.69" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00961" "ADLEVVAATYVLVA" "14" "P10(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 6±11% inhibition at 1 µM;27±5% inhibition at 3 µM; 75±1% inhibition at 10 µM; IC50=6.3µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00961" "DRAVPe00961.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1433.66" "C66H108N14O21" "CFGHIKMNPQRSW" "AV" "3.67" "0" "2" "-2" "2" "10" "161.43" "1500" "4.4 hour" ">20 hour" ">10 hour" "167.14" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00962" "ADLEVVAATFVLVA" "14" "P11(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(-2±7% inhibition at 1 µM; 29±5% inhibition at 3 µM; 83±5% inhibition at 10 µM; IC50=5.72 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00962" "DRAVPe00962.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1417.67" "C66H108N14O20" "CGHIKMNPQRSWY" "AV" "3.67" "0" "2" "-2" "1" "11" "190.71" "1812" "4.4 hour" ">20 hour" ">10 hour" "167.14" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00963" "ADLEVVAATHVLVA" "14" "P12(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 11±16% inhibition at 1 µM; 77±3% inhibition at 3 µM; 95±1% inhibition at 10 µM; IC50=2.2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00963" "DRAVPe00963.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1407.63" "C63H106N16O20" "CFGIKMNPQRSWY" "AV" "4.35" "1" "2" "-1" "1" "10" "147.86" "1048" "4.4 hour" ">20 hour" ">10 hour" "167.14" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00964" "ADLEVVAATYV" "11" "P13(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00964" "DRAVPe00964.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1150.29" "C52H83N11O18" "CFGHIKMNPQRSW" "AV" "3.67" "0" "2" "-2" "2" "7" "116.36" "423" "4.4 hour" ">20 hour" ">10 hour" "141.82" "1490" "149" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00965" "KKKKVVAATYVLVA" "14" "P15(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(30% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00965" "DRAVPe00965.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1517.92" "C72H128N18O17" "CDEFGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "8" "60" "160" "1.3 hour" "3 min" "2 min" "132.14" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00966" "DDDEVVAATYVLVA" "14" "P17(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00966" "DRAVPe00966.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1479.6" "C65H102N14O25" "CFGHIKMNPQRSW" "V" "3.37" "0" "4" "-4" "2" "8" "71.43" "-917" "1.1 hour" "3 min" ">10 hour" "132.14" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00967" "ADLEVVAATYVDDD" "14" "P19(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00967" "DRAVPe00967.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1495.56" "C64H98N14O27" "CFGHIKMNPQRSW" "D" "3.28" "0" "5" "-5" "2" "7" "16.43" "-2193" "4.4 hour" ">20 hour" ">10 hour" "111.43" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00968" "ADLEVVAATYVDVA" "14" "P20(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 18±21% inhibition at 1 µM; 75±1% inhibition at 3 µM; 96±1% inhibition at 10 µM; IC50=2.1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00968" "DRAVPe00968.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1435.59" "C64H102N14O23" "CFGHIKMNPQRSW" "AV" "3.49" "0" "3" "-3" "2" "9" "109.29" "136" "4.4 hour" ">20 hour" ">10 hour" "139.29" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00969" "ADLEVVAATYVLDA" "14" "P21(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00969" "DRAVPe00969.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1449.62" "C65H104N14O23" "CFGHIKMNPQRSW" "A" "3.49" "0" "3" "-3" "2" "9" "106.43" "224" "4.4 hour" ">20 hour" ">10 hour" "146.43" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00970" "ADLEVVAATYVLVD" "14" "P22(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(38% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00970" "DRAVPe00970.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1477.67" "C67H108N14O23" "CFGHIKMNPQRSW" "V" "3.49" "0" "3" "-3" "2" "9" "123.57" "447" "4.4 hour" ">20 hour" ">10 hour" "160" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00971" "ADLEVVAATYVDDA" "14" "P23(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(20% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00971" "DRAVPe00971.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1451.55" "C63H98N14O25" "CFGHIKMNPQRSW" "A" "3.37" "0" "4" "-4" "2" "8" "54.29" "-1140" "4.4 hour" ">20 hour" ">10 hour" "118.57" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00972" "ADLEVVAATYVLDD" "14" "P24(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 5±4% inhibition at 1 µM; 26±4% inhibition at 3 µM; 65±3% inhibition at 10 µM; IC50=7.4 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00972" "DRAVPe00972.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1493.63" "C66H104N14O25" "CFGHIKMNPQRSW" "ADV" "3.37" "0" "4" "-4" "2" "8" "68.57" "-829" "4.4 hour" ">20 hour" ">10 hour" "139.29" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00973" "ADLEVVAATYVDVD" "14" "P25(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00973" "DRAVPe00973.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1479.6" "C65H102N14O25" "CFGHIKMNPQRSW" "V" "3.37" "0" "4" "-4" "2" "8" "71.43" "-917" "4.4 hour" ">20 hour" ">10 hour" "132.14" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00974" "KKKKVVAATYVKKA" "14" "P27(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00974" "DRAVPe00974.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1561.98" "C73H132N20O17" "CDEFGHILMNPQRSW" "K" "10.4" "6" "0" "6" "2" "6" "-52.86" "-1846" "1.3 hour" "3 min" "2 min" "83.57" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00975" "KKKKVVAATYFFFA" "14" "P30(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00975" "DRAVPe00975.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1648.02" "C83H126N18O17" "CDEGHILMNPQRSW" "K" "10.18" "4" "0" "4" "2" "8" "32.86" "-246" "1.3 hour" "3 min" "2 min" "62.86" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00976" "KKKKVVAATYFLVA" "14" "P31(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00976" "DRAVPe00976.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1565.96" "C76H128N18O17" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "8" "50" "54" "1.3 hour" "3 min" "2 min" "111.43" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00977" "KKKKVVAATYVLVF" "14" "P33(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00977" "DRAVPe00977.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1594.02" "C78H132N18O17" "CDEGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "8" "67.14" "277" "1.3 hour" "3 min" "2 min" "125" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00978" "KKKKVVAATYVLFA" "14" "P34(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00978" "DRAVPe00978.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1565.96" "C76H128N18O17" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "8" "50" "54" "1.3 hour" "3 min" "2 min" "111.43" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00979" "KKKKVVAATYKKVA" "14" "P37(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00979" "DRAVPe00979.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1561.98" "C73H132N20O17" "CDEFGHILMNPQRSW" "K" "10.4" "6" "0" "6" "2" "6" "-52.86" "-1846" "1.3 hour" "3 min" "2 min" "83.57" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00980" "AKLKVVAATYVLKK" "14" "P38(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00980" "DRAVPe00980.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1531.95" "C73H130N18O17" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "8" "57.14" "248" "4.4 hour" ">20 hour" ">10 hour" "139.29" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00981" "KKKKVVAATYKKKK" "14" "P42(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00981" "DRAVPe00981.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1648.11" "C77H142N22O17" "CDEFGHILMNPQRSW" "K" "10.54" "8" "0" "8" "2" "4" "-151.43" "-3541" "1.3 hour" "3 min" "2 min" "55.71" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00982" "ADLEVVAATYVKKK" "14" "P44(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00982" "DRAVPe00982.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1534.82" "C70H119N17O21" "CFGHIMNPQRSW" "AKV" "8.47" "3" "2" "1" "2" "7" "7.86" "-1242" "4.4 hour" ">20 hour" ">10 hour" "111.43" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00983" "ADLEVVAATYKKKK" "14" "P45(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00983" "DRAVPe00983.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1563.86" "C71H122N18O21" "CFGHIMNPQRSW" "K" "9.41" "4" "2" "2" "2" "6" "-50" "-2201" "4.4 hour" ">20 hour" ">10 hour" "90.71" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00984" "ADLEVVAATYAAAA" "14" "P47(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00984" "DRAVPe00984.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1335.48" "C59H94N14O21" "CFGHIKMNPQRSW" "A" "3.67" "0" "2" "-2" "2" "10" "112.86" "743" "4.4 hour" ">20 hour" ">10 hour" "119.29" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00985" "KDLKVVAATYVKKK" "14" "P48(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(21% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00985" "DRAVPe00985.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1590.97" "C74H131N19O19" "CEFGHIMNPQRSW" "K" "10" "5" "1" "4" "2" "6" "-35.71" "-1852" "1.3 hour" "3 min" "2 min" "104.29" "1490" "114.62" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00986" "KKKKAVAATYVLV" "13" "P49(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(59% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00986" "DRAVPe00986.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1418.79" "C67H119N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "32.31" "-244" "1.3 hour" "3 min" "2 min" "120" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00987" "KKKKVAAATYVLV" "13" "P50(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±1% inhibition at 1 µM; 51±10% inhibition at 3 µM; 74±1% inhibition at 10 µM; IC50=3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00987" "DRAVPe00987.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1418.79" "C67H119N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "32.31" "-244" "1.3 hour" "3 min" "2 min" "120" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00988" "KKKKVVAAAYVLV" "13" "P51(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00988" "DRAVPe00988.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1416.81" "C68H121N17O15" "CDEFGHIMNPQRSTW" "KV" "10.18" "4" "0" "4" "1" "8" "70" "417" "1.3 hour" "3 min" "2 min" "142.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00989" "KKKKVVAATAVLV" "13" "P52(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00989" "DRAVPe00989.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1354.74" "C63H119N17O15" "CDEFGHIMNPQRSWY" "KV" "10.48" "4" "0" "4" "1" "8" "74.62" "174" "1.3 hour" "3 min" "2 min" "142.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00990" "KKKKVVAATYVAV" "13" "P54(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(21% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00990" "DRAVPe00990.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1404.76" "C66H117N17O16" "CDEFGHILMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "35.38" "-332" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00991" "KKKKVVAATYVLA" "13" "P55(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00991" "DRAVPe00991.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1418.79" "C67H119N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "32.31" "-244" "1.3 hour" "3 min" "2 min" "120" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00992" "KKKKVLAATYVLV" "13" "P57(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00992" "DRAVPe00992.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1460.87" "C70H125N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "47.69" "67" "1.3 hour" "3 min" "2 min" "142.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00993" "KKKKVVLATYVLV" "13" "P58(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 21±8% inhibition at 1 µM; 30±5% inhibition at 3 µM; 61±15% inhibition at 10 µM; IC50=7.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00993" "DRAVPe00993.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1488.92" "C72H129N17O16" "CDEFGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "66.15" "290" "1.3 hour" "3 min" "2 min" "156.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00994" "KKKKVVAALYVLV" "13" "P60(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00994" "DRAVPe00994.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1458.89" "C71H127N17O15" "CDEFGHIMNPQRSTW" "KV" "10.18" "4" "0" "4" "1" "8" "85.38" "728" "1.3 hour" "3 min" "2 min" "164.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00995" "KKKKVVAATYLLV" "13" "P61(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00995" "DRAVPe00995.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1460.87" "C70H125N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "47.69" "67" "1.3 hour" "3 min" "2 min" "142.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00996" "KKKKVVAATYVLL" "13" "P62(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(25% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00996" "DRAVPe00996.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1460.87" "C70H125N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "47.69" "67" "1.3 hour" "3 min" "2 min" "142.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00997" "KKKKFVAATYVLV" "13" "P63(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 32±7% inhibition at 1 µM; 35±8% inhibition at 3 µM; 61±6% inhibition at 10 µM; IC50=7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00997" "DRAVPe00997.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1494.88" "C73H123N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "40" "-127" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00998" "KKKKVFAATYVLV" "13" "P64(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00998" "DRAVPe00998.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1494.88" "C73H123N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "40" "-127" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe00999" "KKKKVVFATYVLV" "13" "P65(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(34% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe00999" "DRAVPe00999.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1522.94" "C75H127N17O16" "CDEGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "58.46" "96" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01000" "KKKKVVAFTYVLV" "13" "P66(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(23% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01000" "DRAVPe01000.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1522.94" "C75H127N17O16" "CDEGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "58.46" "96" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01001" "KKKKVVAAFYVLV" "13" "P67(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01001" "DRAVPe01001.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1492.91" "C74H125N17O15" "CDEGHIMNPQRSTW" "KV" "10.18" "4" "0" "4" "1" "8" "77.69" "534" "1.3 hour" "3 min" "2 min" "134.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01002" "KKKKVVAATFVLV" "13" "P68(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(28% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01002" "DRAVPe01002.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1430.84" "C69H123N17O15" "CDEGHIMNPQRSWY" "KV" "10.48" "4" "0" "4" "1" "8" "82.31" "291" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01003" "KKKKVVAATYFLV" "13" "P69(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01003" "DRAVPe01003.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1494.88" "C73H123N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "40" "-127" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01004" "KKKKVVAATYVFV" "13" "P70(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01004" "DRAVPe01004.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1480.86" "C72H121N17O16" "CDEGHILMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "43.08" "-215" "1.3 hour" "3 min" "2 min" "104.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01005" "KKKKVVAATYVLF" "13" "P71(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01005" "DRAVPe01005.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1494.88" "C73H123N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "40" "-127" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01006" "KKKKEVAATYVLV" "13" "P72(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01006" "DRAVPe01006.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1476.82" "C69H121N17O18" "CDFGHIMNPQRSW" "K" "9.83" "4" "1" "3" "2" "6" "-8.46" "-1106" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01007" "KKKKVVAETYVLV" "13" "P75(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01007" "DRAVPe01007.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1504.88" "C71H125N17O18" "CDFGHIMNPQRSW" "KV" "9.83" "4" "1" "3" "2" "6" "10" "-883" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01008" "KKKKVVAAEYVLV" "13" "P76(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01008" "DRAVPe01008.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1474.85" "C70H123N17O17" "CDFGHIMNPQRSTW" "KV" "9.83" "4" "1" "3" "1" "7" "29.23" "-445" "1.3 hour" "3 min" "2 min" "134.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01009" "KKKKVVAATEVLV" "13" "P77(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01009" "DRAVPe01009.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1412.78" "C65H121N17O17" "CDFGHIMNPQRSWY" "KV" "10" "4" "1" "3" "1" "7" "33.85" "-688" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01010" "KKKKVKAATYVLV" "13" "P82(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(25% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01010" "DRAVPe01010.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1475.88" "C70H126N18O16" "CDEFGHIMNPQRSW" "K" "10.3" "5" "0" "5" "2" "6" "-11.54" "-980" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01011" "KKKKVVKATYVLV" "13" "P83(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 26±12% inhibition at 1 µM; 37±10% inhibition at 3 µM; 63±2% inhibition at 10 µM; IC50=6.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01011" "DRAVPe01011.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1503.94" "C72H130N18O16" "CDEFGHIMNPQRSW" "K" "10.3" "5" "0" "5" "2" "6" "6.92" "-757" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01012" "KKKKVVAKTYVLV" "13" "P84(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01012" "DRAVPe01012.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1503.94" "C72H130N18O16" "CDEFGHIMNPQRSW" "K" "10.3" "5" "0" "5" "2" "6" "6.92" "-757" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01013" "KKKKTVAATYVLV" "13" "P89(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(27% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01013" "DRAVPe01013.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1448.81" "C68H121N17O17" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "3" "6" "13.08" "-682" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01014" "KKKKVTAATYVLV" "13" "P90(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 15±12% inhibition at 1 µM; 44±3% inhibition at 3 µM; 77±6% inhibition at 10 µM; IC50=4.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01014" "DRAVPe01014.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1448.81" "C68H121N17O17" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "3" "6" "13.08" "-682" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01015" "KKKKVVTATYVLV" "13" "P91(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01015" "DRAVPe01015.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1476.87" "C70H125N17O17" "CDEFGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "3" "6" "31.54" "-459" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01016" "KKKKVVATTYVLV" "13" "P92(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01016" "DRAVPe01016.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1476.87" "C70H125N17O17" "CDEFGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "3" "6" "31.54" "-459" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01017" "KKKKVVAATTVLV" "13" "P93(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2223% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01017" "DRAVPe01017.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1384.77" "C64H121N17O16" "CDEFGHIMNPQRSWY" "KV" "10.48" "4" "0" "4" "2" "7" "55.38" "-264" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01018" "KKKKVVAATYVLT" "13" "P96(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01018" "DRAVPe01018.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1448.81" "C68H121N17O17" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "3" "6" "13.08" "-682" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01019" "KKKKVVGATYVLV" "13" "P99(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01019" "DRAVPe01019.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1432.81" "C68H121N17O16" "CDEFHIMNPQRSW" "KV" "10.18" "4" "0" "4" "3" "6" "33.85" "-108" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01020" "KKKKVVAGTYVLV" "13" "P100(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(30% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01020" "DRAVPe01020.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1432.81" "C68H121N17O16" "CDEFHIMNPQRSW" "KV" "10.18" "4" "0" "4" "3" "6" "33.85" "-108" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01021" "KKKKVVAAGYVLV" "13" "P101(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01021" "DRAVPe01021.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1402.79" "C67H119N17O15" "CDEFHIMNPQRSTW" "KV" "10.18" "4" "0" "4" "2" "7" "53.08" "330" "1.3 hour" "3 min" "2 min" "134.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01022" "KKKKVVAATGVLV" "13" "P102(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(26% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01022" "DRAVPe01022.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1340.72" "C62H117N17O15" "CDEFHIMNPQRSWY" "KV" "10.48" "4" "0" "4" "2" "7" "57.69" "87" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01023" "KKKKVVAATYVGV" "13" "P104(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01023" "DRAVPe01023.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1390.73" "C65H115N17O16" "CDEFHILMNPQRSW" "KV" "10.18" "4" "0" "4" "3" "6" "18.46" "-419" "1.3 hour" "3 min" "2 min" "104.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01024" "KKKKVVAATYVLG" "13" "P105(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(13% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01024" "DRAVPe01024.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1404.76" "C66H117N17O16" "CDEFHIMNPQRSW" "K" "10.18" "4" "0" "4" "3" "6" "15.38" "-331" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01025" "KKKKVVAATYVLV" "13" "P106(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(17% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01025" "DRAVPe01025.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1446.84" "C69H123N17O16" "CDEFGHIMNPQRSW" "KV" "10.18" "4" "0" "4" "2" "7" "50.77" "-21" "1.3 hour" "3 min" "2 min" "134.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01026" "KKKKPVAATYVLV" "13" "P107(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(24% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01026" "DRAVPe01026.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1444.82" "C69H121N17O16" "CDEFGHIMNQRSW" "K" "10.18" "4" "0" "4" "2" "6" "6.15" "-425" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01027" "KKKKVPAATYVLV" "13" "P108(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01027" "DRAVPe01027.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1444.82" "C69H121N17O16" "CDEFGHIMNQRSW" "K" "10.18" "4" "0" "4" "2" "6" "6.15" "-425" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01028" "KKKKVVAATYVPV" "13" "P113(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(10% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01028" "DRAVPe01028.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1430.8" "C68H119N17O16" "CDEFGHILMNQRSW" "KV" "10.18" "4" "0" "4" "2" "6" "9.23" "-513" "1.3 hour" "3 min" "2 min" "104.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01029" "KKKKVVLATLVLV" "13" "P116(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(5% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01029" "DRAVPe01029.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1438.9" "C69H131N17O15" "CDEFGHIMNPQRSWY" "KV" "10.48" "4" "0" "4" "1" "8" "105.38" "796" "1.3 hour" "3 min" "2 min" "186.92" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01030" "KKKKLVLPFLFFV" "13" "P119(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(6% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01030" "DRAVPe01030.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1607.1" "C84H135N17O14" "ACDEGHIMNQRSTWY" "K" "10.48" "4" "0" "4" "0" "8" "84.62" "958" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01031" "KKKKLLAPFLFFV" "13" "P120(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01031" "DRAVPe01031.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1579.05" "C82H131N17O14" "CDEGHIMNQRSTWY" "K" "10.48" "4" "0" "4" "0" "8" "66.15" "735" "1.3 hour" "3 min" "2 min" "120" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01032" "KKKKLLLAFLFFV" "13" "P121(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01032" "DRAVPe01032.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1595.09" "C83H135N17O14" "CDEGHIMNPQRSTWY" "KL" "10.48" "4" "0" "4" "0" "9" "107.69" "1227" "1.3 hour" "3 min" "2 min" "150" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01033" "KKKKLLLPTLFFV" "13" "P122(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01033" "DRAVPe01033.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1575.06" "C80H135N17O15" "ACDEGHIMNQRSWY" "KL" "10.48" "4" "0" "4" "1" "7" "54.62" "491" "1.3 hour" "3 min" "2 min" "142.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01034" "KKKKLVLATYVLV" "13" "P126(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01034" "DRAVPe01034.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1502.95" "C73H131N17O16" "CDEFGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "63.08" "378" "1.3 hour" "3 min" "2 min" "164.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01035" "KKKKLVAAFYVLV" "13" "P128(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01035" "DRAVPe01035.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1506.94" "C75H127N17O15" "CDEGHIMNPQRSTW" "K" "10.18" "4" "0" "4" "1" "8" "74.62" "622" "1.3 hour" "3 min" "2 min" "142.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01036" "KKKKLVAATYVFV" "13" "P129(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01036" "DRAVPe01036.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1494.88" "C73H123N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "40" "-127" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01037" "KKKKLVAATYVLF" "13" "P130(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01037" "DRAVPe01037.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1508.91" "C74H125N17O16" "CDEGHIMNPQRSW" "K" "10.18" "4" "0" "4" "2" "7" "36.92" "-39" "1.3 hour" "3 min" "2 min" "120" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01038" "KKKKVLAPTYVLV" "13" "P132(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(1% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01038" "DRAVPe01038.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1486.9" "C72H127N17O16" "CDEFGHIMNQRSW" "K" "10.18" "4" "0" "4" "2" "6" "21.54" "-114" "1.3 hour" "3 min" "2 min" "134.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01039" "KKKKVVLAFYVLV" "13" "P138(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(10% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01039" "DRAVPe01039.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1534.99" "C77H131N17O15" "CDEGHIMNPQRSTW" "KV" "10.18" "4" "0" "4" "1" "8" "93.08" "845" "1.3 hour" "3 min" "2 min" "156.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01040" "KKKKVVAPFYVLV" "13" "P140(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01040" "DRAVPe01040.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1518.95" "C76H127N17O15" "CDEGHIMNQRSTW" "KV" "10.18" "4" "0" "4" "1" "7" "51.54" "353" "1.3 hour" "3 min" "2 min" "126.92" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01041" "KKKKVVAPTLVLV" "13" "P141(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01041" "DRAVPe01041.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1422.86" "C68H127N17O15" "CDEFGHIMNQRSWY" "KV" "10.48" "4" "0" "4" "1" "7" "63.85" "304" "1.3 hour" "3 min" "2 min" "156.92" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01042" "KKKKVVAPTYFLV" "13" "P142(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01042" "DRAVPe01042.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1520.92" "C75H125N17O16" "CDEGHIMNQRSW" "K" "10.18" "4" "0" "4" "2" "6" "13.85" "-308" "1.3 hour" "3 min" "2 min" "104.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01043" "KKKKVVAPTYVLF" "13" "P144(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01043" "DRAVPe01043.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1520.92" "C75H125N17O16" "CDEGHIMNQRSW" "K" "10.18" "4" "0" "4" "2" "6" "13.85" "-308" "1.3 hour" "3 min" "2 min" "104.62" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01044" "KKKKVVAAFLVLV" "13" "P145(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(20% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01044" "DRAVPe01044.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1442.9" "C71H127N17O14" "CDEGHIMNPQRSTWY" "KV" "10.48" "4" "0" "4" "0" "9" "116.92" "1040" "1.3 hour" "3 min" "2 min" "164.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01045" "KKKKVVAAFYFLV" "13" "P146(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(7% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01045" "DRAVPe01045.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1540.96" "C78H125N17O15" "CDEGHIMNPQRSTW" "K" "10.18" "4" "0" "4" "1" "8" "66.92" "428" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01046" "KKKKVVAAFYVLF" "13" "P148(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01046" "DRAVPe01046.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1540.96" "C78H125N17O15" "CDEGHIMNPQRSTW" "K" "10.18" "4" "0" "4" "1" "8" "66.92" "428" "1.3 hour" "3 min" "2 min" "112.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01047" "KKKKVVAATLVLF" "13" "P151(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01047" "DRAVPe01047.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1444.87" "C70H125N17O15" "CDEGHIMNPQRSWY" "K" "10.48" "4" "0" "4" "1" "8" "79.23" "379" "1.3 hour" "3 min" "2 min" "142.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01048" "KKKKVLLPFLFFF" "13" "P154(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(2% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01048" "DRAVPe01048.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1655.15" "C88H135N17O14" "ACDEGHIMNQRSTWY" "FK" "10.48" "4" "0" "4" "0" "8" "73.85" "852" "1.3 hour" "3 min" "2 min" "112.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01049" "KKKKLVLPFLFFF" "13" "P155(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(12% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01049" "DRAVPe01049.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1655.15" "C88H135N17O14" "ACDEGHIMNQRSTWY" "FK" "10.48" "4" "0" "4" "0" "8" "73.85" "852" "1.3 hour" "3 min" "2 min" "112.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01050" "KKKKLLAPFLFFF" "13" "P156(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01050" "DRAVPe01050.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1627.09" "C86H131N17O14" "CDEGHIMNQRSTVWY" "FK" "10.48" "4" "0" "4" "0" "8" "55.38" "629" "1.3 hour" "3 min" "2 min" "97.69" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01051" "KKKKLLLAFLFFF" "13" "P157(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01051" "DRAVPe01051.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1643.13" "C87H135N17O14" "CDEGHIMNPQRSTVWY" "FKL" "10.48" "4" "0" "4" "0" "9" "96.92" "1121" "1.3 hour" "3 min" "2 min" "127.69" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01052" "KKKKLLLPFYFFF" "13" "P159(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(24% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01052" "DRAVPe01052.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1719.19" "C92H135N17O15" "ACDEGHIMNQRSTVW" "FK" "10.18" "4" "0" "4" "1" "7" "31.54" "434" "1.3 hour" "3 min" "2 min" "90" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01053" "KKKKLLLPFLFLF" "13" "P161(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01053" "DRAVPe01053.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1635.16" "C86H139N17O14" "ACDEGHIMNQRSTVWY" "L" "10.48" "4" "0" "4" "0" "8" "78.46" "1134" "1.3 hour" "3 min" "2 min" "150" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01054" "KKKKLLLPFLFFF" "13" "P162(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(19% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01054" "DRAVPe01054.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1669.17" "C89H137N17O14" "ACDEGHIMNQRSTVWY" "FKL" "10.48" "4" "0" "4" "0" "8" "70.77" "940" "1.3 hour" "3 min" "2 min" "120" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01055" "KKKKVVLPFLFFF" "13" "P163(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( -2±1% inhibition at 1 µM; 29±4% inhibition at 3 µM; 69±9% inhibition at 10 µM; IC50=7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01055" "DRAVPe01055.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1641.12" "C87H133N17O14" "ACDEGHIMNQRSTWY" "FK" "10.48" "4" "0" "4" "0" "8" "76.92" "764" "1.3 hour" "3 min" "2 min" "104.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01056" "KKKKLVAPFLFFF" "13" "P164(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(15% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01056" "DRAVPe01056.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1613.06" "C85H129N17O14" "CDEGHIMNQRSTWY" "FK" "10.48" "4" "0" "4" "0" "8" "58.46" "541" "1.3 hour" "3 min" "2 min" "90" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01057" "KKKKLLAAFLFFF" "13" "P165(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 29±5% inhibition at 1 µM; 28±9% inhibition at 3 µM; 61±17% inhibition at 10 µM; IC50=7.6 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01057" "DRAVPe01057.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1601.05" "C84H129N17O14" "CDEGHIMNPQRSTVWY" "FK" "10.48" "4" "0" "4" "0" "9" "81.54" "810" "1.3 hour" "3 min" "2 min" "105.38" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01058" "KKKKLLLATLFFF" "13" "P166(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(16% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01058" "DRAVPe01058.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1597.06" "C82H133N17O15" "CDEGHIMNPQRSVWY" "KL" "10.48" "4" "0" "4" "1" "8" "70" "566" "1.3 hour" "3 min" "2 min" "127.69" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01059" "KKKKLLLPTYFFF" "13" "P167(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01059" "DRAVPe01059.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1673.12" "C87H133N17O16" "ACDEGHIMNQRSVW" "K" "10.18" "4" "0" "4" "2" "6" "4.62" "-121" "1.3 hour" "3 min" "2 min" "90" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01060" "KKKKLLLPFLVLF" "13" "P169(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(4% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01060" "DRAVPe01060.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1587.11" "C82H139N17O14" "ACDEGHIMNQRSTWY" "L" "10.48" "4" "0" "4" "0" "8" "89.23" "1240" "1.3 hour" "3 min" "2 min" "172.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01061" "KKKKVLAPFLFFF" "13" "P170(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01061" "DRAVPe01061.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1613.06" "C85H129N17O14" "CDEGHIMNQRSTWY" "FK" "10.48" "4" "0" "4" "0" "8" "58.46" "541" "1.3 hour" "3 min" "2 min" "90" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01062" "KKKKVLLPFYFFF" "13" "P172(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(27% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01062" "DRAVPe01062.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1705.16" "C91H133N17O15" "ACDEGHIMNQRSTW" "FK" "10.18" "4" "0" "4" "1" "7" "34.62" "346" "1.3 hour" "3 min" "2 min" "82.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01063" "KKKKLVLAFLFFF" "13" "P175(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01063" "DRAVPe01063.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1629.11" "C86H133N17O14" "CDEGHIMNPQRSTWY" "FK" "10.48" "4" "0" "4" "0" "9" "100" "1033" "1.3 hour" "3 min" "2 min" "120" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01064" "KKKKLVLPTLFFF" "13" "P176(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(29% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01064" "DRAVPe01064.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1609.07" "C83H133N17O15" "ACDEGHIMNQRSWY" "K" "10.48" "4" "0" "4" "1" "7" "46.92" "297" "1.3 hour" "3 min" "2 min" "112.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01065" "KKKKLVLPFYFFF" "13" "P177(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(14% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01065" "DRAVPe01065.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1705.16" "C91H133N17O15" "ACDEGHIMNQRSTW" "FK" "10.18" "4" "0" "4" "1" "7" "34.62" "346" "1.3 hour" "3 min" "2 min" "82.31" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01066" "KKKKLVLPFLLFF" "13" "P178(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(18% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01066" "DRAVPe01066.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1621.13" "C85H137N17O14" "ACDEGHIMNQRSTWY" "KL" "10.48" "4" "0" "4" "0" "8" "81.54" "1046" "1.3 hour" "3 min" "2 min" "142.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01067" "KKKKLVLPFLFVF" "13" "P179(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 14±6% inhibition at 1 µM; 34±11% inhibition at 3 µM; 55±11% inhibition at 10 µM; IC50=8.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01067" "DRAVPe01067.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1607.1" "C84H135N17O14" "ACDEGHIMNQRSTWY" "K" "10.48" "4" "0" "4" "0" "8" "84.62" "958" "1.3 hour" "3 min" "2 min" "134.62" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01068" "KKKKLLAPFLVFF" "13" "P180(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(9% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01068" "DRAVPe01068.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1579.05" "C82H131N17O14" "CDEGHIMNQRSTWY" "K" "10.48" "4" "0" "4" "0" "8" "66.15" "735" "1.3 hour" "3 min" "2 min" "120" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01069" "KKKKLLLAFYFFF" "13" "P181(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01069" "DRAVPe01069.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1693.15" "C90H133N17O15" "CDEGHIMNPQRSTVW" "FK" "10.18" "4" "0" "4" "1" "8" "57.69" "615" "1.3 hour" "3 min" "2 min" "97.69" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01070" "KKKKLLLAFLFLF" "13" "P182(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(8% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01070" "DRAVPe01070.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1609.12" "C84H137N17O14" "CDEGHIMNPQRSTVWY" "L" "10.48" "4" "0" "4" "0" "9" "104.62" "1315" "1.3 hour" "3 min" "2 min" "157.69" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01071" "KKKKLLLPTLVFF" "13" "P183(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(3% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01071" "DRAVPe01071.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1575.06" "C80H135N17O15" "ACDEGHIMNQRSWY" "KL" "10.48" "4" "0" "4" "1" "7" "54.62" "491" "1.3 hour" "3 min" "2 min" "142.31" "0" "0" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01072" "KKKKLLLPFYFLF" "13" "P185(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)(22% inhibition at 3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01072" "DRAVPe01072.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1685.17" "C89H137N17O15" "ACDEGHIMNQRSTVW" "KL" "10.18" "4" "0" "4" "1" "7" "39.23" "628" "1.3 hour" "3 min" "2 min" "120" "1490" "124.17" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01073" "AKDLEVVTSTYVLVEA" "16" "P189(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 5±7% inhibition at 1 µM; 74±6% inhibition at 3 µM; 96±3% inhibition at 10 µM; IC50=2.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01073" "DRAVPe01073.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1736.98" "C78H129N17O27" "CFGHIMNPQRW" "V" "4.14" "1" "3" "-2" "4" "8" "63.13" "-695" "4.4 hour" ">20 hour" ">10 hour" "133.75" "1490" "99.33" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01074" "AKDLEVVCSTYVLVEA" "16" "P190(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 24 ±15% inhibition at 1 µM; 86 ±3% inhibition at 3 µM; 99 ±2% inhibition at 10 µM; IC50=1.8 µM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01074" "DRAVPe01074.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1739.01" "C77H127N17O26S" "FGHIMNPQRW" "V" "4.14" "1" "3" "-2" "4" "8" "83.13" "-310" "4.4 hour" ">20 hour" ">10 hour" "133.75" "1490" "99.33" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01075" "AECVVSCSMSYTKA" "14" "P197(derived from HCV polyprotein)" "Synthetic construct(derived from Hepatitis C virus(HCV) polyprotein)" "P26662" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "NS3-6K inhibition assay(determined by Fluorescent probe)" "[Ref.14694985]Hepatitis C virus(HCV):inhibition of activation of NS3-6K protease(50 nM)( 7±7% inhibition at 1 µM; 29±6% inhibition at 3 µM; 66±3% inhibition at 10 µM; IC50=7 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01075" "DRAVPe01075.cif" "Linear" "Free" "Free" "None" "L" "NS3 protease" "HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. The peptide was demonstrated that can indeed block the activity of NS3 and thus inhibit HCV replication" "1478.71" "C60H99N15O22S3" "DFGHILNPQRW" "S" "6.03" "1" "1" "0" "7" "4" "50.71" "-866" "4.4 hour" ">20 hour" ">10 hour" "55.71" "1615" "124.23" "14694985" "Antivir Chem Chemother. 2003 Sep;14(5):225-33." "Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F." "Peptide inhibitors of hepatitis C virus NS3 protease. " "10.1177/095632020301400501" "Anti-HCV" "DRAVPe01076" "SWLRDIWDWICEVLSDFK" "18" "C5A(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,DENV,MeV,RSV,HIV" "Flaviviridae, Paramyxoviridae, Retroviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.79 μM);##HCV (JFH-1) genotype 2a:inhibition of infection in Huh-7.5.1 cells(IC50=0.6 μM);##HCV (H77 envelope) genotype 1a:inhibition of infection in Huh-7.5.1 cells(IC50=3.9 μM);##HCV (Con1 envelope) genotype 1b:inhibition of infection in Huh-7.5.1 cells(IC50=1.6 μM);##HCV (J6CF envelope) genotype 2a:inhibition of infection in Huh-7.5.1 cells(IC50=1.1 μM);##Dengue virus:inhibition of infection in Huh-7.5.1 cells(IC50=2.0 μM);##West Nile virus:inhibition of infection in Huh-7.5.1 cells(IC50=4.5 μM);##Measles virus:inhibition of infection in Huh-7.5.1 cells(IC50=2.7 μM);##Respiratory syncytial virus:inhibition of infection in Huh-7.5.1 cells(IC50=4.5 μM);##Human immunodeficiency virus:inhibition of infection in Huh-7.5.1 cells(IC50=1.3 μM);##IC50>18 μM against Adenovirus,Borna disease virus,Coronavirus 229E,Coxsackie virus,Hepatitis B virus,Influenza virus,Lymphocytic choriomeningitis virus,Rhinovirus,Rotavirus WISC2,Vaccinia virus,Vesicular stomatitis virus." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01076" "DRAVPe01076.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV,Anti-DENV,Anti-MeV,Anti-RSV,Anti-HIV" "DRAVPe01077" "swlrdiwdwicevlsdfk" "18" "2(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.32 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01077" "DRAVPe01077.cif" "Linear" "Free" "Free" "None" "D" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "H-34O-17" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "4.23" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01078" "SWLRDIWDWICEVLSD" "16" "3(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.98 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01078" "DRAVPe01078.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2036.29" "C94H134N22O27S" "AFGHKMNPQTY" "DW" "3.84" "1" "4" "-3" "3" "8" "3.13" "-2270" "1.9 hour" ">20 hour" ">10 hour" "115.63" "16500" "1100" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01079" "SWLRDIWDWICEVL" "14" "4(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=11.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01079" "DRAVPe01079.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1834.12" "C87H124N20O22S" "AFGHKMNPQTY" "W" "4.03" "1" "3" "-2" "2" "8" "34.29" "-1058" "1.9 hour" ">20 hour" ">10 hour" "132.14" "16500" "1269.23" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "DRAVPa1474" "Anti-HCV" "DRAVPe01080" "SWLRDIWDWICEV" "13" "5(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01080" "DRAVPe01080.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1720.96" "C81H113N19O21S" "AFGHKMNPQTY" "W" "4.03" "1" "3" "-2" "2" "7" "7.69" "-1550" "1.9 hour" ">20 hour" ">10 hour" "112.31" "16500" "1375" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01081" "SWLRDIWDWICE" "12" "6(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01081" "DRAVPe01081.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1621.83" "C76H104N18O20S" "AFGHKMNPQTVY" "W" "4.03" "1" "3" "-2" "2" "6" "-26.67" "-1954" "1.9 hour" ">20 hour" ">10 hour" "97.5" "16500" "1500" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01082" "SWLRDIWDWI" "10" "7(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01082" "DRAVPe01082.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1389.58" "C68H92N16O16" "ACEFGHKMNPQTVY" "W" "4.21" "1" "2" "-1" "1" "6" "-22" "-1401" "1.9 hour" ">20 hour" ">10 hour" "117" "16500" "1833.33" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01083" "SWLRDIWD" "8" "8(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01083" "DRAVPe01083.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1090.2" "C51H71N13O14" "ACEFGHKMNPQTVY" "DW" "4.21" "1" "2" "-1" "1" "4" "-72.5" "-2126" "1.9 hour" ">20 hour" ">10 hour" "97.5" "11000" "1571.43" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01084" "LRDIWDWICEVLSDFK" "16" "9(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01084" "DRAVPe01084.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2038.35" "C95H140N22O26S" "AGHMNPQTY" "D" "4.23" "2" "4" "-2" "2" "8" "6.88" "-2420" "5.5 hour" "3 min" "2 min" "115.63" "11000" "733.33" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01085" "DIWDWICEVLSDFK" "14" "10(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01085" "DRAVPe01085.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1769" "C83H117N17O24S" "AGHMNPQRTY" "D" "3.84" "1" "4" "-3" "2" "7" "12.86" "-1420" "1.1 hour" "3 min" ">10 hour" "104.29" "11000" "846.15" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01086" "WDWICEVLSDFK" "12" "11(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01086" "DRAVPe01086.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1540.75" "C73H101N15O20S" "AGHMNPQRTY" "DW" "4.03" "1" "3" "-2" "2" "6" "6.67" "-1040" "2.8 hour" "3 min" "2 min" "89.17" "11000" "1000" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01087" "WICEVLSDFK" "10" "12(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01087" "DRAVPe01087.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "1239.45" "C58H86N12O16S" "AGHMNPQRTY" "CDEFIKLSVW" "4.37" "1" "2" "-1" "2" "5" "52" "-401" "2.8 hour" "3 min" "2 min" "107" "5500" "611.11" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01088" "CEVLSDFK" "8" "13(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01088" "DRAVPe01088.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "940.08" "C41H65N9O14S" "AGHIMNPQRTWY" "CDEFKLSV" "4.37" "1" "2" "-1" "2" "3" "20" "-1126" "1.2 hour" ">20 hour" ">10 hour" "85" "0" "0" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01089" "SGSWLRDIWDWICEVLSDFK" "20" "14(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01089" "DRAVPe01089.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2455.77" "C114H163N27O32S" "AHMNPQTY" "DSW" "4.23" "2" "4" "-2" "5" "9" "-9" "-2773" "1.9 hour" ">20 hour" ">10 hour" "92.5" "16500" "868.42" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01090" "GSWLRDIWDWICEVLSDFK" "19" "15(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.51 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01090" "DRAVPe01090.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2368.69" "C111H158N26O30S" "AHMNPQTY" "DW" "4.23" "2" "4" "-2" "4" "9" "-5.26" "-2433" "30 hour" ">20 hour" ">10 hour" "97.37" "16500" "916.67" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01091" "SWLRDIWDWICEVLSDFKT" "19" "16(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01091" "DRAVPe01091.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2412.74" "C113H162N26O31S" "AGHMNPQY" "DW" "4.23" "2" "4" "-2" "4" "9" "-6.84" "-2784" "1.9 hour" ">20 hour" ">10 hour" "97.37" "16500" "916.67" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01092" "SWLRDIWDWICEVLSDFKTW" "20" "17(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.51 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01092" "DRAVPe01092.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2598.96" "C124H172N28O32S" "AGHMNPQY" "W" "4.23" "2" "4" "-2" "4" "10" "-11" "-2551" "1.9 hour" ">20 hour" ">10 hour" "92.5" "22000" "1157.89" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01093" "SWRLIDWDWICEVLSDFK" "18" "18(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=4.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01093" "DRAVPe01093.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01094" "SWRLDIWDWICESVLDFK" "18" "19(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01094" "DRAVPe01094.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01095" "DWLKAFYDKVAEKLKEAF" "18" "21(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>28 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01095" "DRAVPe01095.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2201.55" "C106H157N23O28" "CGHIMNPQRST" "K" "6.21" "4" "4" "0" "1" "9" "-50" "-2580" "1.1 hour" "3 min" ">10 hour" "76.11" "6990" "411.18" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "DRAVPa1305" "Anti-HCV" "DRAVPe01096" "VLDLIYSLHKQINRGLKKIVL" "21" "22(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50>36 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01096" "DRAVPe01096.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2464.04" "C115H199N31O28" "ACEFMPTW" "L" "10" "5" "1" "4" "4" "10" "40.48" "-1229" "100 hour" ">20 hour" ">10 hour" "176.19" "1490" "74.5" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01097" "KFDSLVECIWDWIDRLWS" "18" "23(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.85 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01097" "DRAVPe01097.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.3 hour" "3 min" "2 min" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01098" "KWLCRIWSWISDVLDDFE" "18" "25(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01098" "DRAVPe01098.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.3 hour" "3 min" "2 min" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01099" "SIWRDWVDLICEFLSDWK" "18" "26(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.40 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01099" "DRAVPe01099.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-3.33" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01100" "SWLRDVWDWICTVLTDFK" "18" "27(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=3.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01100" "DRAVPe01100.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2283.63" "C108H155N25O28S" "AEGHMNPQY" "DW" "4.43" "2" "3" "-1" "4" "9" "11.11" "-2108" "1.9 hour" ">20 hour" ">10 hour" "97.22" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01101" "SWLRDVWDWVCTILTDFK" "18" "28(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=2.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01101" "DRAVPe01101.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2283.63" "C108H155N25O28S" "AEGHMNPQY" "DW" "4.43" "2" "3" "-1" "4" "9" "11.11" "-2108" "1.9 hour" ">20 hour" ">10 hour" "97.22" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01102" "DWLRIIWDWVCSVVSDFK" "18" "29(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.55 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01102" "DRAVPe01102.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2267.63" "C108H155N25O27S" "AEGHMNPQTY" "DVW" "4.43" "2" "3" "-1" "3" "10" "41.67" "-1530" "1.1 hour" "3 min" ">10 hour" "113.33" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01103" "SWLWEVWDWVLHVLSDFK" "18" "30(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=7.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01103" "DRAVPe01103.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2345.68" "C117H157N25O27" "ACGIMNPQRTY" "W" "4.53" "2" "3" "-1" "2" "11" "22.22" "-208" "1.9 hour" ">20 hour" ">10 hour" "113.33" "22000" "1294.12" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01104" "TWLRAIWDWVCTALTDFK" "18" "31(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=7.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01104" "DRAVPe01104.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2225.59" "C106H153N25O26S" "EGHMNPQSY" "TW" "5.62" "2" "2" "0" "4" "10" "27.78" "-1195" "7.2 hour" ">20 hour" ">10 hour" "92.22" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01105" "SWLRDVWDWVCTVLSDFK" "18" "32(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=3.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01105" "DRAVPe01105.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2255.58" "C106H151N25O28S" "AEGHIMNPQY" "DVW" "4.43" "2" "3" "-1" "4" "9" "8.89" "-2279" "1.9 hour" ">20 hour" ">10 hour" "91.67" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01106" "SWLRDIWDWISEVLSDFK" "18" "33[11S](derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=13.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01106" "DRAVPe01106.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2295.58" "C109H155N25O30" "ACGHMNPQTY" "DSW" "4.23" "2" "4" "-2" "3" "9" "-21.67" "-2995" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01107" "SWLRDIWDWIREVLSDFK" "18" "34[11R](derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=12.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01107" "DRAVPe01107.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2364.69" "C112H162N28O29" "ACGHMNPQTY" "DW" "4.68" "3" "4" "-1" "2" "9" "-42.22" "-4147" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01108" "SWLRDIWDWIEEVLSDFK" "18" "35[11E](derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=13.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01108" "DRAVPe01108.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2337.62" "C111H157N25O31" "ACGHMNPQTY" "DW" "4.1" "2" "5" "-3" "2" "9" "-36.67" "-3336" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01109" "SWLDDIWDWICEVLSDFE" "18" "36(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=4.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01109" "DRAVPe01109.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2271.48" "C106H143N21O33S" "AGHKMNPQRTY" "D" "3.25" "0" "6" "-6" "3" "9" "4.44" "-2033" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01110" "SWLRDIWDWICKVLSDFK" "18" "38(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=6.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01110" "DRAVPe01110.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2310.7" "C110H160N26O27S" "AEGHMNPQTY" "DW" "5.76" "3" "3" "0" "3" "9" "-5.56" "-2401" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01111" "SWLDRIWRWICKVLSRFE" "18" "39(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=1.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01111" "DRAVPe01111.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2393.84" "C113H169N31O25S" "AGHMNPQTY" "RW" "9.49" "4" "2" "2" "3" "9" "-14.44" "-3767" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01112" "SWLRDIWRWICKVLSRFK" "18" "40(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.84 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01112" "DRAVPe01112.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2392.9" "C114H174N32O23S" "AEGHMNPQTY" "RW" "10.92" "5" "1" "4" "3" "9" "-16.67" "-3641" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01113" "SWLRRIWRWICKVLSRFK" "18" "41(derived from HCV C5A)" "Synthetic construct(derived from HCV non-structural protein 5A)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT-QPCR assay" "[Ref.18287023]Hepatitis C virus(HCV):inhibition of HCV infection in Huh-7.5.1 cells(IC50=0.89 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01113" "DRAVPe01113.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide destabilizes viral structural integrity and has viral membranolytic activity.It interacts with the viral membrane to disrupt its integrity, release viral capsids, and expose the viral genome to exonucleases for degradation." "2434" "C116H181N35O21S" "ADEGHMNPQTY" "R" "12.01" "6" "0" "6" "3" "9" "-22.22" "-4261" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "18287023" "Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3088-93." "Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV." "A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro." "10.1073/pnas.0712380105" "Anti-HCV" "DRAVPe01114" "RTQRRGRTGRGKPGIYR" "17" "HCVA(1484-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26664" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=27.1±2.4 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=37.1±3.9 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=49.8±4.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01114" "DRAVPe01114.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "2015.31" "C83H147N37O22" "ACDEFHLMNSVW" "R" "12.3" "7" "0" "7" "7" "1" "-210.59" "-9721" "1 hour" "2 min" "2 min" "22.94" "1490" "93.13" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01115" "STQRRGRTGRGRRGIYR" "17" "HCVB(1484-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=24.3±1.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=33.6±3.5 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=47.2±4.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01115" "DRAVPe01115.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "2033.29" "C81H145N39O23" "ACDEFHKLMNPVW" "R" "12.4" "7" "0" "7" "8" "1" "-209.41" "-10998" "1.9 hour" ">20 hour" ">10 hour" "22.94" "1490" "93.13" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01116" "RRGRTGRGRRGIYR" "14" "HCV(1487-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=0.2±0.01 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=2.7±0.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=21.1±2.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01116" "DRAVPe01116.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1716.98" "C69H125N35O17" "ACDEFHKLMNPQSVW" "R" "12.4" "7" "0" "7" "6" "1" "-218.57" "-9847" "1 hour" "2 min" "2 min" "27.86" "1490" "114.62" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01117" "RTGRGRRGIYR" "11" "HCV(1490-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=34.6±3.2 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=106±6.1 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=322±9.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01117" "DRAVPe01117.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1347.55" "C55H98N26O14" "ACDEFHKLMNPQSVW" "R" "12.18" "5" "0" "5" "5" "1" "-192.73" "-6957" "1 hour" "2 min" "2 min" "35.45" "1490" "149" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01118" "RGRRGIYR" "8" "HCV(1493-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=313±11.3 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=397±10.6 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01118" "DRAVPe01118.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1033.2" "C43H76N20O10" "ACDEFHKLMNPQSTVW" "R" "12" "4" "0" "4" "3" "1" "-195" "-5302" "1 hour" "2 min" "2 min" "48.75" "1490" "212.86" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01119" "RGIYR" "5" "HCV(1496-1500)" "Synthetic construct(derived from HCV NS3 helicase protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01119" "DRAVPe01119.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "663.78" "C29H49N11O7" "ACDEFHKLMNPQSTVW" "R" "10.84" "2" "0" "2" "2" "1" "-124" "-2412" "1 hour" "2 min" "2 min" "78" "1490" "372.5" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01120" "SQVGD" "5" "WNV(1968-1972)" "Synthetic construct(derived from WNV NS3 helicase protein)" "P06935" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01120" "DRAVPe01120.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "504.5" "C19H32N6O10" "ACEFHIKLMNPRTWY" "DGQSV" "3.8" "0" "1" "-1" "2" "1" "-80" "-1268" "1.9 hour" ">20 hour" ">10 hour" "58" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01121" "RNPSQVGD" "8" "WNV(1965-1972)" "Synthetic construct(derived from WNV NS3 helicase protein)" "P06935" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=383±12.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=437±13.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01121" "DRAVPe01121.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "871.91" "C34H57N13O14" "ACEFHIKLMTWY" "DGNPQRSV" "5.84" "1" "1" "0" "3" "1" "-170" "-3424" "1 hour" "2 min" "2 min" "36.25" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01122" "RIGRNPSQVGD" "11" "WNV(1962-1972)" "Synthetic construct(derived from WNV NS3 helicase protein)" "P06935" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=417±17.6 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=285±8.1 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=334±12.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01122" "DRAVPe01122.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1198.3" "C48H83N19O17" "ACEFHKLMTWY" "GR" "9.6" "2" "1" "1" "4" "2" "-127.27" "-4330" "1 hour" "2 min" "2 min" "61.82" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01123" "RRGRIGRNPSQVGD" "14" "WNV(1959-1972)" "Synthetic construct(derived from WNV NS3 helicase protein)" "P06935" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=169±6.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=156±6.9 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=191±7.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01123" "DRAVPe01123.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1567.73" "C62H110N28O20" "ACEFHKLMTWY" "R" "12" "4" "1" "3" "5" "2" "-167.14" "-7220" "1 hour" "2 min" "2 min" "48.57" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01124" "AAQRRGRIGRNPSQVGD" "17" "WNV(1956-1972)" "Synthetic construct(derived from WNV NS3 helicase protein)" "P06935" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=358±13.2 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01124" "DRAVPe01124.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1838.02" "C73H128N32O24" "CEFHKLMTWY" "R" "12" "4" "1" "3" "5" "4" "-137.06" "-7412" "4.4 hour" ">20 hour" ">10 hour" "51.76" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01125" "NQVGD" "5" "JEV(1971-1975)" "Synthetic construct(derived from JEV NS3 helicase protein)" "P27395" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01125" "DRAVPe01125.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "531.52" "C20H33N7O10" "ACEFHIKLMPRSTWY" "DGNQV" "3.8" "0" "1" "-1" "2" "1" "-134" "-1592" "1.4 hour" "3 min" ">10 hour" "58" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01126" "RNPNQVGD" "8" "JEV(1968-1975)" "Synthetic construct(derived from JEV NS3 helicase protein)" "P27395" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50>500 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01126" "DRAVPe01126.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "898.93" "C35H58N14O14" "ACEFHIKLMSTWY" "N" "5.84" "1" "1" "0" "3" "1" "-203.75" "-3748" "1 hour" "2 min" "2 min" "36.25" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01127" "RVGRNPNQVGD" "11" "JEV(1965-1975)" "Synthetic construct(derived from JEV NS3 helicase protein)" "P27395" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=374±12.8 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=448±14.3 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01127" "DRAVPe01127.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1211.3" "C48H82N20O17" "ACEFHIKLMSTWY" "GNRV" "9.6" "2" "1" "1" "4" "2" "-154.55" "-4742" "1 hour" "2 min" "2 min" "52.73" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01128" "RRGRVGRNPNQVGD" "14" "JEV(1962-1975)" "Synthetic construct(derived from JEV NS3 helicase protein)" "P27395" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=196±9.4 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50=215±7.2 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50=253±6.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01128" "DRAVPe01128.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1580.73" "C62H109N29O20" "ACEFHIKLMSTWY" "R" "12" "4" "1" "3" "5" "2" "-188.57" "-7632" "1 hour" "2 min" "2 min" "41.43" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01129" "AAQRRGRVGRNPNQVGD" "17" "JEV(1959-1975)" "Synthetic construct(derived from JEV NS3 helicase protein)" "P27395" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,WNV,JEV" "Flaviviridae" "Helicase assay" "[Ref.18479669]Hepatitis C virus (HCV): inhibition of HCV helicase activity(IC50=442±17.7 μM);##West Nile virus (WNV): inhibition of WNV helicase activity(IC50>500 μM);##Japanese encephalitis virus (JEV):inhibition of JEV helicase activity(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01129" "DRAVPe01129.cif" "Linear" "Free" "Free" "None" "L" "NTPase/helicase" "The intact enzymatic properties of NS3 are necessary for the virus propagation,which possesses numerous enzymatic activities including RNA stimulated nucleoside triphosphatase (NTPase) and RNA helicase activities. The peptides inhibited the NTPase/helicase by a direct interaction with the enzyme highly probably by a competitive mechanism." "1851.02" "C73H127N33O24" "CEFHIKLMSTWY" "R" "12" "4" "1" "3" "5" "4" "-154.71" "-7824" "4.4 hour" ">20 hour" ">10 hour" "45.88" "0" "0" "18479669" "Biochem Pharmacol. 2008 Jul 1;76(1):28-38. " "Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A." "Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)." "10.1016/j.bcp.2008.03.018" "Anti-HCV,Anti-WNV,Anti-JEV" "DRAVPe01130" "TTPKFTVAWDWVPKR" "15" "gB64(gB346-360)" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=85 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01130" "DRAVPe01130.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1832.14" "C88H130N22O21" "CEGHILMNQSY" "T" "9.99" "3" "1" "2" "3" "6" "-66" "-2492" "7.2 hour" ">20 hour" ">10 hour" "45.33" "11000" "785.71" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01131" "KTTSSIEFARLQFTY" "15" "gB94(496-510)" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=6.5±1.3 µM);inhibition of virus entry in Vero cells(EC50>200 µM);inhibition of virus infection in Vero cells(EC50=165.0±71.9 µM);ability of inactive virus(EC50=125±11.4 µM);inhibition of virus attachment on Vero cells(EC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM." "DRAVPe01131" "DRAVPe01131.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1792.02" "C82H126N20O25" "CDGHMNPVW" "T" "8.59" "2" "1" "1" "6" "5" "-31.33" "-2986" "1.3 hour" "3 min" "2 min" "58.67" "1490" "106.43" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01132" "GHRRYFTFGGGYVYF" "15" "gB122(636-650)" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=15.0±2.2 µM);inhibition of virus entry in Vero cells(EC50=17.6±2.6 µM);inhibition of virus infection in Vero cells(EC50=71.5±17.4 µM);ability of inactive virus(EC50=118±11.6 µM);inhibition of virus attachment on Vero cells(EC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM." "DRAVPe01132" "DRAVPe01132.cif" "Linear" "Free" "Free" "None" "L" "Not found" "It is also possible that gB122 could either prematurely trigger or inhibit a conformational change in the gB-1 molecule required for entry,and may be acting by blocking a protein-protein interaction." "1827.03" "C89H115N23O20" "ACDEIKLMNPQSW" "G" "9.7" "3" "0" "3" "8" "4" "-38.67" "-2075" "30 hour" ">20 hour" ">10 hour" "19.33" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01133" "HEVVPLEVYTRHEIK" "15" "gB131(681-695)" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay,Virus inactivation assay,cell protection assay,entry assay,attachment assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=18.7±2.70 µM);inhibition of virus entry in Vero cells(EC50=12.2±6.56 µM);inhibition of virus infection in Vero cells(EC50>200 µM);ability of inactive virus(EC50>200 µM);inhibition of virus attachment on Vero cells(EC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.19104014]Not cytotoxic for Vero cells up to 200 µM." "DRAVPe01133" "DRAVPe01133.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The gB131 peptide could be interfering with a conformational change involving interactions between residues in this region or by blocking a binding interaction." "1849.12" "C84H133N23O24" "ACDFGMNQSW" "EV" "6.02" "4" "3" "1" "2" "5" "-53.33" "-3097" "3.5 hour" "10 min" ">10 hour" "110" "1490" "106.43" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01134" "HRRYFTFGGGYVYF" "14" "gB122(637-650)" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=31.2 ± 5.1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01134" "DRAVPe01134.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1769.98" "C87H112N22O19" "ACDEIKLMNPQSW" "FGY" "9.7" "3" "0" "3" "7" "4" "-38.57" "-2169" "3.5 hour" "10 min" ">10 hour" "20.71" "4470" "343.85" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01135" "GHRAYFTFGGGYVYF" "15" "gB122R4A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=26.4 ± 13.5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01135" "DRAVPe01135.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1741.93" "C86H108N20O20" "CDEIKLMNPQSW" "G" "8.5" "2" "0" "2" "8" "5" "3.33" "-402" "30 hour" ">20 hour" ">10 hour" "26" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01136" "GHRRAFTFGGGYVYF" "15" "gB122Y5A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=119.2 ± 26.6 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01136" "DRAVPe01136.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1734.94" "C83H111N23O19" "CDEIKLMNPQSW" "G" "9.99" "3" "0" "3" "7" "5" "-18" "-1880" "30 hour" ">20 hour" ">10 hour" "26" "2980" "212.86" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01137" "GHRRYATFGGGYVYF" "15" "gB122F6A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=67.6 ± 8.1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01137" "DRAVPe01137.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1750.94" "C83H111N23O20" "CDEIKLMNPQSW" "G" "9.7" "3" "0" "3" "8" "4" "-45.33" "-2192" "30 hour" ">20 hour" ">10 hour" "26" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01138" "GHRRYFTAGGGYVYF" "15" "gB122F8A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=37.5 ± 4.2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01138" "DRAVPe01138.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1750.94" "C83H111N23O20" "CDEIKLMNPQSW" "G" "9.7" "3" "0" "3" "8" "4" "-45.33" "-2192" "30 hour" ">20 hour" ">10 hour" "26" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01139" "GHRRYFTFGAGYVYF" "15" "gB122G10L" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=25.1 ± 4.9 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01139" "DRAVPe01139.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1841.06" "C90H117N23O20" "CDEIKLMNPQSW" "FGY" "9.7" "3" "0" "3" "7" "5" "-24" "-1988" "30 hour" ">20 hour" ">10 hour" "26" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01140" "GHRRYFTFGGGYVAF" "15" "gB122Y14A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=58.0 ± 5.2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01140" "DRAVPe01140.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1734.94" "C83H111N23O19" "CDEIKLMNPQSW" "G" "9.99" "3" "0" "3" "7" "5" "-18" "-1880" "30 hour" ">20 hour" ">10 hour" "26" "2980" "212.86" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01141" "GHRRYFTFGGGYVYA" "15" "gB122F15A" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=48.6 ± 6.2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01141" "DRAVPe01141.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1750.94" "C83H111N23O20" "CDEIKLMNPQSW" "G" "9.7" "3" "0" "3" "8" "4" "-45.33" "-2192" "30 hour" ">20 hour" ">10 hour" "26" "4470" "319.29" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01142" "RYFTFGGGYVYF" "12" "gB122Δ1-3" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=34.9 ± 1.8 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01142" "DRAVPe01142.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1476.65" "C75H93N15O17" "ACDEHIKLMNPQSW" "FGY" "8.5" "1" "0" "1" "7" "4" "19.17" "-211" "1 hour" "2 min" "2 min" "24.17" "4470" "406.36" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01143" "TFGGGYVYF" "9" "gB122Δ1-6" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01143" "DRAVPe01143.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1010.11" "C51H63N9O13" "ACDEHIKLMNPQRSW" "G" "5.18" "0" "0" "0" "6" "3" "58.89" "997" "7.2 hour" ">20 hour" ">10 hour" "32.22" "2980" "372.5" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01144" "GHRRYFTFGGGY" "12" "gB122Δ13-15" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50=91.4± 9.8 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01144" "DRAVPe01144.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1417.55" "C66H88N20O16" "ACDEIKLMNPQSVW" "G" "9.99" "3" "0" "3" "7" "2" "-95.83" "-2763" "30 hour" ">20 hour" ">10 hour" "0" "2980" "270.91" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01145" "GHRRYFTFG" "9" "gB122Δ10-15" "Synthetic construct(derived from HSV-1 B glycoprotein (gB))" "P06437" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "beta-galactosidase activity(Comprehensive antiviral assay)" "[Ref.19104014]Herpes simplex virus type 1(HSV-1):comprehensive antiviral activity(EC50>100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01145" "DRAVPe01145.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1140.27" "C53H73N17O12" "ACDEIKLMNPQSVW" "FGR" "10.84" "3" "0" "3" "4" "2" "-104.44" "-2937" "30 hour" ">20 hour" ">10 hour" "0" "1490" "186.25" "19104014" "Antimicrob Agents Chemother. 2009 Mar;53(3):987-96." "Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR." "Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection." "10.1128/AAC.00793-08" "Anti-HSV" "DRAVPe01146" "MDVNPTLLFLKVPAQNAISTTFPYT" "25" "FluA-PB1(1-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=1.80 ±0.49 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01146" "DRAVPe01146.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "2782.25" "C129H201N29O37S" "CEGHRW" "T" "5.59" "1" "1" "0" "8" "10" "31.2" "-722" "30 hour" ">20 hour" ">10 hour" "93.6" "1490" "62.08" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01147" "VNPTLLFLKVPAQNAISTTFPYT" "23" "FluA-PB1(3-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=661.77 ±22.08 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01147" "DRAVPe01147.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "2535.97" "C120H187N27O33" "CDEGHMRW" "T" "8.56" "1" "0" "1" "8" "10" "40.87" "-85" "100 hour" ">20 hour" ">10 hour" "101.74" "1490" "67.73" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01148" "PTLLFLKVPAQNAISTTFPYT" "21" "FluA-PB1(5-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=483.20 ±51.98 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01148" "DRAVPe01148.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "2322.73" "C111H172N24O30" "CDEGHMRW" "T" "9.01" "1" "0" "1" "7" "9" "41.43" "175" ">20 hour" ">20 hour" "?" "97.62" "1490" "74.5" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01149" "LLFLKVPAQNAISTTFPYT" "19" "FluA-PB1(7-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01149" "DRAVPe01149.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "2124.51" "C102H158N22O27" "CDEGHMRW" "LT" "8.59" "1" "0" "1" "6" "9" "57.89" "432" "5.5 hour" "3 min" "2 min" "107.89" "1490" "82.78" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01150" "FLKVPAQNAISTTFPYT" "17" "FluA-PB1(9-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01150" "DRAVPe01150.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1898.19" "C90H136N20O25" "CDEGHMRW" "T" "8.59" "1" "0" "1" "6" "7" "20" "-552" "1.1 hour" "3 min" "2 min" "74.71" "1490" "93.13" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01151" "KVPAQNAISTTFPYT" "15" "FluA-PB1(11-25)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01151" "DRAVPe01151.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1637.85" "C75H116N18O23" "CDEGHLMRW" "T" "8.59" "1" "0" "1" "6" "5" "-21.33" "-1342" "1.3 hour" "3 min" "2 min" "58.67" "1490" "106.43" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01152" "MDVNPTLLFLKVPAQNAIST" "20" "FluA-PB1(1-20)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=33.80 ±5.53 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01152" "DRAVPe01152.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "2172.57" "C98H162N24O29S" "CEGHRWY" "L" "5.59" "1" "1" "0" "5" "9" "46.5" "-492" "30 hour" ">20 hour" ">10 hour" "117" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01153" "MDVNPTLLFLKVPAQNAI" "18" "FluA-PB1(1-18)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=29.45 ±5.16 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01153" "DRAVPe01153.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1984.38" "C91H150N22O25S" "CEGHRSWY" "L" "5.59" "1" "1" "0" "3" "9" "60" "105" "30 hour" ">20 hour" ">10 hour" "130" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01154" "MDVNPTLLFLKVPAQN" "16" "FluA-PB1(1-16)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=45.86 ±4.22 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01154" "DRAVPe01154.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1800.15" "C82H134N20O23S" "CEGHIRSWY" "L" "5.59" "1" "1" "0" "3" "7" "28.13" "-568" "30 hour" ">20 hour" ">10 hour" "115.63" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01155" "MDVNPTLLFLKVPA" "14" "FluA-PB1(1-14)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=34.53±2.19 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01155" "DRAVPe01155.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1557.91" "C73H120N16O19S" "CEGHIQRSWY" "L" "5.59" "1" "1" "0" "2" "7" "82.14" "650" "30 hour" ">20 hour" ">10 hour" "132.14" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01156" "MDVNPTLLFLKVP" "13" "FluA-PB1(1-13)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=138.17 ±7.88 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01156" "DRAVPe01156.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1486.83" "C70H115N15O18S" "ACEGHIQRSWY" "L" "5.59" "1" "1" "0" "2" "6" "74.62" "469" "30 hour" ">20 hour" ">10 hour" "134.62" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01157" "MDVNPTLLFLKV" "12" "FluA-PB1(1-12)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=643.93 ±180.75 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01157" "DRAVPe01157.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1389.72" "C65H108N14O17S" "ACEGHIQRSWY" "L" "5.59" "1" "1" "0" "2" "6" "94.17" "469" "30 hour" ">20 hour" ">10 hour" "145.83" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01158" "MDVNPTLLFLK" "11" "FluA-PB1(1-11)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=899.53 ±54.31 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01158" "DRAVPe01158.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1290.58" "C60H99N13O16S" "ACEGHIQRSWY" "L" "5.59" "1" "1" "0" "2" "5" "64.55" "65" "30 hour" ">20 hour" ">10 hour" "132.73" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01159" "MDVNPTLLFL" "10" "FluA-PB1(1-10)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01159" "DRAVPe01159.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1162.41" "C54H87N11O15S" "ACEGHIKQRSWY" "L" "3.8" "0" "1" "-1" "2" "5" "110" "620" "30 hour" ">20 hour" ">10 hour" "146" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01160" "MDVNPTLLF" "9" "FluA-PB1(1-9)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01160" "DRAVPe01160.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1049.25" "C48H76N10O14S" "ACEGHIKQRSWY" "L" "3.8" "0" "1" "-1" "2" "4" "80" "128" "30 hour" ">20 hour" ">10 hour" "118.89" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01161" "MDVNPTLL" "8" "FluA-PB1(1-8)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01161" "DRAVPe01161.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "902.07" "C39H67N9O13S" "ACEFGHIKQRSWY" "L" "3.8" "0" "1" "-1" "2" "3" "55" "-170" "30 hour" ">20 hour" ">10 hour" "133.75" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01162" "MDVNPTL" "7" "FluA-PB1(1-7)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01162" "DRAVPe01162.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "788.91" "C33H56N8O12S" "ACEFGHIKQRSWY" "DLMNPTV" "3.8" "0" "1" "-1" "2" "2" "8.57" "-662" "30 hour" ">20 hour" ">10 hour" "97.14" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01163" "MDVNPT" "6" "FluA-PB1(1-6)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01163" "DRAVPe01163.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "675.75" "C27H45N7O11S" "ACEFGHIKLQRSWY" "DMNPTV" "3.8" "0" "1" "-1" "2" "1" "-53.33" "-1154" "30 hour" ">20 hour" ">10 hour" "48.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01164" "MDVNPTLLFLKVPAQ" "15" "FluA-PB1(1-15)" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=43.32 ±5.31nM);##Influenza B(FluB):inhibition of PA-binding activity and virus replication(IC50>3000nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01164" "DRAVPe01164.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1686.04" "C78H128N18O21S" "CEGHIRSWY" "L" "5.59" "1" "1" "0" "2" "7" "53.33" "96" "30 hour" ">20 hour" ">10 hour" "123.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01165" "MNINPYPLFIDVPIQ" "15" "PB1-1-15 B" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=45.0 ±12.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01165" "DRAVPe01165.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1774.11" "C84H128N18O22S" "ACEGHKRSTW" "IP" "3.8" "0" "1" "-1" "3" "6" "40.67" "137" "30 hour" ">20 hour" ">10 hour" "123.33" "1490" "106.43" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01166" "MNINPTLLFLKVPIQ" "15" "PB1-1-15 A D2N,V3I,L14I" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=6.69 ±1.73 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01166" "DRAVPe01166.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1741.16" "C82H137N19O20S" "ACDEGHRSWY" "L" "8.5" "1" "0" "1" "3" "7" "73.33" "703" "30 hour" ">20 hour" ">10 hour" "149.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01167" "MDVNPTLLFIDVPAQ" "15" "PB1-1-15 A L10I,K11D" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01167" "DRAVPe01167.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1672.96" "C76H121N17O23S" "CEGHKRSWY" "DLPV" "3.56" "0" "2" "-2" "2" "7" "60.67" "-221" "30 hour" ">20 hour" ">10 hour" "123.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01168" "MNINPTLLFLKVPAQ" "15" "PB1-1-15 A D2N,V3I" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=12.96 ±3.98 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01168" "DRAVPe01168.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1699.08" "C79H131N19O20S" "CDEGHRSWY" "L" "8.5" "1" "0" "1" "3" "7" "55.33" "392" "30 hour" ">20 hour" ">10 hour" "130" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01169" "MDVNPYFLFLKVPAQ" "15" "PB1-1-15 A T6Y,L7F" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=7.51 ±0.71 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=345.0 ±81.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01169" "DRAVPe01169.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1782.13" "C86H128N18O21S" "CEGHIRSTW" "FLPV" "5.59" "1" "1" "0" "2" "7" "42.67" "145" "30 hour" ">20 hour" ">10 hour" "97.33" "1490" "106.43" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01170" "MDVNPTFLFLKVPAQ" "15" "PB1-1-15 A L7F" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01170" "DRAVPe01170.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1720.06" "C81H126N18O21S" "CEGHIRSWY" "FLPV" "5.59" "1" "1" "0" "2" "7" "46.67" "-98" "30 hour" ">20 hour" ">10 hour" "97.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01171" "MDVNPYLLFLKVPAQ" "15" "PB1-1-15 A T6Y" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=21.64 ±1.48 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=107.1 ±31.3 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01171" "DRAVPe01171.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1748.11" "C83H130N18O21S" "CEGHIRSTW" "L" "5.59" "1" "1" "0" "2" "7" "49.33" "339" "30 hour" ">20 hour" ">10 hour" "123.33" "1490" "106.43" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01172" "MDVNPFLLFLKVPAQ" "15" "PB1-1-15 A T6F" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=2.84 ±0.48 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=750.4 ±249.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01172" "DRAVPe01172.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1732.11" "C83H130N18O20S" "CEGHIRSTWY" "L" "5.59" "1" "1" "0" "1" "8" "76.67" "651" "30 hour" ">20 hour" ">10 hour" "123.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01173" "MDVNPWLLFLKVPAQ" "15" "PB1-1-15 A T6W" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=3.40 ±0.51 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=628.3 ±389.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01173" "DRAVPe01173.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1771.15" "C85H131N19O20S" "CEGHIRSTY" "L" "5.59" "1" "1" "0" "1" "8" "52" "586" "30 hour" ">20 hour" ">10 hour" "123.33" "5500" "392.86" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01174" "MDVNPHLLFLKVPAQ" "15" "PB1-1-15 A T6H" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=292.16 ±34.04 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01174" "DRAVPe01174.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1722.08" "C80H128N20O20S" "CEGIRSTWY" "L" "6.5" "2" "1" "1" "1" "7" "36.67" "-113" "30 hour" ">20 hour" ">10 hour" "123.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01175" "MDVNPCLLFLKVPAQ" "15" "PB1-1-15 A T6C" "Synthetic construct(derived from INFV A polymerase (PB1))" "Q6DNS6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A" "Orthomyxoviridae" "ELISA" "[Ref.19841738]Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50=43.58 ±5.67 nM);##Influenza A(FluA):inhibition of PA-binding activity and virus replication(IC50>3000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01175" "DRAVPe01175.cif" "Linear" "Free" "Free" "None" "L" "PA subunit" "Influenza virus replication and transcription is performed in the nucleus by the heterotrimeric viral polymerase complex consisting of the PB1, PB2, and PA subunits.The peptide could bind with PA subunit thus inhibit the virus replication." "1688.08" "C77H126N18O20S2" "EGHIRSTWY" "L" "5.59" "1" "1" "0" "2" "7" "74.67" "481" "30 hour" ">20 hour" ">10 hour" "123.33" "0" "0" "19841738" "PLoS One. 2009 Oct 20;4(10):e7517." "Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M." "Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. " "10.1371/journal.pone.0007517" "Anti-Influenza A" "DRAVPe01176" "GWWYKGRARPVSAVA" "15" "18-c01" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H3N2,H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=3.2 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01176" "DRAVPe01176.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1703.97" "C80H118N24O18" "CDEFHILMNQT" "A" "11" "3" "0" "3" "4" "7" "-36" "-1888" "30 hour" ">20 hour" ">10 hour" "58.67" "12490" "892.14" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H3N2,Anti-H1N1" "DRAVPe01177" "RAVWRHSVATPSHSV" "15" "C18-c03" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H3N2,H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=6.5 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=68 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01177" "DRAVPe01177.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1689.9" "C74H116N26O20" "CDEFGIKLMNQY" "SV" "12" "4" "0" "4" "4" "6" "-32" "-3386" "1 hour" "2 min" "2 min" "71.33" "5500" "392.86" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H3N2,Anti-H1N1" "DRAVPe01178" "GAWYKGRARPVSAVA" "15" "C18-c01W2A" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=53 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01178" "DRAVPe01178.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1588.83" "C72H113N23O18" "CDEFHILMNQT" "A" "11" "3" "0" "3" "4" "7" "-18" "-1940" "30 hour" ">20 hour" ">10 hour" "65.33" "6990" "499.29" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H1N1" "DRAVPe01179" "GWWYKGRARAVSAVA" "15" "C18-c01P10A" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=89 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01179" "DRAVPe01179.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1677.93" "C78H116N24O18" "CDEFHILMNPQT" "A" "11" "3" "0" "3" "4" "8" "-13.33" "-1707" "30 hour" ">20 hour" ">10 hour" "65.33" "12490" "892.14" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H1N1" "DRAVPe01180" "AVASVPRARGKYWWG" "15" "C18-c01r" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H3N2,H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=44 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=17 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01180" "DRAVPe01180.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1703.97" "C80H118N24O18" "CDEFHILMNQT" "A" "11" "3" "0" "3" "4" "7" "-36" "-1888" "4.4 hour" ">20 hour" ">10 hour" "58.67" "12490" "892.14" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H3N2,Anti-H1N1" "DRAVPe01181" "DFRRLPGAFWQLRQP" "15" "C18-p1b" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H3N2,H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=52 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=19 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01181" "DRAVPe01181.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1887.18" "C88H131N27O20" "CEHIKMNSTVY" "R" "11.7" "3" "1" "2" "1" "6" "-90" "-4368" "1.1 hour" "3 min" ">10 hour" "58.67" "5500" "392.86" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H3N2,Anti-H1N1" "DRAVPe01182" "AETVESCLAKPHTEN" "15" "C18-cp3c" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H3N2,H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50=66 μM);##H3N2(A/Aichi/2/68):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01182" "DRAVPe01182.cif" "Linear" "Alkylated(C18)" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1628.77" "C67H109N19O26S" "DFGIMQRWY" "E" "4.75" "2" "3" "-1" "5" "4" "-72" "-3196" "4.4 hour" ">20 hour" ">10 hour" "58.67" "0" "0" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H3N2,Anti-H1N1" "DRAVPe01183" "GWWYKGRARPVSAVA" "15" "c01" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01183.cif" "Linear" "Free" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1703.97" "C80H118N24O18" "CDEFHILMNQT" "A" "11" "3" "0" "3" "4" "7" "-36" "-1888" "30 hour" ">20 hour" ">10 hour" "58.67" "12490" "892.14" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H1N1" "DRAVPe01184" "RAVWRHSVATPSHSV" "15" "c03" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "H1N1" "Orthomyxoviridae" "Plaque assay" "[Ref.19558186]H1N1(A/PR/8/34):inhibition of virus infection in Madin-Darby canine kidney(MDCK) cells(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01184.cif" "Linear" "Free" "Amidation" "None" "L" "sialylgalactose" "The peptide has affinity for glycoconjugates on the cell surface. And its binding to the cell resulted in the significant inhibition of influenza virus infections." "1689.9" "C74H116N26O20" "CDEFGIKLMNQY" "SV" "12" "4" "0" "4" "4" "6" "-32" "-3386" "1 hour" "2 min" "2 min" "71.33" "5500" "392.86" "19558186" "J Med Chem. 2009 Jul 23;52(14):4247-56." "Matsubara T, Sumi M, Kubota H, Taki T, Okahata Y, Sato T." "Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. " "10.1021/jm801570y" "Anti-H1N1" "DRAVPe01185" "RRKKAAVALLPAVLLALLAP" "20" "EB" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(95 ± 2% inhibition at 10 μM,EC50=3.2 ± 0.0 μM)." "[Ref.21220525]Did not lyse red blood cells up to 30 μM." "[Ref.21220525]A549 cells:CD50=83.5 ± 22.0 μM;##MDCK cells:CD50=85.5 ± 1.3 μM." "DRAVPe01185" "DRAVPe01185.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "2084.67" "C98H178N28O21" "CDEFGHIMNQSTWY" "AL" "12.02" "4" "0" "4" "0" "14" "110" "752" "1 hour" "2 min" "2 min" "176" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1689" "Anti-Influenza virus" "DRAVPe01186" "RRKKAAVALLPAVLLALLA" "19" "A2" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 2% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01186" "DRAVPe01186.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1987.55" "C93H171N27O20" "CDEFGHIMNQSTWY" "AL" "12.02" "4" "0" "4" "0" "14" "124.21" "752" "1 hour" "2 min" "2 min" "185.26" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1690" "Anti-Influenza virus" "DRAVPe01187" "RRKKAAVALLPAVLLALL" "18" "A3" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(95 ± 2% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01187" "DRAVPe01187.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1916.47" "C90H166N26O19" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "13" "121.11" "571" "1 hour" "2 min" "2 min" "190" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1691" "Anti-Influenza virus" "DRAVPe01188" "RRKKAAVALLPAVLLAL" "17" "A4" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(89 ± 3% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01188" "DRAVPe01188.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1803.31" "C84H155N25O18" "CDEFGHIMNQSTWY" "AL" "12.02" "4" "0" "4" "0" "12" "105.88" "79" "1 hour" "2 min" "2 min" "178.24" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1692" "Anti-Influenza virus" "DRAVPe01189" "RRKKAAVALLPAVLLA" "16" "A5" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(96 ±32% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01189" "DRAVPe01189.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1690.15" "C78H144N24O17" "CDEFGHIMNQSTWY" "A" "12.02" "4" "0" "4" "0" "11" "88.75" "-413" "1 hour" "2 min" "2 min" "165" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1693" "Anti-Influenza virus" "DRAVPe01190" "RRKKAAVALLP" "11" "A10" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(4 ±8% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01190" "DRAVPe01190.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1222.54" "C55H103N19O12" "CDEFGHIMNQSTWY" "A" "12.02" "4" "0" "4" "0" "6" "-10.91" "-2163" "1 hour" "2 min" "2 min" "124.55" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1698" "Anti-Influenza virus" "DRAVPe01191" "RRKKAVALLPAVLLALLAP" "19" "B6" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 6% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01191" "DRAVPe01191.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "2013.59" "C95H173N27O20" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "13" "106.32" "571" "1 hour" "2 min" "2 min" "180" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1706" "Anti-Influenza virus" "DRAVPe01192" "RRKKVALLPAVLLALLAP" "18" "B7" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01192" "DRAVPe01192.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1942.51" "C92H168N26O19" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "12" "102.22" "390" "1 hour" "2 min" "2 min" "184.44" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1707" "Anti-Influenza virus" "DRAVPe01193" "RRKKALLPAVLLALLAP" "17" "B8" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 3% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01193" "DRAVPe01193.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1843.38" "C87H159N25O18" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "11" "83.53" "-14" "1 hour" "2 min" "2 min" "178.24" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1708" "Anti-Influenza virus" "DRAVPe01194" "RRKKLLPAVLLALLAP" "16" "B9" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01194" "DRAVPe01194.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1772.3" "C84H154N24O17" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "10" "77.5" "-195" "1 hour" "2 min" "2 min" "183.13" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1709" "Anti-Influenza virus" "DRAVPe01195" "RRKKLPAVLLALLAP" "15" "B10" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(94 ± 4% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01195" "DRAVPe01195.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1659.14" "C78H143N23O16" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "9" "57.33" "-687" "1 hour" "2 min" "2 min" "169.33" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1710" "Anti-Influenza virus" "DRAVPe01196" "RRKKPAVLLALLAP" "14" "B11" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(96 ± 0% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01196" "DRAVPe01196.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1545.98" "C72H132N22O15" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "8" "34.29" "-1179" "1 hour" "2 min" "2 min" "153.57" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1006" "Anti-Influenza virus" "DRAVPe01197" "RRKKAVLLALLAP" "13" "B12" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(97 ± 2% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01197" "DRAVPe01197.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1448.86" "C67H125N21O14" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "8" "49.23" "-1179" "1 hour" "2 min" "2 min" "165.38" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "Anti-Influenza virus" "DRAVPe01198" "RRKKVLLALLAP" "12" "C1" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(40 ±19 % inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01198" "DRAVPe01198.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1377.78" "C64H120N20O13" "CDEFGHIMNQSTWY" "L" "12.02" "4" "0" "4" "0" "7" "38.33" "-1360" "1 hour" "2 min" "2 min" "170.83" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1711" "Anti-Influenza virus" "DRAVPe01199" "RRKKAAVALLAVLLALLA" "18" "EBNP(EB without prolines)" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.0 ± 0.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01199" "DRAVPe01199.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1890.43" "C88H164N26O19" "CDEFGHIMNPQSTWY" "AL" "12.02" "4" "0" "4" "0" "14" "140" "752" "1 hour" "2 min" "2 min" "195.56" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1721" "Anti-Influenza virus" "DRAVPe01200" "RRKKVALLAVLLALLA" "16" "B7NP(B7 without prolines)" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=0.3 ± 0.1 μM)." "[Ref.21220525]>50% hemolysis agaisnt human red blood cells at 30 μM." "[Ref.21220525]A549 cells:CD50=126.3± 23.0 μM;##MDCK cells:CD50=105.3 ± 8.0 μM." "DRAVPe01200" "DRAVPe01200.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1748.28" "C82H154N24O17" "CDEFGHIMNPQSTWY" "L" "12.02" "4" "0" "4" "0" "12" "135" "390" "1 hour" "2 min" "2 min" "207.5" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1720" "Anti-Influenza virus" "DRAVPe01201" "RRKKALLAVLLALLA" "15" "B8NP" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=0.4 ± 0.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01201" "DRAVPe01201.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1649.14" "C77H145N23O16" "CDEFGHIMNPQSTWY" "L" "12.02" "4" "0" "4" "0" "11" "116" "-14" "1 hour" "2 min" "2 min" "202" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "Anti-Influenza virus" "DRAVPe01202" "RRKKLLAVLLALLA" "14" "B9NP" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.1 ± 0.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01202" "DRAVPe01202.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1578.06" "C74H140N22O15" "CDEFGHIMNPQSTWY" "L" "12.02" "4" "0" "4" "0" "10" "111.43" "-195" "1 hour" "2 min" "2 min" "209.29" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1722" "Anti-Influenza virus" "DRAVPe01203" "RRKKLAVLLALLA" "13" "B10NP" "Synthetic construct(derived from FGF-4 signal sequence)" "P08620" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.21220525]Influenza virus:inhibit hemagglutination of 64 HA units of virus of MDCK cells(EC50=3.5 ± 2.6 μM)." "[Ref.21220525]Did not lyse human red blood cells up to 30 μM." "[Ref.21220525]A549 cells:CD50=120.0 ± 28.0 μM;##MDCK cells:CD50=90.0 ± 16.3 μM." "DRAVPe01203" "DRAVPe01203.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits influenza virus replication by preventing attachment to cells." "1464.9" "C68H129N21O14" "CDEFGHIMNPQSTWY" "L" "12.02" "4" "0" "4" "0" "9" "90.77" "-687" "1 hour" "2 min" "2 min" "195.38" "0" "0" "21220525" " Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3." "Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. " "Identification of the minimal active sequence of an anti-influenza virus peptide. " "10.1128/AAC.01428-10" "DRAVPa1723" "Anti-Influenza virus" "DRAVPe01204" "LFRLIKSLIKRLVSAFK" "17" "Mucroporin-M1" "Synthetic construct(derived from Mucroporin)" "B9UIY3" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV,H5N1,MeV" "Coronaviridae, Orthomyxoviridae, Paramyxoviridae" "Plaque formation assay" "[Ref.21620914]measles virus (MeV):inhibition of MeV infection in Vero cells(EC50=7.15 μg/ml (3.52 μM));##SARS-CoV(pseudoviruse):inhibition of SARS-CoV infection in MDCK cells(EC50=14.46 μg/ml (7.12 μM));##H5N1(pseudovirus):inhibition of H5N1 infection in MDCK cells(EC50=2.10 μg/ml (1.03 μM))." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21620914]Vero cells:CC50=70.46μg/ ml(34.70μM);##HeLa-ACE2 cells:CC50=61.58 μg/ml (30.31 μM);##MDCK cells:CC50=83.35 μg/ml (41.03 μM)." "DRAVPe01204" "DRAVPe01204.cif" "Linear" "Free" "Amidation" "None" "L" "membrane" "Mucroporin-M1 may bind to the virus envelope by surface charge interactions and inhibits MeV, SARS-CoV and influenza H5N1 by direct virucidal action." "2032.59" "C98H170N26O20" "CDEGHMNPQTWY" "L" "12.02" "5" "0" "5" "2" "10" "79.41" "-1196" "5.5 hour" "3 min" "2 min" "160.59" "0" "0" "21620914" "Peptides. 2011 Jul;32(7):1518-25." "Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. " "Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. " "10.1016/j.peptides.2011.05.015" "Anti-SARS-CoV,Anti-H5N1,Anti-MeV" "DRAVPe01205" "KAKAKAKAKAKAKAKAKAKAK" "21" "RJ1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=53.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>455 μM." "DRAVPe01205" "DRAVPe01205.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2138.72" "C96H184N32O22" "CDEFGHILMNPQRSTVWY" "K" "11" "11" "0" "11" "0" "10" "-118.57" "-4295" "1.3 hour" "3 min" "2 min" "47.62" "0" "0" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01206" "KAAKKAAKAAKKAAKWAKKAA" "21" "RJ3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=117.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>467 μM." "DRAVPe01206" "DRAVPe01206.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2139.66" "C98H175N31O22" "CDEFGHILMNPQRSTVY" "A" "10.9" "9" "0" "9" "0" "12" "-77.14" "-2771" "1.3 hour" "3 min" "2 min" "52.38" "5500" "275" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01207" "AKKAAKKAKKAAKKAKKAAKK" "21" "RJ5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=41.0 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=14.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>468 μM." "DRAVPe01207" "DRAVPe01207.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2195.81" "C99H191N33O22" "CDEFGHILMNPQRSTVWY" "K" "11.04" "12" "0" "12" "0" "9" "-145.71" "-5031" "4.4 hour" ">20 hour" ">10 hour" "42.86" "0" "0" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01208" "AKKAAKKAKKAAKKAKKWAKK" "21" "RJ6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=47.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>433 μM." "DRAVPe01208" "DRAVPe01208.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2310.95" "C107H196N34O22" "CDEFGHILMNPQRSTVY" "K" "11.04" "12" "0" "12" "0" "9" "-158.57" "-4979" "4.4 hour" ">20 hour" ">10 hour" "38.1" "5500" "275" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01209" "AKKAWKKAKKAAKKAKKWAKK" "21" "RJ7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=40.8 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=44.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>412 μM." "DRAVPe01209" "DRAVPe01209.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2426.08" "C115H201N35O22" "CDEFGHILMNPQRSTVY" "K" "11.04" "12" "0" "12" "0" "9" "-171.43" "-4927" "4.4 hour" ">20 hour" ">10 hour" "33.33" "11000" "550" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01210" "ARRAWRRARRAARRARRAARR" "21" "RJ8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=18.2 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=22.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>395 μM." "DRAVPe01210" "DRAVPe01210.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2647.11" "C107H196N58O22" "CDEFGHIKLMNPQSTVY" "R" "13.04" "12" "0" "12" "0" "9" "-192.86" "-16223" "4.4 hour" ">20 hour" ">10 hour" "38.1" "5500" "275" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01211" "ARRAKRRARRAARRARRKARR" "21" "RJ9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=13.0 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=46.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>433 μM." "DRAVPe01211" "DRAVPe01211.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2646.17" "C105H205N59O22" "CDEFGHILMNPQSTVWY" "R" "13.04" "14" "0" "14" "0" "7" "-234.29" "-17747" "4.4 hour" ">20 hour" ">10 hour" "33.33" "0" "0" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01212" "ARRAKRRARRAKRRARRKKRR" "21" "RJ10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque reduction assay,ELISA" "[Ref.15498607]herpes simplex virus 1(HSV-1):inhibition of HSV-1 infection in MRC-5 cells(IC50=24.6 μM);##herpes simplex virus 2(HSV-2):inhibition of HSV-2 infection in MRC-5 cells(IC50=54.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15498607]human fibroblasts(MRC-5 cells):CC50>422 μM." "DRAVPe01212" "DRAVPe01212.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide was able to inhibit the entry of HSV-1 into the host cell, probably by blocking heparan sulfate(HS) at the cell surface." "2760.36" "C111H219N61O22" "CDEFGHILMNPQSTVWY" "R" "13.04" "16" "0" "16" "0" "5" "-288.57" "-19219" "4.4 hour" ">20 hour" ">10 hour" "23.81" "0" "0" "15498607" "Antiviral Res. 2004 Nov;64(2):119-26." "Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. " "A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus." "10.1016/j.antiviral.2004.08.003" "Anti-HSV" "DRAVPe01213" "QLQKWEDWVRWIGNIPQYLKG" "21" "Peptide 59(FIV ectodomain 767-786)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.03 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.01 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01213" "DRAVPe01213.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2658.06" "C126H185N33O31" "ACFHMST" "QW" "8.5" "3" "2" "1" "4" "8" "-90" "-3236" "0.8 hour" "10 min" ">10 hour" "88.1" "17990" "899.5" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01214" "QKWEDWVRWIGN" "12" "C12a(FIV ectodomain 768-779)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.25 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.18 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01214" "DRAVPe01214.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1616.8" "C76H105N21O19" "ACFHLMPSTY" "W" "6.07" "2" "2" "0" "2" "5" "-140" "-3129" "0.8 hour" "10 min" ">10 hour" "56.67" "16500" "1500" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01215" "WEDWVRWIGNIP" "12" "C12b(FIV ectodomain 770-781)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.04 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.09 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01215" "DRAVPe01215.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1570.77" "C76H103N19O18" "ACFHKLMQSTY" "W" "4.37" "1" "2" "-1" "2" "6" "-54.17" "-1528" "2.8 hour" "3 min" "2 min" "89.17" "16500" "1500" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01216" "QLQKWEDWVRWI" "12" "C12c(FIV ectodomain 766-777)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.03 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.04 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01216" "DRAVPe01216.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1686.93" "C81H115N21O19" "ACFGHMNPSTY" "W" "6.07" "2" "2" "0" "0" "6" "-105" "-2621" "0.8 hour" "10 min" ">10 hour" "89.17" "16500" "1500" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01217" "WEDWVRWI" "8" "C8(FIV ectodomain 770-777)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.07 ± 0.02 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.46 ± 0.20 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.05 ± 0.01 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01217" "DRAVPe01217.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1189.34" "C59H76N14O13" "ACFGHKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-68.75" "-1450" "2.8 hour" "3 min" "2 min" "85" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01218" "DWVRWI" "6" "C6a(FIV ectodomain 772-777)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.15 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.07 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01218" "DRAVPe01218.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "874.01" "C43H59N11O9" "ACEFGHKLMNPQSTY" "W" "5.84" "1" "1" "0" "0" "4" "-18.33" "-1002" "1.1 hour" "3 min" ">10 hour" "113.33" "11000" "2200" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01219" "WEDWVR" "6" "C6b(FIV ectodomain 770-775)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01219" "DRAVPe01219.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "889.97" "C42H55N11O11" "ACFGHIKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "3" "-151.67" "-2175" "2.8 hour" "3 min" "2 min" "48.33" "11000" "2200" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01220" "WVRWI" "5" "C5(FIV ectodomain 773-777)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.20 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.11 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01220" "DRAVPe01220.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "758.92" "C39H54N10O6" "ACDEFGHKLMNPQSTY" "W" "9.75" "1" "0" "1" "0" "4" "48" "-130" "2.8 hour" "3 min" "2 min" "136" "11000" "2750" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01221" "WVRW" "4" "C4a(FIV ectodomain 773-776)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=36 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=24 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01221" "DRAVPe01221.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "645.76" "C33H43N9O5" "ACDEFGHIKLMNPQSTY" "W" "9.75" "1" "0" "1" "0" "3" "-52.5" "-622" "2.8 hour" "3 min" "2 min" "72.5" "11000" "3666.67" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01222" "VRWI" "4" "C4b(FIV ectodomain 774-777)" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=7.80 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=4.06 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01222" "DRAVPe01222.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "572.71" "C28H44N8O5" "ACDEFGHKLMNPQSTY" "IRVW" "9.72" "1" "0" "1" "0" "3" "82.5" "-363" "100 hour" ">20 hour" ">10 hour" "170" "5500" "1833.33" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01223" "AEDWVRWI" "8" "C8W->A770" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=4.30 ± 0.70 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=2.10± 0.10 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610147]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01223" "DRAVPe01223.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1074.2" "C51H71N13O13" "CFGHKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-35" "-1502" "4.4 hour" ">20 hour" ">10 hour" "97.5" "11000" "1571.43" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01224" "WADWVRWI" "8" "C8E->A771" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.16 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.22 ± 0.05 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.12 ± 0.01 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610148]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01224" "DRAVPe01224.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1131.3" "C57H74N14O11" "CEFGHKLMNPQSTY" "W" "5.84" "1" "1" "0" "0" "6" "-2.5" "-588" "2.8 hour" "3 min" "2 min" "97.5" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01225" "WEAWVRWI" "8" "C8D->A772" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.10± 0.02 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.40 ± 0.22 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.03 ± 0.06 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610149]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01225" "DRAVPe01225.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1145.33" "C58H76N14O11" "CDFGHKLMNPQSTY" "W" "6" "1" "1" "0" "0" "6" "-2.5" "-397" "2.8 hour" "3 min" "2 min" "97.5" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01226" "WEDAVRWI" "8" "C8W->A773" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610150]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01226" "DRAVPe01226.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1074.2" "C51H71N13O13" "CFGHKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-35" "-1502" "2.8 hour" "3 min" "2 min" "97.5" "11000" "1571.43" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01227" "WEDWARWI" "8" "C8V->A774" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.07 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.54 ± 0.02 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.15 ± 0.12 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610151]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01227" "DRAVPe01227.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1161.28" "C57H72N14O13" "CFGHKLMNPQSTVY" "W" "4.37" "1" "2" "-1" "0" "5" "-98.75" "-1673" "2.8 hour" "3 min" "2 min" "61.25" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01228" "WEDWVAWI" "8" "C8G->A775" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.09 ± 0.03 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.38 ± 0.04 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.25 ± 0.06 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610152]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01228" "DRAVPe01228.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1104.23" "C56H69N11O13" "CFGHKLMNPQRSTY" "W" "3.67" "0" "2" "-2" "0" "6" "10" "223" "2.8 hour" "3 min" "2 min" "97.5" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01229" "WEDWVRAI" "8" "C8W->A776" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50>50 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50>50);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50>50 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610153]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01229" "DRAVPe01229.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1074.2" "C51H71N13O13" "CFGHKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-35" "-1502" "2.8 hour" "3 min" "2 min" "97.5" "11000" "1571.43" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01230" "WEDWVRWA" "8" "C8I->A777" "Synthetic construct(derived from the Membrane-Proximal Ectodomain of Feline Immunodeficiency Virus)" "P16090" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "enzyme-linked immunosorbent assay(ELISA)" "[Ref.12610147]FIV-M2(Feline immunodeficiency virus M2):inhibition of virus replication in MBM cells(IC50=0.15 ± 0.01 µg/ml);##FIV-GL8(Feline immunodeficiency virus GL8):inhibition of virus replication in MBM cells(IC50=0.64± 0.08 µg/ml);##FIV-Pet(Feline immunodeficiency virus Pet):inhibition of virus replication in MBM cells(IC50=0.13 ± 0.04 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12610154]No detectable cytotoxicity on MBM cell viability and proliferation." "DRAVPe01230" "DRAVPe01230.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1147.26" "C56H70N14O13" "CFGHIKLMNPQSTY" "W" "4.37" "1" "2" "-1" "0" "5" "-102.5" "-1761" "2.8 hour" "3 min" "2 min" "48.75" "16500" "2357.14" "12610147" "J Virol. 2003 Mar;77(6):3724-33." "Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M." "Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein." "10.1128/jvi.77.6.3724-3733.2003" "Anti-FIV" "DRAVPe01231" "TDVILMCFSIDSPDSLENI" "19" "77-95(wild type)" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=7.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01231" "DRAVPe01231.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2112.39" "C91H146N20O33S2" "AGHKQRWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "54.21" "-1713" "7.2 hour" ">20 hour" ">10 hour" "117.89" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01232" "CSIELSDIPLSVDFNTMID" "19" "77-95(scrambled)" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01232" "DRAVPe01232.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2112.39" "C91H146N20O33S2" "AGHKQRWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "54.21" "-1713" "1.2 hour" ">20 hour" ">10 hour" "117.89" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01233" "ADVILMCFSIDSPDSLENI" "19" "77-95[77A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.56 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01233" "DRAVPe01233.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2082.37" "C90H144N20O32S2" "GHKQRTWY" "DIS" "3.37" "0" "4" "-4" "5" "8" "67.37" "-1275" "4.4 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01234" "TAVILMCFSIDSPDSLENI" "19" "77-95[78A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.37 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01234" "DRAVPe01234.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2068.38" "C90H146N20O31S2" "GHKQRWY" "IS" "3.49" "0" "3" "-3" "6" "8" "82.11" "-660" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01235" "TDAILMCFSIDSPDSLENI" "19" "77-95[79A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.60 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01235" "DRAVPe01235.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2084.34" "C89H142N20O33S2" "GHKQRVWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "41.58" "-1936" "7.2 hour" ">20 hour" ">10 hour" "107.89" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01236" "TDVALMCFSIDSPDSLENI" "19" "77-95[80A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=11.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01236" "DRAVPe01236.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2070.31" "C88H140N20O33S2" "GHKQRWY" "DS" "3.37" "0" "4" "-4" "6" "7" "40" "-2024" "7.2 hour" ">20 hour" ">10 hour" "102.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01237" "TDVIAMCFSIDSPDSLENI" "19" "77-95[81A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=5.42 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01237" "DRAVPe01237.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2070.31" "C88H140N20O33S2" "GHKQRWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "43.68" "-2024" "7.2 hour" ">20 hour" ">10 hour" "102.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01238" "TDVILACFSIDSPDSLENI" "19" "77-95[82A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.43 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01238" "DRAVPe01238.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2052.28" "C89H142N20O33S" "GHKMQRWY" "DIS" "3.37" "0" "4" "-4" "6" "8" "53.68" "-1767" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01239" "TDVILMAFSIDSPDSLENI" "19" "77-95[83A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01239" "DRAVPe01239.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2080.33" "C91H146N20O33S" "CGHKQRWY" "DIS" "3.37" "0" "4" "-4" "5" "8" "50.53" "-1660" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01240" "TDVILMCASIDSPDSLENI" "19" "77-95[84A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.29 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01240" "DRAVPe01240.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2036.3" "C85H142N20O33S2" "FGHKQRWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "48.95" "-1830" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01241" "TDVILMCFAIDSPDSLENI" "19" "77-95[85A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.82 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01241" "DRAVPe01241.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2096.39" "C91H146N20O32S2" "GHKQRWY" "DI" "3.37" "0" "4" "-4" "5" "8" "67.89" "-1192" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01242" "TDVILMCFSADSPDSLENI" "19" "77-95[86A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=3.52 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01242" "DRAVPe01242.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2070.31" "C88H140N20O33S2" "GHKQRWY" "DS" "3.37" "0" "4" "-4" "6" "7" "40" "-2024" "7.2 hour" ">20 hour" ">10 hour" "102.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01243" "TDVILMCFSIASPDSLENI" "19" "77-95[87A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.36 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01243" "DRAVPe01243.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2068.38" "C90H146N20O31S2" "GHKQRWY" "IS" "3.49" "0" "3" "-3" "6" "8" "82.11" "-660" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01244" "TDVILMCFSIDAPDSLENI" "19" "77-95[88A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.26 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01244" "DRAVPe01244.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2096.39" "C91H146N20O32S2" "GHKQRWY" "DI" "3.37" "0" "4" "-4" "5" "8" "67.89" "-1192" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01245" "TDVILMCFSIDSADSLENI" "19" "77-95[89A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=15.32 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01245" "DRAVPe01245.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2086.36" "C89H144N20O33S2" "GHKPQRWY" "DIS" "3.37" "0" "4" "-4" "6" "8" "72.11" "-1532" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01246" "TDVILMCFSIDSPASLENI" "19" "77-95[90A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.61 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01246" "DRAVPe01246.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2068.38" "C90H146N20O31S2" "GHKQRWY" "IS" "3.49" "0" "3" "-3" "6" "8" "82.11" "-660" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01247" "TDVILMCFSIDSPDALENI" "19" "77-95[91A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.19 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01247" "DRAVPe01247.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2096.39" "C91H146N20O32S2" "GHKQRWY" "DI" "3.37" "0" "4" "-4" "5" "8" "67.89" "-1192" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01248" "TDVILMCFSIDSPDSAENI" "19" "77-95[92A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=2.27 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01248" "DRAVPe01248.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2070.31" "C88H140N20O33S2" "GHKQRWY" "DIS" "3.37" "0" "4" "-4" "6" "7" "43.68" "-2024" "7.2 hour" ">20 hour" ">10 hour" "102.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01249" "TDVILMCFSIDSPDSLANI" "19" "77-95[93A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=9.83 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01249" "DRAVPe01249.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2054.36" "C89H144N20O31S2" "EGHKQRWY" "DIS" "3.42" "0" "3" "-3" "6" "8" "82.11" "-851" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01250" "TDVILMCFSIDSPDSLEAI" "19" "77-95[94A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=18.47 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01250" "DRAVPe01250.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2069.37" "C90H145N19O32S2" "GHKNQRWY" "DIS" "3.37" "0" "4" "-4" "5" "8" "82.11" "-868" "7.2 hour" ">20 hour" ">10 hour" "123.16" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01251" "TDVILMCFSIDSPDSLENA" "19" "77-95[95A]" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.89 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01251" "DRAVPe01251.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2070.31" "C88H140N20O33S2" "GHKQRWY" "DS" "3.37" "0" "4" "-4" "6" "7" "40" "-2024" "7.2 hour" ">20 hour" ">10 hour" "102.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01252" "TDVILMCFSI" "10" "77-86" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01252" "DRAVPe01252.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1141.41" "C51H84N10O15S2" "AEGHKNPQRWY" "I" "3.8" "0" "1" "-1" "3" "5" "192" "1072" "7.2 hour" ">20 hour" ">10 hour" "146" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01253" "TDVILMCFSIDSP" "13" "77–89" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01253" "DRAVPe01253.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1440.69" "C63H101N13O21S2" "AEGHKNQRWY" "DIS" "3.56" "0" "2" "-2" "4" "5" "102.31" "-140" "7.2 hour" ">20 hour" ">10 hour" "112.31" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01254" "TDVILMCFSIDSPDSL" "16" "77-92" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=10.86 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01254" "DRAVPe01254.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1756.02" "C76H122N16O27S2" "AEGHKNQRWY" "DS" "3.42" "0" "3" "-3" "5" "6" "80" "-860" "7.2 hour" ">20 hour" ">10 hour" "115.63" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01255" "DVILMCFSIDSPDSLENI" "18" "78-95" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.23 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01255" "DRAVPe01255.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2011.29" "C87H139N19O31S2" "AGHKQRTWY" "DIS" "3.37" "0" "4" "-4" "5" "7" "61.11" "-1456" "1.1 hour" "3 min" ">10 hour" "124.44" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01256" "VILMCFSIDSPDSLENI" "17" "79-95" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=16.95 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01256" "DRAVPe01256.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1896.2" "C83H134N18O28S2" "AGHKQRTWY" "IS" "3.49" "0" "3" "-3" "5" "7" "85.29" "-584" "100 hour" ">20 hour" ">10 hour" "131.76" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01257" "ILMCFSIDSPDSLENI" "16" "80-95" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=7.17 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01257" "DRAVPe01257.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1797.07" "C78H125N17O27S2" "AGHKQRTVWY" "IS" "3.49" "0" "3" "-3" "5" "6" "64.38" "-988" "20 hour" "30 min" ">10 hour" "121.88" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01258" "CFSIDSPDSLENI" "13" "83-95" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01258" "DRAVPe01258.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1439.56" "C61H94N14O24S" "AGHKMQRTVWY" "S" "3.49" "0" "3" "-3" "5" "4" "0.77" "-2207" "1.2 hour" ">20 hour" ">10 hour" "90" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01259" "ILMCFSIDSPDSLEN" "15" "80-94" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=1.75 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01259" "DRAVPe01259.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1683.91" "C72H114N16O26S2" "AGHKQRTVWY" "S" "3.49" "0" "3" "-3" "5" "5" "38.67" "-1480" "20 hour" "30 min" ">10 hour" "104" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01260" "ILMCFSIDSPDSLE" "14" "80-93" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=3.50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01260" "DRAVPe01260.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1569.8" "C68H108N14O24S2" "AGHKNQRTVWY" "S" "3.49" "0" "3" "-3" "4" "5" "66.43" "-816" "20 hour" "30 min" ">10 hour" "111.43" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01261" "ILMCFSIDSPDSL" "13" "80-92" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=12.40 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01261" "DRAVPe01261.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1440.69" "C63H101N13O21S2" "AEGHKNQRTVWY" "S" "3.56" "0" "2" "-2" "4" "5" "98.46" "-135" "20 hour" "30 min" ">10 hour" "120" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01262" "ILMCFSIDSPDS" "12" "80-91" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=6.36 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01262" "DRAVPe01262.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1327.53" "C57H90N12O20S2" "AEGHKNQRTVWY" "S" "3.56" "0" "2" "-2" "4" "4" "75" "-627" "20 hour" "30 min" ">10 hour" "97.5" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01263" "ILMCFSIDSPD" "11" "80-90" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=4.61 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01263" "DRAVPe01263.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1240.45" "C54H85N11O18S2" "AEGHKNQRTVWY" "DIS" "3.56" "0" "2" "-2" "3" "4" "89.09" "-287" "20 hour" "30 min" ">10 hour" "106.36" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01264" "ILMCFSIDSP" "10" "80-89" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50=35.77 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01264" "DRAVPe01264.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1125.36" "C50H80N10O15S2" "AEGHKNQRTVWY" "IS" "3.8" "0" "1" "-1" "3" "4" "133" "585" "20 hour" "30 min" ">10 hour" "117" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01265" "ILMCFSIDS" "9" "80-88" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01265" "DRAVPe01265.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1028.25" "C45H73N9O14S2" "AEGHKNPQRTVWY" "IS" "3.8" "0" "1" "-1" "3" "4" "165.56" "585" "20 hour" "30 min" ">10 hour" "130" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01266" "ILMCFSID" "8" "80-87" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01266" "DRAVPe01266.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "941.17" "C42H68N8O12S2" "AEGHKNPQRTVWY" "I" "3.8" "0" "1" "-1" "2" "4" "196.25" "925" "20 hour" "30 min" ">10 hour" "146.25" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01267" "ILMCFSI" "7" "80-86" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01267" "DRAVPe01267.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "826.08" "C38H63N7O9S2" "ADEGHKNPQRTVWY" "I" "5.52" "0" "0" "0" "2" "4" "274.29" "1797" "20 hour" "30 min" ">10 hour" "167.14" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01268" "ILMCFS" "6" "80-85" "Synthetic construct(derived from RhoA protein)" "P08134" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "viral antigen reduction assay" "[Ref.14576104]respiratory syncytial virus(RSV):inhibition of RSV replication in HEp-2 cells(IC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01268" "DRAVPe01268.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "712.92" "C32H52N6O8S2" "ADEGHKNPQRTVWY" "CFILMS" "5.52" "0" "0" "0" "2" "3" "245" "1305" "20 hour" "30 min" ">10 hour" "130" "0" "0" "14576104" "Antimicrob Agents Chemother. 2003 Nov;47(11):3470-7." "Budge PJ, Lebowitz J, Graham BS. " "Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers." "10.1128/AAC.47.11.3470-3477.2003" "Anti-RSV" "DRAVPe01269" "NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA" "38" "HR1-1(HR1 region 889–926)" "Synthetic construct(derived from SARS-CoV spike protein)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "luciferase assay" "[Ref.15184046]HIV-luc/SARS pseudotyped virus:inhibition of virus infection in 293T cells(EC50=0.14 μM);##SARS-CoV(wild-type):inhibition of virus infection in 293T cells(EC50=3.68 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01269" "DRAVPe01269.cif" "Linear" "Free" "Free" "None" "L" "membrane" "soluble synthesized HR1, HR2 or homologues can bind the exposed HR1 or HR2 region and block the formation of the six-helix bundle, thus inhibiting virus fusion with the target cell." "4153.57" "C178H291N51O63" "CDHMPRW" "Q" "6.14" "2" "2" "0" "16" "12" "-50.26" "-6646" "1.4 hour" "3 min" ">10 hour" "84.74" "1490" "40.27" "15184046" "Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52." "Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H." "Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein." "10.1016/j.bbrc.2004.05.046" "Anti-SARS-CoV" "DRAVPe01270" "IQKEIDRLNEVAKNLNESLIDLQELGK" "27" "HR2-18(HR2 region 1161–1187)" "Synthetic construct(derived from SARS-CoV spike protein)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "luciferase assay" "[Ref.15184046]HIV-luc/SARS pseudotyped virus:inhibition of virus infection in 293T cells(EC50=1.19 μM);##SARS-CoV(wild-type):inhibition of virus infection in 293T cells(EC50=5.22 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01270.cif" "Linear" "Free" "Free" "None" "L" "membrane" "soluble synthesized HR1, HR2 or homologues can bind the exposed HR1 or HR2 region and block the formation of the six-helix bundle, thus inhibiting virus fusion with the target cell." "3123.55" "C135H232N38O46" "CFHMPTWY" "L" "4.66" "4" "6" "-2" "5" "10" "-64.44" "-6450" "20 hour" "30 min" ">10 hour" "130" "0" "0" "15184046" "Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52." "Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H." "Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein." "10.1016/j.bbrc.2004.05.046" "Anti-SARS-CoV" "DRAVPe01271" "HRILMRIRQMMT" "12" "p9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=56.47 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50=473.00 μM." "DRAVPe01271" "DRAVPe01271.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1586.01" "C66H120N24O15S3" "ACDEFGKNPSVWY" "MR" "12.3" "4" "0" "4" "1" "3" "-20" "-3572" "3.5 hour" "10 min" ">10 hour" "97.5" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01272" "ARILMRIRQMMT" "12" "1-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=56.12263 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01272" "DRAVPe01272.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1519.95" "C63H118N22O15S3" "CDEFGHKNPSVWY" "MR" "12.3" "3" "0" "3" "1" "4" "21.67" "-2925" "4.4 hour" ">20 hour" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01273" "HRALMRIRQMMT" "12" "3-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=34.18095 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01273" "DRAVPe01273.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1543.93" "C63H114N24O15S3" "CDEFGKNPSVWY" "MR" "12.3" "4" "0" "4" "1" "3" "-42.5" "-3883" "3.5 hour" "10 min" ">10 hour" "73.33" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01274" "HRIAMRIRQMMT" "12" "4-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=54.5872 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01274" "DRAVPe01274.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1543.93" "C63H114N24O15S3" "CDEFGKLNPSVWY" "MR" "12.3" "4" "0" "4" "1" "3" "-36.67" "-3883" "3.5 hour" "10 min" ">10 hour" "73.33" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01275" "HRILARIRQMMT" "12" "5-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=435.4996 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01275" "DRAVPe01275.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1525.9" "C64H116N24O15S2" "CDEFGKNPSVWY" "R" "12.3" "4" "0" "4" "1" "4" "-20.83" "-3626" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01276" "HRILMRARQMMT" "12" "7-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=150.1405 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01276" "DRAVPe01276.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1543.93" "C63H114N24O15S3" "CDEFGKNPSVWY" "MR" "12.3" "4" "0" "4" "1" "3" "-42.5" "-3883" "3.5 hour" "10 min" ">10 hour" "73.33" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01277" "HRILMRIAQMMT" "12" "8-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=60.60846 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01277" "DRAVPe01277.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1500.9" "C63H113N21O15S3" "CDEFGKNPSVWY" "M" "12" "3" "0" "3" "1" "4" "32.5" "-1899" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01278" "HRILMRIRAMMT" "12" "9-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=34.13563 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01278" "DRAVPe01278.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1528.96" "C64H117N23O14S3" "CDEFGKNPQSVWY" "MR" "12.3" "4" "0" "4" "1" "4" "24.17" "-2837" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01279" "HRILMRIRQAMT" "12" "10-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=57.98146 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01279" "DRAVPe01279.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1525.9" "C64H116N24O15S2" "CDEFGKNPSVWY" "R" "12.3" "4" "0" "4" "1" "4" "-20.83" "-3626" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01280" "HRILMRIRQMAT" "12" "11-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=120.5239 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01280" "DRAVPe01280.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1525.9" "C64H116N24O15S2" "CDEFGKNPSVWY" "R" "12.3" "4" "0" "4" "1" "4" "-20.83" "-3626" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01281" "HRILMRIRQMMA" "12" "12-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=89.41235 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50=186.2536 μM." "DRAVPe01281" "DRAVPe01281.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1555.98" "C65H118N24O14S3" "CDEFGKNPSTVWY" "MR" "12.3" "4" "0" "4" "0" "4" "0.83" "-3134" "3.5 hour" "10 min" ">10 hour" "105.83" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01282" "LMRIRQMMT" "9" "a-p9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=263.8101 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01282" "DRAVPe01282.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1179.52" "C48H90N16O12S3" "ACDEFGHKNPSVWY" "M" "12" "2" "0" "2" "1" "2" "8.89" "-2106" "5.5 hour" "3 min" "2 min" "86.67" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01283" "HRILMRIR" "8" "b-p9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=43.50202 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01283" "DRAVPe01283.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1094.39" "C47H87N19O9S" "ACDEFGKNPQSTVWY" "R" "12.3" "4" "0" "4" "0" "3" "-25" "-3231" "3.5 hour" "10 min" ">10 hour" "146.25" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01284" "LMRIR" "5" "c-p9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=716.4193 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22743126]MARC-145 cells:CC50>500 μM." "DRAVPe01284" "DRAVPe01284.cif" "Linear" "Free" "Free" "None" "L" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "687.9" "C29H57N11O6S" "ACDEFGHKNPQSTVWY" "R" "12" "2" "0" "2" "0" "2" "24" "-1765" "5.5 hour" "3 min" "2 min" "156" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01285" "hrilmrirqmmt" "12" "D-P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PRRSV" "Arteriviridae" "MTT assay" "[Ref.22743126]Porcine reproductive and respiratory syndrome virus(PRRSV):inhibition of PRRSV replication in MARC-145 cells(IC50=16.12312 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01285" "DRAVPe01285.cif" "Linear" "Free" "Free" "None" "D" "PRRSV polymerase" "PRRSV polymerase is an RNA-dependent RNA polymerase and is an enzyme specific to viruses, RNA-dependent RNA polymerase is one of the most important proteins for intracellular replication of viruses.The peptide could exert antiviral activity by inhibiting polymerase." "1586.01" "H-22O-11" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "12.3" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "22743126" "Virology. 2012 Oct 10;432(1):73-80." "Liu K, Feng X, Ma Z, Luo C, Zhou B, Cao R, Huang L, Miao D, Pang R, He D, Lian X, Chen P. " "Antiviral activity of phage display selected peptides against Porcine reproductive and respiratory syndrome virus in vitro." "10.1016/j.virol.2012.05.010" "Anti-PRRSV" "DRAVPe01286" "AWDFGSIGGVFTSVGKLVHQVFGTAYGVL" "29" "DV1(419-447)" "Synthetic construct(derived from DENV1 E protein stem)" "P27909" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Plaque assay" "[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=1.5 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90>6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01286" "DRAVPe01286.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide shows antiviral activity by inhibiting virus entry." "3013.45" "C143H210N34O38" "CEMNPR" "G" "6.79" "2" "1" "1" "11" "14" "80.69" "1894" "4.4 hour" ">20 hour" ">10 hour" "97.24" "6990" "249.64" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-DENV" "DRAVPe01287" "AWDFGSLGGVFTSIGKALHQVFGAIYGAA" "29" "DV2(419-447)" "Synthetic construct(derived from DENV2 E protein stem)" "P29984" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Plaque assay" "[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=0.3 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=0.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01287" "DRAVPe01287.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide shows antiviral activity by inhibiting virus entry." "2941.34" "C139H202N34O37" "CEMNPR" "G" "6.79" "2" "1" "1" "10" "15" "73.79" "1974" "4.4 hour" ">20 hour" ">10 hour" "91.03" "6990" "249.64" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-DENV" "DRAVPe01288" "AWDFGSVGGVLNSLGKMVHQIFGSAYTAL" "29" "DV3(419-447)" "Synthetic construct(derived from DENV3 E protein stem)" "Q99D35" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Plaque assay" "[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90<0.1 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=2 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90=4 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=1.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01288" "DRAVPe01288.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide shows antiviral activity by inhibiting virus entry." "3026.46" "C139H209N35O39S" "CEPR" "G" "6.79" "2" "1" "1" "11" "13" "56.9" "855" "4.4 hour" ">20 hour" ">10 hour" "94.14" "6990" "249.64" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-DENV" "DRAVPe01289" "AWDFGSVGGLFTSLGKAVHQVFGSVYTTM" "29" "DV4(419-447)" "Synthetic construct(derived from DENV4 E protein stem)" "P27909" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Plaque assay" "[Ref.20881042]Dengue 1 virus(DENV1):inhibition of infection in BHK-21 cells(IC90=5 μM);##Dengue 2 virus(DENV2):inhibition of infection in BHK-21 cells(IC90=6 μM);##Dengue 3 virus(DENV3):inhibition of infection in BHK-21 cells(IC90>6 μM);##Dengue 4 virus(DENV4):inhibition of infection in BHK-21 cells(IC90=6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01289" "DRAVPe01289.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide shows antiviral activity by inhibiting virus entry." "3063.48" "C142H208N34O40S" "CEINPR" "G" "6.79" "2" "1" "1" "12" "12" "53.45" "542" "4.4 hour" ">20 hour" ">10 hour" "73.79" "6990" "249.64" "20881042" "J Virol. 2010 Dec;84(24):12549-54." "Schmidt AG, Yang PL, Harrison SC." "Peptide inhibitors of flavivirus entry derived from the E protein stem." "10.1128/JVI.01440-10" "Anti-DENV" "DRAVPe01290" "YENQKQIANQFNKAISQIQESLTTTSTA" "28" "HR1-a(899-926)" "Synthetic construct(derived from SARS-CoV spike protein)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Luciferase assay" "[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=1.16 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01290" "DRAVPe01290.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3157.44" "C135H218N38O49" "CDGHMPRVW" "Q" "6.14" "2" "2" "0" "11" "8" "-85" "-6487" "2.8 hour" "10 min" "2 min" "66.43" "1490" "55.19" "18442051" "J Cell Biochem. 2008 Aug 15;104(6):2335-47." "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM." "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. " "10.1002/jcb.21790" "Anti-SARS-CoV" "DRAVPe01291" "DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI" "48" "GST-removed HR2(1145-1192)" "Synthetic construct(derived from SARS-CoV spike protein)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Luciferase assay" "[Ref.18442051]HIV‐luc/SARS Pseudotyped Virus:inhibition of viral-entry in Vero E3 cells(EC50=2.15 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01291" "DRAVPe01291.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "5390" "C235H384N62O82" "CFHMPTW" "IL" "4.11" "4" "10" "-6" "13" "18" "-31.67" "-8788" "1.1 hour" "3 min" ">10 hour" "125.83" "2980" "63.4" "18442051" "J Cell Biochem. 2008 Aug 15;104(6):2335-47." "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM." "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. " "10.1002/jcb.21790" "Anti-SARS-CoV" "DRAVPe01292" "ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "64" "sHR2-1(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=43 ± 6.4 μM);##murine coronavirus:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01292" "DRAVPe01292.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR1 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "7244.99" "C316H507N83O111" "CMW" "ELD" "4.34" "8" "15" "-7" "17" "20" "-73.75" "-14963" "1 hour" "30 min" ">10 hour" "100.47" "2980" "47.3" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01293" "PKEELDKYFKNHTSPDVDLGLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "62" "sHR2-2(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=24 ± 2.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01293" "DRAVPe01293.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR2 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "6970.76" "C306H493N81O104" "CMW" "LE" "4.49" "8" "13" "-5" "17" "20" "-64.19" "-12976" ">20 hour" ">20 hour" "?" "103.71" "2980" "48.85" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01294" "LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "56" "sHR2-3(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01294" "DRAVPe01294.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR3 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "6317.03" "C277H446N74O94" "CMW" "LDN" "4.5" "7" "11" "-4" "16" "19" "-54.82" "-11645" "5.5 hour" "3 min" "2 min" "107.86" "2980" "54.18" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01295" "FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "52" "sHR2-4(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01295" "DRAVPe01295.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR4 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "5797.43" "C252H409N69O87" "CMW" "LNDEI" "4.45" "6" "10" "-4" "15" "18" "-49.62" "-10696" "1.1 hour" "3 min" "2 min" "108.65" "1490" "29.22" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01296" "TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "48" "sHR2-5(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01296" "DRAVPe01296.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR5 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "5270.83" "C227H375N61O82" "CFHMW" "L" "4.11" "4" "10" "-6" "14" "17" "-37.5" "-9309" "7.2 hour" ">20 hour" ">10 hour" "117.71" "1490" "31.7" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01297" "VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "44" "sHR2-6(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01297" "DRAVPe01297.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR6 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "4870.45" "C211H351N57O74" "CFHMPTW" "L" "4.21" "4" "9" "-5" "12" "17" "-25.91" "-7840" "100 hour" ">20 hour" ">10 hour" "128.41" "1490" "34.65" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01298" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE" "40" "sHR2-7(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01298" "DRAVPe01298.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR7 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "4486.01" "C194H323N53O68" "CFHMPTW" "EILN" "4.33" "4" "8" "-4" "11" "15" "-38.75" "-7958" "1.1 hour" "3 min" ">10 hour" "124.25" "1490" "38.21" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01299" "ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK" "68" "sHR2-8(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=17 ± 3.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01299" "DRAVPe01299.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR8 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "7827.69" "C346H549N89O117" "CMW" "ELDK" "4.46" "9" "15" "-6" "18" "22" "-69.12" "-15296" "1 hour" "30 min" ">10 hour" "100.29" "4470" "66.72" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01300" "ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "60" "sHR2-9(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50=34 ± 4.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01300" "DRAVPe01300.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR9 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "6817.53" "C298H478N78O104" "CMW" "LDE" "4.27" "7" "14" "-7" "15" "21" "-56.17" "-13509" "1 hour" "30 min" ">10 hour" "107.17" "1490" "25.25" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01301" "ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID" "56" "sHR2-10(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01301" "DRAVPe01301.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR10 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "6283.91" "C272H439N73O97" "CMW" "DELN" "4.32" "7" "13" "-6" "15" "18" "-69.11" "-13556" "1 hour" "30 min" ">10 hour" "100.89" "1490" "27.09" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01302" "DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE" "39" "mHR2(derived from SARS-CoV spike protein heptad repeat)" "Synthetic construct(derived from SARS-CoV spike protein heptad repeat)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Indirect immunofluorescence assay" "[Ref.15150417]SARS-CoV:inhibition of virus infection in Vero cells(EC50>50 μM);##murine coronavirus:inhibition of virus infection in Vero cells(EC50=0.9 ± 0.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01302" "DRAVPe01302.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide exhibits antiviral activity by competitive binding to the HR11 region of the SARS-CoV spike protein, thus blocking the formation of the six-helix bundle and consequently membrane fusion." "4644.31" "C207H337N51O67S" "CGHPW" "L" "4.51" "5" "8" "-3" "10" "14" "-42.56" "-7826" "1.1 hour" "3 min" ">10 hour" "120" "2980" "78.42" "15150417" "Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60." "Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ." "Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides." "10.1073/pnas.0400576101" "Anti-SARS-CoV" "DRAVPe01303" "ATCYCRTGRCATRESLSGVCEISGRLYRLCCR" "32" "Human defensin-5 (HD-5; Defensin, alpha 5; Human, mammals, animals)" "Homo sapiens (Human)" "Q01523##A0JDY6##Q3KNV2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZMP" "SARS-CoV-2,HSV,HIV" "Coronaviridae, Herpesviridae, Retroviridae" "Plaque assay" "[Ref.34206990]SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(60% inhibition at 12.5 μg/mL (3.45 μM));##SARS-CoV-2 variant P.1:inhibition of infection in HeLa-hACE2 cells(72% inbibition at 50 μg/mL);##SARS-CoV-2 variant B.1.1.7:inhibition of infection in HeLa-hACE2 cells(32% inbibition at 50 μg/mL).##[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(47.8% ±3.9% cell protection rates at 25 μg/ml,69.4% ± 5.4% cell protection at 50 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=35 μg/ml);##HIV-1:inhibition of virus infection in JLTRG cells(IC50=7.51 μg/ ml)." "[Ref.26206286] It has 0% hemolysis at 100μM against human red blood cells." "[Ref.34206990]No cytotoxicity on HEK293T cells up to 50 μg/mL.##[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml." "DRAVPe01303" "DRAVPe01303.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "Not found" "The peptide exhibits antiviral activity by inhibiting virus entry." "3588.19" "C144H244N50O45S6" "DFHKMNPQW" "CR" "8.96" "6" "2" "4" "17" "7" "-11.25" "-8349" "4.4 hour" ">20 hour" ">10 hour" "64.06" "3355" "108.23" "34206990##26206286##23269800" "Viruses. 2021 Jun 26;13(7):1246.##Peptides. 2015 Sep;71:128-40.##J Virol. 2013 Mar;87(5):2835-45. " "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.##Basil Mathew Ramakrishnan Nagaraj##Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. " "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.##Antimicrobial activity of human -defensin 5 and its linear analogs: N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs.##Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites." "10.3390/v13071246##10.1016/j.peptides.2015.07.009##10.1128/JVI.02209-12" "Anti-SARS-CoV-2,Anti-HSV,Anti-HIV" "DRAVPe01304" "ATCYCRTGRCATRESLSGVCRISGRLYRLCCR" "32" "HD5[E21R]" "Synthetic construct(derived from human alpha defensin(HD5))" "Q01523" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV,HIV" "Herpesviridae, Retroviridae" "Plaque assay" "[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(61.5% ± 7.1% cell protection rates at 25 μg/ml,90.2% ± 4.9% cell protection at 50 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=25 μg/ml);##HIV-1:inhibition of virus infection in JLTRG cells(IC50=3.53 μg/ ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml." "DRAVPe01304" "DRAVPe01304.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "capsid protein gD" "The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells." "3615.26" "C145H249N53O43S6" "DFHKMNPQW" "R" "9.49" "7" "1" "6" "17" "7" "-14.38" "-9160" "4.4 hour" ">20 hour" ">10 hour" "64.06" "3355" "108.23" "23269800" "J Virol. 2013 Mar;87(5):2835-45. " "Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. " "Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites." "10.1128/JVI.02209-12" "Anti-HSV,Anti-HIV" "DRAVPe01305" "ATCYCRTGRCATRESLSGVCEIRGRLYRLCCR" "32" "HD5[S23R]" "Synthetic construct(derived from human alpha defensin(HD5))" "Q01523" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.23269800]Herpes simplex virus2(HSV-2):neutralization activity against HSV-2 during the preinfection stage(IC50=36 μg/ml);" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml." "DRAVPe01305" "DRAVPe01305.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "capsid protein gD" "The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells." "3657.3" "C147H251N53O44S6" "DFHKMNPQW" "R" "9.22" "7" "2" "5" "16" "7" "-22.81" "-9501" "4.4 hour" ">20 hour" ">10 hour" "64.06" "3355" "108.23" "23269800" "J Virol. 2013 Mar;87(5):2835-45. " "Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. " "Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites." "10.1128/JVI.02209-12" "Anti-HSV" "DRAVPe01306" "ATCYCRRGRCATRESLSGVCEISGRLYRLCCR" "32" "HD5[T7R]" "Synthetic construct(derived from human alpha defensin(HD5))" "Q01523" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.23269800]Herpes simplex virus2(HSV-2):neutralization activity against HSV-2 during the preinfection stage(IC50=40 μg/ml);" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml." "DRAVPe01306" "DRAVPe01306.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "capsid protein gD" "The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells." "3643.27" "C146H249N53O44S6" "DFHKMNPQW" "R" "9.22" "7" "2" "5" "16" "7" "-23.13" "-9584" "4.4 hour" ">20 hour" ">10 hour" "64.06" "3355" "108.23" "23269800" "J Virol. 2013 Mar;87(5):2835-45. " "Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. " "Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites." "10.1128/JVI.02209-12" "Anti-HSV" "DRAVPe01307" "ATCYCRTGRCATRESRSGVCEISGRLYRLCCR" "32" "HD5[L16R]" "Synthetic construct(derived from human alpha defensin(HD5))" "Q01523" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.23269800]Herpes simplex virus2(HSV-2):Potential for CaSki cell protection from HSV-2 infection(51.2% ± 7.2% cell protection at 100 μg/ml);neutralization activity against HSV-2 during the preinfection stage(IC50=67 μg/ml);" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23269800]No cytotoxicity against CaSki cells up to 100μg/ ml." "DRAVPe01307" "DRAVPe01307.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "capsid protein gD" "The interaction between peptide and viral capsid proteins may cause aggregation of virions to prevent viruses from normal binding to target cells. Another possibility is that the binding of HD5 derivatives to the virion envelope blocks the epitopes of interaction between viruses and cell receptors, which are necessary for viral adsorption or entry into host cells." "3631.22" "C144H245N53O45S6" "DFHKMNPQW" "R" "9.22" "7" "2" "5" "17" "6" "-37.19" "-10333" "4.4 hour" ">20 hour" ">10 hour" "51.88" "3355" "108.23" "23269800" "J Virol. 2013 Mar;87(5):2835-46. " "Wang A, Chen F, Wang Y, Shen M, Xu Y, Hu J, Wang S, Geng F, Wang C, Ran X, Su Y, Cheng T, Wang J. " "Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites." "10.1128/JVI.02209-12" "Anti-HSV" "DRAVPe01308" "PPVYTKDVDISSQISSMNQSLQQSKDYIKEAQKILDTVNPSL" "42" "HeV F HRC derived peptide(447-488)" "Synthetic construct(derived from HeV fusion (F) protein)" "O89342" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=75 nM);inhibition of fusion in HeLa cells(IC50=40 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01308" "DRAVPe01308.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 6HB structure that is required for fusion. " "4710.29" "C205H335N53O71S" "CFGHRW" "S" "4.78" "4" "5" "-1" "13" "11" "-62.62" "-8337" ">20 hour" ">20 hour" "?" "88.1" "2980" "72.68" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01309" "VYTDKVDISSQISSMNQSLQQSKDYIKEAQKILDTV" "36" "HeV F HRC derived peptide(449-484)" "Synthetic construct(derived from HeV fusion (F) protein)" "O89342" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=75 nM);inhibition of fusion in HeLa cells(IC50=40 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01309" "DRAVPe01309.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 7HB structure that is required for fusion." "4104.6" "C177H292N46O63S" "CFGHPRW" "S" "4.78" "4" "5" "-1" "11" "10" "-58.33" "-7825" "100 hour" ">20 hour" ">10 hour" "91.94" "2980" "85.14" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01310" "DITLNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN" "45" "HPIV3 F HRC derived peptide(442-486)" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=20 nM);inhibition of fusion in HeLa cells(IC50=7.5 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=500 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01310" "DRAVPe01310.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 8HB structure that is required for fusion." "5083.64" "C218H362N62O77" "CFHMY" "IS" "4.56" "6" "9" "-3" "13" "15" "-70.44" "-11954" "1.1 hour" "3 min" ">10 hour" "106.22" "5500" "125" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01311" "VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI" "36" "HPIV3 F HRC derived peptide(449-484)" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=20 nM);inhibition of fusion in HeLa cells(IC50=7.5 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=500 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01311" "DRAVPe01311.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 9HB structure that is required for fusion." "4154.69" "C181H302N50O61" "CFGHMTY" "IS" "4.77" "6" "8" "-2" "7" "13" "-66.94" "-9571" "100 hour" ">20 hour" ">10 hour" "111.11" "5500" "157.14" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01312" "VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI" "36" "HPIV3 F HRC derived peptide(449-484)[L451N]" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=100 nM);inhibition of fusion in HeLa cells(IC50=3000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=1100 nM);inhibition of fusion in HeLa cells(IC50=750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01312" "DRAVPe01312.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 11HB structure that is required for fusion." "4155.63" "C179H297N51O62" "CFGHMTY" "IS" "4.77" "6" "8" "-2" "8" "12" "-87.22" "-10727" "100 hour" ">20 hour" ">10 hour" "100.28" "5500" "157.14" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01313" "VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD" "36" "HPIV3 F HRC derived peptide(449-484)[I484D]" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50=100 nM);inhibition of fusion in HeLa cells(IC50=8000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=500 nM);inhibition of fusion in HeLa cells(IC50=350 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01313" "DRAVPe01313.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 12HB structure that is required for fusion." "4156.62" "C179H296N50O63" "CFGHMTY" "DS" "4.56" "6" "9" "-3" "7" "12" "-89.17" "-10935" "100 hour" ">20 hour" ">10 hour" "100.28" "5500" "157.14" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01314" "VANDPIDISIELNKAKSDLEESKEWIRRSNQKLDSD" "36" "HPIV3 F HRC derived peptide(449-484)[L451N,I484D]" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50=1100 nM);inhibition of fusion in HeLa cells(IC50=750 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01314" "DRAVPe01314.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 13HB structure that is required for fusion." "4157.56" "C177H291N51O64" "CFGHMTY" "DS" "4.56" "6" "9" "-3" "8" "11" "-109.44" "-12091" "100 hour" ">20 hour" ">10 hour" "89.44" "5500" "157.14" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01315" "VALDPIDISIELNKAKSDLEESKEWIRR" "28" "HPIV3 F HRC derived peptide(449-476)" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01315" "DRAVPe01315.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 14HB structure that is required for fusion." "3268.71" "C144H239N39O47" "CFGHMQTY" "EI" "4.72" "5" "7" "-2" "4" "11" "-58.57" "-7230" "100 hour" ">20 hour" ">10 hour" "115" "5500" "203.7" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01316" "SIELNKAKSDLEESKEWIRRSNQKLDSI" "28" "HPIV3 F HRC derived peptide(457-484)" "Synthetic construct(derived from HPIV3 fusion (F) protein)" "P06828" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HeV,HPIV3" "Paramyxoviridae" "Luminescence fusion assay" "[Ref.16973588]Henda virus(HeV):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>1000 nM);##human parainfluenza virus 3 (HPIV3):inhibition of virus infection in HeLa cells(IC50>10000 nM);inhibition of fusion in HeLa cells(IC50>10000 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01316" "DRAVPe01316.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The HeV receptor-binding protein (G) is required in order for the fusion protein (F) to mediate fusion. HeV F, once triggered by the receptor-bound G, undergoes multistep conformational changes leading to a six-helix bundle (6HB) structure that accomplishes fusion of the viral and cellular membranes. Peptides derived from the HRN and HRC regions of F are proposed to inhibit fusion by preventing F, after the initial triggering step, from forming the 15HB structure that is required for fusion." "3317.7" "C142H238N42O49" "CFGHMPTVY" "S" "6.06" "6" "6" "0" "7" "8" "-122.5" "-9888" "1.9 hour" ">20 hour" ">10 hour" "87.14" "5500" "203.7" "16973588" "J Virol. 2006 Oct;80(19):9837-49." "Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, Moscona A." "Inhibition of hendra virus fusion." "10.1128/JVI.00736-06" "Anti-HeV,Anti-HPIV3" "DRAVPe01317" "MANAGLQLLGFILAFLGW" "18" "CL58" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=2.1 ± 0.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22378192]Huh7.5.1 cells:CC50~200 Μm." "DRAVPe01317" "DRAVPe01317.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1935.36" "C94H143N21O21S" "CDEHKPRSTVY" "L" "5.28" "0" "0" "0" "4" "12" "151.67" "3623" "30 hour" ">20 hour" ">10 hour" "146.67" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-15. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01318" "GLQLLGFILAFLGWIGAI" "18" "CL58.1" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01318" "DRAVPe01318.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1902.35" "C96H148N20O20" "CDEHKMNPRSTVY" "L" "5.52" "0" "0" "0" "4" "13" "198.33" "4949" "30 hour" ">20 hour" ">10 hour" "184.44" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-16. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01319" "LLGFILAFLGWIGAIVST" "18" "CL58.2" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=4.3 ± 0.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01319" "DRAVPe01319.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1891.33" "C95H147N19O21" "CDEHKMNPQRY" "L" "5.52" "0" "0" "0" "5" "13" "213.89" "4724" "5.5 hour" "3 min" "2 min" "178.89" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-17. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01320" "FILAFLGWIGAIVSTALP" "18" "CL58.3" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=8.9± 1.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01320" "DRAVPe01320.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1889.31" "C95H145N19O21" "CDEHKMNQRY" "AIL" "5.52" "0" "0" "0" "4" "13" "196.11" "4319" "1.1 hour" "3 min" "2 min" "162.78" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-18. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01321" "AFLGWIGAIVSTALPQWR" "18" "CL58.4" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=12.5± 1.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01321" "DRAVPe01321.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1986.35" "C96H144N24O22" "CDEHKMNY" "A" "9.79" "1" "0" "1" "4" "11" "85" "1224" "4.4 hour" ">20 hour" ">10 hour" "119.44" "11000" "647.06" "22378192" "Hepatology. 2012 Aug;56(2):507-19. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01322" "GWIGAIVSTALPQWRIYS" "18" "CL58.5" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=21.5± 1.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01322" "DRAVPe01322.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2018.35" "C96H144N24O24" "CDEFHKMN" "I" "8.75" "1" "0" "1" "6" "9" "51.67" "391" "30 hour" ">20 hour" ">10 hour" "113.89" "12490" "734.71" "22378192" "Hepatology. 2012 Aug;56(2):507-20. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01323" "GAIVSTALPQWRIYSYAG" "18" "CL58.6" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=23.8 ± 2.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01323" "DRAVPe01323.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1953.23" "C91H137N23O25" "CDEFHKMN" "A" "8.59" "1" "0" "1" "7" "8" "34.44" "-167" "30 hour" ">20 hour" ">10 hour" "97.78" "8480" "498.82" "22378192" "Hepatology. 2012 Aug;56(2):507-21. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01324" "VSTALPQWRIYSYAGDNI" "18" "CL58.7" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01324" "DRAVPe01324.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2054.29" "C94H140N24O28" "CEFHKM" "AISY" "5.81" "1" "1" "0" "7" "7" "-12.22" "-1978" "100 hour" ">20 hour" ">10 hour" "92.22" "8480" "498.82" "22378192" "Hepatology. 2012 Aug;56(2):507-22. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01325" "ALPQWRIYSYAGDNIVTA" "18" "CL58.8" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01325" "DRAVPe01325.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2038.29" "C94H140N24O27" "CEFHKM" "A" "5.88" "1" "1" "0" "6" "8" "2.22" "-1457" "4.4 hour" ">20 hour" ">10 hour" "97.78" "8480" "498.82" "22378192" "Hepatology. 2012 Aug;56(2):507-23. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01326" "MANAGLQLLGFILA" "14" "CL58-4" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01326" "DRAVPe01326.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1431.76" "C66H110N16O17S" "CDEHKPRSTVWY" "L" "5.28" "0" "0" "0" "3" "9" "157.14" "2506" "30 hour" ">20 hour" ">10 hour" "160.71" "0" "0" "22378192" "Hepatology. 2012 Aug;56(2):507-24. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01327" "MANAGLQLLGFILAFL" "16" "CL58-2" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=7.6± 0.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01327" "DRAVPe01327.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1692.09" "C81H130N18O19S" "CDEHKPRSTVWY" "L" "5.28" "0" "0" "0" "3" "11" "178.75" "3296" "30 hour" ">20 hour" ">10 hour" "165" "0" "0" "22378192" "Hepatology. 2012 Aug;56(2):507-25. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01328" "MANAGLQLLGFILAFLGWIG" "20" "CL58+2" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=17.8 ± 1.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01328" "DRAVPe01328.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2105.57" "C102H157N23O23S" "CDEHKPRSTVY" "L" "5.28" "0" "0" "0" "5" "13" "157" "4209" "30 hour" ">20 hour" ">10 hour" "151.5" "5500" "289.47" "22378192" "Hepatology. 2012 Aug;56(2):507-26. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01329" "MANAGLQLLGFILAFLGWIGAI" "22" "CL58+4" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=4.0 ± 0.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01329" "DRAVPe01329.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2289.81" "C111H173N25O25S" "CDEHKPRSTVY" "L" "5.28" "0" "0" "0" "5" "15" "171.36" "4882" "30 hour" ">20 hour" ">10 hour" "160" "5500" "261.9" "22378192" "Hepatology. 2012 Aug;56(2):507-27. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01330" "MANAGLQLLGFILAFLGWIGAIVS" "24" "CL58+6" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=5.1 ± 0.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01330" "DRAVPe01330.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "2476.02" "C119H187N27O28S" "CDEHKPRTY" "L" "5.28" "0" "0" "0" "6" "16" "171.25" "4946" "30 hour" ">20 hour" ">10 hour" "158.75" "5500" "239.13" "22378192" "Hepatology. 2012 Aug;56(2):507-28. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01331" "managlqllgfilaflgw" "18" "CL58.d" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50=1.8 ± 0.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01331.cif" "Linear" "Free" "Free" "None" "D" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1935.36" "H-34O-17" "ACDEFGHIKLMNPQRSTVWY" "ACDEFGHIKLMNPQRSTVWY" "5.28" "0" "0" "0" "0" "0" "0" "0" "0" "0" "0" "22378192" "Hepatology. 2012 Aug;56(2):507-29. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01332" "AGALMFAWLLLGLQGIFN" "18" "CL58.S" "Synthetic construct(derived from human claudin-1)" "O95832" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01332" "DRAVPe01332.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1935.36" "C94H143N21O21S" "CDEHKPRSTVY" "L" "5.57" "0" "0" "0" "4" "12" "151.67" "3623" "4.4 hour" ">20 hour" ">10 hour" "146.67" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-29. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01333" "MASAGMQILGVVLTLLGW" "18" "CL-6" "Synthetic construct(derived from human claudin-1)" "P56747" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01333" "DRAVPe01333.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1860.3" "C85H142N20O22S2" "CDEFHKNPRY" "L" "5.28" "0" "0" "0" "5" "10" "157.78" "3464" "30 hour" ">20 hour" ">10 hour" "151.67" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-30. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01334" "MANSGLQLLGFSMALLGW" "18" "CL-7" "Synthetic construct(derived from human claudin-1)" "Q3B794" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01334" "DRAVPe01334.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1909.29" "C87H137N21O23S2" "CDEHIKPRTVY" "L" "5.28" "0" "0" "0" "6" "9" "102.78" "2207" "30 hour" ">20 hour" ">10 hour" "119.44" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-31. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01335" "MASTGLELLGMTLAVLGW" "18" "CL-9" "Synthetic construct(derived from human claudin-1)" "O95484" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Pseudoviral particle infection assay" "[Ref.22378192]Hepatitis C virus(HCV):inhibition of viral-entry in Huh7.5.1 cells(IC50>25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01335" "DRAVPe01335.cif" "Linear" "Free" "Free" "None" "L" "membrane protein" "The peptide inhibits virus entry in a postbinding step." "1863.26" "C84H139N19O24S2" "CDFHIKNPQRY" "L" "4" "0" "1" "-1" "6" "9" "126.67" "2676" "30 hour" ">20 hour" ">10 hour" "135.56" "5500" "323.53" "22378192" "Hepatology. 2012 Aug;56(2):507-32. " "Si Y, Liu S, Liu X, Jacobs JL, Cheng M, Niu Y, Jin Q, Wang T, Yang W. " "A human claudin-1-derived peptide inhibits hepatitis C virus entry." "10.1002/hep.25685" "Anti-HCV" "DRAVPe01336" "EELRVRLASHLRKLRKRLLRDADDLQKRLAVYEEQAQQIRLQAEAFQARLKSWFEPLVEDM" "61" "hEP-1" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.67 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22334503]Huh7.5.1 cell:CC50>100 μg/ ml(〜14μM)." "DRAVPe01336" "DRAVPe01336.cif" "Linear" "Free" "Free" "None" "L" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "7405.56" "C327H539N101O93S" "CGNT" "L" "9.4" "14" "11" "3" "3" "25" "-74.1" "-18940" "1 hour" "30 min" ">10 hour" "102.46" "6990" "116.5" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01337" "CEELRVRLASHLRKLRKRLLRDADDLQKRLAVY" "33" "hEP-2" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01337" "DRAVPe01337.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "4034.79" "C175H306N60O47S" "FGIMNPTW" "L" "10.4" "11" "5" "6" "3" "13" "-69.09" "-12046" "1.2 hour" ">20 hour" ">10 hour" "121.21" "1490" "46.56" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01338" "EELRVRLASHLRKLRKRLLRDADDLQKRLAVY" "32" "hEP-2/deltaCys" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01338" "DRAVPe01338.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3931.65" "C172H301N59O46" "CFGIMNPTW" "L" "10.87" "11" "5" "6" "2" "13" "-79.06" "-12174" "1 hour" "30 min" ">10 hour" "125" "1490" "48.06" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01339" "CEEIRARLSTHLRKMRKRLMRDADDLQKRLAVY" "33" "mEP-2" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01339" "DRAVPe01339.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "4072.83" "C172H300N60O48S3" "FGNPW" "R" "10.4" "11" "5" "6" "4" "10" "-93.33" "-13221" "1.2 hour" ">20 hour" ">10 hour" "88.79" "1490" "46.56" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01340" "CEEQAQQIRLQAEAFQARLKSWFEPLVEDM" "30" "hEP-3" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01340" "DRAVPe01340.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3595.06" "C158H245N43O49S2" "GHNTY" "EQ" "4.42" "3" "6" "-3" "2" "12" "-58" "-6638" "1.2 hour" ">20 hour" ">10 hour" "75" "5500" "189.66" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01341" "CVRLASHLRKLRKRLLRDADDL" "22" "hEP-4" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01341" "DRAVPe01341.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "2648.17" "C113H203N41O30S" "EFGIMNPQTWY" "L" "10.79" "8" "3" "5" "2" "9" "-53.18" "-8146" "1.2 hour" ">20 hour" ">10 hour" "128.64" "0" "0" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01342" "CIRLQAEAFQARLKSWFEPLV" "21" "hEP-5" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01342" "DRAVPe01342.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "2505.96" "C116H181N31O29S" "DGHMNTY" "AL" "8.22" "3" "2" "1" "2" "11" "16.19" "-2477" "1.2 hour" ">20 hour" ">10 hour" "102.38" "5500" "275" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01343" "VRLASHLRKLRKRLLRDADDLIRLQAEAFQARLKSWFEPLV" "41" "hEP-6" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01343" "DRAVPe01343.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "4929.84" "C223H372N70O56" "CGMNTY" "L" "11.29" "11" "5" "6" "2" "20" "-32.44" "-10879" "100 hour" ">20 hour" ">10 hour" "121.46" "5500" "137.5" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01344" "LRVRLASHLRKLRKRLLRDADDLQKRLAVY" "30" "hEP-7" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01344" "DRAVPe01344.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3673.42" "C162H287N57O40" "CEFGIMNPTW" "L" "11.63" "11" "3" "8" "2" "13" "-61" "-10812" "5.5 hour" "3 min" "2 min" "133.33" "1490" "51.38" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01345" "EELRVRLASHLRKLRKRLLRDADDL" "25" "hEP-8" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01345" "DRAVPe01345.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3072.61" "C132H235N47O37" "CFGIMNPQTWY" "L" "10.74" "9" "5" "4" "1" "10" "-87.6" "-10636" "1 hour" "30 min" ">10 hour" "128.8" "0" "0" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01346" "VRLASHLRKLRKRLLRDADDLQKRLAVY" "28" "hEP-9" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01346" "DRAVPe01346.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3404.07" "C150H264N52O38" "CEFGIMNPTW" "L" "11.38" "10" "3" "7" "2" "12" "-62.86" "-9812" "100 hour" ">20 hour" ">10 hour" "128.93" "1490" "55.19" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01347" "CVRLASHLRKLRKRLLRDADDLQKRLAVY" "29" "hEP-10" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=0.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01347" "DRAVPe01347.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "3507.21" "C153H269N53O39S" "EFGIMNPTW" "L" "10.91" "10" "3" "7" "3" "12" "-52.07" "-9684" "1.2 hour" ">20 hour" ">10 hour" "124.48" "1490" "53.21" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01348" "CLRVRLASHLRKLRKRLLRDADDL" "24" "hEP-11" "Synthetic construct(derived from human apolipoprotein E)" "P02649" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50=4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01348" "DRAVPe01348.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "2917.52" "C125H226N46O32S" "EFGIMNPQTWY" "L" "11.35" "9" "3" "6" "2" "10" "-51.67" "-9146" "1.2 hour" ">20 hour" ">10 hour" "134.17" "0" "0" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01349" "CLRKLRKRLLRC" "12" "hEP-12" "Synthetic construct(derived from human apolipoprotein E)" "P28995" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "RT PCR" "[Ref.22334503]hepatitis C virus(HCVpp):inhibition of infection in Huh7.5.1 cells(IC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01349" "DRAVPe01349.cif" "Linear" "Free" "Free" "None" "L" "Not found" "hEP peptide blocks the binding of virus to cells, suggesting a role of apoE at the very early stage of HCV entry. " "1558.03" "C66H128N26O13S2" "ADEFGHIMNPQSTVWY" "LR" "11.56" "6" "0" "6" "2" "4" "-46.67" "-4854" "1.2 hour" ">20 hour" ">10 hour" "130" "125" "11.36" "22334503" "Hepatology. 2012 Aug;56(2):484-91." "Liu S, McCormick KD, Zhao W, Zhao T, Fan D, Wang T." "Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding." "10.1002/hep.25665" "Anti-HCV" "DRAVPe01350" "ECRSTSYAGAVVNDL" "15" "H2-(1-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=42 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01350" "DRAVPe01350.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "1584.72" "C65H105N19O25S" "FHIKMPQW" "ASV" "4.37" "1" "2" "-1" "7" "5" "-4.67" "-2776" "1 hour" "30 min" ">10 hour" "78" "1490" "106.43" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01351" "STSYAGAVVNDL" "12" "H2-(4-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=29 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01351" "DRAVPe01351.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "1196.28" "C51H81N13O20" "CEFHIKMPQRW" "ASV" "3.8" "0" "1" "-1" "6" "5" "40" "-731" "1.9 hour" ">20 hour" ">10 hour" "97.5" "1490" "135.45" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01352" "YAGAVVNDL" "9" "H2-(7-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=36-60 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01352" "DRAVPe01352.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C41H64N10O14" "CEFHIKMPQRSTW" "AV" "3.8" "0" "1" "-1" "3" "5" "78.89" "206" "2.8 hour" "10 min" "2 min" "130" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01353" "AGAVVNDL" "8" "H2-(8-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=283 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01353" "DRAVPe01353.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "757.84" "C32H55N9O12" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "105" "220" "4.4 hour" ">20 hour" ">10 hour" "146.25" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01354" "GAVVNDL" "7" "H2-(9-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=225 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01354" "DRAVPe01354.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "686.76" "C29H50N8O11" "CEFHIKMPQRSTWY" "V" "3.8" "0" "1" "-1" "2" "4" "94.29" "39" "30 hour" ">20 hour" ">10 hour" "152.86" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01355" "AVVNDL" "6" "H2-(10-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=190 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01355" "DRAVPe01355.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "629.71" "C27H47N7O10" "CEFGHIKMPQRSTWY" "V" "3.8" "0" "1" "-1" "1" "4" "116.67" "-55" "4.4 hour" ">20 hour" ">10 hour" "178.33" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01356" "VVNDL" "5" "H2-(11-15)" "Synthetic construct(derived from HSV ribonucleotide reductase subunit 2)" "P10224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=760 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01356" "DRAVPe01356.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "558.63" "C24H42N6O9" "ACEFGHIKMPQRSTWY" "V" "3.8" "0" "1" "-1" "1" "3" "104" "-236" "100 hour" ">20 hour" ">10 hour" "194" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01357" "YAGAVVNDL" "9" "Ac-H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01357.cif" "Linear" "Acetylation" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C41H64N10O14" "CEFHIKMPQRSTW" "AV" "3.8" "0" "1" "-1" "3" "5" "78.89" "206" "2.8 hour" "10 min" "2 min" "130" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01358" "YAGAVVNDL" "9" "H2-(7-15) amide" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=190 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01358.cif" "Linear" "Free" "Amidation" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C41H64N10O14" "CEFHIKMPQRSTW" "AV" "3.8" "0" "1" "-1" "3" "5" "78.89" "206" "2.8 hour" "10 min" "2 min" "130" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01359" "YAGAVVNDL" "9" "Ac-H2-(7-15) amide" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=76 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01359.cif" "Linear" "Acetylation" "Amidation" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C41H64N10O14" "CEFHIKMPQRSTW" "AV" "3.8" "0" "1" "-1" "3" "5" "78.89" "206" "2.8 hour" "10 min" "2 min" "130" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01360" "VVNDL" "5" "Ac-H2-(11-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=400 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01360.cif" "Linear" "Acetylation" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "558.63" "C24H42N6O9" "ACEFGHIKMPQRSTWY" "V" "3.8" "0" "1" "-1" "1" "3" "104" "-236" "100 hour" ">20 hour" ">10 hour" "194" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01361" "YAVVNDL" "7" "[Tyr9]H2-(9-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=340 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01361" "DRAVPe01361.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "792.89" "C36H56N8O12" "CEFGHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "2" "4" "81.43" "-69" "2.8 hour" "10 min" "2 min" "152.86" "1490" "248.33" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01362" "YAVVNDL" "7" "Ac-[Tyr9]H2-(9-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=330 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01362.cif" "Linear" "Acetylation" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "792.89" "C36H56N8O12" "CEFGHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "2" "4" "81.43" "-69" "2.8 hour" "10 min" "2 min" "152.86" "1490" "248.33" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01363" "YGAVVNDL" "8" "[Tyr8]H2-(8-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=330 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01363" "DRAVPe01363.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "849.94" "C38H59N9O13" "CEFHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "3" "4" "66.25" "25" "2.8 hour" "10 min" "2 min" "133.75" "1490" "212.86" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01364" "YGAVVNDL" "8" "Ac-[Tyr8]H2-(8-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=150 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01364.cif" "Linear" "Acetylation" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "849.94" "C38H59N9O13" "CEFHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "3" "4" "66.25" "25" "2.8 hour" "10 min" "2 min" "133.75" "1490" "212.86" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01365" "AAGAVVNDL" "9" "[Ala7]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=280 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01365" "DRAVPe01365.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "828.92" "C35H60N10O13" "CEFHIKMPQRSTWY" "A" "3.8" "0" "1" "-1" "2" "6" "113.33" "401" "4.4 hour" ">20 hour" ">10 hour" "141.11" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01366" "yAGAVVNDL" "9" "[D-Tyr7]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01366.cif" "Linear" "Free" "Free" "None" "Mixed(D-Tyr1)" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C32H53N9O11" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "93.33" "220" "130" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01367" "yAGAVVNDL" "9" "Ac-[D-Tyr7]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=165 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01367.cif" "Linear" "Acetylation" "Free" "None" "Mixed(D-Tyr1)" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C32H53N9O11" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "93.33" "220" "130" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01368" "XAGAVVNDL" "9" "[Tyr7(OMe)]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=88 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01368.cif" "Linear" "Free" "Free" "The 'X' at position 1 is methoxy Tyrosine." "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "869.17" "C32H53N9O11" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "93.33" "220" "130" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01369" "XAGAVVNDL" "9" "Ac[Tyr7(OMe)]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=40 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01369.cif" "Linear" "Acetylation" "Free" "The 'X' at position 1 is methoxy Tyrosine." "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "869.17" "C32H53N9O11" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "93.33" "220" "130" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01370" "XAGAVVNDL" "9" "[desamino-Tyr7]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=33 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01370.cif" "Linear" "Free" "Free" "The 'X' at position 1 is 3-(4-hydroxyphenyl)propionic acid." "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "869.17" "C32H53N9O11" "CEFHIKMPQRSTWY" "AV" "3.8" "0" "1" "-1" "2" "5" "93.33" "220" "130" "0" "0" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01371" "YaGAVVNDL" "9" "[D-Ala8]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01371.cif" "Linear" "Free" "Free" "None" "Mixed(D-Ala2)" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C38H57N9O12" "CEFHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "3" "4" "58.89" "25" "2.8 hour" "10 min" "2 min" "118.89" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01372" "YaGAVVNDL" "9" "Ac-[D-Ala8]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=230 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01372.cif" "Linear" "Acetylation" "Free" "None" "Mixed(D-Ala2)" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "921.02" "C38H57N9O12" "CEFHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "3" "4" "58.89" "25" "2.8 hour" "10 min" "2 min" "118.89" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01373" "YXGAVVNDL" "9" "[β-Ala8]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=100 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01373.cif" "Linear" "Free" "Free" "The 'X' at position 2 is 3-aminoproprionic acid." "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "961.27" "C38H57N9O12" "CEFHIKMPQRSTW" "V" "3.8" "0" "1" "-1" "3" "4" "58.89" "25" "2.8 hour" "10 min" "2 min" "118.89" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01374" "YAGAVANDL" "9" "[Ala12]H2-(7-15)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=760 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01374" "DRAVPe01374.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "892.96" "C39H60N10O14" "CEFHIKMPQRSTW" "A" "3.8" "0" "1" "-1" "3" "5" "52.22" "-17" "2.8 hour" "10 min" "2 min" "108.89" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01375" "YTMLVVDDL" "9" "EBV H2-(7-15)" "Synthetic construct(derived from EBV ribonucleotide reductase subunit 2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=110 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01375" "DRAVPe01375.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "1068.25" "C48H77N9O16S" "ACEFGHIKNPQRSW" "DLV" "3.56" "0" "2" "-2" "2" "4" "98.89" "12" "2.8 hour" "10 min" "2 min" "151.11" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01376" "YAGTVINDL" "9" "VZV H2-(7-15)" "Synthetic construct(derived from VZV ribonucleotide reductase subunit 2)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "Ribonucleotide reductase assay" "[Ref.3040743]Herpes simplex virus type 1:inhibition of HSV-1 ribonucleotide reductase activity(IC50=15 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01376" "DRAVPe01376.cif" "Linear" "Free" "Free" "None" "L" "ribonucleotide reductase" "The peptide inhibits the activity of ribonucleotide rductase." "965.07" "C43H68N10O15" "CEFHKMPQRSW" "ADGILNTVY" "3.8" "0" "1" "-1" "4" "4" "54.44" "-144" "2.8 hour" "10 min" "2 min" "130" "1490" "186.25" "3040743" "J Biol Chem. 1987 Sep 15;262(26):12413-6." "Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P." "Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase." "Not available" "Anti-HSV" "DRAVPe01377" "FKLRAKIKVRLRAKIKL" "17" "D4E1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.46 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.43 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=5.90 μM." "DRAVPe01377" "DRAVPe01377.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2081.71" "C98H181N31O18" "CDEGHMNPQSTWY" "K" "12.32" "8" "0" "8" "0" "9" "-11.76" "-3727" "1.1 hour" "3 min" "2 min" "143.53" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01378" "FAVAVKAVAVKAVAVKAVKKAVKKVKKAVKKAVKKKK" "37" "DC1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.75 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.78 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=9.20 μM." "DRAVPe01378" "DRAVPe01378.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3889.05" "C184H340N52O38" "CDEGHILMNPQRSTWY" "K" "11.15" "15" "0" "15" "0" "22" "22.97" "-1773" "1.1 hour" "3 min" "2 min" "113.24" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01379" "FLAAARIAKRVAKKARKLAKRAARKRK" "27" "D1D6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=0.94 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=1.47 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=8.93 μM." "DRAVPe01379" "DRAVPe01379.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3077.86" "C137H254N52O28" "CDEGHMNPQSTWY" "A" "12.71" "13" "0" "13" "0" "14" "-70.37" "-9030" "1.1 hour" "3 min" "2 min" "87.41" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01380" "FRFKIKFRLKFRFKARFKFRAKFRA" "25" "D4C3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=1.32 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=3.81 μM." "DRAVPe01380" "DRAVPe01380.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3341.15" "C165H255N49O26" "CDEGHMNPQSTVWY" "F" "12.71" "12" "0" "12" "0" "13" "-57.2" "-8371" "1.1 hour" "3 min" "2 min" "43.2" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01381" "FAVGLRAIKRALKKLRRGVRKVAKDL" "26" "D5F" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=5.47 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=8.73 μM." "DRAVPe01381" "DRAVPe01381.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2963.7" "C134H244N46O29" "CEHMNPQSTWY" "KR" "12.19" "10" "1" "9" "2" "13" "-15.38" "-6225" "1.1 hour" "3 min" "2 min" "123.85" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01382" "KRKRAVKRVGRRLKKLARKIARLGVAKLAGLRAVKLF" "37" "D5C1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.38 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=5.26 μM." "DRAVPe01382" "DRAVPe01382.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "4226.36" "C191H355N69O38" "CDEHMNPQSTWY" "KR" "12.85" "16" "0" "16" "3" "18" "-28.92" "-9650" "1.3 hour" "3 min" "2 min" "121.35" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01383" "GAKKGAKKGKKGAKKGAKGAGAKGAGAFKKKK" "32" "D2B15" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=4.07 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=6.19 μM." "DRAVPe01383" "DRAVPe01383.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3041.73" "C135H246N46O33" "CDEHILMNPQRSTVWY" "K" "11.11" "14" "0" "14" "9" "9" "-128.13" "-5178" "30 hour" ">20 hour" ">10 hour" "25" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01384" "FAKKFAKKFKKFAKKFAKFAFAF" "23" "D2A21" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.05 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=3.43 μM." "DRAVPe01384" "DRAVPe01384.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2775.47" "C144H212N32O24" "CDEGHILMNPQRSTVWY" "K" "10.9" "9" "0" "9" "0" "14" "-8.26" "-1525" "1.1 hour" "3 min" "2 min" "26.09" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01385" "KKKKFVKKVAKKVKKVAKKVAKVAVAV" "27" "D2A3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.00 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=3.24 μM." "DRAVPe01385" "DRAVPe01385.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2979.91" "C142H264N40O28" "CDEGHILMNPQRSTWY" "K" "11.08" "13" "0" "13" "0" "14" "-19.63" "-2780" "1.3 hour" "3 min" "2 min" "104.44" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01386" "FLFAFRIFKRVFKKFRKLFKRAF" "23" "D1A22" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=10.51 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=10.79 μM." "DRAVPe01386" "DRAVPe01386.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3041.82" "C155H234N40O24" "CDEGHMNPQSTWY" "F" "12.49" "9" "0" "9" "0" "14" "20.87" "-4117" "1.1 hour" "3 min" "2 min" "72.17" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01387" "KRKRAVKRVGRRLKKKLARKIARLGVAF" "28" "D5C" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=7.82 μM);##Feline immunodeficiency virus(FIV-Black):inhibition of reverse transcriptase activity in CrFK cells(IC50=6.84 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=7.48 μM." "DRAVPe01387" "DRAVPe01387.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3304.18" "C148H276N56O29" "CDEHMNPQSTWY" "KR" "12.78" "14" "0" "14" "2" "12" "-75.36" "-9939" "1.3 hour" "3 min" "2 min" "101.07" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01388" "KRKRFAKKFLRFLRKVIRFLKRFIRRF" "27" "D3A15" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.69 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=3.28 μM." "DRAVPe01388" "DRAVPe01388.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "3655.63" "C176H293N57O28" "CDEGHMNPQSTWY" "R" "12.85" "14" "0" "14" "0" "13" "-60" "-10433" "1.3 hour" "3 min" "2 min" "86.67" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01389" "FALALKALKKALKKLKKALKKAL" "23" "DP1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=7.07 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=5.17 μM." "DRAVPe01389" "DRAVPe01389.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2537.35" "C123H226N32O24" "CDEGHIMNPQRSTVWY" "K" "10.9" "9" "0" "9" "0" "14" "22.17" "-167" "1.1 hour" "3 min" "2 min" "144.78" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01390" "FAIAIKAIKKAIKKIKKAIKKAI" "23" "D1D2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=8.71 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=5.87 μM." "DRAVPe01390" "DRAVPe01390.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2537.35" "C123H226N32O24" "CDEGHLMNPQRSTVWY" "K" "10.9" "9" "0" "9" "0" "14" "43.48" "-167" "1.1 hour" "3 min" "2 min" "144.78" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01391" "FKVKAKVKAKVKAKVKAKKKK" "21" "D4B" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=2.85 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12208971]CrFK cell:TC50=0.92 μM." "DRAVPe01391" "DRAVPe01391.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2384.13" "C113H211N33O22" "CDEGHILMNPQRSTWY" "K" "11.04" "12" "0" "12" "0" "9" "-95.24" "-4022" "1.1 hour" "3 min" "2 min" "74.29" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01392" "AVKRVGRRLKKLARKIARLGVAF" "23" "D5D" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIV" "Retroviridae" "reverse transcriptase (RT) assay" "[Ref.12208971]Feline immunodeficiency virus(FIV-Petaluma):inhibition of reverse transcriptase activity in CrFK cells(IC50=3.37 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01392" "DRAVPe01392.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may facilitate interference with viral assembly or release and reduce the number of infectious progeny virions." "2607.28" "C118H216N42O24" "CDEHMNPQSTWY" "R" "12.61" "9" "0" "9" "2" "12" "-1.74" "-5290" "4.4 hour" ">20 hour" ">10 hour" "123.04" "0" "0" "12208971" "J Virol. 2002 Oct;76(19):9952-61." "Ma J, Kennedy-Stoskopf S, Jaynes JM, Thurmond LM, Tompkins WA." "Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. " "10.1128/jvi.76.19.9952-9961.2002" "Anti-FIV" "DRAVPe01393" "LPRRLHLEPAFLPYSVKAHECC" "22" "UL54(1221-1242)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01393" "DRAVPe01393.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2580.06" "C117H183N33O29S2" "DGIMNQTW" "L" "8.06" "5" "2" "3" "4" "8" "-10.91" "-2899" "5.5 hour" "3 min" "2 min" "93.18" "1615" "76.9" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01394" "PGGETARKDKFLHMVLPRRL" "20" "UL54(1206-1225)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01394" "DRAVPe01394.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2321.77" "C103H173N33O26S" "CINQSWY" "LR" "10.91" "6" "2" "4" "3" "6" "-70.5" "-5080" ">20 hour" ">20 hour" "?" "78" "0" "0" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01395" "EQVLKAVTNVLSPVFPGGET" "20" "UL54(1191-1210)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=280 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01395" "DRAVPe01395.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2085.39" "C94H153N23O30" "CDHIMRWY" "V" "4.53" "1" "2" "-1" "6" "8" "24.5" "-722" "1 hour" "30 min" ">10 hour" "102" "0" "0" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01396" "YVREHGVPIHADKYFEQVLK" "20" "UL54(1176-1195)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01396" "DRAVPe01396.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2428.78" "C113H170N30O30" "CMNSTW" "V" "6.92" "5" "3" "2" "3" "7" "-59" "-3581" "2.8 hour" "10 min" "2 min" "87.5" "2980" "156.84" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01397" "PPSAVCNYEVAEDPSYVREH" "20" "UL54(1161-1180)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01397" "DRAVPe01397.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2262.44" "C98H144N26O34S" "FGIKLMQTW" "EPV" "4.4" "2" "4" "-2" "6" "5" "-77.5" "-4543" ">20 hour" ">20 hour" "?" "53.5" "2980" "156.84" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01398" "RRLHLEPAFLPYSVKAHECC" "20" "UL54(1223-1242)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01398" "DRAVPe01398.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2369.79" "C106H165N31O27S2" "DGIMNQTW" "L" "8.06" "5" "2" "3" "4" "7" "-23" "-3391" "1 hour" "2 min" "2 min" "83" "1615" "85" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01399" "LPRRLHLEPAFLPYSVKAHEC" "21" "UL54(1221-1241)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50=75 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01399" "DRAVPe01399.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2476.93" "C114H178N32O28S" "DGIMNQTW" "L" "8.22" "5" "2" "3" "3" "8" "-23.33" "-3027" "5.5 hour" "3 min" "2 min" "97.62" "1490" "74.5" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01400" "LPRRLHLEPAFLPYSVKAHE" "20" "UL54(1221-1240)" "Synthetic construct(derived from human cytomegalovirus(HCMV) UL54 protein)" "P08546" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "ELISA" "[Ref.12857903]human cytomegalovirus(HCMV):inhibition of phyical interaction between UL54 and UL44(IC50>500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01400" "DRAVPe01400.cif" "Linear" "Free" "Free" "None" "L" "DNA polymerase" "Peptide derived from C-terminus of UL54 can block the physical interaction between UL54 and UL44,thus inhibits the activity of DNA polymerase." "2373.79" "C111H173N31O27" "CDGIMNQTW" "L" "8.6" "5" "2" "3" "2" "8" "-37" "-3155" "5.5 hour" "3 min" "2 min" "102.5" "1490" "78.42" "12857903" "J Virol. 2003 Aug;77(15):8336-44." "Loregian A, Rigatti R, Murphy M, Schievano E, Palu G, Marsden HS." "Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit." "10.1128/jvi.77.15.8336-8344.2003" "Anti-HCMV" "DRAVPe01401" "ACFPWGNTWCGGK" "13" "NTW (S-S)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=13.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01401" "DRAVPe01401.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1426.63" "C65H87N17O16S2" "DEHILMQRSVY" "G" "8.1" "1" "0" "1" "7" "4" "-23.85" "7" "4.4 hour" ">20 hour" ">10 hour" "7.69" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01402" "ACFPWGNTWCGGK" "13" "NTW (L)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01402.cif" "Linear" "Free" "Free" "None" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1426.63" "C65H87N17O16S2" "DEHILMQRSVY" "G" "8.1" "1" "0" "1" "7" "4" "-23.85" "7" "4.4 hour" ">20 hour" ">10 hour" "7.69" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01403" "ACFPWGKEYCGGK" "13" "KEY (S-S)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=22.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01403" "DRAVPe01403.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1445.67" "C66H92N16O17S2" "DHILMNQRSTV" "G" "8.07" "2" "1" "1" "6" "3" "-51.54" "-555" "4.4 hour" ">20 hour" ">10 hour" "7.69" "7115" "592.92" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01404" "ACFPWGKEYCGGK" "13" "KEY (L)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01404.cif" "Linear" "Free" "Free" "None" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1445.67" "C66H92N16O17S2" "DHILMNQRSTV" "G" "8.07" "2" "1" "1" "6" "3" "-51.54" "-555" "4.4 hour" ">20 hour" ">10 hour" "7.69" "7115" "592.92" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01405" "ACFPWGNQWCGGK" "13" "NQW (S-S)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=6.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01405" "DRAVPe01405.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1453.66" "C66H88N18O16S2" "DEHILMRSTVY" "G" "8.1" "1" "0" "1" "6" "4" "-45.38" "-290" "4.4 hour" ">20 hour" ">10 hour" "7.69" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01406" "ACFPWGNQWCGGK" "13" "NQW (L)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=37.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01406.cif" "Linear" "Free" "Free" "None" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1453.66" "C66H88N18O16S2" "DEHILMRSTVY" "G" "8.1" "1" "0" "1" "6" "4" "-45.38" "-290" "4.4 hour" ">20 hour" ">10 hour" "7.69" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01407" "CFPWGC" "6" "FPWG (S-S)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=50.0 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01407" "DRAVPe01407.cif" "Cyclic" "Cyclization of a n-terminal Cys residue (forming a disulfide bond)" "Cyclization of a C-terminal Cys residue (forming a disulfide bond)" "Disulfide bond between Cys1 and Cys6" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "711.85" "C33H41N7O7S2" "ADEHIKLMNQRSTVY" "C" "5.51" "0" "0" "0" "3" "2" "81.67" "881" "1.2 hour" ">20 hour" ">10 hour" "0" "5625" "1125" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01408" "CFPWGC" "6" "FPWG (L)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>150 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "711.85" "C33H41N7O7S2" "ADEHIKLMNQRSTVY" "C" "5.51" "0" "0" "0" "3" "2" "81.67" "881" "1.2 hour" ">20 hour" ">10 hour" "0" "5625" "1125" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01409" "ACAPWGNTWCGGK" "13" "NTW (S-S)[F1A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50>200 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01409" "DRAVPe01409.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1350.53" "C59H83N17O16S2" "DEFHILMQRSVY" "G" "8.1" "1" "0" "1" "7" "4" "-31.54" "-110" "4.4 hour" ">20 hour" ">10 hour" "15.38" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01410" "ACFAWGNTWCGGK" "13" "NTW (S-S)[P2A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=39 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01410" "DRAVPe01410.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1400.59" "C63H85N17O16S2" "DEHILMPQRSVY" "G" "8.1" "1" "0" "1" "7" "5" "2.31" "188" "4.4 hour" ">20 hour" ">10 hour" "15.38" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01411" "ACFPAGNTWCGGK" "13" "NTW (S-S)[W3A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=43 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01411" "DRAVPe01411.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1311.5" "C57H82N16O16S2" "DEHILMQRSVY" "G" "8.1" "1" "0" "1" "7" "4" "-3.08" "-45" "4.4 hour" ">20 hour" ">10 hour" "15.38" "5625" "468.75" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01412" "ACFPWANTWCGGK" "13" "NTW (S-S)[G4A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=7.4 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01412" "DRAVPe01412.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1440.66" "C66H89N17O16S2" "DEHILMQRSVY" "ACGW" "8.1" "1" "0" "1" "6" "5" "-6.92" "94" "4.4 hour" ">20 hour" ">10 hour" "15.38" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01413" "ACFPWGATWCGGK" "13" "NTW (S-S)[N5A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=40 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01413" "DRAVPe01413.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1383.61" "C64H86N16O15S2" "DEHILMNQRSVY" "G" "8.1" "1" "0" "1" "6" "5" "16.92" "852" "4.4 hour" ">20 hour" ">10 hour" "15.38" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01414" "ACFPWGNAWCGGK" "13" "NTW (S-S)[T6A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=11 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01414" "DRAVPe01414.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1396.6" "C64H85N17O15S2" "DEHILMQRSTVY" "G" "8.1" "1" "0" "1" "6" "5" "-4.62" "445" "4.4 hour" ">20 hour" ">10 hour" "15.38" "11125" "927.08" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01415" "ACFPWGNTACGGK" "13" "NTW (S-S)[W7A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Surface plasmon resonance" "[Ref.12951030]Hepatitis C virus(HCV):inhibition of polymerase activity(IC50=80 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01415" "DRAVPe01415.cif" "Cyclic" "Free" "Free" "Disulfide bond between Cys2 and Cys10" "L" "RNA-dependent RNA polymerase" "The peptide inhibits the de novo synthesis catalyzed by the enzyme, which suggests that it likely inhibited the formation of a preinitiation complex between the enzyme and the 3′OH end of the linear poly (C) substrate." "1311.5" "C57H82N16O16S2" "DEHILMQRSVY" "G" "8.1" "1" "0" "1" "7" "4" "-3.08" "-45" "4.4 hour" ">20 hour" ">10 hour" "15.38" "5625" "468.75" "12951030" "Virology. 2003 Aug 15;313(1):158-69." "Amin A, Zaccardi J, Mullen S, Olland S, Orlowski M, Feld B, Labonte P, Mak P." "Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase." "10.1016/s0042-6822(03)00313-1" "Anti-HCV" "DRAVPe01416" "MWKTPTLKYFGGFNFSQI" "18" "SARSWW-I(770-788)" "Synthetic construct(derived from SARS-CoV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(58% inhibition at ~30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01416" "DRAVPe01416.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "2165.54" "C105H149N23O25S" "ACDEHRV" "F" "9.7" "2" "0" "2" "7" "6" "-16.67" "-662" "30 hour" ">20 hour" ">10 hour" "43.33" "6990" "411.18" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01417" "ATAGWTFGAGAALQIPFAMQMAY" "23" "SARSWW-II(864-886)" "Synthetic construct(derived from SARS-CoV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(39% inhibition at ~30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01417" "DRAVPe01417.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "2374.76" "C110H160N26O29S2" "CDEHKNRSV" "A" "5.57" "0" "0" "0" "6" "12" "73.48" "2196" "4.4 hour" ">20 hour" ">10 hour" "64.35" "6990" "317.73" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01418" "GYHLMSFPQAAPHGVVFLHVTW" "22" "SARSWW-III(1028-1049)" "Synthetic construct(derived from SARS-CoV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(90% inhibition at ~30 μM,IC50=2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01418" "DRAVPe01418.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "2494.9" "C120H168N30O27S" "CDEIKNR" "HV" "7.02" "3" "0" "3" "5" "10" "47.73" "1247" "30 hour" ">20 hour" ">10 hour" "84.09" "6990" "332.86" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01419" "GVFVFNGTSWFITQRNFFS" "19" "SARSWW-IV(1075-1093)" "Synthetic construct(derived from SARS-CoV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(83% inhibition at ~30 μM,IC50=2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01419" "DRAVPe01419.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "2254.53" "C109H148N26O27" "ACDEHKLMPY" "F" "9.75" "1" "0" "1" "8" "9" "37.89" "-1357" "30 hour" ">20 hour" ">10 hour" "51.05" "5500" "305.56" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01420" "AACEVAKNLNESLIDLQELGKYEQYIKW" "28" "SARSWW-Vb(1169-1194)" "Synthetic construct(derived from SARS-CoV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(42% inhibition at ~30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01420" "DRAVPe01420.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "3269.72" "C147H230N36O46S" "FHMPRT" "EL" "4.59" "3" "5" "-2" "7" "11" "-41.43" "-3711" "4.4 hour" ">20 hour" ">10 hour" "104.64" "8480" "314.07" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01421" "GYFVQDDGEWKFTGSSYYY" "19" "MHVWW-IV(1144-1162)" "Synthetic construct(derived from MHV spike protein)" "P11224" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Plaque formation assay" "[Ref.16616792]SARS-CoV:inhibition of plaque information on Vero E6 cells(IC50=4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16616792]No cytotoxicity against Vero E6 cells up to 30 μM." "DRAVPe01421" "DRAVPe01421.cif" "Linear" "Free" "Free" "None" "L" "membrane" "No machanism information found in the reference(s) presented in this entry" "2312.43" "C110H138N22O34" "ACHILMNPR" "Y" "4.03" "1" "3" "-2" "10" "4" "-93.16" "-3012" "30 hour" ">20 hour" ">10 hour" "15.26" "11460" "636.67" "16616792" "Virus Res. 2006 Sep;120(1-2):146-55." "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. " "Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein" "10.1016/j.virusres.2006.03.001" "Anti-SARS-CoV" "DRAVPe01422" "AAHLIDALYAEFLGGRVLTTPVVHRALFYASAVLRQPFLAGVPSA" "45" "gH493-537(derived from HSV-1 H glycoprotein)" "Synthetic construct(derived from HSV-1 H glycoprotein (gH))" "Q9DHD5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250μM-500μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM." "DRAVPe01422" "DRAVPe01422.cif" "Linear" "Free" "Free" "None" "L" "mambrane" "The peptide inhibits virus entry and thus protects cells from infection." "4780.6" "C224H349N59O57" "CKMNW" "A" "8.64" "5" "2" "3" "9" "25" "77.11" "24" "4.4 hour" ">20 hour" ">10 hour" "121.56" "2980" "67.73" "18572274" "Peptides. 2008 Sep;29(9):1461-71." "Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M." "Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity." "10.1016/j.peptides.2008.04.022" "Anti-HSV" "DRAVPe01423" "AAHLIDALYAEFLGGRVLTT" "20" "gH493-512(derived from HSV-1 H glycoprotein)" "Synthetic construct(derived from HSV-1 H glycoprotein (gH))" "Q9DHD5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(60% inhibition at 250μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM." "DRAVPe01423" "DRAVPe01423.cif" "Linear" "Free" "Free" "None" "L" "mambrane" "The peptide inhibits virus entry and thus protects cells from infection." "2131.46" "C98H155N25O28" "CKMNPQSW" "AL" "5.32" "2" "2" "0" "5" "11" "78.5" "35" "4.4 hour" ">20 hour" ">10 hour" "132" "1490" "78.42" "18572274" "Peptides. 2008 Sep;29(9):1461-71." "Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M." "Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity." "10.1016/j.peptides.2008.04.022" "Anti-HSV" "DRAVPe01424" "GLASTLTRWAHYNALIRAF" "19" "gH626-644(derived from HSV-1 H glycoprotein)" "Synthetic construct(derived from HSV-1 H glycoprotein (gH))" "Q9DHD5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Plaque assay" "[Ref.18572274]Herpes simplex virus type 1(HSV-1):inhibition of viral-entry in Vero cells(50-60% inhibition at 250μM-500μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18572274]No cytotoxicity against Vero cells up to 500 μM." "DRAVPe01424" "DRAVPe01424.cif" "Linear" "Free" "Free" "None" "L" "mambrane" "The peptide inhibits virus entry and thus protects cells from infection." "2161.49" "C100H153N29O25" "CDEKMPQV" "A" "10.84" "3" "0" "3" "6" "10" "28.42" "-1665" "30 hour" ">20 hour" ">10 hour" "103.16" "6990" "388.33" "18572274" "Peptides. 2008 Sep;29(9):1461-71." "Galdiero S, Falanga A, Vitiello M, D'Isanto M, Cantisani M, Kampanaraki A, Benedetti E, Browne H, Galdiero M." "Peptides containing membrane-interacting motifs inhibit herpes simplex virus type 1 infectivity." "10.1016/j.peptides.2008.04.022" "Anti-HSV" "DRAVPe01425" "CCFLNITNSHVSILQERPPLENRVLTGWGL" "30" "Pcr-400" "Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))" "P14075" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HTLV" "Retroviridae" "Luciferase assay" "[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=0.18 ± 0.01 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01425" "DRAVPe01425.cif" "Linear" "Acetylation" "Amidation" "None" "L" "mambrane" "The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry." "3410.96" "C151H241N43O43S2" "ADKMY" "L" "6.74" "3" "2" "1" "11" "11" "10.33" "-3325" "1.2 hour" ">20 hour" ">10 hour" "110.33" "5625" "193.97" "19114713" "J Biol Chem. 2009 Mar 6;284(10):6575-84. " "Lamb D, Mirsaliotis A, Kelly SM, Brighty DW." "Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry." "10.1074/jbc.M806725200" "Anti-HTLV" "DRAVPe01426" "LNITNSHVSILQERPPLENRVL" "22" "Pcr-Δ8" "Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))" "P14075" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HTLV" "Retroviridae" "Luciferase assay" "[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=5.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01426" "DRAVPe01426.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry." "2542.92" "C111H188N34O34" "ACDFGKMWY" "L" "6.76" "3" "2" "1" "6" "8" "-27.73" "-4535" "5.5 hour" "3 min" "2 min" "132.73" "0" "0" "19114713" "J Biol Chem. 2009 Mar 6;284(10):6575-84. " "Lamb D, Mirsaliotis A, Kelly SM, Brighty DW." "Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry." "10.1074/jbc.M806725200" "Anti-HTLV" "DRAVPe01427" "CFLNITNSHVSILQERPPLENRV" "23" "Pcr-Δ7" "Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))" "P14075" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HTLV" "Retroviridae" "Luciferase assay" "[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=0.19± 0.01 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01427" "DRAVPe01427.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry." "2680.08" "C117H191N35O35S" "ADGKMWY" "LN" "6.75" "3" "2" "1" "7" "8" "-20" "-4601" "1.2 hour" ">20 hour" ">10 hour" "110" "0" "0" "19114713" "J Biol Chem. 2009 Mar 6;284(10):6575-84. " "Lamb D, Mirsaliotis A, Kelly SM, Brighty DW." "Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry." "10.1074/jbc.M806725200" "Anti-HTLV" "DRAVPe01428" "CFLNITNSHVSILQEAPPLENRV" "23" "Pcr-R416A" "Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))" "P14075" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HTLV" "Retroviridae" "Luciferase assay" "[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=1.55 ± 0.08 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01428" "DRAVPe01428.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry." "2594.97" "C114H184N32O35S" "DGKMWY" "LN" "5.4" "2" "2" "0" "7" "9" "7.39" "-2928" "1.2 hour" ">20 hour" ">10 hour" "114.35" "0" "0" "19114713" "J Biol Chem. 2009 Mar 6;284(10):6575-84. " "Lamb D, Mirsaliotis A, Kelly SM, Brighty DW." "Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry." "10.1074/jbc.M806725200" "Anti-HTLV" "DRAVPe01429" "CFLNITNSHVSILQEAPPLENAV" "23" "Pcr-R422A" "Synthetic construct(derived from HTLV-1 envelope glycoprotein (gp21))" "P14075" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HTLV" "Retroviridae" "Luciferase assay" "[Ref.19114713]:Human T cell leukemia virus type 1(HTLV-1):inhibition of mambrane fusion in 293T cells(IC50=8.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01429" "DRAVPe01429.cif" "Linear" "Acetylation" "Amidation" "None" "L" "membrane" "The peptide is an effective inhibitor of HTLV-1 envelope-catalyzed membrane fusion and thus inhibits virus entry." "2509.86" "C111H177N29O35S" "DGKMRWY" "LN" "4.51" "1" "2" "-1" "7" "10" "34.78" "-1255" "1.2 hour" ">20 hour" ">10 hour" "118.7" "0" "0" "19114713" "J Biol Chem. 2009 Mar 6;284(10):6575-84. " "Lamb D, Mirsaliotis A, Kelly SM, Brighty DW." "Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry." "10.1074/jbc.M806725200" "Anti-HTLV" "DRAVPe01430" "KQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK" "49" "G149-197(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01430" "DRAVPe01430.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "5687.62" "C253H395N75O67S4" "LMY" "K" "9.88" "11" "2" "9" "16" "11" "-107.35" "-11980" "1.3 hour" "3 min" "2 min" "37.76" "5750" "119.79" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01431" "FHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKK" "35" "G163-197(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01431" "DRAVPe01431.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4054.82" "C185H282N50O45S4" "DLMQY" "K" "9.44" "7" "1" "6" "12" "11" "-28" "-4511" "1.1 hour" "3 min" "2 min" "52.86" "5750" "169.12" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01432" "VPCSICSNNPTCWAICKRIPNKKPGKK" "27" "G171-197(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>165 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01432" "DRAVPe01432.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2986.62" "C129H217N39O34S4" "DEFHLMQY" "K" "9.7" "6" "0" "6" "11" "6" "-55.56" "-4296" "100 hour" ">20 hour" ">10 hour" "57.78" "5750" "221.15" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01433" "CSICSNNPTCWAICKRIPNKKPGKK" "25" "G173-197(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>177 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01433" "DRAVPe01433.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2790.37" "C119H201N37O32S4" "DEFHLMQVY" "K" "9.7" "6" "0" "6" "11" "5" "-70.4" "-4700" "1.2 hour" ">20 hour" ">10 hour" "50.8" "5750" "239.58" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01434" "KQRQNKPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI" "41" "G149-189(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=12 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01434" "DRAVPe01434.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4809.54" "C213H324N62O58S4" "GLMY" "N" "9.21" "7" "2" "5" "14" "11" "-72.93" "-9190" "1.3 hour" "3 min" "2 min" "45.12" "5750" "143.75" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01435" "KPPSKPNNDFHFEVFNFVPCSICSNNPTCWAICKRI" "36" "G154-189(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=12 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01435" "DRAVPe01435.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4154.81" "C187H278N50O50S4" "GLMQY" "NP" "8.52" "5" "2" "3" "13" "11" "-30.56" "-5371" "1.3 hour" "3 min" "2 min" "51.39" "5750" "164.29" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01436" "KPNNDFHFEVFNFVPCSICSNNPTCWAICKRI" "32" "G158-189(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01436" "DRAVPe01436.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3745.32" "C168H247N45O45S4" "GLMQY" "N" "7.89" "4" "2" "2" "12" "11" "-9.69" "-4476" "1.3 hour" "3 min" "2 min" "57.81" "5750" "185.48" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01437" "KQRQNKPPSKPNNDFHFEVFN" "21" "G149-169(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>190 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01437" "DRAVPe01437.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2571.84" "C115H171N35O33" "ACGILMTWY" "N" "9.7" "5" "2" "3" "5" "4" "-192.38" "-7982" "1.3 hour" "3 min" "2 min" "13.81" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01438" "KQRQNKPPSKPNNDFHF" "17" "G149-165(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>240 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01438" "DRAVPe01438.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2082.31" "C92H140N30O26" "ACEGILMTVWY" "KNP" "10.29" "5" "1" "4" "4" "2" "-237.65" "-7339" "1.3 hour" "3 min" "2 min" "0" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01439" "KPPSKPNNDFHFEVFNFVP" "19" "G154-172(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=220 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01439" "DRAVPe01439.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2260.54" "C108H150N26O28" "ACGILMQRTWY" "FP" "6.75" "3" "2" "1" "4" "6" "-84.74" "-3461" "1.3 hour" "3 min" "2 min" "30.53" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01440" "KPPSKPNNDFHFEVFNFV" "18" "G154-171(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=14 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01440" "DRAVPe01440.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2163.42" "C103H143N25O27" "ACGILMQRTWY" "F" "6.75" "3" "2" "1" "4" "6" "-80.56" "-3461" "1.3 hour" "3 min" "2 min" "32.22" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01441" "KPPSKPNNDFHFEVFNF" "17" "G154-170(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01441" "DRAVPe01441.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2064.29" "C98H134N24O26" "ACGILMQRTWY" "F" "6.75" "3" "2" "1" "4" "5" "-110" "-3865" "1.3 hour" "3 min" "2 min" "17.06" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01442" "KPPSKPNNDFHFEVFN" "16" "G154-169(derived from RSV attachment glycoprotein)" "Synthetic construct(derived from RSV attachment glycoprotein)" "P03423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>510 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01442" "DRAVPe01442.cif" "Cyclic" "Acetylation" "Amidation" "The peptide formed two disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1917.11" "C89H125N23O25" "ACGILMQRTWY" "FNP" "6.75" "3" "2" "1" "4" "4" "-134.38" "-4163" "1.3 hour" "3 min" "2 min" "18.13" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01443" "KQRQNKPPSKPNNDFHFEVFNFVPBSIBG" "29" "G149-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01443" "DRAVPe01443.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 25,28 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3401.86" "C145H211N41O38" "ACLMTWY" "FNP" "9.7" "5" "2" "3" "7" "7" "-109.31" "-7034" "1.3 hour" "3 min" "2 min" "33.45" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01444" "KPPSKPNNDFHFEVFNFVPBSIBG" "24" "G154-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01444" "DRAVPe01444.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2747.13" "C119H165N29O30" "ACLMQRTWY" "FP" "6.75" "3" "2" "1" "6" "7" "-53.33" "-3215" "1.3 hour" "3 min" "2 min" "40.42" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01445" "KPNNDFHFEVFNFVPBSIBG" "20" "G158-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01445" "DRAVPe01445.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 16,19 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2337.65" "C100H134N24O25" "ACLMQRTWY" "F" "5.32" "2" "2" "0" "5" "7" "-24.5" "-2320" "1.3 hour" "3 min" "2 min" "48.5" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01446" "DFHFEVFNFVPBSIBG" "16" "G162-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=60 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01446" "DRAVPe01446.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 12,15 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1884.15" "C81H103N17O19" "ACKLMQRTWY" "F" "4.35" "1" "2" "-1" "3" "7" "47.5" "-437" "1.1 hour" "3 min" ">10 hour" "60.63" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01447" "EVFNFVPBSIBG" "12" "G166-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01447" "DRAVPe01447.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 8,11 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1337.57" "C53H73N11O13" "ACDHKLMQRTWY" "FV" "4" "0" "1" "-1" "3" "5" "72.5" "305" "1 hour" "30 min" ">10 hour" "80.83" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01448" "FVPBSIBG" "8" "G170-177" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50》500 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01448" "DRAVPe01448.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 4,7 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "848.04" "C30H42N6O6" "ACDEHKLMNQRTWY" "FGIPSV" "5.52" "0" "0" "0" "2" "3" "108.75" "948" "1.1 hour" "3 min" "2 min" "85" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01449" "KQRQNKPPSKPNNDFHFEVFNFVPB" "25" "G149-173" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=80 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01449" "DRAVPe01449.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 25 is S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3029.92" "C134H194N38O35" "ACGILMTWY" "FNP" "9.7" "5" "2" "3" "5" "6" "-140" "-7280" "1.3 hour" "3 min" "2 min" "23.2" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01450" "KPPSKPNNDFHFEVFNFVPBSIAG" "24" "G154-177[B176A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01450" "DRAVPe01450.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20 is S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2703.56" "C122H172N30O32" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "6" "8" "-45.83" "-3034" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01451" "KPPSKPNNDFHFEVFNFVPBSABG" "24" "G154-177[I175A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=22 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01451" "DRAVPe01451.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2705.05" "C116H159N29O30" "CILMQRTWY" "FP" "6.75" "3" "2" "1" "6" "7" "-64.58" "-3526" "1.3 hour" "3 min" "2 min" "28.33" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01452" "KPPSKPNNDFHFEVFNFVPBAIBG" "24" "G154-177[S174A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01452" "DRAVPe01452.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2731.13" "C119H165N29O29" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "5" "8" "-42.5" "-2694" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01453" "KPPSKPNNDFHFEVFNFVPASIBG" "24" "G154-177[B173A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01453" "DRAVPe01453.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 23 is S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2703.56" "C122H172N30O32" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "6" "8" "-45.83" "-3034" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01454" "KPPSKPNNDFHFEVFNFVABSIBG" "24" "G154-177[P172A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01454" "DRAVPe01454.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2721.09" "C117H163N29O30" "CLMQRTWY" "F" "6.75" "3" "2" "1" "6" "8" "-39.17" "-3034" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01455" "KPPSKPNNDFHFEVFNFAPBSIBG" "24" "G154-177[V171A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01455" "DRAVPe01455.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2719.08" "C117H161N29O30" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "6" "7" "-63.33" "-3438" "1.3 hour" "3 min" "2 min" "32.5" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01456" "KPPSKPNNDFHFEVFNAVPBSIBG" "24" "G154-177[F170A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=22 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01456" "DRAVPe01456.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2671.03" "C113H161N29O30" "CLMQRTWY" "P" "6.75" "3" "2" "1" "6" "7" "-57.5" "-3332" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01457" "KPPSKPNNDFHFEVFAFVPBSIBG" "24" "G154-177[N169A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01457" "DRAVPe01457.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2704.11" "C118H164N28O29" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "5" "8" "-31.25" "-2370" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01458" "KPPSKPNNDFHFEVANFVPBSIBG" "24" "G154-177[F168A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=90 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01458" "DRAVPe01458.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2671.03" "C113H161N29O30" "CLMQRTWY" "P" "6.75" "3" "2" "1" "6" "7" "-57.5" "-3332" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01459" "KPPSKPNNDFHFEAFNFVPBSIBG" "24" "G154-177[V167A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=11 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01459" "DRAVPe01459.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2719.08" "C117H161N29O30" "CLMQRTWY" "FP" "6.75" "3" "2" "1" "6" "7" "-63.33" "-3438" "1.3 hour" "3 min" "2 min" "32.5" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01460" "KPPSKPNNDFHFAVFNFVPBSIBG" "24" "G154-177[E166A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=0.75 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01460" "DRAVPe01460.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2689.1" "C117H163N29O28" "CELMQRTWY" "FP" "8.6" "3" "1" "2" "6" "8" "-31.25" "-2353" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01461" "KPPSKPNNDFHAEVFNFVPBSIBG" "24" "G154-177[F165A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50=5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01461" "DRAVPe01461.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 20,23 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2671.03" "C113H161N29O30" "CLMQRTWY" "P" "6.75" "3" "2" "1" "6" "7" "-57.5" "-3332" "1.3 hour" "3 min" "2 min" "44.58" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01462" "KQRQNKPPSKPNNDFHFEVANAVPBSIBG" "29" "G149-177[F168/170A]" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "NMR" "[Ref.11487583]Respiratory syncytial virus(RSV):inhibition of the cytopathic effect of RSV in HEp-2 cells(IC50>165 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01462" "DRAVPe01462.cif" "Linear" "Acetylation" "Amidation" "The 'B' at position 25,28 are S-acetamidomethyl cysteine." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3249.66" "C133H203N41O38" "CLMTWY" "NP" "9.7" "5" "2" "3" "7" "7" "-116.21" "-7268" "1.3 hour" "3 min" "2 min" "40.34" "0" "0" "11487583" "J Biol Chem. 2001 Oct 19;276(42):38988-94." "Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. " "Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein." "10.1074/jbc.M106288200" "Anti-RSV" "DRAVPe01463" "DTRACDVIALLCHLNT" "16" "P1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV,DENV" "Flaviviridae" "RT-QPCR" "[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P1 significantly inhibited WNV infectivity at a concentration of 1 mM,IC50=67.0 ± 0.1 μM);##Dengue virus serotype 2:inhibition of virus infection in Vero cells(99.3±0.7% inhibition at 200 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17151121]No cytotoxicity against Vero cells up to 500μM." "DRAVPe01463" "DRAVPe01463.cif" "Linear" "Free" "Free" "None" "L" "E proteins" "No machanism information found in the reference(s) presented in this entry" "1758.04" "C73H124N22O24S2" "EFGKMPQSWY" "L" "5.21" "2" "2" "0" "5" "7" "56.88" "-1890" "1.1 hour" "3 min" ">10 hour" "128.13" "125" "8.33" "17151121" "J Virol. 2007 Feb;81(4):2047-55. " "Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E." "Antiviral peptides targeting the west nile virus envelope protein." "10.1128/JVI.01840-06" "Anti-WNV,Anti-DENV" "DRAVPe01464" "CDVIALLCHLNT" "12" "P8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "WNV" "Flaviviridae" "RT-QPCR" "[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01464" "DRAVPe01464.cif" "Linear" "Free" "Free" "None" "L" "E proteins" "No machanism information found in the reference(s) presented in this entry" "1314.58" "C56H95N15O17S2" "EFGKMPQRSWY" "L" "5.08" "1" "1" "0" "4" "6" "133.33" "550" "1.2 hour" ">20 hour" ">10 hour" "162.5" "125" "11.36" "17151121" "J Virol. 2007 Feb;81(4):2047-55. " "Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E." "Antiviral peptides targeting the west nile virus envelope protein." "10.1128/JVI.01840-06" "Anti-WNV" "DRAVPe01465" "CDVIALLACHLNT" "13" "P9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "WNV" "Flaviviridae" "RT-QPCR" "[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(96.3±2.8% inhibition at 100 μM,IC50=2.60 ± 0.01 μM);inhibition of virus entry in Vero cells(65.2±14.5% inhibition at 100 μM);inhibition of virus attachment to Vero cells(96.3±2.7% inhibition at 1mM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17151121]No cytotoxicity against Vero cells up to 500μM." "DRAVPe01465" "DRAVPe01465.cif" "Linear" "Free" "Free" "None" "L" "E proteins" "P9 blocked cirus attachment" "1385.66" "C59H100N16O18S2" "EFGKMPQRSWY" "L" "5.08" "1" "1" "0" "4" "7" "136.92" "731" "1.2 hour" ">20 hour" ">10 hour" "157.69" "125" "10.42" "17151121" "J Virol. 2007 Feb;81(4):2047-55. " "Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E." "Antiviral peptides targeting the west nile virus envelope protein." "10.1128/JVI.01840-06" "Anti-WNV" "DRAVPe01466" "CDVIALLCHLNTPSF" "15" "P10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV" "Flaviviridae" "RT-QPCR" "[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01466" "DRAVPe01466.cif" "Linear" "Free" "Free" "None" "L" "E proteins" "No machanism information found in the reference(s) presented in this entry" "1645.95" "C73H116N18O21S2" "EGKMQRWY" "L" "5.08" "1" "1" "0" "5" "7" "109.33" "508" "1.2 hour" ">20 hour" ">10 hour" "130" "125" "8.93" "17151121" "J Virol. 2007 Feb;81(4):2047-55. " "Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E." "Antiviral peptides targeting the west nile virus envelope protein." "10.1128/JVI.01840-06" "Anti-WNV" "DRAVPe01467" "CDVIALLCHLNTPSFNTTHYRESWY" "25" "P11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WNV" "Flaviviridae" "RT-QPCR" "[Ref.17151121]west nile virus(WNV):inhibition of virus infection in Vero cells(P10 significantly inhibited WNV infectivity)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01467" "DRAVPe01467.cif" "Linear" "Free" "Free" "None" "L" "E proteins" "No machanism information found in the reference(s) presented in this entry" "2984.35" "C134H195N35O39S2" "GKMQ" "LT" "5.99" "3" "2" "1" "11" "8" "-16" "-3444" "1.2 hour" ">20 hour" ">10 hour" "78" "8605" "358.54" "17151121" "J Virol. 2007 Feb;81(4):2047-55. " "Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E." "Antiviral peptides targeting the west nile virus envelope protein." "10.1128/JVI.01840-06" "Anti-WNV" "DRAVPe01468" "SSCNMGWDTPACCVWFPYWV" "20" "A4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "GFP assay" "[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(70% inhibition)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01468" "DRAVPe01468.cif" "Linear" "Free" "Free" "None" "L" "pUL84(nonconventional nuclear localization signal of the essential viral replication factor)" "The peptide specifically bind to UL84 protein and utilized to inhibit HCMV replication." "2352.7" "C108H142N24O28S4" "EHIKLQR" "CW" "3.8" "0" "1" "-1" "9" "7" "27.5" "212" "1.9 hour" ">20 hour" ">10 hour" "34" "18115" "953.42" "19740994" "J Virol. 2009 Nov;83(22):11902-13. " "Kaiser N, Lischka P, Wagenknecht N, Stamminger T." "Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84." "10.1128/JVI.01378-09" "Anti-HCMV" "DRAVPe01469" "MAVGLVLCDWWLGEYLLEA" "19" "A8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "GFP assay" "[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(70% inhibition)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01469" "DRAVPe01469.cif" "Linear" "Free" "Free" "None" "L" "pUL84(nonconventional nuclear localization signal of the essential viral replication factor)" "The peptide specifically bind to UL84 protein and utilized to inhibit HCMV replication." "2181.59" "C103H153N21O27S2" "FHIKNPQRST" "L" "3.57" "0" "3" "-3" "4" "11" "110.53" "2399" "30 hour" ">20 hour" ">10 hour" "143.68" "12490" "693.89" "19740994" "J Virol. 2009 Nov;83(22):11902-13. " "Kaiser N, Lischka P, Wagenknecht N, Stamminger T." "Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84." "10.1128/JVI.01378-09" "Anti-HCMV" "DRAVPe01470" "PVLQPALSLSCGPEPLLLSC" "20" "A56" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "GFP assay" "[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(40% inhibition)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01470" "DRAVPe01470.cif" "Linear" "Free" "Free" "None" "L" "pUL84(nonconventional nuclear localization signal of the essential viral replication factor)" "The peptide specifically bind to UL84 protein and utilized to inhibit HCMV replication." "2037.46" "C91H153N21O27S2" "DFHIKMNRTWY" "L" "4" "0" "1" "-1" "6" "8" "88" "1632" ">20 hour" ">20 hour" "?" "136.5" "125" "6.58" "19740994" "J Virol. 2009 Nov;83(22):11902-13. " "Kaiser N, Lischka P, Wagenknecht N, Stamminger T." "Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84." "10.1128/JVI.01378-09" "Anti-HCMV" "DRAVPe01471" "IEVTFVNRRGDGAELWYLSA" "20" "A110" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCMV" "Herpesviridae" "GFP assay" "[Ref.19740994]human cytomegalovirus(HCMV):inhibition of virus replication in HeLa cells(35% inhibition)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01471" "DRAVPe01471.cif" "Linear" "Free" "Free" "None" "L" "pUL84(nonconventional nuclear localization signal of the essential viral replication factor)" "The peptide specifically bind to UL84 protein and utilized to inhibit HCMV replication." "2296.57" "C104H158N28O31" "CHKMPQ" "AEGLRV" "4.68" "2" "3" "-1" "6" "9" "-3" "-3128" "20 hour" "30 min" ">10 hour" "97.5" "6990" "367.89" "19740994" "J Virol. 2009 Nov;83(22):11902-13. " "Kaiser N, Lischka P, Wagenknecht N, Stamminger T." "Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84." "10.1128/JVI.01378-09" "Anti-HCMV" "DRAVPe01472" "SFAIKWEYVLLLFLL" "15" "Peptide 75(710-725)[Δ1]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(91% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01472" "DRAVPe01472.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1855.29" "C96H143N17O20" "CDGHMNPQRT" "L" "5.72" "1" "1" "0" "2" "11" "164.67" "2776" "1.9 hour" ">20 hour" ">10 hour" "182" "6990" "499.29" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01473" "FAIKWEYVLLLFLL" "14" "Peptide 75(710-725)[Δ1-2]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(95% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01473" "DRAVPe01473.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1768.22" "C93H138N16O18" "CDGHMNPQRST" "L" "6" "1" "1" "0" "1" "11" "182.14" "3116" "1.1 hour" "3 min" "2 min" "195" "6990" "537.69" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01474" "AIKWEYVLLLFLL" "13" "Peptide 75(710-725)[Δ1-3]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(92% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01474" "DRAVPe01474.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1621.04" "C84H129N15O17" "CDGHMNPQRST" "L" "6.05" "1" "1" "0" "1" "10" "174.62" "2818" "4.4 hour" ">20 hour" ">10 hour" "210" "6990" "582.5" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01475" "IKWEYVLLLFLL" "12" "Peptide 75(710-725)[Δ1-4]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(88% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01475" "DRAVPe01475.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1549.96" "C81H124N14O16" "ACDGHMNPQRST" "L" "6" "1" "1" "0" "1" "9" "174.17" "2637" "20 hour" "30 min" ">10 hour" "219.17" "6990" "635.45" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01476" "KWEYVLLLFLL" "11" "Peptide 75(710-725)[Δ1-5]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(78% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01476" "DRAVPe01476.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1436.8" "C75H113N13O15" "ACDGHIMNPQRST" "L" "6" "1" "1" "0" "1" "8" "149.09" "2145" "1.3 hour" "3 min" "2 min" "203.64" "6990" "699" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01477" "WEYVLLLFLL" "10" "Peptide 75(710-725)[Δ1-6]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(82% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01477" "DRAVPe01477.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1308.63" "C69H101N11O14" "ACDGHIKMNPQRST" "L" "4" "0" "1" "-1" "1" "8" "203" "2700" "2.8 hour" "3 min" "2 min" "224" "6990" "776.67" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01478" "VSFAIKWEYVLLLFL" "15" "Peptide 75(710-725)[Δ16]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(63% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01478" "DRAVPe01478.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1841.27" "C95H141N17O20" "CDGHMNPQRT" "L" "5.97" "1" "1" "0" "2" "11" "167.33" "2688" "100 hour" ">20 hour" ">10 hour" "175.33" "6990" "499.29" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01479" "VSFAIKWEYVLLLF" "14" "Peptide 75(710-725)[Δ15-16]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(49% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01479" "DRAVPe01479.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1728.11" "C89H130N16O19" "CDGHMNPQRT" "L" "5.97" "1" "1" "0" "2" "10" "152.14" "2196" "100 hour" ">20 hour" ">10 hour" "160" "6990" "537.69" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01480" "VSFAIKWEYVLLL" "13" "Peptide 75(710-725)[Δ14-16]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(49% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01480" "DRAVPe01480.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1580.93" "C80H121N15O18" "CDGHMNPQRT" "L" "5.97" "1" "1" "0" "2" "9" "142.31" "1898" "100 hour" ">20 hour" ">10 hour" "172.31" "6990" "582.5" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01481" "VSFAIKWEYVLL" "12" "Peptide 75(710-725)[Δ13-16]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(44% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01481" "DRAVPe01481.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1467.77" "C74H110N14O17" "CDGHMNPQRT" "LV" "5.97" "1" "1" "0" "2" "8" "122.5" "1406" "100 hour" ">20 hour" ">10 hour" "154.17" "6990" "635.45" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01482" "VSFAIKWEYVL" "11" "Peptide 75(710-725)[Δ12-16]" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(17% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01482" "DRAVPe01482.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1354.61" "C68H99N13O16" "CDGHMNPQRT" "V" "5.97" "1" "1" "0" "2" "7" "99.09" "914" "100 hour" ">20 hour" ">10 hour" "132.73" "6990" "699" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01483" "VSFAIKWEYVLLLFLL" "16" "Peptide 75(710-725)" "Synthetic construct(derived from HCV envelope protein)" "P26663" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "Luciferase assay" "[Ref.20156485]hepatitis C virus(HCVpp):inhibition of virus infection in Huh-7 human hepatoma cells(EC50=0.3 ± 0.4 μM,EC90=14 ± 12 μM);inhibition of virus infection in primary human hepatocytes(EC50=0.3μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20156485]No cytotoxicity against Huh-7 cells." "DRAVPe01483" "DRAVPe01483.cif" "Linear" "Free" "Free" "None" "L" "envelope protein" "The peptide inhibits a post-binding step in HCV entry." "1954.43" "C101H152N18O21" "CDGHMNPQRT" "L" "5.97" "1" "1" "0" "2" "12" "180.63" "3180" "100 hour" ">20 hour" ">10 hour" "188.75" "6990" "466" "20156485" "Antiviral Res. 2010 May;86(2):172-9." "Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R." "A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. " "10.1016/j.antiviral.2010.02.316" "Anti-HCV" "DRAVPe01484" "RWMVWRHWFHRLRLPYNPGKNKQNQQWP" "28" "DN57opt" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus reduction assay" "[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=8±1 μM,97% inhibition at 20μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20582308]the peptide was found to be mildly toxic to LLC-MK2 cells at 40 µM." "DRAVPe01484" "DRAVPe01484.cif" "Linear" "Free" "Free" "None" "L" "E glycoprotein" "The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein." "3760.35" "C176H252N56O36S" "ACDEIST" "RW" "12.01" "8" "0" "8" "5" "8" "-167.14" "-8731" "1 hour" "2 min" "2 min" "38.21" "23490" "870" "20582308" "PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. " "Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF." "Structural optimization and de novo design of dengue virus entry inhibitory peptides." "10.1371/journal.pntd.0000721" "Anti-DENV" "DRAVPe01485" "RQMRAWGQDYQHGGMGYSC" "19" "DN81opt" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus reduction assay" "[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=36±6 μM,57% inhibition at 50μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01485" "DRAVPe01485.cif" "Linear" "Free" "Free" "None" "L" "E glycoprotein" "The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein." "2231.47" "C93H135N31O28S3" "EFIKLNPTV" "G" "8.21" "3" "1" "2" "8" "2" "-126.32" "-4964" "1 hour" "2 min" "2 min" "5.26" "8480" "471.11" "20582308" "PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. " "Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF." "Structural optimization and de novo design of dengue virus entry inhibitory peptides." "10.1371/journal.pntd.0000721" "Anti-DENV" "DRAVPe01486" "FWFTLIKTQAKQPARYRRFC" "20" "1OAN1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus reduction assay" "[Ref.20582308]dengue 2 virus(DENV-2):inhibition of virus infection in LLC-MK2 cells(IC50=7±4 μM,99% inhibition at 50 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.20582308]the peptide showed no toxic to LLC-MK2 cells at 50 µM." "DRAVPe01486" "DRAVPe01486.cif" "Linear" "Free" "Free" "None" "L" "E glycoprotein" "The peptide blocks virus:cell binding, interfere with a step during viral entry, alter the surface structure of dengue viral particles, and that they interact directly with dengue virus envelope protein." "2561.05" "C121H182N34O26S" "DEGHMNSV" "FR" "11.01" "5" "0" "5" "4" "8" "-53.5" "-4621" "1.1 hour" "3 min" "2 min" "49" "6990" "367.89" "20582308" "PLoS Negl Trop Dis. 2010 Jun 22;4(6):e721. " "Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF." "Structural optimization and de novo design of dengue virus entry inhibitory peptides." "10.1371/journal.pntd.0000721" "Anti-DENV" "DRAVPe01487" "LLDCWVRLGRYLLRRLKT" "18" "GBVA1(1-18)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=10 μM,88% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01487" "DRAVPe01487.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2274.8" "C104H176N32O23S" "AEFHIMNPQS" "L" "10.85" "5" "1" "4" "4" "8" "4.44" "-3855" "5.5 hour" "3 min" "2 min" "146.11" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01488" "LLDCWVRLGRYLLRRLKTPFTRL" "23" "GBVA2(1-23)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=15 μM,50% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01488" "DRAVPe01488.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2889.55" "C134H222N40O29S" "AEHIMNQS" "L" "11.44" "6" "1" "5" "5" "10" "2.61" "-4814" "5.5 hour" "3 min" "2 min" "131.3" "6990" "317.73" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01489" "LLDCWVRLGRYLLRRLKTPFT" "21" "GBVA3(1-21)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01489" "DRAVPe01489.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2620.2" "C122H199N35O27S" "AEHIMNQS" "L" "10.85" "5" "1" "4" "5" "9" "6.19" "-3814" "5.5 hour" "3 min" "2 min" "125.24" "6990" "349.5" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01490" "LLDCWVRLGRYLLRRLKTP" "19" "GBVA4(1-19)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=3 μM,99% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01490" "DRAVPe01490.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2371.92" "C109H183N33O24S" "AEFHIMNQS" "L" "10.85" "5" "1" "4" "4" "8" "-4.21" "-3855" "5.5 hour" "3 min" "2 min" "138.42" "6990" "388.33" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01491" "LLDCWVRLGRYLLRRLK" "17" "GBVA5(1-17)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=5 μM,99% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01491" "DRAVPe01491.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2173.7" "C100H169N31O21S" "AEFHIMNPQST" "L" "10.85" "5" "1" "4" "3" "8" "8.82" "-3598" "5.5 hour" "3 min" "2 min" "154.71" "6990" "436.88" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01492" "LDCWVRLGRYLLRRLKTPFTRL" "22" "GBVA6(2-23)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0 inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01492" "DRAVPe01492.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2776.39" "C128H211N39O28S" "AEHIMNQS" "L" "11.44" "6" "1" "5" "5" "9" "-14.55" "-5306" "5.5 hour" "3 min" "2 min" "119.55" "6990" "332.86" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01493" "CWVRLGRYLLRRLKTPFTRL" "20" "GBVA7(4-23)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,89% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01493" "DRAVPe01493.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2548.14" "C118H195N37O24S" "ADEHIMNQS" "LR" "11.83" "6" "0" "6" "5" "8" "-17.5" "-4926" "1.2 hour" ">20 hour" ">10 hour" "112" "6990" "367.89" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01494" "LDCWVRLGRYLLRRLKTP" "18" "GBVA8(2-19)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=4 μM,99% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01494" "DRAVPe01494.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2258.76" "C103H172N32O23S" "AEFHIMNQS" "L" "10.85" "5" "1" "4" "4" "7" "-25.56" "-4347" "5.5 hour" "3 min" "2 min" "124.44" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01495" "DCWVRLGRYLLRRLKTPF" "18" "GBVA9(3-20)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,90% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01495" "DRAVPe01495.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2292.78" "C106H170N32O23S" "AEHIMNQS" "LR" "10.85" "5" "1" "4" "4" "7" "-31.11" "-4541" "1.1 hour" "3 min" ">10 hour" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01496" "CWVRLGRYLLRRLKTPFT" "18" "GBVA10(4-21)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2 μM,100% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01496" "DRAVPe01496.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2278.79" "C106H172N32O22S" "ADEHIMNQS" "LR" "11.56" "5" "0" "5" "5" "7" "-15.56" "-3926" "1.2 hour" ">20 hour" ">10 hour" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01497" "WVRLGRYLLRRLKTPFTR" "18" "GBVA11(5-22)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=12 μM,58% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01497" "DRAVPe01497.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2331.84" "C109H179N35O22" "ACDEHIMNQS" "R" "12.18" "6" "0" "6" "4" "7" "-54.44" "-5546" "2.8 hour" "3 min" "2 min" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01498" "VRLGRYLLRRLKTPFTRL" "18" "GBVA12(6-23)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "Q69422" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM,0 inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01498" "DRAVPe01498.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2258.79" "C104H180N34O22" "ACDEHIMNQSW" "LR" "12.18" "6" "0" "6" "4" "7" "-28.33" "-5287" "100 hour" ">20 hour" ">10 hour" "124.44" "1490" "87.65" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01499" "CWVRLGRYKLRRLKTPFT" "18" "GBVA10-1(L9K)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01499" "DRAVPe01499.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2293.81" "C106H173N33O22S" "ADEHIMNQS" "R" "11.57" "6" "0" "6" "5" "6" "-58.33" "-4973" "1.2 hour" ">20 hour" ">10 hour" "81.11" "6990" "411.18" "23175360" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01500" "CWVRLGRYSLRRLKTPFT" "18" "GBVA10-2(L9S)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=18 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01500" "DRAVPe01500.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2252.71" "C103H166N32O23S" "ADEHIMNQ" "R" "11.56" "5" "0" "5" "6" "6" "-41.11" "-4758" "1.2 hour" ">20 hour" ">10 hour" "81.11" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01501" "CWVRLGRYALRRLKTPFT" "18" "GBVA10-3(L9A)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01501" "DRAVPe01501.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2236.71" "C103H166N32O22S" "DEHIMNQS" "R" "11.56" "5" "0" "5" "5" "7" "-26.67" "-4237" "1.2 hour" ">20 hour" ">10 hour" "86.67" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01502" "CWVRLGRYVLRRLKTPFT" "18" "GBVA10-4(L9V)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=16 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01502" "DRAVPe01502.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2264.77" "C105H170N32O22S" "ADEHIMNQS" "R" "11.56" "5" "0" "5" "5" "7" "-13.33" "-4014" "1.2 hour" ">20 hour" ">10 hour" "97.22" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01503" "CWVRLARYLLRRLKTPFT" "18" "GBVA10-5(G6A)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=2.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01503" "DRAVPe01503.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2292.82" "C107H174N32O22S" "DEGHIMNQS" "LR" "11.56" "5" "0" "5" "4" "8" "-3.33" "-3839" "1.2 hour" ">20 hour" ">10 hour" "108.33" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01504" "CWVRLVRYLLRRLKTPFT" "18" "GBVA10-6(G6V)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01504" "DRAVPe01504.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2320.87" "C109H178N32O22S" "ADEGHIMNQS" "LR" "11.56" "5" "0" "5" "4" "8" "10" "-3616" "1.2 hour" ">20 hour" ">10 hour" "118.89" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01505" "CWVRLLRYLLRRLKTPFT" "18" "GBVA10-7(G6L)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01505" "DRAVPe01505.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2334.9" "C110H180N32O22S" "ADEGHIMNQS" "L" "11.56" "5" "0" "5" "4" "8" "7.78" "-3528" "1.2 hour" ">20 hour" ">10 hour" "124.44" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01506" "CWVRLLRYLLRRLKTLFT" "18" "GBVA10-8(G6L/P16L)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=1.25 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01506" "DRAVPe01506.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2350.94" "C111H184N32O22S" "ADEGHIMNPQS" "L" "11.56" "5" "0" "5" "4" "9" "37.78" "-3036" "1.2 hour" ">20 hour" ">10 hour" "146.11" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01507" "CWVRLGRYLLRRLKTLFT" "18" "GBVA10-9(P16L)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=0.16 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23175359]HepG2 cell:LC50=90 μM(4h of treatment);##HeLa cell:LC50=40 μM(4h of treatment);##Huh7.5.1 cell:LC50=90 μM(4h of treatment);LC50=50 μM(24h of treatment)." "DRAVPe01507" "DRAVPe01507.cif" "Linear" "Free" "Free" "None" "L" "Not found" "GBVA10-9 can inhibit virus entry at a postattachment step." "2294.84" "C107H176N32O22S" "ADEHIMNPQS" "L" "11.56" "5" "0" "5" "5" "8" "14.44" "-3434" "1.2 hour" ">20 hour" ">10 hour" "124.44" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01508" "CWVRLGRYILRRLKTPFT" "18" "GBVA10-10(L9I)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01508" "DRAVPe01508.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2278.79" "C106H172N32O22S" "ADEHMNQS" "R" "11.56" "5" "0" "5" "5" "7" "-11.67" "-3926" "1.2 hour" ">20 hour" ">10 hour" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01509" "CWVRLGRYILRRIKTPFT" "18" "GBVA10-11(L9I/L13I)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50=0.63 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01509" "DRAVPe01509.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2278.79" "C106H172N32O22S" "ADEHMNQS" "R" "11.56" "5" "0" "5" "5" "7" "-7.78" "-3926" "1.2 hour" ">20 hour" ">10 hour" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01510" "CWVRIGRYILRRIKTPFT" "18" "GBVA10-12(L5I/L9I/L13I)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01510" "DRAVPe01510.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2278.79" "C106H172N32O22S" "ADEHMNQS" "R" "11.56" "5" "0" "5" "5" "7" "-3.89" "-3926" "1.2 hour" ">20 hour" ">10 hour" "102.78" "6990" "411.18" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01511" "KWVRLGRKLLRRLKKPFK" "18" "GBVA10-13(C1K/Y8K/T15K/T18K)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01511" "DRAVPe01511.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2322.96" "C110H192N36O19" "ACDEHIMNQSTY" "K" "12.49" "9" "0" "9" "1" "7" "-101.11" "-5746" "1.3 hour" "3 min" "2 min" "102.78" "5500" "323.53" "23175361" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01512" "KWVRLGRKLLRRLKKPFT" "18" "GBVA10-14(C1K/Y8K/T15K)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01512" "DRAVPe01512.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2295.9" "C108H187N35O20" "ACDEHIMNQSY" "KLR" "12.48" "8" "0" "8" "2" "7" "-83.33" "-5448" "1.3 hour" "3 min" "2 min" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01513" "CWVRLGRKLLRRLKKPFT" "18" "GBVA10-15(Y8K/T15K)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01513" "DRAVPe01513.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2270.86" "C105H180N34O20S" "ADEHIMNQSY" "LR" "12.01" "7" "0" "7" "3" "7" "-47.78" "-4765" "1.2 hour" ">20 hour" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01514" "CWVRLGRKLLRRLKTPFT" "19" "GBVA10-16(Y8K)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01514.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2243.79" "C103H175N33O21S" "ADEHIMNQSY" "LR" "12.01" "6" "0" "6" "4" "7" "-30" "-4467" "1.2 hour" ">20 hour" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01515" "EWVRLGRELLRRLKEPFT" "18" "GBVA10-17(C1E/Y8E/T15E)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01515" "DRAVPe01515.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2298.72" "C105H172N32O26" "ACDHIMNQSY" "LR" "10.67" "5" "3" "2" "2" "7" "-76.67" "-5826" "1 hour" "30 min" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01516" "EWVRLGRELLRRLKEPFE" "19" "GBVA10-18(C1E/Y8E/T15E/T18E)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "DRAVPe01516.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2326.73" "C106H172N32O27" "ACDHIMNQSTY" "ELR" "8.84" "5" "4" "1" "1" "7" "-92.22" "-6250" "1 hour" "30 min" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01517" "CWVRLGRELLRRLKEPFT" "18" "GBVA10-19(Y8E/T15E)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01517" "DRAVPe01517.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2272.74" "C103H170N32O24S" "ADHIMNQSY" "LR" "10.69" "5" "2" "3" "3" "7" "-43.33" "-5017" "1.2 hour" ">20 hour" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01518" "CWVRLGRELLRRLKTPFT" "18" "GBVA10-20(Y8E)" "Synthetic construct(derived from GBVA non-structutal protein 5A)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "qRT-PCR assay" "[Ref.23175359]hepatitis C virus(Jc1-Luc HCVcc):inhibition of virus entry in Huh7.5.1 cells(IC50>20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01518" "DRAVPe01518.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide inhibits virus entry." "2244.73" "C102H170N32O23S" "ADHIMNQSY" "LR" "11.54" "5" "1" "4" "4" "7" "-27.78" "-4593" "1.2 hour" ">20 hour" ">10 hour" "102.78" "5500" "323.53" "23175359" "J Virol. 2013 Feb;87(3):1649-57." "Liu X, Huang Y, Cheng M, Pan L, Si Y, Li G, Niu Y, Zhao L, Zhao J, Li X, Chen Y, Yang W." "Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A." "10.1128/JVI.02201-12" "Anti-HCV" "DRAVPe01519" "IPESSELTLQELLGEERR" "18" "E6ap18" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=10.5±1.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01519" "DRAVPe01519.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "2099.33" "C89H151N25O33" "ACDFHKMNVWY" "E" "4.33" "2" "5" "-3" "4" "5" "-81.11" "-5326" "20 hour" "30 min" ">10 hour" "108.33" "0" "0" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01520" "YKFACPECPKRFMRSDHLTLHILLHENKK" "29" "E6apc1" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50>1000 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01520" "DRAVPe01520.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "3556.23" "C160H252N46O40S3" "GQVW" "KL" "9.24" "9" "3" "6" "6" "8" "-69.66" "-6383" "2.8 hour" "10 min" "2 min" "70.69" "1615" "57.68" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01521" "YKFACPECPKRFMRSDHLSKHITLHELLGEERR" "33" "E6apc2" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=19.3±2.9μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01521" "DRAVPe01521.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "4028.68" "C177H280N54O48S3" "NQVW" "ELR" "8.82" "10" "5" "5" "7" "8" "-90.91" "-9756" "2.8 hour" "10 min" "2 min" "62.12" "1615" "50.47" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01522" "ALQELLGQWLKDGGPSSGRPPPS" "23" "E6apn1" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=36.8±3.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01522" "DRAVPe01522.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "2390.68" "C106H168N30O33" "CFHIMNTVY" "GLP" "6.11" "2" "2" "0" "7" "6" "-72.61" "-2970" "4.4 hour" ">20 hour" ">10 hour" "72.17" "5500" "250" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01523" "ALQELLGEYIQWLKDGGPSSGRPPPS" "26" "E6apn2" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=26.2±4.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01523" "DRAVPe01523.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "2796.13" "C126H195N33O39" "CFHMNTV" "GLP" "4.68" "2" "3" "-1" "8" "7" "-65.38" "-3173" "4.4 hour" ">20 hour" ">10 hour" "78.85" "6990" "279.6" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01524" "YLQELLGE" "8" "E6apm" "Synthetic construct(derived from E6-associated protein (E6AP))" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "CD spectroscopy" "[Ref.15182185]Human papillomavirus(HPV):inhibition of E6-E6ap interaction(IC50=74.3±1.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01524" "DRAVPe01524.cif" "Linear" "Acetylation" "Amidation" "None" "L" "E6 protein" "No machanism information found in the reference(s) presented in this entry" "964.08" "C44H69N9O15" "ACDFHIKMNPRSTVW" "L" "3.79" "0" "2" "-2" "2" "3" "-10" "-360" "2.8 hour" "10 min" "2 min" "146.25" "1490" "212.86" "15182185" "Biochemistry. 2004 Jun 15;43(23):7421-31. " "Liu Y, Liu Z, Androphy E, Chen J, Baleja JD." "Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus." "10.1021/bi049552a" "Anti-HPV" "DRAVPe01525" "LLPIVGNLLKSLL" "13" "Temporin B" "Rana temporaria(European common frog)" "P79874" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "6GIL" "HSV" "Herpesviridae" "[Ref.29483113]Herpes simplex virus 1 (HSV-1):viral titer inhibition on Vero cells(IC50=2.507 μg/ml);inhibition of HSV-1 replication in HeLa S3 cells(IC50=93 μg/ml);inhibition of HSV-1 replication in HEK-293 cells(IC50=84 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29483113]Vero cells:CC50=90.4μg/ml;##no toxicity was observed at concentrations as high as 50 μg/ml against HeLa S3 and HEK-293 cells." "DRAVPe01525" "DRAVPe01525.cif" "Linear" "Free" "Amidation" "None" "L" "envelope" "Temporin B could disrupt the envelope of virus,and partially affected different stages of the HSV-1 life cycle, including the attachment and the entry of the virus into the host cell, as well as the subsequent postinfection phase." "1392.79" "C67H121N15O16" "ACDEFHMQRTWY" "L" "8.75" "1" "0" "1" "3" "8" "163.85" "2383" "5.5 hour" "3 min" "2 min" "232.31" "0" "0" "29483113" "Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02367-17." "Marcocci ME, Amatore D, Villa S, Casciaro B, Aimola P, Franci G, Grieco P, Galdiero M, Palamara AT, Mangoni ML, Nencioni L. " "The Amphibian Antimicrobial Peptide Temporin B Inhibits In Vitro Herpes Simplex Virus 1 Infection." "10.1128/AAC.02367-17" "Anti-HSV" "DRAVPe01526" "VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR" "32" "RatNP-1" "Rattus norvegicus" "Q62716" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.12543649]HSV-2:inhibition of HSV-2 infection in Vero cells(98.7%±0.7% inhibition at 25 μg/ ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.12543649]No cytotoxic effect on CaSki cells was observed at the concentration of 25 or 100 μg/ml." "DRAVPe01526" "DRAVPe01526.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys31,Cys5 and Cys20,Cys10 and Cys30." "L" "membrane" "NP-1 inactivates HSV and prevents viral entry and cell-to-cell spread. NP-1 blocks fusion events important in HSV acquisition and transmission." "3835.54" "C158H261N59O41S6" "DHKMNPQW" "R" "9.99" "9" "1" "8" "16" "6" "-49.38" "-11502" "100 hour" ">20 hour" ">10 hour" "48.75" "4845" "156.29" "12543649" "Antimicrob Agents Chemother. 2003 Feb;47(2):494-500." "Sinha S, Cheshenko N, Lehrer RI, Herold BC." "NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. " "10.1128/AAC.47.2.494-500.2003" "Anti-HSV" "DRAVPe01527" "FLSGIVGMLGKLF" "13" "Temporin-SHa (temporin SHa; Temporin-1Sa, Temp-1Sa; XXA; UCLL1c; natural AMPs; frog, amphibians, animals)" "Pelophylax saharica, North Africa" "B3KYH4" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(52% inhibition at 10 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 20 μM with a cell viability of 77%" "DRAVPe01527" "DRAVPe01527.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1381.74" "C67H108N14O15S" "ACDEHNPQRTWY" "GL" "8.75" "1" "0" "1" "4" "7" "166.92" "2590" "1.1 hour" "3 min" "2 min" "142.31" "0" "0" "30669255" "Viruses. 2019 Jan 18;11(1):77." "Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. " "Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1." "10.3390/v11010077" "Anti-HSV" "DRAVPe01528" "FLKGIVGMLGKLF" "13" "Temporin-Sha[K3]" "Synthetic construct(derived from Temporin-SHa)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(48% inhibition at 2.5 µM,57% inhibition at 5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 10 μM with a cell viability of 74%." "DRAVPe01528" "DRAVPe01528.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1422.84" "C70H115N15O14S" "ACDEHNPQRSTWY" "GL" "10" "2" "0" "2" "3" "7" "143.08" "2375" "1.1 hour" "3 min" "2 min" "142.31" "0" "0" "30669255" "Viruses. 2019 Jan 18;11(1):77." "Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. " "Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1." "10.3390/v11010077" "Anti-HSV" "DRAVPe01529" "LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES" "37" "LL-37 (human cathelicidin LL-37)" "neutrophils, monocytes; mast cells; lymphocytes, Mesenchymal Stem Cells; islets; skin, sweat; airway surface liquid, saliva; Homo sapiens; Also Pan troglodytes" "P49913" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "2K6O" "HSV, EBOV" "Herpesviridae, Filoviridae" "Plaque assay" "[Ref.30669255]HSV-1:inhibition of HSV-1 replication in human keratinocytes(75% inhibition at 1.25 µM,94% inhibition at 2.5 µM).##[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=4.03 µM);inhibition of viral infection in primary macrophages(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30669255]Significant cytotoxicity was observed on Keratinocyte at the concentration of 5 μM with a cell viability of 80%." "DRAVPe01529" "DRAVPe01529.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "None" "L" "Not found" "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." "4493.32" "C205H340N60O53" "ACHMWY" "K" "10.61" "11" "5" "6" "6" "13" "-72.43" "-11100" "5.5 hour" "3 min" "2 min" "89.46" "0" "0" "30669255##32252021" "Viruses. 2019 Jan 18;11(1):77.##iScience. 2020 Apr 24;23(4):100999." "Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N. ##Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." "Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.##Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection." "10.3390/v11010077##10.1016/j.isci.2020.100999" "Anti-HSV, Anti-EBOV" "DRAVPe01530" "LLGDLLRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES" "37" "LL-37[F5,6L]" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.6 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=18.4 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01530" "DRAVPe01530.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "4425.29" "C199H344N60O53" "ACHMWY" "KL" "10.61" "11" "5" "6" "6" "13" "-67.03" "-10712" "5.5 hour" "3 min" "2 min" "110.54" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01531" "LLGDLLRKSKEKIGKEFKRIVQR" "23" "LL-23" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>35.4 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50>35.4 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01531" "DRAVPe01531.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2755.35" "C124H220N38O32" "ACHMNPTWY" "K" "10.55" "8" "3" "5" "3" "8" "-75.65" "-6537" "5.5 hour" "3 min" "2 min" "114.35" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01532" "KRIVQRIKDFLRNLVPRTES" "20" "KR-20" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>40.5 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50>40.5 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01532" "DRAVPe01532.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2468.93" "C109H190N36O29" "ACGHMWY" "R" "11.55" "6" "2" "4" "3" "7" "-75.5" "-7372" "1.3 hour" "3 min" "2 min" "107" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01533" "SKEKIGKEFKRIVQRIKDFLR" "21" "SK-21" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=10.8 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=22.5 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01533" "DRAVPe01533.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2619.15" "C119H204N36O30" "ACHMNPTWY" "K" "10.55" "8" "3" "5" "2" "7" "-100.48" "-7317" "1.9 hour" ">20 hour" ">10 hour" "88.1" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01534" "FKRIVQRIKDFLR" "13" "FK-13" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=3.4 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=10.4 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01534" "DRAVPe01534.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1719.11" "C80H135N25O17" "ACEGHMNPSTWY" "R" "11.72" "5" "1" "4" "0" "6" "-43.85" "-4536" "1.1 hour" "3 min" "2 min" "112.31" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01535" "RLFDKIRQVIRKF" "13" "Retro-FK-13" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>58.1 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=33.7 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01535" "DRAVPe01535.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1719.11" "C80H135N25O17" "ACEGHMNPSTWY" "R" "11.72" "5" "1" "4" "0" "6" "-43.85" "-4536" "1 hour" "2 min" "2 min" "112.31" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01536" "KRIVQRIKDFLR" "12" "KR-12" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>63.5 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50>63.5 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01536" "DRAVPe01536.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1571.93" "C71H126N24O16" "ACEGHMNPSTWY" "R" "11.72" "5" "1" "4" "0" "5" "-70.83" "-4834" "1.3 hour" "3 min" "2 min" "121.67" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01537" "SKVNGQSGRMEFFWTILK" "18" "HA-pep25" "Synthetic construct(derived from influenza viral HA)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Infection assay" "[Ref.27623031]Influenza A Virus(A/PuertoRico/8/1934):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=34.0 ± 11.5μM);##AInfluenza A Virus(/Vietnam/1203/2004):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=12.0 ± 2.1μM);##influenza A virus(A/Goose/Qinghai/59/2005):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=34.8 ± 1.5μM);##influenza A virus(A/Duck/Anhui/SC702/2013):inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(IC50=51.0 ± 0.6μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01537.cif" "Linear" "Free" "Free" "None" "L" "HA receptor binding domain (RBD)" "Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry." "2128.48" "C97H150N26O26S" "ACDHPY" "FGKS" "9.99" "3" "1" "2" "6" "6" "-37.78" "-2798" "1.9 hour" ">20 hour" ">10 hour" "59.44" "5500" "323.53" "27623031" "ACS Infect Dis. 2016 Mar 11;2(3):187-93" "Chen Q, Guo Y" "Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor" "10.1021/acsinfecdis.5b00139" "Anti-Influenza A virus" "DRAVPe01538" "GFKRIVQRiKDFLRNLV" "17" "GF-17d1" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>47.5 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=22.7 μM.(TC50:the concentration that reduced cell viability by 50%)" "No predicted structure available" "DRAVPe01538.cif" "Linear" "Free" "Free" "None" "Mixed(D-Ile9)" "Not found" "No machanism information found in the reference(s) presented in this entry" "2102.56" "C91H151N29O20" "ACEHMPSTWY" "R" "11.72" "5" "1" "4" "2" "7" "-35.88" "-4702" "30 hour" ">20 hour" ">10 hour" "102.94" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01539" "GFKRIVQRiKDFlRNLV" "17" "GF-17d2" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>47.5μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50>47.5 μM.(TC50:the concentration that reduced cell viability by 50%)" "No predicted structure available" "DRAVPe01539.cif" "Linear" "Free" "Free" "None" "Mixed(D-Ile9,D-Leu13)" "Not found" "No machanism information found in the reference(s) presented in this entry" "2102.56" "C85H138N28O18" "ACEHMPSTWY" "R" "11.72" "5" "1" "4" "2" "6" "-58.24" "-5194" "30 hour" ">20 hour" ">10 hour" "80" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01540" "GIKEFKRIVQRIKDFLRNLV" "20" "GI-20" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.08 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=22.7 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01540" "DRAVPe01540.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2473.01" "C114H194N34O27" "ACHMPSTWY" "IKR" "11" "6" "2" "4" "2" "9" "-22.5" "-4954" "30 hour" ">20 hour" ">10 hour" "126.5" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01541" "GIKEXKRIVQRIKDFLRNLV" "20" "GI-20X17" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>40.6 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=7.3 μM.(TC50:the concentration that reduced cell viability by 50%)" "No predicted structure available" "DRAVPe01541.cif" "Linear" "Free" "Free" "The 'X' at position 5 is phenylglycine" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2437.16" "C105H183N33O25" "ACHMPSTWY" "IKR" "11" "6" "2" "4" "2" "8" "-36.5" "-5252" "30 hour" ">20 hour" ">10 hour" "126.5" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01542" "GIKEWKRIVQRIKDFLRNLV" "20" "GI-20W17" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=7.4 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=23.6 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01542" "DRAVPe01542.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2512.04" "C116H195N35O27" "ACHMPSTY" "IKR" "11" "6" "2" "4" "2" "9" "-41" "-5019" "30 hour" ">20 hour" ">10 hour" "126.5" "5500" "289.47" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01543" "GIKQFKRIVQRIKDFLRNLV" "20" "GI-20Q16" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.91 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=13.7 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01543" "DRAVPe01543.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2472.02" "C114H195N35O26" "ACEHMPSTWY" "IKR" "11.73" "6" "1" "5" "2" "9" "-22.5" "-4827" "30 hour" ">20 hour" ">10 hour" "126.5" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01544" "GIKEFKREFQRIKDFLRNLV" "20" "GI-20EF" "Synthetic construct(derived from human cathelicidin LL-37)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=1.6 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=9.9 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01544" "DRAVPe01544.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2537.01" "C117H190N34O29" "ACHMPSTWY" "FKR" "10.27" "6" "3" "3" "2" "8" "-69.5" "-6233" "30 hour" ">20 hour" ">10 hour" "92.5" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01545" "GRFKRFRKKFKKLFKKIS" "18" "BMAP-18" "Synthetic construct(derived from BMAP-27)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.35 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=8.45 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01545" "DRAVPe01545.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2342.95" "C113H188N34O20" "ACDEHMNPQTVWY" "K" "12.32" "10" "0" "10" "2" "6" "-125" "-6431" "30 hour" ">20 hour" ">10 hour" "43.33" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01546" "GRFKRFRKPFKKLFKKIS" "18" "BMAP-18P9" "Synthetic construct(derived from BMAP-27)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=3.20 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=18.9 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01546" "DRAVPe01546.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2311.89" "C112H183N33O20" "ACDEHMNQTVWY" "K" "12.32" "9" "0" "9" "2" "6" "-112.22" "-5876" "30 hour" ">20 hour" ">10 hour" "43.33" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01547" "GRFKRXRKKXKKLFKKIS" "18" "BMAP-18X6X10" "Synthetic construct(derived from BMAP-27)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.68 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=10.2 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01547" "DRAVPe01547.cif" "Linear" "Free" "Free" "The 'X' at position 6 and 10 are phenylglycine" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2271.26" "C95H166N32O16" "ACDEHMNPQTVWY" "K" "12.32" "10" "0" "10" "2" "4" "-156.11" "-7027" "30 hour" ">20 hour" ">10 hour" "43.33" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01548" "GRFKRIRKKLKKLFKKIS" "18" "BMAP-18I6L10" "Synthetic construct(derived from BMAP-27)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>44.0 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50=2.79 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01548" "DRAVPe01548.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2274.92" "C107H192N34O20" "ACDEHMNPQTVWY" "K" "12.32" "10" "0" "10" "2" "6" "-110" "-6043" "30 hour" ">20 hour" ">10 hour" "86.67" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01549" "GRFKRFRKKFKKLFK" "15" "BMAP-15" "Synthetic construct(derived from BMAP-27)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50>49.6 μM).(EC50:50% effective concentration for inhibition of virus replication)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.18591279]CEM-SS cells:TC50>49.6 μM.(TC50:the concentration that reduced cell viability by 50%)" "DRAVPe01549" "DRAVPe01549.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2014.54" "C98H160N30O16" "ACDEHIMNPQSTVWY" "K" "12.32" "9" "0" "9" "1" "5" "-148.67" "-6028" "30 hour" ">20 hour" ">10 hour" "26" "0" "0" "18591279" "Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. " "Wang G, Watson KM, Buckheit RW Jr. " "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins." "10.1128/AAC.00452-08" "Anti-HIV" "DRAVPe01550" "GGLRSLGRKILRAWKKYGPIIVPIIRIG" "28" "BMAP-28 (BMAP28, bovine myeloid antimicrobial peptide 28; natural AMPs; cathelicidin-5, cattle, ruminant, mammals, animals; BBMm;ZZP; UCLL1; Derivatives: mBMAP-28" "Cow Bos taurus" "P54229" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2NDC" "HSV,PRCV" "Herpesviridae, Coronaviridae" "[Ref.15019203]Herpes simplex virus type 1(HSV-1):72% protection from HSV-1 and 72% inhibited of viral replication in Vero cells at 5 μM;##porcine respiratory corona virus(PRCV):did not prove active against PRCV at 0.5–50 μM in Swine Testicular (ST) cells." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15019203]17% cytotoxic against Vero76 cells at 5 μM;95% cytotoxic against Vero76 cells at 50 μM." "DRAVPe01550" "DRAVPe01550.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3131.89" "C147H252N44O31" "CDEFHMNQT" "I" "12.02" "7" "0" "7" "7" "12" "23.21" "-2271" "30 hour" ">20 hour" ">10 hour" "139.29" "6990" "258.89" "15019203" "Peptides. 2003 Nov;24(11):1723-31." "Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M. " "In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs." "10.1016/j.peptides.2003.07.025" "Anti-HSV,Anti-PRCV" "DRAVPe01551" "FFPVIGRILNGIL" "13" "Temporin G" "European common frog, Rana temporaria" "P79875" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "influenza virus,Sendai virus" "Orthomyxoviridae, Paramyxoviridae" "[Ref.33538061]influenza virus:inhibition of replication in A549 cells(IC50=13 μM);##Sendai virus:inhibit the replication of Sendai virus in A549 cells." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33538061]A549 cells:CC50=73 μM;" "DRAVPe01551" "DRAVPe01551.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "Temporin G block the conformational rearrangements of HA2 subunit, which are essential for the viral envelope fusion with intracellular endocytic vesicles, thereby neutralizing the virus entry into the host cell. " "1458.81" "C72H115N17O15" "ACDEHKMQSTWY" "I" "9.75" "1" "0" "1" "3" "8" "157.69" "1492" "1.1 hour" "3 min" "2 min" "172.31" "0" "0" "33538061" "FASEB J. 2021 Feb;35(2):e21358. " "De Angelis M, Casciaro B, Genovese A, Brancaccio D, Marcocci ME, Novellino E, Carotenuto A, Palamara AT, Mangoni ML, Nencioni L. " "Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: Insights into biological activity and mechanism of action. " "10.1096/fj.202001885RR" "Anti-Influenza virus,Anti-Sendai virus" "DRAVPe01552" "MKTFSVAVAVAIVLAFICTQESSALPVTGVEELVELVSSDDPVADHQELPVELGERLFNIRKKRASPKCTPYCYPTRDGVFCGVRCDF" "88" "EC-hepcidin1" "Epinephelus coioides" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "SGIV" "Iridoviridae" "[Ref.21145974]Singapore grouper iridovirus (SGIV):strongly inhibit the replication of SGIV.(EC-hepcidin1 is more active than EC-hepcidin2)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01552" "DRAVPe01552.cif" "Cyclic" "Free" "Free" "There are two pairs of disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "9665.17" "C429H682N112O129S6" "W" "V" "4.99" "10" "12" "-2" "23" "34" "17.73" "-10622" "30 hour" ">20 hour" ">10 hour" "91.82" "3230" "37.13" "21145974" "Fish Shellfish Immunol. 2011 Feb;30(2):559-68. " "Zhou JG, Wei JG, Xu D, Cui HC, Yan Y, Ou-Yang ZL, Huang XH, Huang YH, Qin QW." "Molecular cloning and characterization of two novel hepcidins from orange-spotted grouper, Epinephelus coioides. " "10.1016/j.fsi.2010.11.021" "Anti-SGIV" "DRAVPe01553" "MKTFSVAVAVAVVLAFICTQESSALPVTGIEELVEPVSSDNNDNHQGLPVELRERLVNIRKKRAPTDCIPYCYPTGDGFHCGVTCRF" "87" "EC-hepcidin2" "Epinephelus coioides" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SGIV" "Iridoviridae" "[Ref.21145974]Singapore grouper iridovirus (SGIV):strongly inhibit the replication of SGIV.(EC-hepcidin1 is more active than EC-hepcidin2)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01553" "DRAVPe01553.cif" "Cyclic" "Free" "Free" "There are two pairs of disulfide bonds." "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "9525.93" "C418H665N115O127S6" "W" "V" "5.55" "10" "10" "0" "27" "31" "5.06" "-11678" "30 hour" ">20 hour" ">10 hour" "88.39" "3230" "37.56" "21145974" "Fish Shellfish Immunol. 2011 Feb;30(2):559-68. " "Zhou JG, Wei JG, Xu D, Cui HC, Yan Y, Ou-Yang ZL, Huang XH, Huang YH, Qin QW." "Molecular cloning and characterization of two novel hepcidins from orange-spotted grouper, Epinephelus coioides. " "10.1016/j.fsi.2010.11.021" "Anti-SGIV" "DRAVPe01554" "ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ" "34" "Dermaseptin-1" "Phyllomedusa sauvagei (Sauvage's leaf frog)" "P24302##P80277" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CCV,FV3" "Herpesviridae, Iridoviridae" "[Ref.15193922]Channel Catfish virus(CCV): inhibition of CCV infection in catfish ovary(CCO) cells(reduce viral infectivity by 50% at 3 μM);##Frog Virus 3(FV3): inhibition of FV3 infection in fathead minnow(FHM) cells(reduce viral infectivity by 50% at 12 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.11601906]No cytotoxicity against catfish ovary(CCO) cells at 0.1-11.4 μM." "DRAVPe01554" "DRAVPe01554.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "3455.09" "C152H257N43O44S2" "CEFNPRVY" "A" "10" "5" "1" "4" "9" "15" "18.53" "-555" "4.4 hour" ">20 hour" ">10 hour" "92.35" "5500" "166.67" "15193922" "Virology. 2004 Jun 1;323(2):268-75." "Chinchar VG, Bryan L, Silphadaung U, Noga E, Wade D, Rollins-Smith L." "Inactivation of viruses infecting ectothermic animals by amphibian and piscine antimicrobial peptides." "10.1016/j.virol.2004.02.029" "Anti-CCV,Anti-FV3" "DRAVPe01555" "ALWMTLLKKVLKAAAKAALNAVLVGANA" "28" "Dermaseptin-4 (DS IV; Dermaseptin-S4, DS4; Frogs, amphibians, animals)" "Phyllomedusa sauvagei (Sauvage's leaf frog)" "P80280" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV,HIV" "Herpesviridae, Retroviridae" "Chemiluminescence Reporter Gene Assay" "[Ref.23161023]HSV-2 acyclovir-sensitive strain(911411):inhibition the cytopathic effect(CPE) of HSV-2 in Vero cells(EC50=2.10 μM);##HSV-2 acyclovir-resistant strain(ROI2):inhibition of cytopathic effet(CPE) of HSV-2 in Vero cells(EC50=6 μM). ##[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=2 µM)." "[Ref:11850249]IC50=20 μM against human erythrocytes" "[Ref.23161023]Vero cells:CC50=7.50 μM.##[Ref.15780876]P4-CCR5 cells:CC50=4.5 μM." "DRAVPe01555" "DRAVPe01555.cif" "Linear" "Free" "Free" "None" "L" "viral membrane" "exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. " "2850.55" "C132H229N35O32S" "CDEFHIPQRSY" "A" "10.48" "4" "0" "4" "4" "19" "103.21" "2550" "4.4 hour" ">20 hour" ">10 hour" "146.79" "5500" "203.7" "11850249##23161023##15780876" "Antimicrob Agents Chemother. 2002 Mar;46(3):689-694.##J Med Virol. 2013 Feb;85(2):272-81.##Virology. 2005 Apr 10;334(2):264-75. " "Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A.##Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. ##Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F." "Antibacterial properties of dermaseptin S4 derivatives with in vivo activity.## In vitro antiviral activity of dermaseptin S(4) and derivatives from amphibian skin against herpes simplex virus type 2.##The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. " "10.1128/AAC.46.3.689-694.2002##10.1002/jmv.23450##10.1016/j.virol.2005.02.002" "Anti-HSV,Anti-HIV" "DRAVPe01556" "GFCRCLCRRGVCRCICTR" "18" "RTD-1(Rhesus theta-defensin 1)" "Macaca mulatta (Rhesus macaque)" "P82271##P82270##Q9TU01" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1HVZ" "HIV" "Retroviridae" "[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=3.63 ± 0.85 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=0.94 ± 0.59 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=3.98 ± 0.70 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=2.55 ± 1.92 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=0.94 ± 0.42 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=1.15 ± 0.59 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=2.38 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01556" "DRAVPe01556.cif" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2105.62" "C82H145N33O20S6" "ADEHKMNPQSWY" "C" "9.3" "5" "0" "5" "9" "4" "35" "-5075" "30 hour" ">20 hour" ">10 hour" "59.44" "375" "22.06" "15210812" "J Immunol. 2004 Jul 1;173(1):515-20." "Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI." "Activity of alpha- and theta-defensins against primary isolates of HIV-1. " "10.4049/jimmunol.173.1.515" "Anti-HIV" "DRAVPe01557" "GVCRCLCRRGVCRCLCRR" "18" "RTD-2 (RTD 2, rhesus theta-defensin 2)" "Macaca mulatta (Rhesus macaque)" "P82271" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=5.20 ± 1.58 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.78± 0.57 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=6.74 ± 1.27 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=3.66 ± 0.69 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=3.02 ± 0.10 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.08 ± 1.35 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=5.16 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01557" "DRAVPe01557.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2112.66" "C80H150N36O19S6" "ADEFHIKMNPQSTWY" "CR" "9.69" "6" "0" "6" "8" "4" "17.78" "-6204" "30 hour" ">20 hour" ">10 hour" "75.56" "375" "22.06" "15210812" "J Immunol. 2004 Jul 1;173(1):515-20." "Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI." "Activity of alpha- and theta-defensins against primary isolates of HIV-1. " "10.4049/jimmunol.173.1.515" "Anti-HIV" "DRAVPe01558" "GFCRCICTRGFCRCICTR" "18" "RTD-3 (rhesus theta defensin 3)" "Macaca mulatta (Rhesus macaque)" "P82270,Q9TU01" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=3.26 ± 0.58 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.74± 0.40 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=4.31 ± 0.90 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=2.09 ± 0.60 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=2.31 ± 0.21 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.04 ± 0.64 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=0.89 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01558" "DRAVPe01558.cif" "Cyclic" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2098.58" "C84H140N30O21S6" "ADEHKLMNPQSVWY" "C" "9.01" "4" "0" "4" "10" "4" "52.22" "-3946" "30 hour" ">20 hour" ">10 hour" "43.33" "375" "22.06" "15210812" "J Immunol. 2004 Jul 1;173(1):515-20." "Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI." "Activity of alpha- and theta-defensins against primary isolates of HIV-1. " "10.4049/jimmunol.173.1.515" "Anti-HIV" "DRAVPe01559" "GICRCICGRGICRCICGR" "18" "Retrocyclin-1 (RC1)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=5.51 ± 1.13 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=4.15± 0.99 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=5.33± 0.80 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=4.57 ± 0.53 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=5.86 ± 0.95 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=7.24 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01559" "DRAVPe01559.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "1942.44" "C74H136N30O19S6" "ADEFHKLMNPQSTVWY" "C" "9.01" "4" "0" "4" "10" "4" "74.44" "-2856" "30 hour" ">20 hour" ">10 hour" "86.67" "375" "22.06" "15210812" "J Immunol. 2004 Jul 1;173(1):515-20." "Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI." "Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1" "10.4049/jimmunol.173.1.515" "DRAVPa0039" "Anti-HIV" "DRAVPe01560" "GICRCICGRRICRCICGR" "18" "Retrocyclin-2 (RC2; HTD-2)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "2LZI" "HIV" "Retroviridae" "[Ref.15210812]HIV-1 A:inhibition of infection in JC53-BL cells(IC50=2.30 ± 1.41 µg/ml);##HIV-1 B:inhibition of infection in JC53-BL cells(IC50=1.05± 0.28 µg/ml);##HIV-1 C:inhibition of infection in JC53-BL cells(IC50=3.32 ± 0.76 µg/ml);##HIV-1 CRF01_AE:inhibition of infection in JC53-BL cells(IC50=1.14 ± 0.29 µg/ml);##HIV-1 D:inhibition of infection in JC53-BL cells(IC50=3.17 ± 1.53 µg/ml);##HIV-1 G:inhibition of infection in JC53-BL cells(IC50=3.06 ± 0.43 µg/ml);##HIV-1 BF:inhibition of infection in JC53-BL cells(IC50=0.18 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01560" "DRAVPe01560.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2041.58" "C78H145N33O19S6" "ADEFHKLMNPQSTVWY" "C" "9.3" "5" "0" "5" "9" "4" "51.67" "-4442" "30 hour" ">20 hour" ">10 hour" "86.67" "375" "22.06" "15210812" "J Immunol. 2004 Jul 1;173(1):515-20." "Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI." "Activity of alpha- and theta-defensins against primary isolates of HIV-1." "10.4049/jimmunol.173.1.515" "DRAVPa0166" "Anti-HIV" "DRAVPe01561" "GICRCICGKGICRCICGR" "18" "RC-101" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50=2.3 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=0.8 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=1.7 µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=3.6 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=4.0 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=0.9 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=0.5 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=2.8 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50=8.5 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50=4.9 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=1.5 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=1.0 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=0.8 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=2.2 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=0.6µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=3.0 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01561" "DRAVPe01561.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "1914.43" "C74H136N28O19S6" "ADEFHLMNPQSTVWY" "C" "8.98" "4" "0" "4" "10" "4" "77.78" "-1919" "30 hour" ">20 hour" ">10 hour" "86.67" "375" "22.06" "15588337" "AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65." "Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. " "RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates." "10.1089/aid.2004.20.1157" "DRAVPa0040" "Anti-HIV" "DRAVPe01562" "GICRCICGRYICRCICGR" "18" "RC-115" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=2.1 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=5.4 µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=4.53 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=4.5 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=2.7 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=1.9 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=5.4 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=>10 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=3.9 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=4.1 µg/ml);##HIV-1 94UG114:inhibition of virus replication in JC53-BL cells(IC50=3.5 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=3.4 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=5.0 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=3.3µg/ml);##HIV-1 RU132:inhibition of virus replication in JC53-BL cells(IC50=3.0µg/ml);##HIV-1 RU570:inhibition of virus replication in JC53-BL cells(IC50= 5.8µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=4.7 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=4.5 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=4.6 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01562" "DRAVPe01562.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys16,Cys5 and Cys14,Cys7 and Cys12." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2048.57" "C81H142N30O20S6" "ADEFHKLMNPQSTVW" "C" "8.98" "4" "0" "4" "10" "4" "69.44" "-2964" "30 hour" ">20 hour" ">10 hour" "86.67" "1865" "109.71" "15588337" "AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65." "Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. " "RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates." "10.1089/aid.2004.20.1157" "DRAVPa0164" "Anti-HIV" "DRAVPe01563" "RYICRCICGRGICRCICG" "18" "RC-116" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "[Ref.15588337]HIV-1 92US714:inhibition of virus replication in JC53-BL cells(IC50=9.5 µg/ml);##HIV-1 93US151:inhibition of virus replication in JC53-BL cells(IC50=1.3 µg/ml);##HIV-1 92HT593:inhibition of virus replication in JC53-BL cells(IC50=3.7 µg/ml);##HIV-1 92US727:inhibition of virus replication in JC53-BL cells(IC50=4.6µg/ml);##HIV-1 5148-1382:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 5157-1326:inhibition of virus replication in JC53-BL cells(IC50=4.8 µg/ml);##HIV-1 5157-35097:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 193317:inhibition of virus replication in JC53-BL cells(IC50=7.1 µg/ml);##HIV-1 196554:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 196531:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 92UG037:inhibition of virus replication in JC53-BL cells(IC50=3.1 µg/ml);##HIV-1 192431:inhibition of virus replication in JC53-BL cells(IC50=2.4 µg/ml);##HIV-1 193358:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 98CN009:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 98TZ017:inhibition of virus replication in JC53-BL cells(IC50>10 µg/ml);##HIV-1 93UG053:inhibition of virus replication in JC53-BL cells(IC50=6.6 µg/ml);##HIV-1 92UG005:inhibition of virus replication in JC53-BL cells(IC50=5.2 µg/ml);##HIV-1 94UG114:inhibition of virus replication in JC53-BL cells(IC50=4.2 µg/ml);##HIV-1 HM14:inhibition of virus replication in JC53-BL cells(IC50=3.3 µg/ml);##HIV-1 93TH060:inhibition of virus replication in JC53-BL cells(IC50=6.5 µg/ml);##HIV-1 HM16:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 RU132:inhibition of virus replication in JC53-BL cells(IC50=4.9 µg/ml);##HIV-1 RU570:inhibition of virus replication in JC53-BL cells(IC50=9.6 µg/ml);##HIV-1 92BR023:inhibition of virus replication in JC53-BL cells(IC50=2.9 µg/ml);##HIV-1 92RW009:inhibition of virus replication in JC53-BL cells(IC50=7.8 µg/ml);##HIV-1 92RW024:inhibition of virus replication in JC53-BL cells(IC50=6.6 µg/ml);##HIV-1 93UG059:inhibition of virus replication in JC53-BL cells(IC50=5.7 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "DRAVPe01563" "DRAVPe01563.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys4 and Cys17,Cys6 and Cys15,Cys8 and Cys13." "L" "gp120,CD4" "The peptide binds to gp120 and CD4, thereby inhibiting HIV entry." "2048.57" "C81H142N30O20S6" "ADEFHKLMNPQSTVW" "C" "8.98" "4" "0" "4" "10" "4" "69.44" "-2964" "1 hour" "2 min" "2 min" "86.67" "1865" "109.71" "15588337" "AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65." "Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI. " "RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates." "10.1089/aid.2004.20.1157" "DRAVPa0165" "Anti-HIV" "DRAVPe01564" "RPRLSHKGPMPF" "12" "Apelin-12" "Synthetic construct" "Q9TUI9##K7GLR4" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=63.0 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01564" "DRAVPe01564.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1422.71" "C64H103N21O14S" "ACDEINQTVWY" "P" "12.01" "4" "0" "4" "2" "2" "-113.33" "-3226" "1 hour" "2 min" "2 min" "32.5" "0" "0" "10802050" "FEBS Lett. 2000 May 4;473(1):15-8." "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H." "Apelin peptides block the entry of human immunodeficiency virus (HIV)." "10.1016/s0014-5793(00)01487-3" "Anti-HIV" "DRAVPe01565" "QRPRLSHKGPMPF" "13" "Apelin-13" "Bos taurus (Bovine)" "Q9TUI9##A0A484GMR2##A0A5N3XG03##A0A2Y9M6A9##A0A5G2R3Z5##A0A2Y9SZ03##A0A2U4A1K6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=26.0 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01565" "DRAVPe01565.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1550.84" "C69H111N23O16S" "ACDEINTVWY" "P" "12.01" "4" "0" "4" "2" "2" "-131.54" "-3780" "0.8 hour" "10 min" ">10 hour" "30" "0" "0" "10802050" "FEBS Lett. 2000 May 4;473(1):15-8." "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H." "Apelin peptides block the entry of human immunodeficiency virus (HIV)." "10.1016/s0014-5793(00)01487-3" "Anti-HIV" "DRAVPe01566" "KFRRQRPRLSHKGPMPF" "17" "Apelin-17" "Synthetic construct" "Q9TUI9##K7GLR4" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=4.8 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01566" "DRAVPe01566.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "2138.57" "C96H156N34O20S" "ACDEINTVWY" "R" "12.48" "7" "0" "7" "2" "3" "-160" "-7021" "1.3 hour" "3 min" "2 min" "22.94" "0" "0" "10802050" "FEBS Lett. 2000 May 4;473(1):15-8." "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H." "Apelin peptides block the entry of human immunodeficiency virus (HIV)." "10.1016/s0014-5793(00)01487-3" "Anti-HIV" "DRAVPe01567" "LVQPRGPRSGPGPWQGGRRKFRRQRPRLSHKGPMPF" "36" "Apelin-36" "Bos taurus (Bovine)" "Q9TUI9##A0A484GMR2##A0A5N3XG03##A0A2Y9M6A9##A0A5G2R3Z5##A0A2Y9SZ03##A0A2U4A1K6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.10802050]HIV:Inhibition of HIV infection in NP-2/CD4/APJ cells(IC50=0.3 μg/ml).##[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01567" "DRAVPe01567.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "4178.89" "C185H298N68O42S" "ACDEINTY" "R" "12.85" "11" "0" "11" "8" "6" "-150.83" "-12838" "5.5 hour" "3 min" "2 min" "29.72" "5500" "157.14" "10802050##11090199" "FEBS Lett. 2000 May 4;473(1):15-8.##J Virol. 2000 Dec;74(24):11972-6." "Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.##Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin peptides block the entry of human immunodeficiency virus (HIV).##Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1016/s0014-5793(00)01487-3##10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01568" "RRQRPRLSHKGPMPF" "15" "Apelin-15" "Synthetic construct" "Q9TUI9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=12μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01568" "DRAVPe01568.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1863.22" "C81H135N31O18S" "ACDEINTVWY" "R" "12.48" "6" "0" "6" "2" "2" "-174" "-6764" "1 hour" "2 min" "2 min" "26" "0" "0" "11090199" "J Virol. 2000 Dec;74(24):11972-6." "Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01569" "RRKFRRQRPRLSHKGPMPF" "19" "Apelin-19" "Synthetic construct" "Q9TUI9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=4.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01569" "DRAVPe01569.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "2450.95" "C108H180N42O22S" "ACDEINTVWY" "R" "12.7" "9" "0" "9" "2" "3" "-190.53" "-10005" "1 hour" "2 min" "2 min" "20.53" "0" "0" "11090199" "J Virol. 2000 Dec;74(24):11972-6." "Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01570" "RRQRPRLSHKGPM" "13" "Apelin-15-(63-75)-peptide" "Synthetic construct" "Q9TUI9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=3.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01570" "DRAVPe01570.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1618.93" "C67H119N29O16S" "ACDEFINTVWY" "R" "12.48" "6" "0" "6" "2" "1" "-210" "-7062" "1 hour" "2 min" "2 min" "30" "0" "0" "11090199" "J Virol. 2000 Dec;74(24):11972-6." "Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01571" "RRQRPRLSHKGPX" "13" "[Met(O)75]apelin-15-(63-75)-peptide" "Synthetic construct" "Q9TUI9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=45 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "" "Linear" "Free" "Free" "The 'X' at position 13 indicates oxidized methionine." "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1599.06" "C62H108N28O14" "ACDEFIMNTVWY" "R" "12.48" "6" "0" "6" "2" "1" "-224.62" "-7297" "1 hour" "2 min" "2 min" "30" "0" "0" "11090199" "J Virol. 2000 Dec;74(24):11972-6." "Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01572" "RRQRPRLSHKGP" "12" "Apelin-15-(63-74)-peptide" "Synthetic construct" "Q9TUI9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Reverse transcriptase assay" "[Ref.11090199]HIV-1:inhibition of HIV-1 infection in CD4 APJ cells(IC50=37 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01572" "DRAVPe01572.cif" "Linear" "Free" "Free" "None" "L" "APJ receptor" "APJ receptor could help HIV virus enter the target cells. The peptide can bind with APJ receptor and block virus entry, thus inhibiting virus infection." "1487.73" "C62H110N28O15" "ACDEFIMNTVWY" "R" "12.48" "6" "0" "6" "2" "1" "-243.33" "-7297" "1 hour" "2 min" "2 min" "32.5" "0" "0" "11090199" "J Virol. 2000 Dec;74(24):11972-6." "Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J." "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. " "10.1128/jvi.74.24.11972-11976.2000" "Anti-HIV" "DRAVPe01573" "GRKKRRQRRR" "10" "TAT(48-57)" "Synthetic construct" "P04610" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "infection inhibition assay" "[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.094 mg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22319541]No cytotoxicity against P4-R5 MAGI cells up to 100 μM." "DRAVPe01573" "DRAVPe01573.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1396.67" "C55H109N31O12" "ACDEFHILMNPSTVWY" "R" "12.7" "8" "0" "8" "1" "0" "-387" "-10522" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "22319541" "Int J Pept. 2012;2012:349427." "Keogan S, Passic S, Krebs FC." "Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat." "10.1155/2012/349427" "DRAVPa1019" "Anti-HIV" "DRAVPe01574" "RRKKRRQRRR" "10" "TAT(48-57)[G1R]" "Synthetic construct" "P04610" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "infection inhibition assay" "[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.065 mg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01574" "DRAVPe01574.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1495.81" "C59H118N34O12" "ACDEFGHILMNPSTVWY" "R" "12.78" "9" "0" "9" "0" "0" "-428" "-12108" "1 hour" "2 min" "2 min" "0" "0" "0" "22319541" "Int J Pept. 2012;2012:349427." "Keogan S, Passic S, Krebs FC." "Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat." "10.1155/2012/349427" "Anti-HIV" "DRAVPe01575" "GRKKRRRRRR" "10" "TAT(48-57)[Q7R]" "Synthetic construct" "P04610" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "infection inhibition assay" "[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.071 mg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01575" "DRAVPe01575.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1424.73" "C56H113N33O11" "ACDEFHILMNPQSTVWY" "R" "12.78" "9" "0" "9" "1" "0" "-397" "-11460" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "22319541" "Int J Pept. 2012;2012:349427." "Keogan S, Passic S, Krebs FC." "Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat." "10.1155/2012/349427" "Anti-HIV" "DRAVPe01576" "RRKKRRRRRR" "10" "TAT(48-57)[G1R,Q7R]" "Synthetic construct" "P04610" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "infection inhibition assay" "[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.025 mg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01576" "DRAVPe01576.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1523.86" "C60H122N36O11" "ACDEFGHILMNPQSTVWY" "R" "12.85" "10" "0" "10" "0" "0" "-438" "-13046" "1 hour" "2 min" "2 min" "0" "0" "0" "22319541" "Int J Pept. 2012;2012:349427." "Keogan S, Passic S, Krebs FC." "Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat." "10.1155/2012/349427" "Anti-HIV" "DRAVPe01577" "RRRRRRRRRR" "10" "R-10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "infection inhibition assay" "[Ref.22319541]HIV-1 IIIB:inhibition of virus infection in P4-R5 MAGI cells(EC50=0.014 mg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01577" "DRAVPe01577.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1579.89" "C60H122N40O11" "ACDEFGHIKLMNPQSTVWY" "R" "12.95" "10" "0" "10" "0" "0" "-450" "-14920" "1 hour" "2 min" "2 min" "0" "0" "0" "22319541" "Int J Pept. 2012;2012:349427." "Keogan S, Passic S, Krebs FC." "Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat." "10.1155/2012/349427" "Anti-HIV" "DRAVPe01578" "KGEAMHGQVDCSPGIWQLDC" "20" "#4330 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1:inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(IC50=4 μM);inhibition of reverse transcriptase(DNA-dependent DNA polymerase) activity(IC50=6.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01578" "DRAVPe01578.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "2174.45" "C91H140N26O30S3" "FNRTY" "G" "4.54" "2" "3" "-1" "6" "5" "-39.5" "-2319" "1.3 hour" "3 min" "2 min" "58.5" "5625" "296.05" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01579" "ASCDKCQLKGEAMHG" "15" "#5649 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(91.5 ± 2.5% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01579" "DRAVPe01579.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1577.81" "C62H104N20O22S3" "FINPRTVWY" "ACGK" "6.77" "3" "2" "1" "5" "3" "-58.67" "-2490" "4.4 hour" ">20 hour" ">10 hour" "39.33" "125" "8.93" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01580" "KCQLKGEAMHGQVDC" "15" "#5650 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(63± 3% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01580" "DRAVPe01580.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1646.91" "C66H111N21O22S3" "FINPRSTWY" "CGKQ" "6.73" "3" "2" "1" "4" "3" "-60.67" "-2481" "1.3 hour" "3 min" "2 min" "52" "125" "8.93" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01581" "KGEAMHGQVDCSPGI" "15" "#5651 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(99 ± 6% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01581" "DRAVPe01581.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1528.72" "C62H101N19O22S2" "FLNRTWY" "G" "5.32" "2" "2" "0" "5" "3" "-42" "-1746" "1.3 hour" "3 min" "2 min" "52" "0" "0" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01582" "MHGQVDCSPGIWQLD" "15" "#5652 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(79 ± 3% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01582" "DRAVPe01582.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1685.89" "C72H108N20O23S2" "AEFKNRTY" "DGQ" "4.2" "1" "2" "-1" "4" "4" "-29.33" "-1486" "30 hour" ">20 hour" ">10 hour" "71.33" "5500" "392.86" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01583" "VDCSPGIWQLDCTHL" "15" "#5653 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(58 ± 3% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01583" "DRAVPe01583.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1686.92" "C73H111N19O23S2" "AEFKMNRY" "CDL" "4.2" "1" "2" "-1" "5" "5" "21.33" "-898" "100 hour" ">20 hour" ">10 hour" "97.33" "5625" "401.79" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01584" "PGIWQLDCTHLEGKI" "15" "#5654 derived from HIV-1 integrase" "Synthetic construct" "P04587" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "Assay for the enzymatic activities of RT" "[Ref.17257575]HIV-1: inhibition of reverse transcriptase(RNA-dependent DNA polymerase) activity(62.5 ± 0.5% residual DNA polymerase activity at 30 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01584" "DRAVPe01584.cif" "Linear" "Free" "Free" "None" "L" "Reverse Transcriptase" "The peptide could bind the reverse transcriptase and inhibits its DNA-polymerase activity and thus inhibits virus replication." "1709.98" "C77H120N20O22S" "AFMNRSVY" "GIL" "5.33" "2" "2" "0" "4" "5" "-16.67" "-868" ">20 hour" ">20 hour" "?" "104" "5500" "392.86" "17257575" "Arch Biochem Biophys. 2007 Feb 15;458(2):202-12." "Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A." "Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase." "10.1016/j.abb.2006.12.007" "Anti-HIV" "DRAVPe01585" "SWLRDLWDWICEVLSDFK" "18" "NS5A-derived peptide C5A [I6L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.13 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM)." "[Ref.21801309]Human erythrocytes:MHC=13.84 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01585" "DRAVPe01585.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DLW" "4.23" "2" "4" "-2" "3" "9" "-7.22" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01586" "SWLRDIWDWLCEVLSDFK" "18" "NS5A-derived peptide C5A [I10L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.09 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=1.84±0.16 μM)." "[Ref.21801309]Human erythrocytes:MHC=6.92 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01586" "DRAVPe01586.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2311.64" "C109H155N25O29S" "AGHMNPQTY" "DLW" "4.23" "2" "4" "-2" "3" "9" "-7.22" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01587" "SWLRDIWDWICELLSDFK" "18" "NS5A-derived peptide C5A [V13L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.11 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.76±0.19 μM)." "[Ref.21801309]Human erythrocytes:MHC=3.44 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01587" "DRAVPe01587.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2325.67" "C110H157N25O29S" "AGHMNPQTVY" "DLW" "4.23" "2" "4" "-2" "3" "9" "-5.56" "-2439" "1.9 hour" ">20 hour" ">10 hour" "108.33" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01588" "SWLRDLWDWLCEVLSDFK" "18" "NS5A-derived peptide C5A [I6L,I10L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.15 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM)." "[Ref.21801309]Human erythrocytes:MHC=6.92 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01588" "DRAVPe01588.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2311.64" "C109H155N25O29S" "AGHIMNPQTY" "L" "4.23" "2" "4" "-2" "3" "9" "-11.11" "-2527" "1.9 hour" ">20 hour" ">10 hour" "102.78" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01589" "SWLRDLWDWICELLSDFK" "18" "NS5A-derived peptide C5A [I6L,V13L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=0.78±0.07 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=3.31±0.31 μM)." "[Ref.21801309]Human erythrocytes:MHC=53.75 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01589" "DRAVPe01589.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2325.67" "C110H157N25O29S" "AGHMNPQTVY" "L" "4.23" "2" "4" "-2" "3" "9" "-9.44" "-2439" "1.9 hour" ">20 hour" ">10 hour" "108.33" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01590" "SWLRDIWDWLCELLSDFK" "18" "NS5A-derived peptide C5A [I10L,V13L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=0.82±0.10 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.58±0.22 μM)." "[Ref.21801309]Human erythrocytes:MHC=3.44 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01590" "DRAVPe01590.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2325.67" "C110H157N25O29S" "AGHMNPQTVY" "L" "4.23" "2" "4" "-2" "3" "9" "-9.44" "-2439" "1.9 hour" ">20 hour" ">10 hour" "108.33" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01591" "SWLRDLWDWLCELLSDFK" "18" "NS5A-derived peptide C5A [I6L,I10L,V13L]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.20±0.14 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=0.59±0.03 μM)." "[Ref.21801309]Human erythrocytes:MHC=107.50 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01591" "DRAVPe01591.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2325.67" "C110H157N25O29S" "AGHIMNPQTVY" "L" "4.23" "2" "4" "-2" "3" "9" "-13.33" "-2439" "1.9 hour" ">20 hour" ">10 hour" "108.33" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01592" "SWLRDIWDWVCEVLSDFK" "18" "NS5A-derived peptide C5A [I10V]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=1.40±0.117 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=1.86±0.25 μM)." "[Ref.21801309]Human erythrocytes:MHC=13.93 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01592" "DRAVPe01592.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2297.61" "C108H153N25O29S" "AGHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-5" "-2615" "1.9 hour" ">20 hour" ">10 hour" "97.22" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01593" "SWLRDIWDWACEVLSDFK" "18" "NS5A-derived peptide C5A [I10A]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50=4.00±0.36 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=2.21±0.28 μM)." "[Ref.21801309]Human erythrocytes:MHC=14.10 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01593" "DRAVPe01593.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2269.56" "C106H149N25O29S" "GHMNPQTY" "DW" "4.23" "2" "4" "-2" "3" "9" "-18.33" "-2838" "1.9 hour" ">20 hour" ">10 hour" "86.67" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01594" "SWLRDIWDWGCEVLSDFK" "18" "NS5A-derived peptide C5A [I10G]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50=3.50±0.36 μM)." "[Ref.21801309]Human erythrocytes:MHC=28.38 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01594" "DRAVPe01594.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2255.53" "C105H147N25O29S" "AHMNPQTY" "DW" "4.23" "2" "4" "-2" "4" "8" "-30.56" "-2925" "1.9 hour" ">20 hour" ">10 hour" "81.11" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01595" "SWLRDIWDWSCEVLSDFK" "18" "NS5A-derived peptide C5A [I10S]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM)." "[Ref.21801309]Human erythrocytes:MHC=28.00 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01595" "DRAVPe01595.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2285.56" "C106H149N25O30S" "AGHMNPQTY" "DSW" "4.23" "2" "4" "-2" "4" "8" "-32.78" "-3359" "1.9 hour" ">20 hour" ">10 hour" "81.11" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01596" "SWLRDIWDWECEVLSDFK" "18" "NS5A-derived peptide C5A [I10E]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM)." "[Ref.21801309]Human erythrocytes:MHC=214.91 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01596" "DRAVPe01596.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2327.6" "C108H151N25O31S" "AGHMNPQTY" "DW" "4.1" "2" "5" "-3" "3" "8" "-47.78" "-3700" "1.9 hour" ">20 hour" ">10 hour" "81.11" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01597" "SWLRDIWDWKCEVLSDFK" "18" "NS5A-derived peptide C5A [I10K]" "Synthetic construct" "V5RF15" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV,HIV" "Flaviviridae, Retroviridae" "Pseudotyped HIV (HIVpp) and antiviral assay,HCV production and infection assay" "[Ref.21801309]HCV: inhibition of HCVcc infection in Huh7.5.1 cells(IC50>5.00 μM);##HIV-1:inhibition of pseudotyped HIV infection in TZM-BL cells(IC50>5.00 μM)." "[Ref.21801309]Human erythrocytes:MHC=214.81 μM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01597" "DRAVPe01597.cif" "Linear" "Free" "Free" "None" "L" "membrane" "The peptide inhibits HCV and HIV infection in vitro, which can disrupt the integrity of the viral membrane and capsid core while preserving the integrity of host membranes." "2326.65" "C109H156N26O29S" "AGHMNPQTY" "DW" "4.68" "3" "4" "-1" "3" "8" "-50" "-3574" "1.9 hour" ">20 hour" ">10 hour" "81.11" "16500" "970.59" "21801309" "Chem Biol Drug Des. 2011 Nov;78(5):835-43." "Li GR, He LY, Liu XY, Liu AP, Huang YB, Qiu C, Zhang XY, Xu JQ, Yang W, Chen YX." "Rational design of peptides with anti-HCV/HIV activities and enhanced specificity." "10.1111/j.1747-0285.2011.01201.x" "Anti-HCV,Anti-HIV" "DRAVPe01598" "TRQARRNRRRRWRERQR" "17" "Rev (34-50)" "Synthetic construct" "P05866" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ULL" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=1.7±0.25 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01598" "DRAVPe01598.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "2437.77" "C97H173N51O24" "CDFGHIKLMPSVY" "R" "12.6" "10" "1" "9" "2" "2" "-345.88" "-17216" "7.2 hour" ">20 hour" ">10 hour" "5.88" "5500" "343.75" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01599" "TRQARRNRRRRWRERQRAAAAC" "22" "Rev (34-50) -A4C" "Synthetic construct" "P05866" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=0.35±0.07 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01599" "DRAVPe01599.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "2825.22" "C112H198N56O29S" "DFGHIKLMPSVY" "R" "12.37" "10" "1" "9" "3" "6" "-223.18" "-16364" "7.2 hour" ">20 hour" ">10 hour" "22.73" "5500" "261.9" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01600" "TRQARRNRRRRWRERQRAAAACYGRKKRRQRRR" "33" "Rev (34-50) -A4C-RTD" "Synthetic construct" "P05866##P04612" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=0.37±0.09 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01600" "DRAVPe01600.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "4367.05" "C176H314N88O42S" "DFHILMPSV" "R" "12.48" "18" "1" "17" "5" "6" "-270" "-26900" "7.2 hour" ">20 hour" ">10 hour" "15.15" "6990" "218.44" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01601" "MPKTRRRPRRSQRKRPPTPWP" "21" "Rex (1-21)" "Synthetic construct" "P0C207" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01601" "DRAVPe01601.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "2685.2" "C116H198N46O26S" "ACDEFGHILNVY" "R" "12.78" "9" "0" "9" "3" "1" "-255.24" "-12494" "30 hour" ">20 hour" ">10 hour" "0" "5500" "275" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01602" "MPKTRRRPRRSQRKRPPTPWPYGRKKRRQRRR" "32" "Rex (1-21) -RTD" "Synthetic construct" "P0C207##P04612" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=2.5±0.76 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01602" "DRAVPe01602.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "4227.03" "C180H314N78O39S" "ACDEFHILNV" "R" "12.74" "17" "0" "17" "5" "1" "-292.5" "-23030" "30 hour" ">20 hour" ">10 hour" "0" "6990" "225.48" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01603" "RPRGRRGSRPSGAERRRRRAAAA" "23" "RSG-P2G4" "Synthetic construct" "None" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "MAGI assay" "[Ref.20580677]HIV-1 IIIB:inhibition of virus replication in PM1-CCR5 cells(EC50=2.2±0.51 μM);##HIV-1 Bal:inhibition of virus replication in PM1-CCR5 cells(EC50>10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01603" "DRAVPe01603.cif" "Linear" "Free" "Free" "None" "L" "Not found" "Peptide derived from the RNA-binding domain of HIV-1 Rev can act as dual-target inhibitors that inhibit HIV-1 entry and viral production in the early and late phases of replication. " "2603.95" "C102H187N53O28" "CDFHIKLMNQTVWY" "R" "12.6" "10" "1" "9" "5" "5" "-197.83" "-15094" "1 hour" "2 min" "2 min" "21.74" "0" "0" "20580677" "Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8." "Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M." "Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4." "10.1016/j.biocel.2010.05.005" "Anti-HIV" "DRAVPe01604" "RSQKEGLHYTCSSHFPYSQYQFWK" "24" "CCR5 ECL2 (168-191)" "Synthetic construct" "P51681" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV neutralization assay" "[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=136 ± 49 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=138± 36 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=89±31 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=103±37 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01604" "DRAVPe01604.cif" "Linear" "Free" "Free" "None" "L" "gp120" "The peptide binds gp120 and inhibits virus entry." "3008.32" "C138H191N37O38S" "ADIMNV" "S" "9.05" "5" "1" "4" "10" "4" "-131.25" "-5993" "1 hour" "2 min" "2 min" "16.25" "9970" "433.48" "22403408" "J Biol Chem. 2012 Apr 27;287(18):15076-86." "Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA." "Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1." "10.1074/jbc.M111.332361" "Anti-HIV" "DRAVPe01605" "CSSHFPYSQYQFWK" "14" "CCR5 ECL2 (178-191)" "Synthetic construct" "P51681" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV neutralization assay" "[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=28 ±7 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=65± 3 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=54±2 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=53±2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01605" "DRAVPe01605.cif" "Linear" "Free" "Free" "None" "L" "gp120" "The peptide binds gp120 and inhibits virus entry." "1808" "C86H110N20O22S" "ADEGILMNRTV" "S" "8.18" "2" "0" "2" "6" "3" "-96.43" "-2220" "1.2 hour" ">20 hour" ">10 hour" "0" "8480" "652.31" "22403408" "J Biol Chem. 2012 Apr 27;287(18):15076-86." "Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA." "Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1." "10.1074/jbc.M111.332361" "Anti-HIV" "DRAVPe01606" "QKEGLHYTCSSHFPYSQYQF" "20" "CCR5 ECL2 (170-189)" "Synthetic construct" "P51681" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV neutralization assay" "[Ref.22403408]HIV-1 YU2:inhibition of virus infection in TZM-bl cells(IC50=237 ± 31 μM);##HIV-1 BaL26:inhibition of virus infection in TZM-bl cells(IC50=612± 21 μM);##HIV-1 HxB2:inhibition of virus infection in TZM-bl cells(IC50=374±28 μM);##HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=600±24 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01606" "DRAVPe01606.cif" "Linear" "Free" "Free" "None" "L" "gp120" "The peptide binds gp120 and inhibits virus entry." "2450.67" "C112H152N28O33S" "ADIMNRVW" "QSY" "6.91" "3" "1" "2" "9" "3" "-107" "-3839" "0.8 hour" "10 min" ">10 hour" "19.5" "4470" "235.26" "22403408" "J Biol Chem. 2012 Apr 27;287(18):15076-86." "Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA." "Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1." "10.1074/jbc.M111.332361" "Anti-HIV" "DRAVPe01607" "RRWYRWW" "7" "Octa 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01607" "DRAVPe01607.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "1208.39" "C60H77N19O9" "ACDEFGHIKLMNPQSTV" "RW" "11.71" "3" "0" "3" "1" "3" "-250" "-3791" "1 hour" "2 min" "2 min" "0" "17990" "2998.33" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01608" "RRWYRWWRRRWYRWWR" "16" "MU89 (Octa 1 dp)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=8.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01608" "DRAVPe01608.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2711.15" "C132H176N46O19" "ACDEFGHIKLMNPQSTV" "R" "12.22" "8" "0" "8" "2" "6" "-275" "-10566" "1 hour" "2 min" "2 min" "0" "35980" "2398.67" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01609" "RWWRWWR" "7" "Hepta 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01609" "DRAVPe01609.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "1231.43" "C62H78N20O8" "ACDEFGHIKLMNPQSTVY" "W" "12.3" "3" "0" "3" "0" "4" "-244.29" "-3544" "1 hour" "2 min" "2 min" "0" "22000" "3666.67" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01610" "RWWRWWRRWWRWWR" "14" "MU92 (Hepta 1 dp)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=3.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01610" "DRAVPe01610.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2444.85" "C124H154N40O15" "ACDEFGHIKLMNPQSTVY" "W" "12.7" "6" "0" "6" "0" "8" "-244.29" "-7088" "1 hour" "2 min" "2 min" "0" "44000" "3384.62" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01611" "YRWWRWARRW" "10" "Deca 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01611" "DRAVPe01611.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "1621.87" "C80H104N26O12" "CDEFGHIKLMNPQSTV" "RW" "12" "4" "0" "4" "1" "5" "-211" "-4869" "2.8 hour" "10 min" "2 min" "10" "23490" "2610" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01612" "YRWWRWARRWYRWWRWARRW" "20" "MU94 (Deca 1 dp)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=5 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01612" "DRAVPe01612.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "3225.73" "C160H206N52O23" "CDEFGHIKLMNPQSTV" "RW" "12.22" "8" "0" "8" "2" "10" "-211" "-9738" "2.8 hour" "10 min" "2 min" "10" "46980" "2472.63" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01613" "APKAMRLLRRLLRRLLR" "17" "N-[RLLR]3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=7.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01613" "DRAVPe01613.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2132.74" "C94H178N36O18S" "CDEFGHINQSTVWY" "LR" "12.7" "7" "0" "7" "0" "8" "-24.71" "-5958" "4.4 hour" ">20 hour" ">10 hour" "149.41" "0" "0" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01614" "RLLRRLLRRLLRRLLRRLLR" "20" "RLLR5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50<3.3 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01614" "DRAVPe01614.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2711.48" "C120H232N50O21" "ACDEFGHIKMNPQSTVWY" "LR" "12.95" "10" "0" "10" "0" "10" "-35" "-10000" "1 hour" "2 min" "2 min" "195" "0" "0" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01615" "RRRRRRRWWWRRRRRRRR" "18" "MU103" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50>20 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01615" "DRAVPe01615.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2919.47" "C123H212N66O19" "ACDEFGHIKLMNPQSTVY" "R" "13.15" "15" "0" "15" "0" "3" "-390" "-21681" "1 hour" "2 min" "2 min" "0" "16500" "970.59" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01616" "RRRRRRRRRRRRRRRWWW" "18" "MU104" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=9.25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01616" "DRAVPe01616.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2919.47" "C123H212N66O19" "ACDEFGHIKLMNPQSTVY" "R" "13.15" "15" "0" "15" "0" "3" "-390" "-21681" "1 hour" "2 min" "2 min" "0" "16500" "970.59" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV" "DRAVPe01617" "WRKWRKRWWWRKWRKRWW" "18" "ApoEdpL-W" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV,HIV,VSV" "Herpesviridae, Retroviridae, Rhabdoviridae" "plaque reduction assay" "[Ref.17681018]HSV-1:inhibition of virus infection in NP-2/CD4/CCR5 cells(IC50=3.1 µM);##HIV-1:inhibition of virus replication(>80% inhibition at 10 µM)." "[Ref.17681018]15% hemolysis against human red blood cells at 35 μM." "[Ref.17681018]No significant cytotoxicity against Vero cells up to 40 μM." "DRAVPe01617" "DRAVPe01617.cif" "Linear" "Free" "Free" "None" "L" "Not found" "The anti-HSV1 activity of apoEdp involves inhibition of virus particle attachment to cells, with this likely being related to the derivation of this peptide from the apoE HSPG/LDLR binding region." "2957.54" "C148H202N48O19" "ACDEFGHILMNPQSTVY" "W" "12.7" "10" "0" "10" "0" "8" "-276.67" "-9308" "2.8 hour" "3 min" "2 min" "0" "44000" "2588.24" "17681018" "FEBS J. 2007 Sep;274(17):4511-25." "Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB." "Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity." "10.1111/j.1742-4658.2007.05981.x" "Anti-HSV,Anti-HIV,Anti-VSV" "DRAVPe01618" "HCKFWW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01618" "DRAVPe01618.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "906.07" "C46H55N11O7S" "ADEGILMNPQRSTVY" "W" "8.23" "2" "0" "2" "1" "3" "-60" "-129" "3.5 hour" "10 min" ">10 hour" "0" "11000" "2200" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01619" "HCKFWI" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01619" "DRAVPe01619.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "833.02" "C41H56N10O7S" "ADEGLMNPQRSTVY" "CFHIKW" "8.23" "2" "0" "2" "1" "3" "30" "130" "3.5 hour" "10 min" ">10 hour" "65" "5500" "1100" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01620" "HCKFWF" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01620" "DRAVPe01620.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "867.04" "C44H54N10O7S" "ADEGILMNPQRSTVY" "F" "8.23" "2" "0" "2" "1" "3" "1.67" "-64" "3.5 hour" "10 min" ">10 hour" "0" "5500" "1100" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01621" "HCKFAW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=150 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01621" "DRAVPe01621.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "790.94" "C38H50N10O7S" "DEGILMNPQRSTVY" "ACFHKW" "8.23" "2" "0" "2" "1" "3" "-15" "-181" "3.5 hour" "10 min" ">10 hour" "16.67" "5500" "1100" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01622" "HCKFWA" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=210 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01622" "DRAVPe01622.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "790.94" "C38H50N10O7S" "DEGILMNPQRSTVY" "ACFHKW" "8.23" "2" "0" "2" "1" "3" "-15" "-181" "3.5 hour" "10 min" ">10 hour" "16.67" "5500" "1100" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01623" "HCKAWW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01623" "DRAVPe01623.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "829.97" "C40H51N11O7S" "DEFGILMNPQRSTVY" "W" "8.23" "2" "0" "2" "1" "3" "-76.67" "-246" "3.5 hour" "10 min" ">10 hour" "16.67" "11000" "2200" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01624" "ACKFWW" "6" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "integrase assay" "[Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=51 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01624" "DRAVPe01624.cif" "Linear" "Free" "Amidation" "None" "L" "integrase" "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." "840.01" "C43H53N9O7S" "DEGHILMNPQRSTVY" "W" "8.27" "1" "0" "1" "1" "4" "23.33" "518" "4.4 hour" ">20 hour" ">10 hour" "16.67" "11000" "2200" "8524782" "Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60." "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library." "10.1073/pnas.92.25.11456" "Anti-HIV" "DRAVPe01812" "GWINEKKMQQKIDEKIGKNIIGGMAKAVIHKMAKNEFQCVANVDTLGNCKKHCAKTTGEKGYCHGTKCKCGIELSY" "76" "Smp76" "Scorpio maurus palmatu" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Plaque assay" "[Ref.32435168]Dengue Virus(DENV):inhibition of viral infection in Vero/SLAM cells(IC50= 0.01 μg/ml)." "[Ref.32435168]human red blood cells:HC50>10 μg/ml." "[Ref.32435168]Huh7it-1 cells:CC50>10 μg/ml." "No predicted structure available" "DRAVPe01812.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys39 and Cys63, Cys49 and Cys68, Cys53 and Cys70." "L" "Not found" "No mechanism information found in the reference(s)." "8402.89" "C362H595N105O106S9" "PR" "K" "9.22" "17" "7" "10" "27" "19" "-56.84" "-11300" "30 hour" ">20 hour" ">10 hour" "64.21" "8855" "118.07" "32435168" "Int J Pept Res Ther. 2020;26(2):811-821. " "El-Bitar AMH, Sarhan M, Abdel-Rahman MA, Quintero-Hernandez V, Aoki-Utsubo C, Moustafa MA, Possani LD, Hotta H." "Smp76, a Scorpine-Like Peptide Isolated from the Venom of the Scorpion Scorpio maurus palmatus, with a Potent Antiviral Activity Against Hepatitis C Virus and Dengue Virus." "10.1007/s10989-019-09888-2" "Anti-DENV" "DRAVPe01813" "GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR" "37" "BmKDfsin4" "Mesobuthus martensii" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "ELISA" "[Ref.27128943]hepatitic B Virus (HBV): Pharmacological profiles of BmKDfsin4 against HBeAg, HBsAg and HBV DNA on HepG2.2.15 cells(HBeAg: IC50= 3.95 μM; HBsAg: IC50= 2.28 μM; HBV DNA: IC50= 1.26 μM)." "[Ref.27128943]Human erythrocytes: 50% hemolysis concentration was 66.85 μM." "[Ref.27128943]HepG2.2.15 cells: CC50= 167.82 μM;##HepG2 cells: CC50= 154.24 μM;##L-02 cells: CC50= 103.77 μM." "No predicted structure available" "DRAVPe01813.cif" "Cyclic" "Free" "Free" "Disulfide bonds between Cys4 and Cys25, Cys11 and Cys33, Cys15 and Cys35." "L" "Not found" "BmKDfsin4 had been shown to exhibit powerful inhibitory activity against HBV replication by reducing the production of HBeAg, HBsAg, and HBV DNAin cell culture medium and the production of intracellular HBsAg, HBV core protein, HBx protein, and HBV RT." "4282.95" "C181H278N62O48S6" "AEMW" "CG" "9.38" "9" "1" "8" "17" "6" "-71.35" "-9711" "30 hour" ">20 hour" ">10 hour" "28.92" "3355" "93.19" "27128943" "Toxins (Basel). 2016 Apr 27;8(5):124." "Zeng Z, Zhang Q, Hong W, Xie Y, Liu Y, Li W, Wu Y, Cao Z. " "A Scorpion Defensin BmKDfsin4 Inhibits Hepatitis B Virus Replication in Vitro." "10.3390/toxins8050124" "Anti-HBV" "DRAVPe01814" "ILGKIWEGIKSIF" "13" "Hp1036" "Heterometrus petersii" "P0DME6" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque forming assay" "[Ref.24315793]Herpes simplex virus type 1(HSV-1):inhibition of viral inactivation in Vero cells(EC50=0.43 ± 0.09 μM);inhibition of viral attachment in Vero cells(EC50=2.87 ± 0.16 μM);inhibition of viral entry in Vero cells(EC50=4.29 ± 0.35 μM);inhibition of postentry in Vero cells(EC50=7.86 ± 0.80 μM)." "[Ref.24315793]Human erythrocytes: HC50 = 34.91 ± 0.47 μM." "[Ref.24315793]Vero cells: CC50 = 46.71 ± 3.80 μM." "No predicted structure available" "DRAVPe01814.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" " inhibit HSV-1 when it attaches to the cell surface and when it has already bound to the cells but not entered yet and also exhibited potent inhibitory effects against viral particles proliferation in postentry stage." "1503.85" "C74H118N16O17" "ACDHMNPQRTVY" "I" "8.59" "2" "1" "1" "3" "7" "83.08" "1048" "20 hour" "30 min" ">10 hour" "150" "5500" "458.33" "24315793" "Antiviral Res. 2014 Feb;102:1-10." "Hong W, Li T, Song Y, Zhang R, Zeng Z, Han S, Zhang X, Wu Y, Li W, Cao Z." " Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1. " "10.1016/j.antiviral.2013.11.013" "Anti-HSV-1" "DRAVPe01815" "ILSYLWNGIKSIF" "13" "Hp1239" "Heterometrus petersii" "P0DME8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV-1" "Herpesviridae" "Plaque forming assay" "[Ref.24315793]Herpes simplex virus type 1(HSV-1):inhibition of viral inactivation in Vero cells(EC50=0.41 ± 0.06 μM);inhibition of viral attachment in Vero cells(EC50=5.73 ± 0.61 μM);inhibition of viral entry in Vero cells(EC50=4.32 ± 0.47 μM);inhibition of postentry in Vero cells(EC50=8.41 ± 0.73 μM)." "[Ref.24315793]Human erythrocytes: HC50 = 33.32 ± 0.96 μM." "[Ref.24315793]Vero cells: CC50 = 26.15 ± 1.91 μM." "No predicted structure available" "DRAVPe01815.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" " inhibit HSV-1 when it attaches to the cell surface and when it has already bound to the cells but not entered yet and also exhibited potent inhibitory effects against viral particles proliferation in postentry stage." "1553.86" "C77H116N16O18" "ACDEHMPQRTV" "I" "8.59" "1" "0" "1" "5" "7" "94.62" "1172" "20 hour" "30 min" ">10 hour" "150" "6990" "582.5" "24315793" "Antiviral Res. 2014 Feb;102:1-10." "Hong W, Li T, Song Y, Zhang R, Zeng Z, Han S, Zhang X, Wu Y, Li W, Cao Z." " Inhibitory activity and mechanism of two scorpion venom peptides against herpes simplex virus type 1. " "10.1016/j.antiviral.2013.11.013" "Anti-HSV-1" "DRAVPe01816" "LWGEIWNTVKGLI" "13" "Eval418" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=2.48 µg/mL); inhibition of viral attachment in Vero cells(IC50=3.70 µg/mL); inhibition of viral entry in Vero cells(IC50=31.71 µg/mL)." "[Ref.29290802]The hemolysis rate of human erythrocytes was less than 50% when the concentration of Eval418 was as high as 200 μg/mL." "[Ref.29290802]Vero cells: CC50 = 68.50 µg/mL." "No predicted structure available" "DRAVPe01816.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1528.81" "C74H113N17O18" "ACDFHMPQRSY" "GILW" "6" "1" "1" "0" "4" "7" "50.77" "869" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV-1" "DRAVPe01817" "LWGHIWNFVHGLI" "13" "Eval418-FH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=1.50 µg/mL); inhibition of viral attachment in Vero cells(IC50=1.43 µg/mL); inhibition of viral entry in Vero cells(IC50=8.63 µg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cells: CC50 = 27.60 µg/mL." "No predicted structure available" "DRAVPe01817.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1591.88" "C80H110N20O15" "ACDEKMPQRSTY" "GHILW" "6.92" "2" "0" "2" "3" "8" "85.38" "1728" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211. " "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV-1" "DRAVPe01818" "LWHHIWNFVHGLI" "13" "Eval418-FH3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=1.01 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.86 µg/mL); inhibition of viral entry in Vero cells(IC50=4.23 µg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cells: CC50 = 26.83 µg/mL." "No predicted structure available" "DRAVPe01818.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1671.97" "C84H114N22O15" "ACDEKMPQRSTY" "H" "7.02" "3" "0" "3" "2" "8" "63.85" "1168" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211." "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV-1" "DRAVPe01819" "LWHHIWNTVHHLI" "13" "Eval418-FH4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=0.87 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.63 µg/mL); inhibition of viral entry in Vero cells(IC50=4.37 µg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cells: CC50 = 27.58 µg/mL." "No predicted structure available" "DRAVPe01819.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1705.99" "C83H116N24O16" "ACDEFGKMPQRSY" "H" "7.1" "4" "0" "4" "2" "7" "15.38" "53" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211." "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV-1" "DRAVPe01820" "LWHHIWHTVHHLI" "13" "Eval418-FH5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.29290802]Herpes simplex virus type 1(HSV-1): inhibition of viral inactivation in Vero cells(IC50=0.86 µg/mL); inhibition of viral attachment in Vero cells(IC50=0.67 µg/mL); inhibition of viral entry in Vero cells(IC50=2.88 µg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.29290802]Vero cells: CC50 = 106.68 µg/mL." "No predicted structure available" "DRAVPe01820.cif" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1729.02" "C85H117N25O15" "ACDEFGKMNPQRSY" "H" "7.16" "5" "0" "5" "1" "7" "17.69" "251" "5.5 hour" "3 min" "2 min" "142.31" "11000" "916.67" "29290802" "Theranostics. 2018 Jan 1;8(1):199-211." "Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, Ji Z, Wu Y, Li W, Xie Y, Cao Z." "Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1." "10.7150/thno.21425" "Anti-HSV-1" "DRAVPe01821" "LLMVNEATRFQTVSGFV" "17" "BPIP" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "MBP-tagged (SARS-CoV-2) assay" "[Ref.35896605]SARS-CoV-2: inhibition of Mpro (IC50= 0.52 nM)." "[Ref.35896605]BRIP is not hemolytic at 500 nM and slightly hemolytic at 50 µM." "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "DRAVPe01821.cif" "Linear" "Free" "Free" "None" "L" "Mpro" "The peptide inhibits Mpro, a protein crucial for viral replication." "1912.23" "C86H138N22O25S" "CDHIKPWY" "V" "6" "1" "1" "0" "5" "8" "70" "-943" "5.5 hour" "3 min" "2 min" "102.94" "0" "0" "35896605" "Sci Rep. 2022 Jul 27;12(1):12802" "Kashyap P, Bhardwaj VK, Chauhan M, Chauhan V, Kumar A, Purohit R, Kumar A, Kumar S" "A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2" "10.1038/s41598-022-15977-y" "Anti-SARS-CoV-2" "DRAVPe01822" "KFFRKKSVKK" "10" "BF-30" "Bungarus fasciatus" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Cytopathic effect (CPE) reduction assay" "[Ref.30447229]Influenza A virus H1N1:inhibition of viral replication in MDCK cells(EC50=5.20±0.9 μM);##influenza A virus H3N2: inhibition of viral replication in MDCK cells(EC50=7.36 ± 1.2 μM);##influenza A virus(oseltamivir-resistant strain): inhibition of viral replication in MDCK cells(EC50=18.91 ± 7.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30447229]MDCK cells:CC50=67.7μM." "No predicted structure available" "DRAVPe01822.cif" "Linear" "Free" "Free" "None" "L" "Not found" "BF-30 could inhibit the replication of various influenza subtypes by fusing virion membranes and reducing infectivity. " "1295.64" "C62H106N18O12" "ACDEGHILMNPQTWY" "K" "11.39" "6" "0" "6" "1" "3" "-150" "-3607" "1.3 hour" "3 min" "2 min" "29" "0" "0" "30447229" "Peptides. 2019 Feb;112:14-22. " "Xu J, Chen S, Jin J, Ma L, Guo M, Zhou C, Dou J." "Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion." "10.1016/j.peptides.2018.10.004" "Anti-Anti-Influenza A virus" "DRAVPe01823" "FLGAILKIGHALAKTVLPMVTNAFKPKQ" "28" "Figainin 2" "Boana raniceps (Hypsiboas raniceps)" "A0A2L2DDD0" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CHIKV,DENV,YFV" "immunofluorescence assay" "[Ref.32443921]chikungunya virus (CHIKV):inhibition of viral infection in Huh7 cells(EC50=17 μM);##Dengue Serotype 4 Virus(DENV4):inhibition of viral infection in Huh7 cells(EC50=20.8 μM);##Yellow Fever viral (YFV):inhibition of viral infection in Huh7 cells(EC50=21.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32443921]No cytotoxicity against noninfected Huh7 cells at concentrations as high as 25 µM." "No predicted structure available" "DRAVPe01823.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "3007.72" "C142H236N36O33S" "CDERSWY" "AKL" "10.48" "5" "0" "5" "5" "14" "57.5" "1085" "1.1 hour" "3 min" "2 min" "118.57" "0" "0" "32443921" "Biomolecules. 2020 May 20;10(5):790. " "Santana CJC, Magalhães ACM, Prías-Márquez CA, Falico DA, Dos Santos Júnior ACM, Lima BD, Ricart CAO, de Pilger DRB, Bonotto RM, Moraes CB, Freitas-Júnior LH, Álvares ADCM, Freitas SM, Luz IS, Pires OR Jr, Fontes W, Castro MS." "Biological Properties of a Novel Multifunctional Host Defense Peptide from the Skin Secretion of the Chaco Tree Frog, Boana raniceps." "10.3390/biom10050790" "Anti-CHIKV,Anti-DENV,Anti-YFV" "DRAVPe01824" "QMRRKVELFTYMRFD" "15" "SP40 " "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EV-A71" "Picornaviridae" "cell protection assay" "[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=18 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34314773]RD cells: CC50=228.7 μM." "No predicted structure available" "DRAVPe01824.cif" "Linear" "Acetylation" "Amidation" "Free" "L" "Not found" "SP40 peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors" "2020.4" "C90H142N26O23S2" "ACGHINPSW" "R" "9.98" "4" "2" "2" "2" "4" "-83.33" "-5447" "0.8 hour" "10 min" ">10 hour" "45.33" "1490" "106.43" "34314773" "Virus Res. 2021 Oct 2;303:198456. " "Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL." "Stability and antiviral activity of SP40 peptide in human serum." "10.1016/j.virusres.2021.198456." "Anti-EV-A71" "DRAVPe01825" "MRRKVELFTYMRFD" "14" "TP1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EV-A71" "Picornaviridae" "cell protection assay" "[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34314773]RD cells: CC50=683.6 μM." "No predicted structure available" "DRAVPe01825.cif" "Linear" "Acetylation" "Amidation" "Free" "L" "Not found" "The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors." "1892.27" "C85H134N24O21S2" "ACGHINPQSW" "R" "9.98" "4" "2" "2" "2" "4" "-64.29" "-4893" "30 hour" ">20 hour" ">10 hour" "48.57" "1490" "114.62" "34314773" "Virus Res. 2021 Oct 2;303:198456. " "Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL." "Stability and antiviral activity of SP41 peptide in human serum." "10.1016/j.virusres.2021.198456." "Anti-EV-A71" "DRAVPe01826" "RRKVELFTYMRFD" "13" "TP2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "EV-A71" "Picornaviridae" "cell protection assay" "[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34314773]RD cells: CC50=345 μM." "No predicted structure available" "DRAVPe01826.cif" "Linear" "Acetylation" "Amidation" "Free" "L" "Not found" "The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors." "1761.07" "C80H125N23O20S" "ACGHINPQSW" "R" "9.98" "4" "2" "2" "2" "4" "-83.85" "-5128" "1 hour" "2 min" "2 min" "52.31" "1490" "124.17" "34314773" "Virus Res. 2021 Oct 2;303:198456." "Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL." "Stability and antiviral activity of SP42 peptide in human serum." "10.1016/j.virusres.2021.198456." "Anti-EV-A71" "DRAVPe01827" "RKVELFTYMRFD" "12" "TP3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "EV-A71" "Picornaviridae" "cell protection assay" "[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=5.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34314773]RD cells: CC50=1123 μM." "No predicted structure available" "DRAVPe01827.cif" "Linear" "Acetylation" "Amidation" "Free" "L" "Not found" "The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors." "1604.89" "C74H113N19O19S" "ACGHINPQSW" "FR" "8.59" "3" "2" "1" "2" "4" "-53.33" "-3636" "1 hour" "2 min" "2 min" "56.67" "1490" "135.45" "34314773" "Virus Res. 2021 Oct 2;303:198456." "Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL." "Stability and antiviral activity of SP43 peptide in human serum." "10.1016/j.virusres.2021.198456." "Anti-EV-A71" "DRAVPe01828" "QMRRKVELFTYMRF" "14" "TP10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EV-A71" "Picornaviridae" "cell protection assay" "[Ref.34314773]Enterovirus A71 (EV-A71):inhibition of viral replication into RD cells(IC50=6.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.34314773]RD cells: CC50=231 μM." "No predicted structure available" "DRAVPe01828.cif" "Linear" "Acetylation" "Amidation" "Free" "L" "Not found" "The peptide could associate with the cellular receptors at the surface of cells and prevented the attachment of EV-A71 to the cellular receptors." "1905.31" "C86H137N25O20S2" "ACDGHINPSW" "R" "10.9" "4" "1" "3" "2" "4" "-64.29" "-4575" "0.8 hour" "10 min" ">10 hour" "48.57" "1490" "114.62" "34314773" "Virus Res. 2021 Oct 2;303:198456." "Zarif F, Anasir MI, Koh JX, Chew MF, Poh CL." "Stability and antiviral activity of SP44 peptide in human serum." "10.1016/j.virusres.2021.198456." "Anti-EV-A71" "DRAVPe01829" "AKVTMTCSAS" "10" "KP" "Synthetic construct" "P01680" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque reduction assay" "[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (96% inhibition at 50 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01829.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "998.18" "C39H71N11O15S2" "DEFGHILNPQRWY" "AST" "8.27" "1" "0" "1" "5" "3" "53" "-620" "4.4 hour" ">20 hour" ">10 hour" "49" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-HSV-1" "DRAVPe01830" "KKVTMTCSAS" "10" "K10S" "Synthetic construct" "P01680" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1, CoxV B5, AdV, VSV" "Herpesviridae, Picornaviridae, Adenoviridae, Rhabdoviridae" "Plaque reduction assay" "[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (45% inhibition at 10 µg/ml, 76% inhibition at 50 µg/ml, 89% inhibition at 100 µg/ml);##Coxsackie virus B5:inhibition of viral replication in Vero cells (75% inhibition at 50 µg/ml, 94% inhibition at 100 µg/ml);##Vesicular Stomatitis Virus (VSV):inhibition of viral replication in Vero cells (78% inhibition at 50 µg/ml, 96% inhibition at 100 µg/ml);##Adenovirus:inhibition of viral replication in Vero cells (75% inhibition at 50 µg/ml, 91% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]20% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01830.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1055.27" "C42H78N12O15S2" "DEFGHILNPQRWY" "KST" "9.31" "2" "0" "2" "5" "2" "-4" "-1356" "1.3 hour" "3 min" "2 min" "39" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-HSV-1, Anti-CoxV B5, Anti-AdV, Anti-VSV" "DRAVPe01831" "NQVSATCSVK" "10" "L5A" "Synthetic construct" "P0DOX5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "VSV" "Rhabdoviridae" "Plaque reduction assay" "[Ref.30654366]Vesicular Stomatitis Virus (VSV):inhibition of viral replication in Vero cells (45% inhibition at 50 µg/ml, 50% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]20% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01831.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1036.17" "C41H73N13O16S" "DEFGHILMPRWY" "SV" "8.22" "1" "0" "1" "5" "3" "-5" "-1593" "1.4 hour" "3 min" ">10 hour" "68" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-VSV" "DRAVPe01832" "KKLVAASQAALGL" "13" "K13L" "Synthetic construct" "P02768-2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CoxV B5" "Picornaviridae" "Plaque reduction assay" "[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 80% inhibition at 50 µg/ml, 87% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]30% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01832.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1269.55" "C57H104N16O16" "CDEFHIMNPRTWY" "A" "10" "2" "0" "2" "2" "8" "79.23" "694" "1.3 hour" "3 min" "2 min" "143.08" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-CoxV B5" "DRAVPe01833" "DSGEGDFLAEGGGVR" "15" "D15R" "Synthetic construct" "P02671" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CoxV B5" "Picornaviridae" "Plaque reduction assay" "[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (82% inhibition at 10 µg/ml, 85% inhibition at 50 µg/ml, 93% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01833.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1465.5" "C60H92N18O25" "CHIKMNPQTWY" "G" "3.92" "1" "4" "-3" "6" "4" "-58" "-3093" "1.1 hour" "3 min" ">10 hour" "52" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-CoxV B5" "DRAVPe01834" "GLEEELQFSLGSKINVK" "17" "G17K" "Synthetic construct" "P0C0L5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CoxV B5" "Picornaviridae" "Plaque reduction assay" "[Ref.30654366]Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 75% inhibition at 50 µg/ml, 88% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01834.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1891.15" "C84H139N21O28" "ACDHMPRTWY" "EL" "4.79" "2" "3" "-1" "5" "6" "-28.24" "-2193" "30 hour" ">20 hour" ">10 hour" "108.82" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-CoxV B5" "DRAVPe01835" "SEETKENEGFTVTAEGK" "17" "S17K" "Synthetic construct" "P01024" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "AdV" "Adenoviridae" "Plaque reduction assay" "[Ref.30654366]Adenovirus:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 65% inhibition at 50 µg/ml, 80% inhibition at 100 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01835.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1855.93" "C77H122N20O33" "CDHILMPQRWY" "E" "4.32" "2" "5" "-3" "7" "3" "-139.41" "-5219" "1.9 hour" ">20 hour" ">10 hour" "22.94" "0" "0" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-AdV" "DRAVPe01836" "LCLRNWDQGHRP" "12" "L12P" "Synthetic construct" "A0M8Q8" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1, CoxV B5" "Herpesviridae, Picornaviridae" "Plaque reduction assay" "[Ref.30654366]HSV-1:inhibition of viral replication in Vero cells (78% inhibition at 10 µg/ml, 84% inhibition at 50 µg/ml);##Coxsackie virus B5:inhibition of viral replication in Vero cells (60% inhibition at 10 µg/ml, 42% inhibition at 50 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30654366]<10% cytotoxicity against Vero cells at the concentration of 100μg/ mL." "No predicted structure available" "DRAVPe01836.cif" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1494.69" "C64H99N23O17S" "AEFIKMSTVY" "LR" "8.26" "3" "1" "2" "3" "3" "-129.17" "-4101" "5.5 hour" "3 min" "2 min" "65" "5500" "500" "30654366" "Intervirology. 2018;61(4):166-173." "Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C" "Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. " "10.1159/000494354" "Anti-HSV-1, Anti-CoxV B5" "DRAVPe01837" "GKRKSGCA" "8" "Entry 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 114.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "805.95" "C31H59N13O10S" "DEFHILMNPQTVWY" "GK" "10.06" "3" "0" "3" "4" "1" "-120" "-2445" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01838" "GKRKSGAA" "8" "Entry 6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 57.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "773.89" "C31H59N13O10" "CDEFHILMNPQTVWY" "AGK" "11.17" "3" "0" "3" "3" "2" "-128.75" "-2392" "30 hour" ">20 hour" ">10 hour" "25" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01839" "GKRKSXCA" "8" "Entry 7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 22.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates phenylglycine(Phg). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "860.23" "C29H54N12O8S" "DEFHILMNPQTVWY" "K" "10.06" "3" "0" "3" "3" "1" "-115" "-2539" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01840" "GKRKSFCA" "8" "Entry 8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 39.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "896.08" "C38H65N13O10S" "DEHILMNPQTVWY" "K" "10.06" "3" "0" "3" "3" "2" "-80" "-2241" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01841" "GKRKSXCA" "8" "Entry 9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 9.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "860.23" "C29H54N12O8S" "DEFHILMNPQTVWY" "K" "10.06" "3" "0" "3" "3" "1" "-115" "-2539" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01842" "GKRKSxCA" "8" "Entry 10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 38.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'x' at position 6 indicates D-homophenylalanine(D-hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-hPhe6)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "860.23" "C29H54N12O8S" "DEFHILMNPQTVWY" "K" "10.06" "3" "0" "3" "3" "1" "-115" "-2539" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01843" "GKRKSXAA" "8" "Entry 11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 18.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "828.17" "C29H54N12O8" "CDEFHILMNPQTVWY" "AK" "11.17" "3" "0" "3" "2" "2" "-123.75" "-2486" "30 hour" ">20 hour" ">10 hour" "25" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01844" "GKRKSXAX" "8" "Entry 12" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 22.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates homophenylalanine(Phg). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "868.42" "C26H47N11O6" "CDEFHILMNPQTVWY" "KX" "11.17" "3" "0" "3" "2" "1" "-146.25" "-2667" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01845" "GKRKSXAx" "8" "Entry 13" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 15.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates D-homophenylalanine(D-Phg). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Phg8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "868.42" "C26H47N11O6" "CDEFHILMNPQTVWY" "K" "11.17" "3" "0" "3" "2" "1" "-146.25" "-2667" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01846" "GKRKSXAF" "8" "Entry 14" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 19.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "904.27" "C35H58N12O8" "CDEHILMNPQTVWY" "K" "11.17" "3" "0" "3" "2" "2" "-111.25" "-2369" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01847" "GKRKSXAf" "8" "Entry 15" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 7.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "904.27" "C26H47N11O6" "CDEFHILMNPQTVWY" "K" "11.17" "3" "0" "3" "2" "1" "-146.25" "-2667" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01848" "GKRKSXAX" "8" "Entry 16" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 25.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 and 8 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "L" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "868.42" "C26H47N11O6" "CDEFHILMNPQTVWY" "KX" "11.17" "3" "0" "3" "2" "1" "-146.25" "-2667" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01849" "GKRKSXAx" "8" "Entry 17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 16.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 and 8 indicates homophenylalanine(hPhe/D-hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-hPhe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "868.42" "C26H47N11O6" "CDEFHILMNPQTVWY" "K" "11.17" "3" "0" "3" "2" "1" "-146.25" "-2667" "30 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01850" "GKRKSXSf" "8" "Entry 18" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 5.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "920.27" "C26H47N11O7" "ACDEFHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "3" "0" "-178.75" "-3188" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01851" "AKRKSXSf" "8" "Entry 19" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 28.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "934.29" "C27H49N11O7" "CDEFGHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "2" "1" "-151.25" "-3101" "4.4 hour" ">20 hour" ">10 hour" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01852" "aKRKSXSf" "8" "Entry 20" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Ala1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "934.29" "C24H42N10O5" "ACDEFGHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "2" "0" "-173.75" "-3282" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01853" "PKRKSXSf" "8" "Entry 21" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 52.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "960.33" "C29H51N11O7" "ACDEFGHILMNQTVWY" "KS" "11.17" "3" "0" "3" "2" "0" "-193.75" "-3282" ">20 hour" ">20 hour" "?" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01854" "pKRKSXSf" "8" "Entry 22" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 0.95 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Pro1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "960.33" "C24H42N10O5" "ACDEFGHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "2" "0" "-173.75" "-3282" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01855" "pKRKSXSf" "8" "Entry 23" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 2.6 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=306.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50>400 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates L-2-naphthylalanine(l-2Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Pro1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "960.33" "C24H42N10O5" "ACDEFGHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "2" "0" "-173.75" "-3282" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01856" "pKRKSXSf" "8" "Entry 24" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.8 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=293.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50>400 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Pro1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "960.33" "C24H42N10O5" "ACDEFGHILMNPQTVWY" "KS" "11.17" "3" "0" "3" "2" "0" "-173.75" "-3282" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01857" "pRRKSXSf" "8" "Entry 25" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.8 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=108.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50>400 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Pro1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "988.34" "C24H42N12O5" "ACDEFGHILMNPQTVWY" "RS" "12.01" "3" "0" "3" "2" "0" "-181.25" "-4219" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01858" "rRRKSXSf" "8" "Entry 26" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 3.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=87.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50>400 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1047.42" "C24H42N12O5" "ACDEFGHILMNPQTVWY" "RS" "12.3" "3" "0" "3" "2" "0" "-181.25" "-4219" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01859" "rRRKSXSr" "8" "Entry 27" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 2.3 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=141.1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50>400 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates biphenylalanine (L-bPhe). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, 8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1056.43" "C24H42N12O5" "ACDEFGHILMNPQTVWY" "RS" "12.48" "3" "0" "3" "2" "0" "-181.25" "-4219" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01860" "rRRKSXXf" "8" "Entry 28" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.6 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=23.2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50=233 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-1-naphthylalanine(L-1Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1071.67" "C21H35N11O2" "ACDEFGHILMNPQTVWY" "RX" "12.3" "3" "0" "3" "1" "0" "-171.25" "-3879" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01861" "rRRKAXXf" "8" "Entry 29" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=11.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50=134.1 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-1-naphthylalanine(L-1Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1055.67" "C21H35N11O" "CDEFGHILMNPQSTVWY" "RX" "12.3" "3" "0" "3" "0" "1" "-138.75" "-3358" "12.5" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01862" "rRRKSXXf" "8" "Entry 30" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.5 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=48.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50=210 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 7 indicates L-2-naphthylalanine(L-2Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, Phe8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1071.67" "C21H35N11O2" "ACDEFGHILMNPQTVWY" "RX" "12.3" "3" "0" "3" "1" "0" "-171.25" "-3879" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01863" "rRRKfXFx" "8" "Entry 31" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.7 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=4.6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50=86 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 8 indicates D-2-naphthylalanine(D-2Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, Phe5, 2Nal8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1131.77" "C27H39N11O" "ACDEGHILMNPQSTVWY" "R" "12.3" "3" "0" "3" "0" "1" "-126.25" "-3241" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01864" "rRRKxXFx" "8" "Entry 32" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Fluorimetric assay" "[Ref.28539222]dengue virus 2(DENV2):inhibition of the activity of NS2B-NS3 protease(IC50= 1.1 μM); inhibition of virus-induced cytopathic effects (CPE) in BHK-21 cells(EC50=2.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28539222]BHK-21 cells: CC50=24 μM." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 6 indicates homophenylalanine(hPhe), position 5 and 8 indicates D-2-naphthylalanine(D-2Nal). The N-terminal and C-terminal cyclized by a amide bond." "Mixed(D-Arg1, 2Nal5, 8)" "NS2B-NS3 protease" "The cyclic peptide could inhibit the activity of NS2B-NS3 protease, which is an essential enzyme for the replication of dengue virus." "1095.92" "C27H39N11O" "ACDEGHILMNPQSTVWY" "R" "12.3" "3" "0" "3" "0" "1" "-126.25" "-3241" "0" "0" "0" "28539222" "Bioorg Med Chem Lett. 2017 Aug 1;27(15):3586-3590." "Takagi Y, Matsui K, Nobori H, Maeda H, Sato A, Kurosu T, Orba Y, Sawa H, Hattori K, Higashino K, Numata Y, Yoshida Y." "Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity." "10.1016/j.bmcl.2017.05.027" "Anti-DENV" "DRAVPe01865" "CGGGGGSLTEINTELLDLEYEMKKLEEVVKKLEESYIDLKEL" "42" "PIH" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "[Ref.31099550]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.171 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.31099550]PIH displayed no significant cytotoxicity to 293T, Huh-7, and L02 cells even at a high concentration of 100 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "Inhibits MERS-Cov S protein-mediated cell fusion, which is the major pathway of MERS-CoV-induced host infections." "4717.37" "C207H340N48O72S2" "AFHPQRW" "E" "4.32" "5" "11" "-6" "13" "12" "-40.24" "-5973" "1.2 hour" ">20 hour" ">10 hour" "106.67" "2980" "72.68" "31099550" "ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19799-19807." "Huang X, Li M, Xu Y, Zhang J, Meng X, An X, Sun L, Guo L, Shan X, Ge J, Chen J, Luo Y, Wu H, Zhang Y, Jiang Q, Ning X. " "Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus." "10.1021/acsami.9b04240" "Anti-MERS-CoV" "DRAVPe01866" "PWLKPGDLDL" "10" "DET2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Plaque formation assay" "[Ref.23630436]dengue virus 2(DENV2):inhibition of viral replication in LLC-MK2 cells(41.5±20.0% inhibition at 200 µM, IC50>500 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23630436]Monkey kidney epithelial cells LLC-MK2: 8% Cell death at 500 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "E protein" "The peptide caused structural abnormalities and alteration of the arrangement of the viral E protein, which interferes with virus binding and entry. " "1153.34" "C55H84N12O15" "ACEFHIMNQRSTVY" "L" "4.21" "1" "2" "-1" "1" "4" "-40" "-496" ">20 hour" ">20 hour" "?" "117" "5500" "611.11" "23630436" "Int J Med Sci. 2013 Apr 16;10(6):719-29. " "Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD." "Inhibition of dengue virus entry into target cells using synthetic antiviral peptides." "10.7150/ijms.5037" "Anti-DENV" "DRAVPe01867" "AGVKDGKLDF" "10" "DET4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Plaque formation assay" "[Ref.23630436]dengue virus 2(DENV2):inhibition of viral replication in LLC-MK2 cells(84.6±5.6% inhibition at 500 µM, IC50=35 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.23630436]Monkey kidney epithelial cells LLC-MK2: 5% Cell death at 500 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "E protein" "The peptide caused structural abnormalities and alteration of the arrangement of the viral E protein, which interferes with virus binding and entry. " "1049.19" "C47H76N12O15" "CEHIMNPQRSTWY" "DGK" "6" "2" "2" "0" "2" "4" "-30" "-1291" "4.4 hour" ">20 hour" ">10 hour" "78" "0" "0" "23630436" "Int J Med Sci. 2013 Apr 16;10(6):719-29. " "Alhoot MA, Rathinam AK, Wang SM, Manikam R, Sekaran SD." "Inhibition of dengue virus entry into target cells using synthetic antiviral peptides." "10.7150/ijms.5037" "Anti-DENV" "DRAVPe01868" "WLVFFVIFYFFR" "12" "FP1 (Tkip)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.09360 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "1684.06" "C93H118N16O14" "ACDEGHKMNPQST" "F" "8.75" "1" "0" "1" "1" "10" "200" "2009" "2.8 hour" "3 min" "2 min" "113.33" "6990" "635.45" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01869" "WLVFFVIAYFAR" "12" "FP2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00087 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "1531.86" "C81H110N16O14" "CDEGHKMNPQST" "F" "8.75" "1" "0" "1" "1" "10" "183.33" "1775" "2.8 hour" "3 min" "2 min" "130" "6990" "635.45" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01870" "WLVFFVIFYFFRRRKK" "16" "FP3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00003 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "2252.78" "C117H166N28O18" "ACDEGHMNPQST" "F" "11.73" "5" "0" "5" "1" "10" "45" "-2085" "2.8 hour" "3 min" "2 min" "85" "6990" "466" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01871" "RRKKWLVFFVIFYFFR" "16" "FP4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.00004 µM);##influenza A virus PR8/Eng09 (H1N1):inhibition of viral replication in MDCK cells(IC50=0.0778 µM);##influenza A virus PR8/Vic (H3N2):inhibition of viral replication in MDCK cells(IC50=0.0535 µM);##influenza A virus PR8/Viet (H5N1):inhibition of viral replication in MDCK cells(IC50=0.1325 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "2252.78" "C117H166N28O18" "ACDEGHMNPQST" "F" "11.73" "5" "0" "5" "1" "10" "45" "-2085" "1 hour" "2 min" "2 min" "85" "6990" "466" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01872" "RRKKIFYFFR" "10" "FP7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.15483 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "1460.79" "C72H109N21O12" "ACDEGHLMNPQSTVW" "FR" "11.73" "5" "0" "5" "1" "4" "-97" "-4214" "1 hour" "2 min" "2 min" "39" "1490" "165.56" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01873" "WLVFFVRRKK" "10" "FP8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=0.63806 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "1378.73" "C69H107N19O11" "ACDEGHIMNPQSTY" "FKRV" "12.02" "4" "0" "4" "0" "6" "1" "-1965" "2.8 hour" "3 min" "2 min" "97" "5500" "611.11" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01874" "FFVIFYRRKK" "10" "FP9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus" "Orthomyxoviridae" "Plaque reduction assay" "[Ref.22258859]influenza A virus A/WSN/33 H1N1:inhibition of viral replication in MDCK cells(IC50=1.48175 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "the mechanism whereby FluPep mediates its antiviral effects is likely to involve inhibiting the binding of HA to sialic acid receptors or through interference with the fusion process by blocking protease cleavage." "1403.74" "C71H106N18O12" "ACDEGHLMNPQSTW" "F" "11.1" "4" "0" "4" "1" "5" "-10" "-2318" "1.1 hour" "3 min" "2 min" "68" "1490" "165.56" "22258859" "J Gen Virol. 2012 May;93(Pt 5):980-986." "Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. " "A novel family of peptides with potent activity against influenza A viruses. " "10.1099/vir.0.038679-0" "Anti-Influenza virus" "DRAVPe01875" "GYRARPKFKAGKR" "13" "HPV-31 L1 Cta" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "luminescence assay" "[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(86±3% inhibition at 10 μg/ml); inhibition of pseudovirions infection(91±4% inhibition at 10 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1534.83" "C69H115N25O15" "CDEHILMNQSTVW" "KR" "11.74" "6" "0" "6" "3" "3" "-173.08" "-5307" "30 hour" ">20 hour" ">10 hour" "15.38" "1490" "124.17" "15170645" "J Med Virol. 2004 Jul;73(3):474-80." "Bousarghin L, Touzé A, Yvonnet B, Coursaget P." "Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity." "10.1002/jmv.20114" "Anti-HPV" "DRAVPe01876" "TTTPAKRKKTKK" "12" "HPV-31 L1 Ctb" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HPV" "Papillomaviridae" "luminescence assay" "[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(12±10% inhibition at 10 μg/ml); inhibition of pseudovirions infection(15±8% inhibition at 10 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1387.69" "C60H114N20O17" "CDEFGHILMNQSVWY" "K" "11.39" "6" "0" "6" "4" "1" "-221.67" "-5114" "7.2 hour" ">20 hour" ">10 hour" "8.33" "0" "0" "15170645" "J Med Virol. 2004 Jul;73(3):474-80." "Bousarghin L, Touzé A, Yvonnet B, Coursaget P." "Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity." "10.1002/jmv.20114" "Anti-HPV" "DRAVPe01877" "MLRKRRKRL" "9" "HPV-16 L2 Ct" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "luminescence assay" "[Ref.15170645]human papillomavirus(HPV):inhibition of HPV virus-like particle cell entry(78±6% inhibition at 10 μg/ml); inhibition of pseudovirions infection(96±20% inhibition at 10 μg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1256.62" "C53H105N23O10S" "ACDEFGHINPQSTVWY" "R" "12.48" "6" "0" "6" "0" "2" "-181.11" "-5859" "30 hour" ">20 hour" ">10 hour" "86.67" "0" "0" "15170645" "J Med Virol. 2004 Jul;73(3):474-80." "Bousarghin L, Touzé A, Yvonnet B, Coursaget P." "Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity." "10.1002/jmv.20114" "Anti-HPV" "DRAVPe01878" "GCKKYRRFRWKFKGKFWFWG" "20" "Pep19-2.5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HIV, HSV-1, HCV, HBV" "Retroviridae,Herpesviridae, Flaviviridae, Hepadnaviridae" "luciferase infection assay" "[Ref.22457281]HIV-1 BaL:inhibition of viral entry in 293T cells(IC50=8 µg/ml);##HIV-1 NL4-3:inhibition of viral entry in 293T cells(IC50=16 µg/ml);##HSV-1:inhibition of viral entry in Vero cells(IC50=0.42 µg/ml);##Hepatitis C virus (HCV):inhibition of viral entry in 293T cells(IC50=40 µg/ml);##Hepatitis B virus (HBV):inhibition of viral entry in 293T cells(IC50=1 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22457281]No significant cytotoxicity to Vero, TZM-bl and Jurkat cells even at a high concentration of 20 μg/mL." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "SALPs block entry of a variety of human pathogenic enveloped viruses, such as HIV-1, HBV, HCV, and HSV 1 and 2 by blocking heparan sulfate on the host cell plasma membrane, which serves as a the docking molecule for these pathogens." "2712.26" "C135H187N37O22S" "ADEHILMNPQSTV" "K" "11.17" "8" "0" "8" "5" "7" "-122.5" "-4964" "30 hour" ">20 hour" ">10 hour" "0" "17990" "946.84" "22457281" "J Infect Dis. 2012 Jun;205(11):1654-64." "Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U." "A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses." "10.1093/infdis/jis273" "Anti-HIV, Anti-HSV-1, Anti-HCV, Anti-HBV" "DRAVPe01879" "GKKYRRFRWKFKFGKWFWFG" "20" "Pep19-4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV, HSV-1, HCV" "Retroviridae,Herpesviridae, Flaviviridae" "luciferase infection assay" "[Ref.22457281]HIV-1 BaL:inhibition of viral entry in 293T cells(IC50=22 µg/ml);##HIV-1 NL4-3:inhibition of viral entry in 293T cells(IC50=10 µg/ml);##HSV-1:inhibition of viral entry in Vero cells(IC50=1.8 µg/ml);##Hepatitis C virus (HCV):inhibition of viral entry in 293T cells(IC50=37 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22457281]No significant cytotoxicity to Vero, TZM-bl and Jurkat cells even at a high concentration of 20 μg/mL." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "SALPs block entry of a variety of human pathogenic enveloped viruses, such as HIV-1, HBV, HCV, and HSV 1 and 2 by blocking heparan sulfate on the host cell plasma membrane, which serves as a the docking molecule for these pathogens." "2756.3" "C141H191N37O22" "ACDEHILMNPQSTV" "FK" "11.76" "8" "0" "8" "4" "8" "-121" "-4794" "30 hour" ">20 hour" ">10 hour" "0" "17990" "946.84" "22457281" "J Infect Dis. 2012 Jun;205(11):1654-64." "Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U." "A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses." "10.1093/infdis/jis273" "Anti-HIV, Anti-HSV-1, Anti-HCV" "DRAVPe01880" "ATSSANSKA" "9" "Loop3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JEV" "Flaviviridae" "Plaque assay" "[Ref.22465300]Japanese encephalitis virus(JEV):inhibition of viral replication in BHK-21 cells(IC50=10 ± 1.4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22465300]Did not stimulate significant cytotoxicity in BHK-21 cells even at 200 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Envelope protein" "prevent JEV infection by interfering in virus attachment to the cells." "835.87" "C32H57N11O15" "CDEFGHILMPQRVWY" "AS" "8.8" "1" "0" "1" "5" "3" "-56.67" "-1953" "4.4 hour" ">20 hour" ">10 hour" "33.33" "0" "0" "22465300" "Antiviral Res. 2012 May;94(2):179-83." "Li C, Zhang LY, Sun MX, Li PP, Huang L, Wei JC, Yao YL, Isahg H, Chen PY, Mao X." "Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII." "10.1016/j.antiviral.2012.03.002" "Anti-JEV" "DRAVPe01881" "SISNALNKLEESNRNLDKVNVKLT" "24" "C24" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "NDV" "Paramyxoviridae" "Plaque reduction assay" "[Ref.12127571]Newcastle disease virus (NDV):inhibition of syncytium formation between NDV-infected cells(IC50=3.27 μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "By binding to the opposite HR region in the F protein, peptides would inhibit fusion from the initial steps (lipid- and contents-mixing), blocking the conformational changes in the fusion protein required for triggering fusion." "2700.04" "C114H199N35O40" "CFGHMPQWY" "N" "8.22" "4" "3" "1" "9" "8" "-72.5" "-6539" "1.9 hour" ">20 hour" ">10 hour" "109.58" "0" "0" "12127571" "Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20." "San Román K, Villar E, Muñoz-Barroso I." "Mode of action of two inhibitory peptides from heptad repeat domains of the fusion protein of Newcastle disease virus." "10.1016/s1357-2725(02)00045-6" "Anti-NDV" "DRAVPe01882" "KQNAANILRLKESIAATNEAVHEV" "24" "N24" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "NDV" "Paramyxoviridae" "Plaque reduction assay" "[Ref.12127571]Newcastle disease virus (NDV):inhibition of syncytium formation between NDV-infected cells(IC50=22.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "By binding to the opposite HR region in the F protein, peptides would inhibit fusion from the initial steps (lipid- and contents-mixing), blocking the conformational changes in the fusion protein required for triggering fusion." "2619.96" "C112H191N35O37" "CDFGMPWY" "A" "6.76" "4" "3" "1" "5" "11" "-31.25" "-4573" "1.3 hour" "3 min" "2 min" "110" "0" "0" "12127571" "Int J Biochem Cell Biol. 2002 Oct;34(10):1207-20." "San Román K, Villar E, Muñoz-Barroso I." "Mode of action of two inhibitory peptides from heptad repeat domains of the fusion protein of Newcastle disease virus." "10.1016/s1357-2725(02)00045-6" "Anti-NDV" "DRAVPe01883" "GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA" "49" "HLFcin 1-49" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "Western blotting" "[Ref.17481742]human papillomavirus(HPV):inhibition of pseudovirus infection in C33A cells(IC50=0.32±0.18μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "Free" "Free" "Disulfide bonds between Cys10 and Cys46, Cys20 and Cys37." "L" "Not found" "No mechanism information found in the reference(s)." "5743.71" "C244H403N85O66S5" "HLY" "R" "11.24" "11" "2" "9" "12" "13" "-85.1" "-15425" "30 hour" ">20 hour" ">10 hour" "53.67" "11250" "234.38" "17481742" "Antiviral Res. 2007 Sep;75(3):258-65." "Mistry N, Drobni P, Näslund J, Sunkari VG, Jenssen H, Evander M." "The anti-papillomavirus activity of human and bovine lactoferricin." "10.1016/j.antiviral.2007.03.012" "Anti-HPV" "DRAVPe01884" "FKCRRWQWRMKKLGAPSITCVRRAFA" "26" "BLfcinB 17-42" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "Western blotting" "[Ref.17481742]human papillomavirus(HPV):inhibition of pseudovirus infection in C33A cells(IC50=0.25±0.24 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "Free" "Free" "Disulfide bonds between Cys3 and Cys20." "L" "Not found" "No mechanism information found in the reference(s)." "3196.9" "C144H231N47O30S3" "DEHNY" "R" "11.84" "8" "0" "8" "5" "10" "-48.46" "-6698" "1.1 hour" "3 min" "2 min" "52.69" "11125" "445" "17481742" "Antiviral Res. 2007 Sep;75(3):258-65." "Mistry N, Drobni P, Näslund J, Sunkari VG, Jenssen H, Evander M." "The anti-papillomavirus activity of human and bovine lactoferricin." "10.1016/j.antiviral.2007.03.012" "Anti-HPV" "DRAVPe01885" "AGDDQGLDKCVPNSKEK" "17" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral replication in MDCK cells(EC50=3.7±0.35 pM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral replication in MDCK cells(EC50=3.4±0.14 pM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral replication in MDCK cells(EC50=7.3±0.65 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22595270]MDCK cells:CC50>25 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "The peptide may bind with HA and precent the attachment to target cells." "1803.96" "C73H122N22O29S" "FHIMRTWY" "DK" "4.68" "3" "4" "-1" "5" "3" "-138.82" "-5127" "4.4 hour" ">20 hour" ">10 hour" "45.88" "0" "0" "22595270" "Pathog Glob Health. 2012 Mar;106(1):12-9." "Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F." "Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus." "10.1179/2047773212Y.0000000004" "Anti-Anti-Influenza A virus" "DRAVPe01886" "NGESSADWAKN" "11" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral replication in MDCK cells(EC50=225±5.8 fM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral replication in MDCK cells(EC50=50±1.37 fM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral replication in MDCK cells(EC50=22.5±1.16 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22595270]MDCK cells:CC50>25 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "The peptide may bind with HA and precent the attachment to target cells." "1178.18" "C48H71N15O20" "CFHILMPQRTVY" "ANS" "4.37" "1" "2" "-1" "5" "3" "-156.36" "-3427" "1.4 hour" "3 min" ">10 hour" "18.18" "5500" "550" "22595270" "Pathog Glob Health. 2012 Mar;106(1):12-9." "Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F." "Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus." "10.1179/2047773212Y.0000000004" "Anti-Anti-Influenza A virus" "DRAVPe01887" "SKHSSLDCVLRP" "12" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.22595270]Influenza A virus (A/Roma-ISS/2/08 H1N1):inhibition of viral replication in MDCK cells(EC50=4±0.37 pM);##Influenza A virus (A/Parma/24/09 H1N1):inhibition of viral replication in MDCK cells(EC50=3.1±0.12 pM);##Influenza A virus (A/Parma/05/06 H3N2):inhibition of viral replication in MDCK cells(EC50=5.8±0.7 pM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.22595270]MDCK cells:CC50>25 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "The peptide may bind with HA and precent the attachment to target cells." "1341.55" "C56H96N18O18S" "AEFGIMNQTWY" "S" "7.97" "3" "1" "2" "4" "3" "-40" "-2889" "1.9 hour" ">20 hour" ">10 hour" "89.17" "0" "0" "22595270" "Pathog Glob Health. 2012 Mar;106(1):12-9." "Ammendolia MG, Agamennone M, Pietrantoni A, Lannutti F, Siciliano RA, De Giulio B, Amici C, Superti F." "Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus." "10.1179/2047773212Y.0000000004" "Anti-Anti-Influenza A virus" "DRAVPe01888" "AVSKVLHLEGEVNKISALLSTNKAVVSLSNGVSVLTSKVLDLDNYIDKQLLPIVNK" "56" "HR1-30a" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cell fusion assay" "[Ref.12615056]respiratory syncytial virus(RSV):inhibition of cell fusion in Hep2 cells( IC50=1.68 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "Peptide derived from hRSV F protein give strong virus–cell fusion inhibition effect. " "5989" "C268H458N70O83" "CFMRW" "LV" "8.35" "7" "5" "2" "17" "25" "33.75" "-3793" "4.4 hour" ">20 hour" ">10 hour" "142.5" "1490" "27.09" "12615056" "Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. " "Wang E, Sun X, Qian Y, Zhao L, Tien P, Gao GF." "Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion." "10.1016/s0006-291x(03)00197-9" "Anti-RSV" "DRAVPe01889" "NFYDPLVFPSDEFDASISQVNEKINQSLASIRKSDELLHNVNAGK" "45" "HR2-30a" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "RSV" "Paramyxoviridae" "Cell fusion assay" "[Ref.12615056]respiratory syncytial virus(RSV):inhibition of cell fusion in Hep2 cells( IC50=2.93 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "Peptide derived from hRSV F protein give strong virus–cell fusion inhibition effect. " "5051.56" "C223H346N60O74" "CMTW" "S" "4.65" "5" "7" "-2" "13" "16" "-51.11" "-9449" "1.4 hour" "3 min" ">10 hour" "86.67" "1490" "33.86" "12615056" "Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75. " "Wang E, Sun X, Qian Y, Zhao L, Tien P, Gao GF." "Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion." "10.1016/s0006-291x(03)00197-9" "Anti-RSV" "DRAVPe01890" "NKGCATCSIGAACLVDGPIPDFEIAGAtGLfGLWG" "35" "Subtilosin-A" "Bacillus subtilis" "O07623" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1PXQ" "HSV-2" "Herpesviridae" "Plaque formation assay" "[Ref.25087911]herpes simplex virus type 2(HSV-2): inhibition of viral replication in Vero cells(90% inhibition at 25 μg/mL,EC50= 18.2μg/mL)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.25087911]Vero cells: CC50=316.8 μg/mL." "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The N-terminal and C-terminal cyclized by a amide bond. Thioether bridges between Cys4 and Phe31,Cys7 and Thr28,Cys13 and Phe22." "Mixed(D-Thr28,D-Phe31)" "Not found" "Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport." "3425.94" "C139H214N36O41S3" "HMQRY" "G" "4.03" "1" "3" "-2" "13" "14" "63.14" "1593" "1.4 hour" "3 min" ">10 hour" "89.43" "5625" "165.44" "25087911" "J Appl Microbiol. 2014 Nov;117(5):1253-9." "Quintana VM, Torres NI, Wachsman MB, Sinko PJ, Castilla V, Chikindas M." "Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin." "10.1111/jam.12618" "Anti-HSV-2" "DRAVPe01891" "RRKKAAVALLPAVLLALLAP" "20" "EB" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutinin assay" "[Ref.17005658]Influenza A virus(A/Hong Kong/483/97 ([HK/483] strain H5N1)): inhibition of viral replication by preventing attachment to cRBCs(IC50=8 μM); inhibition of influenza virus-induced cell death and replication in vitro(IC50=4.5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17005658]No cytotoxicity against MDCK cells up to 50μM" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HA" "The binding of EB to HA could lead to a conformation change in HA, decreasing the affinity for sialic acids on the cell surface. " "2084.67" "C98H178N28O21" "CDEFGHIMNQSTWY" "AL" "12.02" "4" "0" "4" "0" "14" "110" "752" "1 hour" "2 min" "2 min" "176" "0" "0" "17005658" "J Virol. 2006 Dec;80(24):11960-7." "Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S." "Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells." "10.1128/JVI.01678-06" "Anti-Anti-Influenza A virus" "DRAVPe01892" "EF" "2" "EF" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming reduction assay" "[Ref.24612829]dengue virus 2(DENV2):inhibition of viral entry in Vero cells(IC50=96.50 µM); inhibition of viral replication in Vero cells(83.47% inhibition at 200 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24612829]No cytotoxicity against Vero cells up to 500 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "E protein" "No mechanism information found in the reference(s)." "294.31" "C14H18N2O5" "ACDGHIKLMNPQRSTVWY" "EF" "4" "0" "1" "-1" "0" "1" "-35" "-383" "1 hour" "30 min" ">10 hour" "0" "0" "0" "24612829" "Chem Biol Drug Des. 2014 Aug;84(2):148-57." "Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. " "Peptide inhibitors against dengue virus infection." "10.1111/cbdd.12309" "Anti-DENV" "DRAVPe01893" "KEN" "3" "KEN" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming reduction assay" "[Ref.24612829]dengue virus 2(DENV2):inhibition of viral entry in Vero cells(IC50=331.9 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24612829]No cytotoxicity against Vero cells up to 500 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "E protein" "No mechanism information found in the reference(s)." "389.41" "C15H27N5O7" "ACDFGHILMPQRSTVWY" "EKN" "6" "1" "1" "0" "1" "0" "-363.33" "-1900" "1.3 hour" "3 min" "2 min" "0" "0" "0" "24612829" "Chem Biol Drug Des. 2014 Aug;84(2):148-57." "Panya A, Bangphoomi K, Choowongkomon K, Yenchitsomanus PT. " "Peptide inhibitors against dengue virus infection." "10.1111/cbdd.12309" "Anti-DENV" "DRAVPe01894" "SVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPG" "41" "MLH40" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "cell-based flavivirus immunodetection assay" "[Ref.25891143]dengue virus 1(DENV1):inhibition of viral infection in Vero cells(IC50=30.35 ± 1.25 μM);##dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=31.41 ± 1.09 μM);##dengue virus 3(DENV3):inhibition of viral infection in Vero cells(IC50=27.95 ± 1.41 μM);##dengue virus 4(DENV4):inhibition of viral infection in Vero cells(IC50=24.45 ± 1.20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "4684.37" "C209H325N61O58S2" "CDFNY" "EGTV" "6.79" "7" "4" "3" "11" "14" "-30.73" "-5772" "1.9 hour" ">20 hour" ">10 hour" "80.73" "16500" "412.5" "25891143" "Chem Biol Drug Des. 2015 Nov;86(5):1093-104." "Panya A, Sawasdee N, Junking M, Srisawat C, Choowongkomon K, Yenchitsomanus PT. " "A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection. " "10.1111/cbdd.12576" "Anti-DENV" "DRAVPe01895" "GLLYFAIFFVAAWHIRGR" "18" "H2-2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=1.60 ± 0.11 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=2.19 ± 0.16 μM)." "[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes." "[Ref.26251517]Huh7.5.1 cells: CC50=83.64 ± 6.95 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2137.56" "C107H153N27O20" "CDEKMNPQST" "AF" "10.84" "3" "0" "3" "3" "12" "107.78" "766" "30 hour" ">20 hour" ">10 hour" "119.44" "6990" "411.18" "26251517" "J Biol Chem. 2015 Sep 18;290(38):23254-63." "Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. " "A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. " "10.1074/jbc.M115.662452" "Anti-HCV" "DRAVPe01896" "HGLLYFAIFFVAAWHIRGR" "19" "H2-3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=0.54 ± 0.08 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=1.09 ± 0.11 μM);H2-3 peptide inactivated HCV(EC50=82.11 nM)." "[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes." "[Ref.26251517]Huh7.5.1 cells: CC50=115.99 ± 16.68 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2274.7" "C113H160N30O21" "CDEKMNPQST" "AF" "10.84" "4" "0" "4" "3" "12" "85.26" "300" "3.5 hour" "10 min" ">10 hour" "113.16" "6990" "388.33" "26251517" "J Biol Chem. 2015 Sep 18;290(38):23254-63." "Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. " "A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. " "10.1074/jbc.M115.662452" "Anti-HCV" "DRAVPe01897" "WPFCLLLMAL" "10" "H3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "[Ref.26251517]Hepatitis C Virus(HCV):inhibition of viral infection in Huh7.5.1 cells(EC50=0.52 ± 0.07 μM); inhibition of post-infection in Huh7.5.1 cells(EC50=1.54 ± 0.73 μM)." "[Ref.26251517]<10% hemolysis even at 400 μM against human erythrocytes." "[Ref.26251517]Huh7.5.1 cells: CC50=47.22 ± 5.29 μM;##Bel7402 cells:CC50~200 μM;##HeLa cells:CC50~200 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1206.57" "C60H91N11O11S2" "DEGHIKNQRSTVY" "L" "5.52" "0" "0" "0" "1" "7" "217" "3043" "2.8 hour" "3 min" "2 min" "166" "5500" "611.11" "26251517" "J Biol Chem. 2015 Sep 18;290(38):23254-63." "Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. " "A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. " "10.1074/jbc.M115.662452" "Anti-HCV" "DRAVPe01898" "LYGNEGCGWAGWLLSPRG" "18" "SL173" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "ELISA" "[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(80% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1936.17" "C88H126N24O24S" "DFHIKMQTV" "G" "5.99" "1" "1" "0" "9" "6" "-18.33" "-470" "5.5 hour" "3 min" "2 min" "70.56" "12490" "734.71" "19264632" "J Gen Virol. 2009 Jun;90(Pt 6):1319-1328." "Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. " "Peptide inhibitors of hepatitis C virus core oligomerization and virus production." "10.1099/vir.0.008565-0" "Anti-HCV" "DRAVPe01899" "GWAGWLLSPRGSRPSWGP" "18" "SL174" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HCV" "Flaviviridae" "ELISA" "[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(15% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1967.22" "C92H131N27O22" "CDEFHIKMNQTVY" "G" "12" "2" "0" "2" "7" "6" "-61.67" "-1764" "30 hour" ">20 hour" ">10 hour" "48.89" "16500" "970.59" "19264632" "J Gen Virol. 2009 Jun;90(Pt 6):1319-1328." "Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. " "Peptide inhibitors of hepatitis C virus core oligomerization and virus production." "10.1099/vir.0.008565-0" "Anti-HCV" "DRAVPe01900" "GWAGWLLSPRGSRPS" "15" "SL175" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "ELISA" "[Ref.19264632]hepatitis C virus(J6/JFH1):inhibition of viral infection in Huh-7.5 cells(50% inhibition at 20 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1626.84" "C74H111N23O19" "CDEFHIKMNQTVY" "GS" "12" "2" "0" "2" "6" "5" "-54.67" "-2091" "30 hour" ">20 hour" ">10 hour" "58.67" "11000" "785.71" "19264632" "J Gen Virol. 2009 Jun;90(Pt 6):1319-1328." "Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. " "Peptide inhibitors of hepatitis C virus core oligomerization and virus production." "10.1099/vir.0.008565-0" "Anti-HCV" "DRAVPe01901" "MDVNP" "5" "PB1 (1–5)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=185 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "574.65" "C23H38N6O9S" "ACEFGHIKLQRSTWY" "DMNPV" "3.8" "0" "1" "-1" "1" "1" "-50" "-897" "30 hour" ">20 hour" ">10 hour" "58" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments. " "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01902" "MDVNPTLLFLKVPAQNAISTTFPYT" "27" "PB1 (1–25)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=122 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "2782.25" "C129H197N29O35S" "CEGHRW" "T" "5.59" "1" "1" "0" "8" "10" "28.89" "-722" "30 hour" ">20 hour" ">10 hour" "86.67" "1490" "57.31" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments. " "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01903" "TLLFLKVPAQNAISTTFPYT" "21" "PB1 (6–25)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=129 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "2225.61" "C106H163N23O28" "CDEGHMRW" "T" "8.26" "1" "0" "1" "7" "9" "49.05" "175" "7.2 hour" ">20 hour" ">10 hour" "97.62" "1490" "74.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01904" "AQNAISTTFPYT" "12" "PB1 (14–25)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=380 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1313.43" "C59H88N14O20" "CDEGHKLMRVW" "T" "5.57" "0" "0" "0" "6" "4" "-15.83" "-1191" "4.4 hour" ">20 hour" ">10 hour" "49.17" "1490" "135.45" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01905" "MEVVQQTRMDKLTQGRQTYD" "21" "PB1 (111–130)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=58 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "2427.73" "C100H165N31O34S2" "ACFHINPSW" "Q" "5.88" "3" "3" "0" "5" "3" "-120" "-7101" "30 hour" ">20 hour" ">10 hour" "46.19" "1490" "74.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01906" "LPVGGNEKKAKLANVVRKMM" "21" "PB1 (271–290)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=33 ± 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "2183.7" "C95H169N29O24S2" "CDFHIQSTWY" "K" "10.46" "5" "1" "4" "4" "7" "-25.71" "-2505" "5.5 hour" "3 min" "2 min" "88.1" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01907" "FNESTR" "6" "PB1 (381–386)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=664 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "752.78" "C31H48N10O12" "ACDGHIKLMPQVWY" "EFNRST" "6" "1" "1" "0" "3" "1" "-170" "-3136" "1.1 hour" "3 min" "2 min" "0" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01908" "FNESTRKKIE" "10" "PB1 (381–390)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=400 ± 8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1251.41" "C54H90N16O18" "ACDGHLMPQVWY" "EK" "8.59" "3" "2" "1" "3" "2" "-170" "-4435" "1.1 hour" "3 min" "2 min" "39" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01909" "FNESTRKKIEKIRPLLVEGT" "21" "PB1 (381–400)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=23 ± 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "2358.77" "C105H178N30O30" "ACDHMQWY" "EK" "9.7" "5" "3" "2" "5" "6" "-72.86" "-5446" "1.1 hour" "3 min" "2 min" "88.1" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01910" "KIRPLLVEGT" "10" "PB1 (391–400)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=71 ± 3μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1125.38" "C51H92N14O14" "ACDFHMNQSWY" "L" "8.75" "2" "1" "1" "2" "4" "17" "-1011" "1.3 hour" "3 min" "2 min" "146" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01911" "MFNMLSTVLG" "10" "PB1 (411–420)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=369 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1112.37" "C49H81N11O14S2" "ACDEHIKPQRWY" "LM" "5.28" "0" "0" "0" "4" "4" "130" "989" "30 hour" ">20 hour" ">10 hour" "107" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01912" "IGVTVI" "6" "PB1 (525–530)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=833 ± 6 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "600.76" "C28H52N6O8" "ACDEFHKLMNPQRSWY" "IV" "5.52" "0" "0" "0" "2" "4" "271.67" "1629" "20 hour" "30 min" ">10 hour" "226.67" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01913" "IGVTVIKNNMI" "11" "PB1 (525–535)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=416 ± 3μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1201.49" "C53H96N14O15S" "ACDEFHLPQRSWY" "I" "8.75" "1" "0" "1" "4" "5" "107.27" "473" "20 hour" "30 min" ">10 hour" "159.09" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01914" "TLLFLKVP" "8" "PB1 (6–13)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=102 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "930.2" "C47H79N9O10" "ACDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "5" "152.5" "1366" "7.2 hour" ">20 hour" ">10 hour" "182.5" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01915" "TLLFLKVP" "8" "PB1 (6–13)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=35 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "930.2" "C47H79N9O10" "ACDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "5" "152.5" "1366" "7.2 hour" ">20 hour" ">10 hour" "182.5" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01916" "TLLFLKVP" "8" "Ac-PB1 (6–13)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=33 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "930.2" "C47H79N9O10" "ACDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "5" "152.5" "1366" "7.2 hour" ">20 hour" ">10 hour" "182.5" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01917" "TLLFLKVP" "8" "Ac-PB1 (6–13)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=12 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "930.2" "C47H79N9O10" "ACDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "5" "152.5" "1366" "7.2 hour" ">20 hour" ">10 hour" "182.5" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01918" "TLLFLKVPA" "9" "PB1 (6–14)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=34 ± 2 μM);##Influenza A virus(A/Puerto Rico/8/34 (H1N1)):antiviral activity of the peptide in MDCK cells(ED50=8.9 ± 1.0 μM);##Influenza A virus(A/Aichi/2/68 (H3N2)):antiviral activity of the peptide in MDCK cells(ED50=10.7 ± 0.9 μM);##Influenza A virus(A/Mallard/Pennsylvania/10218/84 (H5N2)):antiviral activity of the peptide in MDCK cells(ED50=8.5 ± 1.1 μM);##Influenza A virus(A/Vladivostok/02/09 of H1N1):antiviral activity of the peptide in MDCK cells(ED50=1.7 ± 0.8 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1001.28" "C50H84N10O11" "CDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "6" "155.56" "1547" "7.2 hour" ">20 hour" ">10 hour" "173.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01919" "TLLFLKVPA" "9" "PB1 (6–14)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=6 ± 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1001.28" "C50H84N10O11" "CDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "6" "155.56" "1547" "7.2 hour" ">20 hour" ">10 hour" "173.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01920" "TLLFLKVPA" "9" "Ac-PB1 (6–14)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=82 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1001.28" "C50H84N10O11" "CDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "6" "155.56" "1547" "7.2 hour" ">20 hour" ">10 hour" "173.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01921" "TLLFLKVPA" "9" "Ac-PB1 (6–14)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=4 ± 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1001.28" "C50H84N10O11" "CDEGHIMNQRSWY" "L" "8.41" "1" "0" "1" "1" "6" "155.56" "1547" "7.2 hour" ">20 hour" ">10 hour" "173.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01922" "GDPPY" "5" "PB1 (26–30)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=115 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "547.57" "C25H33N5O9" "ACEFHIKLMNQRSTVW" "P" "3.8" "0" "1" "-1" "2" "0" "-168" "-792" "30 hour" ">20 hour" ">10 hour" "0" "1490" "372.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01923" "GDPPY" "5" "PB1 (26–30)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=100 ± 5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "547.57" "C25H33N5O9" "ACEFHIKLMNQRSTVW" "P" "3.8" "0" "1" "-1" "2" "0" "-168" "-792" "30 hour" ">20 hour" ">10 hour" "0" "1490" "372.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01924" "GDPPY" "5" "Ac-PB1 (26–30)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=95 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "547.57" "C25H33N5O9" "ACEFHIKLMNQRSTVW" "P" "3.8" "0" "1" "-1" "2" "0" "-168" "-792" "30 hour" ">20 hour" ">10 hour" "0" "1490" "372.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01925" "GDPPY" "5" "Ac-PB1 (26–30)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=254 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "547.57" "C25H33N5O9" "ACEFHIKLMNQRSTVW" "P" "3.8" "0" "1" "-1" "2" "0" "-168" "-792" "30 hour" ">20 hour" ">10 hour" "0" "1490" "372.5" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01926" "LLVEGT" "6" "PB1 (395–400)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=91 ± 2 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "630.74" "C28H50N6O10" "ACDFHIKMNPQRSWY" "L" "4" "0" "1" "-1" "2" "3" "120" "544" "5.5 hour" "3 min" "2 min" "178.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01927" "LLVEGT" "6" "PB1 (395–400)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=794 ± 4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "630.74" "C28H50N6O10" "ACDFHIKMNPQRSWY" "L" "4" "0" "1" "-1" "2" "3" "120" "544" "5.5 hour" "3 min" "2 min" "178.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01928" "LLVEGT" "6" "Ac-PB1 (395–400)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=297 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "630.74" "C28H50N6O10" "ACDFHIKMNPQRSWY" "L" "4" "0" "1" "-1" "2" "3" "120" "544" "5.5 hour" "3 min" "2 min" "178.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01929" "LLVEGT" "6" "Ac-PB1 (395–400)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=744 ± 4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "630.74" "C28H50N6O10" "ACDFHIKMNPQRSWY" "L" "4" "0" "1" "-1" "2" "3" "120" "544" "5.5 hour" "3 min" "2 min" "178.33" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01930" "KNNMINNDLG" "10" "PB1 (531–540)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=51 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1132.26" "C45H77N15O17S" "ACEFHPQRSTVWY" "N" "5.84" "1" "1" "0" "5" "2" "-116" "-2770" "1.3 hour" "3 min" "2 min" "78" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01931" "KNNMINNDLG" "10" "PB1 (531–540)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=44 ± 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1132.26" "C45H77N15O17S" "ACEFHPQRSTVWY" "N" "5.84" "1" "1" "0" "5" "2" "-116" "-2770" "1.3 hour" "3 min" "2 min" "78" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01932" "KNNMINNDLG" "10" "Ac-PB1 (531–540)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=71 ± 3 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Free" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1132.26" "C45H77N15O17S" "ACEFHPQRSTVWY" "N" "5.84" "1" "1" "0" "5" "2" "-116" "-2770" "1.3 hour" "3 min" "2 min" "78" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01933" "KNNMINNDLG" "10" "Ac-PB1 (531–540)-NH2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A virus" "Orthomyxoviridae" "Hemagglutination assay" "[Ref.25446335]Influenza A virus(A/California/07/2009 (H1N1)pdm09/):antiviral activity of the peptide in MDCK cells(ED50=109 ± 4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "The peptide may affect the early stages of the viral life cycle, which includes the synthesis of polymerase subunits and their subsequent assembly into functionally active complex. The peptide could interfere with these processes thus inhibiting virus replication." "1132.26" "C45H77N15O17S" "ACEFHPQRSTVWY" "N" "5.84" "1" "1" "0" "5" "2" "-116" "-2770" "1.3 hour" "3 min" "2 min" "78" "0" "0" "25446335" "Antiviral Res. 2015 Jan;113:4-10." "Matusevich OV, Egorov VV, Gluzdikov IA, Titov MI, Zarubaev VV, Shtro AA, Slita AV, Dukov MI, Shurygina AP, Smirnova TD, Kudryavtsev IV, Vasin AV, Kiselev OI." "Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments." "10.1016/j.antiviral.2014.10.015" "Anti-Anti-Influenza A virus" "DRAVPe01934" "LNLFKKTINGLISDSLVIR" "19" "AVP-p" "Synthetic construct" "A0A7D5DRX8## P03540" "Experimentally Validated" "3052300" "GPC" "QLA46850.1" "348 to 366" "pfam00798" "MK896487" "Genomic RNA" "Not Available" "None" "PICV,JUNV" "Arenaviridae" "Plaque reduction assay" "[Ref.24850726]Pichinde virus (PICV):inhibition of viral infection in Vero cells(IC50=7.05 ± 2.19 μM);##Arenaviruses (TAMV, JUNV, MACV, LASV): Inhibition (IC50 = 2–10 μM);##Complete inhibition of viral plaque formation at ~20 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24850726]No significant loss of viability was observed in Vero cells or human foreskin fibroblasts (HFF) up to 100 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "That untimely deployment of fusion machinery by the peptide could render virions less able to engage in on-pathway receptor binding or endosomal fusion. " "2144.59" "C98H170N26O27" "ACEHMPQWY" "L" "9.99" "3" "1" "2" "6" "9" "53.68" "-1499" "5.5 hour" "3 min" "2 min" "158.95" "0" "0" "24850726" "J Virol. 2014 Aug;88(15):8556-64." "Spence JS, Melnik LI, Badani H, Wimley WC, Garry RF. " "Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism. " "10.1128/JVI.01133-14" "Anti-PICV" "DRAVPe01935" "GRKKRRQRRRC" "11" "TAT-Cd0" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Antiviral assay" "[Ref.21029018]Herpes simplex virus type 1(HSV-1):inhibition of viral infection in human corneal epithelial (HCE) cells(EC50=0.20 μM); exert antiviral activity by entry block(EC50=0.1 μM);exert antiviral activity by postentry(EC50~30.0 μM);exert antiviral activity by cell protection(EC50=0.4 μM);exert antiviral activity by virus inactivation(EC50=9.5 μM);exert antiviral activity by inhibitng attachment(EC50=3.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.21029018]human corneal epithelial (HCE) cells:CC50~100 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1499.81" "C58H114N32O13S" "ADEFHILMNPSTVWY" "R" "12.3" "8" "0" "8" "2" "0" "-329.09" "-10394" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "21029018" "J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. " "Larsen IV, Brandt CR." "A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells." "10.1089/jop.2010.0076" "DRAVPa1018" "Anti-HSV-1" "DRAVPe01936" "GREERRQRRRC" "11" "E50,51TAT-Cd0" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Antiviral assay" "[Ref.21029018]Herpes simplex virus type 1(HSV-1):inhibition of viral infection in human corneal epithelial (HCE) cells(EC50~30.0 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "1501.69" "C56H104N30O17S" "ADFHIKLMNPSTVWY" "R" "11.7" "6" "2" "4" "2" "0" "-321.82" "-10646" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "21029018" "J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. " "Larsen IV, Brandt CR." "A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells." "10.1089/jop.2010.0076" "Anti-HSV-1" "DRAVPe01937" "NDSRGIDAEEELETKAELVITKLKTPLMRGKVVVGAAGA" "39" "MDVgHH2L" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "NDV,MDV" "Paramyxoviridae, Herpesviridae" "Plaque formation assay" "[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=43.4 ± 2.0 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=34.0 ± 2.00 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes " "4110.74" "C177H306N50O59S" "CFHQWY" "AE" "5.15" "6" "7" "-1" "9" "15" "-17.44" "-6044" "1.4 hour" "3 min" ">10 hour" "102.56" "0" "0" "24412629" "J Virol Methods. 2014 Apr;199:11-6." "Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ." "In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. " "10.1016/j.jviromet.2013.12.022" "Anti-NDV,Anti-MDV" "DRAVPe01938" "NADIIKSLIRKTIINASKNTASLSILQHLYVLRS" "34" "MDVgBH3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "NDV,MDV" "Paramyxoviridae, Herpesviridae" "Plaque formation assay" "[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=52.9 ± 0.9 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=37.5 ± 1.2 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes " "3795.48" "C169H293N49O49" "CEFGMPW" "I" "10.45" "6" "1" "5" "11" "15" "22.06" "-4402" "1.4 hour" "3 min" ">10 hour" "143.53" "1490" "45.15" "24412629" "J Virol Methods. 2014 Apr;199:11-6." "Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ." "In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. " "10.1016/j.jviromet.2013.12.022" "Anti-NDV,Anti-MDV" "DRAVPe01939" "LGNVNNSISNALDKLEESNSKLDKVNVKLTGTSAL" "35" "NDVHR2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "NDV,MDV" "Paramyxoviridae, Herpesviridae" "Plaque formation assay" "[Ref.24412629]Newcastle disease virus(NDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=18.9 ± 2.8 μmol/L);##Marek's disease virus(MDV):inhibition of viral infection in chicken embryo fibroblasts(IC50=65.3 ±0.9 μmol/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "peptides from the hydrophobic fusogenic domains of gB and gH can block virus entry, disrupt cellular membranes by interacting with the cellular factors, or play a role in the glycoprotein conformational changes " "3687.12" "C156H269N45O57" "CFHMPQRWY" "LN" "6.21" "4" "4" "0" "15" "12" "-38" "-6318" "5.5 hour" "3 min" "2 min" "108.57" "0" "0" "24412629" "J Virol Methods. 2014 Apr;199:11-6." "Chi XJ, Wang XJ, Wang CY, Cui XJ, Wang XJ." "In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus. " "10.1016/j.jviromet.2013.12.022" "Anti-NDV,Anti-MDV" "DRAVPe01940" "TIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFV" "43" "HRA1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HMPV" "Paramyxoviridae" "RT-PCR assay " "[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=177 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM)." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the process." "4656.4" "C204H353N59O64" "CHMPQWY" "V" "9.52" "7" "5" "2" "12" "19" "4.65" "-6990" "7.2 hour" ">20 hour" ">10 hour" "115.58" "0" "0" "17967906" "Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. " "Deffrasnes C, Hamelin ME, Prince GA, Boivin G." "Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus." "10.1128/AAC.00793-07" "Anti-MPV" "DRAVPe01941" "AKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKN" "48" "HRA2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HMPV" "Paramyxoviridae" "RT-PCR assay " "[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=2.1 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM)." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the process." "5185.01" "C226H393N67O71" "CHMPQWY" "AKV" "9.99" "9" "5" "4" "14" "20" "-17.29" "-8923" "4.4 hour" ">20 hour" ">10 hour" "105.63" "0" "0" "17967906" "Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. " "Deffrasnes C, Hamelin ME, Prince GA, Boivin G." "Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus." "10.1128/AAC.00793-07" "Anti-MPV" "DRAVPe01942" "LESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRE" "35" "HRA3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HMPV" "Paramyxoviridae" "RT-PCR assay " "[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=3240 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM)." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the process." "3683.22" "C158H277N47O53" "CDFHMPQWY" "AV" "8.5" "5" "4" "1" "11" "15" "-2" "-5500" "5.5 hour" "3 min" "2 min" "111.43" "0" "0" "17967906" "Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. " "Deffrasnes C, Hamelin ME, Prince GA, Boivin G." "Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus." "10.1128/AAC.00793-07" "Anti-MPV" "DRAVPe01943" "FNVALDQVFESIENSQALVDQSNRILSSAEKGNTG" "35" "HRB5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HMPV" "Paramyxoviridae" "RT-PCR assay " "[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=1520 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM)." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the process." "3782.09" "C161H258N46O59" "CHMPWY" "S" "4.18" "2" "5" "-3" "12" "13" "-34" "-7110" "1.1 hour" "3 min" "2 min" "89.14" "0" "0" "17967906" "Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. " "Deffrasnes C, Hamelin ME, Prince GA, Boivin G." "Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus." "10.1128/AAC.00793-07" "Anti-MPV" "DRAVPe01944" "PEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTG" "39" "HRB6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HMPV" "Paramyxoviridae" "RT-PCR assay " "[Ref.17967906]Human Metapneumovirus(hMPV):inhibition of viral infection in LLC-MK2 cells(IC50=3310 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.17967906]No cytotoxicity against LLC-MK2 cells at the highest concentrations tested (9 μM)." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "F protein" "In hMPV, the F proteins assemble as trimers inside which three HRA (as well as three HRB) are creating a coiled coil. Then, the two pairs of coiled-coils (HRA and HRB) interact, creating a six-helix bundle structure that brings the viral and the cellular membranes close together, causing membrane merge and fusion pore dilatation. Peptide designed based in the HRA and HRB domains of the F protein can inhibit the process." "4251.54" "C180H285N51O68" "CHMWY" "S" "3.95" "2" "7" "-5" "12" "13" "-61.54" "-9217" ">20 hour" ">20 hour" "?" "80" "0" "0" "17967906" "Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. " "Deffrasnes C, Hamelin ME, Prince GA, Boivin G." "Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus." "10.1128/AAC.00793-07" "Anti-MPV" "DRAVPe01945" "SWLVNRDWFHDLNLPWTGSSAGTWQ" "25" "TP1" "Synthetic construct" "No entry found" "Experimentally Validated" "64293" "Genome polyprotein" "Genome polyprotein" "Genome polyprotein" "Not Available" "JF895923" "Genomic RNA" "Not Available" "6ZQJ" "TMUV" "Flaviviridae" "Plaque assay, Western blotting" "[Ref.32456819]Tembusu virus (TMUV):inhibition of viral infection in BHK-21 cells(IC50=14.19 mg/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32456819]No cytotoxicity against BHK-21 cells up to 150mg / L." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "TP1 functions through a mechanism that involves release of the viral genome and interference with cellular TMUV binding" "2974.24" "C138H189N37O38" "CEIKMY" "W" "5.19" "2" "2" "0" "9" "10" "-59.2" "-3639" "1.9 hour" ">20 hour" ">10 hour" "62.4" "22000" "916.67" "32456819" "Vet Microbiol. 2020 Jun;245:108708." "Zhao D, Zhang L, Han K, Liu Q, Yang J, Huang X, Liu Y, Li Y, Zhao P. " "Peptide inhibitors of tembusu virus infection derived from the envelope protein. " "10.1016/j.vetmic.2020.108708" "Anti-TMUV" "DRAVPe01946" "MVALGDTAWDFGSVGGVLTSIGKGIHQVFGSAFKSL" "36" "TP2" "Synthetic construct" "No entry found" "Experimentally Validated" "64293" "10971339" "JF895923.2" "Not Available" "TIGR04240" "JF895923" "Genomic RNA" "Not available" "None" "TMUV" "Flaviviridae" "Plaque assay, Western blotting" "[Ref.32456819]Tembusu virus (TMUV):inhibition of viral infection in BHK-21 cells(IC50=7.64 mg/L)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.32456819]No cytotoxicity against BHK-21 cells up to 150mg / L." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "TP2 might be an interference factor between TMUV and the cell. " "3654.2" "C167H258N42O48S" "CENPRY" "G" "6.5" "3" "2" "1" "13" "16" "64.17" "891" "30 hour" ">20 hour" ">10 hour" "94.72" "5500" "157.14" "32456819" "Vet Microbiol. 2020 Jun;245:108708." "Zhao D, Zhang L, Han K, Liu Q, Yang J, Huang X, Liu Y, Li Y, Zhao P. " "Peptide inhibitors of tembusu virus infection derived from the envelope protein. " "10.1016/j.vetmic.2020.108708" "Anti-TMUV" "DRAVPe01947" "RRRQRRKKRGYGFVNLLFLVVE" "22" "TAT-Kα2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "VSV,NDV,RSV,Influenza virus, HSV" "Herpesviridae,Paramyxoviridae,Orthomyxoviridae" "Plaque assay" "[Ref.28687749]Vesicular stomatitis virus(VSV):inhibition of viral infection in 293T cells(IC50=2.9 μM);##Respiratory Syncytial Virus(RSV):inhibition of viral infection in Hep2 cells(IC50=3.4 μM);##Newcastle disease virus(NDV):inhibition of viral infection(IC50=0.8 μM);##Parainfluenza virus:inhibition of viral infection(IC50=2.4 μM);##Influenza virus (H1N1) A/Puerto Rico/8/34:inhibition of viral infection(IC50=0.5 μM);##Influenza virus (H5N2) A/bird/Korea/W81/2005:inhibition of viral infection(IC50=0.8 μM);##Influenza virus (H7N3) A/Aquatic bird/Korea/W44/2005:inhibition of viral infection(IC50=1.2 μM);##Influenza virus (H9N2) A/Chicken/Korea/116/2004:inhibition of viral infection(IC50=0.7 μM);##Porcine epidemic diarrhea virus:inhibition of viral infection(IC50=3.5 μM);##Herpes simplex virus:inhibition of viral infection(IC50=5.7 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.28687749]No cytotoxicity against MDCK cells up to 100 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Envolope" "display virucidal activity by disrupting viral envelopes." "2791.35" "C126H212N44O28" "ACDHIMPSTW" "R" "12.01" "8" "1" "7" "4" "8" "-80.91" "-8503" "1 hour" "2 min" "2 min" "92.73" "1490" "70.95" "28687749" "Sci Rep. 2017 Jul 7;7(1):4875." "Moon HJ, Nikapitiya C, Lee HC, Park ME, Kim JH, Kim TH, Yoon JE, Cho WK, Ma JY, Kim CJ, Jung JU, Lee JS." "Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses" "10.1038/s41598-017-04777-4" "Anti-VSV,NDV,Anti-RSV,Anti-Influenza virus, Anti-HSV" "DRAVPe01948" "MGRFKRFRKKFKKLFKKLS" "19" "Bomidin" "Synthetic construct" "P54228" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV, HSV,SARS-CoV-2" "Flaviviridae,Herpesviridae,Coronaviridae" "Plaque-formation assay,fluorescent focus assay, ELISA" "[Ref.35663971]Dengue virus 2(DENV2):inhibition of viral infection in Huh7 cells(50% inhibition at 10 μM);##HSV:inhibition of viral infection in Huh7 cells(50% inhibition at 10 μM);##SARS-CoV-2:inhibition of viral infection in Huh7 cells(80% inhibition at 10 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.35663971]Vero E6 cells:CC50=169.6 ± 1.1 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "membrane" "bomidin readily disrupted viral membranes (with components similar to those in the endoplasmic reticulum) and bacterial membranes but did not alter the overall structures of the cell membranes" "2474.14" "C118H197N35O21S" "ACDEHINPQTVWY" "K" "12.32" "10" "0" "10" "2" "6" "-112.11" "-6196" "30 hour" ">20 hour" ">10 hour" "41.05" "0" "0" "35663971" "Front Immunol. 2022 May 19;13:851642." "Liu R, Liu Z, Peng H, Lv Y, Feng Y, Kang J, Lu N, Ma R, Hou S, Sun W, Ying Q, Wang F, Gao Q, Zhao P, Zhu C, Wang Y, Wu X. " "Bomidin: An Optimized Antimicrobial Peptide With Broad Antiviral Activity Against Enveloped Viruses." "10.3389/fimmu.2022.851642" "Anti-DENV, Anti-HSV,Anti-SARS-CoV-2" "DRAVPe01949" "DHVTPDIAYNPRTYM" "15" "Pep-RTYM" "Acacia catechu" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus-Forming Unit (FFU) Assay" "[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=7.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells." "1792.98" "C79H117N21O25S" "CEFGKLQSW" "DPTY" "5.21" "2" "2" "0" "5" "3" "-86.67" "-3596" "1.1 hour" "3 min" ">10 hour" "52" "2980" "212.86" "33172110" "Viruses. 2020 Nov 6;12(11):1267." "Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. " "Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry." "10.3390/v12111267" "Anti-DENV" "DRAVPe01950" "DHVTPDIAYNPWAYF" "15" "Pep-WAYF" "Acacia catechu" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Focus-Forming Unit (FFU) Assay" "[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=15.67 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells." "1808.97" "C87H113N19O24" "CEGKLMQRS" "ADPY" "4.2" "1" "2" "-1" "4" "6" "-40" "-1370" "1.1 hour" "3 min" ">10 hour" "58.67" "8480" "605.71" "33172110" "Viruses. 2020 Nov 6;12(11):1267." "Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. " "Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry." "10.3390/v12111267" "Anti-DENV" "DRAVPe01951" "DHVTPDIAYNP" "11" "Pep-CORE" "Acacia catechu" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "DENV" "Flaviviridae" "Focus-Forming Unit (FFU) Assay" "[Ref.33172110]Dengue virus 2(DENV2):inhibition of viral infection in Vero cells(IC50=20.89 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.33172110]No cytotoxicity against Vero cells up to 1000 μM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "the biding of peptide to virus particles might disrupt the ability of the virus to bind to the host cell receptor or possibly block the internalization of the virus into the host cells." "1241.32" "C55H80N14O19" "CEFGKLMQRSW" "DP" "4.2" "1" "2" "-1" "3" "3" "-76.36" "-2068" "1.1 hour" "3 min" ">10 hour" "70.91" "1490" "149" "33172110" "Viruses. 2020 Nov 6;12(11):1267." "Panya A, Sawasdee N, Songprakhon P, Tragoolpua Y, Rotarayanont S, Choowongkomon K, Yenchitsomanus PT. " "Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant Acacia catechu Binds to Dengue Virus and Inhibits Cell Entry." "10.3390/v12111267" "Anti-DENV" "DRAVPe01952" "KKR" "3" "Cmpd 2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "ZIKV" "Flaviviridae" "Protease assay" "[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(IC50=41.0 ± 3.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Phenylacetyl" "Free" "None" "L" "NS2B-NS3 viral serine protease" "The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication." "430.55" "C18H38N8O4" "ACDEFGHILMNPQSTVWY" "K" "11.17" "3" "0" "3" "0" "0" "-410" "-2602" "1.3 hour" "3 min" "2 min" "0" "0" "0" "35123179" "Bioorg Med Chem. 2022 Mar 1;57:116631." "Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. " "SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. " "10.1016/j.bmc.2022.116631" "Anti-ZIKV" "DRAVPe01953" "KKR" "3" "Cmpd 11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV" "Flaviviridae" "Protease assay" "[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(IC50=3.6 ± 0.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Phenylacetyl" "Amidation" "None" "L" "NS2B-NS3 viral serine protease" "The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication." "430.55" "C18H38N8O4" "ACDEFGHILMNPQSTVWY" "K" "11.17" "3" "0" "3" "0" "0" "-410" "-2602" "1.3 hour" "3 min" "2 min" "0" "0" "0" "35123179" "Bioorg Med Chem. 2022 Mar 1;57:116631." "Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. " "SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. " "10.1016/j.bmc.2022.116631" "Anti-ZIKV" "DRAVPe01954" "GKR" "3" "Cmpd 12" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV" "Flaviviridae" "Protease assay" "[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(40% inhibition at 100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Phenylacetyl" "Free" "None" "L" "NS2B-NS3 viral serine protease" "The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication." "359.43" "C14H29N7O4" "ACDEFHILMNPQSTVWY" "GKR" "11" "2" "0" "2" "1" "0" "-293.33" "-1953" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "35123179" "Bioorg Med Chem. 2022 Mar 1;57:116631." "Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. " "SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. " "10.1016/j.bmc.2022.116631" "Anti-ZIKV" "DRAVPe01955" "GKR" "3" "Cmpd 13" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "ZIKV" "Flaviviridae" "Protease assay" "[Ref.35123179]Zika virus(ZIKV):inhibition the activity of Zika virus NS2B-NS3 protease(40% inhibition at 100 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Phenylacetyl" "Amidation" "None" "L" "NS2B-NS3 viral serine protease" "The peptide inhibits the NS2B-NS3 protease and thus inhibits virus replication." "359.43" "C14H29N7O4" "ACDEFHILMNPQSTVWY" "GKR" "11" "2" "0" "2" "1" "0" "-293.33" "-1953" "30 hour" ">20 hour" ">10 hour" "0" "0" "0" "35123179" "Bioorg Med Chem. 2022 Mar 1;57:116631." "Colarusso S, Ferrigno F, Ponzi S, Pavone F, Conte I, Abate L, Beghetto E, Missineo A, Amaudrut J, Bresciani A, Paonessa G, Tomei L, Montalbetti C, Bianchi E, Toniatti C, Ontoria JM. " "SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease. " "10.1016/j.bmc.2022.116631" "Anti-ZIKV" "DRAVPe01956" "ALWMTLLKKVLKAAAKAALNAVLVGANA" "28" "Dermaseptin-4" "Phyllomedusa sauvagii" "P80280" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Chemiluminescence Reporter Gene Assay" "[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=2 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15780876]P4-CCR5 cells:CC50=5.6 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "viral membrane" "exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. " "2850.55" "C132H229N35O32S" "CDEFHIPQRSY" "A" "10.48" "4" "0" "4" "4" "19" "103.21" "2550" "4.4 hour" ">20 hour" ">10 hour" "146.79" "5500" "203.7" "15780876" "Virology. 2005 Apr 10;334(2):264-75. " "Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F." "The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. " "10.1016/j.virol.2005.02.002" "Anti-HIV" "DRAVPe01957" "ALWKTLLKKVLKAAAK" "16" "Dermaseptin S4 (1-16)[M4K]" "Synthetic construct" "P80280" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Chemiluminescence Reporter Gene Assay" "[Ref.15780876]human immunodeficiency virus type 1 (HIV-1):Inhibition of viral infection in Vero P4-CCR5 cells(IC50=28 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.15780876]P4-CCR5 cells:CC50>100 μM." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "viral membrane" "exerts a selective activity on viral particles and disturbs their organization by breaking the viral membrane, leading to the exposure of HIV-1 core and its dissociation. " "1782.29" "C86H152N22O18" "CDEFGHIMNPQRSY" "K" "10.6" "5" "0" "5" "1" "10" "34.38" "297" "4.4 hour" ">20 hour" ">10 hour" "140.63" "5500" "366.67" "15780876" "Virology. 2005 Apr 10;334(2):264-75. " "Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F." "The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. " "10.1016/j.virol.2005.02.002" "Anti-HIV" "DRAVPe01958" "GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP" "41" "Beta-defensin 2(BD-2, hBD-2, SAP1)" "Homo sapiens" "O15263" "Experimentally Validated" "9606" "DEFB4A; DEFB4B" "Z71389.1" "24-65" "pfam00711" "Z71389" "mRNA" "Chromosome 8 - NC_000008.11" "1FD4" "HIV" "Retroviridae" "ELISA" "[Ref.16254366]HIV-1 BaL:inhibition of viral infection in TZM-bl cells(80% Inhibition at 100 µg/ml, 68% Inhibition at 50 µg/ml, 55% Inhibition at 25 µg/ml, 45% Inhibition at 12.5 µg/ml, 32% Inhibition at 6.2 µg/ml, 28% Inhibition at 3.1 µg/ml, 18% Inhibition at 1.6 µg/ml, 20% Inhibition at 0.8 µg/ml,);##HIV-1 IIIB:inhibition of viral infection in TZM-bl cells(95% Inhibition at 100 µg/ml, 87% Inhibition at 50 µg/ml, 75% Inhibition at 25 µg/ml, 62% Inhibition at 12.5 µg/ml, 55% Inhibition at 6.2 µg/ml, 35% Inhibition at 3.1 µg/ml, 28% Inhibition at 1.6 µg/ml, 25% Inhibition at 0.8 µg/ml,)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "DRAVPe01958" "Cyclic" "Free" "Free" "Disulfide bonds between Cys8 and Cys37, Cys15 and Cys30, Cys20 and Cys38." "L" "Not found" "No mechanism information found in the reference(s)." "4334.24" "C188H311N55O50S6" "EMNW" "CG" "9.3" "8" "1" "7" "17" "9" "-10.24" "-3697" "30 hour" ">20 hour" ">10 hour" "64.15" "1865" "46.63" "16254366" "J Virol. 2005 Nov;79(22):14318-29. " "Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, Lu W, Garzino-Demo A." "Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. " "10.1128/JVI.79.22.14318-14329.2005" "Anti-HIV" "DRAVPe01959" "NEYHGFVDKANNENKRKKQQGRDDFVVKPNNFANRRRKDDYNENYYDDVDAADVV" "55" "Cicadin" "Cicada flammata" "P83282" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.11814612]HIV-1:inhibition the activity of reverse transcriptase(11.35±1.8% Inhibition at 0.1 µM, 85.8±2.3% Inhibition at 1 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "6596.04" "C283H427N89O95" "CILMSTW" "DN" "5.7" "12" "12" "0" "15" "13" "-175.27" "-24057" "1.4 hour" "3 min" ">10 hour" "38.91" "5960" "110.37" "11814612" "Peptides. 2002 Jan;23(1):7-11. " "Wang H, Ng TB." "Isolation of cicadin, a novel and potent antifungal peptide from dried juvenile cicadas." "10.1016/s0196-9781(01)00573-3" "Anti-HIV" "DRAVPe01960" "CGESCAXISFCFTEVIGCSCKNKVCYLNSIS" "31" "Leaf cyclotide, Vhl-1" "Viola hederacea" "P84522" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1ZA8" "HIV" "Retroviridae" "cytopathic effect assay" "[Ref.15824119]HIV-1:inhibition of cytopathic effect(EC50=0.87 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Cyclic" "No specific N-terminal" "No specific C-terminal" "The 'X' at position 7 indicates Methionine sulfoxide. The N-terminal and C-terminal cyclized by a amide bond. Disulfide bonds between Cys1 and Cys18, Cys5 and Cys20, Cys11 and Cys25." "L" "Not found" "No mechanism information found in the reference(s)." "3321.08" "C135H212N34O43S6" "DHMPQRW" "C" "6.1" "2" "2" "0" "17" "9" "62.9" "-1262" "1.2 hour" ">20 hour" ">10 hour" "72.26" "1865" "62.17" "15824119" "J Biol Chem. 2005 Jun 10;280(23):22395-405." "Chen B, Colgrave ML, Daly NL, Rosengren KJ, Gustafson KR, Craik DJ. " "Isolation and characterization of novel cyclotides from Viola hederaceae: solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide." "10.1074/jbc.M501737200" "Anti-HIV" "DRAVPe01961" "QSHLSLCRWCCNCCRSNKGC" "20" "Hepcidin TH2-3" "Oreochromis mossambicus" "I3KHK3" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FMDV" "Picornaviridae" "Plaque forming assay" "[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=25.1±1.5 µg/ml, IC90=78.5±7.6 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=120.2±2.5 µg/ml." "No predicted structure available" "Cyclic" "Free" "Cyclization(Cys7 and Cys20)" "Disulfide bonds between Cys7 and Cys20, Cys10 and Cys13, Cys11 and Cys14." "L" "Not found" "No mechanism information found in the reference(s)." "2301.7" "C89H145N33O27S6" "ADEFIMPTVY" "C" "8.7" "4" "0" "4" "12" "3" "-38.5" "-4828" "0.8 hour" "10 min" ">10 hour" "39" "5875" "309.21" "30012343" "Peptides. 2018 Aug;106:91-95." "Huang HN, Pan CY, Chen JY. " "Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro." "10.1016/j.peptides.2018.07.003" "Anti-FMDV" "DRAVPe01962" "FIHHIIGGLFSVGKHIHSLIHGH" "23" "Tilapia piscidin 3, TP3" "Oreochromis niloticus" "L0CMD2" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FMDV" "Picornaviridae" "Plaque forming assay" "[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=2.5±0.2 µg/ml, IC90=25.0±3.2 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=39.0±1.2 µg/ml." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2557" "C121H182N36O26" "ACDEMNPQRTWY" "H" "8.79" "7" "0" "7" "6" "10" "59.13" "789" "1.1 hour" "3 min" "2 min" "131.3" "0" "0" "30012343" "Peptides. 2018 Aug;106:91-95." "Huang HN, Pan CY, Chen JY. " "Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro." "10.1016/j.peptides.2018.07.003" "Anti-FMDV" "DRAVPe01963" "FIHHIIGGLFSAGKAIHRLIRRRRR" "25" "Tilapia piscidin 4, TP4" "Oreochromis niloticus" "L0CKG3" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FMDV" "Picornaviridae" "Plaque forming assay" "[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=1.5±0.1 µg/ml, IC90=7.5±1.3 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=9.7±1.5 µg/ml." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2981.6" "C135H226N50O27" "CDEMNPQTVWY" "R" "12.7" "10" "0" "10" "4" "11" "-12.8" "-6561" "1.1 hour" "3 min" "2 min" "117.2" "0" "0" "30012343" "Peptides. 2018 Aug;106:91-95." "Huang HN, Pan CY, Chen JY. " "Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro." "10.1016/j.peptides.2018.07.003" "Anti-FMDV" "DRAVPe01964" "GFIFHIIKGLFHAGKMIHGLV" "21" "Epinecidin-1 (22-42)" "Synthetic construct" " Q6JWQ9" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "FMDV" "Picornaviridae" "Plaque forming assay" "[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=0.6±0.1 µg/ml, IC90=12.5±1.1 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=19.5±3.1 µg/ml." "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2335.88" "C114H175N29O22S" "CDENPQRSTWY" "GI" "10" "5" "0" "5" "4" "11" "109.05" "2534" "30 hour" ">20 hour" ">10 hour" "130" "0" "0" "30012343" "Peptides. 2018 Aug;106:91-95." "Huang HN, Pan CY, Chen JY. " "Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro." "10.1016/j.peptides.2018.07.003" "Anti-FMDV" "DRAVPe01965" "GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE" "33" "Pardaxin P-4" "Pardachirus marmoratus" "P81861" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "1XC0" "FMDV" "Picornaviridae" "Plaque forming assay" "[Ref.30012343]Foot-and-Mouth Disease virus(FMDV):Inhibition of viral replication in BHK-21 cells(IC50=2.4±0.1 µg/ml, IC90=12.1±1.1 µg/ml)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.30012343]Baby Hamster Kidney cells BHK-21:CC50=19.5±3.2 µg/ml." "DRAVPe01965" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "3323.88" "C154H248N36O45" "CDHMNRWY" "S" "8.59" "2" "1" "1" "12" "15" "74.55" "1171" "30 hour" ">20 hour" ">10 hour" "112.42" "0" "0" "30012343" "Peptides. 2018 Aug;106:91-95." "Huang HN, Pan CY, Chen JY. " "Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro." "10.1016/j.peptides.2018.07.003" "Anti-FMDV" "DRAVPe01966" "AKKAAKKAKKAAKKIEKAAKK" "21" "RJ5-I15E16" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=112 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2238.84" "C101H192N32O24" "CDFGHLMNPQRSTVWY" "K" "10.65" "11" "1" "10" "0" "9" "-130.95" "-4846" "4.4 hour" ">20 hour" ">10 hour" "56.67" "0" "0" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01967" "AKKAKKKAKKAAKKIKKKAKK" "21" "RJ9-I15" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=11 µM); inhibition of viral infection in MRC-5 cells(IC50=119 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2352.08" "C108H211N35O22" "CDEFGHLMNPQRSTVWY" "K" "11.11" "14" "0" "14" "0" "7" "-187.14" "-6192" "4.4 hour" ">20 hour" ">10 hour" "47.14" "0" "0" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01968" "ARRARRRARRAARRARRGARR" "21" "RJ8-R5G18" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=1.9 µM); inhibition of viral infection in MRC-5 cells(IC50=4.8 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=96 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2603.06" "C101H196N60O22" "CDEFHIKLMNPQSTVWY" "R" "13.08" "13" "0" "13" "1" "7" "-220.48" "-18035" "4.4 hour" ">20 hour" ">10 hour" "33.33" "0" "0" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01969" "ARRARRRARRAARRARRWARR" "21" "RJ8-R5W18" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=9.2 µM); inhibition of viral infection in MRC-5 cells(IC50=2.8 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=162 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2732.22" "C110H203N61O22" "CDEFGHIKLMNPQSTVY" "R" "13.08" "13" "0" "13" "0" "8" "-222.86" "-17896" "4.4 hour" ">20 hour" ">10 hour" "33.33" "5500" "275" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01970" "KAAKKAAKWAKKAAKWAKKAA" "21" "RJ2-W9,16" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=111 µM); inhibition of viral infection in MRC-5 cells(IC50=32 µM);##Herpes simplex virus 2(HSV-2):inhibition of viral infection in MRC-5 cells(IC50=48 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2254.8" "C106H180N32O22" "CDEFGHILMNPQRSTVY" "A" "10.9" "9" "0" "9" "0" "12" "-90" "-2719" "1.3 hour" "3 min" "2 min" "47.62" "11000" "550" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01971" "KYAKKAAKYAKKAAKYAKKAA" "21" "RJ2-Y2,9,16" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=146 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2300.82" "C108H182N30O25" "CDEFGHILMNPQRSTVW" "AK" "10.3" "9" "0" "9" "3" "9" "-108.57" "-3408" "1.3 hour" "3 min" "2 min" "42.86" "4470" "223.5" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01972" "AAKAWKKAKAWKKAKWWKKAA" "21" "RJ2-A1,4,8; K3,6,7,9,13; W5,11,17" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Not found" "[Ref.16923027]Herpes simplex virus 1(HSV-1):inhibition of viral entry into Vero cells(IC50=238 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.16923027]No cytotoxicity against Human fibroblasts MRC-5 cells up to 448 µM." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "No mechanism information found in the reference(s)." "2485.07" "C122H190N34O22" "CDEFGHILMNPQRSTVY" "K" "10.9" "9" "0" "9" "0" "12" "-115.71" "-2615" "4.4 hour" ">20 hour" ">10 hour" "38.1" "22000" "1100" "16923027" "Chem Biol Drug Des. 2006 Jul;68(1):58-66." "Jenssen H, Gutteberg TJ, Rekdal Ø, Lejon T." "Prediction of activity, synthesis and biological testing of anti-HSV active peptides. " "10.1111/j.1747-0285.2006.00412.x" "Anti-HSV" "DRAVPe01973" "WNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ" "36" "CHR-1, Env GP (623-658)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=17.27 ± 0.31 nM; IC90=26.41 ± 0.55 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "cell membrane" "The peptide can interact with the viral NHR to form stable heterologous 6-HBs, resulting in inhibition of fusion between the viral and target cell membranes." "4532.84" "C196H288N56O67S" "ACFGPV" "E" "4.53" "4" "7" "-3" "12" "8" "-156.39" "-11884" "2.8 hour" "3 min" "2 min" "54.17" "17990" "514" "17276993" "J Biol Chem. 2007 Mar 30;282(13):9612-9620." "Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. " "HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides" "10.1074/jbc.M609148200" "Anti-HIV" "DRAVPe01974" "WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL" "36" "C36, Env GP (628-663)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=4.67 ± 0.07 nM; IC90=7.04 ± 0.12 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "cell membrane" "The peptide can interact with the viral NHR to form stable heterologous 6-HBs, resulting in inhibition of fusion between the viral and target cell membranes." "4490.88" "C195H298N52O68S" "ACFGPV" "E" "4.14" "3" "9" "-6" "9" "10" "-119.17" "-10359" "2.8 hour" "3 min" "2 min" "86.67" "12490" "356.86" "17276993" "J Biol Chem. 2007 Mar 30;282(13):9612-9620." "Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. " "HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides" "10.1074/jbc.M609148200" "DRAVPa0917" "Anti-HIV" "DRAVPe01975" "REINNYTSLIHSLIEESQNQQEKNEQELLELDKWAS" "36" "CHR-3, Env GP (633-668)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=1,470.00 ± 20.0 nM; IC90=2,380.00 ± 35.00 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "CHR-3 interacts with N46 to form unstable 6-HB" "4330.69" "C186H294N52O67" "CFGMPV" "E" "4.42" "4" "8" "-4" "10" "10" "-120.28" "-10860" "1 hour" "2 min" "2 min" "89.44" "6990" "199.71" "17276993" "J Biol Chem. 2007 Mar 30;282(13):9612-9620." "Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. " "HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides" "10.1074/jbc.M609148200" "Anti-HIV" "DRAVPe01976" "HSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW" "36" "CHR-5, Env GP (643-678)" "Synthetic construct" "P04578" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref.17276993]human immunodeficiency virus (HIV):inhibition of cell-cell fusion in MT-2 cells(IC50=2,185.00 ± 15.00 nM; IC90=2,858.00 ± 6.00 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not found" "CHR-5 can bind to LUVs of POPC" "4501.89" "C203H295N53O64" "CGMPRVY" "E" "4.3" "3" "7" "-4" "9" "13" "-114.17" "-8492" "3.5 hour" "10 min" ">10 hour" "78.61" "22000" "628.57" "17276993" "J Biol Chem. 2007 Mar 30;282(13):9612-9620." "Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S. " "HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides" "10.1074/jbc.M609148200" "Anti-HIV" "DRAVPe01977" "STSQKSIVAYTM" "12" "SARS-CoV S (668–679), SP-10" "Synthetic construct(derived from SARS-CoV S protein)" "P59594##P26436" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.1" "668-679" "Not Available" "CM000673.2##AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC" "SARS-CoV" "Coronaviridae" "Biochemical Assay" "[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=1.88 ± 0.52 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "ACE2" "block the binding of S protein to ACE2." "1315.5" "C56H94N14O20S" "CDEFGHLNPRW" "S" "8.31" "1" "0" "1" "6" "3" "-0.83" "-1345" "1.9 hour" ">20 hour" ">10 hour" "65" "1490" "135.45" "16337697" "Antiviral Res. 2006 Feb;69(2):70-6." "Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY." "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction." "10.1016/j.antiviral.2005.10.005" "Anti-SARS-CoV" "DRAVPe01978" "GFLYVYKGYQPI" "12" "SARS-CoV S (192-203), SP-4" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=4.30 ± 2.18 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "ACE2" "block the binding of S protein to ACE2." "1447.7" "C73H102N14O17" "ACDEHMNRSTW" "Y" "8.43" "1" "0" "1" "5" "4" "13.33" "723" "30 hour" ">20 hour" ">10 hour" "89.17" "4470" "406.36" "16337697" "Antiviral Res. 2006 Feb;69(2):70-6." "Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY." "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction." "10.1016/j.antiviral.2005.10.005" "Anti-SARS-CoV" "DRAVPe01979" "FYTTTGIGYQPY" "12" "SARS-CoV S (483-494), SP-8" "Synthetic construct" "P59594" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref.16337697]SARS-CoV:Inhibition of pseudovirus infection in Vero cells(IC50=6.99 ± 0.71 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "ACE2" "block the binding of S protein to ACE2." "1410.55" "C68H91N13O20" "ACDEHKLMNRSVW" "TY" "5.52" "0" "0" "0" "8" "2" "-38.33" "-389" "1.1 hour" "3 min" "2 min" "32.5" "4470" "406.36" "16337697" "Antiviral Res. 2006 Feb;69(2):70-6." "Ho TY, Wu SL, Chen JC, Wei YC, Cheng SE, Chang YH, Liu HJ, Hsiang CY." "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction." "10.1016/j.antiviral.2005.10.005" "Anti-SARS-CoV" "DRAVPe01980" "IHAEIKNSLKIDNLDVNRCIEAL" "23" "LEDGF/p75 (355-377)" "Synthetic construct" "O75475" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "IN enzymatic assay" "[Ref.18331842]Human immunodeficiency virus (HIV): Inhibition of integrase activity (3' end processing)(IC50=165±28 µM); inhibition of integrase activity(strand transfer)(IC50=153±28 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Integrase" "The LEDGF/p75 peptide modestly inhibited IN catalysis and was dependent on IN–DNA assembly. The peptide was also effective at disrupting LEDGF/p75–IN complex formation." "2622.03" "C113H193N33O36S" "FGMPQTWY" "I" "5.48" "4" "4" "0" "5" "10" "-4.78" "-4168" "20 hour" "30 min" ">10 hour" "140" "0" "0" "18331842" "FEBS Lett. 2008 Apr 30;582(10):1425-30. " "Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N." "Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis." "10.1016/j.febslet.2008.02.076" "Anti-HIV" "DRAVPe01981" "IEEQAKTFLDKFQHEVEEIYWQS" "23" "Peptide1(ACE2 (21-43)[N13Q,A16V,D18E,L19I,F20Y,Y21W])" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=11 ± 1 nM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "2898.18" "C133H193N31O42" "CGMNPR" "E" "4.41" "3" "6" "-3" "3" "8" "-94.78" "-5236" "20 hour" "30 min" ">10 hour" "67.83" "6990" "317.73" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01982" "QDKHEEDYQMYNKGDKED" "18" "Peptide2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=18 ± 2 nM, 95% inhibition at 0.39 µM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "2272.34" "C94H138N26O38S" "ACFILPRSTVW" "D" "4.38" "4" "7" "-3" "4" "0" "-283.33" "-9133" "0.8 hour" "10 min" ">10 hour" "0" "2980" "175.29" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01983" "DKFNHEAEDLFYQSSLASWNYNT" "23" "Peptide3" "Synthetic construct" "Q9BYF1" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=6 ± 4 nM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "2779.92" "C125H171N31O42" "CGIMPRV" "NS" "4.31" "2" "4" "-2" "9" "7" "-108.26" "-5803" "1.1 hour" "3 min" ">10 hour" "42.61" "8480" "385.45" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01984" "IDENARSYIDKFQHDAEEMWYQ" "22" "Peptide4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=32 ± 2 nM, 95% inhibition at 0.39 µM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "2788.98" "C123H174N32O41S" "CGLPTV" "DE" "4.29" "3" "6" "-3" "4" "6" "-136.82" "-7200" "20 hour" "30 min" ">10 hour" "44.55" "8480" "403.81" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01985" "IYALLENAEDYNLVN" "15" "Peptide5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=9 ± 4 nM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "1753.93" "C79H120N18O27" "CFGHKMPQRSTW" "LN" "3.57" "0" "3" "-3" "5" "7" "0.67" "-1520" "20 hour" "30 min" ">10 hour" "136.67" "2980" "212.86" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01986" "SRDKHEEHEKENDRGQ" "16" "Peptide6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "luciferase assay" "[Ref.34328726]SARS-CoV-2:Inhibition of virus entry in HEK293T/ACE2 cells (via inhibition of SRBD:ACE2 interaction)(IC50=10 ± 5 nM, 100% inhibition at 25 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Spike protein" "antagonizes the SARS-CoV-2 S-RBD:ACE2 interaction and inhibits the virus entry." "1994.02" "C78H124N30O32" "ACFILMPTVWY" "E" "5.43" "6" "6" "0" "3" "0" "-327.5" "-10958" "1.9 hour" ">20 hour" ">10 hour" "0" "0" "0" "34328726" "J Med Chem. 2022 Feb 24;65(4):2836-2847. " "Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno AJ, Monti A, Wang C, Azad T, Bell JC, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Smit J, Dömling A, van Goor H, Groves MR." "Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein" "10.1021/acs.jmedchem.1c00477" "Anti-SARS-CoV-2" "DRAVPe01987" "LLGRMKG" "7" "None" "Synthetic construct" "Q91L67" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "Scintillation count" "[Ref.12469306]Hepatitis B virus(HBV): inhibition of the association of L-HBsAg with HBcAg(IC50=78±5 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "core antigen (HBcAg)(Viral assembly)" "During HBV morphogenesis, both the PreS and S domains of L-HBsAg form docking sites for the viral nucleocapsids. Thus, a compound that disrupts the interaction between the L-HBsAg and nucleocapsids could serve as a therapeutic agent against the virus based upon inhibition of morphogenesis. Peptide inhibits the association of L-HBsAg with core antigen (HBcAg)." "773.99" "C33H63N11O8S" "ACDEFHINPQSTVWY" "GL" "11" "2" "0" "2" "2" "2" "4.29" "-640" "5.5 hour" "3 min" "2 min" "111.43" "0" "0" "12469306" "J Gen Appl Microbiol. 2002 Apr;48(2):103-7." "Tan WS." "Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens." "10.2323/jgam.48.103" "Anti-HBV" "DRAVPe01988" "LDPAFR" "6" "None" "Synthetic construct" "O92921" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "Scintillation count" "[Ref.12469306]Hepatitis B virus(HBV): inhibition of the association of L-HBsAg with HBcAg(IC50>1000 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "core antigen (HBcAg)(Viral assembly)" "During HBV morphogenesis, both the PreS and S domains of L-HBsAg form docking sites for the viral nucleocapsids. Thus, a compound that disrupts the interaction between the L-HBsAg and nucleocapsids could serve as a therapeutic agent against the virus based upon inhibition of morphogenesis. Peptide inhibits the association of L-HBsAg with core antigen (HBcAg)." "717.82" "C33H51N9O9" "CEGHIKMNQSTVWY" "ADFLPR" "5.84" "1" "1" "0" "0" "3" "-20" "-1393" "5.5 hour" "3 min" "2 min" "81.67" "0" "0" "12469306" "J Gen Appl Microbiol. 2002 Apr;48(2):103-7." "Tan WS." "Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens." "10.2323/jgam.48.103" "Anti-HBV" "DRAVPe01989" "PLSPPLRNTHPQAMQWNSTTF" "21" "None" "Synthetic construct" "O92921" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "Scintillation count" "[Ref.12469306]Hepatitis B virus(HBV): inhibition of the association of L-HBsAg with HBcAg(IC50=30±1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "core antigen (HBcAg)(Viral assembly)" "During HBV morphogenesis, both the PreS and S domains of L-HBsAg form docking sites for the viral nucleocapsids. Thus, a compound that disrupts the interaction between the L-HBsAg and nucleocapsids could serve as a therapeutic agent against the virus based upon inhibition of morphogenesis. Peptide inhibits the association of L-HBsAg with core antigen (HBcAg)." "2423.73" "C108H163N31O31S" "CDEGIKVY" "P" "10.18" "2" "0" "2" "7" "5" "-88.57" "-3914" ">20 hour" ">20 hour" "?" "41.9" "5500" "275" "12469306" "J Gen Appl Microbiol. 2002 Apr;48(2):103-7." "Tan WS." "Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens." "10.2323/jgam.48.103" "Anti-HBV" "DRAVPe01990" "PTSNHSPTSCPPTCPGYRWMCLRRF" "25" "HBV S(56-80)" "Synthetic construct" "O92921" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HBV" "Hepadnaviridae" "Scintillation count" "[Ref.12469306]Hepatitis B virus(HBV): inhibition of the association of L-HBsAg with HBcAg(IC50=35±4 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "core antigen (HBcAg)(Viral assembly)" "During HBV morphogenesis, both the PreS and S domains of L-HBsAg form docking sites for the viral nucleocapsids. Thus, a compound that disrupts the interaction between the L-HBsAg and nucleocapsids could serve as a therapeutic agent against the virus based upon inhibition of morphogenesis. Peptide inhibits the association of L-HBsAg with core antigen (HBcAg)." "2895.34" "C125H188N38O34S4" "ADEIKQV" "P" "9.27" "4" "0" "4" "12" "3" "-77.2" "-5675" ">20 hour" ">20 hour" "?" "15.6" "7115" "296.46" "12469306" "J Gen Appl Microbiol. 2002 Apr;48(2):103-7." "Tan WS." "Inhibition of hepatitis B virus assembly with synthetic peptides derived from the viral surface and core antigens." "10.2323/jgam.48.103" "Anti-HBV" "DRAVPe01991" "GELGRLVYLLDGPGYDPIHCSLAYGDASTLVVF" "33" "K5-66" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=20.7±3.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-4A site that is of particular interest。" "3511.99" "C161H244N38O48S" "KMNQW" "L" "4.22" "2" "4" "-2" "12" "13" "47.58" "-320" "30 hour" ">20 hour" ">10 hour" "115.15" "4470" "139.69" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01992" "GELGRLVYLLDGPGYDPI" "18" "K5-66-A" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=125.4 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-5A site that is of particular interest。" "1947.22" "C90H139N21O27" "ACFHKMNQSTW" "GL" "4.03" "1" "3" "-2" "6" "6" "8.33" "-705" "30 hour" ">20 hour" ">10 hour" "124.44" "2980" "175.29" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01993" "GELGRPVYVLGDPGYYATHCIYATTNDALIFSV" "33" "K6-10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=25.6±3.5 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-6A site that is of particular interest。" "3577.03" "C164H243N39O49S" "KMQW" "GY" "4.54" "2" "3" "-1" "14" "12" "27.58" "-1197" "30 hour" ">20 hour" ">10 hour" "94.55" "5960" "186.25" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01994" "GELGRPVYVLGDPGYYAT" "18" "K6-10-A" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=227.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-7A site that is of particular interest。" "1927.14" "C89H131N21O27" "CFHIKMNQSW" "G" "4.37" "1" "2" "-1" "8" "5" "-17.22" "-995" "30 hour" ">20 hour" ">10 hour" "81.11" "4470" "262.94" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01995" "GELGRLVYLLDGPGYDPIHCDVVTRGGSHLFNF" "33" "CP5-46" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=11.3±1.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-8A site that is of particular interest。" "3618.08" "C164H246N44O47S" "AKMQW" "G" "5.26" "4" "4" "0" "12" "11" "4.85" "-3050" "30 hour" ">20 hour" ">10 hour" "97.27" "2980" "93.13" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01996" "GELDELVYLLDGPGYDPIHCDVVTRGGSRLFNF" "33" "CP5-46-4D5E" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=1.14±0.053 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-9A site that is of particular interest。" "3668.09" "C165H248N42O51S" "AKMQW" "GL" "4.23" "3" "6" "-3" "11" "11" "-5.45" "-4231" "30 hour" ">20 hour" ">10 hour" "97.27" "2980" "93.13" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01997" "GELGRLVYLLDGPGYDPIHCD" "21" "CP5-46-A" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=124 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-10A site that is of particular interest。" "2302.59" "C103H156N26O32S" "AFKMNQSTW" "GL" "4.22" "2" "4" "-2" "7" "6" "-12.86" "-1915" "30 hour" ">20 hour" ">10 hour" "106.67" "2980" "149" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01998" "GELDELVYLLDGPGYDPIHS" "20" "CP5-46A-4D5E" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=22.8 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-11A site that is of particular interest。" "2202.4" "C100H148N22O34" "ACFKMNQRTW" "L" "3.77" "1" "5" "-4" "6" "6" "-23" "-1666" "30 hour" ">20 hour" ">10 hour" "112" "2980" "156.84" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe01999" "RQIKINFQNRRMKNKKGELDELVYLLDGPGYDPIHS" "36" "Ant-CP5-46A-4D5E" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "FRET assay" "[Ref.22965230]hepatitis C virus(HCV): inhibition of NS3–4A activity(IC50=23.6 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information or data found in the reference(s) presented in this entry" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "inhibitory peptides (IPs) capping the active site and binding via a novel ""tyrosine"" finger at an alternative NS3-12A site that is of particular interest。" "4286.92" "C190H306N56O55S" "ACTW" "KL" "9.31" "8" "5" "3" "9" "9" "-104.17" "-9945" "1 hour" "2 min" "2 min" "83.89" "2980" "85.14" "22965230" "J Biol Chem. 2012 Nov 9;287(46):39224-32. " "Kugler J, Schmelz S, Gentzsch J, Haid S, Pollmann E, van den Heuvel J, Franke R, Pietschmann T, Heinz DW, Collins J." "High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants." "10.1074/jbc.M112.393843" "Anti-HCV" "DRAVPe02000" "ELLVTFKNAHAKKQEVVVLG" "20" "peptide 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 1 at 200 μM exhibited cell protection effects against DENV-1 (69.58%) and DENV-4 (59.44%), but lower inhibitory effects were observed against DENV-2 (32.95%) and DENV-3 (12.59%); Peptides 1(200 μM) demonstrated the highest inhibitions of DENV-3 (67.18%) plaque formations; Peptides 1 (200 μM) demonstrated inhibitions of all four DENV serotypes, but much lower inhibitions were observed against DENV-3 at 26.92%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2223.64" "C102H171N27O28" "CDIMPRSWY" "V" "8.6" "4" "2" "2" "3" "10" "23" "-1122" "1 hour" "30 min" ">10 hour" "126.5" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02001" "LKMDKLTLKGMSY" "13" "peptide 3" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]peptide 3 showed the most promising cell protection effects against DENV-1 (60.28%), DENV(36.23%), DENV-3 (73.85%), and DENV-4 (64.84%) at 200 μM. The IC50 of the cell protection effects of peptide 3 against DENV-3 was determined to be 182.27 μM; peptide 3 demonstrated the most promising antiviral activity during post-infection with good inhibitions of DENV-2 (69.05%) and DENV-3 (61.35%) whereas lower inhibitions were observed against DENV-1 (48.47%) and DENV-4 (34.72%) at 200 μM; Peptide 3 showed the highest inhibitions of plaque formations by DENV-2 (69.05%) and DENV-3 (61.35%); Peptide 3 reduced the RNA copy numbers of DENV-2 and DENV-3 by 43.83% and 50.72%, DENV-1 (31.85%); peptide 3 inhibited DENV-4 attachment to Vero cells by 39.58% but almost no inhibition was observed against DENV-1 (7.62%) and DENV-3 (2.56%). " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "It is possible that peptide 3 inhibited DENV-2 by inhibiting the virus particle itself and this was supported by the observation that peptide 3 showed good direct virus-inactivating effects against DENV-2." "1527.9" "C68H118N16O19S2" "ACEFHINPQRVW" "KL" "9.529999999999999" "3" "1" "2" "4" "3" "-24.62" "-1108" "5.5 hour" "3 min" "2 min" "90" "1490" "124.17" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02002" "TGKFKVVKEIAETQHGTIVIRVQYE" "25" "Peptide 4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]peptides 4 demonstrated some cell protection effects against DENV-2 and DENV-4 at 47.38%, inhibitions against the other DENV serotypes were very low; Peptide 4 at 200 μM showed the highest inhibitory effects against DENV-2 (74.26%), but it exhibited very low inhibition of DENV-4 and it could not inhibit DENV-1 and DENV-3 plaque formations; peptide 4 demonstrated the highest inhibitory effects against DENV-1 (80.37%),DENV-2 (44.77%) and DENV-4 (72.22%) during post-infection. The IC50 of the inhibitory effects of peptide 4 against DENV-1 during post-infection was determined to be 161.07 μM; Peptide 4 was observed to inhibit DENV-1 and DENV-4 replications significantly with reductions of RNA copy numbers by 63.86% and 70.37%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "2874.33" "C130H213N35O38" "CDLMNPSW" "V" "8.130000000000001" "5" "3" "2" "6" "9" "-24.8" "-3800" "7.2 hour" ">20 hour" ">10 hour" "97.2" "1490" "62.08" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02003" "PFGDSYIVIGVGDSALTLHWFRK" "23" "Peptide 5" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]peptides 5 demonstrated some cell protection effects against DENV-2 and DENV-4 at 59.72%, inhibitions against the other DENV serotypes were very low; exhibited good direct virus-inactivating effects against DENV-2 (64.61%) and DENV-4 (77.08%) whereas lower inhibitions were observed against DENV-1 (16.90%) and DENV-3 (29.80%). The IC50 of the direct virus-inactivating effects of peptide 5 against DENV-4 was determined to be 121.26 μM; peptide 5 demonstrated the highest inhibitory effects against DENV-4 (89.31%) and DENV-2 (19.94%) during post-infection. The IC50 of the inhibition of DENV-4 by peptide 5 during post-infection was determined to be 141.42 μM; Peptide 5 was observed to inhibit DENV-4 replications significantly with reductions of RNA copy numbers by 75.80%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "peptide 5 could exert virucidal activity by damaging the protein coat of the virus, penetrating the virion, or destroying the viral genome to reduce viral infectivity. " "2578.95" "C122H180N30O32" "CEMNQ" "G" "7.17" "3" "2" "1" "7" "10" "28.26" "-1140" ">20 hour" ">20 hour" "?" "97.39" "6990" "317.73" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02004" "IQTSGGTSI" "9" "Peptide 6" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 6 at 200 μM exhibited cell protection effects against DENV-1 (40.88%) and DENV-4 (51.27%), but lower inhibitory effects were observed against DENV-2 (10%) and DENV-3 (22.05%); Peptides 6 (200 μM) demonstrated inhibitions of all four DENV serotypes, but much lower inhibitions were observed against DENV-3 at 3.33%, respectively." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "862.94" "C35H62N10O15" "ACDEFHKLMNPRVWY" "GIST" "5.52" "0" "0" "0" "6" "2" "18.89" "-576" "20 hour" "30 min" ">10 hour" "86.67" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02005" "MVDRGWGNGCGLFGKGGI" "18" "Peptide 7" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 7 at 200 μM exhibited good inhibitions of DENV-1 (67.17%) plaque formation, but much lower inhibitions were observed against DENV-2 to 4 ranging from 28.31 to 37.73%; peptide 7 (200 μM) showed good direct virus-inactivating effects against DENV-3 (64.03%) and DENV-4 (78.76%) whereas lower inhibitions were observed against DENV-1 (32.66%) and DENV-2 (47.84%); peptide 7 demonstrated highly significant inhibition of DENV-4 at 84.82% during post-infection, much lower inhibitions were observed against DENV-2 and 3 at 9.13% and 2.24%; Peptide 7 was observed to inhibit DENV-4 replications significantly with reductions of RNA copy numbers by 77.01%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1824.11" "C79H122N24O22S2" "AEHPQSTY" "G" "7.98" "2" "1" "1" "9" "5" "3.33" "-643" "30 hour" ">20 hour" ">10 hour" "59.44" "5500" "323.53" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02006" "GAMHTALTGATE" "12" "Peptide 8" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 8 at 200 μM exhibited good inhibitions of DENV-1 (70.19%) plaque formation, but much lower inhibitions were observed against DENV-2 to 4 ranging from 28.31 to 37.73%; Peptides 8 showed highly significant inhibitions of DENV-4 plaque formation (80.31–83.92%), but lower inhibitions were observed against DENV-1 to 3 (5.34–55.46%); Peptide 8 was observed to inhibit DENV-4 replications significantly with reductions of RNA copy numbers by 73.42%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1159.28" "C47H78N14O18S" "CDFIKNPQRSVWY" "AT" "5.24" "1" "1" "0" "5" "4" "12.5" "-460" "30 hour" ">20 hour" ">10 hour" "57.5" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02007" "HAVGNDTSNHGVTA" "14" "Peptide 9" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 9 showed highly significant inhibitions of DENV-4 plaque formation (80.31–83.92%), but lower inhibitions were observed against DENV-1 to 3 (5.34–55.46%); Peptides 9 (200 μM) demonstrated the highest inhibitions of DENV-4 (83.92%) plaque formations; Peptide 9 at 200 μM showed inhibitions of all four DENV serotypes, but significantly lower inhibitions against DENV-2 (1.67%) and DENV-3 (3.48%) were observed. " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1379.41" "C55H86N20O22" "CEFIKLMPQRWY" "AGHNTV" "5.97" "2" "1" "1" "7" "4" "-56.43" "-2628" "3.5 hour" "10 min" ">10 hour" "55.71" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02008" "SPRTGLDFNEMI" "12" "Peptide 10" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptide 10 (200 μM) exhibited inhibitions of all four DENV serotypes, with high inhibitions of DENV-4 at 81.13%, followed by DENV-3 at 60.47% and DENV-1 at 47.01%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1379.55" "C59H94N16O20S" "ACHKQVWY" "DEFGILMNPRST" "4.37" "1" "2" "-1" "4" "3" "-45.83" "-2695" "1.9 hour" ">20 hour" ">10 hour" "65" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02009" "TNTTT" "5" "Peptide 11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 11 at 200 μM exhibited cell protection effects below 50% against all four DENV serotypes(DENV-1, DENV-2, DENV-3, DENV-4); peptides 11 (200 μM) also showed inhibitions of all four DENV serotypes, but significantly lower inhibitions were observed against DENV-3 at 3.57%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "536.54" "C20H36N6O11" "ACDEFGHIKLMPQRSVWY" "T" "5.19" "0" "0" "0" "5" "0" "-126" "-1692" "7.2 hour" ">20 hour" ">10 hour" "0" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02010" "DANFV" "5" "Peptide 12" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]Peptides 12 at 200 μM exhibited cell protection effects below 50% against all four DENV serotypes(DENV-1, DENV-2, DENV-3, DENV-4); peptide 12 (200 μM) also showed inhibitions of all four DENV serotypes, but significantly lower inhibitions were observed against DENV-3 at 2.28%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "564.6" "C25H36N6O9" "CEGHIKLMPQRSTWY" "ADFNV" "3.8" "0" "1" "-1" "1" "3" "36" "-653" "1.1 hour" "3 min" ">10 hour" "78" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02011" "PFGDSYIVI" "9" "peptides 5F" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]At 100 μM, peptides 5F demonstrated some cell protection effects against DENV-1 (22.89%), DENV-2 (48.28%) and DENV-4(66.72%); Peptide 5F at 100 μM was observed to exhibit higher inhibition of DENV-4 at 66.72% during the pre-infection stage when compared to peptide 5 which only demonstrated 59.72% inhibition of DENV-4 at 200 μM; Peptides 5F(100 μM) also demonstrated direct virus-inactivating effects against DENV-1 at 46.75%, DENV-2(75.15%), DENV-3(10.81%), DENV-4(70.15%); Peptides 5F at 100 μM showed inhibitions against DENV-1 during the post-infection stage at 49.65%, DENV-2(47.49%), DENV-4(91.58%)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM.(cell viability was found to range between 92.98 and 100% at 200 μM)." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1010.15" "C49H71N9O14" "ACEHKLMNQRTW" "I" "3.8" "0" "1" "-1" "3" "4" "93.33" "554" ">20 hour" ">20 hour" "?" "118.89" "1490" "186.25" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02012" "VIGVGDSAL" "9" "peptides 5FG" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]At 100 μM, peptides 5FG demonstrated some cell protection effects against DENV-1 (24.83%), DENV-4(57.09%) and DENV-2 (52.21%); Peptides 5FG (100 μM) also demonstrated direct virus-inactivating effects against DENV-1 at 46.72%, DENV-2 at (66.48%), DENV-4(70.3%); Peptides 5FG at 100 μM showed inhibitions against DENV-1 during the post-infection stage at 35.96%, DENV-2(6.85%), DENV-4(81.19%)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM.(cell viability was found to range between 92.98 and 100% at 200 μM)." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "829.95" "C36H63N9O13" "CEFHKMNPQRTWY" "GV" "3.8" "0" "1" "-1" "3" "5" "148.89" "949" "100 hour" ">20 hour" ">10 hour" "162.22" "0" "0" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02013" "LTLHWFRK" "8" "peptides 5G" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Antiviral assays(Cell protection assay, Direct virus inhibition assay, Post-infection assay, Viral attachment assay, Viral entry assay)" "[Ref.36739680]At 100 μM, peptides 5G demonstrated some cell protection effects against DENV-1 (25.24%), DENV-4(26.80%), DENV-2 (49.24%) and DENV-3(41.08%); Peptide 5G (100 μM) demonstrated a slight increase in inhibition of DENV-3 at 41.08% during pre-infection whereas peptide 5 at 200 μM only showed 37.41% inhibition against DENV-3; Peptides 5G (100 μM) also demonstrated direct virus-inactivating effects against DENV-1 at 48.23%, DENV-2 (56.25%), DENV-3(29.91%), DENV-4(72.27%); Peptides 5G at 100 μM showed inhibitions against DENV-1 during the post-infection stage at 24.59%, DENV-4(71.95%)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.36739680]did not exhibit any significant cytotoxic effects towards Vero cells up to 200 μM.(cell viability was found to range between 92.98 and 100% at 200 μM)." "No predicted structure available" "Linear" "Acetylation" "Amidation" "None" "L" "Not found" "No machanism information found in the reference(s) presented in this entry" "1100.33" "C54H81N15O10" "ACDEGIMNPQSVY" "L" "11" "3" "0" "3" "1" "4" "-35" "-1255" "5.5 hour" "3 min" "2 min" "97.5" "5500" "785.71" "36739680" "Virology. 2023 Mar;580:10-27." "Lee MF, Anasir MI, Poh CL. " "Development of novel antiviral peptides against dengue serotypes 1-4. " "10.1016/j.virol.2023.01.016" "Anti-DENV" "DRAVPe02014" "QLESLTDRELLLLIARKTCGSVE" "23" "E30pep-wt" "Synthetic construct" "Q05323" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Immunofluorescence" "[Ref.12912982]Ebola virus(EBOV): inhibition of the oligomerization of VP30(IC50= 1 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Amination" "Carboxylation" "None" "L" "Transcription" "E30pep-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30pep-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs. " "2588.01" "C111H195N31O37S" "FHMNPWY" "L" "4.87" "3" "4" "-1" "6" "9" "8.7" "-3951" "0.8 hour" "10 min" ">10 hour" "135.65" "0" "0" "12912982" "J Biol Chem. 2003 Oct 24;278(43):41830-6." "Hartlieb B, Modrof J, Mühlberger E, Klenk HD, Becker S." "Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. " "10.1074/jbc.M307036200" "Anti-EBOV" "DRAVPe02015" "GWKRIKQRIKDKLRNL" "16" "WL-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Plaque-forming assay" "[Ref.37342565]herpes simplex virus 1(HSV-1): WL-1 significantly inhibited the replication of HSV-1 on Vero cells(10 μM concentration with a 50% antiviral activity)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.37342565]WL-1 did not exert toxic effects on neuronal cell (U251) and epithelial cell (Vero) up to 50 μM concentration." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "virus replication" "WL-1 may damage the viral membrane envelope or inhibit HSV-1 adsorption to cells, or perhaps participates in the regulation of the viral replication cycle and inflammatory response caused by viral infection." "2052.5" "C92H162N32O21" "ACEFHMPSTVY" "K" "11.74" "7" "1" "6" "2" "5" "-151.88" "-6491" "30 hour" ">20 hour" ">10 hour" "97.5" "5500" "366.67" "37342565" "Front Microbiol. 2023 Jun 5;14:1201505." "Guo X, An Y, Tan W, Ma L, Wang M, Li J, Li B, Hou W, Wu L." "Cathelicidin-derived antiviral peptide inhibits herpes simplex virus 1 infection. " "10.3389/fmicb.2023.1201505." "Anti-HSV-1" "DRAVPe02055" "Not reported" "0" "Salaciachinensis" "Natural Construct(isolated from digest of thai medicinal plants) " "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 0.25 µg/mL " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13404" "Anti-DENV" "DRAVPe02053" "Not reported" "0" "Andrographispaniculata (Burm.f.) Wall.exNees" "Natural Construct(isolated from digest of thai medicinal plants) " "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 2.31 µg/mL " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13402" "Anti-DENV" "DRAVPe02054" "Not reported" "0" "Sennagarrettiana (Craib) Irwin & Barneb" "Natural Construct(isolated from digest of thai medicinal plants) " "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 0.31 µg/mL " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13403" "Anti-DENV" "DRAVPe02052" "Not reported" "0" "Diospyros Mollis Griff" "Natural Construct(isolated from digest of thai medicinal plants) " "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 2.4 µg/mL " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13401" "Anti-DENV" "DRAVPe02051" "Not reported" "0" "Thunbergia laurifolia Lindl" "Natural Construct(isolated from digest of thai medicinal plants) " "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 1.54 µg/mL " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13400" "Anti-DENV" "DRAVPe02049" "EDVLL " "5" "SLP9" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 12.8 ± 0.5 μg/ml" "[Ref:30973929] high hemolytic activity " "[Ref:30973929] CC50: 52.2 ± 2.0 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "587.67" "C26H45N5O10" "ADCHMSTWYOU" "L" "3.67" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215236" "Anti-PEDV" "DRAVPe02050" "EVLDL" "5" "SLP10" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 10.6 ± 0.5 μg/ml" "[Ref:30973929] high hemolytic activity " "[Ref:30973929] CC50: 82.8 ± 3.4 μg/ml" "No predicted structure available" "Cyclic" "Heptaalkyl-biphenyl-acid-" "Amination" "Heptaalkyl-biphenyl-acid-" "L/D" "Membrane" "Inhibiting viral membrane fusion" "587.67" "C26H45N5O10" "ARNCQGHIKMFPSTWYOU" "L" "3.67" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215237" "Anti-PEDV" "DRAVPe02047" "EVLDL " "5" "SLP7 " "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 14.0 ± 0.6 μg/ml" "[Ref:30973929] high hemolytic activity " "[Ref:30973929] CC50: 274.1 ± 21.0 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "SLP7 is a version of SLP3 that contains only L-amino acids" "L" "Membrane" "Inhibiting viral membrane fusion" "814" "C26H45N5O10" "ARNCQGHIKMFPSTWYOU" "L" "3.36" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215234" "Anti-PEDV" "DRAVPe02048" "EVLLD" "5" "SLP8" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 2.6 ± 0.2 μg/ml" "[Ref:30973929] SLP8 has a low hemolytic activity," "[Ref:30973929] CC50: 217.5 ± 18.9 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "587.67" "C26H45N5O10" "ADCHMSTWYOU" "L" "3.67" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215235" "Anti-PEDV" "DRAVPe02046" "KVLKL " "5" "SLP6" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 6.1 ± 0.3 μg/ml" "[Ref:30973929] high hemolytic activity " "[Ref:30973929] CC50: 12.6 ± 0.4 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "599.81" "C29H57N7O6" "ARNDCQEGHIMFPSTWYOU" "LK" "10" "0" "2" "-2" "2" "3" "0.8" "0.8133" "1.3 hours" "3 mins" "3 mins" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215233" "Anti-PEDV" "DRAVPe02045" "EVLDL " "5" "SLP5" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" " [Ref:30973929]PEDV:EC50 16.5 ± 0.6 μg/ml" "[Ref:30973929] hemolytic activity is reduced" "[Ref:30973929] CC50: 847.2 ± 124.9 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Carboxylation" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "587.67" "C26H45N5O10" "ARNCQGHIKMFPSTWYOU" "L" "3.67" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215232" "Anti-PEDV" "DRAVPe02043" "EVLDL" "5" "SLP3" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 16.9 ± 1.6 μg/ml" "[Ref:30973929] hemolytic activity is reduced" "[Ref:30973929] CC50: 69.7 ± 2.6 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "587.67" "C26H45N5O10" "ARNCQGHIKMFPSTWYOU" "L" "3.67" "0" "2" "-2" "2" "3" "0.96" "0.8133" "1 hour" "30 mins" ">10 hours" "214" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215230" "Anti-PEDV" "DRAVPe02044" "EVLL " "4" "SLP4" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 5.4 ± 0.4 μg/ml" "[Ref:30973929] high hemolytic activity " "[Ref:30973929] CC50: 12.9 ± 0.2 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "526.64" "C22H46N4O10" "ARNCQGHIKMFPSTWYOU" "EVL" "4.25" "0" "1" "-1" "1" "3" "0.905" "0.656" "1.3 hours" "3 mins" "3 mins" "10.7" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215231" "Anti-PEDV" "DRAVPe02041" "EVLADLV " "7" "SLP1" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV: EC50 8.0 ± 0.3 μg/ml" "[Ref:30973929] Low Hemolytic Activity" "[Ref:30973929] CC50: 52.6 ± 2.3 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "757.88" "C34H59N7O12" "RNCQGHIKMFPSTWWYOU" "LV" "3.67" "0" "2" "-2" "2" "5" "1.543" "0.7771" "1 hour" "30 mins" ">10 hours" "208.57" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215228" "Anti-PEDV" "DRAVPe02042" "EVLDLV " "6" "SLP2" "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV; EC50 5.3 ± 0.5 μg/ml" "[Ref:30973929] Low Hemolytic Activity" "[Ref:30973929] CC50: 33.0 ± 1.6 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Amination" "None" "L" "Membrane" "Inhibiting viral membrane fusion" "686.8" "C31H54N6O11" "ARNCQGHIKMFPSTWYOU" "LV" "3.67" "0" "2" "-2" "2" "4" "1.5" "0.7771" "1 hour" "30 mins" ">10 hours" "226.67" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215229" "Anti-PEDV" "DRAVPe02040" "EVLADL" "6" "Surfactin " "Synthetic Construct(derived from Bacillus subtilis)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque reduction assay" "[Ref:30973929] PEDV; EC50 11.4 ± 0.7 μg/ml" "[Ref:30973929] Low Hemolytic Activity" "[Ref:30973929] CC50:45.9 ± 0.9 μg/ml" "No predicted structure available" "Linear" "palmitoylation" "Free" "None" "L" "Membrane" "surfactin exerts its antiviral effects by inhibiting viral membrane fusion. Membrane fusion between the viral envelope and the cell membrane is essential for enveloped viruses to invade host cells. Surfactin can act directly on virus particles by insertion into the viral envelopes’ lipid bilayer and thereby reduce the membrane fusion rate." "644.72" "C28H48N6O11" "RNCQGHIKMFPSTWWYOU" "V" "3.67" "0" "2" "-2" "2" "5" "1.167" "0.7771" "1 hour" "30 mins" ">10 hours" "178.33" "0" "0" "30973929" "PloS one, 14(4), e0215227." "Yuan, L., Zhang, S., Peng, J., Li, Y., & Yang, Q. (2019)." "Synthetic surfactin analogues have improved anti-PEDV properties" "10.1371/journal.pone.0215227" "Anti-PEDV" "DRAVPe02039" "KLTILNKDGILRSVILSFN" "19" "Scrambled-2" "Synthetic Construct (AVP-p scrambled form)" "No entry found" "Experimentally Validated" "None" "GPC" "Not Available" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JUNV" "Arenaviridae" "Plaque Reduction Assays" "[Ref.24850726]JUNV:demonstrated some inhibitory activity. " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24850726]no acute cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Membrane" "Fusion inhibitor, deployment of fusion machinery by the peptide could render virions less able to engage in on-pathway receptor binding or endosomal fusion" "2144.59" "C98H170N26O27" "ACQEHMPWYOU" "IL" "9.99" "3" "1" "2" "6" "9" "0.537" "-1499" "5.5 hours" "3 min" "2 min" "158.95" "0" "0" "24850726" "Journal of virology, 88(15), 8556–8564." "Spence, J. S., Melnik, L. I., Badani, H., Wimley, W. C., & Garry, R. F. (2014)." "Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism" "10.1128/JVI.01133-14" "Anti-JUNV" "DRAVPe02035" "VNKKIEEIDKKIEELNKKLEELEKKLEEVNKK" "32" "NOVEL-2" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "HR1, HR2" "AAS00690, AAK27168" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" " NDV, IBV" "Paramyxoviridae" "Fusion Assay" "[Ref. 21601229]NDV : Inhibition by NOVEL-1 and NOVEL-2 (~90% inhibition at 5 μM, plaque formation inhibition at 25 μM).##IBV:Inhibition by NOVEL-1 and NOVEL-2 (~90% inhibition at 5 μM, plaque formation inhibition at 26 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Entry inhibition" "3909.58" "C173H303N45O56" "ARCQMFPSTUOYW" "EK" "6.45" "10" "10" "0" "-1.481" "100 hours" ">20 hours" ">10 hours " "103.44" "0" "0" "21601229" "Virology, 416(1-2), 65–74." "Wang, X. J., Li, C. G., Chi, X. J., & Wang, M. (2011)." "Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins" "10.1016/j.virol.2011.05.001" "Anti-NDU,Anti-IBV" "DRAVPe02036" "TLTTKLY" "7" "TLTTKLY" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" " NDV, IBV" "Paramyxoviridae" "competition assay" "[Ref. 12021868]NDV: Inhibition of hemolytic activity and viral propagation in embryonated chicken eggs. Inhibition of phage binding with the same sequence." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Entry inhibition" "839" "C39H66N8O12" "ARNDCQEGHIMFPSWVOu" "LT" "8.26" "1" "0" "1" "2" "5" "0.043" "7.2 hours" ">20 hours" ">10 hours" "111.43" "1490" "1.776" " 12021868##16377031" "Archives of virology, 147(5), 981–993;## Peptides, 27(6), 1217–1225." "Ramanujam, P., Tan, W. S., Nathan, S., & Yusoff, K. (2002);##Chia, S. L., Tan, W. S., Shaari, K., Abdul Rahman, N., Yusoff, K., & Satyanarayanajois, S. D. (2006)." "Novel peptides that inhibit the propagation of Newcastle disease virus;##Structural analysis of peptides that interact with Newcastle disease virus" " 10.1007/s00705-001-0778-y;##10.1016/j.peptides.2005.11.018" "Anti-NDU" "DRAVPe02037" "CTLTTKLYC" "9" "CTLTTKLYC" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" " NDV, IBV" "Paramyxoviridae" "competition assay" "[Ref. 12021868]NDV: Inhibition of hemolytic activity and viral propagation in embryonated chicken eggs. Inhibition of phage binding with the same sequence." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Entry inhibition" "1045.28" "C45H76N10O14S2" "ARNDQEGHIMFPWVOU" "CLT" "8.05" "1" "0" "1" "0.589" "1.2 hours" ">20 hours" ">10 hours" "86.67" "1490" "1.425" " 12021868##16377031" "Archives of virology, 147(5), 981–993;## Peptides, 27(6), 1217–1225." "Ramanujam, P., Tan, W. S., Nathan, S., & Yusoff, K. (2002);##Chia, S. L., Tan, W. S., Shaari, K., Abdul Rahman, N., Yusoff, K., & Satyanarayanajois, S. D. (2006)." "Novel peptides that inhibit the propagation of Newcastle disease virus;##Structural analysis of peptides that interact with Newcastle disease virus" " 10.1007/s00705-001-0778-y;##10.1016/j.peptides.2005.11.018" "Anti-NDU" "DRAVPe02034" "NASDMEIKKVNKKIEEYIKKIEEVEKKLEEVNKK" "34" "NOVEL-1" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "HR1, HR2" "AAS00690, AAK27168" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" " NDV, IBV" "Paramyxoviridae" "Fusion Assay" "[Ref. 21601229]NDV:Inhibition by NOVEL-1 and NOVEL-2 (~90% inhibition at 5 μM, plaque formation inhibition at 25 μM).##IBV:Inhibition by NOVEL-1 and NOVEL-2 (~90% inhibition at 5 μM, plaque formation inhibition at 25μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Spike Protein" "Entry inhibition, The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections. The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections.The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections.The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections.The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections.The novel peptides completely inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum class of antiviral peptides that can reduce the effects of mixed-infections." "4105.8" "C181H311N47O58S1" "RCQGHFPTWOU" "EK" "8.19" "10" "9" "1" "0.2941" "-1.324" "2.9788" "1.4 hours" "3 min" ">10 hours " "85.88" "1490" "0.363" "21601229" "Virology, 416(1-2), 65–74." "Wang, X. J., Li, C. G., Chi, X. J., & Wang, M. (2011)." "Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins" "10.1016/j.virol.2011.05.001" "Anti-NDU,Anti-IBV" "DRAVPe02032" "YKYRYL " "6" "BD-11b" "S protein of SARS-CoV" "No entry found" "Experimentally Validated" "None" "S1 Protein" "Not Available" "Y438-L443" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Cell-cell fusion" "[Ref.22265858]SARS-CoV:14 mM (IC90) Vero Ex cells, 7 mM (IC90) CaCo2 cells" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Block attachment to the host cells" "905.06" "C45H64N10O10" "ANDCQEGHIMFPSTWVOU" "Y" "9.53" "2" "0" "2" "-1.417" "2.8 hours" "10 min" "2 min" "65" "4470" "4.939" "22265858" "Antiviral research, 94(3), 288–296." "Struck, A. W., Axmann, M., Pfefferle, S., Drosten, C., & Meyer, B. (2012)" "A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2" "10.1016/j.antiviral.2011.12.012" "Anti-SARS-Cov" "DRAVPe02033" "WNFFDWFSGLMSWFGGPLK" "19" "RVFV-6" "Synthetic Construct" "P03518" "Experimentally Validated" "11588" "GP" "P03518" "450-468" "pfam19019" "M11157" "Genomic RNA" "Not Available" "4HJ1" "RVFV, Ebola virus" "Nil" "Not Available" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Fusion inhibitor" "2322.67" "C117H148N24O25S1" "ARCQEHITYVOU" "GFW" "5.84" "1" "1" "0" "0" "0.142" "2.8 hours" "3 min" "2 min" "41.05" "16500" "7.104" "24069485" "PLoS neglected tropical diseases, 7(9), e2430. " "Koehler, J. W., Smith, J. M., Ripoll, D. R., Spik, K. W., Taylor, S. L., Badger, C. V., Grant, R. J., Ogg, M. M., Wallqvist, A., Guttieri, M. C., Garry, R. F., & Schmaljohn, C. S. (2013)." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-RVFV,Anti-Ebola virus,Anti-Andes virus,Anti-vesicular stomatitis virus" "DRAVPe02031" "LEAIPCSIPPEFLFGKPFVFLEAIPCSIPPEFLFGKPFVF" "40" "VIR-576" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "E2 Protein" "Not Available" "29 -72 " "cd02056##cd02056" "Not Available" "Not Available" "Not Available" "2L6S## 2L6T" "HIV-1" "Retroviridae" "inhibition assay " "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Not Available" "4485.41" "C224H324N42O51S2" "RNDQHMTWYOU" "EILFP" "4.49" "2" "4" "-2" "0.89" "5.5 hours" "3 min" "2 min" "97.5" "125" "0.028" "21543477##17448989##21178138" "Journal of virology, 85(14), 7037–7047## Cell, 129(2), 263–275 ## Science translational medicine, 2(63), 63re3." "Koedel, Y., Eissmann, K., Wend, H., Fleckenstein, B., & Reil, H. (2011)## Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., Meyer, B.,## Wilhelm, D., Lu, H., Jing, W., Jiang, S., Forssmann, W. G., & Kirchhoff, F.## Forssmann, W. G., The, Y. H., Stoll, M., Adermann, K., Albrecht, U., Tillmann, H. C., Barlos, K., Busmann, A., Canales-Mayordomo, A., Giménez-Gallego, G., Hirsch, J., Jiménez-Barbero, J., Meyer-Olson, D" "Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition## Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide##Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide." "10.1128/JVI.02366-10##10.1016/j.cell.2007.02.042##10.1126/scitranslmed.3001697" "Anti-HIV-1" "DRAVPe02030" "CANLLLQYGSFCTQLNRALSGIA" "23" "P9" "synthetic Construct (Derived from SARS-CoV: 694009))" "P59594" "Experimentally Validated" "694009 " "S2 (918758), " "AY278741.1" "731-753" "pfam01601##cd22378" "AY278741" "Genomic RNA" "N/A" "7SG4" "SARS-CoV" "Coronaviridae" "Syncytia inhibition assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Spike Protein" "P9 themselves can markedly inhibit syncytia formation" "2456.86" "C107H174N30O32S2" "DEHKMPVW" "ALCGNQS" "6.72" "1" "0" "1" "0.6" "1.2 hours" ">20 hours" ">10 hours" "114.78" "1490" "0.606" "15811330" "Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential" "Lu, W., Wu, X. D., Shi, M. D., Yang, R. F., He, Y. Y., Bian, C., Shi, T. L., Yang, S., Zhu, X. L., Jiang, W. H., Li, Y. X., Yan, L. C., Ji, Y. Y., Lin, Y., Lin, G. M., Tian, L., Wang, J., Wang, H. X., Xie, Y. H., Pei, G., … Sun, B. (2005)." "FEBS letters, 579(10), 2130–2136." "10.1016/j.febslet.2005.02.070" "Anti-SARS-CoV" "DRAVPe02038" "RTILLFIGVKDLLKNSNSI" "19" "Scrambled-1" "Synthetic Construct (AVP-p scrambled form)" "No entry found" "Experimentally Validated" "None" "GPC" "Not Available" "Not available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "JUNV" "Arenaviridae" "Plaque Reduction Assays" "[Ref.24850726]JUNV:demonstrated some inhibitory activity" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref.24850726]no acute cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Membrane" "Fusion inhibitor, deployment of fusion machinery by the peptide could render virions less able to engage in on-pathway receptor binding or endosomal fusion" "2144.59" " C98H170N26O27" "ACQEHMPWYOU" "IL" "9.99" "3" "1" "2" "6" "9" "0.537" "-1499" "5.5 hours" "3 min" "2 min" "158.95" "0" "0" "24850726" "Journal of virology, 88(15), 8556–8564." "Spence, J. S., Melnik, L. I., Badani, H., Wimley, W. C., & Garry, R. F. (2014)." "Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism" "10.1128/JVI.01133-14" "Anti-JUNV" "DRAVPe02029" "RNTREVFAQVKQMYKTPTLKYFG" "23" "P10" "synthetic Construct (Derived from SARS-CoV: 694009)" "P59594" "Experimentally Validated" "694009 " "S2 (918758), " "AY278741.1" "amino acid residues fragments (758–780)" "cd22378" "AY278741" "Genomic RNA" "N/A" "5XJK" "SARS-CoV" "Coronaviridae" "Syncytia inhibition assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "P10 antisera had specific binding to the S fragments and S protein expressed in E. coli and SARS‐CoV infected cell lysates, suggesting that those Abs have a potential to recognize S protein of SARS‐CoV in its natural form" "2806.6" "C128H201N35O34S1" "CDHISW" "KTEQRY" "10.58" "5" "1" "4" "-0.865" "1 hours" "2 min" "2 min" "46.52" "2980" "1.06" "15811330" "Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. FEBS letters, 579(10), 2130–2136. https://doi.org/10.1016/j.febslet.2005.02.070" "Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., & Lu, L. (2020)" "Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential" "10.1016/j.febslet.2005.02.070" "Anti-SARS-CoV" "DRAVPe02028" "PSSKRFQPFQQFGRDVSDFTDSVRDPKTSE" "30" "PL8" "Synthetic construct" "U5WLK5##P59594" "Experimentally Validated" "694009 " "S2 (918758)" "KC881005" "N/A" "cd22378" "KC881005" "Genomic RNA" "N/A" "8WLY##5WRG## 5XLR## 6M3W" "SARS-CoV" "Coronaviridae" "Syncytia inhibition assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "P8 antisera had specific binding to the S fragments and S protein expressed in E. coli and SARS‐CoV infected cell lysates, suggesting that those Abs have a potential to recognize S protein of SARS‐CoV in its natural form" "3489.76" "C152H230N44O51" "ACHILMNWY" "DFSPQR" "6.1" "5" "5" "0" "0" "-1.343" ">20 hours" ">20 hours " "19.33" "0" "0" "15811330" "FEBS letters, 579(10), 2130–2136. " "Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., & Lu, L. (2020)" "Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential" "10.1016/j.febslet.2005.02.070" "Anti-SARS-CoV" "DRAVPe02026" "ARLPRTMV" "8" "Pal M1" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "IAV(H5N1)" "Orthomyxoviridae" "Not Available" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "micelle" "C16" "Free" "None" "L" "HA" "Not Available" "1181" "C40H74N14O10S1" "NDCQEGHIKFSWYOU" "RALPPTV" "12" "2" "0" "2" "7" "7" "0.05" "1.1429" "4.4 hours (mammalian reticulocytes, in vitro)" ">20 hours " ">10 hours " "97.5" "0" "0" "23777281" "BMC biotechnology, 13, 51." "Hüttl, C., Hettrich, C., Miller, R., Paulke, B. R., Henklein, P., Rawel, H., & Bier, F. F. (2013)" "Self-assembled peptide amphiphiles function as multivalent binder with increased hemagglutinin affinity" "10.1186/1472-6750-13-51" "Anti-IAV(H5N1)" "DRAVPe02027" "ARLPR" "5" "Pal S1" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "IAV(H5N1)" "Orthomyxoviridae" "Not Available" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "micelle" "C16" "Free" "None" "L" "HA" "Not Available" "849" "C26H49N11O6" "NDCQEGHIKMFPSTWYVOU" "ARLP" "12" "2" "0" "2" "5" "5" "-1" "1.12" "4.4 hours (mammalian reticulocytes, in vitro)" ">20 hours " ">10 hours " "98" "0" "0" "23777281" "BMC biotechnology, 13, 51." "Hüttl, C., Hettrich, C., Miller, R., Paulke, B. R., Henklein, P., Rawel, H., & Bier, F. F. (2013)" "Self-assembled peptide amphiphiles function as multivalent binder with increased hemagglutinin affinity" "10.1186/1472-6750-13-51" "Anti-IAV(H5N1)" "DRAVPe02025" "ARLPRTMVHPKPAQP" "15" "C18-s2" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "Influenza virus" "Orthomyxoviridae" "Not Available" "[Ref:20476787]C17H35CO-ARLPRTMV-NH2:Inhibition of influenza A/H1N1/Puerto Rico/8/34 virus (IC50=3.0 and 1.9 μM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "C17H35CO" "Amidation" "None" "L" "Membrane" "Not Available" "1699.05" "C75H127N25O18S1" "NDCEGIFSWYOU" "ARP" "12" "3" "0" "3" "6" "9" "-0.88" "1.2143" "4.4 hours (mammalian reticulocytes, in vitro)" ">20 hours " ">10 hours " "58.67" "0" "0" "36232735##20476787" "International journal of molecular sciences, 23(19), 11433##Journal of medicinal chemistry, 53(11), 4441–4449" "Agamennone, M., Fantacuzzi, M., Vivenzio, G., Scala, M. C., Campiglia, P., Superti, F., & Sala, M. (2022)##Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., Nagata, K., Okahata, Y., & Sato, T. (2010)." "Antiviral Peptides as Anti-Influenza Agents##Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy" "10.3390/ijms231911433##10.1021/jm1002183" "Anti-IAV" "DRAVPe02023" "ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE" "38" "CRAMP-2" "Natural Construct (obtained from Mouse cathelicidin)" "P51437" "Experimentally Validated" "10090" "CAMP(12796)" "U43409.1" "135-172" "pfam12153" "CM001002.3" "mRNA" "Chromosome 9,(125-172)" "None" "EV71" "Picornaviridae" "Hemagglutination inhibition assay" "[Ref:33508330]CRAMP:Reduction of intracellular EV71 RNA copy numbers by 95.7% and 97.6%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:33508330]CRAMP:No cytotoxicity against U251 cells." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "CRAMP significantly inhibited EV71 replication, suggesting that CRAMP possibly enhanced the antiviral immune response of host cells.CRAMP did not directly inactivate EV71 virons, but effectively regulated IFN-β and IL-6 response and markedly inhibited viral binding. " "4291.2" "C197H338N56O50" "DCHMTWYOU" "K" "10.46" "10" "3" "7" "18" "12" "-0.582" "1.59" "20 hours" "30 mins" ">10 hours " "102.63" "0" "0" "33508330" "Antiviral research, 187, 105021." "Yu, J., Dai, Y., Fu, Y., Wang, K., Yang, Y., Li, M., Xu, W., & Wei, L. (2021)" "Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding" "10.1016/j.antiviral.2021.105021" "Anti-EV71" "DRAVPe02024" "NDFRSKT" "7" "L-P1" "Synthetic Construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza virus,AIV(H9N2)" "Orthomyxoviridae" "Hemagglutination inhibition assay" "[Ref:19680476]Peptide P1:Inhibition of early-stage viral infection independent of virus entry.[Ref:19497129]AIV(H9N2):IC50=100 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Prevent the viral replication by inhibiting the attachment or entry of the virus into the target cells" "866.93" "C36H58N12O13" "ACQEGHILMPWYVOU" "RNDKFST" "8.75" "2" "1" "1" "7" "0" "-2.014" "1.3714" "1.4 hours" "3 min" ">10 hours " "0" "0" "0" "19680476##19497129" " International journal of biological sciences, 5(6), 543–548##Virology journal, 6, 74." "Rajik, M., Omar, A. R., Ideris, A., Hassan, S. S., & Yusoff, K. (2009)##Rajik, M., Jahanshiri, F., Omar, A. R., Ideris, A., Hassan, S. S., & Yusoff, K. (2009)." "A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells##Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2" "10.7150/ijbs.5.543## 10.1186/1743-422X-6-74" "Anti-IAV,Anti-AIV(H9N2)" "DRAVPe02022" "GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE" "33" "CRAMP-1" "Mus musculus(Mouse)" "P51437" "Experimentally Validated" "10090" "CAMP(12796)" "U43409.1" "135-172" "pfam12153" "CM001002.3" "mRNA" "Chromosome 9,(125-172)" "None" "HRV,AV" "Picornaviridae" "Not Available" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "Not Available" "Not Available" "3750.53" "C173H294N48O44" "ADCHMSTWYOU" "K" "10.22" "9" "3" "6" "16" "12" "-0.815" "1.0286" "30 hours" ">20 hours " ">10 hours " "91.52" "0" "0" "16020269##33508330" "Current eye research, 30(5), 385–394##Antiviral research, 187, 105021." "Gordon, Y. J., Huang, L. C., Romanowski, E. G., Yates, K. A., Proske, R. J., & McDermott, A. M. (2005)##Yu, J., Dai, Y., Fu, Y., Wang, K., Yang, Y., Li, M., Xu, W., & Wei, L. (2021)" "Human Cathelicidin (LL-37), a Multifunctional Peptide, is Expressed by Ocular Surface Epithelia and has Potent Antibacterial and Antiviral Activity##Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding" "10.1080/02713680590934111##10.1016/j.antiviral.2021.105021" "Anti-HRV,Anti-AV" "DRAVPe02021" "LVLQTM" "6" "LVLQTM" "Derived from the very C terminus of the RBM6Δ6 protein " "No entry found" "Experimentally Validated" "None" "RBM6Δ6 protein" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HRVs,EV-71" "Picornaviridae" "Not Available" "[Ref:22072773]LVLQTM peptide:Effective substrate analogue of EV-71 2A(pro) (Kd=9.6 μM);Inhibition of eIF4G cleavage activity of 2A(pro);Inhibition of EV-71 replication in HeLa cells." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Available" "peptide inhibited the activity of protease 2 A, which plays several essential roles during viral replication, by coupling in the active site of this enzyme. The in vitro assay with A549 cells and the in vivo assay with mice demonstrated viral replication inhibition" "703.9" "C31H57N7O9S1" "ARNDCEGHIKFPSWYOU" "L" "5.52" "0" "0" "0" "2" "4" "1.583" "0.8067" "5.5 hours" "3 mins" "2 mins" "178.33" "0" "0" "22072773##22865380" "Journal of virology, 86(2), 691–704;##The Journal of antimicrobial chemotherapy, 67(12), 2865–2869." "Falah, N., Violot, S., Décimo, D., Berri, F., Foucault-Grunenwald, M. L., Ohlmann, T., Schuffenecker, I., Morfin, F., Lina, B., Riteau, B., & Cortay, J. C. (2012);##Falah, N., Montserret, R., Lelogeais, V., Schuffenecker, I., Lina, B., Cortay, J. C., & Violot, S. (2012)." "Ex Vivo and In Vivo Inhibition of Human Rhinovirus Replication by a New Pseudosubstrate of Viral 2A Protease;##Blocking human enterovirus 71 replication by targeting viral 2A protease" " 10.1128/JVI.05263-11;## 10.1093/jac/dks304" "Anti-HRVs,Anti-EV-71" "DRAVPe02019" "KREHGQHCEF" "10" "SU2" "Purified from R. paludosa extract" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1(RT)" "Retroviridae" "Plaque reduction assay" "[Ref:17113195]HIV-1:IC50=11µM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Available" "Not Available" "1270.39" "C53H79N19O16S1" "ANDILPSTWVYOU" "EH" "6.92" "2" "2" "0" "7" "2" "-2.04" "0.924" "1.3 hours" "3 mins" "3 mins" "0" "0" "0" "17113195" "Peptides, 28(3), 560–565." "Wang, J., Wang, H. X., & Ng, T. B. (2007)." "A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa" "10.1016/j.peptides.2006.10.004" "Anti-HIV-1(RT)" "DRAVPe02020" "IPLRGAFINGRWDSQCHRFSNGAIACA" "27" "Urumin" "Skin of the South Indian frog(Hydrophylax bahuvistara)" "P0DTB9" "Experimentally Validated" "1690667" "Not Available" "Not Available" "1 to 27" "P0DTB9.1" "Not Available" "Not Available" "Not Available" "None" "H1N1" "Orthomyxoviridae" "Not Available" "[Ref:28423338]IC50=11.25 µg/mL²;IC50 of urumin=3.8 µM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:28423338]Urumin:TD50=2,450 μM;Therapeutic index (TI)=TD50/IC50=644.7, indicating a favorable therapeutic profile." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Stalk region of H1" "Amphibian peptide that shows viricidal activity against human H1N1 influenza A virus. It specifically targets the conserved stalk region of H1 hemagglutinin, and acts by actively destroying influenza virions. It shows a reduced activity on human H3N2 influenza A virus and no activity against other viruses (HIV, SIV, HSV-II, hepatitis C, Ebola, Zika, and Dengue viruses). In vivo, the peptide also protects mice infected with mouse-adapted influenza virus from lethal influenza infection. The peptide synthesized in D-amino acids is inactive." "2961.39" "C129H201N40O35S2" "EKMTYVOU" "A" "9.02" "3" "1" "2" "14" "10" "-0.033" "1.2512" "20 hours" "30 mins" ">10 hours" "72.59" "5500" "1.857" "28423338" "Immunity, 46(4), 587–595" "Holthausen, D. J., Lee, S. H., Kumar, V. T., Bouvier, N. M., Krammer, F., Ellebedy, A. H., Wrammert, J., Lowen, A. C., George, S., Pillai, M. R., & Jacob, J. (2017)" "An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses" "10.1016/j.immuni.2017.03.018" "DRAVPa0001" "Anti-H1N1" "DRAVPe02018" "EGVKSKLNIVCNEIGLLKSLCRKFVNSHIW" "30" "Nk-lysin" "Synthetic Construct" "A0A1P8CXN4" "Experimentally Validated" "52904 " "SMAX5B_000299" "KU705506.1" "Nkl71-100" "APD51552.1" "KU705506" "mRNA" "Not available" "None" "SVCV" "Rhabdoviridae" "MTT cell-viability assay" "[Ref:30717094]SVCV:IC50= 24.69 µg/mL²" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:30717094]No significant toxic effect at concentrations <32 μM (84.5 ± 1.9% viability);Severe viability drop at higher concentrations." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Nkl71-100exerts strong antiviral activity against spring viremia of carp virus (SVCV) by inhibiting not only the binding of viral particles to host cells, but also the fusion of virus and cell membranes, which requires a low pH context. Such antiviral activity seems to be related to the important role that PS plays in these steps of the replication cycle of SVCV, a feature that is shared by other families of virus-comprising members with health and veterinary relevance. Consequently, Nkl71⁻100 is shown as a promising broad-spectrum antiviral candidate. it was observed that Nkl71–100 alters the binding ability of SVCV to cell membranes since virus-cell binding levels significantly decreased in the presence of peptide in comparison to what it is observed in its absence." "3429.1" "C154H255N43O41S2" "ADQMTOU" "LK" "9.31" "5" "2" "3" "6" "5" "0.14" "2.3" "1 hours" "30 min" ">10 hours" "120" "5625" "1.64" "30717094" "Marine drugs, 17(2), 87." "Falco, A., Medina-Gali, R. M., Poveda, J. A., Bello-Perez, M., Novoa, B., & Encinar, J. A. (2019)." "Antiviral Activity of a Turbot (Scophthalmus maximus) NK-Lysin Peptide by Inhibition of Low-pH Virus-Induced Membrane Fusion" "10.3390/md17020087" "Anti-SVCV" "DRAVPe02016" "SPATAFTVYVFCFLL" "15" "E5-type 18" "Synthetic Construct" "No entry found" "In silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "Not included yet" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not inlcuded yet" "Not Available" "E5-type 18 (SPATAFTVYVFCFLL) and E7-type 45 (TLQEIVLHLEPQNELDPVDLL) peptides presented the best results for inducing the production of IFN-γ, an essential cytokine in intracellular immunity against HPV infection." "1679.01" "C83H119N15O20S1" "RNDQEGHIKMWOU" "F" "5.24" "0" "0" "0" "3" "10" "1.693" "1.69" "1.9 hours" ">20 hours" ">10 hours " "84.44" "1740" "0.887" "31915962##35853393" "Biotechnology letters, 42(3), 403–418.;##Colloids and surfaces. B, Biointerfaces, 217, 112693." "Namvar, A., Panahi, H. A., Agi, E., & Bolhassani, A. (2020);##Freitas, E. D., Bataglioli, R. A., Oshodi, J., & Beppu, M. M. (2022)." "Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools;##Antimicrobial peptides and their potential application in antiviral coating agents" "10.1007/s10529-020-02792-6;## 10.1016/j.colsurfb.2022.112693" "Anti-HPV" "DRAVPe02017" "TLQEIVLHLEPQNELDPVDLL" "21" "E7-type 45" "Synthetic Construct" "No entry found" "In silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not available" "None" "HPV" "Papillomaviridae" "Not included yet" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "E5-type 18 (SPATAFTVYVFCFLL) and E7-type 45 (TLQEIVLHLEPQNELDPVDLL) peptides presented the best results for inducing the production of IFN-γ, an essential cytokine in intracellular immunity against HPV infection." "2428.76" "C109H178N26O36" "ARCGKMSTYOU" "L" "3.83" "0" "5" "-5" "10" "12" "0.029" "1.02" "7.2 hours" ">20 hours" ">10 hours " "157.62" "0" "0" "31915962##35853393" "Biotechnology letters, 42(3), 403–418.;##Colloids and surfaces. B, Biointerfaces, 217, 112693." "Namvar, A., Panahi, H. A., Agi, E., & Bolhassani, A. (2020);##Freitas, E. D., Bataglioli, R. A., Oshodi, J., & Beppu, M. M. (2022)." "Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools;##Antimicrobial peptides and their potential application in antiviral coating agents" "10.1007/s10529-020-02792-6;## 10.1016/j.colsurfb.2022.112693" "Anti-HPV" "DRAVPe02056" "DHVTPDIAYNPRTMY" "15" "Peptide-1" "Acacia catechu extract" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "1792.98" "C79H117N21O25S1" "CQEGLKFWOU" "DPTY" "5.21" "2" "1" "-1" "14" "11" "-0.867" "1.0171" "1.1 hours" "3 mins" ">10 hours" "52" "2980" "1.662" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13405" "Anti-DENV" "DRAVPe02057" "DHVTPDIAYNPRTYM" "15" "Peptide-2" "Acacia catechu extract" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "1792.98" "C79H117N21O25S2" "CQEGLKFWOU" "DPTY" "5.21" "2" "1" "-1" "14" "11" "-0.867" "1.0171" "1.1 hours" "4 mins" ">10 hours" "52" "2980" "1.662" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13406" "Anti-DENV" "DRAVPe02058" "DHVTPDIAYNPWAFY" "15" "Peptide-3" "Acacia catechu extract" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "1808.97" "C87H113N19O24" "RCQEGLKMSOU" "ADPY" "4.2" "0" "2" "-2" "14" "11" "-0.4" "0.9743" "1.1 hours" "3 mins" ">10 hours" "58.67" "8480" "4.688" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13407" "Anti-DENV" "DRAVPe02059" "DHVTPDIAYNPWAYF" "15" "Peptide-4" "Acacia catechu extract" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "No activity information or data found in the reference(s) presented in this entry" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "1808.97" "C87H113N19O24" "RCQEGLKMSOU" "ADPY" "4.2" "1" "2" "-2" "14" "11" "-0.4" "0.9743" "1.1 hours" "3 mins" ">10 hours" "58.67" "8480" "4.688" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019). " "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13408" "Anti-DENV" "DRAVPe02060" "Not reported" "0" "Acacia catechu extract" "Natural Construct((isolated from digest of thai medicinal plants) )" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV,DENV,DENV,DENV" "Flaviviridae" "Foci-forming unit (FFU) assay" "[Ref:30225997] DENV:IC50 values of 0.18 µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:30225997]No toxicity was observed at the peptide concentration between 0.01 µM and 1mM." "No predicted structure available" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not included yet" "Not Available" "Not Available" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "30225997" "Chemical biology & drug design, 93(2), 100–109." "Panya, A., Yongpitakwattana, P., Budchart, P., Sawasdee, N., Krobthong, S., Paemanee, A., Roytrakul, S., Rattanabunyong, S., Choowongkomon, K., & Yenchitsomanus, P. T. (2019)." "Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant Acacia Catechu" "10.1111/cbdd.13400" "Anti-DENV" "DRAVPe02061" "CDIPIGAGICAS" "12" "SP-10-1 " "Synthetic Construct(derived from SARS-CoV S protein)" "P26436##P59594" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.1" "648–659" "Not Available" "CM000673.2##AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC##1ZV7" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref:16337697] SARS-CoV IC50= >20µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "ACE2" "Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis." "1119.32" "C46H78N12O16S2" "RNQEHLKMFTWYVOU" "I" "3.8" "0" "1" "-1" "9" "9" "1.283" "0.5877" "1.2 hours" ">20 hours" ">10 hours" "114.17" "0" "0" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)" "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.002" "Anti-SARS-CoV" "DRAVPe02062" "YHTVSLLRSTSQ" "12" "SP-10-2" "Synthetic Construct(derived from SARS-CoV S protein)" "P26436##P59594" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.2" "660–671" "Not Available" "CM000673.2##AY274119.4" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC##1ZV8" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref:16337697] SARS-CoV IC50=6.21 ± 2.13µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "ACE2" "Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis." "1391.55" "C60H98N18O20" "ANDCEGIKMFPWOU" "S" "8.75" "1" "0" "1" "11" "11" "-0.375" "0.8833" "2.8 hours" "10 min" "2 min" "89.17" "1490" "1.071" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)" "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.003" "Anti-SARS-CoV" "DRAVPe02063" "SLLRSTSQKSIV" "12" "SP-10-3 " "Synthetic Construct(derived from SARS-CoV S protein)" "P26436##P59594" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.3" "664–675" "Not Available" "CM000673.2##AY274119.5" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC##1ZV9" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref:16337697] SARS-CoV IC50=5.47 ± 0.41µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "ACE2" "Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis." "1318.54" "C56H103N17O19" "ANDCEGHMFPWYOU" "S" "11" "2" "0" "2" "12" "12" "0.042" "0.97" "1.9 hours" ">20 hours" ">10 hours" "121.67" "0" "0" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)" "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.004" "Anti-SARS-CoV" "DRAVPe02064" "KSIVAYTMSLGA" "12" "SP-10-4 " "Synthetic Construct(derived from SARS-CoV S protein)" "P26436##P59594" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.5" "672–683" "Not Available" "CM000673.2##AY274119.7" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC##1ZV11" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref:16337697] SARS-CoV IC50=2.07 ± 1.01µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "ACE2" "Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis." "1240.48" "C55H93N13O17S1" "RNDCQEHFPWOU" "AS" "8.59" "1" "0" "1" "12" "12" "0.842" "0.8667" "1.3 hours" "3 min" "3 mins" "105.83" "1490" "1.201" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)" "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.006" "Anti-SARS-CoV" "DRAVPe02065" "AYTMSLGADSSI" "12" "SP-10-5" "Synthetic Construct(derived from SARS-CoV S protein)" "P26436##P59594" "Experimentally Validated" "694009" "S2(MAX5B_000299)" "AY278741.6" "676–687" "Not Available" "CM000673.2##AY274119.8" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WNC##1ZV12" "SARS-CoV" "Coronaviridae" "ELISA" "[Ref:16337697] SARS-CoV IC50=>20µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "ACE2" "Acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis." "1215.34" "C51H82N12O20S1" "RNCQEHKFPWVOU" "S" "3.8" "0" "1" "-1" "12" "12" "0.458" "0.8667" "4.4 hours" ">20 hours" ">10 hours" "81.67" "1490" "1.226" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)" "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.007" "Anti-SARS-CoV" "DRAVPe02125" "GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK" "45" "Human beta defensin 3" "Skin, tonsils, oral/saliva, colonic mucosa, H. sapiens" "P81534" "Experimentally validated" "9606" "DEFB103A; DEFB103B" "23-67" "CAC03097.1" "CM000670.2" "mRNA" "Chromosome 8: 7,881,392-7,882,663 forward strand." "1KJ6" "HIV-1" "Retroviridae" "Not Available" "[Ref:16672548]HIV: hBD-3 inhibited infection, greater activity against X4 strains" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Linear" "Free" "Free" "None" "L" "Not Found" " Both hBD-2 and hBD-3 inhibit R5 and X4 types of HIV-1 infection in a dose-dependent manner (Sun et al. 2005 J Virol 79: 14318-29). Its anti-HIV-1 effect may be due to a direct inactivation of cell-free virions and inhibition viral replication after cDNA formation。 (1) HIV-1 X4 and R5 phenotypes induce hBD-2 and -3 mRNA in normal human oral epithelial cells; (2) hBD-2 and -3 inhibit HIV-1 infection by both viral strains, with greater activity against X4 viruses; and (3) this inhibition is due to a direct interaction with virions and through modulation of the CXCR4 co-receptor" "5161.2" "C216H377N75O59S6" "DHMFOU" "R" "10.08" "13" "2" "11" "32" "24" "-0.7" "2.87" "30 hours" ">20 hours" ">10 hours" "67.11" "2980" "0.577" "16672548" "Advances in Dental Research. 2006;19(1):42-48." "Weinberg A, Quiñones-Mateu ME, Lederman MM. " "Role of Human β-defensins in HIV Infection" "10.1177/154407370601900109" "Anti-HIV" "DRAVPe02124" "GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP" "41" "Human beta defensin 2" "Homo sapiens (Human)" "O15263,Q52LC0" "Experimentally validated" "9606" "DEB4A" "CAA95992.1" "24-64" "Z71389.1" "CM000670.2" "mRNA" "Chromosome 8: 7,414,855-7,416,863" "1FD4,1FD3 resolved by X-ray. 1FQQ resolved by NMR." "HIV-1" "Retroviridae" "Not given" "[Ref:16672548]HIV: hBD-2 and hBD-3 inhibited infection, greater activity against X4 strains" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Cyclic" "Free" "Free" " The 3 disulfide bonds are between residues 8-37, 15-30, and 20-38. The structure (one N-terminal helix and 3 beta strands) was found to be monomer in solution" "L" "Not Available" " Both hBD-2 and hBD-3 inhibit R5 and X4 types of HIV-1 infection in a dose-dependent manner (Sun et al. 2005 J Virol 79: 14318-29). Its anti-HIV-1 effect may be due to a direct inactivation of cell-free virions and inhibition viral replication after cDNA formation。 (1) HIV-1 X4 and R5 phenotypes induce hBD-2 and -3 mRNA in normal human oral epithelial cells; (2) hBD-2 and -3 inhibit HIV-1 infection by both viral strains, with greater activity against X4 viruses; and (3) this inhibition is due to a direct interaction with virions and through modulation of the CXCR4 co-receptor" "4334.24" "C188H311N55O50S6" "EMNW" "CG" "9.3" "8" "1" "7" "17" "9" "-0.102" "0.9" "30 hours" ">20 hours" ">10 hours" "64.15" "1490" "0.344" "16672548" "Advances in Dental Research. 2006;19(1):42-48." "Weinberg A, Quiñones-Mateu ME, Lederman MM. " "Role of Human β-defensins in HIV Infection" "10.1177/154407370601900109" "anti-HIV" "DRAVPe02123" "DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK" "36" "Human beta defensin 1" "Airway, hemofiltrates, urine, kidney; keratinocytes; skin; platelets; oral saliva; milk, mammary gland epithelium, colonic mucosa, H. sapiens" "P60022" "Experimentally validated" "9606" "DEFB1" "AAC51728.1" "33-68" "AH006699.2" "CM000670.2" "Genomic DNA" "Chromosome 8: 6,870,592-6,877,936 " "1E4S##1IJU" "IAV(H1N1)" "Orthomyxoviridae" "Plaque Assay" "[Ref:36678471]IAV: DEFB1 overexpression reduced viral copy number in bronchial epithelial cells" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "β-defensin-1 plays a key role in regulating IAV survival through STAT3 and is a potential target for antiviral drug development." "3934.57" "C167H262N48O50S6" "EMWOU" "GK" "8.87" "5" "1" "4" "32" "24" "-0.272" "1.3" "1.1 hours" "3 min" ">10 hours" "46.11" "4470" "1.136" "36678471" "Pathogens (Basel, Switzerland), 12(1), 123." "Othumpangat, S., & Noti, J. D. (2023)." "β-Defensin-1 Regulates Influenza Virus Infection in Human Bronchial Epithelial Cells through the STAT3 Signaling Pathway" "10.3390/pathogens12010123" "Anti-IAV" "DRAVPe02121" "DSHAKRHHGYKRKFHEKHHSHRGY" "24" "Human histatin 5" "Salivary glands, H. sapiens" "P15516" "Experimentally validated" "9606" "HTN3" "AAA58646.1" "20-43" "M26665.1" "CM000666.2" "mRNA" "Chromosome 4: 70,028,455-70,036,538" "None" "HIV" "Retroviridae" "Peptide depletion assay" "[Ref:16940535]HIV: Dh-5 reduced infectivity; T20 inhibition dominant over Dhvar2" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Dh-5 inhibited HIV-1 replication" "3036.33" "C133H195N51O33" "NCQILMPTWVOU" "H" "10.28" "7" "2" "5" "22" "18" "-2.454" "4.81" "1.1 hours" "3 min" ">10 hours" "4.17" "2980" "0.981" "16940535" "Journal of virology, 80(18), 9236–9243" "Groot, F., Sanders, R. W., ter Brake, O., Nazmi, K., Veerman, E. C., Bolscher, J. G., & Berkhout, B. (2006)." "Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry" "10.1128/JVI.00796-06" "Anti-HIV" "DRAVPe02122" "GIKCRFCCGCCTPGICGVCCRF" "22" "Hepcidin 1–5" "tilapia, Oreochromis mossambicus" "No entry found" "Experimentally validated" "106582" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "NNV" "Nodaviridae" "Not Available" "[Ref:20214942]Fish virus model: Hepcidin 1–5 (10 µg/fish), survival=68%" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "The mechanism of action (MOA) of hepcidin 1-5 against the nervous necrosis virus (NNV) involves a combination of direct antiviral and immunomodulatory effects. Hepcidin 1-5 functions as a lytic peptide, disrupting the viral structure through direct interaction, as demonstrated in vitro. Additionally, treatment with hepcidin 1-5 was shown to downregulate NNV gene expression, as verified by RT-PCR, indicating its ability to inhibit viral replication or transcription. The peptide also modulates the host immune response by reducing interferon gene expression, which may help control excessive inflammation while supporting viral clearance. Importantly, hepcidin 1-5 proved effective in pretreatment, co-treatment, and post-treatment scenarios, demonstrating its versatility in preventing infection, combating active viral presence, and rescuing infected organisms" "2329.91" "C94H153N29O24S8" "ANDQEHLMSWYOU" "C" "8.54" "3" "0" "3" "24" "18" "1" "0.81" "30 hours" ">20 hours" ">10 hours" "48.64" "0" "0" "20214942" "Peptides, 31(6), 1026–1033. " "Wang, Y. D., Kung, C. W., & Chen, J. Y. (2010)." "Antiviral activity by fish antimicrobial peptides of epinecidin-1 and hepcidin 1–5 against nervous necrosis virus in medaka" "10.1016/j.peptides.2010.02.025" "Anti-NNV" "DRAVPe02120" "ATCYCRTGR" "9" "HD-5(1–9)" "H. sapiens" "Q01523" "Experimentally validated" "9606" "DEFA5(1670)" "AAA35754.1" "63-71" "M97925.1" "CM000670.2" "Genomic DNA" "chr8:7055304-7056739:-" "1ZMP" "HCMV" "Herpesviridae" "Inhibition Assay" "[Ref:32209394]HCMV: HD5(1–9) blocked infection, reduced viability at 18.75 µM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:32209394]HD5(1–9) was not cytotoxic for any of the cell types tested " "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Cell Membrane" "HD5(1–9) inhibited HCMV cellular attachment and thereby entry and was active against primary as well as a multiresistant HCMV isolate" "1030.18" "C40H67N15O13S2" "NDQEHILKMFPSTWVOU" "RCT" "8.96" "2" "0" "2" "9" "8" "-0.589" "3.31" "4.4 hours" ">20 hours" ">10 hours" "11.11" "1490" "1.446" "32209394" "Antiviral research, 177, 104779." "Böffert, R., Businger, R., Preiß, H., Ehmann, D., Truffault, V., Simon, C., Ruetalo, N., Hamprecht, K., Müller, P., Wehkamp, J., & Schindler, M. (2020)." "The human α-defensin-derived peptide HD5(1-9) inhibits cellular attachment and entry of human cytomegalovirus" "10.1016/j.antiviral.2020.104779" "Anti-HCMV" "DRAVPe02119" "KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL" "30" "Hc-CATH" "Venom gland, spleen, and lung, annulated sea snake, Hydrophis cyanocinctus" "A0A0G3DRW6" "Experimentally validated" "8686" "Not Available" "Not Available" "158-171" "Not Available" "Not Available" "Not Available" "Not Found" "None" "ZIKV" "Flaviviridae" "Inhibition Assay" "[Ref:36089062]ZIKV: At 5 µM, reduced 70.3% CPE, 52.7% RNA, 67.4% NS3, 71.6% particles" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:36089062]MammalianCells: No cytotoxicity at 1.25, 2.5, and 5 µM" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Cell Membrane" "Hc-CATH can bind to ZIKV, disrupt viral membrane, induce the leakage of viral genomic RNA, and then inactivate ZIKV virions" "3628.59" "C171H300N52O34" "NDCQEHIMWYOU" "K" "12.61" "12" "0" "12" "22" "18" "-0.273" "2.28" "1.3 hours" "3 min" "3 min" "113.67" "0" "0" "36089062" "The Journal of biological chemistry, 298(10), 102471." "Wang, J., Jiang, B., Wang, K., Dai, J., Dong, C., Wang, Y., Zhang, P., Li, M., Xu, W., & Wei, L. (2022)." "A cathelicidin antimicrobial peptide from Hydrophis cyanocinctus inhibits Zika virus infection by downregulating expression of a viral entry factor" "10.1016/j.jbc.2022.102471" "Anti-ZIKV" "DRAVPe02118" "VGALAVVVWLWLWLW" "15" "Gramicidin A" "Soil bacterium, Bacillus brevis" "None " "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "1MAG" "HIV,HSV" "Retroviridae" "ELISA" "[Ref:9672588]HSV-1,HSV-2: IC50=0.2–0.4 mg/ml (HSV-1), 0.1–0.3 mg/ml (HSV-2)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "Synthesized non-ribosomally by a multienzyme complex. Both the N- and C-termini are chemically modified (CHO at the N-terminus and NHCH2CH2OH at the C-terminus). N-terminus is rich in Val, while the C-terminus is rich in Trp. Amino acids 4, 6, 8, 10, and 12 are D-amino acids." "L" "Not Found" "gramicidin suppressed the replication of ACV-resistant thymidine kinase and DNA polymerase HSV mutants at doses effective against ACV-sensitive strains." "1811.25" "C96H135N19O16" "RNDCQEHIKMFPSTYOU" "LV" "5.49" "0" "0" "0" "12" "10" "2.107" "-3.31" "100 hours" ">20 hours" ">10 hours" "194.67" "22000" "12.146" "9672588" "Archives of virology, 142(11), 2225–2235." "Bourinbaiar, A. S., & Coleman, C. F. (1997)." "The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro" "10.1007/s007050050237" "Anti-HIV, Anti-HSV" "DRAVPe02117" "ANTAFVSSAHNTQKIPAGAPFNRNLRAMLADLRQNAAFAG" "40" "Ginkbilobin" "Seeds, Ginkgo biloba, Asia" "P83171" "Experimentally validated" "3311" "GNK1" "Not Available" "1-40" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV" "Retroviridae" "Inhibition Assay" "[Ref:11118300]HIV: Suppressed HIV-1 reverse transcriptase activity" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "It suppressed the activity of HIV-1 reverse transcriptase " "4213.75" "C183H291N59O54S1" "CEWYOU" "A" "11.71" "4" "1" "3" "32" "24" "-0.18" "1.62" "4.4 hours" ">20 hours" ">10 hours" "71.25" "0" "0" "11118300" "Biochemical and biophysical research communications, 279(2), 407–411." "Wang, H., & Ng, T. B. (2000)." "Ginkbilobin, a novel antifungal protein from Ginkgo biloba seeds with sequence similarity to embryo-abundant protein" "10.1006/bbrc.2000.3929" "Anti-HIV" "DRAVPe02116" "GLVGTLLGHIGKAILGG" "17" "Frenatin 2.3S" "The Orinoco lime treefrog, Sphaenorhynchus lacteus, South America" "L0L3V3" "Experimentally validated" "279984" "Not Available" "Not Available" "55-71" "AGB51284.1 " "Not Available" "Not Available" "Not Found" "None" "YFV" "Flaviviridae" "antiviral colorimetric assay" "[Ref:27049440]YFV: 35% protective effect in Vero E6 cells at 20 µg/ml" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27049440]VeroE6: No cytotoxicity at 100 µg/ml" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Not Available" "1575.91" "C72H126N20O19" "RNDCQEMFPSTWYOU" "G" "8.76" "1" "0" "1" "14" "12" "1.176" "-1.66" "30 hours" ">20 hours" ">10 hours" "160.59" "0" "0" "27049440" "The Journal of antibiotics, 69(11), 783–790." "Muñoz-Camargo, C., Méndez, M. C., Salazar, V., Moscoso, J., Narváez, D., Torres, M. M., Florez, F. K., Groot, H., & Mitrani, E. (2016)." "Frog skin cultures secrete anti-yellow fever compounds" "10.1038/ja.2016.16" "Anti-YFV" "DRAVPe02115" "GLLGTLGNLLNGLGL" "15" "Frenatin-2" "White-lipped treefrog Litoria infrafrenata, Australia" "P82022" "Experimentally validated" "61195" "Not Available" "Not Available" "1to 15" "Not Available" "Not Available" "Not Available" "Not Found" "None" "YFV" "Flaviviridae" "antiviral colorimetric assay" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27049440]CMs were not cytotoxic to the CHO-K1 cell line" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Not Available" "1424.7" "C64H113N17O19" "ARDCQEHIKMFPSWYVOU" "L" "5.52" "0" "0" "0" "12" "10" "1.127" "-1.55" "30 hours" ">20 hours" ">10 hours" "182" "0" "0" "27049440" "The Journal of antibiotics, 69(11), 783–790." "Muñoz-Camargo, C., Méndez, M. C., Salazar, V., Moscoso, J., Narváez, D., Torres, M. M., Florez, F. K., Groot, H., & Mitrani, E. (2016)." "Frog skin cultures secrete anti-yellow fever compounds" "10.1038/ja.2016.16" "Anti-YFV" "DRAVPe02114" "GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC" "37" "Esculentin-2P" "North American frog, Rana pipiens" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1" "Retroviridae" "HIV infection and cell viability assay" "[Ref:16140737]HIV: Inhibited infection at a concentration also toxic to T cells" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Envelope/outer leaflet of the membrane" "Highly effective in inhibiting HIV infection by disrupting the viral membrane and preventing the entry of the virus into target cells. " "3870.63" "C173H290N50O46S2" "HPTWYOU" "GK" "10.21" "7" "1" "6" "24" "18" "0.357" "0.73" "30 hours" ">20 hours" ">10 hours" "97.57" "0" "0" "16140737" " Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)" "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe02113" "GLFSKKGGKGGKSWIKGVFKGIKGIGKEVGGDVIRTGIEIAACKIKGEC" "46" "Esculentin-1GN" "The crawfish frog, Rana areolata, North America" "No entry found" "Experimentally validated" "A0A3G6VAR4" "110109" "Not Available" "39-87" "Not Available" "Not Available" "Not Available" "mRNA" "None" "IAV(H1N1)" "Orthomyxoviridae" "Inhibition Assay" "[Ref:33624755]H5N1,H1N1: IC50=1.29–4.59 µM for viral entry inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "E105, N50 and the residues around them on HA2 subunit could form hydrogen bonds with amino acid on ESC-1GN" "L" "Cell Membrane" "ESC-1GN disrupted membrane fusion activity of IAVs by interaction with HA2 subunit" "5006.99" "C225H379N63O61S2" "NQHMPYOU" "G" "9.87" "11" "4" "7" "32" "24" "-0.078" "0.62" "30 hours" ">20 hours" ">10 hours" "85.51" "5500" "1.098" "33624755" "Journal of biochemistry, 169(6), 757–765." "Yang, J., Zhang, B., Huang, Y., Liu, T., Zeng, B., Chai, J., Wu, J., & Xu, X. (2021)." "Antiviral activity and mechanism of ESC-1GN from skin secretion of Hylarana guentheri against influenza A virus" "10.1093/jb/mvab019" "Anti-IAV" "DRAVPe02112" "GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC" "46" "Anti-NN+B14:B21" "Rana areolata" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1" "Retroviridae" "HIV infection and cell viability assay" "[Ref:16140737]HIV: Inhibited infection at a concentration also toxic to T cells" "[Ref:16140737]Not hemolytic HC50=120 uM" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Highly effective in inhibiting HIV infection by disrupting the viral membrane and preventing the entry of the virus into target cells. " "4997.05" "C226H381N59O61S3" "QHSWYOU" "K" "9.57" "10" "5" "5" "32" "24" "0.03" "0.89" "30 hours" ">20 hours" ">10 hours" "95.22" "0" "0" "16140737" " Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)" "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe02111" "ALWFTMLKKLGTMALHAGKAALGAAANTISQGTQ" "34" "Dermaseptin-S2" "Sauvage's leaf frog, Phyllomedusa sauvagii, South America" "P80278" "Experimentally validated" "8395" "Not Available" "Not Available" "1-34" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HSV-1" "[Ref:16672548]hBD3 inhibit HIV-1 inT2:T27fection by both viral strains, with greater activity against X4 viruses" "Inhibition Assay" "[Ref:20718719]HSV-1: EC50=16 µg/ml" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "3473.11" "C155H255N43O43S2" "CDEPRVY" "A" "10.3" "4" "0" "4" "10" "16" "0.382" "5.06" "4.4 hour" ">20 hour" ">10 hour" "92.35" "5500" "166.67" "20718719" " acta pathologica, microbiologica, et immunologica Scandinavica, 118(9), 674–680" "Savoia, D., Donalisio, M., Civra, A., Salvadori, S., & Guerrini, R. (2010)." "In vitro activity of dermaseptin S1 derivatives against genital pathogens" "10.1111/j.1600-0463.2010.02637.x" "Anti-HSV" "DRAVPe02109" "GSKKPVPIIYCNRRTGKCQRI " "21" "SB1" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV,HSV: EC50=13.1 µg/ml in CEM-SS cells, 64.9 µg/ml in Vero cells (HSV)" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50:>100 µg/ml in CEM-SS Cells, >100 µg/ml in Vero Cells (HSV)" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C11-C18 disulfide linkage" "L" "Not Found" "Not Available" "2417.92" "C104H181N35O27S2" "ADEHLMFWOU" "RCGIK" "10.47" "6" "0" "6" "22" "16" "-0.776" "1.24" "30 hours" ">20 hours" ">10 hours" "69.52" "1490" "0.616" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S11" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2020" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-012" "Anti-HIV" "DRAVPe02110" "MAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAF" "33" "Z2" "synthetic peptide derived from the stem region of ZIKV envelope protein" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "ZIKV" "Flaviviridae" "plaque reduction assay " "[Ref:28742068]ZIKV: IC50=1.75±0.13 µM in BHK21 cells, 3.69±0.27 µM in Vero cells; plaque assay IC50=2.61±0.46 µM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "E protein" "The mechanism by which a peptide derived from the stem region of a flavivirus can inhibit infection by a broad spectrum of flaviviruses remains a point of controversy. It was reported that DN59, a 33-mer peptide that mimics a fragment of stem region of DENV E protein, acts like a disrupter of the DENV membrane, possibly inducing hole formation, leading to release of the viral genome. Z2 peptide could bind to the E protein of ZIKV and disrupt the integrity of ZIKV membrane, resulting in the inactivation of virions" "3308.76" "C151H227N39O43S1" "RCEPYOU" "AG" "5.19" "1" "2" "-1" "25" "18" "0.636" "1.1704" "30 hours" ">20 hours" ">10 hours" "91.82" "5500" "1.662" "28742068" "Nat Commun 8, 15672 (2017)" "Yu, Y., Deng, YQ., Zou, P. et al." "A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses" "10.1038/ncomms15672" "Anti-ZIKV" "DRAVPe02108" "GSRRPVPIIYCNRRTGRCQRI " "21" "SB2 " "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "Ref:Not Available]HIV,HSV: EC50=3.33 µg/ml in CEM-SS cells, >100 µg/ml in Vero cells (HSV)" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50:>100 µg/ml in CEM-SS Cells, >100 µg/ml in Vero Cells (HSV)" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C11-C18 disulfide linkage" "L" "Not Found" "Not Available" "2417.92" "C104H181N35O27S2" "ADEHMFWOU" "RK" "10.47" "7" "0" "7" "22" "16" "-0.776" "1.24" "30 hours" ">20 hours" ">10 hours" "69.52" "1615" "0.668" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S10" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2019" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-011" "Anti-HIV" "DRAVPe02107" "GCRRLLGRLLRRLGRLLCR" "19" "GLRC-1" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV,HSV: EC50>100 µg/ml in CEM-SS cells, 30 µg/ml in Vero cells (HSV)" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50:59.2 µg/ml in CEM-SS Cells, >100 µg/ml in Vero Cells (HSV)" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C2-C18 disulfide linkage" "L" "Not Found" "Not Available" "2280.88" "C96H182N40O20S2" "ANDQEHIKMFPSTWYVOU" "RL" "12.13" "7" "0" "7" "17" "13" "-0.058" "1.0824" "30 hours" ">20 hours" ">10 hours" "143.68" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S9" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2018" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-010" "Anti-HIV" "DRAVPe02106" "GLRCRLGRLLRRLGRCLLR" "19" "GLRC-2" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV,HSV: EC50=1.81 µg/ml in CEM-SS cells, 5.43 µg/ml in Vero cells (HSV)" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50: 17.8 µg/ml in CEM-SS cells, 31.8 µg/ml in Veo Cells" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C4-C16 disulfide linkage" "L" "Not Found" "Not Available" "2280.88" "C96H182N40O20S2" "ANDQEHIKMFPSTWYVOU" "RL" "12.13" "7" "0" "7" "16" "12" "-0.058" "1.05" "30 hours" ">20 hours" ">10 hours" "143.68" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S8" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2017" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-009" "Anti-HIV" "DRAVPe02105" "GLRRLCGRLGRRLCRLLLR" "19" "GLRC-3" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV,HSV: EC50=6.37 µg/ml in CEM-SS cells (HIV), 15 µg/ml in Vero cells (HSV)" "No hemolysis information or data found in the reference(s) presented in this entry" "18.5 µg/ml in CEM-SS cells, 62.3 µg/ml in Vero Cells (HSV)" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C6-C14 disulfide linkage" "L" "Not Found" "Not Available" "2280.88" "C96H182N40O20S2" "ANDQEHIKMFPSTWYVOU" "RL" "12.13" "7" "0" "7" "16" "12" "-0.058" "1.12" "30 hours" ">20 hours" ">10 hours" "143.68" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S7" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2016" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-008" "Anti-HIV" "DRAVPe02104" "GCRRLCGRLGRRLCRLLCR " "19" "GLRC_4" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB, HSV-2MS" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HSV: EC50=69.3 µg/ml in CEM-SS cells, 64.7 µg/ml in Vero cells" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50: >100 µg/ml in CEM-SS cells, TC50: >100 µg/ml in Vero Cells (HSV)" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C2-C18, C6-C14 disulfide linkage" "L" "Not Found" "Not Available" "2280.88" "C90H170N40O20S4" "ANDQEHIKMFPSTWYVOU" "RL" "12.13" "7" "0" "7" "16" "12" "-0.058" "1.12" "30 hours" ">20 hours" ">10 hours" "143.68" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S6" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2015" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-007" "Anti-HIV" "DRAVPe02103" "GLRCRLGRLLRRLGRC" "16" "GLRC-5" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV: EC50>100 µg/ml in CEM-SS cells" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50: 59.5 µg/ml in CEM-SS cells " "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C4-C16 disulfide linkage" "L" "Not Found" "Not Available" "1898.37" "C78H148N34O17S2" "ANDQEHIKMFPSTWYVOU" "RL" "12" "7" "0" "7" "14" "12" "-0.263" "1.0857" "30 hours" ">20 hours" ">10 hours" "121.88" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S5" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2014" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-006" "Anti-HIV" "DRAVPe02101" "GLRCLRLRGRLRLGRCLLR" "19" "GLRC-8 " "De novo designed" "No entry found" "De Novo" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV: EC50>100 µg/ml in CEM-SS cells" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50:31 µg/ml in CEM-SS cells " "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C4-C16 disulfide linkage" "L" "Not Found" "Not Available" "2280.88" "C96H182N40O20S2" "ANDQEHIKMFPSTWYVOU" "RL" "12.13" "6" "0" "6" "16" "12" "-0.058" "1.12" "30 hours" ">20 hours" ">10 hours" "143.68" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S3" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2012" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-004" "Anti-HIV" "DRAVPe02102" "CRLGRLLRRLGRC" "13" "GLRC-7" "De novo designed" "No entry found" "Experimentally validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV: EC50>100 µg/ml in CEM-SS cells" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50: >100 µg/ml in CEM-SS cells " "No predicted structure available" "Linear" "Not included yet" "Not included yet" "C1-C13 disulfide linkage" "L" "Not Found" "Not Available" "1571.97" "C64H122N28O14S2" "ANDQEHIKMFPSTWYVOU" "RL" "11.83" "8" "0" "8" "12" "10" "-0.238" "1.1" "1.2 hours" ">20 hours" ">10 hours" "120" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S4" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2013" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-005" "Anti-HIV" "DRAVPe02100" "CRLGRLLRRLGRCLLR" "16" "GLRC-6 " "De novo designed" "No entry found" "De Novo" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Found" "None" "HIV-1IIIB" "Retroviridae" "Anti-HIV assays" "[Ref:Not Available]HIV: EC50=7.72 µg/ml in CEM-SS cells (T2:T27)" "No hemolysis information or data found in the reference(s) presented in this entry" "TC50:41.9 (µg/ml) in CEM-SS cells." "No predicted structure available" "Linear" "Not included yet" "Not included yet" "hairpin structure with a single disulfide bond (C11-C18) between the two strands" "L" "Not Found" "Not Available" "1954.48" "C82H156N34O17S2" "ANDQEHIKMFPSTWYVOU" "RL" "12" "7" "0" "7" "13" "10" "0" "1.0571" "1.2 hours" ">20 hours" ">10 hours" "146.25" "0" "0" "Not Avaialbe" "Reginald et al. J AIDS Clinic Res 2011, S2" "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011" "De Novo Design of Antiviral and Antibacterial Peptides with Varying Loop Structures" "10.4172/2155-6113.S2-003" "Anti-HIV" "DRAVPe02099" "GVSGHGQHGVHG" "12" "Alloferon 2" "Calliphora vicina (Blue blowfly) (Calliphora erythrocephala)" "P83412" "Experimentally Validated" "7373" "Not Available" "Not Available" "2to13" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV,IBV" "Orthomyxoviridae" "Antiviral activity assay." "[Ref:12235362]General antiviral activity: Stimulated antiviral and antitumoral resistance when injected in mice." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Carboxylation" "amidation" "None" "L" "Membrane" "Alloferon can (i) stimulate natural cytotoxicity of human peripheral blood lymphocytes, (ii) induces IFN synthesis in mouse and human models, and (iii) enhances antiviral and antitumor resistance in mice." "1128.63" "C46H69N19O15" "ARNDCEILMKFPTWYOU" "GH" "7.02" "3" "0" "3" "6" "2" "-0.823" "-10.14" "3.5 hours" " 10 min" ">10 hours" "44.62" "0" "0" "12235362" " Proceedings of the National Academy of Sciences of the United States of America, 99(20), 12628–12632." "Chernysh, S., Kim, S. I., Bekker, G., Pleskach, V. A., Filatova, N. A., Anikin, V. B., Platonov, V. G., & Bulet, P. (2002)." "Antiviral and antitumor peptides from insects" "10.1073/pnas.192301899" "DRAVPa1832" "Anti-IAV-Anti-IBV" "DRAVPe02098" "HGVSGHGQHGVHG" "13" "Alloferon 1" "Calliphora vicina (Blue blowfly) (Calliphora erythrocephala)" "P83412" "Experimentally Validated" "7373" "Not Available" "Not Available" "1to13" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HHV-1,IAV" "Orthomyxoviridae" "Antiviral activity assay." "[Ref:12235362]General antiviral activity: Stimulated antiviral and antitumoral resistance when injected in mice." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Carboxylation" "Amidation" "The three imidazoles of H1, H6, and H9 participate in the coordination of Zn(II)" "L" "Membrane" "Alloferon can (i) stimulate natural cytotoxicity of human peripheral blood lymphocytes, (ii) induces IFN synthesis in mouse and human models, and (iii) enhances antiviral and antitumor resistance in mice." "1265.15" "C52H76N22O16" "ARNDCEILMKFPTWYOU" "GH" "7.1" "4" "0" "4" "4" "2" "0.9" "-14.8" "20 hours" "30 min" ">10 hours" "209.29" "0" "0" "21766388##12235362" "Journal of peptide science : an official publication of the European Peptide Society, 17(11), 715–719##Proceedings of the National Academy of Sciences of the United States of America, 99(20), 12628–12632." "Kuczer, M., Midak-Siewirska, A., Zahorska, R., Luczak, M., & Konopińska, D. (2011)##Chernysh, S., Kim, S. I., Bekker, G., Pleskach, V. A., Filatova, N. A., Anikin, V. B., Platonov, V. G., & Bulet, P. (2002)." "Further studies on the antiviral activity of alloferon and its analogues##Antiviral and antitumor peptides from insects" "10.1002/psc.1388##10.1073/pnas.192301899" "DRAVPa1831" "Anti-HHV-1,Anti-IAV" "DRAVPe02097" "INLKILARLAKKIL" "14" "[I5, R8]Mastoparan" "Venom, Vespula lewisii" "P01514" "Experimentally Validated" "7452" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "6DUL##1D7N" "HSV-1" "Herpesviridae " "Plaque Assay" "[Ref:38932240]Human alphaherpesvirus 1 (HSV-1): Inhibited entry (EC50 = 6.22 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:38932240]CC50 > 50 µg.mL−1. Mastoparan showed no cytotoxicity even at higher concentrations (LC50 > 200 µM).However, in THP-1-derived macrophages, LC50 ranged between 24.5~12.9 µM." "No predicted structure available" "Linear" "Free" "Amination" "None" "L" "Membrane" "Mastoparan can be classified as entry inhibitors, for which characteristics such as cationicity and hydrophobicity play a significant role, primarily against enveloped viruses. Nevertheless, further assays with other enveloped and non-enveloped viruses are needed to address this matter.mastoparan, it is inferred that this peptide may also affect lipid vesicles mimicking the viral envelope" "1607.1" "C76H143N21O16" "DCQEGHMFPSTUQYOV" "KLI" "11.26" "4" "0" "4" "5" "9" "1.157" "0.01" "20 hours" "30 min" ">10 hours" "195.71" "0" "0" "38932240" "Viruses. 2024 Jun 12;16(6)" "Vilas Boas LCP, Buccini DF, Berlanda RLA, Santos BPO, Maximiano MR, Lião LM, Gonçalves S, Santos NC, Franco OL." "Antiviral Activities of Mastoparan-L-Derived Peptides against Human Alphaherpesvirus 1" " 10.3390/v16060948" "Anti-HSV-1" "DRAVPe02096" "INLKALAALAKKIL" "14" "Mastoparan-L" "Venom, Vespula lewisii" "P01514" "Experimentally Validated" "7452" "Not Available" "Not Available" "1to14" "Not Available" "Not Available" "Not Available" "Not Available" "6DUL##1D7N" "HSV-1" "Herpesviridae " "Plaque Assay" "[Ref:38932240]No significant inhibition." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:38932240]CC50 > 200 µg.mL−1" "No predicted structure available" "Linear" "Free" "Amination" "None" "L" "Membrane" "Mastoparan can be classified as entry inhibitors, for which characteristics such as cationicity and hydrophobicity play a significant role, primarily against enveloped viruses. Nevertheless, further assays with other enveloped and non-enveloped viruses are needed to address this matter.mastoparan, it is inferred that this peptide may also affect lipid vesicles mimicking the viral envelope" "1479.91" "C70H130N18O16" "RDCQEGHMFPSTWYVOU" "AILK" "10.3" "3" "0" "3" "4" "10" "1.157" "-0.96" "20 hours" "30 min" ">10 hours" "195.71" "0" "0" "38932240" "Viruses. 2024 Jun 12;16(6)" "Vilas Boas LCP, Buccini DF, Berlanda RLA, Santos BPO, Maximiano MR, Lião LM, Gonçalves S, Santos NC, Franco OL." "Antiviral Activities of Mastoparan-L-Derived Peptides against Human Alphaherpesvirus 1" " 10.3390/v16060948" "Anti-HSV-1" "DRAVPe02095" "EKYTEAPEYI" "10" "Ala-6-fenycin" "Bacillus sp. strain P34" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EAV, FHV-1" "Arteriviridae" "Antiviral assay." "[Ref:25477947]Equine arteritis virus (EAV): P34 peptide inhibited replication by 99.9%, and Feline herpesvirus-1 (FHV-1) by 94.4%." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:25477947]MDCK cells: CC50 = 2.11 µg/mL,CRFK cells: CC50 = 2.5 µg/mL,RK13 cells: CC50 = 3.92 µg/mL,MDCK cells: No cytotoxicity observed at 1.37 µg/mL of peptide P34,CRFK cells: No cytotoxicity obs" "No predicted structure available" "Linear" "Free" "Carboxylation" "None" "L" "Membrane" "This peptide inactivates the virus through an interaction with a non-lipidic structural component." "1242.35" "C57H83N11O20" "RNDCQLMFSWVOU" "E" "4.25" "1" "3" "-2" "5" "5" "-1.3" "2.21" "1 hour" "30 min" ">10 hours" "49" "2980" "2.399" "25477947##28083516" "Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 45(3), 1089–1094##Frontiers in cellular and infection microbiology, 6, 194" "Scopel e Silva, D., de Castro, C. C., da Silva e Silva, F., Sant'anna, V., Vargas, G. D., de Lima, M., Fischer, G., Brandelli, A., da Motta, A.deS., & Hübner, S.deO. (2014)##Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016)" "Antiviral activity of a Bacillus sp: P34 peptide against pathogenic viruses of domestic animals##Antimicrobial Peptides: An Emerging Category of Therapeutic Agents" "10.1590/s1517-83822014000300043##10.3389/fcimb.2016.00194" "Anti-EAV,Anti-FHV-1" "DRAVPe02094" "GIGAVLKYLTTGLPALISWIKRKROQ" "26" "Melittin of bee venom" "Bee Venom" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "MTT assay/ RT-qPCR Assay" "[Ref:33652894]SARS-CoV-2: Sitagliptin and melittin-nanoconjugates complex exhibited significant antiviral activity (IC50 = 8.439 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:34261542]C654 cells: Melittin CC50 = 6.45 µg/mL." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Melittin disrupts viral membranes, activates Toll-like receptors to reduce inflammatory cytokines, suppresses metabolic regulators like transketolase, and activates host RNA-binding proteins," "3020.7" "C142H239N39O33" "NDCHMFU" "ARGILKT" "11.17" "5" "0" "5" "10" "16" "0.196" "2.21" "30 hours" ">20 hours" ">10 hours" "123.85" "6990" "2.314" "35236909" "Scientific reports, 12(1), 3446" "Enayathullah, M. G., Parekh, Y., Banu, S., Ram, S., Nagaraj, R., Kumar, B. K., & Idris, M. M" "Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection" "10.1038/s41598-022-07341-x" "Anti-SARS-CoV-2" "DRAVPe02093" "GAICHPVFCPRRYKQIGTCGLPGTKCCKKP" "30" "4H30" "human beta-defensin 2 (HBD2)" "O15263" "Experimentally Validated" "9606" "DEFB4A(100289462)" "AF040153.1" "20-64" "pfam00711" "CM000670.2" "mRNA" "Chromosome 8:7,894,677-7,896,716" "1FD3" "SARS-CoV-2" "Coronaviridae" "plaque reduction assay/" "[Ref:35768416]SARS-CoV-2: 4H30 significantly inhibited infection (IC50 = 0.59 µg/mL or 44 nM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:35768416]Vero E6, Calu-3: TC50 > 400 µg/mL." "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Lipid Bilayer" "4H30 can inhibit three distinct steps of the SARS-CoV-2 life cycle. Specifically, 4H30 blocks viral entry by clustering SARS-CoV-2 virions; prevents membrane fusion by inhibiting endosomal acidification; and inhibits the release of virions by cross-linking SARS-CoV-2 with cellular glycosaminoglycans." "1973.46" "C87H157N23O24S2" "ARNDQEHIMFPTWYOU" "GLV" "8.9" "7" "0" "7" "8" "11" "-1.36" "1.12" "30 hours" ">20 hours" ">10 hours" "152.86" "125" "0.063" "35768416" "Cell Discov. 2022 Jun 30;8(1):62" "Zhao H, To KK, Lam H, Zhang C, Peng Z, Meng X, Wang X, Zhang AJ, Yan B, Cai J, Yeung ML, Chan JF, Yuen KY" "A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters" "10.1038/s41421-022-00428-9" "DRAVPa2313" "Anti-SARS-CoV-2" "DRAVPe02092" "GADFQECMKEHSQKQHQHQG" "20" "Alpha-basrubrin" "isolated from seeds of the Ceylon spinach Basella rubra" "P83186" "Experimentally Validated" "3589" "Not Available" "Not Available" "1to20" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref:11688973]HIV-1: Alpha-Basrubrin inhibited reverse transcriptase activity (79.4 ± 7.8% at 400 µM, 10.6 ± 0.9% at 40 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "" "Free" "None" "L" "Not given" "Inhibits HIV-1 reverse transcriptase and cell-free translation" "2353.53" "C96H145N33O33S2" "RNILTWYVOU" "Q" "6.27" "2" "3" "-1" "0" "0" "-1.9" "3.41" "30 hours" ">20 hours" ">10 hours" "5" "0" "0" "11688973" "Biochemical and biophysical research communications, 288(4), 765–770." "Wang, H., & Ng, T. B. (2001)" "Novel antifungal peptides from Ceylon spinach seeds" "10.1006/bbrc.2001.5822" "Anti-HIV" "DRAVPe02091" "LNCYWPLNDYGFYTTTGIGYK" "21" "S5" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "SARS-CoV-2 inhibition assay" "[Ref:38917689]SARS-CoV: S5 peptide targeted the binding site of SARS.-CoV-1 " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" " All peptides (S2, S4, and S5) in this study bound to the ACE2 receptor and established a competitive inhibitory relationship with the RBD" "2489.78" "C118H161N25O33S1" "ARQEHMSVOU" "Y" "5.83" "1" "1" "0" "8" "13" "-0.381" "0.55" "5.5 hours" "3 min" "2 min" "55.71" "11460" "4.603" "38917689" "Virology, 597, 110149." "Liang, Z., Wang, J., Zhang, H., Gao, L., Xu, J., Li, P., Yang, J., Fu, X., Duan, H., Liu, J., Liu, T., Ma, W., & Wu, K." "Peptide S4 is an entry inhibitor of SARS-CoV-2 infection" "10.1016/j.virol.2024.110149" "Anti-SARS-CoV-2" "DRAVPe02090" "YNYLYRLFC" "9" "S2" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "SARS-CoV-2 inhibition assay" "[Ref:38917689]SARS-CoV-2: S2 and S4 peptides targeted the binding site of SARS-CoV-2 " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" " All peptides (S2, S4, and S5) in this study bound to the ACE2 receptor and established a competitive inhibitory relationship with the RBD" "1254.47" "C61H83N13O14S1" "ADQEGHIKMPSTWVOU" "Y" "8.17" "1" "0" "1" "3" "6" "0.111" "0.87" "2.8 hours" "10 min" "3 min" "86.67" "4470" "3.563" "38917689" "Virology, 597, 110149." "Liang, Z., Wang, J., Zhang, H., Gao, L., Xu, J., Li, P., Yang, J., Fu, X., Duan, H., Liu, J., Liu, T., Ma, W., & Wu, K." "Peptide S4 is an entry inhibitor of SARS-CoV-2 infection" "10.1016/j.virol.2024.110151" "Anti-SARS-CoV-2" "DRAVPe02089" "FNCYFPLQSYGFQPTNGVGYK" "21" "S4" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "SARS-CoV-2 inhibition assay" "[Ref:38917689] PT (Vero E6): EC50 = 4.40 µM (TI = 163.68), BA.2 (Vero E6): EC50 = 4.87 µM (TI = 147.88), EG.5 (Vero E6): EC50 = 8.44 µM (TI = 85.33), XBB.1.16 (Vero E6): EC50 = 9.59 µM (TI = 75.10)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:38917689]PT(Vero E6): CC₅₀=720.20 µM,BA.2 (Vero E6): CC₅₀=720.20 µM,EG.5 (Vero E6): CC₅₀= 720.20 µM,XBB.1.16 (Vero E6): CC₅₀= 720.20 µM,HEK293T: CC₅₀=730.20 µM,HEK293T/ACE2: CC₅₀=714.0 µM" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "peptide S4 inhibited the ACE2 receptor and competed with the HCoV-NL63 virus for binding while exhibiting good inhibitory activity against HCoV-NL63 infection." "2430.72" "C115H156N26O31S1" "ARDEHIMWOU" "GFY" "8.15" "1" "0" "1" "13" "8" "-0.419" "0.68" "1.1 hours" "3 min" "2 min" "32.38" "4470" "1.839" "38917689" "Virology, 597, 110149." "Liang, Z., Wang, J., Zhang, H., Gao, L., Xu, J., Li, P., Yang, J., Fu, X., Duan, H., Liu, J., Liu, T., Ma, W., & Wu, K." "Peptide S4 is an entry inhibitor of SARS-CoV-2 infection" "10.1016/j.virol.2024.110150" "Anti-SARS-CoV-2" "DRAVPe02088" "CYCRIPACIAGERRYGTCIYQGRLWAFCC" "29" "HNP-1" "Synthetic construct" "P59665" "Experimentally Validated" "9606" "DEFA1; DEFA1B" "M21130.1" "59-74" "pfam00323##smart00048" "CM000670.2" "mRNA" "Chromosome 8:6996766-6999198" "1DFN##2KHT##3GNY" "IAV(H3N2)" "Orthomyxoviridae" "Antiviral activity assay." "[Ref:17703413]IAV: Inhibited replication and viral protein synthesis" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" " HNP-1 treatment inhibited protein kinase C (PKC) activation in infected cells, suggesting the involvement of the PKC pathway" "17703413" "The Journal of infectious diseases, 196(6), 835–843" "Mirella Salvatore 1, Adolfo Garcia-Sastre, Piotr Ruchala, Robert I Lehrer, Theresa Chang, Mary E Klotman" "alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s)" "10.1086/521027" "DRAVPe00300" "Anti-IAV" "DRAVPe02087" "ESGRIKKEEFAEIMKICSTIEELGRQK" "27" "PB1731–757" "Synthetic construct (derived from the C-terminus of PB1)" "Q9Q0V0" "Experimentally Validated" "93838##384505" "PB1(3654616)" " AAD51923.1" "731-757" "Not Available" "AF144301.1" "Genomic RNA" "Chromosome:25 - 2,298" "3J9B##8H69" "IAV(H5N1)" "Orthomyxoviridae" "BiFC disruption assay" "[Ref:23279951]IAV: PB1731–757 effectively blocked the replication of human influenza virus A/WSN/33 (H1N1)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "PB1(731-757) is capable of inhibiting viral polymerase activity and viral replication." "3153.66" "C135H230N38O44S2" "NDHPWYVOU" "E" "6.46" "6" "6" "0" "2" "9" "-0.793" "2.7" "1 hour" "30 min" ">10 hours" "75.93" "0" "0" "23279951##23340380" "The FEBS journal, 280(4), 1139–1149##Viruses, 5(1), 352–373" "Li, C., Ba, Q., Wu, A., Zhang, H., Deng, T., & Jiang, T. (2013)##Jie Yang 1, Minmin Li, Xintian Shen, Shuwen Liu" "A peptide derived from the C-terminus of PB1 inhibits influenza virus replication by interfering with viral polymerase assembly##Influenza A virus entry inhibitors targeting the hemagglutinin" "10.1111/febs.12107##10.3390/v5010352" "Anti-IAV" "DRAVPe02086" "MERIKELRDLMSWSRTREILTKTTVDHMAIIKKYTSG" "37" "PB21-37" "Synthetic construct" "No entry found" "In silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV(H1N1,H5N1)" "Orthomyxoviridae" "ELISA" "[Ref:21867756]H1N1: IC50 = 375 nM " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "The N-terminus of PB2 consists of 3 alpha-helices, one of which binds to 3 alpha-helices in the C-terminus of PB1 " "L" "Membrane" "Inhibit Viral Replication" "4439.23" "C193H326N56O57S3" "NCQFPOU" "REDIKMST" "9.82" "8" "5" "3" "1" "13" "-0.586" "2.62" "30 hours (mammalian reticulocytes, in vitro)" ">20 hours" ">10 hours" "84.32" "6990" "1.575" "21867756" "Methods (San Diego, Calif.), 55(2), 188–191." "Chase, G., Wunderlich, K., Reuther, P., & Schwemmle, M. (2011). I" "Identification of influenza virus inhibitors which disrupt of viral polymerase protein-protein interactions" "10.1016/j.ymeth.2011.08.007" "Anti-IAV" "DRAVPe02085" "ACYCRIPACIAGERRYGTCIYQGRLWAFCC" "30" "Defensins" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV(H1N1,H3N2)" "Orthomyxoviridae" "Antiviral assay." "[Ref:19494312]No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Inhibit Virus Attachment and Virus-Cell Membrane Fusion" "3448.09" "C150H228N44O38S6" "NDHKMSVOU" "ARCGIY" "8.68" "4" "1" "3" "20" "13" "0.3" "1.1704" "4.4 hours" ">20 hours" ">10 hours" "65.33" "10345" "3" "19494312" "Journal of immunology (Baltimore, Md. : 1950), 182(12), 7878–7887." "Doss, M., White, M. R., Tecle, T., Gantz, D., Crouch, E. C., Jung, G., Ruchala, P., Waring, A. J., Lehrer, R. I., & Hartshorn, K. L. (2009)." "Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D" "10.4049/jimmunol.0804049" "Anti-IAV" "DRAVPe02084" "FLPIIINLKALAALAKKIL" "19" "Mastoparan-MO" "Venom, Vespula lewisii" "P01514" "Experimentally Validated" "7452" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "6DUU)" "HSV-1" "Herpesviridae " "Plaque Assay" "[Ref:38932240]Human alphaherpesvirus 1 (HSV-1): Inhibited entry (EC50 = 6.68 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:38932240]:CC50=>200 µg.mL−1" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "Membrane" "Mastoparan-MO exhibited over 80% HSV-1 inhibition, with up to 99% viral replication inhibition, particularly in the early infection stages." "2063.68" "C102H179N23O21" "RDCEQGHMSTWYVOU" "L" "10.03" "3" "0" "3" "4" "15" "1.589" "0.8211" "1.1 hours" "3 min" "2 min" "205.79" "0" "0" "38932240" "Viruses. 2024 Jun 12;16(6)" "Vilas Boas LCP, Buccini DF, Berlanda RLA, Santos BPO, Maximiano MR, Lião LM, Gonçalves S, Santos NC, Franco OL." "Antiviral Activities of Mastoparan-L-Derived Peptides against Human Alphaherpesvirus 1" " 10.3390/v16060948" "Anti-HSV-1" "DRAVPe02083" "GFWFKGKWRFKKYRGGRYKKFRWKGKFWFG" "30" "PEP 19-8D" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H7N7,H3N2,H1N2" "Orthomyxoviridae" "Hemagglutination assay" "[Ref:24486207]Influenza virus: SALPs PEP 19-8D inhibited virus hemagglutination up to 75% depending on virus subtype and dilution" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Inhibit Virus Attachment and Virus-Cell Membrane Fusion" "3964.73" "C200H276N54O33" "ANDCQEHILMPSTVOU" "RGKFWY" "11.64" "12" "0" "12" "10" "17" "-1.367" "1.1" "30 hours" ">20 hours (yeast, in" ">10 hours" "0" "24980" "6.301" "24486207" "Antiviral research, 104, 23–33. " "Hoffmann, J., Schneider, C., Heinbockel, L., Brandenburg, K., Reimer, R., & Gabriel, G. (2014). " "A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment" "10.1016/j.antiviral.2014.01.016" "Anti-IAV" "DRAVPe02082" "GKKYRRFRWKFKGKWFWFG" "19" "PEP 19-4" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV(H7N7,H3N2,H1N1)" "Orthomyxoviridae" "Hemagglutination assay" "[Ref:24486207]Influenza virus: SALPs inhibited virus hemagglutination up to 75% depending on virus subtype and dilution." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Membrane" "Inhibit Virus Attachment and Virus-Cell Membrane Fusion" "2609.13" "C132H182N36O21" "ANDCQEHILMPSTVOU" "RGKFWY" "11.76" "8" "0" "8" "3" "7" "-1.421" "2.68" "30 hours" ">20 hours (yeast, in" ">10 hours" "0" "17990" "6.895" "24486207" "Antiviral research, 104, 23–33. " "Hoffmann, J., Schneider, C., Heinbockel, L., Brandenburg, K., Reimer, R., & Gabriel, G. (2014). " "A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment" "10.1016/j.antiviral.2014.01.015" "Anti-IAV" "DRAVPe02081" "GLLASLGKVFGGYLAEKLKPK" "21" "Dahlein 5.6" "Litoria dahlii, Australia" "P84272" "Experimentally Validated" "299727" "Not Available" "Not Available" "1to21" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV infection and cell viability assay." "[Ref:16140737]HIV: This peptide could inhibit HIV infection at a specific concentration." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Cell Membrane" "inhibit HIV infection at significantly lower concentrations than those required to affect the viability of the T cells." "2189.67" "C104H173N25O26" "RNDCQHIMTWOU" "L" "9.83" "4" "1" "3" "22" "16" "0.248" "-0.3" "30 hours" ">20 hours" ">10 hours" "116.19" "1490" "0.68" "16140737" "Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)." "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV-1" "DRAVPe02080" "CGESCVFIPCITTVLGCSCSIKVCYKNGSIP" "31" "Cycloviolacin VY1" "Viola yedoensis" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV" "Orthomyxoviridae" "In vitro assay" "[Ref:25212039]Influenza A virus (H1N1): IC50 = 2.27 µg/mL." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Found" "3225.88" "C138H226N34O42S6" "ARDQMWOU" "C" "7.77" "2" "1" "1" "24" "18" "0.874" "-0.21" "1.2 hours" ">20 hours" ">10 hours" "90.97" "1490" "0.462" "25212039" "Yao xue xue bao = Acta pharmaceutica Sinica, 49(6), 905–912." "Liu, M. Z., Yang, Y., Zhang, S. X., Tang, L., Wang, H. M., Chen, C. J., Shen, Z. F., Cheng, K. D., Kong, J. Q., & Wang, W. (2014)." "[A cyclotide against influenza A H1N1 virus from Viola yedoensis]" "Not Available" "Anti-IAV" "DRAVPe02078" "SPIHACRYQRGVCIPGPCRWPYYRVGSCGSGLKSCCVRNRWA" "42" "Chicken AvBD6" "G. gallus domestic; duck, A. platyrhynchos" "Q6QLR3" "Experimentally Validated" "9031" "GAL6" "Not Available" "26-67" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IBRV" "Orthomyxoviridae" "ELISA" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Found" "4744.55" "C205H317N67O52S6" "DEFTOU" "C" "9.61" "7" "0" "7" "32" "24" "-0.343" "1.86" "1.9 hours" ">20 hours" ">10 hours" "53.33" "15470" "3.261" "26142390" "Applied microbiology and biotechnology, 99(21), 9011–9024." "Xu, Y., Zhang, T., Xu, Q., Han, Z., Liang, S., Shao, Y., Ma, D., & Liu, S. (2015)." "Differential modulation of avian β-defensin and Toll-like receptor expression in chickens infected with infectious bronchitis virus" "10.1007/s00253-015-6786-8" "Anti-IBrV" "DRAVPe02079" "EQCREEEDDR" "10" "Coconut antifungal peptide" "Cocos nucifera" "No entry found " "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Not Found" "[Ref:16308082]HIV-1 reverse transcriptase: IC50 = 52.5 µM; Inhibition at 8 and 80 µM coconut antifungal peptide = 20.1% and 68.4%, respectively." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" " It lowered the HIV-1 reverse transcriptase activity" "1308.3" "ANGHILKMNFPSTWYVOU" "E" "4.08" "2" "6" "-4" "10" "0" "-3.1" "7.87" "1 hour" "30 min" ">10 hours" "0" "0" "0" "16308082" "Peptides, 26(12), 2392–2396" "Wang, H. X., & Ng, T. B. (2005)" "An antifungal peptide from the coconut" "10.1016/j.peptides.2005.05.009" "Anti-HIV-1" "DRAVPe02077" "GLPQDCERRGGFCSHKSCPPGIGRIGLCSKEDFCCRSRWYS" "41" "Chicken AvBD5" "Gallus gallus domestic" "Q6IV26" "Experimentally Validated" "9031" "GAL5" "Not Available" "26-66" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IBV" "Orthomyxoviridae" "ELISA" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Found" "4593.25" "C193H300N62O57S6" "ANMVOU" "CG" "8.67" "7" "4" "3" "32" "24" "-0.663" "2.5" "30 hours" ">20 hours" ">10 hours" "38.05" "6990" "1.603" "26142390" "Applied microbiology and biotechnology, 99(21), 9011–9024." "Xu, Y., Zhang, T., Xu, Q., Han, Z., Liang, S., Shao, Y., Ma, D., & Liu, S. (2015)." "Differential modulation of avian β-defensin and Toll-like receptor expression in chickens infected with infectious bronchitis virus" "10.1007/s00253-015-6786-8" "Anti-IBV" "DRAVPe02076" "KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK" "37" "Cecropin A" "Giant silk moth, Hyalophora cecropia" "P01507" "Experimentally Validated" "7123" "Not Available" "Not Available" "27-63" "Not Available" "Not Available" "Not Available" "Not Available" "1D9L" "HIV" "Retroviridae" "Transient transfection assays" "[Ref:9568968]HIV: Cecropin ID50 = 2–3 µM; HIV LTR activity reduced in cells with retroviral expression of cecropin" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "cecropin is capable of inhibiting cell-associated production of HIV-1 by suppressing HIV-1 gene expression." "4004.82" "C184H312N52O47" "CHMSYOU" "K" "10.39" "8" "2" "6" "32" "24" "-0.073" "0.84" "1.3 hours" "3 min" "3 min" "108.11" "5500" "1.373" "9568968" "The Journal of general virology, 79 ( Pt 4), 731–740." "Wachinger, M., Kleinschmidt, A., Winder, D., von Pechmann, N., Ludvigsen, A., Neumann, M., Holle, R., Salmons, B., Erfle, V., & Brack-Werner, R. (1998)." "Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression" "10.1099/0022-1317-79-4-731" "Anti-HIV" "DRAVPe02075" "GLWQKIKSAAGDLASGIVEGIKS" "23" "Caerin 4.1" "Green tree frog Litoria caerula, Australia" "P56242" "Experimentally Validated" "30344" "Not Available" "Not Available" "1to23" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV infection and cell viability assay." "[Ref:16140737]HIV: This peptide could inhibit HIV infection at a specific concentration" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16140737]Toxic to T cells" "No predicted structure available" "Linear" "Free" "Amination" "None" "L" "T cells" "inhibit HIV infection at significantly lower concentrations than those required to affect the viability of the T cells." "2328.69" "C104H174N28O32" "RNCHMFPTYOU" "G" "8.5" "3" "2" "1" "22" "16" "0.157" "0.33" "30 hours" ">20 hours" ">10 hours" "110.43" "5500" "2.362" "16140737" "Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)." "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe02073" "GLLSVLGSVAQHVLPHVVPVIAEHL" "25" "Caerin 1.3" "L. caerulea" "P56228" "Experimentally Validated" "30344" "Not Available" "Not Available" "1to25" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV infection and cell viability assay." "[Ref:26026377]HIV: Less effective inhibitor of infection." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26026377]Non-toxic or only modestly toxic at the concentrations tested" "No predicted structure available" "Linear" "Free" "Amination" "None" "L" "Membrane" "The disruption of the viral envelope and release p24 core protein" "2585.09" "C120H198N32O31" "RNDCKMFTWYOU" "V" "6.26" "0" "1" "-1" "22" "16" "1.204" "-1.04" "30 hours" ">20 hours" ">10 hours" "171.2" "0" "0" "26026377" "Peptides, 71, 296–303." "VanCompernolle, S., Smith, P. B., Bowie, J. H., Tyler, M. J., Unutmaz, D., & Rollins-Smith, L. A. (2015)." "Inhibition of HIV infection by caerin 1 antimicrobial peptides" "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe02074" "GLLSSLSSVAKHVLPHVVPVIAEHL" "25" "Caerin 1.4" "Australian frog Litoria caerula" "P62544##P62545" "Experimentally Validated" "30344" "Not Available" "Not Available" "1to25" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV infection and cell viability assay." "[Ref:26026377]HIV: Less effective inhibitor of infection" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26026377]Non-toxic or only modestly toxic at the concentrations tested" "No predicted structure available" "Linear" "Free" "Amination" "None" "L" "Cell Membrane" "The disruption of the viral envelope and release p24 core protein" "2603.1" "C120H200N32O32" "RNDCKMFTWYOU" "V" "7.02" "1" "1" "0" "22" "16" "0.972" "-0.57" "30 hours" ">20 hours" ">10 hours" "159.6" "0" "0" "26026377" "Peptides, 71, 296–303." "VanCompernolle, S., Smith, P. B., Bowie, J. H., Tyler, M. J., Unutmaz, D., & Rollins-Smith, L. A. (2015)." "Inhibition of HIV infection by caerin 1 antimicrobial peptides" "10.1016/j.peptides.2015.05.004" "Anti-HIV" "DRAVPe02072" "FLPVLAGIAAKVVPALFCKITKKC" "24" "Brevinin-1" "Frog, Rana brevipoda porsa, Japan, Asia" "P32423" "Experimentally Validated" "88447" "Not Found" "Not Available" "1to24" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1,HSV-2" "Herpesviridae" "Inhibition assay" "[Ref:10795591]HSV-1: IC50 = 93.4 µg/mL; HSV-2: IC50 = 89.8 µg/m" "[Ref:10795591]EC50:13.4 µg/ml" "[Ref:10795591]CC50=14.4µg/ml" "No predicted structure available" "Linear" "Free" "Free" "Brevinin-1 was reduced and alkylated" "L" "Cell Membrane" "Brevinin-1 has demonstrated antiviral activity against herpes simplex virus (HSV), primarily by targeting the viral envelope and interfering with viral entry" "2527.5" "C121H204N28O26S2" "RNDQEQMSWYOU" "AK" "99.7" "4" "0" "4" "20" "14" "1.288" "-1.19" "1.1 hours" "3 mins" "2 miins" "134.17" "0" "0" "10795591" "European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 19(3), 187–194." "Yasin, B., Pang, M., Turner, J. S., Cho, Y., Dinh, N. N., Waring, A. J., Lehrer, R. I., & Wagar, E. A. (2000)" "Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides" "10.1007/s100960050457" "Anti-HSV" "DRAVPe02071" "SDSVVSDIICTTFCSVTWCQSNCC" "24" "Brevicillin" "Brevibacillus" "J2FTU4" "Experimentally Validated" "2825881" "PMI05_05757" "EJL20520.1" "20-43" "Not Available" "AKIX01000128" "Genomic DNA" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Cell Culture-based Assay" "[Ref:36914211]SARS-CoV-2: Peptide inhibited ~99% virus growth at 10 µg/mL in cell culture-based assay." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Found" "2601.93" "C106H165N27O39S5" "AREGHLKMPYOU" "CS" "3.56" "0" "2" "-2" "24" "18" "0.662" "0.86" "1.9 hours" ">20 hours " ">10 hours" "68.75" "5500" "2.114" "36914211" "Journal of applied microbiology, 134(3), lxad054." "Singh, S. S., Sharma, D., Singh, C., Kumar, S., Singh, P., Sharma, A., Das, D. K., Pinnaka, A. K., Thakur, K. G., Ringe, R. P., & Korpole, S. (2023)" "Brevicillin, a novel lanthipeptide from the genus Brevibacillus with antimicrobial, antifungal, and antiviral activity" "10.1093/jambio/lxad054" "Anti-SARS-CoV-2" "DRAVPe02070" "FIGAIARLLSKIF" "13" "BmKn2" "venom, Buthus martensii Karsch" "No entry found" "Experimentally Validated" "34649" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Antiviral effect assay" "[Ref:22536342]HIV-1: BmKn2 and Kn2-7 decreased infectivity of HIV-1 clade B b12-resistant pseudotyped virus CAAN5342" "[Ref22536342] human RBC, HC50 12.5 ug/ml, hemolytic" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "While deletions of 1 to 4 residues from the peptide (Kn2-1 to Kn2-6) reduced its activity against S. aureus, peptide Kn2-7 (changes of G3, A4, and S10 to cationic K/R) showed increased activity due to an increase in cationicity. However, C-terminally truncated or cyclic BmKn2 lost activity against N. gonorrhoeae, indicating both the linear and intact sequence are important for peptide activity. " "L" "Not Found" "BmKn2 aggregates and inserts into viral envelope so that the hydrophobic peptide region aligns with the lipid core region and the hydrophilic peptide regions form the interior region of the pore, with the help of positive charge of peptide somehow" "1448.81" "C71H117N17O15" "NDCQEHMPTWYVOU" "I" "11" "3" "0" "3" "13" "10" "1.592" "-0.86" "1.1 hours" "3 mins" "2 miins" "165.38" "0" "0" "22536342" "PloS one, 7(4), e34947." "Chen, Y., Cao, L., Zhong, M., Zhang, Y., Han, C., Li, Q., Yang, J., Zhou, D., Shi, W., He, B., Liu, F., Yu, J., Sun, Y., Cao, Y., Li, Y., Li, W., Guo, D., Cao, Z., & Yan, H. (2012)." "Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7" "10.1371/journal.pone.0034947" "Anti-HIV-1" "DRAVPe02069" "DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV" "40" "Beta-amyloid peptide (1–40)" "Homo sapiens" "A0A0A0MRG2##P05067" "Experimentally Validated" "9606" "APP(351)" "Y00264" "672-711" "pfam03494" "CM000683.2" "Genomic DNA" "Chromosome21:25,881,673 - 26,112,098" "1AML##1AMC##1BA4" "HSV-1, IAV(H3N1,H1N1)" "Orthomyxoviridae" "inhibition assay" "[Ref:25376108]HSV-1: Aβ 1-40 and Aβ 1-42 caused 82% and 91% decreases in HSV-1 DNA replication in MRC-5 cells.[Ref:24988208]Influenza A virus (H3N2 - Phil82): βA40 at 16 µg/mL reduced infectivity to 29±12% of control; Cal09 strain: 47±15% of control." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Aβ 1-40 acted directly on HSV-1 in a cell-free system and prevented viral entry into cells.The sequence homology between Aβ and a proximal transmembrane region of HSV-1 glycoprotein B suggested that Aβ interference with HSV-1 replication could involve its insertion into the HSV-1 envelope." "4329.86" "C194H295N53O58S1" "CPTWOU" "GV" "5.31" "3" "6" "-3" "32" "24" "0.057" "0.98" "1.1 hours" "3 mins" ">10 hours" "90" "1490" "0.344" "25376108##24988208" "Biogerontology, 16(1), 85–98## PloS one, 9(7), e101364." "Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G., Frost, E. H., & Fülöp, T., Jr (2015)##White, M. R., Kandel, R., Tripathi, S., Condon, D., Qi, L., Taubenberger, J., & Hartshorn, K. L. (2014)." "β-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1##Alzheimer's associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes" "10.1007/s10522-014-9538-8" "Anti-HSV,Anti-IAV" "DRAVPe02068" "GLFDIIKKIAESF" "13" "Aurein 1.2" "Southern bell frog Litoria aurea and Litoria raniformis, Australia" "P82387 " "Experimentally Validated" "116057" "Not Available" "Not Available" "1to13" "Not Available" "Not Available" "Not Available" "Not Available" "1VM5" "HIV-1" "Retroviridae" "Inhibition assay" "[Ref:9568968]HIV-1: Aurein 1.2 EC₅₀ = 7.7 µM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Amidation" "F13 " "L" "Membrane" "Aurein 1.2 interacts with membranes and can induce curvature and disintegration, which is crucial for its antimicrobial activity .This mechanism could theoretically be effective against viral membranes, although this has not been extensively studied in the context of HIV" "1480.77" "C71H113N15O19" "RNCQHMPTWYVOU" "I" "6.07" "2" "2" "0" "13" "10" "0.669" "0.12" "30 hours" ">20 hours" ">10 hours" "127.69" "0" "0" "20086159##9568968" "Antimicrobial agents and chemotherapy, 54(3), 1343–1346##The Journal of general virology, 79 ( Pt 4), 731–740" "Wang, G., Watson, K. M., Peterkofsky, A., & Buckheit, R. W., Jr (2010)##Wachinger, M., Kleinschmidt, A., Winder, D., von Pechmann, N., Ludvigsen, A., Neumann, M., Holle, R., Salmons, B., Erfle, V., & Brack-Werner, R. (1998)" "Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database##Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression" "10.1128/AAC.01448-09##10.1099/0022-1317-79-4-731" "Anti-HIV-1" "DRAVPe02067" "GRFKRFRKKFKKLFKKLSPVIPLLHLG" "27" "BMAP-27" "Cattle, Bos taurus" "P54228" "Experimentally Validated" "9913" "CATHL6(317651)" "X97608.1" "132-158" "Not Available" "X97608" "mRNA" "Chromosome 22(NC_037349.1 (51663351..51665275, complement))" "2KET" "HIV-1" "Retroviridae" "Inhibition assay" "[Ref:18591279]HIV-1: BMAP-27 blocks HIV-1 infection" "[Ref:18591279]HC50>100 uM to hRBC (3.5% hemolysis at 3 uM; 32.7% hemolysis at 100 uM), but not hemo.lytic to bovine RBC even at 100 uM. Thus, hemolysis is related to cell sources, indicating the need " "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Carboxylation" "Amidation" " a 26mer was mad with a hydrophobic tail " "L" "Membrane" "inhibit viral replication" "3283.15" "C160H265N45O29" "ANDCQEMTWYOU" "K" "12.32" "10" "0" "10" "20" "14" "-0.367" "1.64" "30 hours" ">20 hours" ">10 hours" "97.41" "0" "0" "18591279" "Antimicrobial agents and chemotherapy, 52(9), 3438–3440." "Wang, G., Watson, K. M., & Buckheit, R. W., Jr (2008)." "Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins" "10.1128/AAC.00452-08" "Anti-HIV-1" "DRAVPe02066" "GFGCPLDQMQCHNHCQSVRYRGGYCTNFLKMTCKCY" "36" "Av-LCTX-An1a " "venom gland of the A. nagpag spider" "A0A5Q1NCA8" "Experimentally Validated" "2664917" "Not Found" "QGD15041.1" "25-60" "NF038042##pfam01097" "MN319466" "mRNA" "Not Available" "None" "DENV-2,ZIKV" "Flaviviridae" "protease inhibition assay" "[Ref:31658707]Dengue virus-2 (DENV2): An1a showed ~10 µM 50% inhibition in Vero cells.Zika virus (ZIKV):An1a showed ~2 µM 50% inhibition in Vero cells. It acts as a competitive inhibitor of ZIKV NS2B–NS3 protease (Ki = 12.54 ± 1.88 µM). Inhibited replication in HUVEC and A549 cells.DENV2 and ZIKV NS2B–NS3 protease: Ki = 9.47 µM for DENV2; Ki = 12.54 µM for ZIKV." "[Ref:31658707]hemolytic: no hemolysis of hRBC below 20 uM" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "Gly4–Ser–Gly4 linker," "L" "Protease" "An1a suppresses DENV2 replication and infectious virus production.Also An1a may inhibit DENV2 replication and particle production by interacting with the NS2B–NS3 protease." "4193.919" "C177H269N51O50S8" "AEIWOU" "C" "8.65" "4" "1" "3" "24" "18" "-0.481" "1.71" "30 hours" ">20 hours" ">10 hours" "29.72" "4845" "1.55" "31658707" "Toxins, 11(10), 584. " "Ji, M., Zhu, T., Xing, M., Luan, N., Mwangi, J., Yan, X., Mo, G., Rong, M., Li, B., Lai, R., & Jin, L. (2019)." "An Antiviral Peptide from Alopecosa nagpag Spider Targets NS2B-NS3 Protease of Flaviviruses" "10.3390/toxins11100584" "Anti-DENV-2,ANTi-ZIKV" "DRAVPe02126" "XYXTAGXAXLXPXQXKXVXGX" "11" "Mirabamide G" " sponge Stelletta clavosa" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Neutralization Assays." "[Ref:21280591]HIV-1:IC50=68±13μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "The N-terminal is blocked by the Dhtda-like moiety," "Free" "X at position 1 is β-O-methyltyrosine (β-OMeTyr).X at position 2 is N-methylthreonine (NMeThr).X at position 5 is 3-O-methylalanine (3-OMeAla).X at position 6 is 3-hydroxyleucine (3-OHLeu).X at position 7 is 4 chlorohydroxyproline (4-ClHpr).X at position 8 is 3,4-dimethylglutamine (3,4-DiMeGln).X at position 9 is diaminobutyric acid (Dab).X at position 10 is aminobutyric acid (Aba)" "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "1104.27" "C66H103ClN13O20" "RNDCEIMFSWOU" "A" "8.59" "1" "0" "1" "6" "6" "-0.018" "0.92" "2.8 hours" "10 min" "2 min" "80" "1490" "1.349" "21280591" "J Nat Prod. 2011 Feb 25;74(2):185-93." "Lu Z, Van Wagoner RM, Harper MK, Baker HL, Hooper JN, Bewley CA, Ireland CM." "Mirabamides E-H, HIV-Inhibitory Depsipeptides from the Sponge Stelletta clavosa" "10.1021/np100613p" "Anti-HIV-1" "DRAVPe02127" "XYXTAGXAXLXPXQXKXVXG" "11" "Mirabamide H" " sponge Stelletta clavosa" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Neutralization Assays." "[Ref:21280591]HIV-1:IC50=42±5μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "The N-terminal is blocked, likely due to structural truncation involving the Dhtda-like group." "Free" "X at position 1: β-O-methyltyrosine (β-OMeTyr).X at position 2: N-methylthreonine (NMeThr).X at position 5: 3-O-methylalanine (3-OMeAla).X at position 6: 3-hydroxyleucine (3-OHLeu).X at position 7: 4-chlorohydroxyproline (4-ClHpr) .X at position 8: 3,4-dimethylglutamine (3,4-DiMeGln).X at position 9: Diaminobutyric acid (Dab).X at position 10: Aminobutyric acid (Aba) " "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "1104.27" "C66H103ClN13O19" "RNDCEIMFSWOU" "A" "8.59" "1" "0" "1" "6" "6" "-0.018" "0.92" "2.8 hours" "10 min" "2 min" "80" "1490" "1.349" "21280591" "J Nat Prod. 2011 Feb 25;74(2):185-93." "Lu Z, Van Wagoner RM, Harper MK, Baker HL, Hooper JN, Bewley CA, Ireland CM." "Mirabamides E-H, HIV-Inhibitory Depsipeptides from the Sponge Stelletta clavosa" "10.1021/np100613p" "Anti-HIV-1" "DRAVPe02128" "XAXYXQLGXATXQXKXQXNH" "12" "Stellettapeptin A " "Isolated from Stelletta sponge" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV integrase inhibition assay" "[Ref:26139946]HIV-1:EC50=23nM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26139946]CC50: 367 nM" "No predicted structure available" "Cyclic" "The N-terminal residue in both peptides is Hdna (3-hydroxy-6,8-dimethylnon-4-enoic acid), a unique polyketide moiety. This polyketide is linked to the peptide chain through the 3-OHAsn residue in Stel" "C-terminal is esterified to a threonine hydroxyl group, forming a cyclic structure. This ester bond is a defining feature of these cyclic depsipeptides." "Contains 3-OHGln and 3-OHAsn residues, rarely found in peptides.Macrocycle closure via esterification.X at position 1: N-methylalanine (NMeAla) → A (Alanine with an additional methyl group on the nitrogen),X at position 2: β-O-methyltyrosine (β-OMeTyr) → Y (Tyrosine with a methyl group on the hydroxyl group),X at position 3: N-methylglutamine (NMeGln) → Q (Glutamine with an additional methyl group on the nitrogen),X at position 4: Leucine (Unmodified),X at position 5: Glycine (Unmodified),X at p" "L" "Viral entry (Viral membrane)" "The cyclic structure and amphipathic nature of these peptides likely enable interaction with the lipid bilayer of viral or host cell membranes.This interaction may disrupt the membrane integrity, inhibiting viral entry or replication.The peptides may interact with HIV-1 envelope proteins, preventing the virus from attaching or fusing with host cells.Some depsipeptides are known to inhibit the reverse transcriptase enzyme of HIV-1, disrupting the viral replication process.By binding to host or viral targets, the peptides may alter immune responses to enhance antiviral effects" "1358.48" "C58H91N19O19" "RDCEIMFPSWVOU" "Q" "8.64" "1" "0" "1" "10" "8" "-1.342" "1.04" "4.4 hours" ">20 hour" ">10 hours" "49.17" "1490" "1.097" "26139946" "2015 Jul 8;56(28):4215-4219." "Shin HJ, Rashid MA, Cartner LK, Bokesch HR, Wilson JA, McMahon JB, Gustafson KR. " "Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp" "10.1016/j.tetlet.2015.05.058" "Anti-HIV-1" "DRAVPe02129" "XAXYXTLGGXATTXQXKXH" "12" "Stellettapeptin B " "Isolated from Stelletta sponge" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV integrase inhibition assay" "[Ref:26139946]HIV-1:EC50=27nM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26139946]CC50: 367nM" "No predicted structure available" "Cyclic" "The N-terminal residue in both peptides is Hdna (3-hydroxy-6,8-dimethylnon-4-enoic acid), a unique polyketide moiety. This polyketide is linked to the peptide chain through the 3-OHAsn residue in Stel" "C-terminal is esterified to a threonine hydroxyl group, forming a cyclic structure. This ester bond is a defining feature of these cyclic depsipeptides." "Replaces NMeGln, 3-OHGln, and 3-OHAsn from A with NMeThr, Thr, and Gly, respectively. Similar macrocycle.X at position 1: N-methylalanine (NMeAla) → A,X at position 2: β-O-methyltyrosine (β-OMeTyr) → Y,X at position 5: 3-O-methylalanine (3-OMeAla) → A,X at position 6: Threonine (Thr) → T,X at position 8: 3,4-dimethylglutamine (3,4-DiMeGln) → Q,X at position 9: Diaminobutyric acid (Dab) → K,X at position 10: Histidine (Hdna) → H" "L" "Viral entry (Viral membrane)" "The cyclic structure and amphipathic nature of these peptides likely enable interaction with the lipid bilayer of viral or host cell membranes.This interaction may disrupt the membrane integrity, inhibiting viral entry or replication.The peptides may interact with HIV-1 envelope proteins, preventing the virus from attaching or fusing with host cells.Some depsipeptides are known to inhibit the reverse transcriptase enzyme of HIV-1, disrupting the viral replication process.By binding to host or viral targets, the peptides may alter immune responses to enhance antiviral effects" "1247.37" "C54H86N16O18" "RNDCEIMFPSWVOU" "T" "8.44" "1" "0" "1" "9" "7" "-0.617" "1" "4.4 hours" ">20 hour" ">10 hours" "49.17" "1490" "1.195" "26139946" "2015 Jul 8;56(28):4215-4219." "Shin HJ, Rashid MA, Cartner LK, Bokesch HR, Wilson JA, McMahon JB, Gustafson KR. " "Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp" "10.1016/j.tetlet.2015.05.058" "Anti-HIV-1" "DRAVPe02130" "XFPSLTCLSTXC" "10" "Mollamide E" "Tunicate Didemnum molle PNG07-2-050" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV integrase inhibition assay and cytoprotective cell-based assay" "[Ref:22845329]HIV-1:No inhibition at78μM;NoHIV integrase inhibition at 100μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Phenylalanine (Phe)" "Thiazoline (Cys-derived residue)" "The cysteine residue forms a thiazoline ring, contributing to the rigidity and cyclic nature of the peptide.Attached to the threonine residue, this modification is a unique structural feature.Contains d-Phe and d-thiazoline, resulting from thermodynamic relaxation under constrained peptide geometry.X at position 1: D-Phenylalanine (D-Phe) → Mirror image of L-Phe, not commonly found in natural peptides, X at position 7: D-Cysteine in thiazoline ring → Modified residue, involved in heterocyclic st" "L" "Viral integrase" "Mollamide E does not exhibit significant HIV inhibition activity in cytoprotective or integrase assays. Its mechanism of action remains uncharacterized but may involve steric or structural features that prevent integrase binding, unlike its analog Mollamide F" "1071.27" "C35H50N6O7S" "ARNDQEGHIKMWYVOU" "CLST" "5.51" "0" "0" "0" "8" "8" "1.08" "0.96" "1.1hours" "3 min" "2 min" "78" "0" "0" "22845329" "J Nat Prod. 2012 Aug 24;75(8):1436-40." "Lu Z, Harper MK, Pond CD, Barrows LR, Ireland CM, Van Wagoner RM." "Thiazoline Peptides and a Tris-Phenethyl Urea from Didemnum molle with Anti-HIV Activity" "10.1021/np300270p" "Anti-HIV-1" "DRAVPe02131" "XFPPVIXC" "6" "Mollamide F" "Tunicate Didemnum molle PNG07-2-050" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV integrase inhibition assay and cytoprotective cell-based assay" "[Ref:22845329]HIV-1:IC50=78μM;HIV integrase IC50=39μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Phenylalanine (Phe)" "Thiazoline (Cys-derived residue)" "Similar to Mollamide E, it contains a thiazoline ring derived from cysteine.The sequence includes two proline residues, with a cis geometry at the Pro-Pro peptide bond.Contains d-Phe and d-thiazoline, similar to Mollamide E, due to stereochemical lability. Unlike Mollamide E, the reversed isoprene group is missing, which impacts its structural dynamics and activity.X at position 1: D-Phenylalanine (D-Phe) → This is a D-isomer, which is not naturally common in ribosomally synthesized peptides.X a" "L" "Viral integrase" "Mollamide F inhibits HIV-1 integrase with an IC50 value of 39 µM, suggesting it interacts with integrase's active site. Residues in the ""southern region"" of the peptide are crucial for binding. The thiazoline moiety likely contributes to molecular rigidity and facilitates integrase interaction." "674.86" "C33H46N6O5S" "ARNDQEGHLKMSTWTOU" "P" "5.52" "0" "0" "0" "6" "6" "1.8" "0.88" "1.1 hours" "3 min" "2 min" "113.33" "0" "0" "22845329" "J Nat Prod. 2012 Aug 24;75(8):1436-40." "Lu Z, Harper MK, Pond CD, Barrows LR, Ireland CM, Van Wagoner RM." "Thiazoline Peptides and a Tris-Phenethyl Urea from Didemnum molle with Anti-HIV Activity" "10.1021/np300270p" "Anti-HIV-1" "DRAVPe02132" "EISKINTTLLDLSDEMAMLQQEVVKQLNDSYIDLKEL" "37" "HKU4-HR2P2" "HR2 domain of bat" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV , SARS-CoV." "Coronaviridae" "Time-of-addition assay" "[Ref:30646495]MERS-CoV,SARS-CoV:IC50=0.38μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HR2 " "HKU4-HR2 peptides could cross-target the MERS-CoV HR1 region." "4281.9" "C186H311N45O65S2" "RCGHFPWOU" "L" "4.07" "3" "8" "5" "22" "18" "-0.222" "0.9185" "1 hour" "30 min" ">10 hours" "123.78" "1490" "0.348" "30646495" "Viruses, 11(1), 56." "Xia, S., Lan, Q., Pu, J., Wang, C., Liu, Z., Xu, W., Wang, Q., Liu, H., Jiang, S., & Lu, L. (2019). " "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4" "10.3390/v11010056" "Anti-MERS-CoV,Anti-SARS-CoV" "DRAVPe02133" "XCXCVXLL" "6" "Malformin C" "marine-derived fungus Aspergillus niger SCSIO Jcsw6F30" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV integrase inhibition assay" "[Ref:26711143]HIV-1:IC50=1.4±0.06μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26711143]No cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "X1 at position 1: D-Cys → Cysteine in D-configuration (mirror image of natural L-Cys),X2 at position 2: D-Cys → D-isomer of Cysteine,X at position 4: D-Leu → Leucine in D-form,Cyclic structure: The peptide is cyclized, forming a closed ring via peptide bonds, often enhancing stability and bioactivity." "L" "Not found" "Not Available" "529.2392" "C23H39N5O5S2" "CL" "0" "0" "0" "0" "5" "5" "3.36" "0.72" "1.2 hours" ">20 hour" ">10 hours" "214" "0" "0" "26711143" "Bioorganic & medicinal chemistry letters, 26(2), 361–365." "Zhou, X., Fang, W., Tan, S., Lin, X., Xun, T., Yang, B., Liu, S., & Liu, Y. (2016)" "Aspernigrins with anti-HIV-1 activities from the marine-derived fungus Aspergillus nigerSCSIO Jcsw6F30" "10.1016/j.bmcl.2015.12.005" "Anti-HIV-1" "DRAVPe02134" "GENFAISKINTTLLDISDEMAMIQEVVKQLNDSYI" "35" "HKU4-HR2P1" "HR2 domain of bat" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV " "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref:30646495]SARS-CoV:IC50=1.09μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HR2 " "These peptides target the viral fusion and entry stages." "3944.48" "C172H280N42O59S2" "RCHPWOU" "I" "4.02" "2" "6" "-4" "22" "18" "0.02" "0.9185" "30 hours" ">20 hour" ">10 hours" "111.43" "1490" "0.378" "30646495" "Viruses, 11(1), 56." "Xia, S., Lan, Q., Pu, J., Wang, C., Liu, Z., Xu, W., Wang, Q., Liu, H., Jiang, S., & Lu, L. (2019). " "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU6" "10.3390/v11010058" "Anti-MERS-CoV" "DRAVPe02135" "ECASTCSFGIVTIVCDGTTK" "20" "Divamide A" "TunicateDidemnum molle E11-036" "A0A2H4GZ80" "Experimentally Validated" "1216" "divA" "ARD09202.1" "72-91" "Not Available" "KY115608" "Genomic DNA" "Not Available" "None" "HIV-1" "Retroviridae" "HIV assay" "[Ref:29291350]HIV-1:IC50=0.225μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:29291350]CC50=2.63µm" "No predicted structure available" "Cyclic" "Free" "Free" "the tertiary structure conferred by the cyclic lysinoalanine residue is necessary to block infection" "L" "PE binding" " duramycin inhibits entry of Ebola and Dengue viruses, indicating that TIM proteins also interact with PE.Thus, lipid binding appears a likely mechanism for the anti-HIV activity of the divamides. However, the stark differences in potency and toxicity between individual divamides and 4 may reflect additional interactions with non-membrane components, potentially including TIM proteins, that are substantially affected by the peptide sequence. " "2035.33" "C84H139N21O31S3" "RNQHMWYOU" "T" "4.37" "1" "2" "-1" "16" "14" "0.671" "0.9576" "1 hour" "3 min" ">10 hours" "73" "0" "0" "29291350" "Nat Chem Biol. 2018 Feb;14(2):179-185." "Smith TE, Pond CD, Pierce E, Harmer ZP, Kwan J, Zachariah MM, Harper MK, Wyche TP, Matainaho TK, Bugni TS, Barrows LR, Ireland CM, Schmidt EW." "Accessing chemical diversity from the uncultivated symbionts of small marine animals" "10.1038/nchembio.2537" "Anti-HIV-1" "DRAVPe02136" "2Abz-A-xiIle-N(Me)Phe(bS-OH)" "3" "Asperterrestide A" "marine-derived fungus Aspergillus terreus SCSGAF0162." "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "H1N1/H3N2" "Orthomyxoviridae" "HIV assay" "[Ref:23806112]H1N1:IC50=20.2μM,H3N2:IC50=0.41μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23806112]Negligible cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "2Abz at position 1: 2-Aminobenzoyl (Aromatic modification).D-Ala at position2:D-Alanine (Natural enantiomer of alanine).D-xiIle at position 3:D-X-isoleucine (Modified or non-standard isoleucine).D-N(Me)Phe at position 4:D-N-Methylphenylalanine (Methyl group added to the nitrogen of phenylalanine).bS-OH at position5:b-Sulfhydroxyphenylalanine (Phenylalanine derivative with a hydroxyl group attached to a sulfur atom." "L" "Not found" "Not Available" "480.6 g/mol" "C12H15N5O2" "RNDECQMFPSTWYVOU" "A" "6" "0" "0" "0" "1" "4" "2.65" "-0.67" "4 hours" ">20 hour" ">10 hours" "85" "0" "0" "23806112" "Journal of natural products, 76(6), 1182–1186." "He, F., Bao, J., Zhang, X. Y., Tu, Z. C., Shi, Y. M., & Qi, S. H. (2013)." "Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162" "10.1021/np300897v" "Anti-H1N1,Anti-H3N2" "DRAVPe02137" "VXYXYXYP" "5" "Aspergillipeptide D" "Endophytic fungus Aspergillus sp. SCSIO 41501 " "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "plaque reduction assay." "[Ref:32192525]HSV-1:IC50=9.5μM,HSV-1:IC50=12.5μM(ACV-HSV-1)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:32192525]Negligible cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "X at position 2: N-methyltyrosine (N-Me-Tyr) → Y (Tyrosine with a methyl group on the nitrogen),X at position 3: O-methyltyrosine (O-Me-Tyr) → Y (Tyrosine with a methyl group on the hydroxyl group),X at position 4: O-methyltyrosine (O-Me-Tyr) → Y (Tyrosine with a methyl group on the hydroxyl group)" "L" "Glycoprotein." " Aspergillipeptide D did not affect HSV-1 early infection events, including viral inactivation, attachment and penetration. Interestingly, Aspergillipeptide D dramatically reduced both the gene and protein levels of viral late protein gB, and suppressed its location in the endoplasmic reticulum and Golgi apparatus.n contrast, overexpression of gB restored viral production. Finally, proteomic analysis revealed that the numbers of cellular proteins that interacted with gB protein was largely decreased by Aspergillipeptide D. These results suggested that Aspergillipeptide D inhibited gB function to affect HSV-1 intercellular spread." "727.859 g/mol" "C40H49N5O8" "ARNDCQWMFSTWOU" "Y" "5.49" "0" "0" "0" "5" "5" "-0.26" "0.84" "100 hours" ">20 hour" ">10 hours" "58" "1470" "6.351" "32192525" "Virology journal, 17(1), 41. " "Wang, Z., Jia, J., Wang, L., Li, F., Wang, Y., Jiang, Y., Song, X., Qin, S., Zheng, K., Ye, J., Ren, Z., Wang, Y., & Qi, S. (2020). " "Antiviral peptides from marine gorgonian-derived fungus Aspergillus sp. SCSIO 41501" "10.1186/s12985-020-01315-z" "Anti-HSV-1" "DRAVPe02138" "YWV" "3" "Aspergillipeptide E" "Endophytic fungus Aspergillus sp. SCSIO 41501 " "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "plaque reduction assay." "[Ref:32192525]HSV-1:IC50=19.8μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:32192525]Negligible cytotoxicity" "No predicted structure available" "Linear" "Free" "Free" "The configurations of Tyr and Val have been determined as D-Tyr and D-Val, while Trp is speculated to be L-Trp based on the precursor added." "L" "Glycoprotein." "Not Available" "Not inlcuded yet" "C26H36N4O7" "ARNDCQEMFPSVOU" "Y" "0" "0" "0" "0" "3" "3" "0" "0.56" "0" "0" "0" "0" "0" "0" "32192525" "Virology journal, 17(1), 41. " "Wang, Z., Jia, J., Wang, L., Li, F., Wang, Y., Jiang, Y., Song, X., Qin, S., Zheng, K., Ye, J., Ren, Z., Wang, Y., & Qi, S. (2020). " "Antiviral peptides from marine gorgonian-derived fungus Aspergillus sp. SCSIO 41501" "10.1186/s12985-020-01315-z" "Anti-HSV-1" "DRAVPe02139" "XIXYQPXAXTX" "6" "Simplicilliumtide J" "Fungus Simplicillium obclavatum EIODSF 0210" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Anti-HSV-Assay" "[Ref:28578573]HSV-1:IC50=14.1μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "X at position 1: allo-Ile,X at position 2: D-Tyr,X at position 5: D-Ala,X at position 6: D-allo-Thr,X at position 7: 5(S)-HTA (non-standard residue)" "L" "Not found" "Not Available" "691.78" "C25H30N4O5" "RNDCEGHLKMFSVOU" "A" "5.52" "0" "0" "0" "6" "6" "-0.133" "0.92" "20 hour" "30 min" ">10 hours" "81.67" "1490" "2.154" "28578573" "Journal of agricultural and food chemistry, 65(25), 5114–5121." "Liang, X., Nong, X. H., Huang, Z. H., & Qi, S. H. (2017)." "Antifungal and Antiviral Cyclic Peptides from the Deep-Sea-Derived Fungus Simplicillium obclavatum EIODSF 020" " 10.1021/acs.jafc.7b01238" "Anti-HSV-1" "DRAVPe02140" "SAPQYV" "6" "Verlameline A" "Fungus Simplicillium obclavatum EIODSF 0210" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Anti-HSV-Assay" "[Ref:28578573]HSV-1:IC50=16.7μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "A 5-hydroxytetradecanoic acid (HTDA) is attached to the N-terminus — this makes the compound a lipopeptide." "Free" "Macrocyclic lactone ring:The hydroxyl group at C-5 of HTDA is ester-linked to the C-terminal carboxyl of Val, forming a cyclic structure." "L" "Not found" "Not Available" "663.73" "C45H71N7O11" "RNDCEGHLKMFSVOU" "Q" "5.24" "0" "0" "0" "6" "6" "-0.2" "92" "1.9 hours" ">20 hour" ">10 hours" "65" "1490" "2.254" "28578573" "Journal of agricultural and food chemistry, 65(25), 5114–5121" "Liang, X., Nong, X. H., Huang, Z. H., & Qi, S. H. (2017)" "Antifungal and Antiviral Cyclic Peptides from the Deep-Sea-Derived Fungus Simplicillium obclavatum EIODSF 020" "10.1021/acs.jafc.7b01238" "Anti-HSV-1" "DRAVPe02141" "FLSX₃" "3" "Acremonpeptide A" "Fungus Acremonium persicinum SCSIO 115" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1,HSV-2" "Herpesviridae" "Vitro Bioassay" "[Ref:31503476]HSV-1:IC50=16μM,HSV-1:EC50=8.7μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "X = Modified ornithine (specifically N5-acetyl-N5-hydroxy-Orn, repeated three times)" "L" "Cell membrane" "Viral Replication" "365.19" "C39H61N9O13" "ARNDCQEMPWVOU" "FLS" "5.9" "0" "0" "0" "1" "2" "1.93" "0.46" "1.1 hours" "20 mins" "10 mins" "81.6" "0" "0" "31503476" "Journal of natural products, 82(9), 2594–2600." "Luo, M., Zang, R., Wang, X., Chen, Z., Song, X., Ju, J., & Huang, H. (2019)." "Natural Hydroxamate-Containing Siderophore Acremonpeptides A-D and an Aluminum Complex of Acremonpeptide D from the Marine-Derived Acremonium persicinum SCSIO 115" "10.1021/acs.jnatprod.9b00545" "Anti-HSV-1,Anti-HSV-2" "DRAVPe02142" "FLWXOX" "4" "Al(III)-acremonpeptide D" "Fungus Acremonium persicinum SCSIO 115" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Anti-HSV-Assay" "[Ref:31503476]HSV-1:IC50=14μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "X = AcN(OH)Orn" "L" "Cell membrane" "Viral replication" "578.3" "C47H63AlN10O12" "ARNDCQEMPSVOU" "FLW" "9.9" "1" "0" "1" "2" "2" "1.18" "1.95" "30 hours" ">20 hours" ">10 hours" "87.5" "0" "0" "31503476" "Journal of natural products, 82(9), 2594–2600." "Luo, M., Zang, R., Wang, X., Chen, Z., Song, X., Ju, J., & Huang, H. (2019)." "Natural Hydroxamate-Containing Siderophore Acremonpeptides A-D and an Aluminum Complex of Acremonpeptide D from the Marine-Derived Acremonium persicinum SCSIO 115" "10.1021/acs.jnatprod.9b00545" "Anti-HSV-1" "DRAVPe02143" "QSVACRSYYCSKFCGSAGCSLYGCYLLHPGKICYCLHCSR" "40" "Myticin C" "Mollusk Mytilus galloprovincialis" "A7DWR7" "Experimentally Validated" "29158" "mync_MYTGA" "Not Available" "21-60" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Anti-HSV-Assay" "[Ref:27307570]HSV-1:IC50=7.69–8.21μM,HSV-1:IC50=8.32–10.5μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not found" "The intracellular phase of viral replication" "4432.2" "C191H289N53O53S8" "NDEMTWOU" "C" "8.71" "4" "0" "4" "12" "18" "0.227" "0.9185" "0.8 hours" "10 min" "10 hours" "61" "7450" "1.681" "27307570" "Journal of virology, 90(17), 7692–7702." "Novoa, B., Romero, A., Álvarez, Á. L., Moreira, R., Pereiro, P., Costa, M. M., Dios, S., Estepa, A., Parra, F., & Figueras, A. (2016)." "Antiviral Activity of Myticin C Peptide from Mussel: an Ancient Defense against Herpesviruses" "10.1128/JVI.00591-16" "Anti-HSV-1" "DRAVPe02144" "HTASDAAAAAALTAANAAAAAAASMA" "26" "Pa-MAP" "polar fish Pleuronectes americanus" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Anti-HSV-Assay" "[Ref:27161201]HSV-1:IC50=82%(45μM),HSV-1:IC50=90%(23μM)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27161201]Pa-MAP did not reach the concentrations that allowed 50% of cellular viability (CC50), since there were already 80% of viable cells in the first dilution. Even though some peptides showe" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Membrane" "Pa-MAP could possible interact with the viral envelope and the phospholipids of the viral surface, due to the presence of hydrophobic amino acid residues.22 According to such data, further tests were performed in this study to define Pa-MAP’s antiviral mechanism of action. It was verified that this peptide has a virucidal action,like most antiviral peptides described in the literature,13 inhibiting the virus’ action before adsorption, at a percentage above 80%, reinforcing the theory presented by Migliolo et al.,22 and the SI was higher than 5 considering the CC50 at 400 mg." "2213.41" "C90H149N29O34S1" "RCQEGIKFPWYVOU" "A" "5.08" "0" "1" "-1" "22" "18" "0.888" "0.9185" "3.5 hours" "10 min" ">10 hours" "80.38" "0" "0" "27161201" "Biopolymers, 108(2), 10.1002/bip.22871." "Vilas Boas, L. C., de Lima, L. M., Migliolo, L., Mendes, G. D., de Jesus, M. G., Franco, O. L., & Silva, P. A. (2017)." "Linear antimicrobial peptides with activity against herpes simplex virus 1 and Aichi virus" "10.1002/bip.22871" "Anti-HSV-1" "DRAVPe02145" "YP" "2" "Cyclo(l-Tyr-l-Pro) diketopiperazine" "Endophytic fungus Aspergillus versicolor" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Herpesviridae" "Anti-HSV-Assay" "[Ref:Not Available]HCV:IC50: 8.2 μg mL−1" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "NS3-4A protease" "interact with the viral envelope and the phospholipids of the" "Not inlcuded yet" "Not includedd yet" "Not included ye" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "2" "2" "Not inlcuded yet" "0.8" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not inlcuded yet" "Not Available" "Applied Biochemistry and Microbiology, 53(1), 101-106." "Ahmed, Eman; Rateb, Mostafa; El-Kassem, L.T. Abou ; Hawas, Usama" "Anti-HCV protease of diketopiperazines produced by the Red Sea sponge-associated fungus Aspergillus versicolor" "10.1134/S0003683817010021" "Anti-HCV" "DRAVPe02146" "AVVVDAVVVDAVVVDAVVVD" "20" "Valinomycin; streptodepsipeptides P11A and SV21" "Bacterial symbiont Streptomyces sp. SV21" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Herpesviridae" "Anti-HCV assay " "[Ref:33540548]HCV:IC50=0–5%" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not found" "viral surface, due to the presence of hydrophobic amino acid" "1952.28" "C54H90N6O18" "RNCQEGHHILKMFPSTWYOU" "V" "3.32" "0" "4" "-4" "12" "10" "2.18" "0.96" "4.4 hours" ">20 hours" ">10 hours" "194" "0" "0" "33540548" " Marine drugs, 19(2), 81." "Wibowo, J. T., Kellermann, M. Y., Köck, M., Putra, M. Y., Murniasih, T., Mohr, K. I., Wink, J., Praditya, D. F., Steinmann, E., & Schupp, P. J. (2021). " "Anti-Infective and Antiviral Activity of Valinomycin and Its Analogues from a Sea Cucumber-Associated Bacterium, Streptomyces sp. SV 21" "10.3390/md19020081" "Anti-HCV" "DRAVPe02147" "SITQINTTLLDTTYEMISIQQVVKALNESYIDLKEL" "36" "MERS-HR2P" "HR2 domain of bat" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV " "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref:30646495]SARS-CoV:IC50=1.07μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "HR2 " "These peptides target the viral fusion and entry stages." "4129.73" "C183H303N43O62S1" "RCGHFPWOU" "ILT" "4.18" "2" "5" "-3" "22" "18" "0.064" "0.9185" "1.9 hours" ">20 hour" ">10 hours" "127.22" "2980" "0.722" "33082259" "mBio, 11(5), e01935-20." "Outlaw, V. K., Bovier, F. T., Mears, M. C., Cajimat, M. N., Zhu, Y., Lin, M. J., Addetia, A., Lieberman, N. A. P., Peddu, V., Xie, X., Shi, P. Y., Greninger, A. L., Gellman, S. H., Bente, D. A., Moscona, A., & Porotto, M. (2020)." "Inhibition of Coronavirus Entry In Vitro and Ex Vivoby a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain" "10.1128/mBio.01935-20" "Anti-MERS-CoV" "DRAVPe02148" "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGCTEG" "45" "SARS-CoV-2 HRC" "C-terminal HR domain of SARS-CoV-2" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2 ,MERS-CoV" "Coronaviridae" "cell-cell fusion assay" "[Ref:20032190]SARS-CoV:IC50≈3nM and ~6nM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:20032190]No toxicity was observed for the SARS-CoV-2 lipopeptide at its IC90 concentration" "No predicted structure available" "Cyclic" "Free" "Chlo" "None" "L" "Not found" "Not Available" "4744.22" "C198H333N57O75S1" "MFPWTOU" "NILS" "4.12" "3" "8" "-5" "22" "18" "-0.251" "0.9185" "1.1 hours" "3 min" ">10 hours" "110.44" "0" "0" "20032190" "Journal of virology, 84(5), 2511–2521." "O'Keefe, B. R., Giomarelli, B., Barnard, D. L., Shenoy, S. R., Chan, P. K., McMahon, J. B., Palmer, K. E., Barnett, B. W., Meyerholz, D. K., Wohlford-Lenane, C. L., & McCray, P. B., Jr (2010)" "Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae" "10.1128/JVI.02322-09" "Anti-SARS-CoV-2" "DRAVPe02149" "LDLSDEMAMIEVVKQLNDSYIDLKELSNYTYYNKW" "35" "HKU4-HR2P3 " "HR2 domain of bat" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV " "Coronaviridae" "Time-of-addition assay" "[Ref:30646495]SARS-CoV:IC50=0.55μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "HR2 " "These peptides target the viral fusion and entry stages." "4245.78" "C191H291N43O62S2" "RCGHFPOU" "L" "4.14" "3" "7" "-4" "22" "18" "-0.497" "0.91" "5.5 hours" "3 min" "2 min" "97.43" "11460" "2.699" "30646495" "Viruses, 11(1), 56." "Xia, S., Lan, Q., Pu, J., Wang, C., Liu, Z., Xu, W., Wang, Q., Liu, H., Jiang, S., & Lu, L. (2019). " "Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU5" "10.3390/v11010057" "Anti-MERS-CoV" "DRAVPe02150" "GVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQ" "40" "NP-1" "HR1 region of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "892-931" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WYY, 5WRG, 5X58, 5X5B, 5XLR, 5ZVM, 6ACC, 6ACD" "SARS-CoV" "Coronaviridae" "antiviral Assay" "[Ref:15043961]SARS-CoV:Marginal activity at 50μmol/L" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Glycoprotein. Gp41" "like most antiviral peptides described in the literature,13 inhibi-" "4408.93" "C191H316N54O65" "RDCHMPWOU" "LN" "8.43" "3" "2" "1" "22" "18" "-0.497" "0.918" "30 hours" ">20 hour" ">10 hours" "90.25" "1490" "0.338" "15043961" "Lancet (London, England), 363(9413), 938–947." "Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C. R., Xiong, H., Farmar, J., Debnath, A. K., Tien, P., & Jiang, S. (2004). " "Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors" "10.1016/S0140-6736(04)15788-7" "Anti-SARS-CoV" "DRAVPe02151" "SGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL" "34" "N/A" "HR segment of SARS-CoV" "P0DTC2" "Experimentally Validated" "2697049" "S2(43740568)" "QHD43416.1" "1170-1203" "Not Available" "MN908947.3" "Genomic RNA" "Chromosome:21,563 - 25,384" "6LVN##6LXT##6LZG" "SARS-CoV-2" "Coronaviridae" "antiviral Assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "N-terminal leucine/isoleucine zipper-like sequence" "C-terminal heptad repeat located upstream" "None" "L" "Glycoprotein. Gp41" "ting the virus’ action before adsorption, at a percentage above" "3780.25" "C162H276N46O57" "RDCHMPWOU" "NL" "4.36" "3" "6" "-3" "22" "18" "-0.218" "0.9" "1.9 hours" ">20 hour" ">10 hours" "134.71" "0" "0" "14499001" "BMC microbiology, 3, 20." "Kliger, Y., & Levanon, E. Y. (2003)." "Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy" "10.1186/1471-2180-3-20" "Anti-SARS-CoV" "DRAVPe02152" "PTTFMLKYDENGTITDAVDC " "20" "P2" "S1 subunit of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "259-278" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "None" "SARS-CoV-2" "Coronaviridae" "antiviral Assay" "[Ref:15918330]SARS-CoV:IC50=112.5±26.3μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not found" "80%, reinforcing the theory presented by Migliolo et al.,22 and" "2234.48" "C96H148N22O35S2" "RQSWOU" "T" "3.84" "1" "4" "-3" "16" "14" "-0.3" "0.95" ">20 hour" ">20 hour" "Unknown" "58.5" "1490" "0.667" "15918330" "Antiviral therapy, 10(3), 393–403." "Zheng, B. J., Guan, Y., Hez, M. L., Sun, H., Du, L., Zheng, Y., Wong, K. L., Chen, H., Chen, Y., Lu, L., Tanner, J. A., Watt, R. M., Niccolai, N., Bernini, A., Spiga, O., Woo, P. C., Kung, H. F., Yuen, K. Y., & Huang, J. D. (2005)." "Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus" "Not Available" "Anti-SARS-CoV" "DRAVPe02153" "YQDVNCTDVSTAIHADQLTP" "20" "P6" "S1 subunit of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "598-617" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "None" "SARS-CoV-2" "Coronaviridae" "antiviral Assay" "[Ref:15918330]SARS-CoV:IC50=113.0±27.6μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not found" "the SI was higher than 5 considering the CC50 at 400 mg." "2191.35" "C92H143N25O35S1" "RQSWOU" "DT" "3.93" "0" "3" "-3" "16" "14" "-0.36" "0.9576" "2.8 hours" "10 min" "2 min" "78" "1490" "0.68" "15918330" "Antiviral therapy, 10(3), 393–403." "Zheng, B. J., Guan, Y., Hez, M. L., Sun, H., Du, L., Zheng, Y., Wong, K. L., Chen, H., Chen, Y., Lu, L., Tanner, J. A., Watt, R. M., Niccolai, N., Bernini, A., Spiga, O., Woo, P. C., Kung, H. F., Yuen, K. Y., & Huang, J. D. (2005)." "Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus" "Not Available" "Anti-SARS-CoV" "DRAVPe02154" "STSQKSIVAYTM" "12" "SP-10" "S protein of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "668-679" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WYY, 5WRG, 5X58, 5X5B, 5XLR, 5ZVM, 6ACC, 6ACD" "SARS-CoV" "Coronaviridae" "Biotinylated enzyme-linked immunosorbent assay" "[Ref:16337697]SARS-CoV:IC50=1.88±0.52nmol" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "S protein to ACE2 " "Significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay.SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. " "1315.5" "C56H94N14O20S1" "RNDCEGHLFPWOU" "S" "8.31" "1" "0" "1" "12" "10" "-0.008" "0.96" "1.9 hours" ">20 hour" ">10 hours" "65" "1490" "1.113" "16337697" "Antiviral research, 69(2), 70–76." "Ho, T. Y., Wu, S. L., Chen, J. C., Wei, Y. C., Cheng, S. E., Chang, Y. H., Liu, H. J., & Hsiang, C. Y. (2006)." "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction" "10.1016/j.antiviral.2005.10.005" "Anti-SARS-CoV" "DRAVPe02155" "GGGYSKAQKAQAKQAKQAQKAQKAQAKQAKQAQKAQKAQAKQAKQ" "45" "P5 +14" "S1 subunit of SARS-CoV-2" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "antiviral Assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Not Available" "4766.45" "C202H351N71O62" "RNDCEGHLFPWOU" "A" "10.74" "12" "0" "12" "22" "18" "-1.642" "0.9185" "30 hours" ">20 hour" ">10 hours" "31.11" "1490" "0.313" "32913137" "Molecular pharmacology, 98(5), 612–619." "Tavassoly, O., Safavi, F., & Tavassoly, I. (2020)." "Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection" "10.1124/molpharm.120.000098" "Anti-SARS-CoV" "DRAVPe02156" "QYGSFCTQLNRALSGIAAEQ" "20" "P8" "S2 subunit of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "737-756" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WYY, 5WRG, 5X58, 5X5B, 5XLR, 5ZVM, 6ACC, 6ACD" "SARS-CoV" "Coronaviridae" "antiviral Assay" "[Ref:15918330]SARS-CoV:IC90=24.9±6.2μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Not Available" "2157.39" "C92H145N27O31S1" "DHKMPWVOU" "AQ" "5.99" "1" "1" "0" "16" "14" "-0.18" "0.95" "0.8 hours" "10 mins" "10 hours" "73.5" "1490" "0.69" "15918330" "Antiviral therapy, 10(3), 393–403." "Zheng, B. J., Guan, Y., Hez, M. L., Sun, H., Du, L., Zheng, Y., Wong, K. L., Chen, H., Chen, Y., Lu, L., Tanner, J. A., Watt, R. M., Niccolai, N., Bernini, A., Spiga, O., Woo, P. C., Kung, H. F., Yuen, K. Y., & Huang, J. D. (2005)." "Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus" "Not Available" "Anti-SARS-CoV" "DRAVPe02157" "IQKEIDRLNEVAKNLNESLI" "20" "P10" "HR2 region of SARS-CoV" "P59594" "Experimentally Validated" "694009" "S2" "AAP13441.1" "1161-1180" "Not Available" "AY274119.3" "Genomic RNA" "Chromosome:21,492 - 25,259" "1WYY, 5WRG, 5X58, 5X5B, 5XLR, 5ZVM, 6ACC, 6ACD" "SARS-CoV" "Coronaviridae" "antiviral Assay" "[Ref:15918330]SARS-CoV:IC90=73.5±15.7μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "Not Found" "Not Available" "2339.67" "C101H175N29O34" "CGHMFPTWYOU" "NIL" "4.87" "3" "4" "-1" "16" "14" "-0.51" "0.9576" "20 hour" "30 min" ">10 hours" "136.5" "0" "0" "15918330" "Antiviral therapy, 10(3), 393–403." "Zheng, B. J., Guan, Y., Hez, M. L., Sun, H., Du, L., Zheng, Y., Wong, K. L., Chen, H., Chen, Y., Lu, L., Tanner, J. A., Watt, R. M., Niccolai, N., Bernini, A., Spiga, O., Woo, P. C., Kung, H. F., Yuen, K. Y., & Huang, J. D. (2005)." "Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus" "Not Available" "Anti-SARS-CoV" "DRAVPe02158" "GGRGGGGSGGSGGSGGRGGGGSGGSGG" "27" "MERS-5HB" "S2 subunit of MERS-CoV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MERS-CoV" "Coronaviridae" "ELISA" "[Ref:28906430]MERS-CoV:IC50=The 50% inhibitory concentration (IC50) for the inhibition by MERS-5HB of a MERS-CoV infection was about 1 μM, " "[Ref:28906430]The calculated 50% effective concentration (EC50) of binding of MERS-5HB to MERS-HR2P is 5.4 nM.To confirm the binding, the ELISA assay was performed in the reverse way. MERS-5HB was coa" "[Ref: 30646495]No cytotoxicity" "No predicted structure available" "Cyclic" "Free" "Free" "None" "L" "HR2 " " The absence of one HR2 may reserve a hydrophobic groove in MERS-5HB for binding to a native HR2 in the MERS-CoV S protein.It could bind to HR2 in MERS-CoV S2 to inhibit viral entry as well as S protein-mediated syncytial formation." "1906.82" "C67H111N33O33" "ANDCQEHIKLMFPWYVOU" "G" "12" "2" "0" "2" "12" "10" "-0.778" "0.96" "30 hours" ">20 hour" ">10 hours" "0" "0" "0" "28906430" "Viruses. 2017 Sep 14;9(9):255." "Sun Y, Zhang H, Shi J, Zhang Z, Gong R." "Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus" "10.3390/v9090255" "Anti-MERS-CoV" "DRAVPe02159" "VVEQYNQTILNLTSEISTLENKSAELNYTVQKLQTLIDNINSTLVDLKWL" "50" "229E-HR2P" "S2 subunit of HCoV-229E" "P15423" "Experimentally Validated" "11137" "S2" "CAA34723.1" "1056-1105" "Not Available" "AF304460.1" "Genomic RNA" "Chromosome:20,570 - 24,091" "5ZHY##5YL9##5ZUV" "SARS-CoV" "Coronaviridae" "cell-cell fusion assay" "[Ref:29415501]SARS-CoV,IC50=0.3μM,1.96μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:29415501]Neither 229E-HR1P nor 229E-HR2P had significant cytotoxicity to these cells at concentrations up to 1,000 μM" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Fusion Inhibitor" "5752.51" "C256H418N64O85" "RCGHMFPOU" "L" "4.36" "3" "6" "-3" "32" "24" "-0.156" "1.1" "100 hours" ">20 hour" ">10 hours" "126.6" "8480" "1.474" "29415501" "International journal of molecular sciences, 19(2), 487." "Xia, S., Xu, W., Wang, Q., Wang, C., Hua, C., Li, W., Lu, L., & Jiang, S. (2018)" "Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains" "10.3390/ijms19020487" "Anti-SARS-CoV" "DRAVPe02160" "AVLQSGFR" "8" "Octapeptide" "Structure of SARS-CoV Mpro" "P0C6U8" "Experimentally Validated" "694009" "1a" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref:16242214]HCoV-229E,IC50=0.5μM(pseudotyped),1.7μM(livevirus)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16242214]no detectable toxicity is observed on Vero cells .100" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "It inhibits replication" "877.01" "C39H64N12O11" "NDCEHIKMPTWYOU" "ARQGLFSV" "9.79" "1" "0" "1" "6" "8" "0.425" "1.1" "4.4 hours" ">20 hour" ">10 hours" "97.5" "0" "0" "16242214" "Peptides, 27(4), 622–625." "Gan, Y. R., Huang, H., Huang, Y. D., Rao, C. M., Zhao, Y., Liu, J. S., Wu, L., & Wei, D. Q. (2006)." "Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase" "10.1016/j.peptides.2005.09.006" "Anti-SARS-CoV" "DRAVPe02161" "LQQFMK" "6" "6a" "Cleavage site of SARS-CoV Mpro" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref:16451084]SARS-CoV,EC50=0.027μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref16451084]low toxicity in cells" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Available" "793.98" "C36H59N9O9S1" "ARNDCEGHIPSTWYVOU" "Q" "8.75" "1" "0" "1" "6" "6" "8.75" "1.08" "5.5 hours" "3 mins" "2 mins" "65" "0" "0" "16451084" "J. Med. Chem. 2006, 49, 3, 1198–1201" "Zhang, H. Z., Zhang, H., Kemnitzer, W., Tseng, B., Cinatl, J., Jr, Michaelis, M., Doerr, H. W., & Cai, S. X. (2006)." "Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors" "10.1021/jm0507678" "Anti-SARS-CoV" "DRAVPe02162" "AVLQ" "4" "Protected tetrapeptide" "Cleavage site of the main proteases" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Peptide cleavage assay" "[Ref:25224114]SARS-CoV,IC50=2.5μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "carboxybenzyl" "nitrile" "None" "L" "Not Found" "Not Available" "432.53" "C19H36N6O6" "NDCFPSTWYVOUMGK" "Q" "6.02" "0" "0" "0" "1" "3" "0.875" "0.37" "4.4 hours" ">20 hour" ">10 hours" "117.5" "0" "0" "25224114" " Hong Kong medical journal = Xianggang yi xue za zhi, 20 Suppl 4, 22–25." "Chuck, C. P., Ke, Z. H., Chen, C., Wan, D. C., Chow, H. F., & Wong, K. B. (2014). " "Profiling of substrate-specificity and rational design of broad-spectrum peptidomimetic inhibitors for main proteases of coronaviruses" "10.1021/jm0507678" "Anti-SARS-CoV" "DRAVPe02163" "ESTLQ" "5" "Peptide aldehyde 1" "Analyses of the SARS-CoV Mpro" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Peptide cleavage assay" "[Ref:21854807]SARS-CoV,IC50=8.27±1.52μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Acetylation" "Hydogenation" "None" "L" "Not Found" "tight-binding inhibitors" "576.6" "C23H40N6O11" "ANDCFPWYVOU" "QELST" "4" "0" "1" "-1" "5" "5" "-0.94" "1.152" "1 hours" "30 mins" ">10 hours" "78" "0" "0" "21854807" "Antiviral research, 92(2), 204–212." "Vilas Boas, L. C., de Lima, L. M., Migliolo, L., Mendes, G. D., de Jesus, M. G., Franco, O. L., & Silva, P. A. (2017)." "Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease" " 10.1016/j.antiviral.2011.08.001" "Anti-SARS-CoV" "DRAVPe02164" "NSFSQ" "5" "Peptide aldehyde 2" "Analyses of the SARS-CoV Mpro" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Peptide cleavage assay" "[Ref:21854807]SARS-CoV,IC50=40.98±2.63μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Acetylation" "Hydogenation" "None" "L" "Not Found" "tight-binding inhibitors" "581.58" "C24H35N7O10" "ARDCEGHILMPTWYVOU" "S" "5.52" "0" "0" "0" "5" "5" "-1.16" "1.152" "1.4 hours" "3 mins" ">10 hours" "0" "0" "0" "21854807" "Antiviral research, 92(2), 204–212." "Vilas Boas, L. C., de Lima, L. M., Migliolo, L., Mendes, G. D., de Jesus, M. G., Franco, O. L., & Silva, P. A. (2017)." "Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease" " 10.1016/j.antiviral.2011.08.001" "Anti-SARS-CoV" "DRAVPe02165" "DSFDQ" "5" "Peptide aldehyde 3" "Analyses of the SARS-CoV Mpro" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Peptide cleavage assay" "[Ref:21854807]SARS-CoV,IC50=41.24±2.25μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Acetylation" "Hydogenation" "None" "L" "Not Found" "tight-binding inhibitors" "610.58" "C25H34N6O12" "ARNCEGHILKMPTWYVOU" "D" "3.56" "0" "2" "-2" "5" "5" "-1.7" "1.27" "1.1 hours" "3 mins" ">10 hours" "0" "0" "0" "21854807" "Antiviral research, 92(2), 204–212." "Vilas Boas, L. C., de Lima, L. M., Migliolo, L., Mendes, G. D., de Jesus, M. G., Franco, O. L., & Silva, P. A. (2017)." "Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease" " 10.1016/j.antiviral.2011.08.001" "Anti-SARS-CoV" "DRAVPe02166" "NSTSQ" "5" "Peptide aldehyde 4" "Analyses of the SARS-CoV Mpro" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Peptide cleavage assay" "[Ref:21854807]SARS-CoV,IC50=72.73±3.60μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Acetylation" "Hydogenation" "None" "L" "Not Found" "tight-binding inhibitors" "535.51" "C19H33N7O11" "ARNCEGHILKMPTWYVOU" "S" "5.52" "0" "0" "0" "5" "5" "-1.86" "1.24" "1.4 hours" "3 mins" ">10 hours" "0" "0" "0" "21854807" "Antiviral research, 92(2), 204–212." "Vilas Boas, L. C., de Lima, L. M., Migliolo, L., Mendes, G. D., de Jesus, M. G., Franco, O. L., & Silva, P. A. (2017)." "Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease" " 10.1016/j.antiviral.2011.08.001" "Anti-SARS-CoV" "DRAVPe02167" "TVFH" "4" "Tetrapeptide aldehyde" "Analyses of the SARS-CoV 3CL protease" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Cell–Cell Fusion Assay" "[Ref:22014094]SARS-CoV,IC50=8nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "522.61" "C25H37N5O6" "ARNDCEGILMSPTWYOU" "TVFH" "7.52" "1" "0" "1" "1" "2" "0.425" "0.79" "3.5 hours" ">20 hours" ">10 hours" "97.5" "0" "0" "22014094" "Journal of medicinal chemistry, 54(23), 7962–7973." "Akaji, K., Konno, H., Mitsui, H., Teruya, K., Shimamoto, Y., Hattori, Y., Ozaki, T., Kusunoki, M., & Sanjoh, A. (2011)." "Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors" "10.1021/jm200870n" "Anti-SARS-CoV" "DRAVPe02168" "VIQY" "4" "Oligopeptide 1" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "523.61" "C25H41N5O7" "ARNCEGHILKMPWOU" "Q" "6.03" "0" "0" "0" "2" "2" "-0.2" "0.48" "100 hours" ">20 hours" ">10 hours" "112.5" "1490" "0.054" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV" "DRAVPe02169" "ICIY" "4" "Oligopeptide 2" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "522.65" "C25H41N5O6S" "ARNCEGHILKMPTWYVOU" "C" "6.02" "0" "0" "0" "2" "2" "-0.95" "-0.27" "20 hours" ">20 hour" ">10 hours" "137.5" "1490" "0.054" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV" "DRAVPe02170" "PISQF" "5" "Oligopeptide 3" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "590.68" "C28H42N6O8" "ARNDEGHLKMTWVOU" "QIFPS" "5.96" "0" "0" "0" "5" "5" "0.28" "0.944" "> 20 hours" ">20 hours" "Unknown" "78" "0" "0" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV" "DRAVPe02171" "VISAW" "5" "Oligopeptide 4" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "574.68" "C28H42N6O7" "RNDCQEGHLKMFPTYOU" "ISWV" "5.49" "0" "0" "0" "5" "5" "1.76" "0.73" "100 hours" ">20 hours" ">10 hours" "156" "5500" "9.571" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV" "DRAVPe02172" "AIPAW" "5" "Oligopeptide 5" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "556.66" "C28H40N6O6" "RNDCQEGHLKMFSTOU" "A" "5.57" "0" "0" "0" "5" "5" "1.12" "0.82" "4.4 hours" ">20 hours" ">10 hours" "118" "500" "980" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV" "DRAVPe02173" "PVSQF" "5" "Oligopeptide 6" "Marine fish proteins" "No entry found" "In-Silico" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV-2" "Coronaviridae" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Not included yet" "Not included yet" "None" "L" "Not Found" "Not Available" "576.65" "C27H40N6O8" "RNDCGHLMKTSYOU" "QEFPSV" "5.96" "0" "0" "0" "5" "5" "0.22" "0.94" ">20 hours" ">20 hours" "Unknown" "58" "0" "0" "32520031" "Food & function, 11(6), 5565–5572." "Yao, Y., Luo, Z., & Zhang, X. (2020)." "In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients" "10.1039/d0fo00530d" "Anti-SARS-CoV-2" "DRAVPe02174" "GGASCCLYCRCH" "12" "K12" "Sequence of nsp 10 of SARS-CoV" "P0C6U8" "Experimentally Validated" "694009" "1a" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Not Available" "[Ref:22659295]SARS-CoV,IC50=160μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Available" "1272.5" "C49H77N17O15S4" "NDQEIKMFPTWVOU" "C" "7.9" "1" "0" "1" "12" "10" "0.417" "0.633" "30 hours" ">20 hours" ">10 hours" "40.83" "1490" "1.171" "22659295" "Virus research, 167(2), 322–328." "Ke, M., Chen, Y., Wu, A., Sun, Y., Su, C., Wu, H., Jin, X., Tao, J., Wang, Y., Ma, X., Pan, J. A., & Guo, D. (2012)." "Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2'-O-methyltransferase activity of nsp10/nsp16 complex" "10.1016/j.virusres.2012.05.017" "Anti-SARS-CoV" "DRAVPe02175" "FGGASCCLYCRCHIDHPNPKGFCDLKGKY" "29" "K29" "Sequence of nsp 10 of SARS-CoV" "P0C6U8" "Experimentally Validated" "694009" "1a" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SARS-CoV" "Coronaviridae" "Not Available" "[Ref:22659295]SARS-CoV,IC50=160μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Available" "3233.76" "C141H210N40O38S5" "QEMWVOU" "C" "8.4" "4" "2" "2" "22" "18" "-0.321" "0.918" "1.1 hours" "3 min" "2 min" "43.78" "2980" "0.922" "22659295" "Virus research, 167(2), 322–328." "Ke, M., Chen, Y., Wu, A., Sun, Y., Su, C., Wu, H., Jin, X., Tao, J., Wang, Y., Ma, X., Pan, J. A., & Guo, D. (2012). " "Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2'-O-methyltransferase activity of nsp10/nsp16 complex" " 10.1016/j.virusres.2012.05.017" "Anti-SARS-CoV" "DRAVPe02176" "ILPWKWPWWPWRR" "13" "APB-13" "Cattle" "P33046  A3KN14 " "Experimentally Validated" "9913" "CATHL4" "CAA47755.1" "131-143" "282166" "CM008189.2" "mRNA" "Primary_assembly 22: 51,592,817-51,594,193 reverse strand." "1G8C##1G89 " "TGEV" "Coronaviridae" "TCID50 assay." "[Ref:33016025]TGEV,IC50=62.5μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "The results showed that the APB-13 concentrations from 0 to 62.5 µg/mL were relatively non-toxic to the cells, and the cell states and mean OD values of the ST cells treated with APB-13 for these conc" "No predicted structure available" "Linear" "Free" "Amidation" "None" "L" "N Protein" "APB-13 inhibited TGEV replication, and within a certain range, the mRNA and protein expression levels of the N protein increased gradually as the APB-13 concentration decreased." "1907.3" "C100H131N25O14" "ANDCQEGHMFSTYVOU" "P" "12.01" "3" "0" "3" "12" "10" "-1.069" "0.9" "20 hours" "30 mins" ">10 hours" "60" "27500" "14.418" "33016025" "Journal of veterinary science, 21(5), e80." "Liang, X., Zhang, X., Lian, K., Tian, X., Zhang, M., Wang, S., Chen, C., Nie, C., Pan, Y., Han, F., Wei, Z., & Zhang, W. (2020). " "Antiviral effects of Bovine antimicrobial peptide against TGEV in vivo and in vitro" "10.4142/jvs.2020.21.e80" "Anti-TGEV" "DRAVPe02177" "FKPSSPPSITLW" "12" "F" "S protein of TGEV (synthetic Construct)" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "TGEV" "Coronaviridae" "ELISA" "[Ref:21176936]TGEV,IC50=20μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "S protein" "The peptides showed an effective binding to pAPN and inhibition to TGEV infection, although their sequences are not completely identical to the homologous regions in the S1 protein" "1359.59" "C66H98N14O17" "ARNDCQEGHMYVOU" "PS" "8.75" "1" "0" "1" "12" "10" "-0.133" "0.9" "1.1 hours" "3 min" "2 min" "65" "5500" "4.045" "21176936" "Virology, 410(2), 299–306." "Ren, X., Liu, B., Yin, J., Zhang, H., & Li, G. (2011)." "Phage displayed peptides recognizing porcine aminopeptidase N inhibit transmissible gastroenteritis coronavirus infection in vitro" "10.1016/j.virol.2010.11.014" "Anti-TGEV" "DRAVPe02178" "HVTTTFAPPPPR" "12" "H" "S protein of TGEV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "TGEV" "Coronaviridae" "ELISA" "[Ref:21176937]TGEV,IC50=" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "S protein" "The peptides showed an effective binding to pAPN and inhibition to TGEV infection, although their sequences are not completely identical to the homologous regions in the S1 protein" "1320.51" "C61H93N17O16" "NDCQEGILKMOUW" "T" "9.76" "1" "0" "1" "12" "10" "-0.617" "0.99" "3.5 hours" "10 min" ">10 hours" "32.5" "0" "0" "21176936" "Virology, 410(2), 299–306." "Ren, X., Liu, B., Yin, J., Zhang, H., & Li, G. (2011)." "Phage displayed peptides recognizing porcine aminopeptidase N inhibit transmissible gastroenteritis coronavirus infection in vitro" "10.1016/j.virol.2010.11.015" "Anti-TGEV" "DRAVPe02179" "SVVPSKATWGFA" "12" "S" "S protein of TGEV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "TGEV" "Coronaviridae" "ELISA" "[Ref:21176936]TGEV,IC50=20μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "S protein" "The peptides showed an effective binding to pAPN and inhibition to TGEV infection, although their sequences are not completely identical to the homologous regions in the S1 protein" "1249.43" "C59H88N14O16" "RNDCQEHILMYOU" "ASV" "8.47" "1" "0" "1" "12" "10" "0.475" "0.906" "1.9 hurs" ">20 hour" ">10 hours" "65" "5500" "4.402" "21176936" "Virology, 410(2), 299–306." "Ren, X., Liu, B., Yin, J., Zhang, H., & Li, G. (2011)." "Phage displayed peptides recognizing porcine aminopeptidase N inhibit transmissible gastroenteritis coronavirus infection in vitro" "10.1016/j.virol.2010.11.016" "Anti-TGEV" "DRAVPe02180" "HDAISWTHYHPW" "12" "PM1" " porcine aminopeptidase N (rpAPN-C) protein " "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "TGEV" "Coronaviridae" "MTT assay" "Not Avaialble" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "1549.67" "C74H92N20O18" "RNCQEILKFMSTVOU" "H" "6.25" "0" "1" "-1" "12" "10" "-1.083" "0.99" "3.5 hours" "10 min" ">10 hours" "40.83" "12490" "8.06" "24111863" "Monoclonal antibodies in immunodiagnosis and immunotherapy, 32(5), 326–329." "Guo, D., Zhu, Q., Feng, L., & Sun, D. (2013)." "Screening and antiviral analysis of phages that display peptides with an affinity to subunit C of porcine aminopeptidase" "10.1089/mab.2013.0038" "Anti-TGEV" "DRAVPe02181" "LMQINPTYYQIM" "12" "L" "S1 protein of PEDV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque-reduction assay" "[Ref:26292945]PEDV,IC50=50μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Cell surface" "Two peptides derived from phage display libraries were identified with sequence homology to a specific region of the PEDV S1 protein and that affect binding of the PEDV to the cell surface" "1514.82" "C69H107N15O19S2" "ARDCEGHKFSWVOU" "QIM" "5.52" "0" "0" "0" "12" "10" "0.1" "0.99" "5.5 hours" "3 mins" "2 min" "97.5" "2980" "1.967" "26292945" "Virus genes, 51(2), 217–224." "Cao, L., Ge, X., Gao, Y., Zarlenga, D. S., Wang, K., Li, X., Qin, Z., Yin, X., Liu, J., Ren, X., & Li, G. (2015)." "Putative phage-display epitopes of the porcine epidemic diarrhea virus S1 protein and their anti-viral activity" " 10.1007/s11262-015-1234-5" "Anti-PEDV" "DRAVPe02182" "WSFNPSTYTIAG" "12" "W" "S1 protein of PEDV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "PEDV" "Coronaviridae" "Plaque-reduction assay" "[Ref:26292945]PEDV,IC50=50μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Cell surface" "Two peptides derived from phage display libraries were identified with sequence homology to a specific region of the PEDV S1 protein and that affect binding of the PEDV to the cell surface" "1343.46" "C63H86N14O19" "RDCQEHKMOU" "ST" "5.52" "0" "0" "0" "12" "10" "-0.133" "0.99" "2.8 hours" "3 mins" "2 min" "40.83" "6990" "5.203" "26292945" "Virus genes, 51(2), 217–224." "Cao, L., Ge, X., Gao, Y., Zarlenga, D. S., Wang, K., Li, X., Qin, Z., Yin, X., Liu, J., Ren, X., & Li, G. (2015)." "Putative phage-display epitopes of the porcine epidemic diarrhea virus S1 protein and their anti-viral activity" " 10.1007/s11262-015-1234-5" "Anti-PEDV" "DRAVPe02183" "HALTPIKYIPPG" "12" "TGEV-M7" "M protein of TGEV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "TGEV" "Coronaviridae" "Plaque-reduction assay" "[Ref:23830854]TGEV,IC50=62.5μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "rTGEV-M protein" "pepTGEV-M7 binding to the surface of the virus and either interfering with the ability of the virus to invade the cell or generate progeny virus. " "1306.57" "C63H99N15O15" "RNDCQEMFSWVOU" "P" "8.06" "1" "0" "1" "12" "10" "0.025" "0.99" "3.5 hours" "10 mins" ">10 hours" "105.83" "1490" "1.14" "23830854" "Antiviral research, 99(3), 383–390." "Zou, H., Zarlenga, D. S., Sestak, K., Suo, S., & Ren, X. (2013)." "Transmissible gastroenteritis virus: identification of M protein-binding peptide ligands with antiviral and diagnostic potential" "10.1016/j.antiviral.2013.06.015" "Anti-TGEV" "DRAVPe02184" "YGFWTIAYTNYTDVMVDVNG" "20" "I-S1-9" "S1 protein of FIPV" "A0A1Z2WU95" "Experimentally Validated" "12663" "S" "Not Available" "477-496" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIPV" "Coronaviridae" "plaque reduction assay." "[Ref:25896976]FIPV,IC50=100μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "2329.57" "C108H149N23O33S1" "RCQEHLKPSOU" "TYV" "3.56" "0" "2" "-2" "22" "18" "0.095" "0.9185" "2.8 hours" "10 min" "2 min" "68" "9970" "4.28" "25896976" "Virus research, 204, 13–20." "Doki, T., Takano, T., Koyama, Y., & Hohdatsu, T. (2015)." "Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection" "10.1016/j.virusres.2015.04.011" "Anti-FIPV" "DRAVPe02185" "YHWMNVTLHVVLNDTEKKYD" "20" "I-S1-16" "S1 protein of FIPV" "Q66951" "Experimentally Validated" "11135" "S" "Not Available" "541-560" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIPV" "Coronaviridae" "plaque reduction assay." "[Ref:25896976]FIPV,IC50=100μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "2505.83" "C114H169N29O33S1" "ARCQGIFPSOU" "V" "6" "2" "3" "-1" "22" "18" "-0.725" "0.9185" "2.8 hours" "10 min" "2 min" "82.5" "8480" "3.384" "25896976" "Virus research, 204, 13–20." "Doki, T., Takano, T., Koyama, Y., & Hohdatsu, T. (2015)." "Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection" "10.1016/j.virusres.2015.04.011" "Anti-FIPV" "DRAVPe02186" "LFYKYTSLQGLYTYSNLVEL" "20" "I-S1-22" "S1 protein of FIPV" "A0A0C5CJL1" "Experimentally Validated" "12663" "S" "Not Available" "603-622" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIPV" "Coronaviridae" "plaque reduction assay." "[Ref:25896976]FIPV,IC50=~60μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "2415.77" "C116H171N23O33" "ARDCHIMWOU" "L" "6" "1" "1" "0" "22" "18" "0.15" "0.9185" "5.5 hours" "3 min" "2 min" "112" "5960" "2.467" "25896976" "Virus research, 204, 13–20." "Doki, T., Takano, T., Koyama, Y., & Hohdatsu, T. (2015)." "Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection" "10.1016/j.virusres.2015.04.012" "Anti-FIPV" "DRAVPe02187" "VNFSISSVEEYGFWTIAYTN" "20" "I-S1-8" "S1 protein of FIPV" "Q66951" "Experimentally Validated" "11135" "S" "Not Available" "461-480" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIPV" "Coronaviridae" "Plaque-reduction assay" "[Ref:25896976]FIPV,IC50=~50μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "2327.53" "C109H151N23O34" "RDCQQHLKMPOU" "NEI" "3.79" "0" "2" "-2" "22" "18" "0.155" "0.9185" "100 hours" ">20 hour" ">10 hours" "73" "8480" "3.643" "25896976" "Virus research, 204, 13–20." "Doki, T., Takano, T., Koyama, Y., & Hohdatsu, T. (2015)." "Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection" "10.1016/j.virusres.2015.04.013" "Anti-FIPV" "DRAVPe02188" "YTDVMVDVNGTAITRLFYCD" "20" "I-S1-10" "S1 protein of FIPV" "Q66951" "Experimentally Validated" "11135" "S" "Not Available" "481-500" "Not Available" "Not Available" "Not Available" "Not Available" "None" "FIPV" "Coronaviridae" "Plaque-reduction assay" "[Ref:25896976]FIPV,IC50=~60μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "2296.59" "C101H154N24O33S2" "QEHPSWOU" "DTV" "3.93" "1" "3" "-2" "22" "18" "0.315" "0.9185" "2.8 hours" "10 min" "2 min" "87.5" "2980" "1.298" "25896976" "Virus research, 204, 13–20." "Doki, T., Takano, T., Koyama, Y., & Hohdatsu, T. (2015)." "Identification of the peptide derived from S1 domain that inhibits type I and type II feline infectious peritonitis virus infection" "10.1016/j.virusres.2015.04.014" "Anti-FIPV" "DRAVPe02189" "GSHHRHVHSPFV" "12" "Peptide 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IBV" "Coronaviridae" "Plaque-reduction assay" "[Ref:16704119]IBV,IC50=8.3μg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Not given" "Not Available" "1396.53" "C62H89N23O15" "ANDCQEILKMTWYOU" "H" "9.78" "1" "0" "1" "10" "10" "-0.808" "0.988" "30 hours" ">20 hour" ">10 hours" "48.33" "0" "0" "16704119" "Science in China. Series C, Life sciences, 49(2), 158–163." "Peng, B., Chen, H., Tan, Y., Jin, M., Chen, H., & Guo, A. (2006). " "Identification of one peptide which inhibited infectivity of avian infectious bronchitis virus in vitro" "10.1007/s11427-006-0158-7" "Anti-IBV" "DRAVPe02190" "CRPYGYRCDGVINQCCDPYHCTPPLIGICL" "30" "Alstotide As1" "Alstonia scholaris plant" "A0A0S0ZR07" "Experimentally Validated" "52822" "As1" "Not Available" "63-92" "Not Available" "Not Available" "Not Available" "Not Available" "2MM6" "IBV" "Coronaviridae" "Antiviral Activity Assay" "[Ref:26546678]IBV,EC50=35μM" "No hemolysis information or data found in the reference(s) presented in this entry" "Cytotoxicity assay showed that As1 and As3 did not induce significant cytotoxicity in Vero cells at concentrations up to 100 μm" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "S protein" "We first determined the stage(s) in viral replication cycle which alstotides could inhibit using a time of drug addition assay. As1 (50 and 100 μm) was introduced to synchronized infected cells at different time points during preincubation at 4 °C and the infection at 37 °C As1 was identified as a moderate early acting anti-IBV drug, as supported by three lines of evidence. First, the time of drug addition assay revealed a significant drop of activity when As1 was added at 3 hpi, implicating an antiviral mechanism upstream of genomic replication and gene expression. Second, in transfection assay when the genetic material was electroporated into the host cells to bypass the attachment and entry steps, no inhibition over gene replication within 18 hpi was observed. In contrast, parallel As1-treated samples collected at 40 hpi showed a clear inhibition, probably because of inhibitory activity during the early stage of secondary infection. Third, As1 binds to IBV fusion glycoprotein, S protein, which plays a vital role during viral entry by attaching to Vero cell receptors and triggering membrane fusion between enveloped virus and host cells. In this assay, As1 added during attachment (at 4 °C) or entry (after transfer to 37 °C) exhibited comparable positive effects. As1 significantly lost its activity when added during later stages from 3 hpi onward. Comparable intensities of the endogenous control actin bands for both the treated and untreated samples excluded the effect of As1 on cellular protein synthesis, thus suggesting that As1 acts during an early stage of the viral infection." "3373.96" "C145H222N40O41S6" "AEKMFWOU" "C" "6.7" "2" "2" "0" "32" "24" "0.063" "0.9576" "1.2 hours" ">20 hour" ">10 hours" "74.67" "4470" "1.35" "26546678" "The Journal of biological chemistry, 290(52), 31138–31150." "Nguyen, P. Q., Ooi, J. S., Nguyen, N. T., Wang, S., Huang, M., Liu, D. X., & Tam, J. P. (2015). " "Antiviral Cystine Knot α-Amylase Inhibitors from Alstonia scholaris" " 10.1074/jbc.M115.654855" "Anti-IBV" "DRAVPe02191" "CVPRFGRCDGIINOCCDPYLCTPPLVGICT" "30" "Alstotide As3" "Alstonia scholaris plant" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IBV" "Coronaviridae" "Antiviral Activity Assay" "[Ref:26546678]IBV,EC50=55μM" "No hemolysis information or data found in the reference(s) presented in this entry" "Cytotoxicity assay showed that As1 and As3 did not induce significant cytotoxicity in Vero cells at concentrations up to 100 μm" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "S protein" "The putative antiviral mechanism of As1 is through its interference with S protein function during IBV entry." "3367.05" "C146H233N39O40S6" "AEKMFWOU" "C" "5.92" "2" "2" "0" "32" "24" "0.583" "0.9576" "1.2 hours" ">20 hour" ">10 hours" "84.33" "1490" "0.443" "26546678" "The Journal of biological chemistry, 290(52), 31138–31150." "Nguyen, P. Q., Ooi, J. S., Nguyen, N. T., Wang, S., Huang, M., Liu, D. X., & Tam, J. P. (2015). " "Antiviral Cystine Knot α-Amylase Inhibitors from Alstonia scholaris" " 10.1074/jbc.M115.654855" "Anti-IBV" "DRAVPe02192" "SLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE" "39" "HR2" "HR2 region of MHV" "No entry found" "Experimentally Validated" "None " "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MHV" "Coronaviridae" "Cell-cell fusion assay." "[Ref:2885899]MHV,IC90=50μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "No predicted structure available" "Linear" "Free" "Free" "None" "L" "Spike Protein" "Using biological assays, the HR2 peptide was shown to be a potent inhibitor of virus entry into the cell, as well as of cell-cell fusion" "4616.3" "C206H337N51O66S1" "CGHPWOU" "L" "4.71" "5" "7" "-2" "32" "24" "-0.356" "1.1" "1.9 hours" ">20 hours" ">10 hours" "120" "2980" "0.646" "12885899" "Journal of virology, 77(16), 8801–8811." "Bosch, B. J., van der Zee, R., de Haan, C. A., & Rottier, P. J. (2003)." "The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex" "10.1128/jvi.77.16.8801-8811.2003" "Anti-MHV" "DRAVPe01810" "ARLPRKKWK" "9" "C20-Jp-Hp" "Synthetic construct" "None " "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Orthomyxoviridae" "Cytopathic effect inhibition" "[Ref:26952867]IAV:IC50=0.53 ± 0.25ug/ml" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "C20" "Free" "None" "L" "Hemagglutinin protein" "The ARLPR is a sialic acid mimic, the compound was demonstrated to bind the fusogenic region of HA, as indicated by CD spectra registered for the fusion peptide alone or in presence of C20-Jp-Hp" "1182.48" "C55H95N19O10" "NDCQEGHIMFSTYVOU" "K" "12.02" "5" "0" "5" "0" "3" "-1.956" "4.15" "4.4 hours" ">20 hours" ">10 hours" "54.44" "5500" "4.651" "26952867" "Scientific reports, 6, 22790. " "Lin, D., Li, F., Wu, Q., Xie, X., Wu, W., Wu, J., Chen, Q., Liu, S., & He, J. (2016). " "A ""building block"" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities" "10.1038/srep22790" "Anti-HIV" "DRAVPe02329" "YYTRWQGGLRYIRPCG" "16" "eVpeD2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:28574091]EBOV:IC50=9 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Acetylation" "In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration" "L" "VP24" "The macrocyclic peptide eVpeD2 exhibits potent binding to immobilized Zaire Ebola virus VP24, with a dissociation constant (KD) in the single-digit nanomolar range. Studies show that eVpeD2 disrupts the protein-protein interaction between eVP24 and KPNA5, confirmed through assays like the AlphaLISA-based binding assay. This inhibition suggests eVpeD2's potential as a modulator of a crucial interaction in Ebola virus pathogenesis." "1989.28" "C91H133N27O22S1" "ADEFHKMNOSUV" "GRY" "9.78" "3" "0" "3" "9" "3" "-0.906" "2.31" "2.8hours" "10min" "2min" "48.75" "9970" "5.012" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV" "DRAVPe02328" "YIVPWNGGSRLIRNSRCG" "18" "eVpeD1 " "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:28574091]EBOV:IC50=28 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Acetylation" "In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration.)" "L" "VP24" "eVpeD1 works against the Ebola virus by inhibiting the protein-protein interaction (PPI) between the viral protein VP24 and the host protein karyopherin alpha 5 (KPNA5). VP24 interferes with the host's immune response by binding to KPNA5, which is crucial for transporting antiviral signaling proteins into the nucleus. By binding to VP24, eVpeD1 prevents its interaction with KPNA5, thereby restoring the normal function of the immune signaling pathway. This inhibition was demonstrated in vitro using an AlphaLISA-based binding assay, where eVpeD1 disrupted the VP24-KPNA5 interaction. Consequently, eVpeD1 and similar peptides have potential as novel antiviral agents against Ebola virus by targeting and blocking this critical PPI." "2048.35" "C89H142N30O24S1" "ADEFHKMOQTU" "GR" "10.76" "3" "0" "3" "9" "5" "-0.422" "2.2" "2.8hours" "10min" "2min" "81.11" "6990" "3.413" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV" "DRAVPe02326" "RWLRGLLSGLLR" "12" "DFTavP3" "Designed In-silico (Ab-initio) by using database filtering technology" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:35631348]EBOV:IC50:2.5, 5, or 10 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "DFTavP3 likely inhibits Ebola virus infection by targeting specific parameters designed to disrupt viral entry or replication. Its mechanism of action may involve interference with viral attachment, fusion, or replication processes, ultimately reducing viral infectivity. This inhibition could occur through direct interaction with viral components or through modulation of host cell factors essential for viral propagation, leading to decreased viral replication and infection in Vero cells." "1439.77" "C66H114N22O14" "ACDEFHIKMNOPQTUVY" "L" "12.3" "3" "0" "3" "4" "6" "0.25" "1.61" "1hours" "2min" "2min" "162.5" "5500" "3.82" "35631348" " Pharmaceuticals (Basel). 2022;15(5)." "Ripperda T, Yu Y, Verma A, et al." "Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses." "10.3390/ph15050521" "Anti-EBOV" "DRAVPe02327" "GLRCRLGRLLRRLGRCLLR" "19" "DDIP1" "Designed In-silico (Ab-initio) by using database filtering technology" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "Not Available" "The hemolytic activity of DDIP1 was assessed using murine red blood cells, where the HC50 (concentration causing 50% hemolysis) was greater than 160 microM, indicating low hemolytic activity." "[Ref:35631348]DDIP1 was evaluated for its cytotoxicity using various cell lines, including Vero cells and Calu3 cells. The results indicated that DDIP1 had a TC50 (toxic concentration at 50% cell deat" "not Available" "Linear" "Free" "Free" "None" "L" "glycoprotein." " DDIP1, a database-designed inhibitory peptide, against Ebola virus. In experiments using an Ebola virus pseudo-type system, DDIP1 effectively inhibited the entry of pseudo-Ebola virus (VSV-eGP) into Vero cells at an early stage of infection. These findings suggest DDIP1's potential as a novel treatment for Ebola by targeting viral entry." "2280.88" "C96H182N40O20S2" "ADEFHIKMNOPQSTUVWY" "LR" "12.13" "7" "0" "7" "9" "7" "-0.058" "3.4" "30hours" ">20hours" ">10hours" "143.68" "125" "0.055" "35631348" " Pharmaceuticals (Basel). 2022;15(5)." "Ripperda T, Yu Y, Verma A, et al." "Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses." "10.3390/ph15050521" "Anti-EBOV" "DRAVPe02325" "RWLRGLLSGLLRRLLS" "16" "DFTavP2" "Designed In-silico (Ab-initio) by using database filtering technology" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:35631348]EBOV:IC33=5 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "DFTavP2 likely combats the Ebola virus by interacting with viral glycoproteins or host cell receptors, thereby inhibiting viral entry into host cells. It may disrupt viral membranes, compromising the virus's structural integrity and function. The peptide could also interfere with the virus's replication machinery by binding to viral RNA or essential proteins. Overall, these mechanisms highlight DFTavP2's potential in blocking critical stages of the Ebola virus lifecycle" "1909.35" "C87H153N29O19" "ACDEFHIKMNOPQTUVY" "L" "12.48" "4" "0" "4" "6" "8" "0.331" "1.73" "1hours" "2min" "2min" "170.62" "5500" "2.881" "35631348" " Pharmaceuticals (Basel). 2022;15(5)." "Ripperda T, Yu Y, Verma A, et al." "Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses." "10.3390/ph15050521" "Anti-EBOV" "DRAVPe02324" "RWLRGLLSGLLRRLLSGLLL" "20" "DFTavP1" "Designed In-silico (Ab-initio) by using database filtering technology" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:35631348]EBOV:IC50= 2.5 microM" "[Ref:35631348]DFTavP1 displayed hemolytic activity, with an HC50 (the concentration that caused 50% hemolysis) below 12.5 microM. In contrast, DDIP1, another designed peptide, showed a higher HC50 val" "[Ref:35631348]DFTavP1 showed cytotoxic effects on Vero cells, with a TC50 (the peptide concentration that killed 50% of cells) of 2.4 microM. The peptide also exhibited cytotoxicity to Calu3 cells, wi" "Not Available" "Linear" "Free" "Free" "None" "L" "Viral envelopes." "DFTavP1 is a designed peptide that inhibits Ebola virus by blocking viral entry and disrupting viral envelopes, crucial steps in infection. Studies show DFTavP1 and similar peptides effectively inhibit pseudo-Ebola virus (VSV-eGP) in Vero cells, exhibiting dose-responsive inhibition even post-infection." "2305.88" "C107H189N33O23" "ACDEFHIKMNOPQTUVY" "L" "12.48" "4" "0" "4" "6" "11" "0.815" "0.6" "1hours" "2min" "2min" "195" "5500" "2.385" "35631348" " Pharmaceuticals (Basel). 2022;15(5)." "Ripperda T, Yu Y, Verma A, et al." "Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses." "10.3390/ph15050521" "Anti-EBOV" "DRAVPe02323" "SGWIYWAV" "8" "CP3" "Designed In-silico on VEGAZZ software" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:32998394]EBOV:IC50 = 25.8 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Free" "Free" "None" "L" "VP40." "CP3, a cyclic peptide inhibitor, can inhibit Ebola virus budding by preventing the binding of UEV domain proteins to the P6 motif. CP3 forms hydrogen bonds with UEV domain proteins through its Tyr147 and Trp148 residues. Additionally, its Trp145, Tyr147, Ile146, and Trp148 residues engage in nonbonding interactions with UEV domain proteins. These interactions suggest that CP3 effectively disrupts the protein-protein interactions essential for the budding of both Ebola viruses." "981.12" "C50H64N10O11" "CDEFHKLMNOPQRTU" "W" "5.24" "0" "0" "0" "2" "5" "0.775" "-1.6" "1.9hours" ">20hours" ">10hours" "97.5" "12490" "12.37" "32998394" "Polymers (Basel). 2020;12(10)" "Lin WW, Wang YJ, Ko CW, et al" "Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations" "10.3390/polym12102235" "Anti-EBOV" "DRAVPe02322" "SGWIAWNV" "8" "CP2" "Designed In-silico on VEGAZZ software" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:32998394]EBOV:IC50=296.3 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Free" "Free" "None" "L" "VP40." "CP2, a cyclic peptide inhibitor, has a weaker binding affinity for UEV domain proteins compared to CP1. Consequently, CP1 and CP3 are more effective at preventing UEV domain proteins from binding to the P6 motif, thereby inhibiting Ebola virus budding. In contrast, CP2's weaker binding suggests it is less potent in disrupting the necessary protein-protein interactions for virus budding inhibition." "932.05" "C45H61N11O11" "CDEFHKLMOPQRTUY" "W" "5.24" "0" "0" "0" "2" "5" "0.5" "-0.79" "1.9hours" ">20hours" ">10hours" "97.5" "11000" "11.802" "32998394" "Polymers (Basel). 2020;12(10)" "Lin WW, Wang YJ, Ko CW, et al" "Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations" "10.3390/polym12102235" "Anti-EBOV" "DRAVPe02321" "SGWIYWNV" "8" "CP1" "Designed In-silico on VEGAZZ software" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:32998394]EBOV:IC50=48.6 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Free" "Free" "None" "L" "VP40." "The cyclic peptide CP1 works against Ebola virus by inhibiting the binding of the UEV domain protein to the Ebola Vp40 protein. This interference prevents the budding of the Ebola virus, thereby hindering its replication and spread. The specific residues Trp145, Tyr147, and Trp148 of CP1 play essential roles in the interactions between CP1 and the UEV domain protein, contributing to its inhibitory effect. By disrupting these protein-protein interactions crucial for virus budding, CP1 shows promise as a potential therapeutic agent against Ebola virus infections." "1024.14" "C51H65N11O12" "ACDEFHKLMOPQRTU" "W" "5.24" "0" "0" "0" "3" "4" "0.113" "-0.54" "1.9hours" ">20hours" ">10hours" "85" "12490" "12.196" "32998394" "Polymers (Basel). 2020;12(10)" "Lin WW, Wang YJ, Ko CW, et al" "Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations" "10.3390/polym12102235" "Anti-EBOV" "DRAVPe02320" "CTVALPGGYVRVC" "13" "pep42" "Designed In-silico [Pep42 cyclic peptide (CTVALPGGYVRVC) model was built using I-TASSER web server]" "No entry found" "In-Silico" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Cell-surface HSPA5" "Pep42 works against the Ebola virus by selectively targeting cell-surface HSPA5, also known as GRP78, which interacts with viral glycoproteins GP1 and GP2. By disrupting the interaction between HSPA5 and viral glycoproteins, Pep42 potentially inhibits viral entry into host cells, thereby reducing viral infection" "1337.62" "C58H96N16O16S2" "DEFHIKMNOQSUW" "V" "8.06" "1" "0" "1" "5" "5" "1.1" "-0.43" "1.2hours" ">20hours" ">10hours" "104.62" "1615" "1.207" "32291698" "Cell Stress Chaperones. 2020;25(3):541-548" "Elfiky AA, Elfiky AA" "Ebola virus glycoprotein GP1-host cell-surface HSPA5 binding site prediction." "10.1007/s12192-020-01106-z" "Anti-EBOV" "DRAVPe02319" "IGIEDLSKNIKDKIDKIIHDFVDKTLPDQG" "30" "EBOV-8" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:31473342]EBOV:EC50=18.47 plusminus 4.64 microM;EC90=69.49 microM.EBOV-GP EC50=4.02 plusminus 1.13 microM;EBOV-GP EC90=20.22 microM.ma-EBOV EC50=19.80 plusminus 1953 microM;ma-EBOV EC90=142 microM.GP =>GlycoProtein;ma =>Mouse-Adapted" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342]EBOV-8 show cytotoxicity (CC50) at greater than 30 microM.EBOV-5 show cytotoxicity (CC50) at >= 25 microM (when tested for EBOV-GP).EBOV-5 show cytotoxicity (CC50) at >= 44.0 microM (whe" "Not Available" "Cyclic" "cholesterylation" "PEG12" "In the peptide sequence, the cysteine residue at position 31 is modified with a PEG12-cholesterol (PEG12-Chol) moiety" "L" "Glycoprotein." "Exact MoA explicitly not available (EBOV-8 likely inhibits Ebola virus by targeting viral entry and fusion processes. It may interfere with viral glycoproteins, preventing the virus from attaching to and entering host cells. Additionally, EBOV-8 could disrupt the fusion between the viral envelope and host cell membrane, blocking the release of viral genetic material. By targeting these critical steps, the peptide effectively halts infection and viral replication. The specific antiviral mechanisms of EBOV-8 involve interactions with viral proteins essential for these processes. Detailed studies and assays in the full research paper would provide further insights into these mechanisms.)." "3408.9" "C152H251N39O49" "ACMORUWY" "DI" "4.89" "5" "7" "-2" "17" "10" "-0.55" "2.04" "20hours" "30min" ">10hours" "113.67" "None" "None" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02318" "IEPHDWTKNIKDKIDKIIHDFVDKTLPDQG" "30" "EBOV-7" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:31473342]EBOV:EC50=1.90 plusminus 0.28;EC90=9.44 microM.EBOV-GP EC50=0.60 plusminus 0.20 microM;EBOV-GP EC90=6.15 microM.ma-EBOV EC50=0.50 plusminus 0.09 microM;ma-EBOV EC90=3.45 microM.GP =>GlycoProtein;ma =>Mouse-Adapted" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342]EBOV-7 show cytotoxicity (CC50) at greater than 30 microM.EBOV-5 show cytotoxicity (CC50) at >= 25 microM (when tested for EBOV-GP).EBOV-5 show cytotoxicity (CC50) at >= 42.6 microM (whe" "Not Available" "Cyclic" "cholesterylation" "PEG12" "In the peptide sequence, the cysteine residue at position 31 is modified with a PEG4-cholesterol (PEG4-Chol) moiety" "L" "Glycoprotein." "EBOV-7 works against Ebola virus by targeting its entry and replication processes. It likely prevents the virus from binding to host cell receptors or fusing with cellular membranes, thus inhibiting viral entry. The peptide stabilizes an alpha-helical structure, enhancing its ability to interact with viral components critical for these processes. With a potency of 0.5 microM, EBOV-7 effectively disrupts the viral life cycle. In vivo studies in mice have shown that EBOV-7 has robust antiviral activity against Ebola virus, further confirming its efficacy. Overall, EBOV-7 interferes with viral entry and stabilizes essential structures, making it a strong candidate for therapeutic use against Ebola." "3560.02" "C161H252N42O49" "ACMORSUY" "D" "5.37" "5" "7" "-2" "18" "9" "-1" "2.45" "20hours" "30min" ">10hours" "87.67" "5500" "1.545" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02317" "DWTKNIKDKIDKIIHDFVDKTLPDQGC" "26" "EBOV-6" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:31473342]EBOV:EC50=1.90 plusminus 0.39 microM, 3.67 plusminus 0.89 microM, 5.44 plusminus 0.85 microM; EBOV EC90 = 9.84 microM, 15.33 microM, 25.75 microM.EBOV-GP EC50 = 1.82 plusminus 0.55 microM; EBOV-GP EC90 = 29.46 microM.ma-EBOV EC50 = 7.95 plusminus 28.30 microM; ma-EBOV EC90 = 211 microM.GP => GlycoProtein; ma => Mouse-Adapted" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342]EBOV-6 show cytotoxicity (CC50) at greater than 30 microM.EBOV-5 show cytotoxicity (CC50) at >= 25 microM (when tested for EBOV-GP).EBOV-5 show cytotoxicity (CC50) at >= 47.4 microM (whe" "Not Available" "Cyclic" "cholesterylation" "PEG12" "In the peptide sequence, the cysteine residue at position 27 is modified with a PEG4-cholesterol (PEG4-Chol) moiety.)" "L" "Glycoprotein." "EBOV-6 works against the Ebola virus by targeting the fusion process required for the virus to enter host cells. Specifically, it binds to the C-terminal heptad-repeat (HR2) domain of the Ebola virus glycoprotein GP2. This binding disrupts the formation of the fusion complex, a critical structure that facilitates the merging of the viral and host cell membranes. By interfering with this fusion process, EBOV-6 prevents the virus from entering and infecting the host cells. Consequently, this inhibition leads to a reduction in viral replication and spread, making EBOV-6 a potential antiviral agent against Ebola virus infection" "3186.63" "C142H225N37O44S1" "AEMORSUY" "D" "5.46" "5" "6" "-1" "17" "8" "-0.878" "2.44" "1.1hours" "3min" ">10hours" "82.96" "5500" "1.726" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02316" "DWTKNIKDKIDKIIHDFVDKTLPDQG" "26" "EBOV-5" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "N/A" "[Ref:31473342]EBOV:EC₅₀= 3.88 ± 0.67 μM, 3.89 ± 0.61 μM; EBOV EC₉₀=17.27 μM, 16.86 μM; EBOV-GP EC₅₀=2.45 ± 1.09 μM; EBOV-GP EC₉₀= 29.46 μM; ma-EBOV EC₅₀= 2.34 ± 0.69 μM; ma-EBOV EC₉₀=16.2 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342}EBOV:CC₅₀ > 30 μM; EBOV-5 CC₅₀ ≥ 25 μM (EBOV-GP); EBOV-5 CC₅₀ ≥ 51.7 μM (ma-EBOV)." "Not Available" "Cyclic" "cholesterylation" "PEG4 " "In the peptide sequence, the cysteine residue at position 27 is modified with a PEG4-cholesterol (PEG4-Chol) moiety.)" "L" "Glycoprotein." "Exact MoA explicitly not available (may interfere with the binding of the Ebola virus glycoprotein to host cell receptors, thereby preventing viral entry into host cells)." "3083.49" "C139H220N36O43" "ACEMORSUY" "D" "5.46" "5" "6" "-1" "16" "8" "-1.008" "2.58" "1.1hours" "3min" ">10hours" "86.15" "5500" "1.784" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02315" "DWTKNIKDKIDKIIHDFVDK" "20" "EBOV-4" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:31473342]EBOV:EC50 = 6.29 plusminus 0.66 microM, 8.10 plusminus 0.63 microM, 6.67 plusminus 0.89 microM, 9.04 plusminus 1.23 microM; EC90 = 19.41 microM, 24.79 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342]EBOV-4 show cytotoxicity (CC50) at greater than 30 microM." "Not Available" "Cyclic" "cholesterylation" "PEG4 " "In the peptide sequence, the cysteine residue at position 21 is modified with a PEG4-cholesterol (PEG4-Chol) moiety." "L" "Glycoprotein." "Exact MoA explicitly not available (may interfere with the binding of the Ebola virus glycoprotein to host cell receptors, thereby preventing viral entry into host cells)." "2471.84" "C113H179N29O33" "ACEGLMOPQRSUY" "DK" "6.75" "5" "5" "0" "13" "7" "-1.015" "2.8" "1.1hours" "3min" ">10hours" "92.5" "5500" "2.225" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02314" "IEPHDWTKNITDKIDQIIHDFVDKTLPDQG" "30" "EBOV-3" "Cholesterol-conjugated synthetic peptide" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:31473342]EBOV:EC50 = 12.89 plusminus 1.59 microM, 11.94 plusminus 2.59 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:31473342]EBOV-3 show cytotoxicity (CC50) at greater than 30 microM." "Not Available" "Cyclic" "cholesterylation" "PEG4 " "In the peptide sequence, the cysteine residue at position 31 is modified with a PEG4-cholesterol (PEG4-Chol) moiety." "L" "Glycoprotein." "EBOV-3 is an elongated peptide with five residues downstream of the helical domain. This modification likely contributes to the peptide's potency in inhibiting EBOV infection. By targeting specific regions of the EBOV glycoprotein, EBOV-3 interferes with viral entry and replication processes, ultimately inhibiting the virus's ability to infect host cells" "3532.91" "C158H243N41O51" "ACMORSUY" "D" "4.52" "3" "7" "-4" "18" "9" "-0.88" "2.35" "20hours" "30min" ">10hours" "87.67" "5500" "1.557" "31473342" "Antiviral Res. 2019;171:104592. " "Pessi A, Bixler SL, Soloveva V, et al" "Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo" "10.1016/j.antiviral.2019.104592" "Anti-EBOV" "DRAVPe02313" "SGSWNFFDWFSGLMSWFGGPL" "21" " RVFV-10" " Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21401" "Experimentally Validated" "11588" "GP" "Not Available" "1137-1157" "Not Available" "Not Available" "Not Available" "Not Available" "6EGT" "EBOV" "Filoviridae" "Not Available" "[Ref:24069485]EBOV:IC50=50 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "DII domain of the E protein (RVFV-10 may interact with a specific region of the Ebola virus (EBOV) d" "RVFV-10, a fusion-inhibiting peptide derived from the RVFV Gc stem region, displayed inhibitory effects against Ebola virus (EBOV) in a plaque-reduction assay, albeit less effectively than RVFV-6. Despite demonstrating weaker inhibition compared to RVFV-6, RVFV-10's efficacy against EBOV prompted further evaluation, ultimately leading to the selection of RVFV-6 for subsequent studies due to its superior inhibitory activity." "2425.7" "C119H149N25O29S1" "ACEHIKOQRTUVY" "FGS" "3.8" "0" "1" "-1" "6" "10" "0.219" "-0.28" "1.9hours" ">20hours" ">10hours" "37.14" "16500" "6.802" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR" "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02312" "YGRKKRRQRRRGSGIEPHDWTKNITCKIOQIIHDFVDK" "38" "5-Link" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC50=15 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]Vero cells incubated with concentrations of 5-Link exceeding 15 microM showed signs of toxicity by visual inspection, which prevented assessment of antiviral activity at higher concentra" "Not Available" "Linear" "Free" "Acetylation" "The peptide sequence features N-terminal acetylation (Ac-), which enhances stability by protecting it from enzymatic degradation and making it more resistant to proteolysis. To further enhance the peptide's structure and function, alpha-helical stabilization can be introduced through covalent side chain-side chain cross-links. This is achieved by linking Cys at position 26 (C) with another suitable residue i.e., Ornithine (Orn) Ornithine (Orn) at position 29 (i.e., i and i+3). These cross-links " "L" "Glycoprotein." "5-Link displayed antiviral activity against vesicular stomatitis virus particles containing the Ebola virus glycoprotein (VSV-GP), inhibiting infection at concentrations below 15 microM. It exhibited broad antiviral activity against both VSV-GP and VSV-G at lower concentrations, but induced toxicity in Vero cells at concentrations exceeding 15 microM, limiting further assessment. The peptide's specificity towards VSV-GP over VSV-G suggests a mechanism involving interference with viral entry, similar to its action against VSV-GP particles, thereby inhibiting Ebola virus infection. This indicates 5-Link's potential as a therapeutic agent targeting viral entry mediated by the Ebola virus glycoprotein." "4774.54" "C210H343N71O55S1" "ALMU" "R" "10.6" "11" "4" "7" "25" "8" "-1.384" "None" "2.8hours" "10min" "2min" "58.95" "6990" "1.464" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." "Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02311" "YGRKKRRQRRRGSGIEPHDWTKCITOKIDQIIHDFVDK" "38" "4-Link" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC50=40 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]Non-toxic (At 40 microM concentration, peptide 4-Link demonstrated good tolerance by Vero cells, as evaluated through visual examination and a commercial viability assay. At the same con" "Not Available" "Linear" "Free" "Acetylation" "In the peptide sequence, N-terminal acetylation (Ac-) blocks the free amine group, protecting the peptide from exopeptidase degradation and increasing stability. To promote an alpha-helical conformation, side chain-side chain cross-links were introduced, particularly between Cys (C) at position 23 and an Ornithine (O) residue replacing Lys (K), positioned for cross-linking (at i and i + 3). These modifications help stabilize the helical structure, especially in regions predisposed to alpha-helix" "L" "Glycoprotein." "Peptide 4-Link demonstrated strong neutralization of vesicular stomatitis virus particles carrying the Ebola virus glycoprotein (VSV-GP), resulting in a notable decrease in infection at a concentration of 40 microM. Its effectiveness against Ebola virus was evaluated by measuring the reduction in infection events induced by VSV-GP in its presence. Additionally, 4-Link displayed inhibitory effects on VSV particles bearing their native glycoprotein G (VSV-G), a lesser extent than VSV-GP, suggesting a degree of specificity towards the Ebola virus glycoprotein. These findings suggest that 4-Link likely targets the viral entry process common to both viruses, with a higher affinity for the Ebola virus glycoprotein, thereby inhibiting infection." "4775.52" "C210H342N70O56S1" "ALMNU" "R" "10.28" "11" "5" "6" "25" "8" "-1.384" "None" "2.8hours" "10min" "2min" "58.95" "6990" "1.464" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." "Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02310" "KKKKGSGC" "8" "3-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC90=20 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]Exceeding 15 microM, concentrations of 3-Chol caused observable toxicity in Vero cells, hindering the evaluation of its antiviral activity at higher doses." "Not Available" "Linear" "cholesterylation" "Free" "In the peptide sequence, the cysteine residue at position 8 is modified with a cholesterol (Chol) moiety. HIV-1 C-peptide conjugated to cholesterol contain covalent side chain-side chain crosslinks to promote an alpha-helical conformation. The cholesterol-conjugated C-peptides proved to be potent inhibitors of Ebola virus glycoprotein (GP)-mediated cell entry (~10^3-fold reduction in infection at 40 microM" "L" "Glycoprotein." "3-Chol, comprising a tetralysine segment linked to cholesterol, effectively inhibits both VSV-GP and VSV-G viral entry, with over 90% inhibition at higher concentrations. Despite lacking the GP CHR sequence, its activity against VSV-GP suggests a potential dependency on the native C-heptad repeat sequence. The study underscores the non-specific inhibitory role of cholesterol-conjugated peptides like 3-Chol against VSV-GP entry, implicating a mechanism involving both peptide and cholesterol components in inhibiting Ebola virus glycoprotein-mediated cell entry." "835.03" "C34H66N12O10S1" "ADEFHILMNOPQRTUVWY" "K" "10.04" "4" "0" "4" "6" "0" "-1.837" "2.8" "1.3 hours" "3min" "3min" "0" "0" "0" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." "Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02309" "IEPHDWTKNITDKIDQIIHDFVDKGSGKKKKC" "32" "2-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC50=40 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]2-Chol showed only modest cell toxicity under certain conditions (see MoA)." "Not Available" "Linear" "cholesterylation" "Free" "In the peptide sequence, the cysteine residue at position 32 is modified with a cholesterol (Chol) moiety. HIV-1 C-peptide conjugated to cholesterol contain covalent side chain-side chain crosslinks to promote an alpha-helical conformation. The cholesterol-conjugated C-peptides proved to be potent inhibitors of Ebola virus glycoprotein (GP)-mediated cell entry (~10^3-fold reduction in infection at 40 microM" "L" "Glycoprotein." "2-Chol was evaluated for its effectiveness against Ebola virus. The assay involved assessing the capacity of 2-Chol to inhibit GP-mediated viral entry using a vesicular stomatitis virus particle bearing the Ebola virus GP (VSV-GP) in place of the native glycoprotein G. The primary infection events were quantified by fluorescence confocal microscopy. Results showed that 2-Chol resulted in potent inhibition of VSV-GP entry, with approximately a 10^3-fold reduction in infection at 40 microM peptide concentrations. This level of inhibition was significantly higher than previously reported VSV-GP inhibition by Tat-Ebo at higher peptide concentrations. Notably, 2-Chol also exhibited potent activity for inhibiting VSV bearing its native envelope glycoprotein G (VSV-G), with over 90% reduction at 10 microM peptide concentration and more than 99% reduction at higher concentrations. Importantly, 2-Chol showed only modest cell toxicity under these conditions . Therefore, 2-Chol demonstrated potent inhibition of Ebola virus glycoprotein-mediated cell entry, suggesting a non-specific mechanism of neutralization that may involve a combination of peptide and cholesterol moieties." "3738.28" "C166H266N46O50S1" "ALMORUY" "K" "8.12" "7" "6" "1" "21" "8" "-1.1" "2.56" "20hours" "30min" ">10hours" "70" "5500" "1.471" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." "Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02308" "KKKKGSGIEPHDWTKNITDKIDQIIHDFVDK" "32" "1-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC50=50 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]At certain concentrations, 1-Chol, a cholesterol-conjugated peptide inhibitor, demonstrates only a slight cell toxicity of approximately 20%, indicating a low level of toxicity within th" "Not Available" "Linear" "cholesterylation" "Free" "In the peptide sequence, the cysteine residue at position 1 is modified with a cholesterol (Chol) moiety. This HIV-1 C-peptide conjugated to cholesterol contain covalent side chain-side chain crosslinks to promote an alpha-helical conformation. The cholesterol-conjugated C-peptides proved to be potent inhibitors of Ebola virus glycoprotein (GP)-mediated cell entry (~10^3-fold reduction in infection at 40 microM)" "L" "Glycoprotein." "1-Chol, a cholesterol-conjugated C-peptide inhibitor, disrupts Ebola virus cell entry by targeting the glycoprotein-mediated fusion process. Specifically, it binds to the GP2 C-heptad repeat region (CHR), hindering the formation of the six-helix bundle crucial for membrane fusion. Effective at a concentration of 40 microM, 1-Chol's cholesterol conjugation enhances its alpha-helical structure independently of concentration, contributing to its broad inhibitory activity against Ebola virus. The combined peptide and cholesterol components of 1-Chol play a vital role in its inhibition of viral entry" "3635.14" "C163H261N45O49" "ACLMORUY" "K" "8.32" "7" "6" "1" "20" "8" "-1.216" "2.69" "1.3 hours" "3min" "3min" "72.26" "5500" "1.513" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." " Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking." "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02307" "YGRKKRRQRRRGSGIEPHDWTKNITDKIDQIIHDFVDK" "38" "Tat-Ebo" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Not Available" "[Ref:23962564]EBOV:IC50=75 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23962564]Low cytotoxicity (cytotoxicity assays indicated that Tat-Ebo was well tolerated by Vero cells at concentrations up to 75 microM)." "Not Available" "Linear" "Free" "Free" "None" "L" "Viral membrane." " Tat-Ebo, a peptide combining HIV-1 Tat Arg-rich sequence with Ebola virus GP2 residues 610 - 633, combats Ebola virus within cells. It impedes viral membrane fusion by binding to a GP2 fusion intermediate, particularly targeting the extended conformation during fusion. Tat-Ebo enhances its antiviral efficacy by promoting internalization into cells and accumulating in endosomes. Its mode of action involves sequestering the extended intermediate, crucial for its effectiveness. Tat-Ebo's specificity lies in inhibiting filovirus GP proteins, including various strains, through sequestration. Demonstrating broad-spectrum inhibition, it effectively hampers infection mediated by diverse Ebola virus strains." "4664.27" "C203H329N69O58" "ACLMOU" "R" "10.27" "11" "6" "5" "26" "8" "-1.634" "4.38" "2.8hours" "10min" "2min" "58.95" "6990" "1.499" "21454542## 23962564" "J Biol Chem. 2011;286(18):15854-61;##Bioorg Med Chem Lett. 2013;23(19):5356-60." "Miller EH, Harrison JS, Radoshitzky SR;##Higgins CD, Koellhoffer JF, Chandran K," "Inhibition of Ebola virus entry by a C-peptide targeted to endosomes;##C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1074/jbc.M110.207084;##10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02305" "FFGSVLKLIPKIL" "13" "Temporin-PTa" "Hylarana picturata, Asia" "P0C8U2" "Experimentally Validated" "395594" "Temporin-Pta(protein)" "Not Available" "1 to 13" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Antiviral Activity Assay" "[Ref:30669255]HIV-1:EC50=0.63 uM,Tb inhibited viral replication at 5 μM,HSV-1:EC50=40 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:30669255]Tb was tested at concentrations ranging from 5 (7 µg/mL) to 60 µM (84 µg/mL) [21]. Significant cytotoxicity was only observed at the highest concentration used (60 μM) with a cell viabil" "Linear" "Free" "Free" "None" "L" "Membrane" "Inhibit Viral replication" "1474.89" "C75H123N15O15" "ACDEHMNOQRTUWY" "L" "10" "2" "0" "2" "3" "8" "1.508" "-1.61" "1.1hours" "3min" "2min" "172.31" "0" "0" "30669255" "Viruses, 11(1), 77." "Roy, M., Lebeau, L., Chessa, C., Damour, A., Ladram, A., Oury, B., Boutolleau, D., Bodet, C., & Lévêque, N. (2019)." "Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1" "10.3390/v11010077" "Anti-HIV" "DRAVPe02306" "QKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK" "36" "TEWP" "Red sea turtle Caretta caretta" "P0CAP0" "Experimentally Validated" "8467" "TEWP" "Not Available" "1-36" "Not Available" "Not Available" "Not Available" "Not Available" "None" "CHAV" "Rhabdoviridae" "Viral Inhibition Assays" "[Ref:16700051]CHAV:IC50=10^5mM.Viral infection leads to shrinkage of cell volume by about 80% and addition of TEWP leads to recovery of the cell volume" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Pyroglutamatation" "Carboxylation" "The N-terminal Q is pyroglutamate. There are three disulfide bonds: C1-C6; C2-C5; C3-C4, different from those of the vertebrate beta-defensins." "L" "Not Found" "Antiviral action may occur because of inhibition of viral replication and/or transcription" "4079.99" "C177H297N53O45S6" "ADFMOSUW" "K" "9.54" "9" "1" "8" "23" "6" "-0.608" "1.67" "0.8hours" "10min" "10hours" "56.67" "3355" "0.822" "16700051" "Proteins, 64(2), 524–531." "Chattopadhyay, S., Sinha, N. K., Banerjee, S., Roy, D., Chattopadhyay, D., & Roy, S. (2006)." "Small cationic protein from a marine turtle has beta-defensin-like fold and antibacterial and antiviral activity" "10.1002/prot.20963" "Anti-CHAV" "DRAVPe02304" "GMKCKFCCNCCNLNGCGVCCRF" "22" "SmHep2P" "Turbot, Scophthalmus maximus" "Q5CAP7##Q5CAJ5" "Experimentally Validated" "52904" "thp,TAPP" "Not Available" "52-73" "Not Available" "Not Available" "Not Available" "Not Available" "None" "MV" "Paramyxoviridae" "Antiviral Assay" "[Ref:24647314]Significantly inhibit the megalocytivirus" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" "These peptides inhibit viral propagation by disruption of the viral envelope and/or capsid" "2406.97" "C94H152N30O26S9" "ADEHIOPQSTUWY" "C" "8.53" "3" "0" "3" "14" "5" "0.523" "0.7" "30hours" ">20hours" ">10hours" "30.91" "500" "0.208" "24647314" "Fish & shellfish immunology, 38(1), 127–134." "Zhang, J., Yu, L. P., Li, M. F., & Sun, L. (2014)." "Turbot (Scophthalmus maximus) hepcidin-1 and hepcidin-2 possess antimicrobial activity and promote resistance against bacterial and viral infection" "10.1016/j.fsi.2014.03.011" "Anti-MV" "DRAVPe02303" "QSHISLCRWCCNCCKANKGCGFCCKF" "26" "SmHep1P" "Turbot, Scophthalmus maximus" "Q52PA0" "Experimentally Validated" "52904" "hamp" "AAX92670.1" "65-90" "Not Available" "CM023543.1" "mRNA" "Primary_assembly 1: 14,423,721-14,424,529 forward strand." "None" "MV" "Paramyxoviridae" "Antiviral Assay" "[Ref:24647314]Significantly inhibit the megalocytivirus" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" "These peptides inhibit viral propagation by disruption of the viral envelope and/or capsid" "2943.54" "C121H188N38O32S8" "DEMOPTUVY" "C" "8.75" "4" "0" "4" "18" "6" "0.096" "1.14" "0.8hours" "10min" "10hours" "33.85" "6000" "2.038" "24647314" "Fish & shellfish immunology, 38(1), 127–134." "Zhang, J., Yu, L. P., Li, M. F., & Sun, L. (2014)." "Turbot (Scophthalmus maximus) hepcidin-1 and hepcidin-2 possess antimicrobial activity and promote resistance against bacterial and viral infection" "10.1016/j.fsi.2014.03.011" "Anti-MV" "DRAVPe02302" "CLGIGSCNDFAGCGYAIVCFW" "21" "Siamycin II" "Streptomyces strains AA3891" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "Antiviral Assay" "[Ref:7787424]Active against HIV-1 virus (replication inhibitor)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Cyclic" "Amidation" "Free" "It differs from Siamycin I only by one amino acid. Siamycin I has a valine residue at position 4. In both peptides, disulfide bonds link Cys1 with Cys13 and Cys7 with Cys19, and the side chain of Asp9 forms an amide bond with the N-terminus (XXJ)." "L" "Not Found" "These peptides act by preventing oligomerization of the HIV transmembrane glycoprotein gp41, or by interfering with interactions between gp41 and the envelope glycoprotein gp120, the cell membrane or membrane-bound proteins.binding siamycin II or siamycin I may play a crucial role in blocking interactions between HIV and the T-cell surface, an essential step in the fusion process." "2199.56" "C98H139N23O27S4" "EHKMOPQRTU" "CG" "3.8" "0" "1" "-1" "8" "9" "1.171" "-0.98" "1.2hours" ">20hours" ">10hours" "79.05" "7240" "3.292" "7787424" "ournal of biomolecular NMR, 5(3), 271–286. " "Constantine, K. L., Friedrichs, M. S., Detlefsen, D., Nishio, M., Tsunakawa, M., Furumai, T., Ohkuma, H., Oki, T., Hill, S., & Bruccoleri, R. E. (1995)." "High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion" "10.1007/BF00211754" "Anti-HIV" "DRAVPe02301" "CLGVGSCNDFAGCGYAVVCFW" "21" "Siamycin I" "Streptomyces strain AA6532" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1,HIV-2" "Retroviridae" "Antiviral Assay" "[Ref:8787894]HIV-1 RF (CEM-SS, CPE XTT) ED₅₀ = 0.35 ± 0.26 mM, HIV-1 IIIB (CEM-SS, CPE XTT) ED₅₀ = 0.6 ± 0.10 mM, HIV-2 CBL-20 (CEM-SS, CPE XTT) ED₅₀ = 0.45 ± 0.25 mM, HIV RF (MT-2, p24) ED₅₀ = 0.05 ± 0.02 mM, HIV-1 NL4-3 (MT-2, p24) ED₅₀ = 0.26 ± 0.29 mM, HIV-1 Y181C/NL4-3 (MT-2, p24) ED₅₀ = 0.16 ± 0.09 mM, HIV-1 A71T/V82A/NL4-3 (MT-2, p24) ED₅₀ = 0.45 ± 0.22 mM, HIV-1 A018A (MT-2, p24) ED₅₀ = 0.89 ± 0.09 mM, HIV-1 A018C (MT-2, p24) ED₅₀ = 0.89 ± 0.12 mM, SIV mac 251 (MT-2, p24) ED₅₀ = 3.2 ± 0.48 mM, HIV-1 008-PRE-D4T SI (1) (PBMC, p24) ED₅₀ = 4.3 ± 1.9 mM, HIV-1 008-POST-D4T SI (111) (PBMC, p24) ED₅₀ = 5.7 ± 2.1 mM, HIV-1 002-PRE-D4T NSI (PBMC, p24) ED₅₀ = 3.6 ± 0.9 mM, HIV-1 002-POST-D4T SI (1/2) (PBMC, p24) ED₅₀ = 2.0 ± 1.1 mM." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Cyclic" "Amidation" "Free" " disulfide bonds link Cys1 with Cys13 and Cys7 with Cys19" "L" "Not Found" "Siamycin I acts as an HIV fusion inhibitor, specifically inhibiting the fusion between the HIV-1 gp160 envelope glycoprotein and CD4-expressing cells. It disrupts syncytium formation (fusion of infected cells with uninfected ones), which is a hallmark of HIV cytopathicity.In fusion assays, siamycin I at 0.08 µM reduced syncytium formation by 50% in a 4-hour coculture of HIV-1 RF-infected cells with uninfected T cells. It showed minimal effect on non-HIV fusion processes, indicating retrovirus-specific fusion inhibition." "2171.51" "C96H135N23O27S4" "EHIKMOPQRTU" "CG" "3.8" "0" "1" "-1" "8" "9" "1.143" "-0.9" "1.2hours" ">20hours" ">10hours" "69.52" "7240" "3.334" "8557614" "The Journal of antibiotics, 48(12), 1515–1517." "Detlefsen, D. J., Hill, S. E., Volk, K. J., Klohr, S. E., Tsunakawa, M., Furumai, T., Lin, P. F., Nishio, M., Kawano, K., & Oki, T. (1995)" "Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I" "10.7164/antibiotics.48.1515" "Anti-HIV" "DRAVPe02300" "KTCENLADTY" "10" "Sesquin" "Seeds, Vigna sesquipedalis, ground beans." "P84868" "Experimentally Validated" "138955" "Not Available" "Not Available" "1 to 10" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV reverse transcriptase inhibitory activity Assay " "[Ref:15949629]HIV-1:(% inhibition at 50 μM) = 35 ± 3%,(% inhibition at 100 μM) = 45 ± 5%,(% inhibition at 200 μM) = 61 ± 2%." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" "it inhibits HIV-1 reverse transcriptase." "1157.26" "C48H76N12O19S1" "FGHIMOPQRSUVW" "T" "4.37" "1" "2" "-1" "8" "2" "-0.9" "2.49" "1.3 hours" "3min" "3min" "49" "1490" "1.288" "15949629" " Peptides, 26(7), 1120–1126." "Wong, J. H., & Ng, T. B. (2005). " "Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase" "10.1016/j.peptides.2005.01.003" "Anti-HIV" "DRAVPe02299" "NPAGCRFCCGCCPNMIGCGVCCRF" "24" "SA-hepcidin2" "Liver, spotted scat, Scatophagus argus" "A0A142LQX2" "Experimentally Validated" "None" "Hepcidin(protein)" "Not Available" "65-88" "Not Available" "Not Available" "Not Available" "Not Available" "None" "SCRV, MsReV" "Rhabdoviridae " "Antiviral Assay" "[ReF:26845697]SCRV:IC50: 50 μM,MsReV:Ic50=25 μM,SA-hepcidin2 showed a dose-dependent protective effect against SCRV and MsReV.CPE in GCF and EPC monolayers after co-treatment with SA-hepcidins (50 μM) and virus (0.1TCID50)" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" "direct effects on the virion and effects on the innate and adaptive immunity of target cells " "2515.07" "C99H156N32O27S9" "DEHKLOQSTUWY" "C" "8.23" "2" "0" "2" "12" "6" "0.717" "0.41" "1.4hours" "3min" ">10hours" "32.5" "500" "0.199" "26845697" "Fish & shellfish immunology, 50, 191–199." "Gui, L., Zhang, P., Zhang, Q., & Zhang, J. (2016). " "Two hepcidins from spotted scat (Scatophagus argus) possess antibacterial and antiviral functions in vitro" "10.1016/j.fsi.2016.01.038" "Anti-SCRV, Anti-MsReV" "DRAVPe02298" "IIIQYEGHKH" "10" "Rondonin" "Haemolymph, Eurypelma californicum and Acanthoscurria gomesiana;" "B3EWP8" "Experimentally Validated" "1211104" "Rondonin(protein)" "Not Available" "1 to 10" "Not Available" "Not Available" "Not Available" "Not Available" "None" "McV, IAV, EMCV" "Orthomyxoviridae" "Antiviral Activity Assay" "[Ref:34254458]McV: Rondonin inhibited ½ dilution of the virus (MDCK, titer 1/256); H1N1: Rondonin inhibited 1/64 dilution (Vero Cells); Rondonin (6 µg) inhibited viral mRNA completely at 7.5 ng." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:34254458]Not cytotoxic against mammalian cells" "Linear" "Free" "Free" "None" "L" "Not Found" "the mechanism of action of this peptide probably involves internal components of the microorganisms. With these results of the RNA virus test, enveloped or not, we verified the protection of the cells, avoiding viral replication. At higher concentrations of rondonin, complete blocked of the DNA was observed, showing that the DNA was aggregated by rondonin" "1237.42" "C57H88N16O15" "ACDFLMNOPRSTUVW" "I" "6.92" "1" "1" "0" "6" "3" "-0.55" "1.16" "20hours" "30min" ">10hours" "117" "1490" "1.204" "34254458" "FEBS open bio, 11(9), 2541–2559." "Riciluca, K. C. T., Oliveira, U. C., Mendonça, R. Z., Bozelli Junior, J. C., Schreier, S., & da Silva Junior, P. I. (2021)." "Rondonin: antimicrobial properties and mechanism of action" " 10.1002/2211-5463.13253" "Anti-McV,Anti-IAV,Anti-EMCV" "DRAVPe02297" "RICRCICGRRICRCICGR" "18" "Retrocyclin-3" "Derived from a silent gene (pre-stop)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Luciferase Assay" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Cyclic" "Free" "Free" "three intramolecular disulfide bonds" "L" "Not Found" " It binds to gp120 and CD4, thereby inhibiting HIV entry." "2140.71" "C82H154N36O19S6" "ADEFHKLMNOPQSTUVWY" "CR" "9.69" "6" "0" "6" "12" "4" "0.289" "3.34" "1hours" "2min" "2min" "86.67" "375" "0.175" "15210812" "Journal of immunology (Baltimore, Md. : 1950), 173(1), 515–520." "Wang, W., Owen, S. M., Rudolph, D. L., Cole, A. M., Hong, T., Waring, A. J., Lal, R. B., & Lehrer, R. I. (2004)." "Activity of alpha- and theta-defensins against primary isolates of HIV-1" "10.4049/jimmunol.173.1.515" "Anti-HIV" "DRAVPe02296" "VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR" "33" "NP-1" "Oryctolagus cuniculus (Rabbit)" "P01376" "Experimentally Validated" "9986" "Corticostatin-3(protein)" "AAA31387.1" "63-95" "Not Available" "M28883" "mRNA" "Scaffold GL018713: 117,470-184,536 forward strand" "None" "HSV-2" "Herpesviridae" "Antiviral Assay" "[Ref:12543649] HSV-2:IC50= 98.7% ± 0.7%. NP-1 inhibited ∼90% of viral infection when added at t = 0 h.reduced viral infection by only 15% ± 8.3%.NP-1 reduced the number of plaques by 59.0% ± 16.6% compared to control acetic acid buffer" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:12543649]No cytotoxic effect was observed even after 20 h of exposure to NP-1 at the concentration of 25 or 100 μg/ml" "Linear" "Free" "Free" "None" "L" "Membrane" "NP-1 followed by extensive washing still partially inhibits infection suggests that the defensin may interact with or persist locally on cell surfaces.NP-1,prevents VP16 from being translocated to the nucleus, suggesting that NP-1 blocks viral entry." "3897.79" "C161H283N65O36S6" "DKMNOQSTUWY" "R" "11.4" "10" "1" "9" "18" "11" "-0.112" "3.33" "100hours" ">20hours" ">10hours" "85.76" "375" "0.096" "12543649" "Antimicrobial agents and chemotherapy, 47(2), 494–500" "Sinha, S., Cheshenko, N., Lehrer, R. I., & Herold, B. C. (2003)." "NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2." "10.1128/AAC.47.2.494-500.2003" "Anti-HSV" "DRAVPe02295" "YFKSVRTGLRYVYCS" "15" "eVpeL2 " "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "inhibitory Assay" "[Ref:28574091]EBOV:IC50 = 37 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Acetylation" "In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration" "L" "VP24" "eVpeL2 exhibit inhibitory activity against the protein-protein interaction (PPI) of VP24 and KPNA5." "1842.15" "C85H128N22O22S1" "ADEHIMNOPQUW" "Y" "9.63" "3" "0" "3" "10" "4" "-0.133" "1.79" "2.8hours" "10min" "2min" "64.67" "4470" "2.427" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV" "DRAVPe02293" "YYSSRWNHGHFTPCS" "15" " eVpeL1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "inhibitory Assay" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Acetylation" "Amination" "In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration" "L" "VP24" "Exact MoA not known (eVpeL1, a macrocyclic peptide belonging to the GL1 group from the LY-library, was found to be a poor binder to the immobilized eVP24 compared to other peptides like eVpeD1 and eVpeD2)." "1841.98" "C83H108N24O23S1" "ADEIKLMOQUV" "S" "8.21" "1" "0" "1" "11" "2" "-1.18" "2.42" "2.8hours" "10min" "2min" "0" "8480" "4.604" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV" "DRAVPe02294" "YGRKKRRQRRRGSGIEPHDWTKNITDKIDQIIHDFVDK" "38" "Tat-Ebo" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref: 23962564]EBOV:IC50=75 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 23962564]Low cytotoxicity (cytotoxicity assays indicated that Tat-Ebo was well tolerated by Vero cells at concentrations up to 75 microM)." "Not Available" "Linear" "Free" "Free" "None" "L" "Viral membrane." " Tat-Ebo, a peptide combining HIV-1 Tat Arg-rich sequence with Ebola virus GP2 residues 610 - 633, combats Ebola virus within cells. It impedes viral membrane fusion by binding to a GP2 fusion intermediate, particularly targeting the extended conformation during fusion. Tat-Ebo enhances its antiviral efficacy by promoting internalization into cells and accumulating in endosomes. Its mode of action involves sequestering the extended intermediate, crucial for its effectiveness. Tat-Ebo's specificity lies in inhibiting filovirus GP proteins, including various strains, through sequestration. Demonstrating broad-spectrum inhibition, it effectively hampers infection mediated by diverse Ebola virus strains." "4664.27" "C203H329N69O58" "ACLMOU" "R" "10.27" "11" "6" "5" "26" "8" "-1.634" "4.38" "2.8hours" "10min" "2min" "58.95" "6990" "1.499" "21454542;## 23962564" "J Biol Chem. 2011;286(18):15854-61;##Bioorg Med Chem Lett. 2013;23(19):5356-60." "Miller EH, Harrison JS, Radoshitzky SR;##Higgins CD, Koellhoffer JF, Chandran K," "Inhibition of Ebola virus entry by a C-peptide targeted to endosomes;##C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking" "10.1074/jbc.M110.207084;##10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02292" "RGGRLCYCRRRFCICV" "16" "Protegrin 2" "Leukocytes; porcine neutrophil, pig,S. scrofa" "P32195" "Experimentally Validated" "9823" "NPG2" "Not Available" "131-146" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1,HSV-2.SARS-CoV-2" "Herpesviridae" "BRET-based assay" "[Ref:37576748]SARS-CoV-2:IC50 values of 0.83 ± 0.07 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "Disulfide bridge formation was performed on crude peptides." "L" "Not Found" "Not Available" "1961.42" "C81H137N31O18S4" "ADEHKMNOPQSTUW" "R" "9.88" "5" "0" "5" "10" "4" "0.044" "3.18" "1hours" "2min" "2min" "66.88" "1740" "0.887" "8647100##37576748" "Chem Pharm Bull (Tokyo). 1995 May;43(5):853-858##Computational and structural biotechnology journal, 21, 3665–3671." "Tamamura H, Murakami T, Horiuchi S, Sugihara K, Otaka A, Takada W, Ibuka T, Waki M, Yamamoto N, Fujii N##Jan, Z., Geethakumari, A. M., Biswas, K. H., & Jithesh, P. V. (2023)" "Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity##Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro" " 10.1111/j.1432-1033.1996.0575p.x## 10.1016/j.csbj.2023.07.020" "Anti-HSV" "DRAVPe02291" "KKKKGSGIEPHDWTKNITDKIDQIIHDFVDK" "32" "1-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:23962564] Inhibition concentraion = 50 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "cholesterylation" "Free" "In the peptide sequence, the cysteine residue at position 1 is modified with a cholesterol (Chol) moiety. This HIV-1 C-peptide conjugated to cholesterol contain covalent side chain-side chain crosslinks to promote an alpha-helical conformation. The cholesterol-conjugated C-peptides proved to be potent inhibitors of Ebola virus glycoprotein (GP)-mediated cell entry (~10^3-fold reduction in infection at 40 microM)" "L" "Glycoprotein." "1-Chol, a cholesterol-conjugated C-peptide inhibitor, disrupts Ebola virus cell entry by targeting the glycoprotein-mediated fusion process. Specifically, it binds to the GP2 C-heptad repeat region (CHR), hindering the formation of the six-helix bundle crucial for membrane fusion. Effective at a concentration of 40 microM, 1-Chol's cholesterol conjugation enhances its alpha-helical structure independently of concentration, contributing to its broad inhibitory activity against Ebola virus. The combined peptide and cholesterol components of 1-Chol play a vital role in its inhibition of viral entry" "3635.14" "C163H261N45O49" "ACLMORUY" "K" "8.32" "7" "6" "1" "20" "8" "-1.216" "2.69" "1.3 hours" "3min" "3min" "72.26" "5500" "1.513" "23962564" "Bioorg Med Chem Lett. 2013;23(19):5356-60." " Higgins CD, Koellhoffer JF, Chandran K" "C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking." "10.1016/j.bmcl.2013.07.056" "Anti-EBOV" "DRAVPe02290" "LTTKLWSSWGYYLGKKARWNLKHPYVQF" "28" "Plantaricin NC8 α" "Lactiplantibacillus plantarum; Lactobacillus plantarum NC8" "I6TUU6" "Experimentally Validated" "337330" "plnc8A" "Not Available" "20-47" "Not Available" "Not Available" "Not Available" "Not Available" "None" "LGTV,IAV,HIV-1.SARS-CoV-2" "Orthomyxoviridae,Coronaviridae" "Virus Inhibition assays" "[Ref:36449554]KUNV:A final peptide concentration of 1 μM reduced the viral load by >50%, while concentrations of ≥10 μM completely eliminated all virions.L-PLNC8 αβ or D-PLNC8 αβ caused more than 99.9% reduction in the titer of infective KUNV,WNV:The virus particles are rapidly permeabilized by both enantiomers of PLNC8 αβ that decreased the viral load by >99.9% of WNV.A 50% reduction of PFU with the L- and D-form of PLNC8 αβ was achieved at 0.001 μM.SARS-CoV-2:A 50% reduction of PFU with the L- and D-form of PLNC8 αβ was achieved at 0.001 μM. PLNC8 β (L- and D-form) alone required ~0.5 μM to cause a 50% reduction of the viral load at the same SARS-CoV-2 virus concentration.IAV: reduced IAV by 50% at ~0.5 μM.HIV-1:50% reduction concentration was ~20 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:36449554]Non Cytotoxic in Vero Cells and to human cells." "Linear" "Free" "Free" "A two-chain bacteriocin which requires chain B for optimal activity. The sequence of chain B is SVPTSVYTLGIKILWSAYKHRKTIEKSFNKGFYH" "L" "Membrane" "it mainly targets the lipid compartment of virus envelopes, which is more or less stable since it is derived from membranes of infected host cells." "3472.06" "C169H244N42O38" "CDEIMOU" "KL" "10.12" "5" "0" "5" "15" "10" "-0.654" "1.03" "5.5hours" "3min" "2min" "69.64" "20970" "6.04" "36449554" "PloS one, 17(11), e0278419." "Omer, A. A. M., Hinkula, J., Tran, P. T., Melik, W., Zattarin, E., Aili, D., Selegård, R., Bengtsson, T., & Khalaf, H. (2022)." "Plantaricin NC8 αβ rapidly and efficiently inhibits flaviviruses and SARS-CoV-2 by disrupting their envelopes" "10.1371/journal.pone.0278419" "Anti-LGTV,Anti-IAV,Anti-HIV.Anti-SARS-CoV-2" "DRAVPe02289" "GIFPKIIGKGIVNGIKSLAKGVGMKVFKAGLNNIGNTGCNNRDEC" "45" "Palustrin-3AR" "the crawfish frog, Rana areolata, North America" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Anti-HIV activity Assay" "[Ref:16140737]HIV-1:This peptide could inhibit HIV infection at a concentration that is also toxic to T cells" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16140737]Non Cytotoxic" "Linear" "Free" "Free" "None" "L" "Not Found" "Not Available" "4647.5" "C203H342N60O58S3" "HOQUWY" "G" "9.79" "7" "2" "5" "19" "16" "0.016" "0.78" "30hours" ">20hours" ">10hours" "93.11" "125" "0.027" "16140737" " Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)" "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe02288" "CLGVGSCNDFAGCGYAIVCFW" "21" "NP-06" "Streptomyces strain AA6532" "P85078" "Experimentally Validated" "1931" "Tricyclic peptide MS-271 (protein)" "1 to 21" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "HIV cytopathic effect inhibition assay" "[Ref:8619594]HIV-1LAI:IC50=2.8 mM,HIV-2ROD:IC50=6.0 mM,HIV-1ERS104pre:IC50=1.3 mM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:8619594]HIV-1LAI:CC50=28 mM,HIV-2ROD:CC50=0.23 mM,HIV-1ERS104pre:CC50=33 mM" "Cyclic" "Amidation" "Carboxylation" "A disulfide bond between Cys-7 and Cys-19 was also indicated by the cross peak between Hb of Cys-7 and Hb of Cys-1." "L" "Membrane" "NP-06 appears to block the early stage of HIV-1 infection, most likely at the stage of virus-cell fusion." "2185.53" "C97H137N23O27S4" "EHKMOPQRTU" "CG" "-0.94" "0" "1" "-1" "8" "9" "1.157" "-1.157" "1.2hours" ">20hours" ">10hours" "74.29" "7240" "3.313" "8619594" "Chokekijchai, S., Kojima, E., Anderson, S., Nomizu, M., Tanaka, M., Machida, M., Date, T., Toyota, K., Ishida, S., & Watanabe, K. (1995). " "Antimicrobial agents and chemotherapy, 39(10), 2345–2347." "NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species" "10.1128/AAC.39.10.2345" "Anti-HIV" "DRAVPe02287" "SCASRCKGHCRARRCGYYVSVLYRGRCYCKCLRC" "34" "Mytilin B" "Blue mussel, Mytilus edulis and M. galloprovincialis" "P81613" "Experimentally Validated" "6550" "Not Available" "Not Available" "1-34" "Not Available" "Not Available" "Not Available" "Not Available" "None" "WSSV" "Nimaviridae" "Antiviral Assay" "[Ref:14986940] WSSV:multiplication was prevented by the preincubation with 10 or 50 lm mytilin." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Amidation" "Carboxylation" "None" "L" "Not Found" "Not Available" "3981.76" "C163H267N59O42S8" "DEFIMNOPQTUW" "C" "9.58" "9" "0" "9" "25" "6" "-0.344" "2.83" "1.9hours" ">20hours" ">10hours" "45.88" "6460" "1.622" "14986940" "Journal of fish diseases, 27(1), 57–64." "Dupuy, J. W., Bonami, J. R., & Roch, P. (2004)" "A synthetic antibacterial peptide from Mytilus galloprovincialis reduces mortality due to white spot syndrome virus in palaemonid shrimp" "10.1046/j.1365-2761.2003.00516.x" "Anti-WSSV" "DRAVPe02286" "QEAQSVACTSYYCSKFCGSAGCSLYGCYLLHPGKICYCLHCSR" "43" "Myticin C" "The mediterranean mussel, Mytilus galloprovincialis" "A7DWS7" "Experimentally Validated" "29158" "mync_MYTGA" "Not Available" "18-60" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1,HSV-2,VHSV" "Herpesviridae" " Viral Infectivity Assays" "[Ref:21858010]VHSV:The results showed ≥85% reduced VHSV infectivity in CHSE cells transfected with Myt C.[Ref:23880927]VHSV:Maximal inhibition of viral infectivity (40%) was observed when 125 μM of red-MytCc were pre-incubated with VHSV.[Ref:27307570]The viral titer in infected oyster hemocytes treated with synthetic myticin decreased by 99.95% at 24 h. HSV-1:EC50=5.85 ± 1.24 μM (25.98 ± 5.49 μg/ml),HSV-2:EC50 =5.41 ± 0.95 μM (24.03 ± 4.21 μg/ml)," "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:23880927]No cytotoxicity was observed when the Epithelioma Papulosum Cyprini (EPC) cell monolayers were treated with synthetic red-MytCc at concentrations up to 125 μM during 72 h, indicating tha" "Linear" "Free" "Free" "None" "L" "Not Found" "CHSE cells expressing Myt C had reduced susceptibility to VHSV.viral replication could not be detected in the cells expressing the Myt C variants but was detected in the surrounding non-expressing cells.very low levels of VHSV replication could be detected in the CHSE Myt C-expressing cells compared with the eGFP-transfected or non-transfected cells, suggesting the induction of some protective effect on the surrounding cells by the expression of Myt C, which could act as a cytokine-like molecule. " "4705.44" "C202H304N54O60S8" "DMNOUW" "C" "8.19" "7" "4" "3" "28" "10" "0.179" "0.6" "0.8hours" "10min" "10hours" "59.07" "7950" "1.69" "21858010##23880927##27307570" "PloS one, 6(8), e23140##Marine drugs, 11(7), 2328–2346##journal of virology, 90(17), 7692–7702." "Balseiro, P., Falcó, A., Romero, A., Dios, S., Martínez-López, A., Figueras, A., Estepa, A., & Novoa, B. (2011)##Martinez-Lopez, A., Encinar, J. A., Medina-Gali, R. M., Balseiro, P., Garcia-Valtanen, P., Figueras, A., Novoa, B., & Estepa, A. (2013)##Novoa, B., Romero, A., Álvarez, Á. L., Moreira, R., Pereiro, P., Costa, M. M., Dios, S., Estepa, A., Parra, F., & Figueras, A. (2016)." "Mytilus galloprovincialis myticin C: a chemotactic molecule with antiviral activity and immunoregulatory properties##pH-dependent solution structure and activity of a reduced form of the host-defense peptide myticin C (Myt C) from the mussel Mytilus galloprovincialis##Antiviral Activity of Myticin C Peptide from Mussel: an Ancient Defense against Herpesviruses" "10.1371/journal.pone.0023140##10.3390/md11072328##10.1128/JVI.00591-16" "Anti-HSV,Anti-VSHRV" "DRAVPe02285" "KYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGWKS" "43" "Mundticin(CRL35)" "Enterococcus mundtii NFRI 7397" "B6DSR2" "Experimentally Validated" "1352" "mundKS" "Not Available" "16-58" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Antiviral Assay" "[Ref:10493605]HSV-1 (F):Vero cells:Inhibition = 97.0%, BHK-21 cells:Inhibition = 99.2%.HSV-2 (G):Vero cells:Inhibition = 98.8%, BHK-21 cells:Inhibition = 98.8%.HSV-1 (B2006):Vero cells:Inhibition = 92.4%, BHK-21 cells:Inhibition = 96.7%.HSV-1 (F): EC50 = 11 µg/ml,HSV-1 (B2006): EC50 = 53 µg/ml,HSV-1 (KOS): EC50 = 60 µg/ml for Enterocin,HSV-1 (Field): EC50 = 76 µg/ml for Enterocin,HSV-2 (G): EC50 = 15 µg/ml for Enterocin" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:10493605]CC50 of CRL35:HSV-1 (F): 1363.64 µg/ml,HSV-1 (B2006): 283.02 µg/ml,HSV-1 (KOS): 250.00 µg/ml,HSV-1 (Field isolate): 197.37 µg/ml,HSV-2 (G): 1000.00 µg/ml." "Linear" "Free" "Free" "None" "L" "Not Found" "Enterocin CRL35 exerted a significant inhibitory effect in vitro on the replication of several HSV strains." "4289.81" "C186H291N55O58S2" "EFHMOPQRU" "G" "9.45" "5" "1" "4" "20" "14" "-0.253" "0.73" "1.3 hours" "3min" "3min" "63.72" "14105" "3.288" "10493605" "International journal of antimicrobial agents, 12(4), 293–299." "Wachsman, M. B., Farías, M. E., Takeda, E., Sesma, F., de Ruiz Holgado, A. P., de Torres, R. A., & Coto, C. E. (1999)." "Antiviral activity of enterocin CRL35 against herpesviruses" "10.1016/s0924-8579(99)00078-3" "Anti-HSV" "DRAVPe02284" "WYQLIRTFGNLIHQKYRKLLEAYRKLRD" "28" "ModoCath5" "The gray short-tailed opossum, Monodelphis domestica, South America" "F6W4B4" "Experimentally Validated" "13616" "Not Found" "Not Found" "133-160" "Not Available" "CM000373.1" "Not Found" "Primary_assembly 6: 195,029,250-195,034,644 reverse strand." "None" "WNV" "Flaviviridae" "Antiviral Assay" "[Ref:32194564]ΔModoCath5, resulting in approximately 500-fold decrease in virus production" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:32194564]CC₅₀:HEK293T: 93.7% (8 µg/mL), 67.4% (16 µg/mL), 47.8% (32 µg/mL), 35.0% (64 µg/mL),Human primary keratinocytes: 98.1% (8 µg/mL), 96.2% (16 µg/mL), 79.1% (32 µg/mL), 48.9% (64 µg/mL),MCF" "Linear" "Free" "Free" "None" "L" "Not Found" "The presence of ΔModoCath5 resulted in lower CXCL10, IFIT2, and IL28A mRNA levels, which can be related to the reduced viral replication in keratinocytes treated with this peptide. While viperin expression was not modified, ΔModoCath5 tended to increase ISG20 expression in WNV-infected keratinocytes. However, at the protein level, type III interferon secretion in response to WNV infection was not modulated by ΔModoCath5 treatment" "3623.27" "C169H265N49O40" "CMOPSUV" "L" "10.28" "7" "2" "5" "17" "10" "-0.846" "2.66" "2.8hours" "3min" "2min" "101.07" "9970" "2.752" "32194564" "Broad Spectrum of Pathogens Including West Nile Virus. Frontiers in immunology, 11, 347." "Cho, H. S., Yum, J., Larivière, A., Lévêque, N., Le, Q. V. C., Ahn, B., Jeon, H., Hong, K., Soundrarajan, N., Kim, J. H., Bodet, C., & Park, C. (2020)." "Opossum Cathelicidins Exhibit Antimicrobial Activity Against a Broad Spectrum of Pathogens Including West Nile Virus" "10.3389/fimmu.2020.00347" "Anti-WNV" "DRAVPe02283" "VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR" "33" "MCP-2" "Macrophage, lung, Rabbit,Oryctolagus cuniculus" "P01377" "Experimentally Validated" "9986" "Defensin alpha 4(protein)" "AAA31390.1" "63-95" "Not Available" "M28884" "mRNA" "Scaffold GL018713: 117,470-184,536 forward strand." "None" "HSV-1" "Herpesviridae" "Antiviral Assay" "[Ref:2985808]HSV-1:IC50=3.68 ± 0.11μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" " MCP-1 and MCP-2 can directly neutralize several viruses in vitro and that HSV-1 strain Maclntyre and vesicular stomatitis virus strain Indiana are particularly susceptible to their action." "3854.76" "C161H282N62O36S6" "DKMNOQSTUWY" "R" "11.12" "9" "1" "8" "17" "12" "0.139" "2.73" "100hours" ">20hours" ">10hours" "97.58" "375" "0.097" "2985808" "Journal of virology, 54(2), 467–472." "Lehrer, R. I., Daher, K., Ganz, T., & Selsted, M. E. (1985)." "Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes" "10.1128/JVI.54.2.467-472.1985" "Anti-HSV" "DRAVPe02282" "GICACRRRFCPNSERFSGYCRVNGARYVRCCSRR" "34" "Rabbit neutrophil defensin 3a" "Rabbit, O. cuniculus" "P07469" "Experimentally Validated" "9986" "Corticostatin 1(protein)" "60-93" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV" "Orthomyxoviridae" "Antiviral Assay" "[Ref:12543649]IAV:(reduction >1.1 log)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "Three disulfide bridges" "L" "Not Found" "Not Available" "4003.65" "C163H265N63O44S6" "DHKLMOQTUW" "R" "10.2" "9" "1" "8" "23" "7" "-0.638" "3.87" "30hours" ">20hours" ">10hours" "76.04" "3355" "0.838" "12543649" "Antimicrobial agents and chemotherapy, 47(2), 494–500" "Sinha, S., Cheshenko, N., Lehrer, R. I., & Herold, B. C. (2003)." "NP-1, a rabbit alpha defensin, prevents the entry and intercellular spread of herpes simplex virus type 2." "10.1128/AAC.47.2.494-500.2003" "Anti-IAV" "DRAVPe02281" "SCTTCVCTCSCCTT" "14" "Micrococcin P1" "Staphylococcus epidermidis strain 115; Staphylococcus equorum WS 2733, from a French red smear cheese" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HCV" "Flaviviridae" "HCVcc inhibition assay" "[Ref:27387825]HCV:H77 (Huh7.5 cells), EC₅₀ = 0.222 ± 0.064 μM;Jc1 (Huh7.5 cells), EC₅₀ = 0.396 ± 0.016 μM;S52 (Huh7.5 cells), EC₅₀ = 0.141 ± 0.004 μM;DE43 (Huh7.5 cells), EC₅₀ = 0.269 ± 0.002 μM;SA13 (Huh7.5 cells), EC₅₀ = 0.339 ± 0.054 μM;HK6a (Huh7.5 cells), EC₅₀ = 0.325 ± 0.027 μM;QC69 (Huh7.5 cells), EC₅₀ = 0.304 ± 0.093 μM;JFH1-GFP (Huh7.5 cells), EC₅₀ = 0.80 ± 0.28 μM;Jc1 Renilla (Huh7.5 cells), EC₅₀ = 0.52 ± 0.08 μM; TN NanoLuc (Huh7.5 cells), EC₅₀ = 0.54 ± 0.01 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27387825]CC50 was 11.5 ± 0.14 μM" "Linear" "Free" "Free" "None" "L" "Membrane" "Micrococcin P1 strongly inhibits HCV attachment similar to anti-CD81 antibodies. however, its effect was shown prior to fusion of the viral envelope to the endosomal membrane " "1415.66" "C49H86N14O22S6" "ADEFGHIKLMNOPQRUWY" "C" "5.23" "0" "0" "0" "13" "1" "1.007" "0.56" "1.9hours" ">20hours" ">10hours" "20.71" "375" "0.265" "27387825" "Antiviral research, 132, 287–295." "Lee, M., Yang, J., Park, S., Jo, E., Kim, H. Y., Bae, Y. S., & Windisch, M. P. (2016)." "Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner" "10.1016/j.antiviral.2016.07.002" "Anti-HCV" "DRAVPe02280" "VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR" "33" "MCP-1" "Oryctolagus cuniculus (Rabbit)" "P01376" "Experimentally Validated" "9986" "Not Found" "AAA31387.1" "63-95" "Not Available" "M28883" "mRNA" "Scaffold GL018713: 117,470-184,536 forward strand." "None" "HSV-2" "Herpesviridae" "Antiviral Assay" "[Ref:12543649]HSV-1:IC50=15% ± 8.3%.NP-1 reduced the number of plaques by 59.0% ± 16.6%.HSV-2:IC50=infection by 98.7% ± 0.7%" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:12543649]No cytotoxic effect was observed even after 20 h of exposure to NP-1 at the concentration of 25 or 100 μg/ml" "Linear" "Free" "Free" "None" "L" "Membrane" "NP-1, a cationic peptide, does not compete with viral envelope glycoproteins for binding to cellular heparan sulfate receptors, but it prevents viral entry.NP-1 prevents virally mediated fusion events, entry, and cell-to-cell spread" "3897.79" "C161H283N65O36S6" "DKMNOQSTUWY" "R" "11.4" "10" "1" "9" "18" "11" "-0.112" "3.33" "100hours" ">20hours" ">10hours" "85.76" "375" "0.096" "12543649" "Antimicrobial agents and chemotherapy, 47(2), 494–500" "Sinha, S., Cheshenko, N., Lehrer, R. I., & Herold, B. C. (2003)." "NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2." "10.1128/AAC.47.2.494-500.2003" "Anti-HSV" "DRAVPe02279" "GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ" "34" "mCRAMP" "Adult testis, spleen, stomach, and intestine, Mice, M. musculus" "A0A8C6H0U3" "Experimentally Validated" "10103" "Not Found" "Not Found" "140-173" "Not Available" "Not Available" "Not Found" "Primary_assembly QGOO01036336.1: 6,325-8,294 forward strand." "None" "RSV,ZIKV" "Flaviviridae" "Antiviral Assay" "[Ref:35038500]ZIKV:IC50=At 5, 10, 20 μg/mL concentrtion attenuated ZIKV CPE by 39.8%, 68.9%, 90.1%, respectively." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Not Found" "CRAMP can combat ZIKV outside cells, and consequently inhibit viral attachment and entry.Cathelicidin CRAMP significantly inhibited the attachment and entry of ZIKV in Vero cells" "3878.66" "C178H302N50O46" "ACDHMOSTUWY" "K" "10.22" "9" "3" "6" "17" "10" "-0.894" "1.74" "30hours" ">20hours" ">10hours" "88.82" "0" "0" "26873992##35038500" "Journal of immunology (Baltimore, Md. : 1950), 196(6), 2699–2710##Antiviral research, 198, 105248." "Currie, S. M., Gwyer Findlay, E., McFarlane, A. J., Fitch, P. M., Böttcher, B., Colegrave, N., Paras, A., Jozwik, A., Chiu, C., Schwarze, J., & Davidson, D. J. (2016)##Liu, Z., Wu, J., Qin, Z., Dong, C., Yang, H., Sun, J., Xu, W., & Wei, L. (2022)" "Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans##Endogenous cathelicidin is required for protection against ZIKV-caused testis damage via inactivating virons" "10.4049/jimmunol.1502478##10.1016/j.antiviral.2022.105248" "Anti-RSV,Anti-ZIKV" "DRAVPe02278" "KINNPVSCLRKGGRCWNRCIGNTRQIGSCGVPFLKCCKRK" "40" "MBD-3" "Epithelia, respiratory system and other mucosal surfaces, mouse, M. musculus" "Q9WTL0" "Experimentally Validated" "10090" "Defb3" "AA065510##AJ011800## AF092929" "24-63" "Not Available" "CM001001.3" "Genomic DNA" "Chromosome 8: 19,343,376-19,345,307 forward strand." "None" "IAV" "Orthomyxoviridae" "Cell transfection Assay" "[Ref:24632574]IAV:TCID50=3.4815 ± 0.1844" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Membrane" "mBD1-mBD3 expressed by the recombinant plasmid pcDNA3.1(+)/mBD1-mBD3 could inhibit influenza A virus replication both in vitro and in vivo." "4495.41" "C189H322N66O49S6" "ADEHMOUY" "C" "10.26" "10" "0" "10" "24" "9" "-0.515" "2.33" "1.3 hours" "3min" "3min" "63.25" "5875" "1.307" "22345365##19301094" "Antiviral chemistry & chemotherapy, 22(6), 255–262##Archives of virology, 154(4), 639–647" "Jiang, Y., Yang, D., Li, W., Wang, B., Jiang, Z., & Li, M. (2012)##Jiang, Y., Wang, Y., Kuang, Y., Wang, B., Li, W., Gong, T., Jiang, Z., Yang, D., & Li, M. (2009)" "Antiviral activity of recombinant mouse β-defensin 3 against influenza A virus in vitro and in vivo##Expression of mouse beta-defensin-3 in MDCK cells and its anti-influenza-virus activity" "10.3851/IMP2077##10.1007/s00705-009-0352-6" "Anti-IAV" "DRAVPe02277" "DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS" "37" "mBD-1" "Mus musculus" "P56386" "Experimentally Validated" "10090" "Defb1" "AA071757" "33-69" "Not Available" "CM001001.3" "mRNA" "Chromosome 8: 22,266,615-22,285,201" "None" "IAV" "Orthomyxoviridae" "Cell transfection Assay" "[Ref:24632574]IAV:TCID50=4.1667 ± 0.1443" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Free" "None" "L" "Membrane" "mBD1-mBD3 expressed by the recombinant plasmid pcDNA3.1(+)/mBD1-mBD3 could inhibit influenza A virus replication both in vitro and in vivo." "4076.68" "C168H272N52O54S6" "AEIMOUVW" "C" "8.89" "6" "2" "4" "27" "4" "-0.93" "2.3" "1.1hours" "3min" ">10hours" "31.62" "1865" "0.457" "24632574" "Viruses, 6(3), 1237–1252." "Li, W., Feng, Y., Kuang, Y., Zeng, W., Yang, Y., Li, H., Jiang, Z., & Li, M. (2014)." "Construction of eukaryotic expression vector with mBD1-mBD3 fusion genes and exploring its activity against influenza A virus" "10.3390/v6031237" "Anti-IAV" "DRAVPe02276" "ILGPVISTIGGVLGGLLKNL" "20" "Maximin H1" "B. maxima, China, Asia" "P83080##P83081" "Experimentally Validated" "161274" "Not Available" "Not Available" "124-143" "Not Available" "Not Available" "Not Available" "Not Available" "7OVZ" "HIV" "Retroviridae" "Anti-HIV activity Assay" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Amidation" "Free" "None" "L" "Not Found" "Not Available" "1934.39" "C90H160N22O24" "ACDEFHMOQRUWY" "GL" "8.75" "1" "0" "1" "4" "10" "1.42" "-1.69" "20hours" "30min" ">10hours" "185" "0" "0" "11835991" " Peptides, 23(3), 427–435." "Lai, R., Zheng, Y. T., Shen, J. H., Liu, G. J., Liu, H., Lee, W. H., Tang, S. Z., & Zhang, Y. (2002)." "Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima" "10.1016/s0196-9781(01)00641-6" "Anti-HIV" "DRAVPe02275" "GLFVGVLAKVAAHVVPAIAEHF" "22" "Maculatin 1.1" "Skin secretions, Litoria genimaculate, Litoria eucnemis, Australia" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "HIV infection and cell viability assay" "[Ref:16140737]HIV-1:IC50=11.3 μM " "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref: 16140737] Non toxic to target cells " "Linear" "Free" "Free" "None" "L" "Envelope/outer leaflet of the membrane" "Maculatin 1.1 is an amphibian-derived antimicrobial peptide that demonstrates potent inhibitory effects on HIV infection and transmission. It prevents HIV by disrupting the viral envelope, a critical structure required for viral fusion with target cells. When preincubated with the virus, maculatin 1.1 effectively blocks viral fusion, thereby preventing the virus from entering T cells. This peptide also exhibits the remarkable ability to inhibit the transfer of HIV from dendritic cells (DCs) to T cells, even when DCs are exposed to the peptide up to eight hours after capturing the virus. By accessing and destroying DC-sequestered HIV, maculatin 1.1 halts the progression of infection. These properties, coupled with its non-toxic effects on target cells, suggest that maculatin 1.1 holds significant promise as a topical inhibitor for mucosal HIV transmission and provides a novel approach to understanding the complex mechanisms of HIV capture and transfer by DCs." "2245.7" "C108H169N27O25" "CDMNOQRSTUWY" "AV" "6.92" "1" "1" "0" "4" "15" "1.432" "-1.37" "30hours" ">20hours" ">10hours" "141.82" "0" "0" "16140737" " Journal of virology, 79(18), 11598–11606." "VanCompernolle, S. E., Taylor, R. J., Oswald-Richter, K., Jiang, J., Youree, B. E., Bowie, J. H., Tyler, M. J., Conlon, J. M., Wade, D., Aiken, C., Dermody, T. S., KewalRamani, V. N., Rollins-Smith, L. A., & Unutmaz, D. (2005)" "Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells" "10.1128/JVI.79.18.11598-11606.2005" "Anti-HIV" "DRAVPe02274" "KTCENLADTFRGPCFATSNC" "20" "Lunatusin" "Phaseolus lunatus L. (lima bean)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV" "Retroviridae" "ELISA" "[Ref:16269344]HIV-1: IC50=120 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16269344]The findings indicate that lunatusin was devoid of cytotoxicity on mammalian splenocytes at concentrations below 50 μM." "Linear" "Free" "Free" "None" "L" "Not Found" "This 7 kDa isolate can reduce the activity of HIV-1 reverse transcriptase." "2178.44" "C90H140N26O31S3" "HIMOQUVWY" "CT" "6.05" "2" "2" "0" "13" "5" "-0.34" "2.05" "1.3 hours" "3min" "3min" "29.5" "125" "0.057" "16269344" "Peptides, 26(11), 2086–2092." "Wong, J. H., & Ng, T. B. (2005)." "Lunatusin, a trypsin-stable antimicrobial peptide from lima beans (Phaseolus lunatus L.)" "10.1016/j.peptides.2005.03.004" "Anti-HIV" "DRAVPe02273" "SMWSGMWRRKLKKLRNALKKKLKGE" "25" "Latarcin 1" "Lachesana tarabaevi" "Q1ELT9" "Experimentally Validated" "379576" "Lt1a" "Not Available" "63-87" "Not Available" "Not Available" "Not Available" "Not Available" "2PCO" "DENV" "Filoviridae" "Dengue NS2B-NS3 protease Assay" "[Ref:24885331]Dengue protease NS2B-NS3pro (37°C) IC₅₀ = 12.68 ± 3.2 μM,Dengue protease NS2B-NS3pro (40°C) IC₅₀ = 6.58 ± 4.1 μM,Reduction in viral RNA (24 h) EC₅₀ = 8.3 ± 1.2 μM,Reduction in viral RNA (48 h) EC₅₀ = 7.6 ± 2.7 μM,Reduction in viral RNA (72 h) EC₅₀ = 6.8 ± 2.5 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:24885331]The CC50 value of the Ltc 1 peptide obtained via the optimisation steps was estimated to be approximately 52.51 ± 3.6 μM" "Linear" "Free" "Free" "None" "L" "NS2B-NS3" "The Ltc 1 peptide exhibited significant inhibitory effects against dengue NS2B-NS3pro and virus replication in the infected cells" "3073.8" "C138H238N44O31S2" "DCQHIFPTYV" "K" "11.77" "10" "1" "9" "14" "9" "-1.248" "2.84" "1.9hours" ">20hours" ">10hours" "18.36" "11000" "3.579" "24885331" "BMC microbiology, 14, 140" "Rothan, H. A., Bahrani, H., Rahman, N. A., & Yusof, R. (2014)" "Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus" "10.1186/1471-2180-14-140" "Anti-DENV" "DRAVPe02272" "SDWSLWECCSTGSLFACC" "18" "Labyrinthopeptin A2" "A.namibiensis" "C0MP60" "Experimentally Validated" "182080" "labA2" "Not Available" "21-38" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV,ZIKV,WNV,HCV,CHIKV,KSHV,CMV,HSV" "Herpesviridae" "Antiviral Assay" "[Ref:3166638]CHIKV (pseudotype) IC₅₀ = >5.0 μM,DENV-1 IC₅₀ = 12.0 μM,DENV-2 (Huh-7, high content imaging) IC₅₀ = 8.0 μM,DENV-2 (Huh-7, qRT-PCR) IC₅₀ = 7.6 μM,DENV-2 (MDDC, flow cytometry) IC₅₀ = 5.2 μM,DENV-2 (MDDC, qRT-PCR) IC₅₀ = 4.2 μM,DENV-3 IC₅₀ = 9.4 μM,DENV-4 IC₅₀ = 4.0 μM,HCMV IC₅₀ = 5.4 μM,HCV IC₅₀ = 1.7 μM,HSV-1 IC₅₀ = 12.4 μM,HSV-1 (Tk-deficient) IC₅₀ = 10.7 μM,HSV-2 IC₅₀ = 5.5 μM,HSV-2 (Tk-deficient) IC₅₀ = 3.2 μM,KSHV IC₅₀ = 15.0 μM,TBEV IC₅₀ = >26.0 μM,WNV IC₅₀ = 0.7 μM,ZIKV-976 (Huh-7, high content imaging) IC₅₀ = 9.6 μM,ZIKV-976 (Huh-7, qRT-PCR) IC₅₀ = 5.7 μM,ZIKV-H/PF-2013 (Huh-7, high content imaging) IC₅₀ = 3.3 μM,ZIKV-H/PF-2013 (Huh-7, qRT-PCR) IC₅₀ = 3.4 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:3166638]Labyrinthopeptins exhibited low cytotoxicity and had favorable pharmacokinetic properties in mice (half-life [t1/2] = 10.0 h)," "Linear" "Free" "Free" "None" "L" "Membrane" "LabyA2 exert the antiviral function by disrupting viral envelopes (virolysis)." "1998.24" "C85H120N20O28S4" "RNQHIKMPYVOU" "CS" "3.67" "0" "2" "-2" "10" "6" "0.506" "0.35" "1.9hours" ">20hours" ">10hours" "48.89" "11250" "5.63" "31666384" "Journal of virology, 94(2), e01471-19" "Prochnow, H., Rox, K., Birudukota, N. V. S., Weichert, L., Hotop, S. K., Klahn, P., Mohr, K., Franz, S., Banda, D. H., Blockus, S., Schreiber, J., Haid, S., Oeyen, M., Martinez, J. P., Süssmuth, R. D., Wink, J., Meyerhans, A., Goffinet, C., Messerle, M., Schulz, T. F., … Brönstrup, M. (2020)." "Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis" "10.1128/JVI.01471-19" "Anti-DENV,Anti-ZIKV,Anti-WNV,Anti-HCV,Anti-CHIKV,Anti-KSHV,Anti-CMV,Anti-HSV,Anti-HIV" "DRAVPe02271" "SNASVWECCSTGSWVPFTCC" "20" "Labyrinthopeptin A1" "Actinomycete Actinomadura namibiensis DSM 6313" "C0MP59" "Experimentally Validated" "182080" "labA1" "Not Available" "21-40" "Not Available" "Not Available" "Not Available" "Not Available" "None" "DENV,ZIKV,WNV,HCV,CHIKV,KSHV,CMV,HSV-2,HIV-1" "Retroviridae" "Antiviral Assay" "[Ref:3166638]CHIKV IC₅₀ = 2.2 μM,CHIKV (pseudotype):IC₅₀ = 1.8 μM,DENV-1 IC₅₀ = 0.8 μM,DENV-2 (Huh-7, high content imaging):IC₅₀ = 1.8 μM,DENV-2 (Huh-7, qRT-PCR) :IC₅₀ = 2.0 μM,DENV-2 (MDDC, flow cytometry): IC₅₀ = 0.4 μM,DENV-2 (MDDC, qRT-PCR): IC₅₀ = 0.3 μM,DENV-3 IC₅₀ = 1.1 μM,DENV-4: IC₅₀ = 0.3 μM,HCMV:IC₅₀ = 1.3 μM,HCV:IC₅₀ = 1.1 μM,HIV (laboratory strain, MT-4 T cells);IC₅₀ = 1.9 μM,HIV (laboratory strain, PBMC):IC₅₀ = 1.7 μM,HIV (laboratory strain, MDM):IC₅₀ = 2.4 μM,HIV (clinical isolate, PBMC):IC₅₀ = 1.0 μM,HSV-1:IC₅₀ = 1.6 μM,HSV-1 (Tk-deficient):IC₅₀ = 1.9 μM,HSV-2:IC₅₀ = 0.4 μM,HSV-2 (Tk-deficient):IC₅₀ = 0.3 μM,KSHV:IC₅₀ = 2.0 μM,TBEV:IC₅₀ = 24.1 μM,WNV:IC₅₀ = 0.2 μM,ZIKV-976 (Huh-7, high content imaging):IC₅₀ = 2.0 μM,ZIKV-976 (Huh-7, qRT-PCR):IC₅₀ = 1.8 μM,ZIKV-H/PF-2013 (Huh-7, high content imaging):IC₅₀ = 1.6 μM,ZIKV-H/PF-2013 (Huh-7, qRT-PCR):IC₅₀ = 1.6 μM." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:3166638]Labyrinthopeptins exhibited low cytotoxicity and had favorable pharmacokinetic properties in mice (half-life [t1/2] = 10.0 h)," "Linear" "Free" "Free" "None" "L" "Membrane" "LabyA1 exert the antiviral function by disrupting viral envelopes (virolysis)." "2167.43" "C92H131N23O30S4" "RDPHILKMYOU" "CS" "4" "0" "1" "-1" "12" "6" "0.38" "0.43" "1.9hours" ">20hours" ">10hours" "34" "11250" "5.19" "31666384##23724015" "Journal of virology, 94(2), e01471-19##PloS one, 8(5), e64010." "Prochnow, H., Rox, K., Birudukota, N. V. S., Weichert, L., Hotop, S. K., Klahn, P., Mohr, K., Franz, S., Banda, D. H., Blockus, S., Schreiber, J., Haid, S., Oeyen, M., Martinez, J. P., Süssmuth, R. D., Wink, J., Meyerhans, A., Goffinet, C., Messerle, M., Schulz, T. F., … Brönstrup, M. (2020)##Férir, G., Petrova, M. I., Andrei, G., Huskens, D., Hoorelbeke, B., Snoeck, R., Vanderleyden, J., Balzarini, J., Bartoschek, S., Brönstrup, M., Süssmuth, R. D., & Schols, D. (2013)." "Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis##The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications" "10.1128/JVI.01471-19##10.1371/journal.pone.0064010" "Anti-DENV,Anti-ZIKV,Anti-WNV,Anti-HCV,Anti-CHIKV,Anti-KSHV,Anti-CMV,Anti-HSV,Anti-HIV" "DRAVPe02270" "XXAGXXXXKVGXX" "5" "Mirabamide F" " sponge Stelletta clavosa" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Neutralization Assays." "[Ref: 21280591]62 ± 9" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "The N-terminal is modified by Htda (3-hydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid)," "The C-terminal is linked to rhamnose via β-OMeTyr" "Dhtda replaced with Htda (3-hydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid).β-OMeTyr-NMeThr-Ala-Gly-3-OMeAla-3-OHLeu-4-ClHPr-3,4-DiMeGln-Dab-Aba-Gly-Htda-Rha.This sequence also has several modifications. X at position 1 is β-O-methyltyrosine (β-OMeTyr), X at position 2 is N-methylthreonine (NMeThr), X at position 5 is 3-O-methylalanine (3-OMeAla), X at position 6 is 3-hydroxyleucine (3-OHLeu), X at position 7 is 4-chlorohydroxyproline (ClHPr), X at position 8 is 3,4-dimethylglutamine (3,4-DiMe" "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "403.44" "C72H112ClN13O23" "RNDCQEHILMFPSWYVOU" "G" "5.57" "0" "0" "0" "1" "2" "0.9" "-1.03" "4.4 hours" ">20 hour" ">10 hours" "78" "0" "0" "21280591" "J Nat Prod. 2011 Feb 25;74(2):185-93." "Lu Z, Van Wagoner RM, Harper MK, Baker HL, Hooper JN, Bewley CA, Ireland CM." "Mirabamides E-H, HIV-Inhibitory Depsipeptides from the Sponge Stelletta clavosa" "10.1021/np100613p" "Anti-HIV" "DRAVPe02269" "XXAGXXXXKVGXX" "5" "Mirabamide E" "sponge Stelletta clavosa" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Neutralization Assays." "[Ref: 21280591] 121 ± 20" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "The N-terminal is modified by the Dhtda (2,3-dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid) moiety." "The C-terminal is linked to rhamnose via β-OMeTyr, " "Threonine replaced by Aba (2-amino-2-butenoic acid).OH replaced by H in the polyketide terminal chain.Different rhamnose conformation.Threonine replaced by Aba, Dhtda (2,3-dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid), Rhamnose linked to β-OMeTy.This sequence contains multiple modifications. X at position 1 is β-O-methyltyrosine (β-OMeTyr), X at position 2 is N-methylthreonine (NMeThr), X at position 5 is 3-O-methylalanine (3-OMeAla), X at position 6 is 3-hydroxyleucine (3-OHLeu), X at pos" "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "403.44" "C72H112ClN13O24" "RNDCQEHILMFPSWYVOU" "G" "5.57" "0" "0" "0" "1" "2" "0.9" "-1.03" "4.4 hours" ">20 hour" ">10 hours" "78" "0" "0" " 30154377;##21280591" "Mar Drugs. 2018 Aug 28;16(9):306;##Journal of natural products, 74(2), 185–193." "Frau J, Flores-Holguín N, Glossman-Mitnik D;##Lu, Z., Van Wagoner, R. M., Harper, M. K., Baker, H. L., Hooper, J. N., Bewley, C. A., & Ireland, C. M. (2011)." "Chemical Reactivity Properties, pKa Values, AGEs Inhibitor Abilities and Bioactivity Scores of the Mirabamides A–H Peptides of Marine Origin Studied by Means of Conceptual DFT;##Mirabamides E-H, HIV-inhibitory depsipeptides from the sponge Stelletta clavosa" "10.3390/md16090302;##10.1021/np100613p" "Anti-HIV" "DRAVPe02268" "XXXAGXXXKTGX" "5" "Mirabamide D" "marine sponge Siliquariaspongia mirabilis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "disk diffusion assays." "[Ref: 17963357] mirabamides C and D (IC50 values between 140 nM and 1.3 µM for 3 and 190 nM and 3.9 µM for 4), indicating that these peptides can act at the early stages of HIV-1 entry. " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "The N-terminal contains 4-chloro-L-homoproline (ClHPr) in A and L-homoproline (HPr) in B (without chlorine). but differs in specific substitutions elsewhere in the sequence." "The C-terminal is closed via an ester bond to form a macrocyclic structure. This esterification involves a β-hydroxyl group, making the C-terminal non-free for every variant." "Similar to Mirabamide A.This sequence contains several modified residues. X at position 1 is 4-chlorohydroxyproline (ClHPr), X at position 2 is β-O-methyltyrosine (β-OMeTyr), X at position 3 is N-methylthreonine (NMeThr), X at position 6 is 3-O-methylalanine (3-OMeAla), X at position 7 is 3-hydroxyleucine (3-OHLeu), X at position 8 is 3,4-dimethylglutamine (3,4-DiMeGln), X at position 9 is diaminobutyric acid (Dab), and X at position 12 is Dhtda, a lipid-derived tail." "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "432.48" "C17H32N6O7" "RNDCQEHILMFPSWYVOU" "G" "8.8" "1" "0" "1" "1" "1" "-0.72" "0.88" "4.4 hours" ">20 hour" ">10 hours" "20" "0" "0" " 30154377;## 17963357" "Mar Drugs. 2018 Aug 28;16(9):305;##Journal of natural products, 70(11), 1753–1760." "Frau J, Flores-Holguín N, Glossman-Mitnik D;##Lu, Z., Van Wagoner, R. M., Harper, M. K., Baker, H. L., Hooper, J. N., Bewley, C. A., & Ireland, C. M. (2011)." "Chemical Reactivity Properties, pKa Values, AGEs Inhibitor Abilities and Bioactivity Scores of the Mirabamides A–H Peptides of Marine Origin Studied by Means of Conceptual DFT;##Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion" "10.3390/md16090302;##10.1021/np070306k" "Anti-HIV" "DRAVPe02267" "XXXAGXXXKTGX" "5" "Mirabamide C" "marine sponge Siliquariaspongia mirabilis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "disk diffusion assays." "[Ref: 17963357] mirabamides C and D (IC50 values between 140 nM and 1.3 µM for 3 and 190 nM and 3.9 µM for 4), indicating that these peptides can act at the early stages of HIV-1 entry. " "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Similar to Mirabamide A, but the rhamnose moiety is absent." "The C-terminal is closed via an ester bond to form a macrocyclic structure. This esterification involves a β-hydroxyl group, making the C-terminal non-free for every variant." "No Cl at terminal proline. Rhamnose replaced by H.This variant differs at position 1. X is hydroxyproline (HPr), followed by X at position 2 as β-O-methyltyrosine (β-OMeTyr), X at position 3 as N-methylthreonine (NMeThr), X at position 6 as 3-O-methylalanine (3-OMeAla), X at position 7 as 3-hydroxyleucine (3-OHLeu), X at position 8 as 3,4-dimethylglutamine (3,4-DiMeGln), X at position 9 as diaminobutyric acid (Dab), and X at position 12 as Dhtda." "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "432.48" "C17H32N6O7" "RNDCQEHILMFPSWYVOU" "G" "8.8" "1" "0" "1" "1" "1" "-0.72" "0.88" "4.4 hours" ">20 hour" ">10 hours" "20" "0" "0" " 30154377;## 17963357" "Mar Drugs. 2018 Aug 28;16(9):304;##Journal of natural products, 70(11), 1753–1760." "Frau J, Flores-Holguín N, Glossman-Mitnik D;##Lu, Z., Van Wagoner, R. M., Harper, M. K., Baker, H. L., Hooper, J. N., Bewley, C. A., & Ireland, C. M. (2011)." "Chemical Reactivity Properties, pKa Values, AGEs Inhibitor Abilities and Bioactivity Scores of the Mirabamides A–H Peptides of Marine Origin Studied by Means of Conceptual DFT;##Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibits HIV-1 fusion" "10.3390/md16090302;##10.1021/np070306k" "Anti-HIV" "DRAVPe02266" "XXXAGXXXVTGX" "5" "Mirabamide B" "marine sponge Siliquariaspongia mirabilis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "disk diffusion assays." "[Ref: 17963357] 62nm" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "The N-terminal contains 4-chloro-L-homoproline (ClHPr) in A and L-homoproline (HPr) in B (without chlorine)." "The C-terminal is closed via an ester bond to form a macrocyclic structure. This esterification involves a β-hydroxyl group, making the C-terminal non-free for every variant." "Same as Mirabamide A but replaces Dab (2,3-diaminobutanoic acid) with Aba (2-amino-2-butenoic acid).This sequence also features modified residues. X at position 1 is 4-chlorohydroxyproline (ClHPr), X at position 2 is β-O-methyltyrosine (β-OMeTyr), X at position 3 is N-methylthreonine (NMeThr), X at position 6 is 3-O-methylalanine (3-OMeAla), X at position 7 is 3-hydroxyleucine (3-OHLeu), X at position 8 is 3,4-dimethylglutamine (3,4-DiMeGln), X at position 9 is aminobutyric acid (Aba), and X at " "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "403.44" "C16H29N5O7" "RNDCQEHILMFPSWYVOU" "G" "5.57" "0" "0" "0" "1" "2" "0.9" "-1.03" "4.4 hours" ">20 hour" ">10 hours" "78" "0" "0" " 30154377;## 17963357" "Mar Drugs. 2018 Aug 28;16(9):303;##Journal of natural products, 70(11), 1753–1760." "Frau J, Flores-Holguín N, Glossman-Mitnik D;##Lu, Z., Van Wagoner, R. M., Harper, M. K., Baker, H. L., Hooper, J. N., Bewley, C. A., & Ireland, C. M. (2011)." "Chemical Reactivity Properties, pKa Values, AGEs Inhibitor Abilities and Bioactivity Scores of the Mirabamides A–H Peptides of Marine Origin Studied by Means of Conceptual DFT;##Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion" "10.3390/md16090302;##10.1021/np070306k" "Anti-HIV" "DRAVPe02265" "XXXAGXXXKTGX" "5" "Mirabamide A" "marine sponge Siliquariaspongia mirabilis" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "disk diffusion assays." "[Ref: 17963357] Mirabamide A inhibited HIV-1 in neutralization and fusion assays with IC50 values between 40 and 140 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "The N-terminal contains 4-chloro-L-homoproline (ClHPr) in A and L-homoproline (HPr) in B (without chlorine)." "The C-terminal is closed via an ester bond to form a macrocyclic structure. This esterification involves a β-hydroxyl group, making the C-terminal non-free for every variant." "Cl at terminal proline.Contains ?-methoxytyrosine glycosylated with 4′-o-?-l-rhamnopyranoside.This sequence contains several modified residues. X at position 1 is 4-chlorohydroxyproline (ClHPr), X at position 2 is β-O-methyltyrosine (β-OMeTyr), X at position 3 is N-methylthreonine (NMeThr), X at position 6 is 3-O-methylalanine (3-OMeAla), X at position 7 is 3-hydroxyleucine (3-OHLeu), X at position 8 is 3,4-dimethylglutamine (3,4-DiMeGln), X at position 9 is diaminobutyric acid (Dab), and X at p" "L" "Glycoprotein." "The mechanism of action for peptides E through H likely involves their amphipathic and cyclic nature, which enables them to interact with both viral and host cell components to inhibit HIV-1 infection. These peptides may target the HIV-1 envelope glycoproteins, such as gp120 and gp41, which are critical for viral entry into host cells. By binding to gp120, they could block its interaction with the CD4 receptor or CCR5/CXCR4 co-receptors, preventing viral attachment. Additionally, interference with gp41 could disrupt the membrane fusion process required for viral entry. Their structural properties also suggest potential interactions with the host cell membrane, altering its lipid microdomains and impeding the fusion process. Furthermore, these peptides might inhibit the HIV-1 reverse transcriptase enzyme, blocking viral RNA to DNA transcription, or interact with viral assembly proteins to disrupt the formation of infectious virions. The exact mechanism for each peptide requires further investigation, including binding studies and structural analyses, to elucidate their precise targets and pathways of action." "432.48" "C17H32N6O7" "RNDCQEHILMFPSWYVOU" "G" "8.8" "1" "0" "1" "1" "1" "-0.72" "0.88" "4.4 hours" ">20 hour" ">10 hours" "20" "0" "0" " 30154377;## 17963357" "Mar Drugs. 2018 Aug 28;16(9):302;##Journal of natural products, 70(11), 1753–1760." "Frau J, Flores-Holguín N, Glossman-Mitnik D:##Plaza, A., Gustchina, E., Baker, H. L., Kelly, M., & Bewley, C. A. (2007)." "Chemical Reactivity Properties, pKa Values, AGEs Inhibitor Abilities and Bioactivity Scores of the Mirabamides A–H Peptides of Marine Origin Studied by Means of Conceptual DFT;##Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion" "10.3390/md16090302;##10.1021/np070306k" "Anti-HIV" "DRAVPe02263" "DVREEEQLGERATGLNLNI" "19" "B-HR2-scrambled" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "2156.34" "C89H150N28O34" "CHMFPSWOU" "E" "4.25" "2" "5" "-3" "4" "6" "-0.874" "3.14" "1.1 hours" "3 min" ">10 hours" "102.63" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02264" "ALHALGYQLAFVLDSPSAY" "19" "H-HR1-SC" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "2036.31" "C96H142N22O27" "RNCEHIFWOU" "AL" "5.08" "0" "1" "-1" "5" "10" "0.684" "-0.46" "4.4 hours" ">20 hour" ">10 hours" "118.42" "2980" "1.463" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HIV" "DRAVPe02262" "GENNELRLTRDAI" "13" "B-HR2-S" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=Show no inhibitory effects at 500 µM, implying that these peptides are ineffective at the tested concentrations" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "1500.63" "C61H105N21O23" "CQHKMFPSWYVOU" "RNL" "4.68" "2" "3" "-1" "3" "4" "-1.054" "3.88" "30 hours" ">20 hour" ">10 hours" "97.69" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02260" "TAAGDARANAVAKAGLHDLNIETDTERNH" "29" "B-HR1-scrambled" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "3032.24" "C124H203N43O46" "CQMFPSWYOU" "A" "5.33" "3" "5" "-2" "6" "11" "-0.734" "2.71" "7.2 hours" ">20 hours" ">10 hours" "74.48" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02261" "VEGQLGENNELRLTRDAIE" "19" "B-HR2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=Show no inhibitory effects at 500 µM, implying that these peptides are ineffective at the tested concentrations" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "2156.34" "C89H150N28O34" "CHKMFPSWYOU" "E" "4.25" "2" "5" "-3" "3" "4" "-0.874" "3.88" "100 hours" ">20 hours" ">10 hours" "102.63" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02259" "AGHATLREHLRDIKAENTDAN" "21" "B-HR1-S" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "2332.52" "C96H158N34O34" "CEGIMPYOU" "A" "6.02" "3" "4" "-1" "4" "7" "-1.086" "3.39" "4.4 hours" ">20 hours" ">10 hours" "74.76" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02258" "HATCSLAFALATSVALATRNDLLLRWAAARDAQTILSKRDR" "41" "H-HR2-scrambled" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "4469.15" "C194H324N62O57S1" "CEGIMPYOU" "A" "10.64" "6" "3" "3" "9" "22" "0.132" "1.84" "3.5 hours" "10 min" ">10 hours" "107.56" "5500" "1.231" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02257" "TSDVAAATNADLRTALARADHQKTLFWL" "28" "H-HR2-S" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=No significant inhibition" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "3057.42" "C134H214N40O42" "CEGIMPYOU" "A" "6.42" "3" "3" "0" "7" "14" "-0.118" "1.79" "7.2 hours" ">20 hours" ">10 hours" "91.07" "5500" "1.799" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02256" "RARRSLLIASALCTSDVAAATNADLRTALARADHQKTLFWL" "41" "H-HR2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=40% at 500 µM." "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "H-HR2 and B-HR1 also inhibit this step, but their effects are less pronounced compared to H-HR1." "4469.15" "C194H324N62O57S1" "EGMYOU" "A" "10.64" "6" "3" "3" "9" "22" "0.132" "1.84" "1 hour" "3 min" "2 min" "107.56" "5500" "1.231" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02255" "YQFHLVLHEALRAQALSRQLILGRELAQELVAELAT" "36" "H-HR1-scrambled" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=25–30 %" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxic effect observed for any peptide at the tested concentrations. Cell viability remained similar to untreated cells." "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "4101.76" "C185H303N53O52" "NDCGKMFPSTWYOU" "L" "6.04" "3" "4" "-1" "6" "19" "0.267" "1.04" "2.8 hours" "10 min" "2 min" "141.11" "1490" "0.363" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02253" "TARLQLEARLQHLVAEILEREQSLALHALGYQLAFV" "36" "H-HR1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=65% inhibition at 500 µM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxicity" "Linear" "Free" "Free" "None" "L" "Fusion machinery" "H-HR1 likely disrupts the formation of the fusion complex, as it specifically inhibits HSV-1 entry during the virus attachment-entry phase." "4101.76" "C185H303N53O52" "NDCKMPWOU" "L" "5.98" "3" "4" "-1" "6" "19" "0.267" "1.04" "7.2 hours" ">20 hour" ">10 hours" "141.11" "1490" "0.363" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02254" "LQLEARLQHLVAEILER" "17" "H-HR1-SN" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxicity" "Linear" "Free" "Free" "None" "L" "Fusion machinery" "The peptides derived from the heptad repeat (HR) regions of HSV-1 glycoproteins (gH and gB) inhibit the virus entry process by interfering with membrane fusion." "2031.39" "C90H155N27O26" "NDCGKMFPSTWYOU" "L" "5.5" "2" "3" "-1" "2" "9" "0.094" "1.69" "5.5 hours" "3 min" "2 min" "166.47" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02252" "AGDNATVAAGHATLREHLRDIKAENTDAN" "29" "B-HR1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV-1" "Herpesviridae" "Virus entry assays." "[Ref:16603508]:HSV:IC50=Shows minor inhibitory effects at 500 µM, indicating significantly lower activity. Its IC₅₀ is likely much higher than 500 µM, if effective at all." "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16603508]No cytotoxicity" "Linear" "Free" "Free" "None" "L" "Fusion machinery" "H-HR2 and B-HR1 also inhibit this step, but their effects are less pronounced compared to H-HR1." "3032" "C124H203N43O46" "CQMFPSWYOU" "A" "5.53" "3" "5" "-2" "6" "11" "-0.734" "2.71" "4.4 hours" ">20 hour" ">10 hours" "74.48" "0" "0" "16603508" "The Journal of general virology, 87(Pt 5), 1085–1097." "Galdiero, S., Vitiello, M., D'Isanto, M., Falanga, A., Collins, C., Raieta, K., Pedone, C., Browne, H., & Galdiero, M. (2006)." "Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B. " "10.1099/vir.0.81794-0" "Anti-HSV" "DRAVPe02251" "CLGVGSCNDFAGCGYAVVCFW" "21" "Siamycin I (Bacteriocin)" " Streptomyces strain AA6532" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "CPEb (XTT)" "[Ref:8557614]HSV:ID50=48µg/ml,HIV-1:ID50=7µg/ml" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:8557614]TD50=>100µg/ml" "Linear" "Free" "Amidation" "Two disulfide bonds linking Cys-1 with Cys-13and Cys-7 with Cys-19, as well as an amide bond joining the side chain of Asp-9 to the N-terminus Cys-1. Amino acid anal- ysis revealed that both compounds contained the same residues with the exception that one of two valines in saimycin I is replaced by isoleucine in siamycin II." "L" "Not Found" "Not Available" "2171.51" "C96H135N23O27S4" "EHIKMPQRT" "CG" "3.8" "0" "1" "-1" "11" "9" "1.143" "1.893" "1.2 hour" ">20 hour" ">10 hours" "69.52" "7240" "362" "8557614## 7797448" "J Antibiot (Tokyo). 1995 Dec;48(12):1515-7;##The Journal of antibiotics, 48(5), 433–434." "Detlefsen DJ, Hill SE, Volk KJ, Klohr SE, Tsunakawa M, Furumai T, Lin PF, Nishio M, Kawano K, Oki T, et al;##Tsunakawa, M., Hu, S. L., Hoshino, Y., Detlefson, D. J., Hill, S. E., Furumai, T., White, R. J., Nishio, M., Kawano, K., & Yamamoto, S. (1995). " "Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I;##Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization" "10.7164/antibiotics.48.1515;##10.7164/antibiotics.48.433" "Anti-HIV" "DRAVPe02250" "CLGIGSCNDFAGCGYAIVCFW" "21" "Siamycin II" "Streptomyces strains AA3891" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "CPEb (XTT)" "[Ref:7787424]HIV-1:ED50=0.08μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:7787424]TC50=150" "Linear" "Free" "Amidation" "It differs from Siamycin I only by one amino acid. Siamycin I has a valine residue at position 4. In both peptides, disulfide bonds link Cys1 with Cys13 and Cys7 with Cys19, and the side chain of Asp9 forms an amide bond with the N-terminus (XXJ). The original has been replaced since antimicrobial assays revealed no activity." "L" " as an inhibitor of fusion of gp160- and CD4-expressing cell" "Siamycin I inhibits fusion between C8166 cells and CEM-SS cells chronically infected with HIV (50% effective dose of 0.08 microM) but has no effect on Sendai virus-induced fusion or murine myoblast fusion." "2199.56" "C98H139N23O27S4" "EHKMPQRT" "CG" "3.8" "0" "1" "-1" "11" "9" "1.171" "2.069" "1.2 hour" ">20 hour" ">10 hours" "79.05" "7240" "362" "7787424## 7797448" "Journal of biomolecular NMR, 5(3), 271–286;##The Journal of antibiotics, 48(5), 433–434." "Constantine, K. L., Friedrichs, M. S., Detlefsen, D., Nishio, M., Tsunakawa, M., Furumai, T., Ohkuma, H., Oki, T., Hill, S., & Bruccoleri, R. E. (1995);##Tsunakawa, M., Hu, S. L., Hoshino, Y., Detlefson, D. J., Hill, S. E., Furumai, T., White, R. J., Nishio, M., Kawano, K., & Yamamoto, S. (1995). " "High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion;##Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization" "10.1007/BF00211754;##10.7164/antibiotics.48.433" "Anti-HIV" "DRAVPe02248" "DYNPYLLFLK" "10" "PB1-11" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "Orthomyxoviridae" "AlphaScreen" "[Ref:33166574]IAV:IC50=13 ± 1μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "Not included yet" "L" "PB1 (Basic polymerase 1 )" " The PB1-0 peptide has given excellent results in blocking the PA-PB1 interaction, in particular in the C-terminal domain of the PR8 (H1N1). The same results were confirmed by surface plasmon resonance (SPR) experiments. PB1-10 was obtained with the elimination of some amino acids from the N-terminus and C-terminus. With the addition of two substituents, the authors reached PB1-11, which proved to be the most active of all" "1285.51" "C64H92N12O16" "ARCQEGHIMSTWVOU" "L" "5.83" "1" "1" "0" "3" "4" "-0.09" "0.34" "1.1hour" "3 mins" ">10 hours" "117" "2980" "2.318" "33166574" "Antiviral research, 185, 104971." "Hejdánek, J., Radilová, K., Pachl, P., Hodek, J., Machara, A., Weber, J., Řezáčová, P., Konvalinka, J., & Kožíšek, M. (2021)." "structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor" "10.1016/j.antiviral.2020.104971" "Anti-IAV" "DRAVPe02249" "SRARIDARI" "9" "FluAPep 1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "orthomyxoviridae" "Docking studies" "[Ref:30597438]IAV:binding affinity (score = −246.155)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:30597438]ToxinPred analysis confirmed that designed peptides were non-toxic." "Linear" "Free" "Free" "None" "L" "PB1 (Basic polymerase 1 )" "Not Available" "1057.22" "C43H80N18O13" "NCQEGHLKMFPTWYVOU" "R" "11.7" "3" "1" "-2" "1" "4" "-0.578" "4.82" "1.9 hours" ">20 hours" ">10 hours" "108.89" "0" "0" "30597438" "Computational biology and chemistry, 78, 273–281." "Arivajiagane, A., Ravi Varadharajulu, N., Seerangan, K., & Rattinam, R. (2019)." "In silico structure-based design of enhanced peptide inhibitors targeting RNA polymerase PAN-PB1Cinteraction" " 10.1016/j.compbiolchem.2018.12.009" "Anti-IAV" "DRAVPe02247" "LSTAADMQGVVTDGMASGLDKDYLKPDD" "28" "p28" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "Orthomyxoviridae" "Docking studies" "[Ref:33575983]IAV=22 bonds" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "Not included yet" "L" "PB1 (Basic polymerase 1 )" "Docking studies showed that the p28 region forms strong and stable interactions with the C-terminus of PB1 (C-PB1) and other proteins of H1N1 IAV " "2914.21" "C122H197N31O47S2" "RNCEHIFWOU" "D" "3.85" "2" "6" "-4" "6" "10" "-0.371" "1.61" "5.5 hours" "3 min" "2 min" "73.21" "1490" "0.511" "33575983" "Molecular diversity, 25(3), 1929–1943." "Sasidharan, S., Gosu, V., Shin, D., Nath, S., Tripathi, T., & Saudagar, P. (2021)." "Therapeutic p28 peptide targets essential H1N1 influenza virus proteins: insights from docking and molecular dynamics simulations" "10.1007/s11030-021-10193-8" "Anti-IAV" "DRAVPe02246" "LVRPLAL" "7" "7-1 peptide " "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2, A/Aichi/2/68 (H3N2)" "Orthomyxoviridae" "Plaque reduction" "[Ref:26833245]IAV:IC50=6.4μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26833245]Negligible cytotoxicity" "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" " A random phage display library of 7-mer peptides was screened by affinity selection, obtaining the peptide LVRPLAL that showed the highest affinity toward H1 and H3 HAs. The avidin–biotin-peroxidase complex (ABC) system was exploited to evaluate the binding of this peptide to HA. It showed a Kd of 92 and 194 µM for H1 HA from A/New Caledonia/20/99 (H1N1) and H3 from A/Wyoming/3/2003 (H3N2), respectively. The C18-conjugated form of this peptide was tested in plaque reduction assay, showing a good activity toward A/Aichi/2/68 (H3N2) virus (6.4 µM) and a lower potency against A/Puerto Rico/8/34 (H1N1) virus (101 µM). The Ala scan indicated the importance of Arg3 and Pro4 for the HA binding, which was also assessed by docking calculations" "781.01" "C37H68N10O8" "NDCQEGHIKMFSTWYOU" "L" "9.79" "1" "0" "-1" "0" "5" "1.614" "-0.81" "5.5 hours" "3 min" "2 min" "222.86" "0" "0" "26833245" "Bioorganic & medicinal chemistry, 24(5), 1106–1114." "Matsubara, T., Onishi, A., Yamaguchi, D., & Sato, T. (2016). " "Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy" "10.1016/j.bmc.2016.01.039" "Anti-IAV" "DRAVPe02245" "ARDFYDYDVFYYAMD" "15" "PeB" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2/A/Aichi/2/68 X31 (H3N2)" "Orthomyxoviridae" "Infection inhibition" "[Ref:27415624]IAV:IC50=32 ± 5μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27415624]Neglible cytotoxicity" "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" "Not included yet" "1954.1" "C92H116N18O28S1" "NCQEGHILKPSTWVOU" "D" "3.77" "1" "4" "-3" "4" "6" "-0.506" "2.29" "4.4 hours" ">20 hours" ">10 hours" "32.67" "5960" "3.05" "27415624" "PloS one, 11(7), e0159074." "Memczak, H., Lauster, D., Kar, P., Di Lella, S., Volkmer, R., Knecht, V., Herrmann, A., Ehrentreich-Förster, E., Bier, F. F., & Stöcklein, W. F. (2016)." "Anti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus Binding" " 10.1371/journal.pone.0159074" "Anti-IAV" "DRAVPe02243" "ARDFYGYDVFFYAMD" "15" "C18-PeBGFa" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2/A/Aichi/2/68 X31 (H3N2), Rostock H7N1 " "Orthomyxoviridae" "Infection inhibition" "[Ref:26124860]IAV:IC50=1.2 µM and 2.8 µM," "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26124860]Negligible cytotoxicity" "Linear" "Not included yet" "Not included yet" "C17H35CO-" "L" "Head of HA" "The acylated peptide was able to block hemagglutination produced by the Aichi H3N2 and Rostock H7N1 viruses at 1.2 µM and 2.8 µM," "1880.06" "C90H114N18O25S1" "NQEHILKMPSTWOU" "DFY" "3.93" "1" "3" "-2" "3" "7" "-0.08" "1.44" "4.4 hours" ">20 hours" ">10 hours" "32.67" "4470" "2.378" "26124860" " Beilstein journal of organic chemistry, 11, 589–595." "Lauster, D., Pawolski, D., Storm, J., Ludwig, K., Volkmer, R., Memczak, H., Herrmann, A., & Bhatia, S. (2015)" "Potential of acylated peptides to target the influenza A virus" "10.3762/bjoc.11.65" "Anti-IAV" "DRAVPe02244" "ARDFYGYDVFFYAMD" "15" "PeBGF" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2/A/Aichi/2/68 X31 (H3N2)" "Orthomyxoviridae" "Infection inhibition" "[Ref:27415624]IAV:IC50=25 ± 6μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:27415624]Negligible cytotoxicity" "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" "The most interesting peptide was the PeBGF, which showed a micromolar activity in SPR, HI, neutralization, and infection inhibition assays toward both Aichi H3N2 and Rostock H7N1 viral strains" "1880.06" "C90H114N18O25S1" "NQEHILKMPSTWOU" "DFY" "3.93" "1" "3" "-2" "3" "7" "-0.08" "1.44" "4.4 hours" ">20 hours" ">10 hours" "32.67" "4470" "2.378" "27415624" "PloS one, 11(7), e0159074." "Memczak, H., Lauster, D., Kar, P., Di Lella, S., Volkmer, R., Knecht, V., Herrmann, A., Ehrentreich-Förster, E., Bier, F. F., & Stöcklein, W. F. (2016)." "Anti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus Binding" " 10.1371/journal.pone.0159074" "Anti-IAV" "DRAVPe02242" "LSRMPK" "6" "P1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/chicken/Tunisia/12/2010 (H9N2)" "Orthomyxoviridae" "In ovo antiviral activity" "[Ref:35306102]IAV:IC50=870μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:35306102]two peptides did not show toxicity on eggs and chicken lungs." "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" "Molecular docking calculations, carried out to depict the interaction between active peptides and hemagglutinin, indicated that P1 and P2 peptides bind different regions of the HA globular head: P1 occupies the RBS, while P2 occupies a site close to the RBS and interacts with the 220-loop " "730.92" "C31H58N10O8S1" "ANDQEHIFTWYVOU" "RLKMPS" "11" "2" "0" "2" "0" "2" "-0.85" "2.76" "5.5 hours" "3 mins" "2 min" "65" "0" "0" "35306102" "Virus research, 313, 198745." "Arbi, M., Larbi, I., Nsiri, J., Behi, I. E., Rejeb, A., Miled, K., Ghram, A., & Houimel, M. (2022). " "Inhibition of avian influenza virus H9N2 infection by antiviral hexapeptides that target viral attachment to epithelial cells" "10.1016/j.virusres.2022.198745" "Anti-IAV" "DRAVPe02241" "FAPRWR" "6" "P2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H9N1/A/chicken/Tunisia/12/2010 (H9N2) " "Orthomyxoviridae" "In ovo antiviral activity" "[Ref:35306102]IAV:IC50=620μM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:35306102]two peptides did not show toxicity on eggs and chicken lungs." "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" "Molecular docking calculations, carried out to depict the interaction between active peptides and hemagglutinin, indicated that P1 and P2 peptides bind different regions of the HA globular head: P1 occupies the RBS, while P2 occupies a site close to the RBS and interacts with the 220-loop " "831.98" "C40H57N13O7" "NDCEGIFSYOU" "R" "12" "2" "0" "2" "0" "3" "-1.15" "3.78" "1.1hour" "3 min" "2 min" "16.67" "5500" "6.611" "35306102" "Virus research, 313, 198745." "Arbi, M., Larbi, I., Nsiri, J., Behi, I. E., Rejeb, A., Miled, K., Ghram, A., & Houimel, M. (2022). " "Inhibition of avian influenza virus H9N2 infection by antiviral hexapeptides that target viral attachment to epithelial cells" "10.1016/j.virusres.2022.198745" "Anti-IAV" "DRAVPe02240" "WTGDFFSSHYTVPRC" "15" "iHA-100" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/H5-HA" "Orthomyxoviridae" "Surface Plasmon Resonance" "[Ref:33976181]IAV:IC50=0.0015μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "None" "L" "Head of HA" "Escape mutant isolation demonstrated its binding at the stalk region of HA, confirmed by the stabilization effect its binding produces on HA trypsin degradation, but interaction on the globular head was not excluded. The macrocycle peptide was tested in vivo on mice infected with lethal H5N1 IAV. iHA-100 rescued 40% of mice and showed better efficacy when administered in the early or late phases of infection. " "1802.98" "C83H111N21O23S1" "ANQEILKMOU" "FST" "6.73" "1" "1" "0" "5" "5" "-0.407" "1.72" "2.8 hours" "3 mins" "2 mins" "19.33" "6990" "3.877" "33976181" "Nature communications, 12(1), 2654." "Saito, M., Itoh, Y., Yasui, F., Munakata, T., Yamane, D., Ozawa, M., Ito, R., Katoh, T., Ishigaki, H., Nakayama, M., Shichinohe, S., Yamaji, K., Yamamoto, N., Ikejiri, A., Honda, T., Sanada, T., Sakoda, Y., Kida, H., Le, T. Q. M., Kawaoka, Y., … Kohara, M. (2021). " "Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models" " 10.1038/s41467-021-22964-w" "Anti-IAV" "DRAVPe02238" "ARLPR" "5" "C18-s2(1–5)" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/Puerto Rico/8 (H1N1)" "Orthomyxoviridae" "Plaque reduction" "[Ref:20476787]IAV:IC50=1.9μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Amidation" "C17H35CO" "L" "Binding the head of HA (protein present at the out membrane of the virus)" "Not included yet" "611.75" "C26H49N11O6" "NDCQEGHIKMFSTWYVOU" "R" "12" "2" "0" "2" "0" "2" "-1" "4.62" "4.4 hours" ">20 hours" ">10 hours" "98" "0" "0" "20476787" "Journal of medicinal chemistry, 53(11), 4441–4449." "Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., Nagata, K., Okahata, Y., & Sato, T. (2010)." "Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy" "10.1021/jm1002183" "Anti-IAV" "DRAVPe02239" "MARRPVNHAUMARRPVNHAUMARRPVNHAUMARRPVNHAU" "40" "PVF-tet" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/Puerto Rico/8 (H1N1)" "Orthomyxoviridae" "Infection inhibition" "[Ref:31919357]IAV:IC50=1.4μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "4-3Lys" "L" "Head of HA" "This compound did not block viral entry into the cell as expected because of its binding to HA and did not act on the fusion process or in the HI assay. In fact, PVF-tet does not interact with H1 and H2, but likely does with the H0 of newly synthesized viral particles. PVF-tet is a cell-penetrating peptide, and its addition to the infected cell causes the amassment of HA in a vacuole-like structures named amphisomes" "1348.45" "C55H88N20O13S1Se1" "DCQEGILKSTWYO" "AR" "12" "2" "0" "2" "1" "2" "-0.436" "4.87" "30 hours" ">20 hours" ">10 hours" "44.5" "0" "0" "31919357" "Nature communications, 11(1), 162." "Omi, J., Watanabe-Takahashi, M., Igai, K., Shimizu, E., Tseng, C. Y., Miyasaka, T., Waku, T., Hama, S., Nakanishi, R., Goto, Y., Nishino, Y., Miyazawa, A., Natori, Y., Yamashita, M., & Nishikawa, K. (2020)" "The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection" "10.1038/s41467-019-13974-w" "Anti-IAV" "DRAVPe02237" "ARLPRTMVHPKPAQP" "15" "C18-s2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/Puerto Rico/8 (H1N1)" "Orthomyxoviridae" "Plaque reduction" "[Ref:20476787]IAV:IC50=11μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Free" "Amidation" "C17H35CO" "L" "Binding the head of HA (protein present at the out membrane of the virus)" " Interfering with the fusogenic activity of HA." "1699.05" "C75H127N25O18S1" "NDCEGIFSYOU" "P" "12.01" "3" "0" "3" "2" "5" "-0.88" "2.21" "4.4 hours" ">20 hours" ">10 hours" "58.67" "0" "0" "20476787" "Journal of medicinal chemistry, 53(11), 4441–4449." "Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., Nagata, K., Okahata, Y., & Sato, T. (2010)." "Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy" "10.1021/jm1002183" "Anti-IAV" "DRAVPe02236" "IHAEIKNSLKIDNLDVNRCIEAL" "23" "LEDGF/p75 (355-377)" "Synthetic construct" "O75475" "Experimentally Validated" "9606" "PSIP1" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "Retroviridae" "Not Available" "[Ref.18331842]Human immunodeficiency virus (HIV): Inhibition of integrase activity (3' end processing)(IC50=165±28 µM); inhibition of integrase activity(strand transfer)(IC50=153±28 µM)." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Found" "Linear" "Free" "Free" "None" "L" "Integrase" "The LEDGF/p75 peptide modestly inhibited IN catalysis and was dependent on IN–DNA assembly. The peptide was also effective at disrupting LEDGF/p75–IN complex formation." "2622.03" "C113H193N33O36S" "FGMPQTWY" "I" "5.48" "4" "4" "0" "5" "10" "-0.048" "-41.68" "20 hour" "30 min" ">10 hours" "140" "0" "0" "18331842" "FEBS Lett. 2008 Apr 30;582(10):1425-30." "Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N." "Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis" "10.1016/j.febslet.2008.02.076" "Anti-IAV" "DRAVPe02235" "RRKKWLVFFVIFYFFR" "16" "FP4" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "Orthomyxoviridae" "Plaque reduction" "[Ref:22258859]IAV:IC50=0.00004μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "Not included yet" "L" "Hemagglutinin protein" "The mechanism of action was demonstrated to be the interference with the viral attachment via contact with HA, as demonstrated by ELISA assay, but they do not block hemagglutination produced by the virus, so they do not interact on the receptor binding site. Moreover, the compounds were tested on Balb/c mice infected with a lethal dose of A/WSN/33 virus, showing an ability to reduce the viral titer by 2–4 log units" "2252.78" "C117H166N28O18" "ANDCEQGHMPSTOU" "F" "11.73" "5" "0" "5" "1" "10" "0.45" "1.3" "1 hours" "2 min" "2 mins" "85" "6990" "3.103" "22258859" "The Journal of general virology, 93(Pt 5), 980–986." "Nicol, M. Q., Ligertwood, Y., Bacon, M. N., Dutia, B. M., & Nash, A. A. (2012)." "A novel family of peptides with potent activity against influenza A viruses" "10.1099/vir.0.038679-0" "Anti-IAV" "DRAVPe02234" "GLFGAIAGFIKNGWKGMIKG" "20" "HA-FP-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2" "Orthomyxoviridae" "Cytopathic Effect Reduction" "[Ref:33392200]IAV:IC50=1.73μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "Not included yet" "L" "Hemagglutinin protein" "these peptides specifically blocked the entry of IAV into host cells via the interaction of the pFPs and the HA2 subunit, most likely due to interactions between the N-terminal portion of HA2. The positively charged lysine residues of pFPs strongly interact with glutamic acid or aspartic acid, negatively charged, of the HA2 subunit via ionic contacts and hydrogen bonds" "2065.51" "C98H153N25O22S1" "RDCQEHPSTYVOU" "G" "10.3" "3" "0" "3" "1" "10" "0.495" "-0.81" "30 hours" ">20 hours" ">10 hours" "88" "5500" "2.663" "33392200" "Frontiers in cell and developmental biology, 8, 611121." "Wu, W., Lin, D., Shen, X., Li, F., Fang, Y., Li, K., Xun, T., Yang, G., Yang, J., Liu, S., & He, J. (2015). " "New influenza A Virus Entry Inhibitors Derived from the Viral Fusion Peptides" "10.3389/fcell.2020.611121" "Anti-IAV" "DRAVPe02233" "GTYDHDVYRDEALNNRFQIKGVELKSGYKDWGSGSGC" "37" "P155–185-Chol" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H3N2" "Orthomyxoviridae" "Plaque reduction" "[Ref:21994935]IAV:IC50=27.21µg/mL" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:21994935]The peptides were non-cytotoxic in an ex vivo model and may be safe for in vivo use." "Linear" "Not included yet" "Not included yet" "(PEG4-Chol)NH2, (155–185-Chol and 155–181-Chol)" "L" "Hemagglutinin protein" " The complete sequence (155–185) corresponds to the HA2 portion that bundles to the inner coiled-coil that is crucial for the fusion process; compound P155–181 lacks the four final residues between the N-capped coiled-coil and the transmembrane domain, while compound P155–175 corresponds to the most truncated sequence deficient the N-cap motif. Only cholesterol-tagged compounds containing the N-cap motif (155–185-Chol and 155–181-Chol) demonstrated antiviral activity against IAV/H3N2 in cell culture, most likely due to the ability of the cholesterol to fasten the peptide to the membrane and to form nanoparticles" "4166.51" "C181H270N52O60S1" "MPOU" "G" "5.55" "5" "6" "-1" "10" "9" "-1.03" "2.56" "30 hours" ">20 hours" ">10 hours" "50" "9970" "2.393" "21994935" "The Journal of biological chemistry, 286(49), 42141–42149." "Lee, K. K., Pessi, A., Gui, L., Santoprete, A., Talekar, A., Moscona, A., & Porotto, M. (2011). " "Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus" "10.1074/jbc.M111.254243" "Anti-IAV" "DRAVPe02232" "GYHHQNEQGSGYAADLK" "17" "C3LB-HA" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/Puerto Rico/916/34 (H1N1)" "Orthomyxoviridae" "Cytopathic Effect inhibition" "[Ref:24146939]IAV:IC50=5.90 (µg/mL)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:24146939]inhibit IAV without cytotoxicity." "Linear" "Not included yet" "Not included yet" "None" "L" "Hemagglutinin protein" "The binding to the HA, which prevents the conformational rearrangements inside the endosome, is the most likely mechanism of action.By in silico analysis of different HA1 and HA2, they discovered conserved regions (40–50 amino acids at the N- and C-terminal of HA1, and 80 amino acids at the N-terminal of HA2) that revealed short regions of HA1 N- and C-terminal ends characterized by hydrophilic, flexible, charged, and exposed (antigenic) sequences. Inhibitory activity of those peptides against IAV of various origins (human, swine, and avian) demonstrates the ability to inhibit IAV without cytotoxicity. The binding to the HA, which prevents the conformational rearrangements inside the endosome, is the most likely mechanism of action. Docking studies revealed that AVPs form several hydrogen bonds and electrostatic contacts in the HA stalk region with the fusion peptide, helix A, helix B, and loop B that could be responsible for the inhibition of HA conformational changes. Nevertheless, they did not show the stability at endosomal pH " "1874.94" "C80H115N25O28" "RCIMFPTWVOU" "G" "5.99" "1" "2" "-1" "5" "3" "-1.471" "2.37" "30 hours" ">20 hours" ">10 hours" "34.71" "5500" "1.589" "24146939" "PloS one, 8(10), e76876." "López-Martínez, R., Ramírez-Salinas, G. L., Correa-Basurto, J., & Barrón, B. L. (2013). " "Inhibition of influenza A virus infection in vitro by peptides designed in silico" "10.1371/journal.pone.0076876" "Anti-IAV" "DRAVPe02230" "FHRKKGRGKHK" "11" "None" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "Orthomyxoviridae" "Neutralization" "[Ref:15729820]IAV:1 log unit inhibitory activity" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "None" "L" "Hemagglutinin protein" " interfering with the fusogenic activity of HA." "1378.65" "C61H103N25O12" "ANDCQEILMPSTWYVOU" "K" "12.03" "6" "0" "6" "0" "1" "-2.636" "5.13" "1.1 hours" "3 min" "2 mins" "0" "0" "0" "15729820" "Journal of chromatography. A, 1064(1), 59–66." "Zhao, R., Fanga, C., Yu, X., Liu, Y., Luo, J., Shangguan, D., Xiong, S., Su, T., & Liu, G. (2005)." "Screening of inhibitors for influenza A virus using high-performance affinity chromatography and combinatorial peptide libraries" "10.1016/j.chroma.2004.12.023" "Anti-IAV" "DRAVPe02231" "GLFGAIAGFIKNGWKGMIKG" "20" "HA-FP-1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1/A/Puerto Rico/8/34 (H1N1)" "Orthomyxoviridae" "Cytopathic Effect inhibition" "[Ref:26382764]IAV:IC50=9.61 (µg/mL)" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:26382764]Neglible cytotoxicity" "Linear" "Not included yet" "Not included yet" "None" "L" "Hemagglutinin protein" " interfering with the fusogenic activity of HA. As revealed by fusion and hemolysis inhibition assays, these peptides specifically blocked the entry of IAV into host cells via the interaction of the pFPs and the HA2 subunit,most likely due to interactions between the N-terminal portion of HA2. The positively charged lysine residues of pFPs strongly interact with glutamic acid or aspartic acid, negatively charged, of the HA2 subunit via ionic contacts and hydrogen bonds" "2065.51" "C98H153N25O22S1" "RDCQEHPSTYVOU" "G" "10.03" "3" "0" "3" "1" "10" "0.495" "-0.81" "30 hours" ">20 hours" ">10 hours" "88" "5500" "2.663" "  26382764" "PloS one, 10(9), e0138426." "Wu, W., Lin, D., Shen, X., Li, F., Fang, Y., Li, K., Xun, T., Yang, G., Yang, J., Liu, S., & He, J. (2015). " "New influenza A Virus Entry Inhibitors Derived from the Viral Fusion Peptides" " 10.1371/journal.pone.0138426" "Anti-IAV" "DRAVPe02229" "ELVDPVVAAGAVVTSSGIVFFS" "22" "IntPep" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "Influenza A H1N1" "Orthomyxoviridae" "Structural studies" "[Ref:33392200]IAV:IC50=47 ± 12% and 41 ± 8%μM" "[Ref:33392200]Low hemolytic activity" "[Ref:33392200]Low cytotoxicity " "Linear" "Not included yet" "Not included yet" "None" "L" "Neuraminidase protein" " IntPep peptides were able to interact with the TM2 domain (region 316–333) of human NEU1 and disrupt its dimerization with consequent losses in sialidase activity. Furthermore, these IntPeps inhibit membrane sialidase activity triggered by elastin-derived peptides in macrophages, which are highly dependent on NEU1 ." "2164.48" "C100H158N22O31" "RNCQHKMWYOU" "V" "3.67" "0" "2" "-2" "4" "13" "1.455" "-0.86" "1 hour" "30 min" ">10 hour" "128.18" "0" "0" "33392200" "Frontiers in cell and developmental biology, 8, 611121." "Albrecht, C., Kuznetsov, A. S., Appert-Collin, A., Dhaideh, Z., Callewaert, M., Bershatsky, Y. V., Urban, A. S., Bocharov, E. V., Bagnard, D., Baud, S., Blaise, S., Romier-Crouzet, B., Efremov, R. G., Dauchez, M., Duca, L., Gueroult, M., Maurice, P., & Bennasroune, A. (2020). " "Transmembrane Peptides as a New Strategy to Inhibit Neuraminidase-1 Activation" "10.3389/fcell.2020.611121" "Anti-IAV" "DRAVPe02228" "PGEKGPSGEAGTAGPPGTPGPQGL" "38" "Peptide P" "cod skin hydrolysates" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "H1N1" "Orthomyxoviridae" "Cytopathic Effect Reduction" "[Ref:30308963]IAV:IC50=471 ± 12 g/mL." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Linear" "Not included yet" "Not included yet" "None" "L" "Neuraminidase protein" "This compound showed a NA inhibitory activity with Ki of 0.29 mM, and it was demonstrated to directly bind to free enzymes. The cytopathic effect reduction assay showed that the peptide P protected MDCK cells from viral infection and reduced viral production in a dose-dependent manner with an EC50 value of 471 ± 12 μg/mL against PR8 (H1N1)" "2116.27" "C90H142N26O33" "RNDCHIMFWYVOU" "G" "4.53" "1" "2" "-1" "14" "3" "-0.917" "0.71" ">20 hours" ">20 hours" "Unknown" "24.58" "0" "0" "30308963" "Drugs. 2018;16:377. doi: 10.3390/md16100377. " "Li J., Chen Y., Yuan N., Zeng M., Zhao Y., Yu R., Liu Z., Wu H., Dong S." "A Novel Natural Influenza A H1N1 Virus Neuraminidase Inhibitory Peptide Derived from Cod Skin Hydrolysates and Its Antiviral Mechanism. Mar." " 10.3390/md16100377" "Anti-IAV" "DRAVPe02227" "RRCICTTRTCRFPYRRLGTCLFQNRVYTFCC" "31" "GNCP-2 " "Cavia porcellus" "P49112,Q9R0Z5" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "N/A" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Bridge" "Not included" "Free" "Free" "Three Disulfide bridges. Seq differs from GNCP-1 only at position 21 (L here and I for GNCP-1)." "L" "Not found" "Not Available" "3838.58" "C164H262N54O41S6" "ADEHKMSW" "R" "9.8" "7" "0" "7" "15" "7" "-0.223" "-93.39" "1 hour" "2 min" "2 min" "47.1" "3355" "111.83" "8173076" "DNA Seq. 1993;4(2):123-128" "Nagaoka I, Nonoguchi A, Yamashita T." "Cloning and characterization of the guinea pig neutrophil cationic peptide-1 and -2 genes." "Anti-HIV" "DRAVPe02225" "FLPVLAGIAAKVVPALFCKITKKC" "24" "Brevinin-1 " "frog, Rana brevipoda porsa, Japan, Asia" "P32423" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HSV" "Herpesviridae" "Virus inhibition assays" "[Ref:10795591]HSV-1:IC50=10 ug/ml ,HSV-2:IC50=100 ug/ml" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Cyclization (Cys18 and Cys24)" "Disulfide bond between Cys18 and Cys24." "L" "Not found" "Not Available" "2531.24" "C121H204N28O26S2" "DEHMNQRSWY" "AK" "9.7" "4" "0" "4" "4" "14" "1.288" "28.65" "1.2 hour" ">20 hour" ">10 hour" "134.17" "125" "5.43" "10795591" "official publication of the European Society of Clinical Microbiology, 19(3), 187–194." "Yasin, B., Pang, M., Turner, J. S., Cho, Y., Dinh, N. N., Waring, A. J., Lehrer, R. I., & Wagar, E. A. (2000)." "Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides" "10.1007/s100960050457" "Anti-HSV" "DRAVPe02226" "ALWKNMLKGIGKLAGKAALGAVKKLVGAES" "30" "Dermaseptin-3 " "Phyllomedusa sauvagei (Sauvage's leaf frog)" "P80279" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1" "N/A" "Not Available" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" " Bridge " "Linear" "Cyclization (N termini to C termini)" "Cyclization (N termini to C termini)" "Disulfide bonds between Cys4 and Cys20; Cys8 and Cys22; Cys13 and Cys27." "L" "Not found" "Not Available" "3148.75" "C133H215N37O39S6" "DFHLMQT" "C" "8.33" "3" "1" "2" "15" "9" "0.53" "-9" "30 hour" ">20 hour" ">10 hour" "78" "7365" "253.97" "7989335" "J Biol Chem. 1994;269(50):31635-31641" "Mor A, Hani K, Nicolas P. 1994" "The Vertebrate Peptide Antibiotics Dermaseptins Have Overlapping Structural Features but Target Specific Microorganisms" "N/A" "Anti-HIV" "DRAVPe02223" "SGSWNFFDWFSGLMSWFGG" "19" "RVFV-9" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21403" "Not experimentally validated" "11588" "GP" "Not Available" "1137-1155" "Not Available" "Not Available" "Not Available" "Not Available" "6EGT" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2215.43" "C108H131N23O27S1" "ARCQETVOU" "F" "3.8" "0" "1" "-1" "5" "9" "0.126" "-0.05" "1.9 hours" ">20 hours" ">10 hours" "20.53" "16500" "7.448" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02224" "CLGIGSCNDFAGCGYAVVCFW" "21" "Tricyclic peptide RP 71955 " "Streptomyces sp. (strain SP9440) (Gram-positive bacteria)" "P37046" "Experimentally Validated" "72594" "Not Available" "Not Available" "1 to 21" "Not Available" "Not Available" "Not Available" "Not Available" "1RPB##1RPC" "HIV-1" "Retroviridae" "Antiviral Assay" "[Ref:8286361] inhibited the HIV-1 aspartyl protease (IC50, 35 ug/ml) a" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Beta strand" "Cyclic" "Cyclization of a N-terminal between Cys1 and Asp9" "Free" "An internal amide bond between the NH2 of C1 and the gamma-COOH of D9 was observed, as well as two disulfide bridges, one between C1 and C13 and one between C7 and C19. In contrast. Class 2 lassos do not have disulfide bonds. " "L" "Not found" "Not Available" "2185.53" "C97H137N23O27S4" "EHKMPQRT" "CG" "3.8" "0" "1" "-1" "11" "9" "1.157" "19.81" "1.2 hour" ">20 hour" ">10 hour" "74.29" "7240" "362" "8286361;##8270499 " "Biochemistry. 1994 Jan 11;33(1):42-50;##J Antibiot (Tokyo). 1993 Nov;46(11):1756-1757. " "Fréchet D, Guitton JD, Herman F, Faucher D, Helynck G, Monegier du Sorbier B, Ridoux JP, James-Surcouf E, Vuilhorgne M." "Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus;##Isolation of RP 71955, a new anti-HIV-1 peptide secondary metabolite." "10.1021/bi00167a006;##10.7164/antibiotics.46.1756" "Anti-HIV" "DRAVPe02221" "WNFFDWFSGLMSWFGGPLKTI" "21" "RVFV-7" "Rift Valley fever virus (RVFV) Gc stem region" "P21401" "Not experimentally validated" "11589" "Not Available" "Not Available" "1140-1160" "Not Available" "Not Available" "Not Available" "Not Available" "6EGT" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2536.93" "C127H166N26O28S1" "ARCQETVOU" "F" "5.84" "1" "1" "0" "4" "11" "0.31" "-0.4" "2.8 hours" "16 mins" "8 mins" "55.71" "16500" "6.504" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02222" "SWNFFDWFSGLMSWFGGPLK" "20" "RVFV-8" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21403" "Not experimentally validated" "11588" "GP" "Not Available" "1139-1158" "Not Available" "Not Available" "Not Available" "Not Available" "6EGT" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2409.75" "C120H153N25O27S1" "ARCQETVOU" "F" "5.55" "1" "1" "0" "4" "10" "0.095" "-0.14" "1.9 hours" ">20 hours" ">10 hours" "39" "16500" "6.847" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02218" "FVGAAVSCDAAFLNLTGCY" "19" "RVFV-4" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21403" "Not experimentally validated" "11588" "GP" "Not Available" "1022-1040" "Not Available" "Not Available" "Not Available" "Not Available" "4HJ1##4HJC##6EGT##6F9B" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "1922.2" "C86H128N20O26S2" "RQEHIKMPWOU" "A" "3.8" "0" "1" "-1" "3" "12" "1.221" "-0.74" "1.1 hours" "3 min" "2 min" "92.63" "1490" "0.775" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02219" "WNFFDWFSGLMSWFGGPLKLY" "21" "RVFV-5" "Rift Valley fever virus (RVFV) Gc stem region" " P03518" "Not experimentally validated" "11588" "GP" "Not Available" "1140-1160" "Not Available" "Not Available" "Not Available" "Not Available" "6EGT" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2599" "C132H168N26O28S1" "ARCQETVOU" "F" "5.83" "1" "1" "0" "4" "11" "0.248" "-0.52" "2.8 hours" "3 min" "2 mins" "55.71" "17990" "6.922" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02220" "WNFFDWFSGLMSWFGGPLK" "19" "RVFV-6" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21403" "Not experimentally validated" "11588" "GP" "Not Available" "1140-1158" "Not Available" "Not Available" "Not Available" "Not Available" "4HJ1##4HJC##6EGT##6F9B" "EBOV" "Filoviridae" "Virus inhibition assays" "[Ref:24069485]EBOV:IC50=50µM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:24069485] Very very less toxic (MTT toxicity assays on Vero E6 cells assessed the toxicity of RVFV-6, revealing a reduction in cell viability at peptide concentrations up to 50 microM, suggesting" "Not Available" "Linear" "Free" "Free" "None" "L" "DII domain of the E protein (RVFV-6 interact with a specific region of the Ebola virus (EBOV) during" "RVFV-6, a peptide derived from the RVFV Gc stem region, exhibits potent inhibition of Ebola virus (EBOV), achieving nearly 100% reduction in plaques at a 50 microM concentration. Despite not interfering with EBOV binding to cells, RVFV-6 effectively inhibits EBOV infectivity, suggesting its potential as an antiviral therapy against EBOV and related viruses." "2322.67" "C117H148N24O25S1" "ARCQETVOU" "F" "5.84" "1" "1" "0" "3" "10" "0.142" "-0.32" "2.8 hours" "15 mins" "7 mins" "41.05" "16500" "7.104" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02216" "WGCGCFNVNPSCLFVHTYL" "19" "RVFV-2" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21401" "Not experimentally validated" "11588" "GP" "Not Available" "821-839" "Not Available" "Not Available" "Not Available" "Not Available" "4HJ1##4HJC##6EGT##6F9B" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2160.51" "C99H138N24O25S3" "ARDQEIKMKMOU" "C" "6.71" "0" "0" "0" "10" "10" "0.674" "-0.41" "2.8 hours" "11 mins" "3 mins" "71.58" "6990" "3.235" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02217" "LGASSSRFTNWGSVSLSLD" "19" "RVFV-3" "Rift Valley fever virus (RVFV) Gc stem region" "P03518##P21402" "Not experimentally validated" "11588" "GP" "Not Available" "875-893" "Not Available" "Not Available" "Not Available" "Not Available" "4HJ1##4HJC##6EGT##6F9B" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "1984.15" "C86H134N24O30" "CQEHIKMPYOU" "S" "5.84" "1" "1" "0" "6" "7" "0.079" "1.33" "5.5 hours" "3 min" "2 mins" "82.11" "5500" "2.772" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02214" "HGVSGHGQHGVHG" "13" "Alloferon-1 " "Calliphora vicina (Blue blowfly) (Calliphora erythrocephala)" "P83412" "Experimentally Validated" "7373" "Not Available" "Not Available" "1 to 13" "Not Available" "Not Available" "Not Available" "Not Available" "None" "IAV,IBV, HHV-1" "Orthomyxoviridae" "Antiviral Assay" "[Ref:21766388] HHV:inhibited the Human Herpes Virus type 1 (HHV-1) multiplication" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Amination" "Free" "the N-terminal amine, the three imidazoles of H1, H6, and H9 participate in the coordination of Zn(II)" "L" "Not found" "Not Available" "1265.31" "C52H76N22O16" "ACDEFIKLMNPRTWY" "G" "7.1" "4" "0" "4" "6" "2" "-0.823" "-14.8" "3.5 hour" "30 min" ">10 hour" "44.62" "0" "0" "12235362" "Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32;##an official publication of the European Peptide Society, 17(11), 715–719." "Chernysh S, Kim SI, Bekker G, Pleskach VA, Filatova NA, Anikin VB, Platonov VG, Bulet P;##Kuczer, M., Midak-Siewirska, A., Zahorska, R., Luczak, M., & Konopińska, D." "Antiviral and antitumor peptides from insects;##Further studies on the antiviral activity of alloferon and its analogues" "10.1073/pnas.192301899;##10.1002/psc.1388" "Anti-IAV,Anti-IBV, Anti-HHV-1" "DRAVPe02215" "YWTGSISPKCLSSRRCHLV" "19" "RVFV-1" "Rift Valley fever virus (RVFV) Gc stem region" "P03518" "Not experimentally validated" "11588" "GP" "Not Available" "762-780" "Not Available" "Not Available" "Not Available" "Not Available" "4HJ1##4HJC##6EGT##6F9B" "EBOV" "Filoviridae" "Virus inhibition assays" "Not Available" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "Not Available" "2193.57" "C96H153N29O26S2" "ANDQEMFOU" "S" "9.5" "3" "0" "3" "2" "7" "-0.153" "1.67" "2.8 hours" "10 mins" "2 mins" "76.84" "6990" "3.187" "24069485" "PLoS Negl Trop Dis. 2013;7(9):e2430." "Koehler JW, Smith JM, Ripoll DR, et al." "A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses" "10.1371/journal.pntd.0002430" "Anti-EBOV" "DRAVPe02213" "QLESLTDRELLLLIARKTCGSVE" "23" "E30pep-wt" "Synthetic construct" "Q05323" "Experimentally Validated" "128952" "VP30(911826)" "Not Available" "91-113" "Not Available" "AF086833.2" "Genomic RNA" "Chromosome:8,509 - 9,375" "5DVW##5T3T" "EBOV" "Filoviridae" "Virus inhibition assays" "[Ref:12912982] IC50 = 1 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Cyclic" "Amination" "Carboxylation" "None" "L" "VP30" "E30pep-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30pep-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs." "2588.01" "C111H195N31O37S1" "NHMFPWYOU" "L" "4.87" "3" "4" "-1" "5" "10" "0.087" "1.71" "0.8 hours" "10 mins" "10 hours" "135.67" "0" "0" "12912982" " J Biol Chem. 2003;278(43):41830-6." "Hartlieb B, Modrof J, Mühlberger E, et al." "Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide." "10.1074/jbc.M307036200" "Anti-EBOV" "DRAVPe02212" "DDIWK" "5" "BST-2/Tetherin" "HIV-1" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV-1,EBOV,MV" "Filoviridae" "Antiviral Assay" "[Ref:19036818]HIV-1:tetherin inhibits the release of a variety of lentiviruses in a manner that can be reversed by the HIV-1 Vpu protein." "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Not found" "BST-2, or Tetherin, restricts the release of Ebola virus-like particles (VLPs) from infected cells by tethering the budding virions to the cell membrane, thereby inhibiting their release. This restriction is similar to BST-2's activity against other enveloped viruses like HIV-1. However, Ebola glycoprotein (GP) has evolved mechanisms to counteract BST-2, enabling efficient release of Ebola VLPs. The specific molecular mechanisms by which Ebola GP antagonizes BST-2 are still under investigation, but it likely involves disrupting the interaction between BST-2 and virions, potentially by interfering with BST-2 ectodomain self-interaction." "675.74" "C31H45N7O10" "ARNCQEGHLMFPSTYVOU" "D" "4.21" "1" "2" "-1" "0" "2" "-1.46" "3.14" "1.1 hours" "3 min" ">10 hour" "78" "8800" "8.139" "19929170##19036818" "AIDS research and human retroviruses, 25(12), 1197–1210##Journal of virology, 83(4), 1837–1844." "Tokarev A, Skasko M, Fitzpatrick K, et al##Jouvenet, N., Neil, S. J., Zhadina, M., Zang, T., Kratovac, Z., Lee, Y., McNatt, M., Hatziioannou, T., & Bieniasz, P. D. (2009)." "Antiviral activity of the interferon-induced cellular protein BST-2/tetherin##Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin" "10.1089/aid.2009.0253##10.1128/JVI.02211-08" "Anti-EBOV,Anti-HIV" "DRAVPe02211" "WWIVVV" "6" "BetaWWI-4" "HIV gp41 C-terminus (C-peptides)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,EBOV" "Retroviridae" "HIV infectivity assays" "[Ref:16173723]HIV:EC50=5.3 ± 0.5 μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " Inhibit viral fusion with host cell by intramolecular protein-protein interactions." "801" "C43H60N8O7" "ARNDCQEGHLKMFPSTYOU" "V" "5.49" "0" "0" "0" "0" "6" "2.55" "-3.61" "100 hours" ">20 hours" ">10 hour" "210" "11000" "13.733" "16173723" "J Am Chem Soc. 2005;127(38):13126-7." "Stephens OM, Kim S, Welch BD, et al." "Inhibiting HIV fusion with a beta-peptide foldamer." "10.1021/ja053444+" "Anti-EBOV,Anti-HIV" "DRAVPe02209" "VVVIWW" "6" "BetaWWI-2" "HIV gp41 C-terminus (C-peptides)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,EBOV" "Retroviridae" "HIV infectivity assays" "[Ref:16173723]HIV:EC50=15 ± 1.6μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " Inhibit viral fusion with host cell by intramolecular protein-protein interactions." "801" "C43H60N8O7" "ARNDCQEGHLKMFPSTYOU" "V" "5.49" "0" "0" "0" "0" "6" "2.55" "-3.61" "100 hours" ">20 hours" ">10 hour" "210" "11000" "13.733" "16173723" "J Am Chem Soc. 2005;127(38):13126-7." "Stephens OM, Kim S, Welch BD, et al." "Inhibiting HIV fusion with a beta-peptide foldamer." "10.1021/ja053444+" "Anti-EBOV,Anti-HIV" "DRAVPe02210" "VVVWWI" "6" "BetaWWI-3" "HIV gp41 C-terminus (C-peptides)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,EBOV" "Retroviridae" "HIV infectivity assays" "[Ref:16173723]HIV:EC50=13 ± 1.9μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " Inhibit viral fusion with host cell by intramolecular protein-protein interactions." "801" "C43H60N8O7" "ARNDCQEGHLKMFPSTYOU" "V" "5.49" "0" "0" "0" "0" "6" "2.55" "-3.61" "100 hours" ">20 hours" ">10 hour" "210" "11000" "13.733" "16173723" "J Am Chem Soc. 2005;127(38):13126-7." "Stephens OM, Kim S, Welch BD, et al." "Inhibiting HIV fusion with a beta-peptide foldamer." "10.1021/ja053444+" "Anti-EBOV,Anti-HIV" "DRAVPe02207" "EYLFEVDNL" "9" "P2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "231 to 239" "Not Available" "Not Available" "Not Available" "Not Available" "3CSY, 3S88, 3VE0, 5F1B, 5FHC, 5HJ3, 5JQ3, 5JQ7, 5K" "EBOV" "Filoviridae" "PRNT50 assays" "[Ref:12186901]EBOV:IC50:5.3 ± 0.67" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Other (immunogenic epitope)." "Peptide P2 acts against Ebola virus by stimulating cytotoxic T lymphocytes (CTLs) specific to the Ebola virus glycoprotein (GP). When used in immunization alongside liposome-encapsulated irradiated Ebola virus, P2 contributes to the generation of a CTL response aimed at targeting and eliminating virus-infected cells. This specificity was demonstrated by the enhanced lysis of target cells infected with vaccinia virus GP when effector cells from mice immunized with liposome-encapsulated virus were cultured with peptide P2, suggesting its role in inducing a more precise immune response against Ebola virus GP." "1141.24" "C53H76N10O18" "ARCQGHIKMPSTWOU" "EL" "3.57" "0" "3" "-3" "2" "4" "-0.078" "1.36" "1 hours" "30 min" ">10 hours" "118.89" "1490" "1.306" "12186901" "J Virol. 2002;76(18):9176-85." "Rao M, Bray M, Alving CR, et al." "Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells." "10.1128/jvi.76.18.9176-9185.2002" "Anti-EBOV" "DRAVPe02208" "IWWVVV" "6" "BetaWWI-1" "HIV gp41 C-terminus (C-peptides)" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,EBOV" "Retroviridae" "HIV infectivity assays" "[Ref:16173723]HIV:EC50=27 ± 2.5μM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " Inhibit viral fusion with host cell by intramolecular protein-protein interactions." "801" "C43H60N8O7" "ARNDCQEGHLKMFPSTYOU" "V" "5.52" "0" "0" "0" "0" "6" "2.55" "-3.61" "20 hours" "30 min" ">10 hour" "210" "11000" "13.733" "16173723" "J Am Chem Soc. 2005;127(38):13126-7." "Stephens OM, Kim S, Welch BD, et al." "Inhibiting HIV fusion with a beta-peptide foldamer." "10.1021/ja053444+" "Anti-EBOV,Anti-HIV" "DRAVPe02206" "LYDRLASTVI" "10" "P1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "161 to 169" "Not Available" "Not Available" "Not Available" "Not Available" "3CSY, 3S88, 3VE0, 5F1B, 5FHC, 5HJ3, 5JQ3, 5JQ7, 5K" "EBOV" "Filoviridae" "PRNT50 assays" "[Ref:12186901]EBOV:IC50=6.0 ± 0.94" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Other (immunogenic epitope)." "Peptide P1 likely works against the Ebola virus by serving as an immunogenic epitope, stimulating the activation and proliferation of cytotoxic T lymphocytes (CTLs) specific to the Ebola virus glycoprotein (GP). This activation of CTLs enables them to recognize and eliminate virus-infected cells, contributing to the immune response against Ebola virus infection." "1150.34" "C52H87N13O16" "NCQEGHKMFPWOU" "L" "5.84" "1" "1" "0" "3" "5" "0.73" "0.91" "5.5 hours" "3 min" "2 min" "156" "1490" "1.295" "12186901" "J Virol. 2002;76(18):9176-85." "Rao M, Bray M, Alving CR, et al." "Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells." "10.1128/jvi.76.18.9176-9185.2002" "Anti-EBOV" "DRAVPe02205" "RRRRRRRRRFFC" "13" "PMO" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "HIV,EBOV" "Filoviridae" "Antiviral Assay" "[Ref:16495261]EBOV:EC50= 5.0 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "[Ref:16495261]Cytotoxic at 10 microM concentration" "Not Available" "Linear" "Amination" "Free" "(In the peptide sequence, N-terminus is modified with an amino group (NH2).)" "L" "VP35" "PMOs, a type of single-stranded antisense agents, exert their antiviral action against Ebola virus by binding to specific RNA sequences, particularly within the VP35 translation start site region, thereby impeding viral replication. Their mechanism involves blocking the translation of essential viral proteins, like VP35, crucial for Ebola's replication, leading to a sequence-specific and dose-dependent inhibition of viral amplification both in vitro and in vivo. This inhibition ultimately safeguards against lethal Ebola infection in mice, showcasing PMOs' efficacy in curtailing viral spread." "1821.19" "C75H133N39O13S1" "ANDQEGHILKMPSTWYVOU" "R" "12.54" "9" "0" "9" "0" "3" "-2.7" "10.58" "1 hour" "3 min" "2 min" "0" "0" "0" "16495261" "Antimicrob Agents Chemother. 2006;50(3):984-93." "Enterlein S, Warfield KL, Swenson DL, et al." " VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice." "10.1128/AAC.50.3.984-993.2006" "Anti-EBOV,Anti-HIV" "DRAVPe02204" "RVKRCMK" "7" "Peptidyl chloromethylketone" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Endoproteolytic Cleavage Inhibition Assay. ≥90% (HPLC)" "[Ref:9576958]EBOV:IC50=25 microM or 80 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "Peptidyl chloromethylketones, exemplified by decRVKR-cmk, function as potent inhibitors of the endoproteolytic cleavage of the Ebola virus glycoprotein. They operate by obstructing the cleavage of the glycoprotein specifically at a multibasic amino acid motif situated between positions 497 and 501 of the ORF. This cleavage is essential for the glycoprotein's maturation into its functional state. By impeding this cleavage process, peptidyl chloromethylketones hinder the glycoprotein's transformation into its mature form, thereby disrupting the viral replication cycle and potentially diminishing the virus's infectivity." "920.2" "C37H73N15O8S2" "ANDQEGHILFPSTWYOU" "RK" "11.01" "4" "0" "4" "0" "3" "-1.171" "4.75" "1 hours" "2 min" "2 mins" "41.43" "0" "0" "9576958" "Proc Natl Acad Sci U S A. 1998;95(10):5762-7. " "Volchkov VE, Feldmann H, Volchkova VA, et al." "Processing of the Ebola virus glycoprotein by the proprotein convertase furin" "10.1073/pnas.95.10.5762" "Anti-EBOV" "DRAVPe02202" "WFQRIPLGWFHCTYQKGKQHCRLRIRQKVEE" "31" "delta18-48-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.8" "342-372" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding" "3972.65" "C181H276N56O42S2" "ANDMVOU" "RQ" "10.05" "7" "2" "5" "6" "11" "-1.029" "2.75" "2.8 hours" "3 min" "2 min" "59.68" "12490" "3.144" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02203" "ELQREESPTGPPGSIRT" "17" "delta1-17-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.9" "325-341" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding" "1854.01" "C77H128N24O29" "ANDCHKMFWYVOU" "EP" "4.79" "2" "3" "-1" "5" "2" "-1.371" "3.29" "1 hour" "30 min" ">10 hours" "45.88" "0" "0" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02201" "SPTGPPGSIRTWFQRIPLGWFHCTYQKGKQHCRLRIRQKVEE" "42" "delta7-48-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.7" "331-372" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50<25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding" "5023.82" "C226H350N70O57S2" "ANDMOU" "R" "10.44" "8" "2" "6" "10" "12" "-0.964" "2.5" "1.9 hours" ">20 hours" ">10 hours" "53.33" "12490" "2.486" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02200" "HCTYQKGKQHCRLRIRQKVEE" "21" "delta28-48-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.6" "352-372" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding" "2641.07" "C111H186N40O31S2" "ANDHMFPSWOU" "RQK" "9.7" "6" "2" "4" "5" "5" "-1.619" "4.1" "3.5 houurs" "10 min" ">10 hours" "50.95" "12490" "0.564" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02199" "GSIRTWFQRIPLGWFHCTYQKGKQHCRLRIRQKVEE" "36" "delta13-48-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.5" "337-372" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding" "4487.23" "C202H314N64O49S2" "ANDMOU" "R" "10.44" "8" "2" "6" "8" "12" "-0.939" "2.78" "30 hours" ">20 hours" ">10 hours" "62.22" "12490" "2.783" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02198" "ELQREESPTGPPGSIRTWFQRIPLGWFHCTYQKGKQHCR" "39" "delta1-39-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.4" "325-363" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding to filovirus-permissive cells and inhibition of EBOV glycoprotein GP1,2 entry. These Fc-tagged peptides interfere with the viral entry process, potentially preventing superinfection of producer cells and inhibiting cell transduction with filoviruses. The mechanisms of action involve binding to cell surface receptors or disrupting key viral entry steps." "4656.28" "C208H313N63O56S2" "ANDMVOU" "RQGP" "9.39" "6" "3" "3" "10" "10" "-1.136" "2.58" "1 hour" "30 min" ">10 hour" "40" "12490" "2.682" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02197" "ELQREESPTGPPGSIRTWFQRIPLGWFHCTYQK" "33" "delta1-33-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.3" "325-357" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50<25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." " The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding to filovirus-permissive cells and inhibition of EBOV glycoprotein GP1,2 entry. These Fc-tagged peptides interfere with the viral entry process, potentially preventing superinfection of producer cells and inhibiting cell transduction with filoviruses. The mechanisms of action involve binding to cell surface receptors or disrupting key viral entry steps." "3946.46" "C180H266N50O49S1" "ANDCEQGHMPSTOU" "P" "8.3" "4" "3" "1" "9" "9" "-0.948" "2.19" "1 hour" "30 min" ">10 hour" "47.27" "12490" "3.165" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02196" "ELQREESPTGPPGSIRTWFQRIPLGWFH" "28" "delta1-28-Fc" "eboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.2" "325-352" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50 < 25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding to filovirus-permissive cells and inhibition of EBOV glycoprotein GP1,2 entry. These Fc-tagged peptides interfere with the viral entry process, potentially preventing superinfection of producer cells and inhibiting cell transduction with filoviruses. The mechanisms of action involve binding to cell surface receptors or disrupting key viral entry steps." "3322.73" "C153H225N43O41" "ANDCKMYVOU" "P" "6.86" "3" "3" "0" "6" "8" "-0.871" "2.13" "1 hour" "30 min" ">10 hour" "55.71" "11000" "3.31" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02195" "ELQREESPTGPPGSIRTWFQRIPLGWFHCTYQKGKQHCRLRIRQKVEE" "48" "delta-Fc" "EboV delta peptide" "P60172, Q7T9E0" "Experimentally Validated" "128948" "GP" "AAB37097.1" " 325-372" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "Antiviral Assay" "[Ref:21697477]EBOV:IC50<25 nM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Free" "Free" "None" "L" "Glycoprotein." "The efficacy of delta-Fc and its truncated versions (delta1-28-Fc, delta1-33-Fc, delta1-39-Fc, delta13-48-Fc, delta28-48-Fc, delta7-48-Fc, delta18-48-Fc, delta1-17-Fc) in inhibiting Ebola virus (EBOV) entry was investigated, demonstrating specific binding to filovirus-permissive cells and inhibition of EBOV glycoprotein GP1,2 entry. These Fc-tagged peptides interfere with the viral entry process, potentially preventing superinfection of producer cells and inhibiting cell transduction with filoviruses. The mechanisms of action involve binding to cell surface receptors or disrupting key viral entry steps." "5808.64" "C258H402N80O70S2" "ANDMOU" "R" "9.69" "9" "5" "4" "11" "13" "-1.15" "2.94" "1 hour" "30 min" ">10 hours" "54.79" "12490" "2.15" "21697477" "J Virol. 2011;85(17):8502-13. " "Radoshitzky SR, Warfield KL, Chi X, et al." "Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry" "10.1128/JVI.02600-10" "Anti-EBOV" "DRAVPe02193" "YYSSRWNHGHFTPCS" "15" "eVpeL1" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "AlphaLISA assay," "[Ref:28574091]It inhibits Ebola virus" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Amidation" "Acetylation" "(In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration.)" "L" "VP24" "Exact MoA not known (eVpeL1, a macrocyclic peptide belonging to the GL1 group from the LY-library, was found to be a poor binder to the immobilized eVP24 compared to other peptides like eVpeD1 and eVpeD2)." "1841.98" "C83H108N24O23S1" "AQEILKMVOU" "S" "8.21" "1" "0" "1" "7" "3" "-1.18" "2.42" "2.8 hours" "10 min" "2 min" "0" "8480" "4.604" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV" "DRAVPe02194" "YFKSVRTGLRYVYCS" "15" "eVpeL2" "Synthetic construct" "No entry found" "Experimentally Validated" "None" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "Not Available" "None" "EBOV" "Filoviridae" "AlphaLISA assay," "[Ref:28574091]EBOV:IC50 = 37 microM" "No hemolysis information or data found in the reference(s) presented in this entry" "No cytotoxicity information found in the reference(s) presented" "Not Available" "Linear" "Amidation" "Acetylation" "(In the peptide sequence, the N-terminus is acetylated, and the tyrosine residue at position 1 is in the D-configuration.)" "L" "VP24" "eVpeL2 exhibit inhibitory activity against the protein-protein interaction (PPI) of VP24 and KPNA5." "1842.15" "C85H128N22O22S1" "ANDQEMPWOU" "Y" "9.63" "3" "0" "3" "6" "5" "-0.133" "1.79" "2.8 hours" "10 min" "2 min" "64.67" "4470" "2.427" "28574091" "Org Biomol Chem. 2017;15(24):5155-5160." "Song X, Lu LY, Passioura T, et al." "Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. " "10.1039/c7ob00012j" "Anti-EBOV"